学术周报 · IF≥10

肿瘤领域文献阅读汇编

2026年第41周 (2026-10-08) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
554
临床研究
164
基础研究
390
IF≥20
190
IF 10-20
364
子领域
11
期刊种类
105
数据日期
2026-10-08

★本周 Top 10 高影响力文献

#论文期刊IF
1Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapyIF 81.2
2Histone H4K5 lactylation-driven feedback loop modulates glycerol-linked immunosuppressive activity o...Signal transduction and targeted therapyIF 81.2
3α7 integrin co-regulates chromatin accessibility and gene expression in HPV-negative head and neck c...Signal transduction and targeted therapyIF 81.2
4Glutamine metabolism in health and disease.Signal transduction and targeted therapyIF 81.2
5Multi-omics profiling reveals homologous recombination repair hyperactivation as a therapeutic vulne...Signal transduction and targeted therapyIF 81.2
6The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapyIF 81.2
7Carbon nanoparticle-Fe (II) complex for ferroptosis therapy in refractory solid tumors: a phase I tr...Signal transduction and targeted therapyIF 81.2
8A preinvasive regulatory T cell axis for lung cancer interception.NatureIF 56.1
9tRNA dosage regulates lineage dependency and resistance in prostate cancer.NatureIF 56.1
10Chromatin plasticity and lineage repurposing: When gastric identity turns acidic.Cancer cellIF 56.1

Ŧ期刊分布统计

期刊篇数IF
Cancer letters39IF 11.8
Cancer research28IF 22.6
MedComm26IF 14.1
Biomaterials24IF 13.6
Cancer discovery22IF 29.5
Science advances20IF 13.9
Neuro-oncology19IF 13.1
Blood19IF 23.9
Redox biology19IF 16.2
Pharmacological research16IF 12.2

1血液肿瘤 (183篇)

临床研究 (53篇)

Cancer discovery IF 29.5 2026-10-08 PMID: 42844684
Age at diagnosis among patients with cancer is a predictor of pathogenic germline variant prevalence, yet age thresholds often misclassify genetic risk. We performed germline sequencing of 39,184 unselected patients with solid malignancies spanning 32 tumor types, interrogating >90 cancer predisposition genes independent of clinical suspicion. Patients were stratified into early-, average-, and late-onset groups based on standard deviations from tumor-specific mean age at diagnosis. Pathogenic variant prevalence inversely correlated with age at diagnosis: 18.4% in early-onset tumors, 15.6% in average-onset tumors, and 12.3% in late-onset tumors (P < 0.001). Variants in high/moderate-penetrance genes accounted for the enrichment in early-onset cases (12.4%, early-onset; 8.9%, average-onset; 5.1%, late-onset; P < 0.001). Restricting hereditary cancer testing to patients diagnosed before age 50, as is typically done, would miss 4,601 pathogenic variant carriers, 72% of all variants detected. These findings support broad-based germline testing beyond conventional age-based criteria, reflecting the burden of hereditary risk even among late-onset cases. Across 32 solid tumor types in a pan-cancer cohort, we found enrichment of germline pathogenic variants among patients with subtype-specific early-onset cancer. Using age 50 as a testing cutoff misses most patients with inherited predisposition, supporting universal germline genetic testing for all individuals diagnosed with cancer.
中文摘要:癌症患者的确诊年龄是致病性胚系变异患病率的预测因素,但年龄阈值常会错误划分遗传风险。我们对39,184例未经选择的实体恶性肿瘤患者进行了胚系测序,涵盖32种肿瘤类型,不依赖临床疑诊而对超过90个癌症易感基因进行检测。根据与肿瘤特异性平均确诊年龄的标准差,将患者分为早发、平均发病和晚发组。致病性变异患病率与确诊年龄呈负相关:早发肿瘤为18.4%,平均发病肿瘤为15.6%,晚发肿瘤为12.3%(P < 0.001)。高/中穿透力基因变异解释了早发病例中的富集(早发12.4%,平均发病8.9%,晚发5.1%;P < 0.001)。若按通常做法将遗传性癌症检测限制于50岁前确诊的患者,将漏检4,601例致病性变异携带者,占所有检出变异的72%。这些发现支持超越传统年龄标准的广泛性胚系检测,提示即使晚发病例也存在遗传风险负担。在一个泛癌队列的32种实体瘤类型中,我们发现亚型特异性早发癌症患者的胚系致病性变异存在富集。以50岁作为检测截断值会漏掉大多数具有遗传易感性的患者,支持对所有确诊癌症的个体进行普遍性胚系基因检测。
Trends in cancer IF 21.6 2026-10-08 PMID: 42844118
The emergence of tumor-agnostic therapies has fundamentally transformed precision oncology. Traditionally developed and approved for metastatic disease, nine therapies spanning immunotherapy, targeted agents, and antibody-drug conjugates now demonstrate a compelling rationale for earlier deployment in the neoadjuvant setting. This review examines the paradigm shift from last-resort to first-consideration approaches. Key advantages of neoadjuvant, biomarker-guided therapy include intervention prior to the development of therapeutic resistance, optimal immune system engagement, and opportunities for organ preservation. Single-agent programmed cell death protein-1 blockade has achieved a 100% complete response rate in mismatch repair-deficient rectal cancer with preserved organ function. Neurotrophic tyrosine receptor kinase (NTRK), rearranged during transfection (RET), and B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitors have demonstrated substantial responses that enable curative-intent surgery across malignancies. As precision oncology matures, the neoadjuvant tumor-agnostic approach exemplifies optimized therapeutic sequencing, potentially improving patient outcomes and quality of life.
中文摘要:肿瘤不可知疗法的出现从根本上改变了精准肿瘤学。传统上针对转移性疾病开发和批准的九种疗法涵盖免疫治疗、靶向药物和抗体-药物偶联物,如今为更早用于新辅助治疗场景提供了令人信服的理由。本综述审视了从最后手段到优先考虑方法的范式转变。新辅助、生物标志物指导治疗的关键优势包括在治疗耐药发生前进行干预、最佳免疫系统参与以及器官保留的机会。单药程序性细胞死亡蛋白-1阻断在错配修复缺陷型直肠癌中实现了100%的完全缓解率,并保留了器官功能。神经营养酪氨酸受体激酶(NTRK)、转染期间重排(RET)和B-Raf原癌基因丝氨酸/苏氨酸激酶(BRAF)抑制剂已在多种恶性肿瘤中显示出显著缓解,使以治愈为目的的手术成为可能。随着精准肿瘤学日益成熟,新辅助肿瘤不可知方法体现了优化治疗排序,可能改善患者结局和生活质量。
Journal of obesity & metabolic syndrome IF 12.7 2026-10-08 PMID: 42843855
Obesity has traditionally been defined by body mass index (BMI), a pragmatic but biologically limited measure that fails to capture adiposity distribution, tissue dysfunction, and heterogeneity in disease risk. To address these limitations, a recent Lancet Diabetes & Endocrinology Commission proposed a disease-oriented redefinition of obesity, distinguishing clinical obesity-excess adiposity causing organ dysfunction or functional impairment-from preclinical obesity, characterized by excess adiposity without established dysfunction. This shift has important implications for diagnosis, epidemiology, and health policy. In this review, we critically appraise the conceptual framework, emerging evidence, and implementation challenges of the new Lancet Commission definition of clinical obesity. Population-based studies from diverse regions consistently demonstrate marked discordance between BMI-defined and clinical obesity, with clinical obesity showing stronger associations with cardiometabolic disease, mortality, functional limitation, and cancer risk. These findings highlight the limitations of universal BMI thresholds, particularly in Asian populations with a predisposition to visceral adiposity at lower BMI levels. We compare the Lancet Commission framework with existing staging systems, including the Edmonton Obesity Staging System and the European Association for the Study of Obesity framework, and identify key challenges related to causal attribution, binary classification, scalability, and ethnic adaptation. Finally, we propose a refined, population-sensitive and pragmatic approach that conceptualizes preclinical and clinical obesity as stages along a trajectory, incorporates ethnicity-adapted adiposity thresholds, and emphasizes readily available clinical criteria for determining dysfunction and disease. The resulting definition of clinical obesity should support more precise and equitable obesity care.
中文摘要:肥胖传统上由体质指数(BMI)定义,这是一种实用但生物学上有限的指标,无法反映脂肪分布、组织功能障碍以及疾病风险的异质性。为应对这些局限,近期《柳叶刀糖尿病与内分泌学》委员会提出了一种以疾病为导向的肥胖重新定义,将临床肥胖(导致器官功能障碍或功能受损的脂肪过多)与临床前肥胖(脂肪过多但尚未出现明确功能障碍)区分开来。这一转变对诊断、流行病学和卫生政策具有重要意义。在本综述中,我们批判性评价了柳叶刀委员会关于临床肥胖的新定义的概念框架、新兴证据和实施挑战。来自不同地区的人群研究一致表明,BMI定义的肥胖与临床肥胖之间存在显著不一致,而临床肥胖与心血管代谢疾病、死亡率、功能受限和癌症风险的关联更强。这些发现凸显了统一BMI阈值的局限性,尤其是在较低BMI水平即易发生内脏脂肪堆积的亚洲人群中。我们将柳叶刀委员会框架与现有分期系统进行比较,包括埃德蒙顿肥胖分期系统和欧洲肥胖研究协会框架,并指出与因果归因、二分分类、可扩展性和种族适应性相关的关键挑战。最后,我们提出一种经过完善的、对人群敏感且务实的路径,将临床前肥胖和临床肥胖概念化为同一轨迹上的阶段,纳入适应种族的脂肪阈值,并强调使用易于获得的临床标准来判断功能障碍和疾病。由此形成的临床肥胖定义应有助于实现更精准、更公平的肥胖照护。
Journal of obesity & metabolic syndrome IF 12.7 2026-10-08 PMID: 42843854
Obesity remains a growing global health crisis, affecting nearly one billion adults worldwide and substantially increasing the risk of cardiometabolic disease, malignancy, and premature mortality. Metabolic and bariatric surgery (MBS) has evolved into an effective and durable treatment for severe obesity, providing sustained weight loss and significant remission of obesity-related comorbidities (i.e., type 2 diabetes mellitus and cardiovascular disease). Despite dramatic improvements in safety, efficacy, and long-term outcomes over time, MBS remains markedly underutilized, reaching fewer than 1% of eligible patients. Persistent barriers include limited patient and provider awareness, misconceptions regarding surgical risk, and significant disparities in access to care. Concurrently, the rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed the medical management of obesity, offering effective pharmacologic weight loss but raising questions regarding their impact on MBS utilization, durability, and cost-effectiveness. Emerging evidence demonstrates that while MBS produces greater and more durable weight loss than GLP-1 RAs alone, these therapies need not be competitive. Rather, GLP-1 RAs may serve as 'neoadjuvant' treatment to optimize surgical candidacy or as adjunctive treatment for inadequate weight loss or postoperative weight regain. This review synthesizes contemporary data on MBS procedures, outcomes, disparities in access, and evolving perceptions of obesity treatment in the GLP-1 RA era. We propose a chronic weight management model that integrates pharmacotherapy, surgery, and multidisciplinary care along a continuous treatment spectrum. Positioning MBS and GLP-1 RAs as complementary modalities within individualized care pathways may improve long-term outcomes, expand access, and better address the complex, chronic nature of obesity.
中文摘要:肥胖仍是一场不断加剧的全球健康危机,影响全球近十亿成年人,并显著增加心血管代谢疾病、恶性肿瘤和过早死亡的风险。代谢与减重手术(MBS)已发展为治疗重度肥胖的有效且持久的方法,可实现持续减重并使肥胖相关合并症(即2型糖尿病和心血管疾病)显著缓解。尽管随着时间推移,MBS在安全性、疗效和长期结局方面取得了显著改善,但其利用率仍明显偏低,仅覆盖不到1%的符合条件患者。持续存在的障碍包括患者和医疗服务提供者认知有限、对手术风险的误解,以及获得医疗服务方面的显著差异。与此同时,胰高血糖素样肽-1受体激动剂(GLP-1 RAs)的快速应用改变了肥胖的药物治疗,提供了有效的药物减重,但也引发了关于其对MBS利用率、持久性和成本效果影响的疑问。新出现的证据表明,尽管MBS比单用GLP-1 RAs能产生更大且更持久的减重效果,但这些疗法不必相互竞争。相反,GLP-1 RAs可作为「新辅助」治疗以优化手术候选资格,或作为辅助治疗用于减重不足或术后体重反弹。本综述综合了关于MBS术式、结局、可及性差异以及在GLP-1 RA时代肥胖治疗观念演变的最新数据。我们提出一种慢性体重管理模型,将药物治疗、手术和多学科照护整合到一个连续的治疗谱系中。将MBS和GLP-1 RAs定位为个体化诊疗路径中的互补方式,可能改善长期结局、扩大可及性,并更好地应对肥胖复杂、慢性的本质。
Journal of hematology & oncology IF 47.8 2026-10-07 PMID: 42844631
The management of acute myeloid leukemia (AML) has undergone a remarkable transformation over the past decade, as advances in genomic profiling and drug development have expanded therapeutic options and enabled increasingly personalized treatment approaches. This review summarizes the evolving therapeutic landscape of AML, including current intensive and lower-intensity treatment backbones, approved molecularly targeted therapies, and emerging investigational strategies. We discuss the role of intensive cytarabine plus anthracycline-based regimens and venetoclax-based lower-intensity approaches, as well as targeted therapies directed against FLT3, IDH1/2, NPM1, and KMT2A-rearranged AML. We further examine efforts to optimize existing treatment paradigms through the incorporation of venetoclax into intensive chemotherapy, rational targeted combinations, and novel triplet regimens, in addition to the emerging use of highly active lower-intensity therapies in younger fit patients. Finally, we highlight promising future directions in AML, including therapies targeting RAS/MAPK signaling, emerging approaches for TP53-mutated disease, and immunotherapeutic strategies. AML treatment is rapidly evolving from broadly applied chemotherapy-based approaches toward increasingly molecularly informed and individualized therapeutic strategies. Continued advances in molecular diagnostics, targeted therapies, and synergistic combination regimens have the potential to further increase remission durability, reduce relapses, and improve long-term outcomes for patients with AML.
中文摘要:急性髓系白血病(AML)的管理在过去十年中经历了显著变革,因为基因组分析和药物开发的进展扩大了治疗选择,并使治疗方式日益个体化。本综述总结了AML不断演变的治疗格局,包括当前强化治疗和低强度治疗骨架、已获批的分子靶向治疗以及新兴的研究性策略。我们讨论了强化阿糖胞苷联合蒽环类药物方案和基于维奈克拉的低强度方案的作用,以及针对FLT3、IDH1/2、NPM1和KMT2A重排AML的靶向治疗。我们进一步审视了通过将维奈克拉纳入强化化疗、合理的靶向联合方案和新型三药方案来优化现有治疗模式的努力,以及在年轻适合患者中新兴使用高活性低强度治疗。最后,我们强调了AML有前景的未来方向,包括靶向RAS/MAPK信号通路的治疗、针对TP53突变疾病的新兴方法以及免疫治疗策略。AML治疗正在从广泛应用的化疗为基础的方法迅速向日益基于分子信息且个体化的治疗策略演变。分子诊断、靶向治疗和协同联合方案的持续进展有潜力进一步提高缓解持久性、减少复发,并改善AML患者的长期结局。
Biomarker research IF 14.6 2026-10-07 PMID: 42844622
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) stands as a leading curative approach for AML in China. However, relapse remains a major challenge for patient survival, often occurring within six months post-transplant and associated with a five-year mortality rate of up to 80%. Here, we characterized early immune reconstitution after haplo-HSCT and investigated immune features associated with early relapse (ER) in AML. We analyzed two clinical cohorts: patients with AML (n = 44) and aplastic anemia (AA; n = 38), and AML patients with continuous complete remission (CCR, n = 55) versus ER (n = 38). Single-cell RNA sequencing was performed on longitudinal peripheral blood and bone marrow samples from AML and AA patients (n = 3 and 4), while single-cell RNA/TCR sequencing was performed on bone marrow samples from CCR and ER patients (n = 3 each). Flow cytometry assessed monocyte Galectin-9 surface expression and CD8⁺ T-cell phenotypes. Galectin-9-associated monocyte-T-cell interactions and the effects of the TIM-3 inhibitor MG-T-19 were evaluated in vitro and in a murine AML model. AML and AA patients showed different patterns of early immune reconstitution after haplo-HSCT, including differences in monocyte and T-cell recovery. Within AML, ER patients exhibited increased T-cell representation but reduced basal TNF-α expression and altered exhaustion-associated CD8⁺ T-cell phenotypes before relapse. Monocytes represented a prominent Galectin-9-expressing compartment, and surface Galectin-9 on monocytes was elevated in ER compared with CCR patients as early as day 30 post-transplantation. Exogenous Galectin-9 induced dose-dependent functional and exhaustion-associated changes in CD8⁺ T cells, while Galectin-9-high IFN-conditioned monocytes impaired CD8⁺ T-cell responses in vitro. MG-T-19 partially reversed these alterations, increased CD8⁺ T-cell TNF-α production, and enhanced leukemia-cell apoptosis. In the MLL-AF9 murine AML model, MG-T-19 reduced leukemia burden and prolonged survival. Increased monocyte Galectin-9 during early immune reconstitution is associated with subsequent early relapse and CD8⁺ T-cell dysfunction after haplo-HSCT. Further Galectin-9-specific mechanistic studies and prospective clinical validation are warranted to establish its causal relevance and potential utility as an early relapse biomarker.
中文摘要:急性髓系白血病(AML)是成人中最常见的急性白血病。单倍体相合造血干细胞移植(haplo-HSCT)是中国治疗AML的主要治愈性手段。然而,复发仍是患者生存的主要挑战,常发生于移植后六个月内,并与高达80%的五年死亡率相关。在此,我们刻画了haplo-HSCT后早期免疫重建特征,并研究了与AML早期复发(ER)相关的免疫特征。我们分析了两个临床队列:AML患者(n=44)和再生障碍性贫血(AA)患者(n=38),以及持续完全缓解(CCR)的AML患者(n=55)与ER患者(n=38)。对AML和AA患者的纵向外周血和骨髓样本(分别n=3和4)进行了单细胞RNA测序,同时对CCR和ER患者的骨髓样本(各n=3)进行了单细胞RNA/TCR测序。流式细胞术评估了单核细胞Galectin-9表面表达和CD8+ T细胞表型。在体外和鼠AML模型中评估了Galectin-9相关的单核细胞-T细胞相互作用以及TIM-3抑制剂MG-T-19的作用。AML和AA患者在haplo-HSCT后表现出不同的早期免疫重建模式,包括单核细胞和T细胞恢复的差异。在AML中,ER患者在复发前表现出T细胞比例增加,但基础TNF-α表达降低,且耗竭相关CD8+ T细胞表型改变。单核细胞是突出的Galectin-9表达细胞群,与CCR患者相比,ER患者单核细胞表面Galectin-9早在移植后第30天即升高。外源性Galectin-9诱导CD8+ T细胞出现剂量依赖性的功能改变和耗竭相关变化,而高表达Galectin-9的IFN预处理单核细胞在体外损害了CD8+ T细胞应答。MG-T-19部分逆转了这些改变,增加了CD8+ T细胞TNF-α产生,并增强了白血病细胞凋亡。在MLL-AF9鼠AML模型中,MG-T-19降低了白血病负荷并延长了生存。早期免疫重建期间单核细胞Galectin-9升高与haplo-HSCT后随后的早期复发和CD8+ T细胞功能障碍相关。需要进一步的Galectin-9特异性机制研究和前瞻性临床验证,以确定其因果相关性和作为早期复发生物标志物的潜在用途。
Journal of hematology & oncology IF 47.8 2026-10-07 PMID: 42844619
Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myeloma. Indirect comparisons in heavily pretreated patients have favored cell therapy, but whether that hierarchy holds in early relapse is unknown. We analyzed randomized phase 3 trials comparing a T-cell-redirecting therapy against a daratumumab-pomalidomide-dexamethasone-type control after at least one prior line. Pseudo-individual patient time-to-event data were reconstructed from published survival curves. Regimens were compared indirectly in Bayesian network meta-analyses reported under fixed-effect and random-effects assumptions, re-estimated in a frequentist graph-theoretical model. Control-arm dispersion was quantified by random-effects synthesis of median progression-free survival. Overall survival was additionally analyzed as restricted mean survival differences at 24 and 36 months. Safety and a cost-consequence analysis were assessed descriptively (PROSPERO: CRD420261431847). Four trials (2,174 patients) investigating ciltacabtagene autoleucel, teclistamab-daratumumab, and talquetamab-daratumumab with or without pomalidomide were included. Control-arm median progression-free survival spanned 9.9 to 24.4 months (I-squared 91%). Under fixed effects, teclistamab-daratumumab ranked first for progression-free survival (P-score 98%, the mean probability of outranking a competing treatment rather than the probability of being best) and separated from talquetamab-daratumumab (hazard ratio 0.55, 95% credible interval 0.34 to 0.88). Once between-trial heterogeneity was admitted, every contrast crossed unity (versus ciltacabtagene autoleucel 0.62, 0.21 to 1.81). Overall survival was concordant under both models (teclistamab-daratumumab versus ciltacabtagene autoleucel 0.94, 0.55 to 1.62), with restricted mean survival gains over control of 0.7 to 1.6 months at 24 months and rankings between 56% and 70%. Toxicity profiles differed across modalities, although their overall burden cannot be reliably compared across trials. Cost per progression-free month, computed against a population-standardized denominator, was lowest for cilta-cel and converged with the bispecific regimens only under short, fixed treatment durations. Randomized evidence in early relapse does not establish an efficacy hierarchy among these regimens. Progression-free survival estimates favored teclistamab-daratumumab, but no contrast was robust to plausible between-trial heterogeneity, and equivalence could not be demonstrated. Until comparative data exist, treatment selection cannot rest on efficacy data alone and will be informed by patient- and disease-related factors, toxicity, sequencing, access, and cost.
中文摘要:嵌合抗原受体T细胞和双特异性抗体正从后线挽救治疗进入早期复发多发性骨髓瘤。在经多线治疗患者中的间接比较曾偏向细胞治疗,但这一排序是否适用于早期复发尚不清楚。我们分析了随机3期试验,这些试验在至少一线既往治疗后比较T细胞重定向治疗与达雷妥尤单抗-泊马度胺-地塞米松类方案对照。从已发表的生存曲线重建了伪个体患者时间-事件数据。在固定效应和随机效应假设下报告贝叶斯网络荟萃分析,并在频率学图论模型中重新估计。通过随机效应合成中位无进展生存期来量化对照组离散度。总生存期还以24个月和36个月的限制性平均生存差异进行分析。安全性和成本-后果分析采用描述性评估(PROSPERO:CRD420261431847)。纳入4项试验(2174例患者),研究西达基奥仑赛、特立妥单抗-达雷妥尤单抗和塔奎妥单抗-达雷妥尤单抗联合或不联合泊马度胺。对照组中位无进展生存期为9.9至24.4个月(I²为91%)。在固定效应下,特立妥单抗-达雷妥尤单抗在无进展生存期方面排名第一(P评分98%,即平均超越某一竞争治疗方案的概率,而非成为最佳治疗的概率),并与塔奎妥单抗-达雷妥尤单抗分离(风险比0.55,95%可信区间0.34至0.88)。一旦纳入试验间异质性,所有对比均跨越1(与西达基奥仑赛相比为0.62,0.21至1.81)。总生存期在两种模型下一致(特立妥单抗-达雷妥尤单抗与西达基奥仑赛相比为0.94,0.55至1.62),24个月时相对对照组的限制性平均生存获益为0.7至1.6个月,排名在56%至70%之间。不同治疗模式的毒性特征存在差异,但其总体负担无法在试验间可靠比较。以人群标准化分母计算的无进展生存月成本,西达基奥仑赛最低,并且仅在短程、固定治疗持续时间下才与双特异性抗体方案趋同。早期复发中的随机证据未能确定这些方案之间的疗效层级。无进展生存期估计倾向于特立妥单抗-达雷妥尤单抗,但没有任何对比对合理的试验间异质性稳健,且无法证明等效性。在获得比较数据之前,治疗选择不能仅依赖疗效数据,还将受到患者和疾病相关因素、毒性、序贯治疗、可及性和成本的影响。
EBioMedicine IF 11.2 2026-10-07 PMID: 42843113
Paediatric adrenocortical tumours (pACT) are rare endocrine neoplasms characterised by marked biological heterogeneity and variable clinical behaviour. Current risk stratification relies largely on histopathology and clinical staging, which incompletely capture underlying tumour biology. We aimed to define proteome-based subtypes of pACT and evaluate their biological, clinical, and therapeutic relevance. In this retrospective cohort study, we performed mass spectrometry-based proteomic profiling of 83 pACT and adjacent non-tumour adrenal tissues. Differential abundance analysis, pathway enrichment, consensus clustering, survival analyses, and clinicopathological correlations were performed. A minimal protein classifier was derived using forward feature selection and leave-one-out cross-validation. Cluster-specific therapeutic vulnerabilities were assessed using a curated druggability framework. Tumours displayed profound proteomic differences compared with adjacent non-tumour adrenal cortex, characterised by activation of cholesterol biosynthesis, steroidogenic, MYC, mTORC1, and cell-cycle programs and suppression of extracellular matrix, adhesion, and immune-related pathways. Unsupervised clustering identified four proteome-defined tumour states that only partially overlapped with histopathological diagnosis. These subtypes differed significantly in endocrine phenotype, vascular invasion, Ki67 index, necrosis, and overall survival (log-rank p = 0.00036). Distinct biological programs included stromal-immune-enriched, mitochondrial steroidogenic, IGF/mTOR-driven anabolic, and highly proliferative chromatin-remodelled states. A five-protein classifier (DAAM2, CIP2A, TSC2, PALS2, and P3H1) reproduced cluster assignments with 92.8% leave-one-out cross-validation accuracy. Cluster-specific analyses identified distinct therapeutic target landscapes, including IGF-axis and epigenetic vulnerabilities. Proteomic profiling defines biologically and clinically distinct pACT subtypes that provide prognostic information beyond histopathology. This framework enables proteome-based stratification, identifies candidate therapeutic vulnerabilities, and can be approximated by a five-protein classifier. German Childhood Cancer Foundation, Mitteldeutsche Kinderkrebsforschung, European Union's EU4Health Programme, Max Planck Society, Onassis Foundation, and Joachim Herz Stiftung.
中文摘要:小儿肾上腺皮质肿瘤(pACT)是罕见的内分泌肿瘤,以显著的生物学异质性和多变的临床行为为特征。当前的风险分层主要依赖组织病理学和临床分期,不能完全反映潜在的肿瘤生物学。我们旨在定义pACT的蛋白质组学亚型,并评估其生物学、临床和治疗相关性。在这项回顾性队列研究中,我们对83例pACT及邻近非肿瘤肾上腺组织进行了基于质谱的蛋白质组学分析。开展了差异丰度分析、通路富集、共识聚类、生存分析和临床病理相关性分析。利用前向特征选择和留一交叉验证推导出一个最小蛋白分类器。采用一个经过整理的可成药性框架评估了聚类特异性治疗脆弱性。与邻近非肿瘤肾上腺皮质相比,肿瘤表现出显著的蛋白质组差异,其特征为胆固醇生物合成、类固醇生成、MYC、mTORC1和细胞周期程序的激活,以及细胞外基质、黏附和免疫相关通路的抑制。无监督聚类识别出四种由蛋白质组定义的肿瘤状态,这些状态仅与组织病理学诊断部分重叠。这些亚型在内分泌表型、血管侵犯、Ki67指数、坏死和总生存期方面存在显著差异(log-rank p = 0.00036)。不同的生物学程序包括基质免疫富集状态、线粒体类固醇生成状态、IGF/mTOR驱动的合成代谢状态和高增殖染色质重塑状态。一个五蛋白分类器(DAAM2、CIP2A、TSC2、PALS2和P3H1)以92.8%的留一交叉验证准确率重现了聚类分配。聚类特异性分析识别出不同的治疗靶点图谱,包括IGF轴和表观遗传脆弱性。蛋白质组学分析定义了在生物学和临床上不同的pACT亚型,提供了超越组织病理学的预后信息。该框架能够实现基于蛋白质组的分层,识别候选治疗脆弱性,并可通过一个五蛋白分类器进行近似。资助:德国儿童癌症基金会、中德意志儿童癌症研究、欧盟EU4Health计划、马克斯·普朗克学会、奥纳西斯基金会和约阿希姆·赫茨基金会。
Blood IF 23.9 2026-10-07 PMID: 42842316
Myelodysplastic neoplasms (MDS) relapsing after allogeneic stem cell transplantation (alloSCT) have a poor prognosis. A second alloSCT (alloSCT2) can offer durable remission, however, earlier studies reported <20% long-term survival. Here we summarize contemporary outcome and risk factors after alloSCT2 (2012-2023), particularly focusing on donor change (DoC). We included 313 adults undergoing alloSCT2 for MDS relapse. Donors for alloSCT2 were matched- related/unrelated/haploidentical in 19%/62%/19%, with DoC reported in 71%. Two-year overall-/progression-free survival (OS/PFS), cumulative relapse incidence (RI) and non-relapse mortality (NRM) from alloSCT2 were 45%/33%/37%/30%. Outcome improved over time (2y-OS/PFS: 51%/39% in years 2018-2023). In multivariable analyses, DoC was associated with lower risk of relapse (HR=0.56, 95%-CI: 0.36-0.89), a finding never observed after alloSCT2 for acute leukemia. Additionally, adverse cytogenetics were correlated with relapse risk (HR=1.93, 95%-CI: 1.18-3.17). Risk of NRM decreased in more recent years (HR=0.88, per year later) and in patients with Karnofsky performance score (KPS) ≥90 at alloSCT2 (HR=0.59). Concerning survival, remission after alloSCT1 ≥12 months (HR=0.62/0.67) and KPS ≥90 (HR=0.68/0.69) were associated with better OS/PFS. In summary, we report improved outcomes of alloSCT2 in MDS in more recent years and demonstrate superior disease control by DoC, although a trend toward increased NRM precluded a significant survival benefit.
中文摘要:异基因干细胞移植(alloSCT)后复发的骨髓增生异常性肿瘤(MDS)预后较差。第二次alloSCT(alloSCT2)可实现持久缓解,但早期研究报告长期生存率低于20%。本文总结2012—2023年alloSCT2后的当代结局和危险因素,尤其关注更换供者(DoC)。我们纳入313例因MDS复发而接受alloSCT2的成人患者。alloSCT2的供者类型为全合亲缘、全合无关、单倍体相合者分别占19%、62%、19%,71%报告了DoC。alloSCT2后2年总生存、无进展生存(OS/PFS)、累积复发率(RI)和非复发死亡(NRM)分别为45%、33%、37%、30%。结局随时间改善(2018—2023年2年OS/PFS为51%、39%)。在多变量分析中,DoC与较低复发风险相关(HR=0.56,95%CI:0.36-0.89),这一发现在急性白血病alloSCT2后从未观察到。此外,不良细胞遗传学与复发风险相关(HR=1.93,95%CI:1.18-3.17)。NRM风险在较近年份下降(HR=0.88,每延后一年),在alloSCT2时Karnofsky体能状态评分(KPS)≥90的患者中也下降(HR=0.59)。关于生存,alloSCT1后缓解≥12个月(HR=0.62/0.67)和KPS≥90(HR=0.68/0.69)与更好的OS/PFS相关。总之,我们报告近年来MDS的alloSCT2结局改善,并证明DoC可带来更优的疾病控制,尽管NRM增加的趋势未能转化为显著的生存获益。
JAMA dermatology IF 10.9 2026-10-07 PMID: 42842270
Risk stratification in advanced mycosis fungoides and Sézary syndrome (MF/SS) remains suboptimal given that current TNMB (tumor, node, metastasis, blood) staging has limited prognostic value for clinically relevant outcomes. To determine whether the Cutaneous Lymphoma International Prognostic Index (CLIPI) may be used to predict progression-free survival (PFS) and best objective response (BOR) in patients with advanced MF/SS. This international prospective cohort study included patients with stage IIB to IVB MF/SS from the PROCLIPI trial which ran from July 1, 2015, to May 1, 2025, across 46 referral centers. Median follow-up was 4.75 (95% CI, 4.04-5.13) years; eligible participants had complete data on CLIPI, PFS, and BOR. Data were analyzed from September 1 to December 1, 2025. CLIPI score at diagnosis, based on age (>60 years), elevated serum lactate dehydrogenase, N3 nodal status, and large-cell transformation in the skin. Patients were classified as having low (0 or 1 factor), intermediate (2 factors), or high risk (3 or 4 factors). PFS (defined as diagnosis to disease progression or death) and BOR (complete response, partial response, stable disease, or progressive disease) during follow-up. Exploratory analyses evaluated treatment effects before progression using inverse probability weighting. Among 277 patients (median [IQR] age at diagnosis, 66 [23-89] years; 183 male individuals [65.7%]), 144 (52.0%) were classified as having low risk, 93 (33.6%) intermediate risk, and 40 (14.4%) high risk. They had a median PFS of 4.64 years (95% CI, 3.50-5.76), 2.72 years (95% CI, 1.81-4.56), and 0.89 years (95% CI, 0.65-1.14), respectively (log-rank P < .001). Patients in the intermediate-risk (hazard ratio [HR], 1.45; 95% CI, 1.01-2.08) and high-risk (HR, 3.84; 95% CI, 2.21-6.66) CLIPI groups displayed higher hazards of progression or death than those at low risk. Inclusion of CLIPI improved PFS discrimination over a model with baseline stage alone. Each 1-point increase in CLIPI was associated with approximately 38% lower odds of observing a better response during follow-up (odds ratio, 0.62; 95% CI, 0.43-0.89). In this international prospective cohort of patients with advanced MF/SS, CLIPI scores were associated with risk of disease progression and likelihood of response beyond clinical stage. These findings indicate that CLIPI may help to refine risk stratification and support its integration into clinical decision-making and future trial design.
中文摘要:鉴于当前TNMB(肿瘤、淋巴结、转移、血液)分期对临床相关结局的预后价值有限,晚期蕈样肉芽肿和Sézary综合征(MF/SS)的风险分层仍不理想。本研究旨在确定皮肤淋巴瘤国际预后指数(CLIPI)是否可用于预测晚期MF/SS患者的无进展生存期(PFS)和最佳客观缓解(BOR)。这项国际前瞻性队列研究纳入PROCLIPI试验中IIB至IVB期MF/SS患者,该试验于2015年7月1日至2025年5月1日在46个转诊中心开展。中位随访时间为4.75年(95%CI,4.04-5.13);符合条件的参与者具有完整的CLIPI、PFS和BOR数据。数据分析时间为2025年9月1日至12月1日。诊断时CLIPI评分基于年龄(>60岁)、血清乳酸脱氢酶升高、N3淋巴结状态和皮肤大细胞转化。患者被分为低危(0或1个因素)、中危(2个因素)或高危(3或4个因素)。结局为随访期间的PFS(定义为从诊断至疾病进展或死亡)和BOR(完全缓解、部分缓解、疾病稳定或疾病进展)。探索性分析使用逆概率加权评估进展前的治疗效应。在277例患者中(诊断时中位[IQR]年龄为66[23-89]岁;183例男性[65.7%]),144例(52.0%)为低危,93例(33.6%)为中危,40例(14.4%)为高危。其中位PFS分别为4.64年(95%CI,3.50-5.76)、2.72年(95%CI,1.81-4.56)和0.89年(95%CI,0.65-1.14)(log-rank P < .001)。中危(风险比[HR],1.45;95%CI,1.01-2.08)和高危(HR,3.84;95%CI,2.21-6.66)CLIPI组患者疾病进展或死亡风险高于低危组。与仅包含基线分期的模型相比,纳入CLIPI改善了PFS区分度。CLIPI每增加1分,随访期间观察到更好缓解的比值降低约38%(比值比,0.62;95%CI,0.43-0.89)。在这项晚期MF/SS国际前瞻性队列中,CLIPI评分与疾病进展风险和缓解可能性相关,且超出临床分期之外。这些发现表明CLIPI可能有助于细化风险分层,并支持将其整合到临床决策和未来试验设计中。
Nature medicine IF 52.5 2026-10-06 PMID: 42839103
Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodepletion, with up to 3 months of follow-up. The primary endpoints included safety and tolerability, while the secondary endpoints comprised efficacy, pharmacokinetics and pharmacodynamics. All patients developed dual-phase cytokine release syndrome (grades 1-3) and hematotoxicities (grade ≥3). One patient developed grade 1 immune effector cell-associated neurotoxicity syndrome. The objective response rate reached 100% (two stringent complete response and two partial response). Here we update the data on long‑term safety and response durability with a maximal follow‑up of 15 months. No immunogenicity‑ or integration‑related toxicities occurred, and no important adverse events related to ESO-T01 emerged beyond the initial report. Of the four patients, one maintained stringent complete response for 15 months. The median progression-free survival was 4.0 (range 3.0-15.0) months. After progression, diverse salvage therapies extended overall survival to 5.5-10.9 months after infusion. Three patients experienced relapse or progression, all with extramedullary involvement, and eventually died during follow-up. One patient achieved durable response with robust expansion from ex vivo CAR-T. Collectively, these updated results provide additional insights on the safety and efficacy of in vivo CAR-T therapies. The limited persistence observed necessitates the further optimization of the in vivo CAR-T platform. ClinicalTrials.gov identifier: NCT06691685 .
中文摘要:关于体内嵌合抗原受体T细胞(CAR-T)治疗长期结局的数据仍然稀缺。我们此前报告了体内B细胞成熟抗原(BCMA)CAR-T(ESO-T01)在4例复发/难治性多发性骨髓瘤患者中的初步安全性和有效性数据,该治疗无需白细胞分离术和淋巴细胞清除,随访时间最长3个月。主要终点包括安全性和耐受性,次要终点包括有效性、药代动力学和药效动力学。所有患者均发生双相细胞因子释放综合征(1-3级)和血液学毒性(≥3级)。1例患者发生1级免疫效应细胞相关神经毒性综合征。客观缓解率达到100%(2例严格完全缓解和2例部分缓解)。在此,我们更新长期安全性和缓解持久性数据,最长随访时间为15个月。未发生免疫原性或整合相关毒性,也未出现初始报告之外与ESO-T01相关的重要不良事件。4例患者中,1例维持严格完全缓解达15个月。中位无进展生存期为4.0(范围3.0-15.0)个月。疾病进展后,多种挽救治疗将总生存期延长至输注后5.5-10.9个月。3例患者出现复发或进展,均伴有髓外受累,并最终在随访期间死亡。1例患者通过体外CAR-T的强劲扩增获得持久缓解。总体而言,这些更新结果为了解体内CAR-T疗法的安全性和有效性提供了更多信息。观察到的持续性有限,需要对体内CAR-T平台进一步优化。ClinicalTrials.gov注册号:NCT06691685。
Nature communications IF 18.1 2026-10-06 PMID: 42838965
Whole-genome sequencing (WGS) has been shown to improve diagnosis beyond standard-of-care genetic tests and guide precision treatment for childhood cancer. While WGS is now offered for children with suspected cancer in England, clinical workflows typically return results after several weeks whereas clinical decisions are often required within days. Here we evaluate feasibility and efficacy of a rapid WGS (rWGS) research workflow with streamlined bioinformatics to deliver clinical genomic findings (NCT07201038, Active, not recruiting). In 54 children with suspected or confirmed malignancy, rWGS reduces mean end-to-end turnaround time from 42 to 3 days, whilst increase variant detection rate. Whereby rWGS detected 147 of 155 (95%) clinically actionable variants identified in the cohort, standard of care testing detected 138 of 155 (89%) variants. In a subset of 35 patients assessed prospectively, clinicians report that in 17 (49%), rWGS either (i) facilitates faster access to targeted therapy and risk stratification, or (ii) avoids unnecessary investigations and treatment escalation. These findings indicate feasibility and suggest clinical utility of rWGS when deployed as a first line diagnostic test in pediatric oncology.
中文摘要:全基因组测序(WGS)已被证明可在标准诊疗基因检测之外改善诊断,并指导儿童肿瘤的精准治疗。尽管英国现已为疑似肿瘤患儿提供WGS,但临床工作流程通常需数周才返回结果,而临床决策往往需在数日内作出。在此,我们评估一种采用简化生物信息学流程的快速WGS(rWGS)研究工作流程在提供临床基因组发现方面的可行性和有效性(NCT07201038,进行中,未招募)。在54例疑似或确诊恶性肿瘤的儿童中,rWGS将平均端到端周转时间从42天缩短至3天,同时提高变异检出率。其中,rWGS检出了该队列中155个临床可操作变异中的147个(95%),而标准诊疗检测检出155个变异中的138个(89%)。在对35例患者进行前瞻性评估的亚组中,临床医生报告,在17例(49%)中,rWGS要么(i)促进更快获得靶向治疗和风险分层,要么(ii)避免不必要的检查和治疗升级。这些发现表明,将rWGS作为儿童肿瘤学中的一线诊断检测部署时具有可行性,并提示其临床实用性。
European urology IF 29.1 2026-10-06 PMID: 42838799
Major adverse cardiovascular events (MACE) are a leading cause of noncancer death in men with prostate cancer (PCa). Androgen receptor pathway inhibitors (ARPIs) improve oncologic outcomes but may exacerbate cardiovascular risk. The Systematic Coronary Risk Evaluation 2(SCORE2) estimates 10-yr cardiovascular risk, yet its validity in men receiving treatment for PCa is untested. To evaluate the cardiovascular safety of ARPIs and other treatment intensification strategies within the STAMPEDE trial and assess SCORE2 performance. This post hoc analysis included patients allocated to the abiraterone acetate plus prednisolone (AAP), AAP plus enzalutamide (ENZ), docetaxel (DOC), zoledronic acid (ZA), and radiotherapy (RT) comparisons in STAMPEDE with linked health care records in England. Treatment intensification with AAP, AAP plus ENZ, DOC, ZA, or prostate RT in addition to standard-of-care androgen deprivation therapy (ADT). MACE were identified using prespecified International Classification of Diseases, 10th Revision, and Office of Population Censuses and Surveys Classification of Interventions and Procedures codes. Flexible parametric competing-risk models estimated cumulative incidence and subdistribution hazard ratios (SDHRs). SCORE2 discrimination and calibration were evaluated. A total of 6292 men were included. The 5-yr cumulative MACE incidence with ARPI intensification was 9% in nonmetastatic (M0) disease and 7% in metastatic (M1) disease, comparable to ADT alone. ARPI intensification was not associated with a statistically significant increase in MACE risk (AAP: M0 SDHR 1.15 [95% confidence interval {CI} 0.80-1.67], M1 SDHR 1.36 [95% CI 0.87-2.10]; AAP plus ENZ: M0 SDHR 1.34 [95% CI 0.91-1.98], M1 SDHR 1.28 [95% CI 0.85-1.94]). Cardiovascular disease history was the strongest predictor of MACE. Among 5076 patients eligible for SCORE2 assessment, 4239 had complete baseline data. SCORE2 discrimination was modest (10-yr area under the curve 0.63 for M0 disease and 0.61 for M1 disease), and absolute cardiovascular risk was underestimated. Limitations included underrepresentation of patients with severe cardiovascular comorbidity. No statistically significant increase in MACE was observed with ARPIs, DOC, ZA, or prostate RT compared with ADT alone. SCORE2 underestimated cardiovascular risk, supporting development of PCa-specific cardiovascular risk models.
中文摘要:主要不良心血管事件(MACE)是前列腺癌(PCa)男性非癌症死亡的主要原因。雄激素受体通路抑制剂(ARPI)改善肿瘤结局,但可能加重心血管风险。系统性冠状动脉风险评估2(SCORE2)可估计10年心血管风险,但其在接受PCa治疗的男性中的有效性尚未得到验证。评估STAMPEDE试验中ARPI及其他治疗强化策略的心血管安全性,并评估SCORE2的表现。这项事后分析纳入STAMPEDE中分配至醋酸阿比特龙加泼尼松龙(AAP)、AAP加恩扎卢胺(ENZ)、多西他赛(DOC)、唑来膦酸(ZA)和放疗(RT)比较组、并与英格兰医疗记录链接的患者。在标准治疗雄激素剥夺治疗(ADT)基础上,采用AAP、AAP加ENZ、DOC、ZA或前列腺RT进行强化治疗。MACE通过预先设定的国际疾病分类第10版及人口普查与调查办公室干预与操作分类代码来识别。灵活参数竞争风险模型估计累积发生率和亚分布风险比(SDHR)。评估SCORE2的区分度和校准度。共纳入6292名男性。ARPI强化治疗的5年累积MACE发生率在非转移性(M0)疾病中为9%,在转移性(M1)疾病中为7%,与单用ADT相当。ARPI强化治疗与MACE风险增加无统计学显著关联(AAP:M0 SDHR 1.15[95%置信区间{CI}0.80-1.67],M1 SDHR 1.36[95%CI 0.87-2.10];AAP加ENZ:M0 SDHR 1.34[95%CI 0.91-1.98],M1 SDHR 1.28[95%CI 0.85-1.94])。心血管疾病史是MACE最强的预测因素。在5076名符合SCORE2评估条件的患者中,4239名具有完整基线数据。SCORE2区分度中等(M0疾病10年曲线下面积0.63,M1疾病0.61),且绝对心血管风险被低估。局限性包括严重心血管合并症患者代表性不足。与单用ADT相比,ARPI、DOC、ZA或前列腺RT未观察到MACE有统计学显著增加。SCORE2低估了心血管风险,支持开发针对PCa的特异性心血管风险模型。
Blood IF 23.9 2026-10-06 PMID: 42837325
In this phase II trial, we evaluated the addition of the CD3xCD20 bispecific antibody, glofitamab (glofit) to polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and an international prognostic index (IPI) ³ 2. Patients received two cycles of pola-R-CHP (one cycle of R-CHOP allowed). Glofitamab was added to pola-R-CHP during cycles 3 through 6 and used as monotherapy for cycles 7 and 8. The primary objective was the best complete response (CR) rate. A total of 41 patients enrolled. The median age was 61 years (range 35-86), and 59% were male. IPI scores were 2 (39%), 3 (41%), and 4 (20%), and 86% of patients had stage III/IV disease. Most patients had DLBCL, NOS (78%) and 12% had high grade B-cell lymphoma with translocations in MYC and BCL-2 and/or BCL-6. The best CR rate was 95% (39/41) (95% CI: 83-99) and both patients with a partial response at the end of therapy converted to CR without intervention. With a median follow-up of 23.9 months, the median progression-free survival (PFS) has not been reached and the 24-month PFS was 95% (95% CI: 89-100). Four (10%) patients developed cytokine release syndrome (CRS) (all grade 1), and no immune effector cell-associated neurotoxicity syndrome (ICANS) was reported. Glofit-pola-R-CHP resulted in high rates of CR and preliminary evidence of durable responses and the schedule, with delayed incorporation of glofit, resulted in low rates of CRS and no neurotoxicity. These data support further evaluation of this regimen. NCT05800366.
中文摘要:在这项II期试验中,我们评估了将CD3xCD20双特异性抗体glofitamab(glofit)加入polatuzumab、利妥昔单抗、环磷酰胺、多柔比星和泼尼松(pola-R-CHP)方案,用于新诊断弥漫大B细胞淋巴瘤(DLBCL)且国际预后指数(IPI)≥2的患者。患者接受2个周期pola-R-CHP治疗(允许1个周期R-CHOP)。在第3至第6周期,将glofitamab加入pola-R-CHP;第7和第8周期则作为单药使用。主要目标是最佳完全缓解(CR)率。共入组41例患者。中位年龄61岁(范围35-86),59%为男性。IPI评分为2、3和4的患者分别占39%、41%和20%,86%的患者为III/IV期疾病。大多数患者为DLBCL,非特指型(78%),12%为伴有MYC和BCL-2和/或BCL-6易位的高级别B细胞淋巴瘤。最佳CR率为95%(39/41)(95% CI:83-99),且治疗结束时达到部分缓解的2例患者未经干预即转为CR。中位随访23.9个月,中位无进展生存期(PFS)尚未达到,24个月PFS率为95%(95% CI:89-100)。4例(10%)患者发生细胞因子释放综合征(CRS)(均为1级),未报告免疫效应细胞相关神经毒性综合征(ICANS)。glofit-pola-R-CHP带来了高CR率及持久缓解的初步证据,而延迟加入glofit的给药方案导致CRS发生率低且无神经毒性。这些数据支持对该方案进一步评估。NCT05800366。
Blood IF 23.9 2026-10-06 PMID: 42837320
Telomere length is a prognostic factor in chronic lymphocytic leukemia (CLL), yet its relevance under targeted therapies remains unclear. Here, we analyzed telomere length using qPCR in 917 samples from treatment-naïve CLL patients without TP53 aberrations enrolled in the GAIA/CLL13 trial comparing venetoclax-based combinations with rituximab (RV), obinutuzumab (GV), or obinutuzumab plus ibrutinib (GIV) versus chemoimmunotherapy (CIT). For CLL with TP53 aberrations, samples from 41 treatment-naïve patients receiving GIV in the CLL2-GIVe trial were analyzed. The median telomere lengths in GAIA/CLL13 and CLL2-GIVe were 4.0 kb (1.2-15.2) and 2.8 kb (1.4-14.0), respectively. A prognostic cutoff of 4.17 kb, based on GAIA/CLL13, was used for dichotomization into short and long telomeres. Within GAIA/CLL13, short telomeres significantly correlated with adverse clinical features including advanced Binet stage, high ECOG, high serum ß2-microglobulin and thymidine kinase levels, high lymphocyte count and large lymph nodes (all P<0.01). Among genetic features, short telomeres significantly associated with unmutated IGHV, del(11q), mutations in NOTCH1, SF3B1, XPO1, RPS15, EGR2 and NFKBIE, and karyotypic complexity (all P<0.01). Short telomeres were associated with shorter progression-free survival (PFS) within CIT, RV, GV, GIV in GAIA/CLL13 (all P<0.01) and in CLL2-GIVe (dichotomized by median; P=0.04), and impacted overall survival only in the CIT arm (P=0.024). Multivariable analysis suggested telomere length as an independent prognostic factor for PFS in the overall GAIA/CLL13 cohort. These findings propose telomere length as a prognostic marker for PFS in CLL patients receiving venetoclax-based first-line therapy and could be of relevance for risk stratification in the modern treatment era. NCT02950051.
中文摘要:端粒长度是慢性淋巴细胞白血病(CLL)的预后因素,但其在靶向治疗背景下的相关性仍不明确。在本研究中,我们采用qPCR分析了GAIA/CLL13试验中917份无TP53异常初治CLL患者样本的端粒长度;该试验比较了以维奈克拉为基础的联合方案与利妥昔单抗(RV)、奥妥珠单抗(GV)或奥妥珠单抗联合伊布替尼(GIV)相比化学免疫治疗(CIT)的疗效。对于伴TP53异常的CLL,我们分析了CLL2-GIVe试验中41例接受GIV治疗的初治患者样本。GAIA/CLL13和CLL2-GIVe中的中位端粒长度分别为4.0 kb(1.2-15.2)和2.8 kb(1.4-14.0)。基于GAIA/CLL13确定的4.17 kb预后截断值用于将患者分为短端粒和长端粒。在GAIA/CLL13中,短端粒与不良临床特征显著相关,包括Binet分期较晚、ECOG评分较高、血清ß2微球蛋白和胸苷激酶水平较高、淋巴细胞计数较高以及淋巴结较大(均P<0.01)。在遗传学特征方面,短端粒与IGHV未突变、del(11q)、NOTCH1、SF3B1、XPO1、RPS15、EGR2和NFKBIE突变以及核型复杂性显著相关(均P<0.01)。在GAIA/CLL13中,短端粒与CIT、RV、GV、GIV各治疗组内较短的无进展生存期(PFS)相关(均P<0.01),在CLL2-GIVe中亦如此(按中位数二分;P=0.04),并且仅对CIT组的总体生存产生影响(P=0.024)。多变量分析提示,端粒长度是总体GAIA/CLL13队列中PFS的独立预后因素。这些发现提出,端粒长度可作为接受以维奈克拉为基础一线治疗的CLL患者PFS的预后标志物,并可能对现代治疗时代的风险分层具有意义。NCT02950051。
ACS sensors IF 10.9 2026-10-06 PMID: 42837283
Serological detection of anti-Epstein-Barr virus nuclear antigen 1 immunoglobulin A (anti-EBNA1 IgA) is clinically relevant to nasopharyngeal carcinoma screening, but conventional immunoassays rely on centralized instrumentation and multistep procedures. Here, we developed a disposable origami electrochemical paper-based analytical device integrating hollow C@CuO-CeO2 nanoreactors (HCCO-ePAD) for label-free anti-EBNA1 IgA detection. HCCO was designed as a multifunctional sensing interface in which the hollow carbon framework supports charge and mass transport, Cu-containing domains provide an intrinsic cathodic redox response, and surface carboxyl functionalization enables covalent EBNA1 immobilization. Binding of anti-EBNA1 IgA to surface-bound EBNA1 formed a poorly conductive immunocomplex that restricted interfacial electron transfer, producing a concentration-dependent decrease in the differential pulse voltammetric current. Under optimized conditions, the HCCO-ePAD showed a linear response from 0.1 to 500 ng mL-1, with a detection limit of 0.029 ng mL-1, together with good selectivity, repeatability, reproducibility, and storage stability. Preliminary evaluation using serum samples from 15 patients with nasopharyngeal carcinoma and 15 healthy controls yielded an area under the receiver operating characteristic curve of 0.969 (95% confidence interval, 0.918-1.000). The HCCO-ePAD results were further compared with those obtained using a commercial enzyme-linked immunosorbent assay (ELISA). This work demonstrates an intrinsic-redox nanoreactor interface that integrates electrochemical transduction and bioreceptor immobilization within a disposable origami paper platform for decentralized serological analysis.
中文摘要:抗EB病毒核抗原1免疫球蛋白A(抗-EBNA1 IgA)的血清学检测在临床上与鼻咽癌筛查相关,但传统免疫测定依赖集中式仪器和多步操作。在此,我们开发了一种一次性折纸电化学纸基分析装置,整合了中空C@CuO-CeO2纳米反应器(HCCO-ePAD),用于无标记检测抗-EBNA1 IgA。HCCO被设计为多功能传感界面,其中中空碳骨架支持电荷与质量传输,含铜结构域提供内在的阴极氧化还原响应,表面羧基功能化可实现EBNA1的共价固定。抗-EBNA1 IgA与表面固定的EBNA1结合后形成导电性差的免疫复合物,从而限制界面电子转移,导致差分脉冲伏安电流呈浓度依赖性下降。在优化条件下,HCCO-ePAD在0.1至500 ng mL-1范围内呈线性响应,检出限为0.029 ng mL-1,并具有良好的选择性、重复性、重现性和储存稳定性。使用15例鼻咽癌患者和15例健康对照的血清样本进行初步评估,得到受试者工作特征曲线下面积为0.969(95%置信区间,0.918-1.000)。HCCO-ePAD的结果进一步与商用酶联免疫吸附测定(ELISA)所得结果进行了比较。这项工作展示了一种内在氧化还原纳米反应器界面,将电化学转导和生物受体固定整合于一次性折纸纸平台中,用于分散式血清学分析。
Circulation IF 41.3 2026-10-06 PMID: 42832625
The rapid development of novel cancer therapies has considerably improved the care of cancer patients and cancer-related survival; however, these therapies are associated with a broad range of adverse events that have become a major burden in this population. Alongside other cancer-related factors, vascular toxicity from anticancer therapies contributes to an increased risk of venous thromboembolism. Among anticancer drugs, chemotherapeutic agents (eg, anthracyclines, platinum-based drugs, antimetabolites), hormonal therapies (eg, selective estrogen receptor modulators), agents used for multiple myeloma (including immunomodulatory drugs and proteasome inhibitors), asparaginase, as well as targeted inhibitors to immune checkpoints, vascular endothelial growth factor, epidermal growth factor receptor, tyrosine kinases, cyclin-dependent kinases, and poly(ADP-ribose) polymerase are primarily associated with increased risk of venous thromboembolism. Vascular adverse events associated with anticancer drugs are frequently underestimated, and significant gaps remain in the risk stratification, prevention, and management of thromboembolic events in patients receiving systemic anticancer therapies. This review examines the evidence linking anticancer drug exposure to the incidence of venous thromboembolism, summarizes the key underlying pathobiological mechanisms, and highlights current guideline recommendations for the prevention and treatment of cancer-associated thrombosis. Arterial thrombotic events are also discussed where clinically or mechanistically relevant. This review also offers advanced cardio-oncology perspectives on the identification, risk stratification, and therapeutic targeting of drug-induced vascular toxicity.
中文摘要:新型癌症疗法的快速发展显著改善了癌症患者的诊疗和癌症相关生存;然而,这些疗法与广泛的不良事件相关,这些不良事件已成为该人群的主要负担。除其他癌症相关因素外,抗肿瘤治疗引起的血管毒性也导致静脉血栓栓塞风险增加。在抗肿瘤药物中,化疗药物(如蒽环类药物、铂类药物、抗代谢药)、激素治疗(如选择性雌激素受体调节剂)、用于多发性骨髓瘤的药物(包括免疫调节药物和蛋白酶体抑制剂)、天冬酰胺酶,以及针对免疫检查点、血管内皮生长因子、表皮生长因子受体、酪氨酸激酶、细胞周期蛋白依赖性激酶和聚(ADP-核糖)聚合酶的靶向抑制剂,主要与静脉血栓栓塞风险增加相关。与抗肿瘤药物相关的血管不良事件常被低估,而且在接受全身抗肿瘤治疗的患者中,血栓栓塞事件的风险分层、预防和管理仍存在显著缺口。本综述探讨了抗肿瘤药物暴露与静脉血栓栓塞发生率相关的证据,总结了关键潜在病理生物学机制,并强调了当前指南关于癌症相关血栓预防和治疗的建议。在具有临床或机制相关性的情况下,也讨论了动脉血栓事件。本综述还提供了前沿心脏肿瘤学视角,涉及药物诱导血管毒性的识别、风险分层和治疗靶向。
Blood IF 23.9 2026-10-05 PMID: 42832426
B-cell receptor (BCR) inhibitors have transformed chronic lymphocytic leukemia (CLL) therapy, yet many patients show incomplete responses or develop resistance in the absence of Bruton's tyrosine kinase (BTK) mutations. We investigated Toll-like receptor 9 (TLR9) signaling as a tumor-response mechanism to BCR blockade. Using 102 TLR9-stimulated patient samples, we identified two distinct migratory phenotypes: TLR9-induced migratory Responders (R), with enhanced migration, and TLR9-induced migratory Reverse-Responders (RR), with suppression of migration following TLR9 activation. Transcriptomic and protein analyses showed TLR9-stimulated R samples expressed higher IRAK4/IRAK1 and induced NF-kB p100, consistent with intact TLR9 signaling. In contrast, RR samples exhibited elevated basal BCR activity, and lower IRAK4/IRAK1 with rapid IRAK1 degradation, indicating suppressed TLR9 signaling. In-silico modeling and biochemical validation showed high basal BCR signaling suppresses TLR9 responsiveness, whereas low basal activity permits full TLR9 activation. Functionally, TLR9-induced migration persisted despite BTK inhibition (BTKi) in R but not RR samples, and was abrogated by TLR9 antagonism, consistent with signaling through a BTK-independent pathway in the R subgroup. CLL cells from BTKi-resistant patients expressed higher TLR9 and matched pre- and post-relapse samples showed decreased BCR and increased TLR-associated NF-kB signaling post-relapse. Clinically, in small exploratory.
中文摘要:B细胞受体(BCR)抑制剂已改变慢性淋巴细胞白血病(CLL)的治疗,但许多患者在没有Bruton酪氨酸激酶(BTK)突变的情况下表现出不完全缓解或产生耐药。我们研究了Toll样受体9(TLR9)信号作为BCR阻断的肿瘤反应机制。使用102例TLR9刺激的患者样本,我们识别出两种不同的迁移表型:TLR9诱导迁移应答者(R),其迁移增强;以及TLR9诱导迁移反向应答者(RR),其在TLR9激活后迁移受抑制。转录组和蛋白质分析显示,TLR9刺激的R样本表达较高的IRAK4/IRAK1并诱导NF-kB p100,与完整的TLR9信号一致。相比之下,RR样本表现出升高的基础BCR活性,以及较低的IRAK4/IRAK1并伴IRAK1快速降解,表明TLR9信号受抑制。计算机建模和生化验证显示,高基础BCR信号抑制TLR9反应性,而低基础活性允许完全的TLR9激活。在功能上,TLR9诱导的迁移在R样本中尽管存在BTK抑制(BTKi)仍持续存在,但在RR样本中并非如此,并可被TLR9拮抗作用消除,这与R亚组中通过不依赖BTK的通路进行信号传导一致。来自BTKi耐药患者的CLL细胞表达较高的TLR9,配对的复发前和复发后样本显示复发后BCR降低、TLR相关NF-kB信号增加。临床上,在小型探索性。
Blood IF 23.9 2026-10-05 PMID: 42832423
Older or medically unfit patients with diffuse large B-cell lymphoma (DLBCL) frequently cannot tolerate standard anthracycline-based immunochemotherapy, creating a persistent unmet clinical need. We conducted a multicenter, international, open-label phase I/II trial evaluating an immunotherapy-based first-line approach using subcutaneous mosunetuzumab in combination with polatuzumab vedotin in previously untreated patients classified as unfit or frail by simplified geriatric assessment (sGA). Participants received six cycles of polatuzumab vedotin with step-up-dosing of subcutaneous mosunetuzumab, followed by mosunetuzumab monotherapy for a planned total of eight cycles. The primary endpoint was objective response rate (ORR) at end of treatment, assessed by independent review using PET-CT Lugano 2014 criteria. Among participants treated at full dose (n=101), the median age was 81 years with 58% classified as unfit and 41% as frail by sGA. The ORR at the end of treatment was 61.4% (95% CI, 51.1-70.9), with a complete response (CR) rate of 56.4%. The best observed ORR and CR rates on therapy were 80.2% and 66.3%, respectively. With a median follow-up of 36.5 months, median investigator-assessed duration of response and overall survival were not reached; estimated 2-year progression-free and overall survival were 52.2% and 62.4%, respectively. Cytokine release syndrome occurred in 30.6% of participants and was predominantly grade 1. Infection-related mortality was observed, largely during the COVID-19 pandemic and among participants classified as frail. This geriatric assessment-guided treatment demonstrated durable efficacy and may represent a potential first-line treatment option for carefully selected unfit or frail patients with newly diagnosed DLBCL. Trial registration: #NCT03677154.
中文摘要:年龄较大或医学上不适合的弥漫性大B细胞淋巴瘤(DLBCL)患者常无法耐受标准含蒽环类药物的免疫化疗,这造成了持续存在的未满足临床需求。我们开展了一项多中心、国际、开放标签的I/II期试验,评估一种以免疫治疗为基础的一线方案,即皮下注射mosunetuzumab联合polatuzumab vedotin,用于既往未治疗且经简化老年评估(sGA)判定为不适合或衰弱的患者。参与者接受6个周期polatuzumab vedotin联合皮下注射mosunetuzumab递增剂量给药,随后接受mosunetuzumab单药治疗,计划总共8个周期。主要终点为治疗结束时的客观缓解率(ORR),由独立评审采用PET-CT Lugano 2014标准评估。在接受全剂量治疗的参与者(n=101)中,中位年龄为81岁,58%经sGA判定为不适合,41%为衰弱。治疗结束时的ORR为61.4%(95% CI,51.1-70.9),完全缓解(CR)率为56.4%。治疗期间观察到的最佳ORR和CR率分别为80.2%和66.3%。中位随访36.5个月时,研究者评估的中位缓解持续时间和总生存期均未达到;估计2年无进展生存率和总生存率分别为52.2%和62.4%。30.6%的参与者发生细胞因子释放综合征,且主要为1级。观察到感染相关死亡,主要发生在COVID-19大流行期间以及被判定为衰弱的参与者中。这种以老年评估为指导的治疗显示出持久疗效,可能成为经过仔细筛选的新诊断DLBCL不适合或衰弱患者的一种潜在一线治疗选择。试验注册号:#NCT03677154。
Blood IF 23.9 2026-10-05 PMID: 42832420
TP53 loss-of-function (TP53-LoF) remains the single most important prognostic factor in chronic lymphocytic leukemia (CLL). Comprehensive assessment for TP53-LoF requires testing for both gene deletion and mutation. Historically, patients with TP53-LoF CLL have had poor outcomes and experienced short survival when treated with chemoimmunotherapy. In the novel agent era, multiple studies have demonstrated the effectiveness of continuous covalent BTK inhibitor (cBTKi) therapy, especially in the frontline setting, with a median progression-free survival (PFS) of approximately 7 years. Continuous cBTKi is therefore the de-facto standard for current management of TP53-LoF CLL. In contrast, fixed-duration regimens combining venetoclax with either obinutuzumab or cBTKi have shown slower response kinetics with longer time to undetectable minimal residual disease (uMRD) status, and reduced PFS, in patients with TP53-LoF CLL. Although early data from fixed-duration regimen studies indicate that most patients respond to retreatment, specific data for the TP53-LoF subset have not been reported. Therefore, the application of fixed-duration regimens for treatment of TP53-LoF CLL requires careful deliberation on the risks vs benefits of long-term cBTKi therapy, and acceptance of the uncertainty around the lack of granular retreatment outcomes. Multiple fixed-duration studies have shown that uMRD is a key endpoint in patients with TP53-LoF CLL. In this respect, clinical trials examining consolidation strategies in patients with detectable MRD, or in those with high-risk genomics, may be especially impactful in patients with TP53-LoF CLL.
中文摘要:TP53功能缺失(TP53-LoF)仍然是慢性淋巴细胞白血病(CLL)中最重要的单一预后因素。对TP53-LoF的全面评估需要同时检测基因缺失和突变。历史上,TP53-LoF的CLL患者接受化学免疫治疗后结局不佳,生存期较短。在新药时代,多项研究已证实持续共价BTK抑制剂(cBTKi)治疗的有效性,尤其是在一线治疗中,中位无进展生存期(PFS)约为7年。因此,持续cBTKi治疗是当前TP53-LoF CLL管理的事实标准。相比之下,维奈克拉联合奥妥珠单抗或cBTKi的固定疗程方案在TP53-LoF CLL患者中显示出较慢的缓解动力学、达到不可检测微小残留病(uMRD)状态的时间更长,以及PFS缩短。尽管固定疗程方案研究的早期数据表明大多数患者对再治疗有反应,但尚未报告TP53-LoF亚组的特异性数据。因此,将固定疗程方案用于TP53-LoF CLL的治疗,需要仔细权衡长期cBTKi治疗的风险与获益,并接受缺乏细致再治疗结局数据所带来的不确定性。多项固定疗程研究显示,uMRD是TP53-LoF CLL患者的关键终点。在这方面,探讨可检测MRD患者或高危基因组患者中巩固策略的临床试验,可能对TP53-LoF CLL患者尤为重要。
Blood IF 23.9 2026-10-05 PMID: 42832396
The bispecific CD19/CD3 T-cell engaging antibody blinatumomab is efficacious in front-line therapy in B-cell acute lymphoblastic leukemia (B-ALL) but the biological determinants of response and resistance are incompletely understood. To examine the genomic determinants of outcome, we analyzed genomic and clinical data of 569 adults registered to the ECOG-ACRIN E1910 study of blinatumomab in BCR::ABL1-negative B-ALL (ClinicalTrials.gov NCT02003222). We identified 23 molecular subtypes including the high-risk subtypes BCR::ABL1 (20%), BCR::ABL1-like (18%), low hypodiploid (14%) and KMT2A-R (12%), and 267 putative driver genes. We identified a subtype characterized by CEBPA overexpression or elevated CEBPB expression due to chromosomal translocation-mediated enhancer hijacking, or insertions downstream of CEBPA that generate neoenhancers. Attainment of MRD-negativity patients after induction and intensification chemotherapy was more common in PAX5alt, TCF3::PBX1 and ZNF384-R B-ALL, and less common in BCR::ABL1-like and KMT2A-R B-ALL. Integration of genomic and clinical data suggested that the addition of blinatumomab to chemotherapy was associated with improved relapse-free and overall survival for several B-ALL subtypes, including hyperdiploid, PAX5alt, PAX5 P80R, BCR::ABL1-like JAK-STAT and KMT2A-R B-ALL, although small sample sizes for several subtypes indicate that confirmation is required. Alteration of TP53 or mutations associated with myeloid clonal hematopoiesis of indeterminate potential (CHIP) were identified in 15.3% and 9.8% of patients, respectively. The presence of these mutations was associated with older age at diagnosis and inferior outcome to chemotherapy. In summary, we define the landscape of genomic alterations of adult B-ALL, and identify genomic subtypes that may influence the efficacy of blinatumomab when combined with chemotherapy.
中文摘要:双特异性CD19/CD3 T细胞衔接抗体贝林妥欧单抗在B细胞急性淋巴细胞白血病(B-ALL)一线治疗中有效,但其应答和耐药的生物学决定因素尚未完全明确。为探讨结局的基因组决定因素,我们分析了569例注册于ECOG-ACRIN E1910研究的成人患者的基因组和临床数据,该研究评估贝林妥欧单抗在BCR::ABL1阴性B-ALL中的应用(ClinicalTrials.gov NCT02003222)。我们识别出23种分子亚型,包括高危亚型BCR::ABL1(20%)、BCR::ABL1样(18%)、低亚二倍体(14%)和KMT2A-R(12%),以及267个推定驱动基因。我们识别出一种以CEBPA过表达或CEBPB表达升高为特征的亚型,后者由染色体易位介导的增强子劫持所致,或由CEBPA下游插入产生新增强子所致。诱导和强化化疗后达到MRD阴性的患者在PAX5alt、TCF3::PBX1和ZNF384-R B-ALL中更常见,而在BCR::ABL1样和KMT2A-R B-ALL中较少见。整合基因组和临床数据提示,在化疗基础上加用贝林妥欧单抗与多种B-ALL亚型的无复发生存和总生存改善相关,包括高超二倍体、PAX5alt、PAX5 P80R、BCR::ABL1样JAK-STAT和KMT2A-R B-ALL,不过部分亚型样本量较小,提示仍需验证。分别有15.3%和9.8%的患者发现TP53改变或与意义未明的髓系克隆性造血(CHIP)相关的突变。这些突变的存在与诊断时年龄较大以及化疗结局较差相关。总之,我们描绘了成人B-ALL的基因组改变图谱,并识别出可能影响贝林妥欧单抗联合化疗疗效的基因组亚型。
Blood IF 23.9 2026-10-05 PMID: 42832394
The immune tumor microenvironment (iTME) plays a crucial role in disease biology of plasma cell (PC) dyscrasias, but remains poorly characterized in self-identified Black individuals, a population at increased risk. Mass cytometry and scRNA-seq of 128 bone marrow aspirates revealed significant changes in immune cell composition across the disease spectrum, including shifts from naïve to effector T cells with declines in B cells, MAIT, pDCs, and increases in monocytes with disease progression. Self-identified Black patients had higher relative proportions of terminally differentiated T cells and lower monocytes in newly diagnosed and treated multiple myeloma (MM). ScRNA-seq revealed genes overexpressed in self-identified Black individuals were enriched for E2F targets and G2-M checkpoints, while reduced genes were enriched for TNF-α/NF-kB, interferon and inflammatory responses pathways. These findings were supported by genetic ancestry and validated in an independent dataset of 286 patients with MM from the MMRF Immune Atlas. Self-identified race and African genetic similarity are significantly associated with remodeling the MM iTME, with potential implications for disease biology and treatment response.
中文摘要:免疫肿瘤微环境(iTME)在浆细胞(PC)疾病生物学中发挥关键作用,但在自我认同为黑人的个体这一风险升高人群中仍缺乏充分刻画。对128份骨髓穿刺样本进行质谱流式和单细胞RNA测序,揭示了疾病谱中免疫细胞组成的显著变化,包括从初始T细胞向效应T细胞的转变,随着疾病进展B细胞、MAIT细胞和pDCs减少,而单核细胞增加。在新诊断和接受治疗的多发性骨髓瘤(MM)中,自我认同为黑人的患者具有更高比例的终末分化T细胞和更低的单核细胞。单细胞RNA测序显示,在自我认同为黑人的个体中过表达的基因富集于E2F靶点和G2-M检查点,而表达降低的基因富集于TNF-α/NF-kB、干扰素和炎症反应通路。这些发现得到遗传祖先背景的支持,并在MMRF免疫图谱中286例MM患者的独立数据集中得到验证。自我认同的种族和非洲遗传相似性与MM iTME重塑显著相关,可能对疾病生物学和治疗反应具有影响。
Blood IF 23.9 2026-10-05 PMID: 42832384
The bone marrow immune microenvironment (BMME) is a critical factor in multiple myeloma (MM) pathogenesis. Despite higher incidence of MM among self-identified African Americans, the relationship between African genetic similarity and the BMME remains unclear. We present the largest analysis to date assessing the impact of Ancestry on the BMME in myeloma (N=320, including 64 with ≥50% African genetic similarity, AFR-High) leveraging our recently generated Immune Atlas. AFR-High was associated with enrichment of late T-effector cells, driven by rare cytotoxic CD4⁺ T cells, suggesting a distinct adaptive BMME. AFR-High exhibited expansion of late-differentiated adaptive NK cells with high cytotoxic GNLY and GZMH expression. AFR-High depicted reduced CD14⁺ monocytes, increased CD16⁺ non-classical monocytes, and expansion of macrophage-like monocyte populations with enrichment of metabolic adaptation, efferocytosis and phagocytic clearance programs, and immunoregulatory pathways. These findings reveal a shift from an innate inflammatory immune landscape toward adaptive cytotoxic and immunoregulatory remodeling associated with African genetic similarity in MM.
中文摘要:骨髓免疫微环境(BMME)是多发性骨髓瘤(MM)发病机制中的关键因素。尽管自我认同为非裔美国人的MM发病率更高,但非洲遗传相似性与BMME之间的关系仍不清楚。我们利用近期构建的免疫图谱,开展了迄今规模最大的分析,评估祖先背景对骨髓瘤BMME的影响(N=320,其中64例非洲遗传相似性≥50%,即AFR-High)。AFR-High与晚期T效应细胞富集相关,该富集由罕见的细胞毒性CD4⁺ T细胞驱动,提示存在独特的适应性BMME。AFR-High表现为晚期分化的适应性NK细胞扩增,且高表达细胞毒性GNLY和GZMH。AFR-High显示CD14⁺单核细胞减少、CD16⁺非经典单核细胞增加,以及巨噬细胞样单核细胞群体扩增,并富集代谢适应、胞葬作用和吞噬清除程序以及免疫调节通路。这些发现揭示了在MM中,非洲遗传相似性相关的免疫格局从固有炎症性免疫向适应性细胞毒性和免疫调节性重塑转变。
Advanced healthcare materials IF 11.0 2026-10-04 PMID: 42830423
Fibroblast activation protein (FAP) is a promising pan-tumor target for theranostics, but current FAP-targeted radioligands are limited by insufficient tumor retention and suboptimal therapeutic doses. To address these challenges, we developed a novel LARM platform and synthesized the FAPI dimer TH2103-100. The radiochemical labeling efficiency of TH2103-100 with 68Ga was nearly 100% at room temperature (radio-TLC), significantly surpassing that of FAPI-04 (35.28% at room temperature and 79% at 95°C). The radiochemical purity of 68Ga-TH2103-100 was >97%. In vitro experiments demonstrated that 68Ga-TH2103-100 exhibited superior cellular uptake and enhanced binding affinity. In vivo experiments showed that, compared with FAPI-04, tumor uptake was increased by 3.9-fold with prolonged retention and no significant toxicity. In healthy volunteers, the effective dose was 3.69E-02 mSv/MBq. Preliminary clinical studies showed that 68Ga-TH2103-100 exhibited promising diagnostic performance compared to 18F-FDG. The LARM-based 68Ga-TH2103-100 enables efficient room-temperature labeling and superior tumor targeting, providing complementary diagnostic value for cases with inconclusive 18F-FDG PET/CT findings and offering a new paradigm for next-generation FAP-targeted molecular imaging agents, while its potential as an adjunct to 18F-FDG warrants further validation.
中文摘要:成纤维细胞激活蛋白(FAP)是一种有前景的泛肿瘤诊疗靶点,但现有的FAP靶向放射性配体受限于肿瘤滞留不足和治疗剂量不理想。为应对这些挑战,我们开发了一种新型LARM平台,并合成了FAPI二聚体TH2103-100。TH2103-100与68Ga的放射性化学标记效率在室温下接近100%(放射性薄层色谱),显著优于FAPI-04(室温下为35.28%,95°C下为79%)。68Ga-TH2103-100的放射性化学纯度大于97%。体外实验表明,68Ga-TH2103-100表现出更优的细胞摄取和增强的结合亲和力。体内实验显示,与FAPI-04相比,其肿瘤摄取增加3.9倍,滞留延长,且无明显毒性。在健康志愿者中,有效剂量为3.69E-02 mSv/MBq。初步临床研究显示,与18F-FDG相比,68Ga-TH2103-100表现出有前景的诊断性能。基于LARM的68Ga-TH2103-100可实现高效的室温标记和更优的肿瘤靶向,为18F-FDG PET/CT结果不确定的病例提供补充诊断价值,并为下一代FAP靶向分子影像剂提供了新范式,而其作为18F-FDG辅助手段的潜力仍需进一步验证。
MedComm IF 14.1 2026-10 PMID: 42827632
Single-agent targeted therapies for relapsed or refractory peripheral T-cell lymphoma (R/R peripheral T-cell lymphoma [PTCL]) produce modest, short-lived responses, underscoring the need for tolerable, chemotherapy-free combinations. In an open-label, single-arm Phase Ib trial at two tertiary hospitals, we evaluated parsaclisib plus chidamide with step-down maintenance. Adults with R/R PTCL received parsaclisib 10-20 mg once daily plus chidamide 20 mg twice weekly for 8 weeks using 3+3 escalation; patients without progression or unacceptable toxicity continued parsaclisib 2.5 mg once daily plus chidamide 20 mg twice weekly. Primary endpoints were Cycle 1 dose-limiting toxicities (DLTs), treatment-related adverse events, and recommended Phase II dose; antitumor activity and biomarker correlates were exploratory. Twelve screened patients were enrolled and treated. One Grade 3 hepatotoxicity DLT occurred; no maximum tolerated dose was reached; parsaclisib 20 mg once daily plus chidamide 20 mg twice weekly was selected for Phase II. No Grade 4 treatment-related events or treatment-related deaths occurred. Objective and complete response rates were 58% (95% CI, 28-85) and 42% (95% CI, 15-72). With 26.8 months' median follow-up, 2-year progression-free and overall survival rates were 33.3 and 66.7%. Exploratory analyses suggested TET2 alterations and natural killer-cell expansion as correlates of durable remission. This regimen warrants prospective validation (ClinicalTrials.gov: NCT05083208).
中文摘要:复发或难治性外周T细胞淋巴瘤(R/R PTCL)的单药靶向治疗疗效有限且缓解持续时间短,凸显了对可耐受、无化疗联合方案的需求。在一项于两家三级医院开展的开标签、单臂Ib期试验中,我们评估了帕萨利布联合西达本胺并采用阶梯减量维持治疗的方案。成人R/R PTCL患者接受帕萨利布10–20 mg每日一次联合西达本胺20 mg每周两次,持续8周,采用3+3剂量递增;未出现疾病进展或不可接受毒性的患者继续接受帕萨利布2.5 mg每日一次联合西达本胺20 mg每周两次。主要终点为第1周期剂量限制性毒性、治疗相关不良事件和推荐的II期剂量;抗肿瘤活性和生物标志物相关性为探索性终点。共筛查12例患者并入组接受治疗。发生1例3级肝毒性剂量限制性毒性;未达到最大耐受剂量;选择帕萨利布20 mg每日一次联合西达本胺20 mg每周两次作为II期剂量。未发生4级治疗相关事件或治疗相关死亡。客观缓解率和完全缓解率分别为58%(95% CI,28–85)和42%(95% CI,15–72)。中位随访26.8个月时,2年无进展生存率和总生存率分别为33.3%和66.7%。探索性分析提示TET2改变和自然杀伤细胞扩增与持久缓解相关。该方案值得前瞻性验证(ClinicalTrials.gov:NCT05083208)。
Nature medicine IF 52.5 2026-10-02 PMID: 42827132
Urine biomarkers promise to improve noninvasive detection and molecular characterization of genitourinary malignancies. Here we describe urine random priming and affinity capture of cell-free RNA (cfRNA) fragments for enrichment analysis by sequencing (uRARE-seq), a liquid biopsy method for urine cfRNA profiling, and apply it to 683 urine samples from patients with cancer and controls. Urine cfRNA contained transcripts from genitourinary tissues and, in patients with prostate, kidney or bladder cancer, tumor-derived transcripts. uRARE-seq demonstrated 95% sensitivity at 90% specificity for detecting localized bladder cancer. The method outperformed urine tumor DNA analysis and was unaffected by the presence of field-effect mutations. Urine cfRNA analysis also sensitively detected minimal residual disease and distinguished complete molecular responses after surgery from those after intravesical Bacillus Calmette-Guérin (BCG). Pretreatment urine from complete responders to BCG was enriched for T cell and other immune signatures, suggesting a preexisting antitumor immune response, whereas nonresponders showed higher expression of proliferation-related genes. In pretreatment urine from 114 patients, this biological difference enabled development of a biomarker predicting likelihood of response to BCG versus chemotherapy (area under the curve 0.93) that was strongly associated with risk of recurrence. Urine cfRNA analysis is therefore a promising biomarker approach for bladder cancer and potentially other urologic malignancies, although prospective studies are needed to assess its clinical utility.
中文摘要:尿液生物标志物有望改善泌尿生殖系统恶性肿瘤的无创检测和分子特征描述。在此,我们描述了尿液随机引物和亲和捕获游离RNA(cfRNA)片段并通过测序进行富集分析(uRARE-seq),这是一种用于尿液cfRNA谱分析的液体活检方法,并将其应用于来自癌症患者和对照的683份尿液样本。尿液cfRNA包含来自泌尿生殖组织的转录本,并且在前列腺癌、肾癌或膀胱癌患者中,还包含肿瘤来源的转录本。uRARE-seq在检测局限性膀胱癌时显示出95%的敏感性(90%特异性)。该方法优于尿液肿瘤DNA分析,并且不受场效应突变存在的影响。尿液cfRNA分析还能灵敏地检测微小残留病,并区分手术后与膀胱内卡介苗(BCG)后的完全分子缓解。对BCG完全缓解者的治疗前尿液富集T细胞及其他免疫特征,提示存在预先存在的抗肿瘤免疫反应,而无缓解者则显示增殖相关基因表达更高。在114例患者的治疗前尿液中,这一生物学差异使得开发一种生物标志物成为可能,用于预测对BCG与化疗产生应答的可能性(曲线下面积0.93),且该标志物与复发风险强烈相关。因此,尿液cfRNA分析是一种有前景的膀胱癌及可能其他泌尿系统恶性肿瘤的生物标志物方法,不过仍需前瞻性研究评估其临床效用。
Cancer letters IF 11.8 2026-10-02 PMID: 42826832
CD19 CAR-T has achieved high remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, rapid generation with durable in vivo persistence remains a major challenge. CD45RA-negative T cells exhibit sustained antileukemic activity and preserved immune memory. Here, we developed a rapid protocol (InstanCAR-T) enriched for CD45RA-negative T cells, and systematically compared it with conventional CAR-T across in vitro functional assays, murine B-ALL xenograft models, and a Phase I clinical trial. InstanCAR-T shortened ex vivo culture to 3 days while enriching CD45RA-negative subsets, demonstrating enhanced viability, proliferation, and cytotoxicity in vitro. In vivo, InstanCAR-T achieved durable tumor control with improved expansion and long-term persistence. Clinically, high-dimensional immune profiling revealed sustained stemness, reduced exhaustion, and stable phenotypic differentiation of InstanCAR-T cells. Moreover, InstanCAR-T was well tolerated and achieved comparable overall response rates, with a numerically higher proportion of minimal residual disease-negative remission compared with ConvenCAR-T. In conclusion, InstanCAR-T enriched for CD45RA-negative T cells represents a rapid and effective CAR-T strategy with sustained proliferative capacity and superior in vivo persistence. Integrated high-dimensional profiling further highlights its enhanced immunological fitness, supporting its potential to improve clinical outcomes in B-ALL. TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov as (NCT05309213) and (NCT06209671).
中文摘要:CD19 CAR-T在复发/难治性B细胞急性淋巴细胞白血病(B-ALL)中已取得高缓解率。然而,快速制备并具有持久体内存续仍是一项重大挑战。CD45RA阴性T细胞表现出持续的抗白血病活性和保留的免疫记忆。在本研究中,我们开发了一种富集CD45RA阴性T细胞的快速方案(InstanCAR-T),并在体外功能实验、小鼠B-ALL异种移植模型和一项I期临床试验中将其与传统CAR-T进行了系统比较。InstanCAR-T将体外培养缩短至3天,同时富集CD45RA阴性亚群,在体外显示出增强的活力、增殖和细胞毒性。在体内,InstanCAR-T实现了持久的肿瘤控制,并改善了扩增和长期存续。在临床方面,高维免疫分析显示InstanCAR-T细胞具有持续的干性、减少的耗竭和稳定的表型分化。此外,InstanCAR-T耐受性良好,并取得了与ConvenCAR-T相当的总体缓解率,且微小残留病阴性缓解比例在数值上更高。总之,富集CD45RA阴性T细胞的InstanCAR-T代表了一种快速有效的CAR-T策略,具有持续的增殖能力和更优的体内存续。整合高维分析进一步凸显了其增强的免疫适应度,支持其改善B-ALL临床结局的潜力。试验注册:该试验已在www.clinicaltrials.gov注册,注册号为(NCT05309213)和(NCT06209671)。
Blood IF 23.9 2026-10-02 PMID: 42826158
The Precision-T phase 3 trial is the first randomized, multicenter demonstration that a centrally manufactured defined allograft is effective markedly reducing moderate-to-severe chronic GVHD and non-relapse mortality without loss of graft versus leukemia or graft failure and infection. The engineered graft appears to instruct immune reconstitution toward a regulated, tolerance-associated state, giving the product a mechanism for further studies. The question is how far we can further program it.
中文摘要:Precision-T 3期试验是首个随机、多中心论证,表明一种中心化生产的特定同种移植物可有效显著减少中重度慢性移植物抗宿主病和非复发死亡,同时不丧失移植物抗白血病效应,也不增加移植失败和感染。该工程化移植物似乎引导免疫重建朝向受调控、与耐受相关的状态,从而为该产品提供了进一步研究的机制。问题在于我们还能将其编程到何种程度。
Cancer research IF 22.6 2026-10-02 PMID: 42825518
T cells initiate anticancer immune responses at an early stage of tumorigenesis, thus enabling dynamic monitoring of peripheral blood T-cell receptor (TCR) repertoire changes as a promising strategy for early cancer detection. However, current TCR-based cancer detection methods focus on limited high-frequency TCRs instead of repertoire-scale representation, overlooking numerous crucial cancer-associated TCRs (caTCRs). Herein, we developed ScanTCR, a computational framework for early cancer detection that introduces a reference-guided repertoire-scale encoding method capable of incorporating all TCRs. ScanTCR exhibited remarkable precision in distinguishing cancer patients from non-cancer individuals using peripheral blood TCR. In a pan-cancer analysis encompassing seven cancer types, ScanTCR demonstrated robust performance in detecting both cancer types included in the training data and unseen cancer types, surpassing state-of-the-art TCR-based methods. Furthermore, ScanTCR identified caTCRs whose corresponding T cells exhibit enhanced cellular immune capacity. Collectively, this work proposes a TCR-based approach enabling repertoire-scale representation of immune receptors for noninvasive early cancer detection.
中文摘要:T细胞在肿瘤发生早期即启动抗癌免疫应答,因此动态监测外周血T细胞受体(TCR)谱变化有望成为癌症早期检测的策略。然而,当前基于TCR的癌症检测方法主要关注有限的高频TCR,而非在免疫组库尺度上进行表征,从而忽略了众多关键的癌症相关TCR(caTCR)。在此,我们开发了ScanTCR,这是一种用于早期癌症检测的计算框架,其引入参考引导的免疫组库尺度编码方法,能够纳入所有TCR。ScanTCR利用外周血TCR在区分癌症患者与非癌症个体方面表现出显著精确性。在一项涵盖七种癌症类型的泛癌分析中,ScanTCR在检测训练数据中包含的癌症类型以及未见癌症类型时均表现出稳健性能,优于当前最先进的基于TCR的方法。此外,ScanTCR识别出相应T细胞具有增强细胞免疫能力的caTCR。总体而言,这项工作提出了一种基于TCR的方法,可实现免疫受体的免疫组库尺度表征,用于无创早期癌症检测。
Journal of extracellular vesicles IF 21.7 2026-10 PMID: 42844644
Lethal prostate cancer (PCa) is dominated by treatment-refractory progression in bone. In this study, we used plasma-derived extracellular vesicles (EVs) for monitoring the tumour and therapy-induced changes in the bone tumour microenvironment (bone-TME) in men with bone metastatic PCa (M1b PCa). Transcriptome analysis of differentially expressed genes in plasma EVs from patients with M1b and localized (M0) PCa, identified a 'bone metastasis signature' (BMS) that reflects tumour-induced bone formation. In preclinical studies, the BMS was enriched in plasma EVs from mice inoculated with bone-metastatic MDA PCa-118b but not with adrenal-metastatic MDA PCa-250 tumours. Longitudinal monitoring of the BMS for up to 50 days showed that the levels of several genes increased prior to detectable growth of bone-forming tumours. Real-time monitoring of the BMS from tumour-bearing mice treated with the bone-targeting agent Ra-223 showed reduction of their expression that correlated with reduction in bone formation and tumour growth. Development of resistance to Ra-223 correlated with the induction of the BMS genes. In a cohort of PCa patients with clinically localized PCa with pathologic lymph node involvement, increases in BMS genes following hormonal therapy correlated with the subsequent development of metastasis during long term follow up. The BMS may enable longitudinal monitoring of the initiation, progression and treatment response of M1b PCa.
中文摘要:致死性前列腺癌(PCa)主要表现为骨内难治性进展。在本研究中,我们使用血浆来源的细胞外囊泡(EVs)来监测骨转移性PCa(M1b PCa)男性患者骨肿瘤微环境(bone-TME)中肿瘤及治疗诱导的变化。对M1b和局限性(M0)PCa患者血浆EVs中差异表达基因的转录组分析,鉴定出一个反映肿瘤诱导骨形成的「骨转移特征」(BMS)。在临床前研究中,BMS在接种骨转移性MDA PCa-118b而非肾上腺转移性MDA PCa-250肿瘤的小鼠血浆EVs中富集。对BMS长达50天的纵向监测显示,若干基因的水平在可检测到的成骨性肿瘤生长之前就已升高。对接受骨靶向药物Ra-223治疗的荷瘤小鼠进行BMS实时监测,显示其表达降低,且与骨形成和肿瘤生长的减少相关。对Ra-223耐药性的产生与BMS基因的诱导相关。在一组临床局限性PCa伴病理性淋巴结受累的患者队列中,激素治疗后BMS基因的升高与长期随访期间随后发生的转移相关。BMS可能有助于对M1b PCa的起始、进展和治疗反应进行纵向监测。
JAMA network open IF 11.7 2026-10-01 PMID: 42837151
Postoperative opioid overprescription contributes to the opioid epidemic. To expand and validate a gynecologic oncology-developed postoperative opioid use prediction calculator in a diverse surgical population and evaluate whether it could be modified for preoperative prescribing. This prognostic study in a quaternary health system used patient preoperative surveys and postoperative assessments to measure opioid use and pain scores from November 1, 2023, to November 1, 2024, with follow-up up to 6 weeks. Patients aged 18 years or older who underwent gynecologic surgery were eligible; those undergoing only minor procedures were excluded. Data were analyzed from January 15, 2025, through July 27, 2026. The original 7-predictor model was externally validated. The prespecified updated proportional odds model included anticipated pain medication use, restricted cubic splines for age (3 knots) and anticipated operating time (5 knots), education, smoking, and anxiety. A total of 71 imputation-specific models were fitted. The outcome variable was the number of pills used. Validation methods included model discrimination and calibration. Of 884 identified patients, 870 were eligible, 835 underwent surgery, and 616 had complete opioid use outcome data (median [IQR] age, 48 [39-65] years). The median number of pills used was 2 (IQR, 0-7 pills), and 226 patients (36.7%) used no pills. For the original model, threshold-specific C statistics were 0.70 (95% CI, 0.66-0.74), 0.72 (95% CI, 0.68-0.76), and 0.74 (95% CI, 0.70-0.78) for use of at least 2, 5, and 10 pills, respectively. Calibration intercepts were -0.11 (95% CI, -0.30 to 0.08), -0.35 (95% CI, -0.54 to -0.17), and -0.51 (95% CI, -0.71 to -0.31), respectively, indicating overpredicted use at the higher thresholds of pill use. For the updated model, optimism-corrected C statistics were 0.71 (95% CI, 0.66-0.74), 0.73 (95% CI, 0.68-0.76), and 0.73 (95% CI, 0.67-0.77); calibration intercepts were -0.05 (95% CI, -0.09 to -0.01), -0.04 (95% CI, -0.08 to 0.002), and -0.03 (95% CI, -0.07 to 0.01); and calibration slopes were 0.93 (95% CI, 0.80-1.02), 1.06 (95% CI, 0.89-1.19), and 1.15 (95% CI, 0.85-1.37) for at least 2, 5, and 10 pills, respectively. This prognostic study of patients who underwent major gynecologic surgery found that the original calculator showed moderate threshold-specific discrimination but overpredicted opioid use at the higher thresholds of pill use. The updated model showed moderate discrimination after internal validation, with calibration intercepts near 0 and slopes ranging from 0.93 to 1.15. External institutional validation is needed. Individualized estimates may support opioid stewardship.
中文摘要:术后阿片类药物过度处方加剧了阿片类药物流行。为在多样化手术人群中扩展并验证一个由妇科肿瘤学开发的术后阿片类药物使用预测计算器,并评估其是否可修改用于术前处方。这项在四级医疗系统中开展的预后研究使用患者术前调查和术后评估,测量2023年11月1日至2024年11月1日期间的阿片类药物使用和疼痛评分,随访至6周。年龄18岁及以上接受妇科手术的患者符合条件;仅接受小手术者被排除。数据分析时间为2025年1月15日至2026年7月27日。原始7预测因子模型进行了外部验证。预设的更新比例优势模型包括预期止痛药使用、年龄的限制性立方样条(3个节点)和预期手术时间的限制性立方样条(5个节点)、教育程度、吸烟和焦虑。共拟合了71个插补特异性模型。结局变量为使用的药片数量。验证方法包括模型区分度和校准度。在884名已识别患者中,870名符合条件,835名接受了手术,616名有完整的阿片类药物使用结局数据(中位[IQR]年龄,48[39-65]岁)。使用药片数量的中位数为2片(IQR,0-7片),226名患者(36.7%)未使用药片。对于原始模型,在至少使用2片、5片和10片药片的阈值下,阈值特异性C统计量分别为0.70(95% CI,0.66-0.74)、0.72(95% CI,0.68-0.76)和0.74(95% CI,0.70-0.78)。校准截距分别为-0.11(95% CI,-0.30至0.08)、-0.35(95% CI,-0.54至-0.17)和-0.51(95% CI,-0.71至-0.31),表明在较高药片使用阈值下高估了使用量。对于更新模型,乐观校正后的C统计量分别为0.71(95% CI,0.66-0.74)、0.73(95% CI,0.68-0.76)和0.73(95% CI,0.67-0.77);校准截距分别为-0.05(95% CI,-0.09至-0.01)、-0.04(95% CI,-0.08至0.002)和-0.03(95% CI,-0.07至0.01);在至少使用2片、5片和10片药片时,校准斜率分别为0.93(95% CI,0.80-1.02)、1.06(95% CI,0.89-1.19)和1.15(95% CI,0.85-1.37)。这项针对接受大型妇科手术患者的预后研究发现,原始计算器显示出中等的阈值特异性区分度,但在较高药片使用阈值下高估了阿片类药物使用。更新模型在内部验证后显示出中等区分度,校准截距接近0,斜率范围为0.93至1.15。需要外部机构验证。个体化估计可能支持阿片类药物合理使用。
HemaSphere IF 11.3 2026-10 PMID: 42824995
UKALL14 (NCT01085617) T-cell arm was a phase 3, randomized-controlled trial. Adults aged 25-65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end-point was event-free survival (EFS). From 2011 to 2018, 143 patients were randomly assigned to SOC (N = 75) or SOC + nelarabine (N = 68). There was no significant difference in EFS between the treatment groups; HR 0.86 (95% CI 0.52-1.43) P = 0.57, EFS: 58.2% SOC versus 62.7% SOC + nelarabine. The severe adverse events and nonrelapse mortality rates did not differ between the arms; in particular, there was no difference in grade 3-4 neurotoxicity. The 3-year cumulative incidence of relapse was 31% in the SOC arm versus 28.9% in the SOC+ nelarabine arm. Forty of 44 relapses (90.9%) occurred within 2 years of randomization; the median survival postrelapse was 5.7 months, with no difference by arm. Diagnostic samples were analyzed for level of differentiation arrest by analysis of the TCRg locus to detect the most immature cases through absence of biallelic TCRg deletion (ABD). There was a trend toward more relapses with ABD (37.3%) versus no ABD (19.5%), P = 0.066. Diagnostic samples (N = 133) were analyzed for mutations in NOTCH1, FBXW7, NRAS, KRAS, and PTEN, with no significant differences in CR rates or survival in patients with wild-type (WT) NOTCH1 or FBXW7. The 12 patients with NRAS mutations had significantly inferior CR and EFS compared to patients with wild-type NRAS.
中文摘要:UKALL14(NCT01085617)T细胞臂是一项3期随机对照试验。25至65岁成人入组时按1:1随机分配接受标准治疗(SOC)或标准治疗加奈拉滨1.5 g/m2(第1、3、5天),奈拉滨在第二次诱导后给药。主要终点为无事件生存期(EFS)。2011年至2018年,143例患者随机分配至SOC组(N=75)或SOC加奈拉滨组(N=68)。两组EFS无显著差异;HR 0.86(95% CI 0.52-1.43),P=0.57,EFS为SOC组58.2%对SOC加奈拉滨组62.7%。两组严重不良事件和非复发死亡率无差异;尤其3-4级神经毒性无差异。3年累积复发率为SOC组31%对SOC加奈拉滨组28.9%。44次复发中有40次(90.9%)发生在随机化后2年内;复发后中位生存期为5.7个月,两组无差异。对诊断样本通过分析TCRg位点检测分化阻滞水平,通过无双等位基因TCRg缺失(ABD)识别最不成熟病例。ABD患者复发有增多趋势(37.3%),无ABD者为19.5%,P=0.066。对诊断样本(N=133)分析NOTCH1、FBXW7、NRAS、KRAS和PTEN突变,野生型(WT)NOTCH1或FBXW7患者在完全缓解率或生存方面无显著差异。12例NRAS突变患者与野生型NRAS患者相比,完全缓解率和EFS显著更差。
Biomarker research IF 14.6 2026-10-01 PMID: 42823720
ZNF292 alterations are recurrently detected in patients with chronic lymphocytic leukemia (CLL), occurring in 3%-6% of patients as mutations and in 2% as 6q deletions. Although preliminary evidence suggested an independent prognostic role for ZNF292 mutations, their specific clinical relevance in early-stage CLL and the underlying biological mechanisms remain poorly defined. 488 CLL patients were analyzed using targeted Next-Generation Sequencing (NGS) to characterize the landscape and clinical significance of ZNF292 mutations. CRISPR/Cas9-genome editing was employed to introduce the most prevalent ZNF292 variants into CLL cellular models. Their biological and functional implications were evaluated by integrating RNA-sequencing data from these isogenic cellular models with transcriptomic data from primary patient samples, complemented by functional validation and drug response assays. ZNF292 mutations were associated with shorter time to first treatment (TTFT; median 25 vs. 52 months, P = 0.009) and inferior overall survival (OS, median 93 vs. 148 months, P = 0.004). Importantly, when restricting the analyses to early-stage cases, ZNF292 alterations were independently associated with shorter TTFT and OS, identifying a high-risk subgroup. Mechanistically, transcriptomic analyses revealed that ZNF292 mutations suppress global protein biosynthesis and modulate cell cycle progression in both primary CLL samples and CRISPR/Cas9-edited cells. Furthermore, ZNF292 deficiency impaired replication stress responses via defective CHK1 activation, resulting in DNA damage accumulation. Evaluating potential therapeutic vulnerabilities, ZNF292-mutated cells exhibited enhanced in vitro sensitivity to ibrutinib and venetoclax. Our findings propose ZNF292 alterations as an independent prognostic factor in early-stage CLL and unveil their role in disease progression.
中文摘要:ZNF292改变在慢性淋巴细胞白血病(CLL)患者中反复检测到,3%-6%的患者为突变,2%为6q缺失。尽管初步证据提示ZNF292突变具有独立预后作用,但其在早期CLL中的具体临床相关性及潜在生物学机制仍定义不清。采用靶向二代测序(NGS)分析488例CLL患者,以描述ZNF292突变的图谱和临床意义。采用CRISPR/Cas9基因组编辑将最常见的ZNF292变异引入CLL细胞模型。通过整合这些同基因细胞模型的RNA测序数据与原发患者样本的转录组数据,并辅以功能验证和药物反应试验,评估其生物学与功能意义。ZNF292突变与较短至首次治疗时间(TTFT;中位25个月 vs. 52个月,P=0.009)和较差总生存(OS,中位93个月 vs. 148个月,P=0.004)相关。重要的是,当分析限于早期病例时,ZNF292改变与较短TTFT和OS独立相关,识别出一个高风险亚组。机制上,转录组分析显示,在原发CLL样本和CRISPR/Cas9编辑细胞中,ZNF292突变抑制整体蛋白质生物合成并调节细胞周期进程。此外,ZNF292缺陷通过CHK1激活缺陷损害复制应激反应,导致DNA损伤积累。在评估潜在治疗脆弱性时,ZNF292突变细胞在体外对依鲁替尼和维奈克拉表现出增强敏感性。我们的发现提出ZNF292改变是早期CLL的独立预后因素,并揭示其在疾病进展中的作用。
Blood IF 23.9 2026-10-01 PMID: 42821738
TP53 mutations represent one of the strongest adverse prognostic factors in myelodysplastic neoplasms (MDS). While multi-hit TP53 (TP53multiHit) alterations uniformly lead to very poor outcomes, the prognostic relevance of monoallelic TP53 (TP53mono) mutations remains controversial. TP53 variants can cause dominant-negative, loss-of-function, or gain-of-function effects. We hypothesized that functional heterogeneity among TP53 variants contributes to the variable clinical behavior observed in TP53mono-mutated MDS. Therefore, we analyzed pretreatment samples from 4,505 patients with MDS from two independent cohorts (IWG: n=3,173; J-MDS: n=1,332), including 271 patients with TP53mono and 499 with TP53multiHit. Functional annotation of TP53 variants was performed using a previously published phenotype score (PS) derived from saturation mutagenesis screens, capturing dominant-negative and loss-of-function effects. Median leukemia-free survival (LFS) differed significantly by TP53 allelic state (TP53 wild-type (TP53wt) 37.2 months; TP53mono 19.2 months; TP53multiHit 7.8 months; p<0.001). Within the TP53mono subgroup, functional annotation identified marked heterogeneity. Patients with high PS (≥7) showed a significantly inferior median LFS compared with those with low PS (12.6 vs. 43.3 months; p<0.001), particularly for IPSS-R and IPSS-M low-risk cases. Combining PS and variant allele frequency (VAF) further improved risk stratification. TP53mono patients with PS ≥7 and VAF ≥22% had a median LFS comparable to TP53multiHit cases (9.2 vs. 7.8 months, p=0.3), whereas those with PS <7 and VAF <22% exhibited a median LFS similar to TP53wt cases (44.7 vs. 37.2 months, p=0.8). Overall, functional annotation of TP53 variants refines prognostication in TP53mono-mutated MDS and may enhance individualized risk assessment.
中文摘要:TP53突变是骨髓增生异常性肿瘤(MDS)中最强的不良预后因素之一。虽然多打击TP53(TP53multiHit)改变一致导致极差结局,但单等位TP53(TP53mono)突变的预后相关性仍存争议。TP53变异可导致显性负性、功能丧失或功能获得效应。我们假设TP53变异之间的功能异质性导致了TP53mono突变MDS中观察到的临床行为差异。因此,我们分析了来自两个独立队列的4505例MDS患者的治疗前样本(IWG:n=3173;J-MDS:n=1332),其中包括271例TP53mono患者和499例TP53multiHit患者。TP53变异的功能注释使用先前发表的表型评分(PS)进行,该评分来自饱和诱变筛选,可捕捉显性负性和功能丧失效应。中位无白血病生存(LFS)按TP53等位状态存在显著差异(TP53野生型(TP53wt)37.2个月;TP53mono 19.2个月;TP53multiHit 7.8个月;p<0.001)。在TP53mono亚组内,功能注释识别出显著异质性。高PS(≥7)患者的中位LFS显著劣于低PS患者(12.6个月 vs 43.3个月;p<0.001),尤其是在IPSS-R和IPSS-M低危病例中。结合PS和变异等位基因频率(VAF)进一步改善了风险分层。PS≥7且VAF≥22%的TP53mono患者中位LFS与TP53multiHit病例相当(9.2个月 vs 7.8个月,p=0.3),而PS<7且VAF<22%者的中位LFS与TP53wt病例相似(44.7个月 vs 37.2个月,p=0.8)。总体而言,TP53变异的功能注释改善了TP53mono突变MDS的预后判断,并可能增强个体化风险评估。
Blood IF 23.9 2026-10-01 PMID: 42821736
Primary central nervous system lymphoma (PCNSL) is an aggressive subtype of non-Hodgkin lymphoma with a poor prognosis, high rate of refractory or relapsed (R/R) disease, and no established standard of care for R/R PCNSL. This phase 2 study evaluated the efficacy and safety of tirabrutinib, a potent, highly selective, second-generation Bruton tyrosine kinase inhibitor, in patients with R/R PCNSL in the US. In the open-label PROSPECT study, adults with R/R PCNSL whose disease progressed on or after ≥1 high-dose methotrexate-based therapy received once-daily oral tirabrutinib 480 mg. The primary endpoint was overall response rate (ORR), and secondary endpoints included complete response (CR) rate, duration of response (DOR), and time to response (TTR), as assessed by independent review committee. Safety was assessed by frequency and severity of treatment-emergent adverse events (TEAEs). Among 48 enrolled patients, median follow-up was 11.5 months, ORR was 67% (95% confidence interval [CI], 52-80), and CR rate was 44% (95% CI, 29-59). Median DOR was 9.3 months (95% CI, 4.6-14.6), and median TTR was 1.0 month (range, 0.9-3.7). Treatment-related TEAEs occurred in 36 patients (75%), most commonly anemia (19%), maculopapular rash (17%), fatigue (15%), neutropenia (15%), lymphocytopenia (15%), pruritus (15%), and other rash (15%). Grade ≥3 treatment-related TEAEs occurred in 13 patients (27%), most commonly neutropenia (8%) and maculopapular rash (6%). One death (bronchopulmonary aspergillosis) was treatment related. In patients with R/R PCNSL, once-daily oral tirabrutinib monotherapy resulted in rapid and durable responses and demonstrated a favorable safety profile. This trial was registered at www.clinicaltrials.gov as NCT04947319.
中文摘要:原发性中枢神经系统淋巴瘤(PCNSL)是非霍奇金淋巴瘤的一种侵袭性亚型,预后差,难治或复发(R/R)比例高,且R/R PCNSL尚无确立的标准治疗。本2期研究在美国评估了tirabrutinib(一种强效、高选择性的第二代布鲁顿酪氨酸激酶抑制剂)用于R/R PCNSL患者的疗效与安全性。在开放标签的PROSPECT研究中,既往接受过至少1种以大剂量甲氨蝶呤为基础的治疗后出现疾病进展的R/R PCNSL成人患者,接受每日一次口服tirabrutinib 480 mg治疗。主要终点为总缓解率(ORR),次要终点包括由独立评审委员会评估的完全缓解(CR)率、缓解持续时间(DOR)和至缓解时间(TTR)。安全性通过治疗中出现的不良事件(TEAE)的发生频率和严重程度进行评估。在48例入组患者中,中位随访时间为11.5个月,ORR为67%(95%置信区间[CI],52-80),CR率为44%(95% CI,29-59)。中位DOR为9.3个月(95% CI,4.6-14.6),中位TTR为1.0个月(范围,0.9-3.7)。36例患者(75%)发生治疗相关TEAE,最常见的为贫血(19%)、斑丘疹(17%)、疲乏(15%)、中性粒细胞减少(15%)、淋巴细胞减少(15%)、瘙痒(15%)及其他皮疹(15%)。13例患者(27%)发生≥3级治疗相关TEAE,最常见的为中性粒细胞减少(8%)和斑丘疹(6%)。1例死亡(支气管肺曲霉病)与治疗相关。在R/R PCNSL患者中,每日一次口服tirabrutinib单药治疗可带来快速且持久的缓解,并显示出良好的安全性特征。本试验已在www.clinicaltrials.gov注册,注册号为NCT04947319。
Cancer discovery IF 29.5 2026-10-01 PMID: 42627098
The FDA has approved iberdomide for multiple myeloma based on minimal residual disease negativity, marking a first for the disease. The drug also ushers in a new generation of targeted protein degraders, with several more potent cereblon E3 ligase modulators already in clinical development.
中文摘要:美国FDA已基于微小残留病阴性批准iberdomide用于多发性骨髓瘤,这在该疾病中尚属首次。该药也开启了新一代靶向蛋白降解剂,目前已有多种更强效的cereblon E3连接酶调节剂处于临床开发阶段。
British journal of anaesthesia IF 10.3 2026-10 PMID: 42527295
Opioid receptor-ligand signalling has been implicated in tumour biology and perioperative outcomes; however, its pan-cancer molecular landscape and clinical relevance remain incompletely defined. We performed a pan-cancer multi-omics analysis of eight predefined opioid receptor-ligand genes across 33 tumour types from The Cancer Genome Atlas. Analyses included gene expression analysis using the linear models for microarray data (limma) package, genomic alterations, DNA methylation, regulatory network inference, pathway activity estimation using gene set variation analysis, and survival modelling. Multivariable Cox regression models were adjusted for age, sex, and tumour stage. Opioid receptor-ligand genes exhibited heterogeneous and generally low-to-moderate expression across tumour types. Genomic and epigenetic alterations were tumour-specific and variably associated with gene expression. Selected genes showed associations with overall survival in a tumour-dependent manner; however, these associations were attenuated after adjustment for clinical covariates and were accompanied by wide confidence intervals in some cohorts. Pathway analyses suggested associations with broader biological programmes, including epithelial-mesenchymal transition and immune-related pathways. Regulatory analyses identified candidate transcription factors and miRNAs, although these findings are exploratory. This pan-cancer analysis provides a systematic overview of opioid receptor-ligand gene features across human cancers. The observed associations are context-dependent and should be interpreted as hypothesis-generating. Further mechanistic and prospective studies are required to determine the clinical relevance of opioid signalling in cancer and perioperative settings.
中文摘要:阿片受体-配体信号已被认为与肿瘤生物学及围手术期结局有关;然而,其在泛癌中的分子图谱及临床相关性仍未完全明确。我们对来自癌症基因组图谱的33种肿瘤类型中8个预设的阿片受体-配体基因进行了泛癌多组学分析。分析包括使用微阵列数据线性模型(limma)包进行的基因表达分析、基因组改变、DNA甲基化、调控网络推断、使用基因集变异分析的通路活性估计以及生存建模。多变量Cox回归模型对年龄、性别和肿瘤分期进行了校正。阿片受体-配体基因在肿瘤类型间表现出异质性且总体为低至中等表达。基因组和表观遗传改变具有肿瘤特异性,并与基因表达存在不同程度的关联。部分基因以肿瘤依赖的方式显示与总生存的关联;然而,在校正临床协变量后,这些关联减弱,并且在一些队列中伴随较宽的置信区间。通路分析提示其与更广泛的生物学程序相关,包括上皮-间质转化和免疫相关通路。调控分析识别出候选转录因子和miRNA,尽管这些发现是探索性的。这项泛癌分析提供了对阿片受体-配体基因在人类癌症中特征的系统概述。观察到的关联具有情境依赖性,应被解释为产生假设。需要进一步的机制性和前瞻性研究来确定阿片信号在癌症及围手术期环境中的临床相关性。
Kidney international IF 21.8 2026-10 PMID: 42508612
Dapagliflozin improves kidney outcomes in patients with chronic kidney disease (CKD), yet the underlying mechanisms by which it exerts protective effects are not fully elucidated. Here, we applied plasma proteomics to identify proteins and pathways linked to CKD progression and examined which of these are modulated by dapagliflozin. We measured 3072 circulating plasma proteins (Olink, Uppsala, Sweden) in 2485 of the 4304 (57.7%) patients with CKD from the DAPA-CKD trial (eGFR 25-75 mL/min per 1.73 m2 and urinary albumin-to-creatinine ratio 200-5000 mg/g). Proteins associated with the composite kidney outcome (50% eGFR decline, kidney failure, and kidney death) and with dapagliflozin treatment were respectively identified by multivariable Cox proportional hazard regression and ANCOVA. Ingenuity pathway analysis was used to identify relevant molecular pathways and upstream regulators. Pathways that had the strongest association with the composite kidney outcome were hepatic fibrosis, insulin-like growth factor transport regulation, and tumor necrosis factor signaling. These pathways were generally related to fibrosis and inflammation. After 12 months, dapagliflozin treatment showed a (placebo-corrected) modification of 216 proteins, of which kidney injury molecule-1 showed the strongest reduction (-14.9%; 95% confidence interval: -17.9, -11.7). Of the 137 pathways associated with the kidney outcome, 35 (25%) were modified by dapagliflozin. Among these, activity of 11 (31% of 35) pathways decreased, and 10 (29% of 35) pathways were increased. Pathways associated with kidney outcome and modulated by dapagliflozin were related to extracellular matrix remodeling, inflammation and fibrosis, and immune-vascular interactions. This proteomic analysis reveals mechanisms underlying dapagliflozin's beneficial effects in CKD progression and shows that key pathways associated with CKD progression are modified by dapagliflozin, supporting its anti-inflammatory and antifibrotic potential.
中文摘要:达格列净可改善慢性肾脏病(CKD)患者的肾脏结局,但其发挥保护作用的潜在机制尚未完全阐明。本研究应用血浆蛋白质组学来识别与CKD进展相关的蛋白质和通路,并考察其中哪些可被达格列净调节。我们在DAPA-CKD试验中4304例CKD患者中的2485例(57.7%)中检测了3072种循环血浆蛋白(Olink,瑞典乌普萨拉),这些患者的eGFR为25-75 mL/min/1.73 m2,尿白蛋白与肌酐比值为200-5000 mg/g。分别通过多变量Cox比例风险回归和ANCOVA识别与复合肾脏结局(eGFR下降50%、肾衰竭和肾脏死亡)相关的蛋白以及与达格列净治疗相关的蛋白。使用Ingenuity通路分析来识别相关分子通路和上游调控因子。与复合肾脏结局关联最强的通路为肝纤维化、胰岛素样生长因子转运调节和肿瘤坏死因子信号传导。这些通路通常与纤维化和炎症相关。12个月后,达格列净治疗显示(经安慰剂校正后)可改变216种蛋白,其中肾损伤分子-1的降低幅度最大(-14.9%;95%置信区间:-17.9,-11.7)。在与肾脏结局相关的137条通路中,有35条(25%)被达格列净改变。其中,11条(占35条的31%)通路活性下降,10条(占35条的29%)通路活性升高。与肾脏结局相关且受达格列净调节的通路涉及细胞外基质重塑、炎症和纤维化以及免疫-血管相互作用。该蛋白质组学分析揭示了达格列净在CKD进展中获益的机制,并表明与CKD进展相关的关键通路可被达格列净改变,支持其抗炎和抗纤维化潜力。
Pharmacology & therapeutics IF 13.5 2026-10 PMID: 42492739
Cardiovascular-kidney-metabolic (CKM) syndrome, formally defined by the American Heart Association in 2023, affects approximately 90% of US adults, who meet criteria for stage 1 or higher. The rapid convergence of multiple drug classes on CKM pathways, SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, ARNI, and interleukin-directed therapies, has created an urgent need for pharmacologically grounded frameworks that guide drug selection, interpret biomarker responses, and monitor target engagement across interconnected organ systems. This review proposes a three-dimensional biomarker-guided approach to precision pharmacotherapy in CKM syndrome. In the organ-specific dimension, we map key biomarkers to their corresponding drug targets and elucidate the molecular mechanisms underlying drug-biomarker interactions: SGLT2 inhibitors attenuate myocardial injury through metabolic substrate shifting toward ketone body utilization and, based on preclinical evidence, NHE1 inhibition; neprilysin selectivity of sacubitril/valsartan explains the differential natriuretic peptide response; and tubuloglomerular feedback mediates the renoprotective hemodynamic effects of SGLT2 inhibitors. In the pathway-specific dimension, we identify cross-system biomarkers, such as hs-CRP, IL-6, galectin-3, GDF-15, and FGF21,which reveal shared druggable targets spanning the IL-1β/NLRP3 inflammasome axis (canakinumab, colchicine), IL-6 trans-signaling (ziltivekimab), and FGF21/β-klotho metabolic signaling. In the temporal dimension, we demonstrate how serial biomarker trajectories serve as pharmacodynamic readouts that distinguish therapeutic drug effects from disease progression, including the initial eGFR dip with SGLT2 inhibitors and natriuretic peptide changes during combination therapy. Central to this framework is the concept of "pharmacological phenotyping", using multi-biomarker panels to define drug-responsive pathophysiological states that directly inform therapeutic selection, analogous to companion diagnostics in oncology. We further present a comprehensive drug-biomarker interaction matrix with pharmacological rationale and analyze the emerging drug development pipeline, including RNA-based Lp(a) therapeutics, FGF21 analogues, galectin-3 inhibitors, and in vivo CAR-T anti-fibrotic approaches. This framework provides a practical roadmap for biomarker-guided precision pharmacotherapy in CKM syndrome.
中文摘要:心血管-肾脏-代谢(CKM)综合征由美国心脏协会于2023年正式定义,约90%的美国成人符合1期或更高阶段的诊断标准。多种药物类别迅速汇聚于CKM通路,包括SGLT2抑制剂、非奈利酮、GLP-1受体激动剂、ARNI和白细胞介素导向治疗,这迫切需要以药理学为基础的框架来指导药物选择、解读生物标志物反应,并监测相互关联器官系统中的靶点结合。本综述提出一种三维生物标志物指导的CKM综合征精准药物治疗方法。在器官特异性维度,我们将关键生物标志物映射至其相应药物靶点,并阐明药物-生物标志物相互作用的分子机制:SGLT2抑制剂通过代谢底物向酮体利用转变而减轻心肌损伤,且基于临床前证据,还通过抑制NHE1发挥作用;沙库巴曲/缬沙坦的脑啡肽酶选择性解释了利钠肽反应的差异;管球反馈介导SGLT2抑制剂的肾脏保护性血流动力学效应。在通路特异性维度,我们识别跨系统生物标志物,如hs-CRP、IL-6、半乳糖凝集素-3、GDF-15和FGF21,这些标志物揭示了跨越IL-1β/NLRP3炎症小体轴(卡那津单抗、秋水仙碱)、IL-6反式信号传导(ziltivekimab)和FGF21/β-klotho代谢信号传导的共同可成药靶点。在时间维度,我们展示连续生物标志物轨迹如何作为药效学读数,以区分治疗药物效应与疾病进展,包括SGLT2抑制剂治疗初期的eGFR下降以及联合治疗期间的利钠肽变化。该框架的核心是「药理学表型分型」概念,即使用多生物标志物组合来定义药物反应性病理生理状态,从而直接指导治疗选择,类似于肿瘤学中的伴随诊断。我们进一步提出一个全面的药物-生物标志物相互作用矩阵及药理学依据,并分析新兴药物研发管线,包括基于RNA的Lp(a)疗法、FGF21类似物、半乳糖凝集素-3抑制剂和体内CAR-T抗纤维化方法。该框架为CKM综合征中生物标志物指导的精准药物治疗提供了实用路线图。
European urology IF 29.1 2026-10 PMID: 42476886
Patient-reported outcome measures (PROMs) complement oncological endpoints by capturing what matters most to patients. The TrueNTH surgical collaboration presented 1-yr PROMs following robotic prostatectomy using accessible visual formats. We present 5-yr PROMs from the phase 3, international PACE-B trial, which randomised men with localised prostate cancer to stereotactic body radiotherapy (SBRT) or conventionally fractionated radiotherapy (CRT). PROMs are reported from baseline to 5 yr and presented using waffle charts to enable visual alignment with surgical outcomes. At 5 yr, urinary incontinence outcomes were favourable and comparable between SBRT and CRT. Leak-free rates were 64% (164/258) for SBRT and 69% (172/249) for CRT, pad-free rates were 91% (233/257) for SBRT and 90% (225/250) for CRT, and moderate or big urinary leakage problems were reported by only 6% (15/250) for SBRT and 4% (9/244) for CRT. Intercourse-adequate erections declined in both groups from baseline to 5 yr: from 35% (133/374) to 17% (43/250) for SBRT, and from 40% (157/391) to 20% (47/240) for CRT. Moderate or big sexual problems increased in both groups, from 24% (87/367) to 31% (74/242) for SBRT and from 22% (85/382) to 32% (77/238) for CRT. Bowel effects were low and comparable between groups, with moderate or big bowel problems reported by 2% (7/397) at baseline and 5% (12/265) for SBRT at 5 yr, and 2% (9/415) at baseline and 5% (13/253) for CRT at 5 yr. Stool incontinence as a moderate or big problem rose from <1% (1/374) to 2% (4/240) in the SBRT group and from <1% (1/395) to 3% (7/238) in the CRT group.
中文摘要:患者报告结局测量(PROMs)通过捕捉对患者最重要的内容,补充肿瘤学终点。TrueNTH 外科协作组使用易理解的可视化格式呈现了机器人前列腺切除术后的 1 年 PROMs。我们呈现 3 期国际 PACE-B 试验的 5 年 PROMs,该试验将局限性前列腺癌男性随机分配至立体定向体部放疗(SBRT)或常规分割放疗(CRT)。PROMs 报告从基线至 5 年,并使用华夫图呈现,以便与手术结局进行视觉对齐。在 5 年时,尿失禁结局良好,且 SBRT 与 CRT 之间具有可比性。无漏尿率 SBRT 为 64%(164/258),CRT 为 69%(172/249);无需尿垫率 SBRT 为 91%(233/257),CRT 为 90%(225/250);报告中度或重度尿漏问题的比例,SBRT 仅为 6%(15/250),CRT 为 4%(9/244)。可进行性交的勃起功能从基线至 5 年在两组中均下降:SBRT 从 35%(133/374)降至 17%(43/250),CRT 从 40%(157/391)降至 20%(47/240)。中度或重度性问题在两组中均增加:SBRT 从 24%(87/367)增至 31%(74/242),CRT 从 22%(85/382)增至 32%(77/238)。肠道效应较低,且两组间具有可比性;中度或重度肠道问题在基线时报告为 2%(7/397),SBRT 5 年时为 5%(12/265),CRT 基线时为 2%(9/415),5 年时为 5%(13/253)。大便失禁作为中度或重度问题,在 SBRT 组从 <1%(1/374)升至 2%(4/240),在 CRT 组从 <1%(1/395)升至 3%(7/238)。
Blood IF 23.9 2026-10-01 PMID: 42462111
In the TRANSCEND FL primary analysis, lisocabtagene maraleucel (liso-cel) showed high response rates and favorable safety in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Longer follow-up is needed to assess remission durability and long-term or late-onset toxicities. Here, we report 3-year follow-up results (median on-study follow-up, 41.5 months [range, 0.3-54.0]) in patients with third-line or later (3L+) FL. Patients had R/R FL after ≥2 previous lines of combination systemic therapy, including an anti-CD20 antibody and an alkylator. A total of 107 patients received liso-cel and 103 were efficacy evaluable, with overall and complete response rates per independent review committee of 97% (95% confidence interval [CI], 92-99) and 94% (95% CI, 88-98), respectively. Medians were not reached for all time-to-event outcomes; estimated 36-month rates for duration of response, progression-free survival, time free from next treatment, and overall survival were 70% (95% CI, 60-78), 68% (95% CI, 58-76), 75% (95% CI, 70-80), and 86% (95% CI, 78-92), respectively. Response rates and 36-month time-to-event rates were consistent in high-risk subgroups, including patients with disease progression within 24 months of starting first-line immunochemotherapy, bulky disease, or double-refractory status. Longitudinal safety analyses showed decreasing grade ≥3 cytopenias and hypogammaglobulinemia (immunoglobulin G <500 mg/dL), with use of supportive care (transfusions, growth factors, IV immunoglobulin) mostly limited to the 3 months after infusion, and consistently low incidences of grade ≥3 infections in short- and long-term periods. At 3-year follow-up, a single liso-cel infusion delivered durable efficacy and high survival, including in high-risk subgroups, alongside a favorable long-term safety profile in patients with 3L+ FL. This trial was registered at www.clinicaltrials.gov as NCT04245839.
中文摘要:在TRANSCEND FL主要分析中,lisocabtagene maraleucel(liso-cel)在复发/难治性(R/R)滤泡性淋巴瘤(FL)患者中显示高缓解率和良好安全性。需要更长随访以评估缓解持久性及长期或迟发性毒性。此处,我们报告三线或更后线(3L+)FL患者3年随访结果(中位在研随访41.5个月[范围0.3-54.0])。患者为接受过≥2线既往联合系统治疗(包括抗CD20抗体和烷化剂)后的R/R FL。共107例患者接受liso-cel,103例可评估疗效,独立审查委员会评估的总缓解率和完全缓解率分别为97%(95%置信区间[CI],92-99)和94%(95%CI,88-98)。所有至事件发生结局的中位值均未达到;缓解持续时间、无进展生存期、免于下一次治疗时间及总生存期的估计36个月率分别为70%(95%CI,60-78)、68%(95%CI,58-76)、75%(95%CI,70-80)和86%(95%CI,78-92)。在高危亚组中,包括在开始一线免疫化疗后24个月内出现疾病进展、大包块疾病或双重难治状态的患者,缓解率和36个月至事件发生时间率一致。纵向安全性分析显示,≥3级血细胞减少和低丙种球蛋白血症(免疫球蛋白G<500 mg/dL)逐渐减少,支持治疗(输血、生长因子、静脉注射免疫球蛋白)的使用大多限于输注后3个月内,并且在短期和长期内≥3级感染发生率持续较低。在3年随访时,单次liso-cel输注在3L+ FL患者中产生持久疗效和高生存率,包括高危亚组,并具有良好长期安全性特征。该试验注册于www.clinicaltrials.gov,编号NCT04245839。
Sleep medicine reviews IF 11.6 2026-10 PMID: 42430948
Sleep disturbances are highly prevalent among individuals with chronic non-cancer pain and are associated with worse pain severity and poorer prognosis. The comparative trade-offs between the effectiveness and safety of available pharmacotherapies for sleep outcomes in this population remain poorly defined. Ninety-eight RCTs involving 28,920 participants (mean age 53.2 years, 71.2% female) were included. Moderate-certainty evidence demonstrated that melatonin significantly improved sleep quality compared with placebo (standardized mean difference [SMD] = -0.60, 95%CI: -0.98, -0.22). Ten agents (e.g., amitriptyline, oxycodone, gabapentin, pregabalin, duloxetine) also showed statistically significant improvements in subjective sleep quality (SMD = -0.24 to -1.07), but most effects were supported by low-certainty evidence and were accompanied by an increased risk of adverse events (odds ratio [OR] = 1.90 to 37.00). Conversely, melatonin was not associated with an increased risk (OR = 0.88, 95%CI: 0.19, 3.94). Our findings indicate that melatonin shows promise as a safe, adjunctive option for improving sleep quality in this population, but larger, condition-specific trials are warranted to confirm these effects. Other pharmacological agents are limited by lower-certainty and unfavorable safety profiles. These results should be interpreted cautiously given limited direct comparisons, heterogeneous chronic pain populations, the high proportion of trials at high risk of bias, and the predominance of subjective sleep outcomes.
中文摘要:睡眠障碍在慢性非癌痛个体中高度普遍,并与更严重的疼痛程度和更差的预后相关。该人群中现有药物治疗对睡眠结局的有效性与安全性之间的比较权衡仍不明确。共纳入98项随机对照试验,涉及28,920名参与者(平均年龄53.2岁,71.2%为女性)。中等确信度证据表明,与安慰剂相比,褪黑素显著改善睡眠质量(标准化均数差[SMD]=-0.60,95%CI:-0.98,-0.22)。十种药物(例如阿米替林、羟考酮、加巴喷丁、普瑞巴林、度洛西汀)也显示主观睡眠质量有统计学显著改善(SMD=-0.24至-1.07),但大多数效应由低确信度证据支持,并伴随不良事件风险增加(比值比[OR]=1.90至37.00)。相反,褪黑素与风险增加无关(OR=0.88,95%CI:0.19,3.94)。我们的发现表明,褪黑素作为一种安全、辅助性选择,在改善该人群睡眠质量方面具有前景,但仍需要更大规模、针对特定病症的试验来确认这些效应。其他药物则受限于较低确信度和不利的安全性特征。鉴于直接比较有限、慢性疼痛人群异质性、高风险偏倚试验比例较高以及主观睡眠结局占主导,这些结果应谨慎解读。
Cancer letters IF 11.8 2026-10-01 PMID: 42409256
The spatial organization of the glioblastoma (GBM) microenvironment is a critical determinant of tumor progression and therapeutic resistance. Although cellular heterogeneity and microenvironmental stressors such as hypoxia and inflammation are well recognized, their coordinated spatial organization and functional interplay remain incompletely understood. Here, we developed Spatial PHenotype Ecosystem RElationship (SPHERE), a computational framework that quantitatively decodes the spatial traits of the GBM ecosystem by integrating single-cell-resolution spatial transcriptomic data from a large patient cohort. We identify hypoxic and inflammatory niches as spatially distinct microenvironment states that are frequently peri-necrotic but exhibit a degree of partial overlap or spatial adjacency. Mesenchymal-like tumor cells showed strong spatial coupling to both hypoxic and inflammatory regions, whereas glial-lineage cells preferentially localize to peripheral areas. Immune checkpoint molecules, including LGALS3, HMGB1, CD47, etc., are significantly enriched within hypoxic zones. In contrast, inflammatory regions are characterized by elevated chemokines and cytokines, highlighted by a spatially resolved LIF-LIFR signaling axis. Malignant cells residing in inflammatory niches displayed marked upregulation of LIF, a response reinforced by crosstalk with macrophages and associated with poor patient prognosis. Collectively, our findings establish a quantitative model of the spatially structured GBM microenvironment, linking stress-driven niche formation to malignant cellular states and immune regulation, and reveals spatially defined vulnerabilities that may be exploited for precision therapeutic intervention.
中文摘要:胶质母细胞瘤(GBM)微环境的空间组织是肿瘤进展和治疗耐药的关键决定因素。尽管细胞异质性以及缺氧和炎症等微环境应激因素已得到充分认识,但它们协调的空间组织及功能互作仍未被完全理解。在此,我们开发了空间表型生态系统关系(SPHERE)这一计算框架,通过整合来自大型患者队列的单细胞分辨率空间转录组数据,定量解析GBM生态系统的空间特征。我们鉴定出缺氧生态位和炎症生态位是空间上不同的微环境状态,常位于坏死周围,但表现出一定程度的部分重叠或空间毗邻。间充质样肿瘤细胞与缺氧区和炎症区均表现出强烈的空间耦合,而胶质谱系细胞优先定位于外周区域。包括LGALS3、HMGB1、CD47等在内的免疫检查点分子在缺氧区显著富集。相比之下,炎症区以趋化因子和细胞因子升高为特征,其中以空间分辨的LIF-LIFR信号轴尤为突出。定位于炎症生态位的恶性细胞表现出LIF的显著上调,这一反应通过与巨噬细胞的串扰得到增强,并与患者不良预后相关。总体而言,我们的发现建立了一个空间结构化的GBM微环境定量模型,将应激驱动的生态位形成与恶性细胞状态及免疫调节联系起来,并揭示了可用于精准治疗干预的空间限定脆弱性。
European urology IF 29.1 2026-10 PMID: 42399196
For over a decade the Advanced Prostate Cancer Consensus Conference (APCCC) covers a variety of topics that greatly impact daily practice. In 2025, a dedicated event was organised to discuss key questions in clinical management of patients with prostate cancer (PC) related to diagnostic tools (APCCC Diagnostics). Here we present the voting results of the APCCC Diagnostics questions. APCCC Diagnostics 2025 is a pilot project. The scientific committee for APCCC Diagnostics 2025 developed 88 multiple-choice consensus questions on six different topics. Prior to the conference, the panel members (''panellists'') voted on these questions via a web-based survey. Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. Consensus was only reached on 17 of 88 questions (19%), of which six (7%) received a strong consensus. Specifically, consensus was reached for two of 17 questions (14%) in "how to diagnose PC"; seven of 16 (44%) in "how to stage PC"; three of 14 (21%) in "Biochemical Recurrence Scenario"; two of 11 (18%) in "metastatic disease: what to do?"; zero of 18 (0%) in "monitoring metastatic PC"; and three of 12 (25%) in "radioligand therapy and imaging." The voting results and their discussion may assist physicians in navigating controversial areas of clinical management related to diagnosis, staging, and restaging in the different clinical settings for PC, particularly where high-level evidence is scarce or conflicting. The findings can also help funders and policymakers in prioritising areas for future research.
中文摘要:十余年来,晚期前列腺癌共识会议(APCCC)涵盖了多种对日常实践影响重大的主题。2025年,组织了一次专门会议,讨论与诊断工具相关的前列腺癌(PC)患者临床管理中的关键问题(APCCC Diagnostics)。本文呈现APCCC Diagnostics问题的投票结果。APCCC Diagnostics 2025是一个试点项目。APCCC Diagnostics 2025科学委员会就六个不同主题制定了88个多项选择共识问题。会议前,专家组成员(panellists)通过基于网络的调查对这些问题进行了投票。共识定义为一致率≥75%,强共识定义为一致率≥90%。88个问题中仅有17个(19%)达成共识,其中6个(7%)获得强共识。具体而言,在「如何诊断PC」中,17个问题中有2个(14%)达成共识;在「如何分期PC」中,16个中有7个(44%)达成共识;在「生化复发情景」中,14个中有3个(21%)达成共识;在「转移性疾病:该怎么办?」中,11个中有2个(18%)达成共识;在「监测转移性PC」中,18个中有0个(0%)达成共识;在「放射性配体治疗与影像学」中,12个中有3个(25%)达成共识。投票结果及其讨论可能有助于医生应对PC不同临床背景下与诊断、分期和再分期相关的临床管理争议领域,尤其是在高水平证据稀缺或相互矛盾之处。这些发现还可帮助资助者和政策制定者确定未来研究的优先领域。
Journal of the American Academy of Dermatology IF 12.3 2026-10 PMID: 42364769
Topical-refractory cutaneous field cancerization is challenging to manage and distressing to patients. Evaluate the efficacy, toxicity, and patient satisfaction of long-term, low-dose capecitabine for field cancerization. A retrospective cohort and survey study was performed at a single institution of patients treated with capecitabine for cutaneous field cancerization. Wilcoxon matched-pairs signed-rank test was used to compare annual keratinocyte carcinoma surgeries pre- and post-treatment at years 1, 2, and 3. Twenty patients were treated over 20.8 months (range 0.8-57.5) including 8.0 months (0-33.1) of intervening treatment holidays. Mean keratinocyte carcinoma surgeries decreased in all years of treatment compared to the year before treatment (1-year (n = 18): 3.89 precapecitabine to 2.94, 24% reduction, P = .29; 2-year (n = 11): 3.46 precapecitabine to 0.93, 73% reduction, P = .02; 3-year (n = 5): 3.00 precapecitabine to 2.20, 27% reduction, P > .99). Two patients (10%) discontinued therapy due to toxicity. Of 17 patients offered the survey, 12 responded (response rate 70.6%). A majority (75.0%) felt capecitabine improved their skin lesions at least moderately and 83.3% preferred capecitabine to alternative treatments. Retrospective design, small sample size. Capecitabine reduces incident keratinocyte carcinomas and is well-tolerated long-term.
中文摘要:局部治疗难治性皮肤区域癌化难以管理,且令患者痛苦。评估长期低剂量卡培他滨治疗区域癌化的疗效、毒性及患者满意度。本研究为单中心回顾性队列及调查研究,纳入因皮肤区域癌化接受卡培他滨治疗的患者。采用Wilcoxon配对符号秩检验,比较治疗前与治疗后第1、2、3年每年角质形成细胞癌手术次数。20例患者接受治疗,治疗时长20.8个月(范围0.8-57.5),其中包含8.0个月(0-33.1)的中间治疗间歇期。与治疗前一年相比,各治疗年份的平均角质形成细胞癌手术次数均下降(第1年(n = 18):卡培他滨治疗前3.89次降至2.94次,减少24%,P = .29;第2年(n = 11):治疗前3.46次降至0.93次,减少73%,P = .02;第3年(n = 5):治疗前3.00次降至2.20次,减少27%,P > .99)。2例患者(10%)因毒性停止治疗。在17例被邀请参与调查的患者中,12例回复(回复率70.6%)。多数患者(75.0%)认为卡培他滨至少中等程度改善了其皮肤病变,83.3%的患者更倾向于选择卡培他滨而非其他替代治疗。本研究为回顾性设计,样本量小。卡培他滨可减少新发角质形成细胞癌,且长期耐受性良好。
American journal of respiratory and critical care medicine IF 21.7 2026-10-01 PMID: 42360751
Occupational exposures to dust and fumes are associated with increased respiratory symptoms and worse lung function; however, their effect on future clinical outcomes has been incompletely explored. To examine the associations between self-reported occupational exposure to dust and fumes on future respiratory exacerbations, cardiovascular events, and other clinical outcomes in people with a history of smoking. People with a current or former smoking status, aged 45 to 80 years, enrolled in COPDGene were assigned to 4 mutually exclusive occupational exposure groups (no exposure, dust-only exposure, fumes-only exposure, dust-and-fumes exposure) based on questionnaire responses at baseline. Clinical outcomes were assessed prospectively for up to 15 years. Respiratory exacerbations were defined as worsening respiratory symptoms requiring treatment with steroids and/or antibiotics; binary outcomes included atherosclerotic cardiovascular disease (ASCVD), cancer, pneumonia, and blood clots. Multivariable-adjusted models estimated the association between occupational exposure category and each clinical outcome. Among 8991 participants (mean ± SD age, 60.1 ± 9.0 years; 51.7% male; 49.3% with a current smoking status), the prevalence of dust-only, fumes-only, and dust-and-fumes exposure was 12.0%, 12.4%, and 34.4%, respectively. Self-reported occupational exposure to both dust and fumes was associated with increased risk of future respiratory exacerbations (adjusted rate ratio, 1.38 [95% CI, 1.26-1.52]) relative to those reporting no exposures. Exposure to both dust and fumes was also associated with an increased risk (adjusted odds ratio [95% CI]) for future ASCVD (1.35 [1.17-1.56]) and pneumonia (1.39 [1.19-1.63]), but was not associated with future cancer or blood clots. Self-reported occupational exposure to dust and fumes is associated with increased future risk for multiple clinically relevant outcomes among tobacco-exposed individuals. NCT00608764 (COPDGene).
中文摘要:职业性粉尘和烟雾暴露与呼吸道症状增加及肺功能变差相关;然而,其对未来临床结局的影响尚未被充分探讨。旨在研究有吸烟史人群中,自我报告的职业性粉尘和烟雾暴露与未来呼吸道急性加重、心血管事件及其他临床结局之间的关联。当前吸烟或曾经吸烟、年龄45至80岁并纳入COPDGene的人群,根据基线问卷回答被分为4个互斥的职业暴露组(无暴露、仅粉尘暴露、仅烟雾暴露、粉尘和烟雾暴露)。前瞻性评估临床结局最长15年。呼吸道急性加重定义为呼吸道症状加重且需要糖皮质激素和/或抗生素治疗;二分类结局包括动脉粥样硬化性心血管疾病(ASCVD)、癌症、肺炎和血栓。多变量校正模型估计职业暴露类别与各临床结局之间的关联。在8991名参与者中(平均±标准差年龄60.1±9.0岁;51.7%为男性;49.3%当前吸烟),仅粉尘暴露、仅烟雾暴露以及粉尘和烟雾暴露的患病率分别为12.0%、12.4%和34.4%。相对于报告无暴露者,自我报告的职业性粉尘和烟雾同时暴露与未来呼吸道急性加重风险增加相关(校正率比1.38[95%CI,1.26-1.52])。粉尘和烟雾同时暴露还与未来ASCVD风险增加(校正比值比[95%CI]1.35[1.17-1.56])和肺炎风险增加(1.39[1.19-1.63])相关,但与未来癌症或血栓无关。在有烟草暴露的个体中,自我报告的职业性粉尘和烟雾暴露与多种临床相关结局的未来风险增加相关。NCT00608764(COPDGene)。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42351248
Accurate evaluation of tumor vascularity is essential in neuro-oncology, but conventional cerebral blood volume (CBV) mapping depends on gadolinium-based contrast agents. The aim was to develop a gadolinium-free model to synthesize CBV (CBVsyn) maps from non-contrast MRI (NC-MRI). This multicenter retrospective study analyzed 1227 MRI examinations in patients with primary intracranial tumors, comprising an internal cohort (train/validation/test 438/126/63) and 2 external cohorts (UPENN-GBM Cohort 464; UCSD-PTGBM cohort 136). A tumor-aware generative adversarial network (TA-GAN) was implemented to synthesize CBVsyn maps from various NC-MRI combinations. Image quality was evaluated using structural similarity index (SSIM), peak signal-to-noise ratio (PSNR), and a 4-point Likert scale. The correlation between pathologic markers and CBV parameters was conducted. Diagnostic performance was compared between CBVsyn and DSC-PWI-derived CBV (CBVreal) maps. The incremental diagnostic value of CBVsyn was evaluated. TA-GAN utilizing T2-weighted and diffusion-weighted imaging achieved best performance in CBVsyn synthesis (PSNRGlobal=25.52 ± 1.33dB, SSIMGlobal=67.53 ± 5.88; both P < .05), with 95.34% maps being diagnostically acceptable. CBVsyn parameters showed positive correlation with CD105 markers (r = 0.49, P = .03). CBVsyn maps demonstrated comparable AUC with CBVreal maps for intracranial tumors grading (0.61 vs. 0.66, P = .51), pediatric glioma (0.60 vs. 0.57; P = .57), adult glioma (0.68 vs. 0.73; P = .56), and IDH1 genotype (0.66 vs. 0.81; P = .03). NC-MRI with CBVsyn assistance improved diagnostic accuracy (84.48% vs.75.86%) and consistency (κ  = 0.83 vs. 0.62) for glioma grading compared with NC-MRI alone. As a gadolinium-free alternative, CBVsyn maps synthesized by TA-GAN correlate with pathologic findings and demonstrate promise for characterizing primary intracranial tumors.
中文摘要:准确评估肿瘤血供在神经肿瘤学中至关重要,但传统脑血容量(CBV)图依赖钆基对比剂。本研究旨在开发一种无钆模型,从非增强MRI(NC-MRI)合成CBV(CBVsyn)图。这项多中心回顾性研究分析了1227例原发性颅内肿瘤患者的MRI检查,包括内部队列(训练/验证/测试 438/126/63)和2个外部队列(UPENN-GBM队列464例;UCSD-PTGBM队列136例)。采用肿瘤感知生成对抗网络(TA-GAN)从多种NC-MRI组合合成CBVsyn图。图像质量通过结构相似性指数(SSIM)、峰值信噪比(PSNR)和4点Likert量表评估。分析病理标志物与CBV参数的相关性。比较CBVsyn与DSC-PWI衍生CBV(CBVreal)图的诊断性能。评估CBVsyn的增量诊断价值。使用T2加权和扩散加权成像的TA-GAN在CBVsyn合成中表现最佳(PSNRGlobal=25.52±1.33dB,SSIMGlobal=67.53±5.88;均P<.05),95.34%的图具有诊断可接受性。CBVsyn参数与CD105标志物呈正相关(r=0.49,P=.03)。CBVsyn图在颅内肿瘤分级(0.61 vs. 0.66,P=.51)、儿童胶质瘤(0.60 vs. 0.57;P=.57)、成人胶质瘤(0.68 vs. 0.73;P=.56)和IDH1基因型(0.66 vs. 0.81;P=.03)方面显示出与CBVreal图相当的AUC。与单独NC-MRI相比,NC-MRI联合CBVsyn辅助提高了胶质瘤分级的诊断准确性(84.48% vs.75.86%)和一致性(κ=0.83 vs. 0.62)。作为一种无钆替代方案,TA-GAN合成的CBVsyn图与病理发现相关,并有望用于表征原发性颅内肿瘤。
Journal of the American Academy of Dermatology IF 12.3 2026-10 PMID: 42248252
Condyloma lata is a manifestation of secondary syphilis that is underrecognized histopathologically, reported to mimic other entities, including squamous cell carcinoma. To describe characteristic clinical and histopathologic features of condyloma lata. A retrospective review was conducted of cases with histopathologic diagnoses of syphilis from January 2010 to February 12, 2025. The histopathologic findings were categorized as condyloma lata or other manifestations of secondary syphilis. Of 28 syphilis cases, 12 patients (15 specimens) were diagnosed with condyloma lata. The average age was 36.8 years (range: 21-52), with an equal sex distribution. Twelve of 15 lesions were anogenital, and 3 were extragenital. Syphilis was included in the clinical diagnosis in only 50% of cases, and one oral lesion was initially misdiagnosed as squamous cell carcinoma. In 25% (3/12) of the cases, the patient had other cutaneous manifestations of secondary syphilis. All condyloma lata lesions showed a consistent constellation of findings such as follows: eroded dome-shaped or verrucous plaque with bulbous, jagged, and/or irregular pseudoepitheliomatous hyperplasia, a dense or lichenoid lymphoplasmacytic infiltrate, prominent neutrophilic exocytosis associated with small spongiotic vesicles, and numerous spirochetes concentrated in the lower third of the epidermis. The remaining 16 patients (19 specimens) with noncondyloma lata secondary syphilis demonstrated considerable histopathologic variability. Retrospective design with a small sample size. Condyloma lata exhibits consistent, reliable, reproducible histopathologic features. Recognition of these features can prevent misdiagnosis, particularly at extragenital sites, where syphilis may be clinically unsuspected.
中文摘要:扁平湿疣是二期梅毒的一种表现,在组织病理学上认识不足,据报道可模仿其他病变,包括鳞状细胞癌。旨在描述扁平湿疣的特征性临床和组织病理学表现。对2010年1月至2025年2月12日期间经组织病理学诊断为梅毒的病例进行了回顾性复习。将组织病理学发现归类为扁平湿疣或二期梅毒的其他表现。在28例梅毒病例中,12例患者(15份标本)被诊断为扁平湿疣。平均年龄为36.8岁(范围:21-52岁),性别分布均等。15处皮损中有12处位于肛门生殖器部位,3处位于生殖器外部位。仅50%的病例将梅毒纳入临床诊断,且1处口腔皮损最初被误诊为鳞状细胞癌。在25%(3/12)的病例中,患者有二期梅毒的其他皮肤表现。所有扁平湿疣皮损均显示一组一致的发现,如下:糜烂性圆顶状或疣状斑块,伴球状、锯齿状和/或不规则的假上皮瘤样增生,密集或苔藓样淋巴浆细胞浸润,与小的海绵水肿性水疱相关的显著中性粒细胞外渗,以及大量螺旋体集中于表皮下三分之一。其余16例(19份标本)非扁平湿疣型二期梅毒患者表现出相当大的组织病理学变异性。回顾性设计且样本量小。扁平湿疣表现出一致、可靠、可重复的组织病理学特征。识别这些特征可防止误诊,尤其是在生殖器外部位,临床上可能未怀疑梅毒。
Blood IF 23.9 2026-10-01 PMID: 42227701
Ziftomenib, a potent, selective, oral menin inhibitor, is approved as monotherapy for adults with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (NPM1-m AML). The KOMET-007 phase 1 trial investigated clinical activity and tolerability of ziftomenib in combination with standard therapies for R/R and newly diagnosed AML. Here, we report the outcomes of adults with R/R NPM1-m AML treated with ziftomenib plus venetoclax/azacitidine. In phase 1a, patients received ziftomenib 200, 400, or 600 mg once daily with standard doses of venetoclax/azacitidine. In phase 1b, ziftomenib 600 mg was selected for expansion. A total of 67 patients were treated (27 phase 1a; 40 phase 1b). Median age was 66 years; 55% were male. Median number of previous therapies was 1 (range, 1-8); 55% received previous venetoclax, and 22% had received previous transplantation. Most common (≥20%) grade ≥3 treatment-emergent adverse events were leukopenia (34%), thrombocytopenia (28%), febrile neutropenia and neutropenia (25% each). Six patients developed corrected QT prolongation (1 ziftomenib-related; grade 1), and 2 experienced differentiation syndrome (grade 3); all events were successfully managed. In patients receiving ziftomenib 600 mg, composite complete remission (CRc) rate was 46% (22/48), with 67% (12/18) achieving central measurable residual disease (MRD) negativity (<0.01% threshold). In venetoclax-naïve and -exposed patients, CRc rates were 70% (16/23) and 24% (6/25), with MRD negativity rates of 75% (9/12) and 50% (3/6), respectively. Median duration of response was 8.6 months, and median overall survival was not reached. The combination of ziftomenib 600 mg with venetoclax/azacitidine was well tolerated with deep and durable clinical activity in R/R NPM1-m AML. This trial was registered at www.clinicaltrials.gov as NCT05735184.
中文摘要:Ziftomenib 是一种强效、选择性口服 menin 抑制剂,已获批作为单药用于复发/难治性(R/R)NPM1 突变急性髓系白血病(NPM1-m AML)成人患者。KOMET-007 1 期试验研究了 ziftomenib 联合标准疗法治疗 R/R 和新诊断 AML 的临床活性与耐受性。在此,我们报告接受 ziftomenib 联合 venetoclax/azacitidine 治疗的 R/R NPM1-m AML 成人患者结局。在 1a 期,患者接受 ziftomenib 200、400 或 600 mg 每日一次,联合标准剂量 venetoclax/azacitidine。在 1b 期,选择 ziftomenib 600 mg 进行扩展。共 67 例患者接受治疗(1a 期 27 例;1b 期 40 例)。中位年龄为 66 岁;55% 为男性。既往治疗中位数为 1 线(范围 1-8);55% 既往接受过 venetoclax,22% 既往接受过移植。最常见的(≥20%)≥3 级治疗中出现的不良事件为白细胞减少(34%)、血小板减少(28%)、发热性中性粒细胞减少和中性粒细胞减少(各 25%)。6 例患者发生校正 QT 间期延长(1 例与 ziftomenib 相关;1 级),2 例发生分化综合征(3 级);所有事件均得到成功处理。在接受 ziftomenib 600 mg 的患者中,复合完全缓解(CRc)率为 46%(22/48),其中 67%(12/18)达到中心检测的可测量残留病(MRD)阴性(阈值 <0.01%)。在未接受过 venetoclax 和曾接受过 venetoclax 的患者中,CRc 率分别为 70%(16/23)和 24%(6/25),MRD 阴性率分别为 75%(9/12)和 50%(3/6)。中位缓解持续时间为 8.6 个月,中位总生存期未达到。ziftomenib 600 mg 联合 venetoclax/azacitidine 在 R/R NPM1-m AML 中耐受性良好,并具有深度且持久的临床活性。该试验在 www.clinicaltrials.gov 注册,注册号为 NCT05735184。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42166750
Meningiomas are among the few intracranial tumors that are more common in females than males. The majority of meningiomas express progesterone receptor (PR), and differences in exposure to progestogens are thought to contribute to sex-based disparity in meningioma. Previous epidemiological and clinical data have demonstrated that multiple progestins, such as cyproterone acetate (CPA), are linked to meningioma. More recently, international epidemiological studies have found a significantly increased risk of meningioma with depot medroxyprogesterone acetate (DMPA), a widely used injectable contraceptive sold under the trade name Depo-Provera. Although the absolute risk of meningioma remains small, exposure to DMPA increases the risk of meningioma by 1.5- to 5.5-fold. DMPA-associated meningiomas are clinically significant, as the risk of craniotomy for tumor resection, not just the risk of tumor diagnosis, is elevated after DMPA exposure. These data suggest that DMPA should be avoided in individuals with a history of meningioma when alternatives are available. The risk of meningioma should be discussed with patients during DMPA counseling, and the utility of screening patients with prolonged DMPA exposure for meningiomas should be investigated. Further work is needed to elucidate the mechanisms of PR signaling in meningioma and to understand the complex interplay of tumor genomics, hormone exposure and signaling, and social and structural drivers of health that may contribute to disparities in meningioma.
中文摘要:脑膜瘤是少数女性比男性更常见的颅内肿瘤之一。大多数脑膜瘤表达孕激素受体(PR),而孕激素暴露的差异被认为导致了脑膜瘤的性别差异。此前的流行病学和临床数据显示,多种孕激素,如醋酸环丙孕酮(CPA),与脑膜瘤相关。最近,国际流行病学研究发现,使用长效醋酸甲羟孕酮(DMPA)——一种以商品名 Depo-Provera 销售的广泛使用的注射避孕药——与脑膜瘤风险显著增加相关。尽管脑膜瘤的绝对风险仍然很小,但暴露于 DMPA 可使脑膜瘤风险增加1.5至5.5倍。DMPA相关脑膜瘤具有临床意义,因为DMPA暴露后,因肿瘤切除而接受开颅手术的风险升高,而不仅仅是诊断出肿瘤的风险升高。这些数据表明,在有替代方案时,有脑膜瘤病史的个体应避免使用DMPA。在DMPA咨询期间应与患者讨论脑膜瘤风险,并且应研究对长期暴露于DMPA的患者进行脑膜瘤筛查的效用。需要进一步开展工作,以阐明PR信号在脑膜瘤中的机制,并理解肿瘤基因组学、激素暴露和信号传导以及可能促成脑膜瘤差异的健康社会和结构性驱动因素之间复杂的相互作用。
Gastroenterology IF 29.7 2026-10 PMID: 42142544
Surveillance for nonadvanced adenomas (NAAs) relies on lesion count, but evidence is limited for individuals with 3 to 4 or 5 to 10 NAAs and for size-based risk stratification. We evaluated advanced colorectal neoplasm (ACN; adenomas ≥10 mm, tubulovillous/villous histology, high-grade dysplasia, or cancer) risk by NAA count and size. A total of 16,870 adults aged 50 to 75 years with ≥2 colonoscopies (2004-2023) were classified into 4 groups by NAA count and by size (diminutive ≤5 mm vs small 6-9 mm). Over a median 5.3-year follow-up, ACN risk was assessed using inverse probability of censoring weighting and Cox regression. Participants were categorized by NAA count: 0 (n = 10,023), 1 to 2 (n = 5869), 3 to 4 (n = 781), and 5 to 10 (n = 197). The 5-year cumulative incidences of ACN were 1.3% (95% confidence interval [CI], 1.0%-1.5%), 4.0% (95% CI, 3.4%-4.7%), 5.3% (95% CI, 3.6%-7.8%), and 10.1% (95% CI, 5.8%-17.1%). Compared with no adenomas, hazard ratios were 1.64 (95% CI, 1.36-1.97), 2.75 (95% CI, 1.91-3.97), and 5.21 (95% CI, 2.89-9.38) for 1 to 2, 3 to 4, and 5 to 10 NAAs, respectively. In size-stratified analyses, 5-year ACN incidences were higher with ≥1 small adenoma than diminutive-only within the same count strata: 5.5% (95% CI, 4.0%-7.5%) vs 3.7% (95% CI, 3.0%-4.4%) for 1 to 2 NAAs, and 8.1% (95% CI, 5.1%-12.8%) vs 3.0% (95% CI, 1.5%-5.9%) for 3 to 4 NAAs. ACN risk increased with NAA count, with the highest risk observed in 5 to 10 NAAs, whereas 3 to 4 NAAs had a higher risk than 1 to 2 NAAs. Small adenomas further elevated risk within count-based groups. NAA number and size should both be considered when determining surveillance intervals.
中文摘要:非进展期腺瘤(NAA)的监测依赖病变数量,但对于有3至4枚或5至10枚NAA的个体以及基于大小的风险分层,证据有限。我们根据NAA数量和大小评估了进展期结直肠肿瘤(ACN;腺瘤≥10 mm、管状绒毛状/绒毛状组织学、高级别异型增生或癌)风险。共纳入16,870名年龄50至75岁、接受≥2次结肠镜检查(2004-2023年)的成人,并根据NAA数量和大小(微小≤5 mm vs 小6-9 mm)分为4组。在中位5.3年随访期间,使用删失逆概率加权和Cox回归评估ACN风险。参与者按NAA数量分类:0枚(n=10,023)、1至2枚(n=5,869)、3至4枚(n=781)和5至10枚(n=197)。ACN的5年累积发生率分别为1.3%(95%置信区间[CI],1.0%-1.5%)、4.0%(95%CI,3.4%-4.7%)、5.3%(95%CI,3.6%-7.8%)和10.1%(95%CI,5.8%-17.1%)。与无腺瘤相比,1至2枚、3至4枚和5至10枚NAA的风险比分别为1.64(95%CI,1.36-1.97)、2.75(95%CI,1.91-3.97)和5.21(95%CI,2.89-9.38)。在按大小分层的分析中,同一数量分层内,存在≥1枚小腺瘤者的5年ACN发生率高于仅微小腺瘤者:1至2枚NAA为5.5%(95%CI,4.0%-7.5%)vs 3.7%(95%CI,3.0%-4.4%),3至4枚NAA为8.1%(95%CI,5.1%-12.8%)vs 3.0%(95%CI,1.5%-5.9%)。ACN风险随NAA数量增加而增加,5至10枚NAA风险最高,而3至4枚NAA风险高于1至2枚NAA。在基于数量的分组中,小腺瘤进一步升高风险。在确定监测间隔时,应同时考虑NAA数量和大小。
Cancer discovery IF 29.5 2026-10-01 PMID: 42112793
This single-center prospective phase II trial evaluated [18F]RCCB6 (renal cell carcinoma B6) positron emission tomography (PET)/computed tomography (CT), a cluster of differentiation 70 (CD70)-targeting radiotracer, for detecting metastases in clear-cell renal cell carcinoma (ccRCC). After screening 291 patients, 150 patients with histologically confirmed ccRCC or suspected kidney cancer underwent imaging. Among 1,221 assessable extrarenal lesions, [18F]RCCB6 PET/CT achieved 94.2% sensitivity, 80% specificity, 93.1% accuracy, and 98.3% positive predictive value. In a head-to-head comparison of 99 patients with 683 lesions, [18F]RCCB6 significantly outperformed 2-deoxy-2-[fluorine-18]fluoro-D-glucose ([18F]FDG) PET/CT, with higher diagnostic sensitivity (90.5% vs. 41.1%) and specificity (81.4% vs. 24.3%; both P < 0.001). Compared with conventional imaging across 748 lesions, [18F]RCCB6 PET/CT also demonstrated superior sensitivity (90.8% vs. 75.1%) and specificity (81.6% vs. 56.6%). [18F]RCCB6 uptake (maximum standardized uptake value) strongly correlated with CD70 expression (r = 0.843; P < 0.001). Moreover, the imaging findings changed clinical management in 58.7% of patients. [18F]RCCB6 PET/CT is a highly sensitive imaging modality for diagnosing ccRCC metastases and informing clinical decision-making. This phase II trial demonstrates that [18F]RCCB6 PET/CT significantly outperforms conventional imaging and [18F]FDG PET/CT in detecting metastatic ccRCC, with 94.2% sensitivity and strong correlation with CD70 expression, altering clinical management in 58.7% of patients.
中文摘要:这项单中心前瞻性II期试验评估了[18F]RCCB6(肾细胞癌B6)正电子发射断层扫描(PET)/计算机断层扫描(CT),一种靶向分化簇70(CD70)的放射性示踪剂,用于检测透明细胞肾细胞癌(ccRCC)的转移。在筛选291例患者后,150例经组织学确诊的ccRCC或疑似肾癌患者接受了显像。在1,221个可评估的肾外病灶中,[18F]RCCB6 PET/CT达到94.2%的敏感性、80%的特异性、93.1%的准确性和98.3%的阳性预测值。在对99例患者、683个病灶的头对头比较中,[18F]RCCB6显著优于2-脱氧-2-[氟-18]氟-D-葡萄糖([18F]FDG)PET/CT,具有更高的诊断敏感性(90.5% vs. 41.1%)和特异性(81.4% vs. 24.3%;均P < 0.001)。在748个病灶中与传统影像学比较,[18F]RCCB6 PET/CT也显示出更高的敏感性(90.8% vs. 75.1%)和特异性(81.6% vs. 56.6%)。[18F]RCCB6摄取(最大标准化摄取值)与CD70表达强相关(r = 0.843;P < 0.001)。此外,影像学发现改变了58.7%患者的临床管理。[18F]RCCB6 PET/CT是一种高度敏感的显像方式,用于诊断ccRCC转移并指导临床决策。这项II期试验表明,[18F]RCCB6 PET/CT在检测转移性ccRCC方面显著优于传统影像学和[18F]FDG PET/CT,敏感性达94.2%,并与CD70表达强相关,改变了58.7%患者的临床管理。
Ophthalmology IF 10.9 2026-10 PMID: 42097331
To evaluate the individual and combined diagnostic performance of cytokine, molecular, and clonality biomarkers for primary vitreoretinal lymphoma (PVRL). Systematic review and meta-analysis. A total of 2411 patients from 41 studies with confirmed PVRL or benign ocular inflammatory diseases. Prospectively registered (CRD420251265910). Four databases were searched through November 25, 2025. Methodologic quality was assessed using QUADAS-2 and Comparative tools. Diagnostic accuracy was pooled using hierarchical summary receiver operating characteristic (HSROC) models with GRADE certainty assessment. Pooled sensitivity, specificity, and AUSROC for each biomarker with GRADE certainty ratings. Of 41 included studies, most were rated at high or unclear risk of bias across Quality Assessment of Diagnostic Accuracy Studies 2 domains, predominantly in patient selection because of retrospective designs and nonconsecutive sampling, and in the index test domain because of post hoc threshold selection. The interleukin (IL)-10 to IL-6 ratio (27 studies; 1370 patients; AUSROC, 0.98; sensitivity, 0.89; specificity, 0.98; I2 = 61% and 69%, respectively; low certainty) showed no publication bias. MYD88 (12 studies; 382 patients; AUSROC, 0.89; sensitivity, 0.73, specificity, 0.99; I2 = 37% and 68%, respectively; very low certainty), IGH (12 studies; 649 patients; AUSROC, 0.97; sensitivity, 0.85, specificity, 0.97; I2 = 80% and 87%, respectively; very low certainty), and IL-10 alone (11 studies; 549 patients; AUSROC, 0.94; sensitivity, 0.87, specificity, 0.95; I2 = 58% and 84%, respectively; low certainty) did not outperform IL-10 and IL-6 statistically. CD79B (4 studies; 123 patients; AUSROC, 1.00; sensitivity, 0.40; specificity, 1.00; I2 = 35% and 0%, respectively; low certainty) showed numerically higher accuracy (P = 0.055). Parallel testing of IL-10 to IL-6 ratio and MYD88 achieved 97.1% sensitivity and 97.0% specificity, reducing false-negative rates from 11% to 2.9%. Parallel testing of IL-10 to IL-6 ratio and MYD88 seemed to offer the highest diagnostic performance among evaluated strategies for PVRL, although this finding requires prospective validation given the low to very low certainty of the underlying evidence. Aqueous humor cytokine testing yielded higher diagnostic odds ratios than vitreous fluid, suggesting anterior paracentesis for IL-10 to IL-6 ratio before vitreous biopsy for molecular confirmation. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
中文摘要:评估细胞因子、分子和克隆性生物标志物对原发性玻璃体视网膜淋巴瘤(PVRL)的单独及联合诊断性能。系统综述和荟萃分析。共纳入来自41项研究的2411例确诊PVRL或良性眼部炎性疾病患者。前瞻性注册(CRD420251265910)。检索了4个数据库至2025年11月25日。采用QUADAS-2和Comparative工具评估方法学质量。采用分层汇总受试者工作特征(HSROC)模型合并诊断准确性,并进行GRADE证据确定性评估。报告各生物标志物的合并灵敏度、特异度和AUSROC及GRADE确定性评级。41项纳入研究中,多数在QUADAS-2各领域存在高或不明确的偏倚风险,主要见于患者选择领域,因回顾性设计和非连续抽样;以及指数试验领域,因事后阈值选择。白细胞介素(IL)-10与IL-6比值(27项研究;1370例患者;AUSROC 0.98;灵敏度0.89;特异度0.98;I2分别为61%和69%;低确定性)未显示发表偏倚。MYD88(12项研究;382例患者;AUSROC 0.89;灵敏度0.73,特异度0.99;I2分别为37%和68%;极低确定性)、IGH(12项研究;649例患者;AUSROC 0.97;灵敏度0.85,特异度0.97;I2分别为80%和87%;极低确定性)以及单独IL-10(11项研究;549例患者;AUSROC 0.94;灵敏度0.87,特异度0.95;I2分别为58%和84%;低确定性)在统计学上未优于IL-10与IL-6。CD79B(4项研究;123例患者;AUSROC 1.00;灵敏度0.40;特异度1.00;I2分别为35%和0%;低确定性)在数值上显示出更高的准确性(P = 0.055)。IL-10与IL-6比值和MYD88平行检测达到97.1%的灵敏度和97.0%的特异度,将假阴性率从11%降至2.9%。在PVRL的评估策略中,IL-10与IL-6比值和MYD88平行检测似乎具有最高的诊断性能,但鉴于现有证据的确定性为低至极低,该发现需要前瞻性验证。房水细胞因子检测的诊断比值比高于玻璃体液,提示可在玻璃体活检进行分子确认前,先行前房穿刺检测IL-10与IL-6比值。作者声明对本文讨论的任何材料均无专有或商业利益。

基础研究 (130篇)

Science advances IF 13.9 2026-10-09 PMID: 42842680
Immunoglobulin heavy chain (IGH) enhancer translocations drive multiple myeloma (MM), but routine diagnostics resolve only 32 to 38% of cases. Here, we introduce TransFinder, a multiomic pipeline integrating SMRT long-read sequencing (LRS), Hi-C, H3K27ac ChIP-seq/CUT&Tag, and RNA-seq to systematically resolve cryptic translocations and their hijacked oncogenes by deconvoluting enhancer-promoter neo-loops at rearrangement breakpoints. Applied to MM, TransFinder identified that t(16;22)(q23;q11), a canonical translocation known to activate MAF, also hijacks enhancers to activate RAB36. It further uncovered previously unrecognized t(5;8)(q35;q24) and t(1;22)(q25;q13), which activate MYC and CBX7, respectively, through chromatin topology rewiring. CRISPR-Cas9-engineered t(1;22)(q25;q13) recapitulated CBX7 induction, and pharmacological inhibition of CBX7 suppressed myeloma cell proliferation. Beyond MM, TransFinder identified enhancer hijacking in chronic myeloid leukemia, where t(9;22)(q34;q11) repositioned an enhancer to activate BCR-ABL1, and pancreatic ductal adenocarcinoma, where t(2;12)(p24;q24) hijacked an enhancer to activate SDC1. Linking 3D genome architecture to oncogene activation, TransFinder decodes oncogenic structural variants and their trans-activities, establishing clinically actionable dependencies of noncoding drivers in malignancies.
中文摘要:免疫球蛋白重链(IGH)增强子易位驱动多发性骨髓瘤(MM),但常规诊断仅能解析32%至38%的病例。在此,我们引入TransFinder,一种多组学流程,整合SMRT长读长测序(LRS)、Hi-C、H3K27ac ChIP-seq/CUT&Tag和RNA-seq,通过在重排断点处解卷积增强子-启动子新环,系统解析隐匿性易位及其劫持的癌基因。应用于MM,TransFinder发现t(16;22)(q23;q11)这一已知可激活MAF的经典易位,也劫持增强子以激活RAB36。它还揭示了既往未识别的t(5;8)(q35;q24)和t(1;22)(q25;q13),分别通过染色质拓扑重塑激活MYC和CBX7。CRISPR-Cas9工程化的t(1;22)(q25;q13)重现了CBX7诱导,且药理学抑制CBX7可抑制骨髓瘤细胞增殖。在MM之外,TransFinder在慢性髓性白血病中识别出增强子劫持,其中t(9;22)(q34;q11)重新定位一个增强子以激活BCR-ABL1;在胰腺导管腺癌中,t(2;12)(p24;q24)劫持一个增强子以激活SDC1。将三维基因组结构与癌基因激活联系起来,TransFinder解码致癌结构变异及其反式活性,确立了恶性肿瘤中非编码驱动因素的临床可操作依赖性。
Science advances IF 13.9 2026-10-09 PMID: 42842673
Transcriptional heterogeneity drives malignant progression, yet how it emerges within tumors remains unclear. By combining genetic perturbation and lineage tracing with parallel single-cell multiomics, we tracked the consequences of ARID1A loss within individual clonal lineages. ARID1A deficiency increased transcriptional variability both within and across clones, recurrently giving rise to diverse transcriptional profiles that did not converge on a common, coordinated pattern. This variability was accompanied by broadened chromatin accessibility at normally silenced loci and depended on residual SMARCA4 activity. Clones in which this variability was prominent showed no growth advantage under standard conditions but were preferentially recovered under specific environmental stresses and during lung colonization, a context dependence consistent with bet-hedging. Our findings suggest that loss of an epigenetic regulator can promote tumor evolution by relaxing transcriptional constraints and widening the range of phenotypes accessible to a clonal lineage, rather than by imposing a single fixed phenotype.
中文摘要:转录异质性驱动恶性进展,但其在肿瘤内如何产生仍不清楚。通过将遗传扰动和谱系追踪与平行单细胞多组学相结合,我们追踪了单个克隆谱系内ARID1A缺失的后果。ARID1A缺失增加了克隆内和克隆间的转录变异性,反复产生多样的转录谱,这些转录谱并未趋同于一种共同的、协调的模式。这种变异性伴随着通常沉默位点处染色质可及性的拓宽,并依赖于残留的SMARCA4活性。变异性显著的克隆在标准条件下没有生长优势,但在特定环境应激下以及在肺定植过程中优先被回收,这种情境依赖性与赌注对冲策略一致。我们的研究结果提示,表观遗传调控因子的缺失可通过放松转录限制并拓宽一个克隆谱系可及的表型范围来促进肿瘤进化,而不是强加一种单一固定的表型。
Science advances IF 13.9 2026-10-09 PMID: 42842654
Near-infrared (NIR) photocatalysis promises deep-tissue compatibilities but remains fundamentally constrained by two bottlenecks: insufficient photon energy and rapid charge recombination. Here, we report packing-accelerated consecutive excitation (PACE), a mechanism enabling low energy near-infrared (NIR) photons to drive high energy single electron transfer (SET) reactions. We design a self-assembling ruthenium complex, Ru-3, that forms densely packed nanoaggregates exhibiting aggregation-stabilized excited states, a pronounced excited state absorption band at ∼1315 nm, and nanosecond scale triplet lifetimes. Under dual NIR-I/IIa irradiation (808 nm/1310 nm), Ru-3 nanoparticles exhibit photophysical behavior consistent with consecutive photon harvesting and access to a higher-energy reactive state that supports efficient SET catalysis under aqueous conditions. This PACE-driven reactivity enables robust oxidation of mitochondrial NADH to NAD+, disrupting electron-transport homeostasis, inducing cGAS-STING dependent pyroptosis, and reprogramming tumor-associated macrophages toward an M1 phenotype. In multiple murine tumor models, PACE-mediated photocatalysis elicits strong antitumor immunity and leads to tumor regression with minimal systemic toxicity. This work establishes PACE as a new photochemical paradigm that overcomes the intrinsic energy and charge-separation limits of NIR photoredox chemistry, opening a route toward high-energy photocatalysis in complex biological environments.
中文摘要:近红外(NIR)光催化有望实现深层组织兼容性,但仍受到两个根本瓶颈的制约:光子能量不足和电荷快速复合。在此,我们报道了一种堆叠加速连续激发(PACE)机制,使低能量近红外(NIR)光子能够驱动高能量单电子转移(SET)反应。我们设计了一种自组装钌配合物Ru-3,其形成密集堆叠的纳米聚集体,表现出聚集稳定的激发态、在约1315 nm处显著的激发态吸收带以及纳秒级三重态寿命。在双NIR-I/IIa照射(808 nm/1310 nm)下,Ru-3纳米颗粒表现出与连续光子捕获以及获得更高能量反应态相一致的光物理行为,该反应态可在水相条件下支持高效SET催化。这种PACE驱动的反应性能够将线粒体NADH有效氧化为NAD+,破坏电子传递稳态,诱导cGAS-STING依赖性细胞焦亡,并将肿瘤相关巨噬细胞重编程为M1表型。在多种小鼠肿瘤模型中,PACE介导的光催化可激发强抗肿瘤免疫,并导致肿瘤消退且全身毒性极小。这项工作确立了PACE作为一种新的光化学范式,克服了近红外光氧化还原化学固有的能量和电荷分离限制,为在复杂生物环境中实现高能光催化开辟了途径。
Neuro-oncology IF 13.1 2026-10-08 PMID: 42844997
Glioblastoma (GBM) recurrence is driven by invasive tumor cells that infiltrate surrounding brain tissue and evade surgical and therapeutic eradication. While dysregulated iron handling is a well-recognized feature of malignant cancers, its contribution to invasive GBM cell states in the physiological context of human cortical tissue remains poorly defined. We performed multiregional single-nucleus RNA sequencing of human GBM specimens encompassing tumor core, tumor periphery, and infiltrated cortex to map iron-associated transcriptional programs validated by spatial transcriptomics. Correlative analyses were combined with functional validation using patient-derived GBM cell lines and human organotypic cortical slice cultures exposed to noncytotoxic iron supplementation to model iron-rich tumor microenvironments. Malignant cells from the tumor core exhibited coordinated upregulation of iron uptake and storage pathways alongside invasion-associated gene programs. At single-cell resolution, iron metabolism and invasion signatures were correlated, defining a core-enriched malignant subpopulation with mesenchymal-like transcriptional identity, stress-adaptive features, and angiogenic signaling that aggregate in specific spatial niches. Functionally, iron exposure altered migration in a cell-state-dependent manner and increased tumor growth and invasion in human cortical slice cultures. Increased VIM, MMP9, and HIF1A expression was consistent with activation of mesenchymal-like and stress-response programs, although mechanistic dependence was not tested. Iron-handling and invasion-associated programs co-occur in a core-enriched mesenchymal-like GBM state. In patient-derived cell and human cortical slice models, noncytotoxic particulate and soluble iron altered migration in a cell-state-dependent manner and increased tissue invasion. These findings support iron availability as a component of the microenvironment associated with invasive GBM phenotypes, while its necessity and underlying mechanism remain to be established.
中文摘要:胶质母细胞瘤(GBM)的复发由浸润周围脑组织并逃避手术及治疗清除的侵袭性肿瘤细胞驱动。尽管铁代谢失调是恶性肿瘤公认的特征,但其在人皮质组织生理背景下对侵袭性GBM细胞状态的贡献仍不明确。我们对涵盖肿瘤核心、肿瘤周边及受浸润皮质的人GBM标本进行了多区域单核RNA测序,以绘制经空间转录组学验证的铁相关转录程序。我们将相关性分析与功能验证相结合,使用患者来源的GBM细胞系和暴露于非细胞毒性铁补充的人器官型皮质切片培养物,以模拟富铁肿瘤微环境。肿瘤核心的恶性细胞表现出铁摄取和储存通路的协同上调,同时伴有侵袭相关基因程序。在单细胞分辨率下,铁代谢和侵袭特征相互关联,定义了一个核心富集的恶性亚群,其具有间充质样转录身份、应激适应特征和血管生成信号,并聚集在特定空间生态位中。在功能上,铁暴露以细胞状态依赖的方式改变迁移,并在人皮质切片培养物中增加肿瘤生长和侵袭。VIM、MMP9和HIF1A表达增加与间充质样和应激反应程序的激活一致,但未检测其机制依赖性。铁处理和侵袭相关程序在一个核心富集的间充质样GBM状态中共同出现。在患者来源细胞和人皮质切片模型中,非细胞毒性颗粒态和可溶性铁以细胞状态依赖的方式改变迁移,并增加组织侵袭。这些发现支持铁可利用性是与人侵袭性GBM表型相关的微环境组成部分,但其必要性和潜在机制仍有待确立。
Nature communications IF 18.1 2026-10-08 PMID: 42844286
Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is overexpressed on T‑ALL blasts from children and adolescents compared with lymphoid progenitors from healthy donors and is uniformly upregulated in nodal T-follicular helper cell lymphomas (nTFHL-AI, nTFHL-F). Using CRISPR/Cas9-mediated CD28 knockout to prevent fratricide, we generate highly functional anti‑CD28 CAR T cells with selective cytotoxicity against CD28⁺ T‑ALL. Anti‑CD28 CAR T cells match anti‑CD7 CAR T cells in vitro and in vivo, but cause markedly less lymphodepletion, largely sparing CD8 T cells and NK cells while preferentially depleting CD4 T cells, particularly TH2 and TH17 subsets. These findings establish CD28 as an actionable target for CAR T cell therapy of T cell malignancies.
中文摘要:目前,尚无免疫疗法获批用于T细胞急性淋巴细胞白血病(T-ALL)。靶向CD7的嵌合抗原受体(CAR)T细胞初始缓解率高,但受限于严重的T细胞缺乏和CD7阴性免疫逃逸,这凸显了对替代靶点的需求。在此,我们表明,与健康供者的淋巴祖细胞相比,CD28在儿童和青少年T-ALL原始细胞中过表达,并且在结节性T滤泡辅助细胞淋巴瘤(nTFHL-AI、nTFHL-F)中一致上调。利用CRISPR/Cas9介导的CD28敲除以防止自相残杀,我们生成了具有针对CD28阳性T-ALL选择性细胞毒性的高功能抗CD28 CAR T细胞。抗CD28 CAR T细胞在体外和体内均与抗CD7 CAR T细胞相当,但引起的淋巴细胞耗竭明显更少,在很大程度上保留了CD8 T细胞和NK细胞,同时优先耗竭CD4 T细胞,尤其是TH2和TH17亚群。这些发现确立了CD28作为T细胞恶性肿瘤CAR T细胞治疗的可操作靶点。
Signal transduction and targeted therapy IF 81.2 2026-10-08 PMID: 42844249
Messenger RNA (mRNA) vaccines have reshaped modern vaccinology by enabling rapid antigen design, scalable manufacturing, and coordinated induction of humoral and cellular immunity. Their clinical success has established mRNA as a versatile platform for infectious diseases, cancer immunotherapy, and emerging therapeutic applications. However, expansion into cardiovascular, neurodegenerative, autoimmune, and metabolic disorders imposes indication-specific requirements that cannot be addressed by uniform design strategies. Vaccine performance depends not only on antigen output, but also on how RNA architecture and delivery systems regulate innate sensing, intracellular trafficking, tissue distribution, and adaptive immune programming. In this review, we summarize bioengineering strategies for improving mRNA vaccine immunogenicity by coordinating antigen-expression efficiency with innate immune regulation. We compare non-replicating mRNA, self-amplifying RNA, and circular RNA in terms of expression kinetics, translational logic, safety considerations, and innate immune activation. We then discuss molecular engineering approaches that enhance stability, translation, and immune control, including optimization of cap structures, untranslated regions, poly(A) tails, nucleotide modifications, codon usage, and platform-specific designs for saRNA and circRNA. We further examine delivery systems, including lipid nanoparticles, exosomes, polymer-based carriers, virus-like particles, and hybrid platforms, emphasizing their dual roles in cargo transport and immune modulation. Finally, we discuss indication-specific design principles, manufacturing constraints, and translational challenges. We propose that next-generation mRNA vaccines will require disease-matched co-design of RNA molecules and delivery platforms to enhance antigen expression, tune immune activation, and strengthen clinical translation.
中文摘要:信使RNA(mRNA)疫苗通过实现快速抗原设计、可扩展生产以及协调诱导体液和细胞免疫,重塑了现代疫苗学。其临床成功已使mRNA成为一种通用平台,可用于传染病、癌症免疫治疗和新兴治疗应用。然而,向心血管、神经退行性、自身免疫和代谢性疾病的拓展提出了适应证特异性要求,而统一的设计策略无法满足这些要求。疫苗性能不仅取决于抗原输出,还取决于RNA结构和递送系统如何调控固有免疫识别、细胞内转运、组织分布和适应性免疫编程。在这篇综述中,我们总结了通过协调抗原表达效率与固有免疫调控来提高mRNA疫苗免疫原性的生物工程策略。我们比较了非复制型mRNA、自扩增RNA和环状RNA在表达动力学、翻译逻辑、安全性考虑和固有免疫激活方面的差异。随后,我们讨论了增强稳定性、翻译和免疫控制的分子工程方法,包括帽结构、非翻译区、poly(A)尾、核苷酸修饰、密码子使用优化,以及针对saRNA和circRNA的平台特异性设计。我们进一步审视递送系统,包括脂质纳米颗粒、外泌体、聚合物载体、病毒样颗粒和混合平台,强调其在货物运输和免疫调节中的双重作用。最后,我们讨论了适应证特异性设计原则、生产限制和转化挑战。我们提出,下一代mRNA疫苗将需要RNA分子与递送平台的疾病匹配协同设计,以增强抗原表达、调节免疫激活并加强临床转化。
Journal of biomedical science IF 14.5 2026-10-07 PMID: 42844615
Primary cilia are microtubule-based organelles protruding from the cell surface, which are conventionally understood as passive cellular antennae that detect extracellular stimuli. However, emerging evidence redefines these microtubule-based organelles as dynamic, bidirectional hubs that integrate environmental sensing with cellular metabolic adaptation. By selectively compartmentalizing receptors, ion channels, transporters, and signaling components, they function as specialized signal-processing compartments that receive, integrate, amplify, and relay information to coordinate cellular metabolism, adaptation, and cell-fate determination. Cilia-dependent signaling pathways regulate glucose and lipid metabolism, Ca2⁺ and second-messenger dynamics, and mitochondrial homeostasis. Conversely, environmental and metabolic changes remodel ciliary structure, molecular composition, and signaling competence. In this review, we present primary cilia as a bidirectional interface between environmental sensing and metabolic adaptation. We discuss how cilia respond to nutrient availability, mechanical forces, and oxygen tension, and how disruption of this sensory-metabolic interface contributes to metabolic, cardiovascular, reproductive, neurodegenerative, and cancer-related diseases. Defining the cellular and environmental contexts in which ciliary remodeling is protective or pathogenic will be essential for translating cilia biology into therapeutic strategies.
中文摘要:初级纤毛是突出于细胞表面的微管基细胞器,传统上被视为检测细胞外刺激的被动细胞天线。然而,新出现的证据重新将这些基于微管的细胞器定义为动态的双向枢纽,可将环境感知与细胞代谢适应整合在一起。通过选择性地将受体、离子通道、转运体和信号组分区室化,它们发挥专门的信号处理区室作用,接收、整合、放大并传递信息,以协调细胞代谢、适应与细胞命运决定。纤毛依赖性信号通路调控葡萄糖与脂质代谢、Ca²⁺与第二信使动态以及线粒体稳态。反之,环境与代谢变化会重塑纤毛结构、分子组成和信号传导能力。在本综述中,我们将初级纤毛呈现为环境感知与代谢适应之间的双向界面。我们讨论了纤毛如何响应营养可获得性、机械力和氧张力,以及这一感觉—代谢界面的破坏如何促成代谢性、心血管、生殖、神经退行性以及癌症相关疾病。明确纤毛重塑具有保护性还是致病性的细胞与环境背景,对于将纤毛生物学转化为治疗策略至关重要。
Nature IF 56.1 2026-10-07 PMID: 42844465
Lineage plasticity underlies therapeutic resistance in cancer1,2, yet the translational mechanisms that enable this phenotypic flexibility remain largely unknown. Here using prostate cancer as a model of lineage dependence, we performed unbiased small RNA sequencing and identified tRNA1Arg(UCU) as a regulator of lineage transitions and therapy resistance. tRNA1Arg(UCU) is capable of reprogramming lineage dependence, which can be tuned to restore sensitivity to therapies that target the androgen receptor. We identify TARDBP and ZSCAN29 as DNA-binding proteins that directly engage the genomic locus of tRNA1Arg(UCU) to regulate its expression, a result that highlights the importance of non-canonical tRNA-specific gene regulation. Mechanistically, tRNA1Arg(UCU) controls a translational program centred on SWI/SNF chromatin remodellers, which is necessary to maintain lineage fidelity. In patients, tRNA1Arg(UCU) is downregulated in neuroendocrine prostate cancer and its loss is associated with accelerated metastasis and poor survival. These findings uncover a previously unrecognized tRNA-specific regulatory axis that links codon biology to lineage dependence and therapy resistance in prostate cancer.
中文摘要:谱系可塑性是癌症治疗耐药的基础1,2,但使这种表型灵活性得以实现的翻译机制在很大程度上仍不清楚。在此,我们以前列腺癌作为谱系依赖的模型,进行了无偏小RNA测序,并鉴定出tRNA1Arg(UCU)是谱系转换和治疗耐药的调控因子。tRNA1Arg(UCU)能够重编程谱系依赖性,而调节这一过程可恢复对靶向雄激素受体的治疗的敏感性。我们鉴定出TARDBP和ZSCAN29是直接结合tRNA1Arg(UCU)基因组位点以调控其表达的DNA结合蛋白,这一结果凸显了非经典tRNA特异性基因调控的重要性。在机制上,tRNA1Arg(UCU)控制一个以SWI/SNF染色质重塑因子为中心的翻译程序,该程序是维持谱系保真性所必需的。在患者中,tRNA1Arg(UCU)在神经内分泌前列腺癌中下调,其缺失与转移加速和生存不良相关。这些发现揭示了一个此前未被认识的tRNA特异性调控轴,将密码子生物学与前列腺癌的谱系依赖性和治疗耐药联系起来。
Cancer discovery IF 29.5 2026-10-07 PMID: 42841273
Optogenetics, the Nobel-winning technology developed for neuroscience, is giving cancer researchers an unusually precise way to probe how tumors respond to signals from the nervous system. Scientists are also adapting optogenetics to build light-triggered cancer therapies, although significant technical barriers remain before such treatments can reach patients.
中文摘要:光遗传学是诺贝尔奖获奖技术,最初为神经科学开发,如今正为癌症研究人员提供一种异常精确的方法,以探究肿瘤如何对来自神经系统的信号作出反应。科学家也在改造光遗传学,以构建光触发癌症疗法,尽管此类治疗在能够惠及患者之前仍存在重大技术障碍。
Nature chemical biology IF 15.8 2026-10-06 PMID: 42839083
The precise temporal control of global mRNA methylation during the cell cycle is critical, yet the underlying mechanism remains unknown. Here we elucidate a noncanonical ubiquitination-mediated regulatory mechanism whereby RLIM deposits predominantly K27-linked ubiquitin (K27-Ub) on the m6A methyltransferase METTL14 in a cell-cycle-programmed manner. This modification modulates enzymatic activity by controlling METTL3-METTL14 complex assembly and RNA substrate engagement, independent of protein stability. We discover that transcriptome-wide mRNA m6A level, K27-Ub intensity on METTL14 and RLIM expression exhibit coordinated periodic oscillations during the cell cycle. Furthermore, this periodic regulation is mediated by CDK1/cyclin B1-directed phosphorylation of RLIM, triggering self-ubiquitination and proteasomal degradation. Functional investigations across multiple models, including human RLIM-knockout cells, myeloid-specific Rlim-knockout mice and participants with acute monocytic leukemia, demonstrate the pathophysiological importance of this previously unrecognized CDK1/cyclin B1-RLIM-METTL14-m6A axis. In summary, our findings identify a cell-cycle-coupled quality control mechanism for epitranscriptomic m6A regulation.
中文摘要:细胞周期中全局mRNA甲基化的精确时间控制至关重要,但其潜在机制仍不清楚。在此,我们阐明了一种非经典泛素化介导的调控机制,其中RLIM以细胞周期编程的方式主要将K27连接的泛素(K27-Ub)修饰沉积到m6A甲基转移酶METTL14上。该修饰通过控制METTL3-METTL14复合物组装和RNA底物结合来调节酶活性,而不依赖于蛋白质稳定性。我们发现,在细胞周期中,转录组范围的mRNA m6A水平、METTL14上的K27-Ub强度以及RLIM表达呈现协同的周期性振荡。此外,这种周期性调控由CDK1/cyclin B1导向的RLIM磷酸化介导,触发其自身泛素化和蛋白酶体降解。在多种模型中的功能研究,包括人RLIM敲除细胞、髓系特异性Rlim敲除小鼠以及急性单核细胞白血病参与者,证明了这一先前未被认识的CDK1/cyclin B1-RLIM-METTL14-m6A轴的病理生理重要性。总之,我们的发现鉴定了一种细胞周期偶联的m6A表观转录组调控质量控制机制。
Cancer research IF 22.6 2026-10-06 PMID: 42836583
Dysregulation of kidney organogenesis can lead to the development of Wilms tumor (WT), a common pediatric kidney cancer. Although numerous mutations implicated in WT have been identified through genomic studies, the cellular origin and driver mutations in WT remain unclear due to the lack of human models that preserve the complete lineage diversity of the developing kidney. Here, we established an in vitro condition to generate 3D human fetal kidney organoids (FekOs) phenocopying aspects of in vivo renal cellular heterogeneity and complex organization. FekOs faithfully recapitulated the spatial arrangement of ureteric bud (UB) structures and nephron segments. FekOs could be expanded over long time periods. Screening of clinically relevant mutations in WT identified key driver mutations and combinations that result in tumor-like neoplasms. Notably, distinct lineages were isolated from fetal kidney tissues to generate UB organoids and nephron organoids, mapping driver mutations to their specific cellular origins. Together, this model provides insights into how different mutations and their combinations drive Wilms tumorigenesis, providing a scalable platform for advancing human kidney developmental disease research.
中文摘要:肾脏器官发生的失调可导致肾母细胞瘤(WT)的发生,后者是一种常见的儿童肾脏恶性肿瘤。尽管基因组学研究已鉴定出许多与WT相关的突变,但由于缺乏能够保留发育中肾脏完整谱系多样性的人类模型,WT的细胞起源和驱动突变仍不明确。在此,我们建立了一种体外条件,用于生成三维人类胎儿肾脏类器官(FekOs),其在部分方面模拟了体内肾脏细胞异质性和复杂组织结构。FekOs忠实再现了输尿管芽(UB)结构和肾单位节段的空间排布。FekOs能够在较长时间内扩增。通过对WT中临床相关突变进行筛选,我们鉴定出可导致肿瘤样新生物的关键驱动突变及其组合。值得注意的是,我们从胎儿肾脏组织中分离出不同谱系,以生成UB类器官和肾单位类器官,从而将驱动突变映射到其特定细胞起源。总之,该模型为不同突变及其组合如何驱动肾母细胞瘤发生提供了见解,并为推进人类肾脏发育疾病研究提供了一个可扩展的平台。
Advanced healthcare materials IF 11.0 2026-10-06 PMID: 42834863
Vimentin is a cytoskeletal protein upregulated during epithelial-mesenchymal transition that can also be aberrantly displayed on the surface of multiple tumor cell types, making it a promising target for tumor imaging. Here, we develop epitope-imprinted polymer nanoparticles (nanoMIPs) for vimentin recognition through a two-step strategy comprising screening a library of non-imprinted nanoparticles to identify a lead formulation, followed by peptide-directed molecular imprinting. The resulting nanoMIPs exhibited enhanced apparent affinity for vimentin, with picomolar-range KD values, although these values represent model-dependent ensemble apparent affinities that may include contributions from multiple nanoparticle-ligand contacts and local rebinding rather than intrinsic monovalent affinities. The nanoMIPs preferentially bound cancer cells presenting cell-surface vimentin in vitro. The enhanced target binding and reduced off-target binding were consistent with an imprinting-associated improvement in molecular discrimination, although nonspecific physicochemical interactions were not completely eliminated. These findings extend epitope-guided nanoMIP design to structurally dynamic, cell surface-associated cytoskeletal targets, and support the development of synthetic receptors for tumor imaging. In vivo, the optimized nanoMIPs produced a tumor-associated fluorescence signal approximately 1.44 times that of the matched non-imprinted nanoparticles.
中文摘要:波形蛋白是一种细胞骨架蛋白,在上皮-间质转化过程中表达上调,也可异常展示于多种肿瘤细胞表面,因此成为有前景的肿瘤成像靶点。在此,我们通过两步策略开发用于波形蛋白识别的表位印迹聚合物纳米颗粒(nanoMIPs),包括筛选非印迹纳米颗粒文库以确定先导配方,随后进行肽导向的分子印迹。所得nanoMIPs对波形蛋白表现出增强的表观亲和力,KD值达到皮摩尔范围,尽管这些值代表依赖模型的整体表观亲和力,可能包含多个纳米颗粒-配体接触和局部再结合的贡献,而非内在单价亲和力。nanoMIPs在体外优先结合呈现细胞表面波形蛋白的癌细胞。增强的靶标结合和降低的脱靶结合与印迹相关的分子识别能力改善一致,尽管非特异性物理化学相互作用并未完全消除。这些发现将表位导向的nanoMIP设计拓展至结构动态、与细胞表面相关的细胞骨架靶标,并支持用于肿瘤成像的合成受体的开发。在体内,优化后的nanoMIPs产生的肿瘤相关荧光信号约为匹配的非印迹纳米颗粒的1.44倍。
Signal transduction and targeted therapy IF 81.2 2026-10-06 PMID: 42834042
Glutamine is the most abundant free amino acid in the body. It plays a central role in cellular metabolism, connecting synthetic and catabolic pathways, and maintaining life activities under physiological and pathological conditions. This review systematically explores the dual role of glutamine metabolism in health and disease. Glutamine is not only the main energy and nitrogen source for rapidly proliferating cells, such as immune cells, intestinal epithelial cells, and cancer cells but also participates in several key biological processes, such as nucleotide synthesis, REDOX balance, and immune regulation. Glutamine metabolism is often abnormally activated or disrupted in disease states, such as "glutamine addiction" in cancer and excitotoxicity and mitochondrial dysfunction in neurodegenerative diseases. Disorders of glutamine metabolism are also present in metabolic diseases (such as diabetes and MAFLD) and cardiovascular diseases. In addition, gut microbes regulate host glutamine metabolism through metabolites and signaling pathways, further affecting the disease process. Therapeutic strategies to target glutamine metabolism include inhibition of key enzymes or transporters, as well as exogenous glutamine supplementation. However, the effects of these strategies are context-dependent and need to be applied individually according to the specific pathological status of patients. Future research should focus on tissue-specific metabolic profiling, integrated multiomics analysis, and the development of combined treatment strategies to fully realize the potential of glutamine metabolism in disease treatment.
中文摘要:谷氨酰胺是体内最丰富的游离氨基酸。它在细胞代谢中发挥核心作用,连接合成与分解代谢途径,并在生理和病理条件下维持生命活动。本综述系统探讨谷氨酰胺代谢在健康与疾病中的双重作用。谷氨酰胺不仅是快速增殖细胞(如免疫细胞、肠上皮细胞和癌细胞)的主要能量与氮源,还参与核苷酸合成、氧化还原平衡和免疫调节等多个关键生物学过程。在疾病状态下,谷氨酰胺代谢常被异常激活或遭到破坏,例如癌症中的「谷氨酰胺成瘾」以及神经退行性疾病中的兴奋性毒性和线粒体功能障碍。代谢性疾病(如糖尿病和MAFLD)和心血管疾病中也存在谷氨酰胺代谢紊乱。此外,肠道微生物通过代谢物和信号通路调节宿主谷氨酰胺代谢,进一步影响疾病进程。靶向谷氨酰胺代谢的治疗策略包括抑制关键酶或转运体,以及外源性补充谷氨酰胺。然而,这些策略的效果取决于具体情境,需要根据患者的特定病理状态进行个体化应用。未来研究应聚焦于组织特异性代谢谱分析、整合多组学分析以及联合治疗策略的开发,以充分发挥谷氨酰胺代谢在疾病治疗中的潜力。
HemaSphere IF 11.3 2026-10 PMID: 42835773
Acute myeloid leukemia (AML) is a highly aggressive malignancy with poor prognosis, underlining the need for suitable model systems to develop novel treatments. To complement the few existing AML cell lines and restricted primografts, we transplanted more than 100 primary AML samples into immunocompromised mice and generated 23 exceptionally robust patient-derived xenograft (*PDX) models of AML that allow virtually unlimited serial transplantation and efficient genetic engineering. These models represent individuals of all age groups and several WHO subgroups. *PDX models substantially outperform AML cell lines in preserving leukemia biology and include AML subgroups for which no cell lines exist, such as cytogenetically normal or IDH1/2-mutant AML or simultaneous NPM1 mutation and FLT3-ITD. Their resilience to freeze-thaw cycles supports broad dissemination across research institutions through sharing via CancerModels.org. Using lentiviruses, we stably expressed luciferase for longitudinal, noninvasive, and sensitive real-time monitoring of leukemia burden and therapeutic response in vivo. This approach enabled rigorously controlled preclinical studies, including phase II-like trials, which demonstrated highly variable treatment responses between different *PDX models, mimicking the heterogeneity in patient cohorts. Long-term treatment, including repeated cytarabine exposure over 1 year, showed a yet undescribed decrease in leukemia's proliferation rate. These insights underscore the platform's distinctive capacity to study treatment dynamics over clinically relevant timeframes. Collectively, our unique resource represents a powerful, robust, and versatile platform with strong potential to accelerate translational AML research for the ultimate benefit of patients.
中文摘要:急性髓系白血病(AML)是一种高度侵袭性恶性肿瘤,预后较差,这凸显了开发合适模型系统以研发新疗法的必要性。为补充现有少数AML细胞系和有限的初代移植模型,我们将100多份原发性AML样本移植到免疫缺陷小鼠中,并构建了23个异常稳健的AML患者来源异种移植(PDX)模型,这些模型可实现几乎无限的连续移植和高效的基因工程改造。这些模型代表了所有年龄组和若干WHO亚组的个体。PDX模型在保留白血病生物学特征方面显著优于AML细胞系,并涵盖了一些尚无细胞系存在的AML亚组,例如细胞遗传学正常或IDH1/2突变型AML,或同时存在NPM1突变和FLT3-ITD的AML。它们对冻融循环的耐受性支持通过CancerModels.org共享,从而在研究机构间广泛传播。利用慢病毒,我们稳定表达了荧光素酶,用于在体内对白血病负荷和治疗反应进行纵向、无创且灵敏的实时监测。该方法使严格控制的临床前研究成为可能,包括类似II期的试验,这些试验显示不同PDX模型之间的治疗反应高度可变,模拟了患者队列中的异质性。长期治疗,包括超过1年的反复阿糖胞苷暴露,显示出一种此前未描述的白血病增殖速率下降。这些发现强调了该平台在研究具有临床相关时间跨度的治疗动态方面的独特能力。总体而言,我们这一独特资源代表了一个强大、稳健且多功能的平台,具有很大潜力加速AML的转化研究,最终造福患者。
Medicinal research reviews IF 13.6 2026-10-05 PMID: 42834679
Cancer remains a major clinical challenge due to persistent therapy resistance, despite significant treatment advances. While chemotherapy often induces initial regression, tumors adapt through complex mechanisms, with autophagy playing a pivotal role. As a conserved cytoplasmic turnover pathway, autophagy protects tumor cells under stress by recycling damaged components and reducing drug toxicity. However, it is also paradoxically capable of triggering autophagic cell death when activated excessively. Importantly, the balance is intricately fine-tuned by short non-coding miRNAs, which orchestrate the regulation of autophagy-related genes (ATGs), thereby influencing cancer cell survival and shaping response to chemotherapy. Although several miRNA-based therapeutics have advanced into preclinical and early clinical testing, most target canonical oncogenic signaling or immune modulation, while the autophagy-specific dimension remains largely unexplored, leaving a translational gap. In this review, we highlight the emerging role of the miRNA-autophagy axis in resistance and propose it as a promising frontier for therapeutic intervention. We further suggest that leveraging miRNA-based autophagy modulation with nanodrugs and conventional therapies could provide a multimodal framework to overcome resistance, reduce toxicity, and advance precision cancer treatment.
中文摘要:尽管治疗取得了显著进展,癌症仍因持续存在的治疗耐药而构成重大临床挑战。化疗常可诱导初始缓解,但肿瘤会通过复杂机制发生适应,其中自噬发挥关键作用。作为一种保守的细胞质周转途径,自噬通过在应激条件下回收受损成分并降低药物毒性来保护肿瘤细胞。然而,矛盾的是,当自噬被过度激活时,它也可能触发自噬性细胞死亡。重要的是,这种平衡受到短链非编码miRNA的精细调控,这些miRNA协调自噬相关基因(ATGs)的调控,从而影响癌细胞存活并塑造化疗反应。尽管若干基于miRNA的治疗药物已进入临床前和早期临床测试,但大多数靶向经典致癌信号或免疫调节,而自噬特异性的维度在很大程度上仍未得到探索,留下了转化空白。在这篇综述中,我们强调miRNA-自噬轴在耐药中的新兴作用,并提出其作为治疗干预的一个有前景的前沿方向。我们进一步提出,利用基于miRNA的自噬调节联合纳米药物和常规疗法,可能提供一个多模式框架,以克服耐药、降低毒性并推进精准癌症治疗。
Nature cell biology IF 22.7 2026-10-05 PMID: 42834166
Tryptophan codon-specific mistranslation, in the form of ribosomal frameshifting and tryptophan-to-phenylalanine (W > F) codon reassignments (substitutants), is induced in cancer cells by the limiting level of tryptophan imposed by anti-tumour immunity. While the oncogenic mitogen-activated protein kinase pathway drives frameshifting, whether substitutants are genetically regulated remains unknown. Here we screened for genes that control W > F substitutants following interferon-γ-mediated tryptophan shortage. This screen identified ADAR1, an enzyme that converts adenosine to inosine in double-stranded RNA molecules, and FTSJ1, an enzyme that 2'-O-methylates the anticodon region of several tRNAs. We demonstrate that ADAR1 sustains expression of key players in the ribosome quality control pathway, which in turn is essential for mistranslation events. FTSJ1, in contrast, specifically drives W > F mistranslation by methylation of tRNATrp to promote its binding to WARS1 loaded with phenylalanine instead of tryptophan. As ADAR1 and FTSJ1 levels are elevated in many cancer types, we propose that cancer cells deploy global and specific mechanisms to promote mistranslation in response to anti-tumour immunity.
中文摘要:色氨酸密码子特异性误译,表现为核糖体移码和色氨酸到苯丙氨酸(W>F)的密码子重新分配(替代产物),是由抗肿瘤免疫造成的色氨酸限制在癌细胞中诱导产生的。尽管致癌性丝裂原活化蛋白激酶通路驱动移码,但替代产物是否受遗传调控仍不清楚。在此,我们筛选了在干扰素-γ介导的色氨酸短缺后控制W>F替代产物的基因。该筛选鉴定出ADAR1,一种将双链RNA分子中的腺苷转化为肌苷的酶,以及FTSJ1,一种对若干tRNA反密码子区域进行2'-O-甲基化的酶。我们证明ADAR1维持核糖体质量控制通路中关键因子的表达,而这反过来对误译事件至关重要。相比之下,FTSJ1通过对tRNA^Trp的甲基化特异性驱动W>F误译,从而促进其与装载苯丙氨酸而非色氨酸的WARS1结合。由于ADAR1和FTSJ1水平在多种癌症类型中升高,我们提出癌细胞部署全局性和特异性机制,以在应对抗肿瘤免疫时促进误译。
Journal of hepatology IF 40.1 2026-10-05 PMID: 42833310
Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are inflammatory bile duct disorders affecting mostly young adults that often lead to liver cirrhosis and cancer. Especially for PSC, pathogenic mechanisms remain unclear and treatment options are lacking. To better understand biliary disease processes in bile duct inflammation, we analyzed livers of NOD.c3c4 mice by spatial and single-cell (scRNA-seq) transcriptomics, identifying key cell types, interactions and potential changes over time that were validated in human liver explants. Livers of 10, 20 and 40-week-old male NOD.c3c4 mice were used for spatial transcriptomics and scRNA-seq. Differentially-expressed genes at different time points were analyzed using the CellphoneDB database with a focus on T cell-related interactions. CD226-NECTIN2 interaction was validated using co-culture experiments and antibody treatment in NOD.c3c4 mice. CD226-NECTIN2 in PSC, PBC and alcohol-related liver disease (ALD) explants was analyzed by spatial transcriptomics and immunofluorescence. Spatial transcriptomics consistently distinguished inflamed and non-inflamed liver areas in NOD.c3c4 mice at different ages. When combined with scRNA-seq enriched for immune cells and cholangiocytes, key inflammatory cell types were localized to biliary structures. Using differentially-expressed genes and a curated overview of biologically-validated interactions (CellphoneDB), the CD226-NECTIN2 T cell-cholangiocyte interaction was discovered. Knock-down of Nectin2 in vitro and anti-CD226 blocking in NOD.c3c4 mice specifically reduced T cell activation and diseased human liver showed consistent CD226-NECTIN2 co-localization at inflamed bile ducts. By combining spatial transcriptomics and scRNA-seq in NOD.c3c4 mice, we generated a pipeline for in-depth identification of potential disease relevant genes and interaction partners. The T cell-cholangiocyte interaction CD226-NECTIN2 was identified, functionally validated and detected in human disease highlighting this interaction as a possible future treatment target. PSC is an intractable immune-mediated cholestatic liver disease that mainly affects young people and has a significant impact on families and the healthcare system due to treatment costs and sick leave. Our study aimed to find new ways of understanding PSC and highlight potential treatment targets by first identifying disease-relevant cell interactions in a mouse model, followed by confirmation in human PSC livers.
中文摘要:原发性硬化性胆管炎(PSC)和原发性胆汁性胆管炎(PBC)是炎症性胆管疾病,主要影响年轻成人,常导致肝硬化和癌症。尤其是PSC,其致病机制仍不清楚,且缺乏治疗选择。为更好地理解胆管炎症中的胆道疾病过程,我们通过空间和单细胞(scRNA-seq)转录组学分析了NOD.c3c4小鼠的肝脏,识别出关键细胞类型、相互作用以及可能随时间发生的变化,并在人肝外植体中进行了验证。使用10、20和40周龄雄性NOD.c3c4小鼠的肝脏进行空间转录组学和scRNA-seq。使用CellphoneDB数据库分析不同时间点的差异表达基因,重点关注T细胞相关相互作用。通过共培养实验和在NOD.c3c4小鼠中进行抗体治疗,验证了CD226-NECTIN2相互作用。通过空间转录组学和免疫荧光分析了PSC、PBC和酒精相关性肝病(ALD)外植体中的CD226-NECTIN2。空间转录组学一致地区分了不同年龄NOD.c3c4小鼠的炎症和非炎症肝区域。当与富集免疫细胞和胆管细胞的scRNA-seq结合时,关键炎症细胞类型被定位到胆道结构。利用差异表达基因和经生物学验证的相互作用精选概览(CellphoneDB),发现了CD226-NECTIN2 T细胞-胆管细胞相互作用。体外敲低Nectin2以及在NOD.c3c4小鼠中阻断抗CD226,特异性降低了T细胞活化,患病的人肝脏显示在炎症胆管处一致的CD226-NECTIN2共定位。通过在NOD.c3c4小鼠中结合空间转录组学和scRNA-seq,我们建立了一个流程,用于深入识别潜在的疾病相关基因和相互作用伙伴。T细胞-胆管细胞相互作用CD226-NECTIN2被识别、功能验证,并在人类疾病中检测到,突显该相互作用作为未来可能治疗靶点。PSC是一种难治的免疫介导的胆汁淤积性肝病,主要影响年轻人,并且由于治疗费用和病假对家庭和医疗系统产生重大影响。我们的研究旨在通过首先在小鼠模型中识别疾病相关细胞相互作用,随后在人类PSC肝脏中确认,找到理解PSC的新方法并突出潜在治疗靶点。
EBioMedicine IF 11.2 2026-10-05 PMID: 42832887
Traditional metabolic inhibitors have limited clinical efficacy, with issues such as narrow window periods, and compensatory effects. These barriers indicate that effective metabolic therapy requires spatially restricted, temporally coordinated, cell-context-aware, and clinically stratifiable intervention. This review examines how glucose-lactate, lipid-redox, amino acid-immune checkpoint, and nucleotide-adenosine circuits drive tumour progression, immune suppression, and therapeutic escape. We then define the engineering advantages that distinguish nanomedicine from free metabolic drugs, including spatiotemporal control, smart and responsive release, multi-target co-delivery, and organelle targeting. Representative nanomedicine strategies are discussed according to the immunometabolic circuits they modulate, with emphasis on their ability to overcome metabolic compensation, restore immune cell function, and address tumour heterogeneity. Finally, we evaluate key translational challenges, including chemistry, manufacturing and control (CMC), regulatory obstacles, and biomarker selection. This review proposes clinically actionable design principles of nanomedicine for immunometabolic reprogramming.
中文摘要:传统代谢抑制剂临床疗效有限,存在治疗窗口期窄、代偿效应等问题。这些障碍表明,有效的代谢治疗需要空间受限、时间协调、细胞情境感知且可在临床上分层的干预。本综述探讨葡萄糖-乳酸、脂质-氧化还原、氨基酸-免疫检查点以及核苷酸-腺苷回路如何驱动肿瘤进展、免疫抑制和治疗逃逸。随后,我们界定纳米药物区别于游离代谢药物的工程学优势,包括时空控制、智能响应释放、多靶点共递送和细胞器靶向。文中根据所调控的免疫代谢回路讨论代表性纳米药物策略,重点阐述其克服代谢代偿、恢复免疫细胞功能以及应对肿瘤异质性的能力。最后,我们评估关键转化挑战,包括化学、生产和控制(CMC)、监管障碍以及生物标志物选择。本综述提出用于免疫代谢重编程的纳米药物的临床可行动设计原则。
Blood IF 23.9 2026-10-05 PMID: 42832421
ALK-positive Anaplastic Large Cell Lymphoma (ALK+ ALCL) is a rare yet aggressive T-cell lymphoma, most often characterized by the NPM1::ALK fusion. Because few somatic variants have been identified in ALK+ ALCL, we conducted paired whole-exome sequencing of patient tumors with matched normal tissue. Compared with previous studies, we identified a higher frequency of mutations in cohesin complex genes, mostly STAG2 variants (6/16) predicted to impair protein function. Immunohistochemistry confirmed loss of STAG2 in additional patient tumor samples. Using an original model of NPM1::ALK-driven lymphomagenesis that recapitulates early steps of ALK-driven transformation initiated in primary T lymphocytes, we demonstrated that STAG2 defect accelerates oncogenesis, enhancing early cell proliferation of ALK-positive cells. Single-cell RNA-seq revealed that STAG2 depletion accelerates the early acquisition of the major ALK+ ALCL hallmarks and concomitantly reduces the oncogene-induced senescence signature. Despite higher ALK expression and robust cell transformation, STAG2 depletion resulted in the attenuation of the global ALK+ ALCL transcriptional program. Importantly, STAG2 expression was found decreased upon NPM1::ALK induction, indicating intrinsic downregulation during transformation even without genomic mutations. We also successfully identified STAG2-low/ALK-high cells in both patient-derived tumors and PDX models. Functionally, STAG2-depleted cells exhibit increased cell adhesion and migration, alongside constitutive YAP1 activation and upregulation of adhesion molecule such as ALCAM and CD44 but also increased PD-L1. Overall, our findings reveal that STAG2 loss plays a key role during the earliest stages of ALK+ ALCL lymphomagenesis by promoting cell tolerance to NPM1::ALK expression and increasing permissiveness to malignant transformation while also impacting cell adhesion, migration.
中文摘要:ALK阳性间变性大细胞淋巴瘤(ALK+ ALCL)是一种罕见但侵袭性的T细胞淋巴瘤,最常以NPM1::ALK融合为特征。由于在ALK+ ALCL中已发现的体细胞变异较少,我们开展了患者肿瘤与配对的正常组织的配对全外显子组测序。与既往研究相比,我们发现了黏连蛋白复合体基因突变频率更高,其中大多为STAG2变异(6/16),预计会损害蛋白功能。免疫组织化学在额外的患者肿瘤样本中证实了STAG2缺失。我们利用一种原创的NPM1::ALK驱动淋巴瘤发生模型,该模型重现了在原发性T淋巴细胞中启动的ALK驱动转化的早期步骤,证明STAG2缺陷加速肿瘤发生,增强ALK阳性细胞的早期细胞增殖。单细胞RNA测序显示,STAG2耗竭加速了主要ALK+ ALCL标志的早期获得,并同时降低了癌基因诱导的衰老特征。尽管ALK表达更高且细胞转化显著,STAG2耗竭却导致整体ALK+ ALCL转录程序的减弱。重要的是,在NPM1::ALK诱导后发现STAG2表达降低,表明即使没有基因组突变,转化过程中也存在内在下调。我们还在患者来源肿瘤和PDX模型中成功鉴定出STAG2低/ALK高的细胞。在功能上,STAG2耗竭细胞表现出细胞黏附和迁移增加,同时伴有YAP1持续激活以及黏附分子如ALCAM和CD44的上调,但也出现PD-L1增加。总体而言,我们的发现揭示,STAG2缺失在ALK+ ALCL淋巴瘤发生的最早阶段发挥关键作用,通过促进细胞对NPM1::ALK表达的耐受并增加对恶性转化的允许性,同时还影响细胞黏附和迁移。
Advanced healthcare materials IF 11.0 2026-10-04 PMID: 42830420
On-chip 3D cancer models are important tools to investigate treatment response and tumor biology. With their increasing adoption, there is a need for non-destructive methods that enable the sequential monitoring of cell death and tumor response over time. This study presents quantifying cell-free DNA (cfDNA) as a proxy for cell death for on-chip 3D sarcoma models. qPCR analysis of media cfDNA from spheroids and micro-dissected tumor explants (MDTs) generated from SK-LMS-1 and MCA-205 cell lines cultured on microfluidic chips showed a correlation between baseline cfDNA concentration and on-chip tumor burden. Furthermore, cfDNA levels increased in a dose-dependent manner following cytotoxic treatments, including staurosporine and hydrogen peroxide. Single-dose radiation therapy also raised cfDNA levels in media from MCA-205 but not SK-LMS-1 MDTs, in accordance with their 2D culture response. Finally, cfDNA release within the first days of culture was shown to reflect patient-derived MDT survival, addressing a critical unmet need for ex vivo culture. This study suggests that media cfDNA quantification could be used as a reliable, non-disruptive, and rapidly quantifiable measure of cell death for on-chip 3D models, which facilitates more robust use of 3D model systems for pre-clinical assessment of treatment-induced cell death and biological response.
中文摘要:芯片上三维肿瘤模型是研究治疗反应和肿瘤生物学的重要工具。随着其应用日益增多,需要非破坏性方法以便随时间连续监测细胞死亡和肿瘤反应。本研究提出将游离DNA(cfDNA)定量作为芯片上三维肉瘤模型细胞死亡的替代指标。对在微流控芯片上培养的SK-LMS-1和MCA-205细胞系所形成的球状体及显微切割肿瘤外植体(MDT)的培养基cfDNA进行qPCR分析显示,基线cfDNA浓度与芯片上肿瘤负荷相关。此外,在星形孢菌素和过氧化氢等细胞毒性处理后,cfDNA水平呈剂量依赖性升高。单次剂量放疗也提高了MCA-205而非SK-LMS-1 MDT培养基中的cfDNA水平,这与其二维培养反应一致。最后,培养最初几天内的cfDNA释放被证明可反映患者来源MDT的存活,满足了离体培养中一个关键的未满足需求。本研究表明,培养基cfDNA定量可作为芯片上三维模型中可靠、非破坏性且可快速量化的细胞死亡指标,有助于更稳健地利用三维模型系统进行临床前评估治疗诱导的细胞死亡和生物学反应。
Cancer letters IF 11.8 2026-10-04 PMID: 42830144
Standard chemotherapy effectively induces complete remission in most children with acute myeloid leukemia (AML), however relapse remains the main cause of treatment failure. Leukemia stem cells (LSCs) are proposed to constitute a therapy-resistant reservoir driving disease recurrence, but their reliable identification remains unresolved. We explored intracellular reactive oxygen species (ROS) levels in pediatric AML at diagnosis and sorted ROS-low (RL) and ROS-high (RH) cell fractions. We found that RL cells exhibited increased quiescence, sustained serial colony-forming capacity and engraftment in mice when compared to the RH fraction. Moreover, in a 3D niche model, RL cells preferentially localized to hypoxic regions and were resistant to cytarabine, altogether indicating enrichment for functional LSCs. Transcriptomic analyses revealed enrichment of stemness, adhesion and niche-interaction programs in RL cells, alongside downregulation of mitochondrial and oxidative phosphorylation pathways. Consistently, RL cells displayed reduced oxygen consumption and ATP production, together with remodeled cristae structure despite preserved mitochondrial mass. Paradoxically, complex I inhibition selectively impaired RL cell viability, indicating a dependency on oxidative phosphorylation. Using RL transcriptome, we derived a gene signature that, when applied to single-cell RNA-sequencing data of pediatric AML cases, identified LSCs within the bulk regardless of differentiation status, and showed significant prognostic value. Finally, transcriptional program trajectory indicated that RL fraction contributed to generate the whole AML bulk, whereas gene mutations were maintained in RL and RH cells. Overall, this ROS-based strategy represents a new tool to isolate stem cells transcending traditional markers, and identifies novel clinically relevant vulnerabilities to target LSCs.
中文摘要:标准化学治疗可有效诱导大多数儿童急性髓系白血病(AML)患者获得完全缓解,但复发仍是治疗失败的主要原因。白血病干细胞(LSC)被认为构成一个治疗耐药储库,驱动疾病复发,但其可靠鉴定仍未解决。我们探索了初诊儿童AML的细胞内活性氧(ROS)水平,并分选出ROS低(RL)和ROS高(RH)细胞组分。我们发现,与RH组分相比,RL细胞表现出更强的静止状态、持续的多代集落形成能力以及在小鼠中的植入能力。此外,在三维微环境模型中,RL细胞优先定位于缺氧区域,并对阿糖胞苷耐药,这些结果共同表明RL细胞中富集功能性LSC。转录组分析显示,RL细胞中干性、黏附和微环境相互作用程序富集,同时线粒体和氧化磷酸化通路下调。与此一致,RL细胞表现出氧消耗和ATP生成减少,并且尽管线粒体质量保留,但其嵴结构发生重塑。矛盾的是,复合体I抑制可选择性地损害RL细胞活力,提示其依赖氧化磷酸化。利用RL转录组,我们推导出一个基因特征;将其应用于儿童AML病例的单细胞RNA测序数据时,可在整体细胞群中鉴定出LSC,无论分化状态如何,并显示出显著的预后价值。最后,转录程序轨迹表明,RL组分参与生成整个AML细胞群体,而基因突变在RL和RH细胞中保持不变。总体而言,这种基于ROS的策略代表了一种超越传统标志物来分离干细胞的新工具,并识别出靶向LSC的新的临床相关脆弱点。
Cancer letters IF 11.8 2026-10-03 PMID: 42829068
GlycoRNAs, a recently discovered category of covalently glycosylated RNA molecules that are predominantly enriched in small non-coding RNAs (sncRNAs) and reportedly displayed on the cell surface and within extracellular vesicles (EVs), have emerged as a novel signaling layer in cancer biology. Through specific interactions with sialic acid-binding immunoglobulin-like lectins (Siglecs), P-selectin, and heparan sulfate-vascular endothelial growth factor (VEGF) complexes, glycoRNAs may contribute to intercellular communication, inflammatory responses, and angiogenesis, highlighting their potential involvement in tumor progression and immune evasion. However, as glycoRNA research remains at an early stage, the clinical translation of glycoRNA-based findings is hindered by a series of fundamental unresolved questions. For instance, the biogenesis and trafficking mechanisms of glycoRNAs are still poorly defined, nucleotide-resolution maps of endogenous glycosylation sites are lacking, detection platforms have yet to be standardized and pervasive platform-dependent quantification bias has not been systematically addressed. In this review, we integrate current advances across the structural, mechanistic, and translational dimensions of cancer-associated glycoRNA biology, and propose a roadmap to advance the field from a fundamental biochemical curiosity toward a clinically actionable target in oncology.
中文摘要:GlycoRNAs是最近发现的一类共价糖基化RNA分子,主要富集于小非编码RNA(sncRNA),据报道可展示于细胞表面和细胞外囊泡(EVs)中,已成为癌症生物学中一个新的信号层。通过与唾液酸结合免疫球蛋白样凝集素(Siglecs)、P-选择素以及硫酸乙酰肝素-血管内皮生长因子(VEGF)复合物的特异性相互作用,glycoRNA可能促进细胞间通讯、炎症反应和血管生成,凸显其参与肿瘤进展和免疫逃逸的潜力。然而,由于glycoRNA研究仍处于早期阶段,基于glycoRNA发现的临床转化受到一系列尚未解决的基本问题阻碍。例如,glycoRNA的生物发生和运输机制仍不明确,缺乏内源性糖基化位点的核苷酸分辨率图谱,检测平台尚未标准化,且普遍存在的平台依赖性定量偏倚尚未得到系统解决。在本综述中,我们整合了癌症相关glycoRNA生物学在结构、机制和转化维度上的当前进展,并提出路线图,以推动该领域从基础生物化学上的新奇现象发展为肿瘤学中具有临床可操作性的靶点。
Science advances IF 13.9 2026-10-02 PMID: 42826211
Intraoperative fluorescence imaging holds great promise for achieving complete cytoreduction in ovarian cancer, but its clinical utility is currently constrained by the limitations of existing imaging agents. In particular, the leading clinical probe, OTL38, operates in the near-infrared I (NIR-I; 700 to 1000 nanometers) window, which suffers from limited tissue penetration and suboptimal resolution. Here, a folate receptor α (FRα)-targeted NIR-II (1000 to 3000 nanometers) imaging probe was developed by incorporating a 4-(4-iodophenyl)butanoic acid moiety. This structural modification enables albumin binding, thereby prolonging systemic circulation and enhancing accumulation in FRα-positive tumors. In murine models of peritoneal metastasis, our probe enabled precise visualization of occult lesions undetectable by the naked eye. Compared to OTL38, this probe demonstrated superior tumor detection sensitivity (90.20% versus 78.75%) and allowed for the reliable identification of elusive lesions less than or equal to 3 millimeters in diameter. These findings highlight the potential of albumin-binding NIR-II imaging strategies to overcome the limitations of current clinical probes and enhance precision fluorescence-guided surgery.
中文摘要:术中荧光成像在实现卵巢癌完全肿瘤细胞减灭方面具有巨大前景,但其临床应用目前受限于现有成像剂的局限性。尤其是领先的临床探针OTL38,其工作于近红外I(NIR-I;700至1000纳米)窗口,存在组织穿透有限和分辨率欠佳的问题。在此,通过引入4-(4-碘苯基)丁酸部分,开发了一种靶向叶酸受体α(FRα)的近红外II(NIR-II;1000至3000纳米)成像探针。这种结构修饰可实现白蛋白结合,从而延长全身循环并增强在FRα阳性肿瘤中的蓄积。在腹膜转移小鼠模型中,我们的探针能够精确显示肉眼无法检测的隐匿病灶。与OTL38相比,该探针表现出更高的肿瘤检测灵敏度(90.20%对78.75%),并可可靠识别直径小于或等于3毫米的难以发现病灶。这些发现凸显了白蛋白结合型NIR-II成像策略在克服当前临床探针局限性并提升精准荧光引导手术方面的潜力。
Science advances IF 13.9 2026-10-02 PMID: 42826199
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic cancers but has shown limited efficacy in solid tumors, including pancreatic ductal adenocarcinoma (PDAC). The cellular and molecular factors that influence CAR T cell therapy response remain largely unknown. By integrating modular in vivo CRISPR screens with single-cell genomics and immunocompetent orthotopic models of PDAC, we uncover oxidative and proteotoxic stress pathways as previously unknown modulators of CAR T cell therapy response. Disruption of stress regulatory genes, particularly Keap1 and Slc33a1, sensitizes PDAC tumors to CAR T cell killing in vivo. Hyperactivation of the Nrf2 pathway by genetic ablation of Keap1 or endogenous engineering of clinically observed Keap1 or Nfe2l2 mutations enhances tumor susceptibility to CAR T cell therapy. Thus, tumor-intrinsic molecular stress phenotypes can induce unexpected cell state-specific vulnerabilities to cell-based immunotherapies. These findings provide a foundation to improve efficacy of CAR T cell therapy in solid malignancies and to better stratify patients with cancer by tumor genotype.
中文摘要:嵌合抗原受体(CAR)T细胞疗法已改变血液肿瘤的治疗格局,但在包括胰腺导管腺癌(PDAC)在内的实体瘤中疗效有限。影响CAR T细胞治疗反应的细胞和分子因素在很大程度上仍不清楚。通过将模块化体内CRISPR筛选与单细胞基因组学及具有免疫能力的PDAC原位模型相结合,我们揭示了氧化应激和蛋白质毒性应激通路是此前未知的CAR T细胞治疗反应调节因子。破坏应激调控基因,尤其是Keap1和Slc33a1,可使PDAC肿瘤在体内对CAR T细胞杀伤敏感。通过遗传消融Keap1或对临床观察到的Keap1或Nfe2l2突变进行内源性工程化以过度激活Nrf2通路,可增强肿瘤对CAR T细胞治疗的易感性。因此,肿瘤内在的分子应激表型可诱导对细胞免疫疗法产生意想不到的细胞状态特异性脆弱性。这些发现为改善CAR T细胞疗法在实体恶性肿瘤中的疗效以及根据肿瘤基因型更好地对癌症患者进行分层提供了基础。
Science advances IF 13.9 2026-10-02 PMID: 42826195
The molecular mechanisms linking chromosome homeostasis to fibroblast reprogramming into cancer-associated fibroblasts (CAFs) remain poorly understood. Here, we identify a clinically relevant, telomere-associated nuclear pathway driving CAF activation across multiple human cancers. The long noncoding RNA TERRA is consistently elevated in CAFs from skin, lung, and breast tumors. We show that the androgen receptor (AR) represses TERRA transcription through subtelomeric binding, and its loss enables TERRA up-regulation and interaction with the RNA binding protein NONO. This interaction forms a CAF-specific nuclear complex that reprograms gene expression. Mechanistically, NONO is directly recruited to and binds the promoters of key CAF effector genes, where it regulates their transcription in a TERRA-dependent manner. Disrupting the TERRA-NONO axis, via TERRA silencing or pharmacologic NONO inhibition, reverses CAF activation and suppresses tumor-stroma interactions in vitro and in vivo, highlighting its therapeutic potential.
中文摘要:将染色体稳态与成纤维细胞重编程为癌症相关成纤维细胞(CAFs)联系起来的分子机制仍知之甚少。在此,我们鉴定出一条具有临床相关性、与端粒相关的核内通路,该通路驱动多种人类癌症中的CAF活化。长链非编码RNA TERRA在来自皮肤、肺和乳腺肿瘤的CAF中持续升高。我们发现,雄激素受体(AR)通过亚端粒结合抑制TERRA转录,而其缺失使TERRA上调并与RNA结合蛋白NONO相互作用。这种相互作用形成CAF特异性的核复合物,从而重编程基因表达。在机制上,NONO被直接募集并结合到关键CAF效应基因的启动子上,以TERRA依赖的方式调控其转录。通过沉默TERRA或药物抑制NONO来破坏TERRA-NONO轴,可在体外和体内逆转CAF活化并抑制肿瘤-基质相互作用,凸显其治疗潜力。
Science advances IF 13.9 2026-10-02 PMID: 42826177
Label-free and slide-free histological imaging of surgical tissues is vital for guiding surgical decisions during tumor resection. UV photoacoustic microscopy can be employed to discern atypical cytologic characteristics without using exogenous contrast agents, but the narrow depth of field limits image quality and delays histological visualization when scanning unprocessed tissue specimens with large thicknesses and irregular surfaces. Here, we develop a liquid crystal-based metalens for precise wavefront engineering of the incident UV light to create a droplet-shaped photoacoustic excitation beam. An axially extended depth of field with subcellular lateral resolution is achieved using multiple optical foci during photoacoustic microscopy, enabling parallel discrete multilayer imaging of slide-free specimens. Fast and accurate observations of microarchitectural details offer label-free high-throughput histology insights of unprocessed human glioma specimens without sectioning and staining, demonstrating the feasibility of rapid multilayer histological imaging in thick tissues and supporting the future development of intraoperative pathological assessment techniques.
中文摘要:外科组织的无标记、免切片组织学成像对于在肿瘤切除过程中指导手术决策至关重要。紫外光声显微成像无需使用外源性造影剂即可辨识非典型细胞学特征,但其景深较窄,在扫描厚度大、表面不规则的未处理组织标本时会限制成像质量并延迟组织学可视化。在此,我们开发了一种基于液晶的超透镜,用于对入射紫外光进行精确的波前调控,以产生液滴状的光声激发光束。通过在光声显微成像中利用多个光学焦点,实现了具有亚细胞级横向分辨率的轴向扩展景深,从而可对免切片标本进行并行离散的多层成像。对未经切片与染色的未处理人脑胶质瘤标本进行快速、准确的微结构细节观察,提供了无标记、高通量的组织学信息,证明了在厚组织中进行快速多层组织学成像的可行性,并支持未来术中病理评估技术的发展。
Science immunology IF 16.4 2026-10-02 PMID: 42826173
Malignant ascites is caused by the peritoneal dissemination of cancer and has a poor prognosis. Here, we performed multiomic analyses on ascites samples from patients with cancer and identified RORC-expressing dendritic cells (RORC DCs) enriched in malignant ascites. RORC DCs expressed PIGR and were transcriptionally similar to murine RORγt+ DCs/Thetis cells implicated in immune tolerance. We devised a high-purity sorting strategy to enable in vitro experiments with patient-derived RORC DCs, which indicated that these cells were phenotypically stable and stimulated T cell proliferation while attenuating IFNG expression. Multiplexed immunofluorescence identified RORC DCs in primary tumors and demonstrated their enrichment in regional lymph node metastases. These results associate human RORC DCs with advanced malignancies and suggest a role for these cells in the tumor microenvironment.
中文摘要:恶性腹水由癌症腹膜播散引起,预后较差。在此,我们对癌症患者的腹水样本进行了多组学分析,鉴定出在恶性腹水中富集的表达RORC的树突状细胞(RORC DCs)。RORC DCs表达PIGR,其转录特征与参与免疫耐受的小鼠RORγt+ DCs/Thetis细胞相似。我们设计了一种高纯度分选策略,以便利用患者来源的RORC DCs进行体外实验,结果表明这些细胞表型稳定,可刺激T细胞增殖,同时减弱IFNG表达。多重免疫荧光在原发肿瘤中鉴定出RORC DCs,并证明其在区域淋巴结转移中富集。这些结果将人RORC DCs与晚期恶性肿瘤联系起来,并提示这些细胞在肿瘤微环境中发挥作用。
Blood cancer discovery IF 12.2 2026-10-02 PMID: 42825592
Zhang and colleagues uncover a mechanism of regulation of RAS stability that is active almost exclusively in hematologic (heme) malignancies. This provides new insights into the consequences of a RAS hotspot mutation found in leukemia and myeloma and points to a new therapeutic opportunity in these diseases. See related article by Zhang et al., p. XX.
中文摘要:Zhang及其同事揭示了一种RAS稳定性调控机制,该机制几乎仅在血液系统恶性肿瘤中活跃。这为理解白血病和骨髓瘤中发现的RAS热点突变所带来的后果提供了新见解,并提示这些疾病中存在新的治疗机会。参见Zhang等人相关文章,第XX页。
Signal transduction and targeted therapy IF 81.2 2026-10-02 PMID: 42823398
The gasdermin (GSDM) family of proteins has emerged as the central executioner of pyroptosis, a form of inflammatory cell death characterized by plasma membrane rupture and the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-18 and high mobility group protein B1 (HMGB1). Emerging evidence indicates that GSDMs exert diverse functions in health and various disease contexts, which can be either dependent on or independent of pyroptosis, including facilitating mucus secretion, regulating bone resorption, and modulating mitochondrial metabolism. This review provides a comprehensive overview of the GSDM family, detailing the molecular mechanisms of activation, regulation, pore formation, cell rupture and membrane repair. We explored the extensive crosstalk between GSDMs and other cell death modalities, including apoptosis, necroptosis, NETosis, and PANoptosis. Furthermore, we systematically discuss GSDMs' 'double-edged sword' roles in diverse pathologies, ranging from host defense in infectious diseases and chronic inflammation in autoimmune disorders to their complex, context-dependent function in cancer progression and immunity. Finally, we evaluate emerging therapeutic strategies, encompassing small-molecule inhibitors such as disulfiram (DSF), necrosulfonamide (NSA) and dimethyl fumarate (DMF), as well as novel material-based delivery systems. Collectively, these advances underscore the therapeutic potential of targeting GSDMs for precise clinical intervention to treat both inflammatory and non-inflammatory diseases, as well as to enhance cancer immunotherapy.
中文摘要:Gasdermin(GSDM)蛋白家族已成为细胞焦亡的核心执行者,细胞焦亡是一种炎性细胞死亡形式,其特征是质膜破裂以及释放白细胞介素-1β(IL-1β)、IL-18和高迁移率族蛋白B1(HMGB1)等促炎细胞因子。新出现的证据表明,GSDM在健康和多种疾病情境中发挥多样功能,这些功能可依赖或不依赖细胞焦亡,包括促进黏液分泌、调节骨吸收和调控线粒体代谢。本综述全面概述GSDM家族,详述其激活、调控、成孔、细胞破裂和膜修复的分子机制。我们探讨了GSDM与其他细胞死亡方式之间的广泛串扰,包括凋亡、坏死性凋亡、NETosis和PANoptosis。此外,我们系统讨论GSDM在多种病理中的「双刃剑」作用,从感染性疾病中的宿主防御、自身免疫性疾病中的慢性炎症,到其在癌症进展和免疫中复杂且依赖情境的功能。最后,我们评估新兴治疗策略,包括小分子抑制剂如双硫仑(DSF)、坏死磺酰胺(NSA)和富马酸二甲酯(DMF),以及基于新材料的递送系统。总体而言,这些进展凸显了靶向GSDM用于精准临床干预以治疗炎症性和非炎症性疾病以及增强癌症免疫治疗的潜力。
Trends in biochemical sciences IF 14.4 2026-10-02 PMID: 42823268
Protein tyrosine phosphatases (PTPs) are increasingly recognized as regulators of signaling networks rather than mere antagonists of kinases. Interactome-level analyses reveal that many PTPs function as scaffolds that organize spatially constrained signaling complexes, thereby influencing context-dependent signaling outputs. Focusing on representative nonreceptor PTPs (SHP-2, PTPN23, and PTPN13) and receptor PTPs (PTPRM and PTPRK), this review integrates methodological advances that enable increasingly detailed mapping of PTP-centered interactomes. Across cancer, neurobiology, and immune signaling, changes in these assemblies link scaffold function to disease phenotypes. This framework highlights PTP scaffold functions beyond catalysis and emerging therapeutic strategies targeting protein-protein interactions and scaffold-dependent mechanisms.
中文摘要:蛋白质酪氨酸磷酸酶(PTPs)日益被视为信号网络的调控因子,而不仅仅是激酶的拮抗剂。相互作用组层面的分析揭示,许多PTP作为支架发挥作用,组织空间受限的信号复合物,从而影响具有环境依赖性的信号输出。本文聚焦代表性的非受体PTP(SHP-2、PTPN23和PTPN13)和受体PTP(PTPRM和PTPRK),整合了能够日益精细地绘制以PTP为中心的相互作用组的方法学进展。在癌症、神经生物学和免疫信号传导中,这些组装体的变化将支架功能与疾病表型联系起来。该框架强调了PTP超越催化作用的支架功能,以及靶向蛋白质-蛋白质相互作用和支架依赖机制的新兴治疗策略。
Science advances IF 13.9 2026-10-02 PMID: 42814813
3-Phosphoinositides are essential cellular lipids regulating health and disease. Among them, phosphatidylinositol-3,5-bisphosphate [PI(3,5)P2] remains the least understood. Using a newly developed ratiometric PI(3,5)P2 sensor that enables spatiotemporally resolved PI(3,5)P2 quantification, we demonstrate that growth factor stimulation generates a distinct PI(3,5)P2 pool on lysosomes and late endosomes. Formed sequentially by class II PI3KC2β and PIKfyve, this PI(3,5)P2 pool terminates growth factor-stimulated class I phosphatidylinositol 3-kinase (PI3K) activity through a specific interaction with its regulatory p85 subunit. Disrupting this p85-PI(3,5)P2 interaction via a small-molecule inhibitor or cancer-causing mutations blocks feedback inhibition, driving sustained class I PI3K activation and promoting neurite growth. Our findings uncover a spatiotemporally specific regulatory function of PI(3,5)P2 that links class I and II PI3Ks to tune growth factor signaling. This mechanism offers therapeutic strategies for treating p85-mutant cancers and advancing tissue regeneration.
中文摘要:3-磷酸肌醇是调控健康与疾病的重要细胞脂质。其中,磷脂酰肌醇-3,5-二磷酸[PI(3,5)P2]仍是了解最少的一种。利用新开发的比例型PI(3,5)P2传感器,可实现时空分辨的PI(3,5)P2定量,我们证明生长因子刺激会在溶酶体和晚期内体上产生一个独特的PI(3,5)P2池。该PI(3,5)P2池由II类PI3KC2β和PIKfyve依次形成,并通过与其调节亚基p85的特异性相互作用,终止生长因子刺激的I类磷脂酰肌醇3-激酶(PI3K)活性。通过小分子抑制剂或致癌突变破坏这种p85-PI(3,5)P2相互作用,会阻断反馈抑制,驱动I类PI3K持续激活并促进神经突生长。我们的发现揭示了PI(3,5)P2一种时空特异性的调控功能,其连接I类和II类PI3K以调节生长因子信号。该机制为治疗p85突变癌症和促进组织再生提供了治疗策略。
Cancer research IF 22.6 2026-10-02 PMID: 42447266
Cancer-associated fibroblasts (CAF) are principal determinants of pancreatic ductal adenocarcinoma (PDAC) progression. CAFs can shape tumor behavior via multiple pathways, underscoring the need for a complete understanding of the regulatory mechanisms that govern CAF function. In this study, we identified N6-methyladenosine (m6A) remodeling as a hallmark of CAF activation and defined a critical role for the m6A demethylase ALKBH5 in PDAC metastasis. Activated CAFs exhibited a global reduction in m6A abundance, with ALKBH5 emerging as a key regulator of the CAF epitranscriptome. Functionally, CAF-derived ALKBH5 enhanced pancreatic cancer cell migration and invasion in vitro and promoted epithelial-mesenchymal transition-associated gene expression in tumor cells in an m6A-dependent manner. Orthotopic co-implantation models and host genetic ablation models demonstrated that ALKBH5 plays a critical role in metastatic dissemination, with minimal impact on primary tumor growth. Mechanistically, ALKBH5 enhanced the m6A-dependent translation of HSF1 in CAFs, at least in part by relieving insulin-like growth factor 2 mRNA-binding protein 3-associated translational constraints. Elevated HSF1 subsequently activated leukemia-inhibitory factor (LIF) transcription through distal enhancer elements, establishing an ALKBH5-HSF1-LIF signaling axis that mediated the prometastatic CAF-tumor cell communication. Clinically, enrichment of ALKBH5+HSF1+ CAFs independently predicted poor prognosis and was preferentially observed in metastatic PDAC. Collectively, these findings uncover a CAF-intrinsic epitranscriptomic program that drives PDAC metastasis and highlight stromal m6A regulation as a potential therapeutic vulnerability. Cancer-associated fibroblast-intrinsic ALKBH5 facilitates metastatic dissemination in pancreatic ductal adenocarcinoma via m6A-dependent HSF1-LIF paracrine signaling, uncovering a stroma-specific vulnerability with therapeutic relevance in pancreatic cancer.
中文摘要:癌相关成纤维细胞(CAF)是胰腺导管腺癌(PDAC)进展的主要决定因素。CAF可通过多种途径塑造肿瘤行为,这凸显出全面理解调控CAF功能的机制的必要性。在本研究中,我们将N6-甲基腺苷(m6A)重塑确定为CAF激活的标志,并明确了m6A去甲基化酶ALKBH5在PDAC转移中的关键作用。活化的CAF表现出整体m6A丰度降低,其中ALKBH5成为CAF表观转录组的关键调控因子。在功能上,CAF来源的ALKBH5在体外增强胰腺癌细胞迁移和侵袭,并以m6A依赖的方式促进肿瘤细胞中上皮-间质转化相关基因的表达。原位共植入模型和宿主基因敲除模型表明,ALKBH5在转移播散中发挥关键作用,而对原发肿瘤生长影响极小。机制上,ALKBH5增强CAF中HSF1的m6A依赖性翻译,至少部分是通过解除胰岛素样生长因子2 mRNA结合蛋白3相关的翻译限制实现的。升高的HSF1随后通过远端增强子元件激活白血病抑制因子(LIF)转录,从而建立一个ALKBH5-HSF1-LIF信号轴,介导促转移性CAF与肿瘤细胞之间的通讯。临床上,ALKBH5+HSF1+ CAF的富集可独立预测不良预后,并且更常见于转移性PDAC。总之,这些发现揭示了一个CAF内在的表观转录组程序,其驱动PDAC转移,并强调基质m6A调控是一个潜在的治疗脆弱点。CAF内在的ALKBH5通过m6A依赖性HSF1-LIF旁分泌信号促进胰腺导管腺癌的转移播散,揭示了一个具有胰腺癌治疗相关性的基质特异性脆弱点。
Cancer research IF 22.6 2026-10-02 PMID: 42446922
Noncanonical metabolic functions of signaling molecules contribute to cancer plasticity and metastatic progression. In this study, we demonstrated that phosphodiesterase type 5A (PDE5A) inhibitors, including sildenafil (Sild; Viagra), induced lysosomal cholesterol accumulation across multiple mouse and human cancer models, reducing cholesterol bioavailability and impairing cancer cell migration and metastasis. Cancer cells exhibited heightened sensitivity due to reduced lysosomal gene expression, rendering them particularly vulnerable to disrupted cholesterol trafficking. Mechanistically, elevated guanosine 3',5'-cyclic monophosphate (cGMP) bound the lysosomal cholesterol transporter NPC1, impairing cholesterol export and phenocopying Niemann-Pick type C pathology. The resulting cholesterol depletion disrupted membrane lipid rafts and mitochondrial bioenergetics, thereby limiting metastatic capacity and triggering compensatory sterol regulatory element-binding protein 2 (SREBP2) activation with increased cholesterol synthesis. Combining Sild with statins yields additive antimetastatic effects by concurrently blocking lysosomal cholesterol export and cholesterol biosynthesis. Consistently, analysis of digital health records demonstrated significantly improved survival among Sild users, with a dose-dependent additive benefit observed when combined with statins. Together, these findings identify increasing cGMP levels through PDE5A inhibition as a potential strategy to restrict metastasis and offer a potential mechanistic basis for the beneficial effects of Sild. PDE5A inhibition is linked to lysosomal cholesterol trafficking and reduced metastasis via cGMP-mediated disruption of NPC1 export, providing insights into how non-oncologic drugs and host-tumor metabolism influence progression and outcomes.
中文摘要:信号分子的非经典代谢功能促进癌症可塑性和转移进展。在本研究中,我们证明磷酸二酯酶5A(PDE5A)抑制剂,包括西地那非(Sild;万艾可),在多种小鼠和人类癌症模型中诱导溶酶体胆固醇积聚,降低胆固醇生物利用度,并损害癌细胞迁移和转移。由于溶酶体基因表达降低,癌细胞表现出更高的敏感性,使其特别容易受到胆固醇转运紊乱的影响。机制上,升高的环鸟苷酸(cGMP)与溶酶体胆固醇转运蛋白NPC1结合,损害胆固醇外排,并表型模拟C型尼曼-匹克病病理。由此导致的胆固醇耗竭破坏了膜脂筏和线粒体生物能量学,从而限制转移能力,并触发代偿性固醇调节元件结合蛋白2(SREBP2)激活,伴胆固醇合成增加。将Sild与他汀类药物联用,通过同时阻断溶酶体胆固醇外排和胆固醇生物合成,产生相加的抗转移效应。与此一致,对数字健康记录的分析表明,Sild使用者的生存率显著改善,并且与他汀类药物联用时观察到剂量依赖性的相加获益。总之,这些发现表明,通过抑制PDE5A提高cGMP水平是限制转移的潜在策略,并为Sild的有益作用提供了潜在的机制基础。PDE5A抑制通过cGMP介导的NPC1外排破坏与溶酶体胆固醇转运和转移减少相关,为无肿瘤药物和宿主-肿瘤代谢如何影响疾病进展和结局提供了见解。
Cancer research IF 22.6 2026-10-02 PMID: 42446905
Somatic mutations often predict survival in childhood cancers, as exemplified in rhabdomyosarcoma (RMS), in which FOXO1 gene fusion status is a key prognostic feature. In this study, we examined single-cell transcriptomes and discovered that cancer cells of lethal disease converge on a common cell state with a shared transcriptional landscape, irrespective of fusion status. Nuclear transcriptomics, chromatin accessibility, spatial transcriptomics, perturbation studies, and previously published datasets validated the overarching high-risk cell state. The convergent cell state only partially overlapped with transcriptional effects of the FOXO1 fusion and unexpectedly exhibited neural features. Overall, these findings delineate a cell state of high-risk RMS cells that transcends conventional molecular and histologic boundaries, suggesting an overarching disease phenotype that could transform target discovery and inform clinical practice. Defining a convergent cell state of high-risk rhabdomyosarcoma that transcends existing histological and molecular features predictive of outcome provides biological insights into aggressive disease and uncovers potential biomarkers and therapeutic targets.
中文摘要:在儿童癌症中,体细胞突变常可预测生存,横纹肌肉瘤(RMS)即是例证,其中FOXO1基因融合状态是关键预后特征。在本研究中,我们检测了单细胞转录组,发现致死性疾病的癌细胞无论融合状态如何,都会汇聚到一种具有共享转录景观的共同细胞状态。核转录组学、染色质可及性、空间转录组学、扰动研究以及既往发表的数据集验证了这一总体高风险细胞状态。该汇聚细胞状态仅部分重叠于FOXO1融合的转录效应,并出乎意料地表现出神经特征。总体而言,这些发现描绘了高风险RMS细胞的一种细胞状态,它超越了传统分子和组织学边界,提示存在一种总体性疾病表型,可能改变靶点发现并指导临床实践。界定高风险横纹肌肉瘤的一种超越现有组织学和分子预后特征的汇聚细胞状态,为侵袭性疾病提供了生物学见解,并揭示了潜在的生物标志物和治疗靶点。
Cancer research IF 22.6 2026-10-02 PMID: 42430563
Self-renewing normal tissues generate several somatic mutations at each division. Previous studies have reported that cancer cells have more mutations than their normal counterparts. It is not obvious why dramatic differences in mutational burdens between normal tissues and cancers should exist. To fully understand human tumorigenesis, the increase in mutational burden across cancers will have to be understood. In this study, we provided a systematic comparison of mutational burdens in normal and cancer cells from 5 different organs, revealing a 4-fold increase in mutational burden in cancerous versus noncancerous cells. Three proposed hypotheses could account for the increased mutational burdens in cancer: the classical hypothesis, in which driver gene mutations explain the higher mutational burden; the catastrophic hypothesis, in which extreme mutational events lead to large-scale genomic alterations; and the tail hypothesis, in which differences in baseline mutation rates among individuals account for the differences. Testing through orthogonal observations showed that the observed medians and distributions of mutational burdens in cancers could be explained by the hypotheses to various degrees of significance, and only the tail hypothesis could easily explain the increase in median mutational burdens in the normal tissues of patients with cancer compared with the normal tissues of noncancer patients. Overall, this study characterizes an increased mutational burden across multiple types of cancer compared with normal tissue and provides insights into the contributing factors. A tenable hypothesis proposed in this study involving fundamental differences in baseline mutation rates among individuals could have implications for cancer prevention strategies. Comprehensive analysis of mutation burden distributions across normal and cancerous tissues reveals consistently higher burden in cancers, with a proposed explanation that may improve risk prediction and cancer prevention.
中文摘要:自我更新的正常组织在每次分裂时都会产生若干体细胞突变。既往研究报道,癌细胞比其正常对应细胞具有更多突变。正常组织与癌症之间突变负荷为何存在显著差异尚不清楚。要全面理解人类肿瘤发生,必须理解癌症中突变负荷的增加。在本研究中,我们对来自5种不同器官的正常细胞和癌细胞的突变负荷进行了系统比较,发现癌细胞相较非癌细胞突变负荷增加4倍。有三种假说可以解释癌症中突变负荷升高:经典假说,认为驱动基因突变解释了更高的突变负荷;灾难性假说,认为极端突变事件导致大规模基因组改变;尾部假说,认为个体间基线突变率的差异导致了这些差异。通过正交观察进行检验显示,癌症中观察到的突变负荷中位数和分布可在不同显著性程度上由这些假说解释,而只有尾部假说能够容易地解释癌症患者正常组织相较非癌症患者正常组织中位突变负荷的增加。总体而言,本研究刻画了多种类型癌症相较正常组织的突变负荷增加,并对其促成因素提供了见解。本研究提出的一个合理假说涉及个体间基线突变率的根本差异,可能对癌症预防策略具有启示。对正常组织和癌组织突变负荷分布的综合分析显示癌症中突变负荷持续更高,所提出的解释可能改进风险预测和癌症预防。
Cancer research IF 22.6 2026-10-02 PMID: 42406997
Adoptive T-cell transfer (ACT) therapy offers curative potential for some patients with cancer. Toll-like receptor (TLR) agonists improve the efficacy of ACT therapy, and elucidating the underlying mechanism of potency could help determine the best way to maximize the benefits of TLR agonists. In this study, we identified an innate-adaptive circuit in which TLR9-activated B cells augment CD8+ T-cell fitness and antitumor activity through CD2-dependent costimulation. Among multiple TLR agonists tested, class B CpG uniquely programmed murine and human CD8+ T cells for superior effector differentiation, metabolic fitness, and antitumor control. Disruption of CD2 signaling blunted the benefits of TLR9 agonism, including impaired glycolytic capacity and reduced tumor control. Independently, blocking other costimulatory molecules, such as CD86, CD80, CD28, or inducible T-cell costimulator (ICOS), did not impair the antitumor activity of CpG-conditioned T cells. Gain-of-function experiments revealed that CD2 stimulation recapitulated the effect of TLR9 agonism, bolstering the effector function of tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells. Consistent with these findings, elevated CD2 expression in human tumors correlated with improved overall survival across multiple patient cohorts with cancer, underscoring the clinical importance of this signaling cue. Together, these data uncover a noncanonical B-cell-CD2 costimulation axis through which TLR9 agonists potentiate ACT, revealing a targetable pathway to overcome resistance to cell therapy in solid tumors. B cells activated with TLR9 agonist cross-talk with CD8+ T cells via CD2, which enhances their fitness, cytotoxic function, and antitumor activity against solid tumors.
中文摘要:过继性T细胞回输(ACT)疗法为部分癌症患者提供了治愈可能。Toll样受体(TLR)激动剂可提高ACT疗法的疗效,阐明其增效机制有助于确定最大化TLR激动剂获益的最佳方式。在本研究中,我们发现一个固有免疫-适应性免疫回路,其中TLR9激活的B细胞通过CD2依赖性共刺激增强CD8+ T细胞的适应性和抗肿瘤活性。在测试的多种TLR激动剂中,B类CpG独特地编程小鼠和人CD8+ T细胞,使其具有更强的效应分化、代谢适应性和抗肿瘤控制能力。破坏CD2信号削弱了TLR9激动带来的益处,包括糖酵解能力受损和肿瘤控制减弱。独立地,阻断其他共刺激分子,如CD86、CD80、CD28或诱导性T细胞共刺激分子(ICOS),并未损害CpG处理T细胞的抗肿瘤活性。功能获得实验显示,CD2刺激再现了TLR9激动的作用,增强了肿瘤浸润淋巴细胞和嵌合抗原受体(CAR)T细胞的效应功能。与这些发现一致,在人肿瘤中CD2表达升高与多个癌症患者队列中总生存期改善相关,强调了该信号线索的临床重要性。总之,这些数据揭示了一个非经典的B细胞-CD2共刺激轴,TLR9激动剂通过该轴增强ACT,揭示了一条可靶向的通路,以克服实体瘤细胞治疗耐药。经TLR9激动剂激活的B细胞通过CD2与CD8+ T细胞交叉对话,从而增强其适应性、细胞毒功能和针对实体瘤的抗肿瘤活性。
Biosensors & bioelectronics IF 11.8 2026-10-01 PMID: 42830000
The primer exchange reaction (PER) has emerged as a versatile isothermal amplification technique for biosensing, yet its practical application is severely hampered by non-specific hybridization-induced background signals. Here, we report a high-fidelity PER (Hf-PER) strategy that overcomes this limitation through a rationally designed template architecture integrating exonuclease III (Exo III)-mediated target recycling, blocked primer binding, and self-priming amplification. In this design, Exo III strictly discriminates perfectly matched targets from mismatched sequences, while the absence of free primers and magnetic bead separation effectively suppress spurious amplification. Using miR-21, a prostate cancer-associated biomarker, as a model, the Hf-PER assay achieves a remarkable limit of detection of 0.15 fM with a wide dynamic range spanning five orders of magnitude and single-base discrimination capability. The method demonstrates excellent recovery (95.6%-101.2%) in spiked serum samples, high repeatability (CV < 4.5%), and strong concordance with qPCR (R2 > 0.99). Moreover, it successfully distinguishes prostate cancer cells from normal cells and accurately identifies miR-21 elevation in clinical serum samples from prostate cancer patients. By simply reprogramming the recognition domain, this platform can be readily adapted for other nucleic acid biomarkers; as a proof of concept, we further applied the Hf-PER strategy to detect miR-155, achieving a limit of detection of 0.21 fM and comparable specificity, demonstrating excellent versatility. The Hf-PER strategy offers a robust, sensitive, specific, and programmable tool for early cancer diagnosis, liquid biopsy, and point-of-care testing, addressing a critical need for reliable isothermal amplification in complex biological matrices.
中文摘要:引物交换反应(PER)已成为一种用于生物传感的多功能等温扩增技术,但其实际应用受到非特异性杂交诱导的背景信号的严重制约。在此,我们报道了一种高保真PER(Hf-PER)策略,该策略通过理性设计的模板架构整合外切核酸酶III(Exo III)介导的靶标循环、封闭引物结合以及自引发扩增,从而克服了这一局限。在该设计中,Exo III能够严格区分完全匹配的靶标与错配序列,而游离引物的缺失和磁珠分离则有效抑制了虚假扩增。以与前列腺癌相关的生物标志物miR-21为模型,Hf-PER检测实现了0.15 fM的显著检测限,具有跨越五个数量级的宽动态范围和单碱基区分能力。该方法在加标血清样本中表现出优异的回收率(95.6%-101.2%)、高重复性(CV < 4.5%)以及与qPCR的高度一致性(R2 > 0.99)。此外,它成功区分了前列腺癌细胞与正常细胞,并准确识别了前列腺癌患者临床血清样本中miR-21的升高。通过简单地重新编程识别结构域,该平台可方便地适用于其他核酸生物标志物;作为概念验证,我们进一步应用Hf-PER策略检测miR-155,实现了0.21 fM的检测限和相当的特异性,展示了优异的通用性。Hf-PER策略为早期癌症诊断、液体活检和即时检测提供了一种稳健、灵敏、特异且可编程的工具,满足了复杂生物基质中对可靠等温扩增的关键需求。
HemaSphere IF 11.3 2026-10 PMID: 42824998
Richter transformation (RT), a highly aggressive lymphoma arising from a preexisting chronic lymphocytic leukemia, represents a major unmet clinical need. Recent data have shown that an antibody-drug conjugate (ADC) targeting the cell-surface pseudokinase ROR1 is effective in RT patients. In this work, we explored other members of the ROR1 family and focused on RYK as a novel therapeutic target. Transcriptomic analyses revealed that RYK is expressed across multiple lymphoma subtypes, including indolent and aggressive lymphomas, such as RT, while it is absent in peripheral blood mononuclear cells (PBMCs) from healthy donors. To increase the selectivity of the ADC for highly proliferating B-cell malignancies, as a payload we chose an inhibitor of topoisomerase I (TOP1), which is highly expressed in aggressive lymphomas while being undetectable in PBMCs from healthy donors. Based on these premises, we generated SLV-404, an ADC composed of a chimeric antibody directed against the extracellular domain of RYK, a cleavable linker, and the potent TOP1 inhibitor deruxtecan (DXd). In vitro studies in lymphoma cell lines and in cells obtained from RT patient-derived xenografts (RT-PDXs) consistently showed robust induction of apoptosis following SLV-404 treatment, while normal PBMCs were fully resistant. The antitumor activity of SLV-404 was then confirmed in vivo using subcutaneous and intravenous RT-PDX models. Treated animals survived significantly longer with markedly reduced tumor growth and tumor burden. Together, these findings identify RYK as a therapeutic target in aggressive RT and underline the potential of SLV-404 as an ADC-based strategy for the treatment of aggressive lymphomas.
中文摘要:里氏转化(RT)是一种由既存慢性淋巴细胞白血病演变而来的高度侵袭性淋巴瘤,存在重大未满足的临床需求。近期数据显示,靶向细胞表面假激酶ROR1的抗体药物偶联物(ADC)对RT患者有效。在本工作中,我们探索了ROR1家族的其他成员,并聚焦于RYK作为新的治疗靶点。转录组分析显示,RYK在多种淋巴瘤亚型中表达,包括惰性和侵袭性淋巴瘤,如RT,而在健康供者外周血单个核细胞(PBMC)中不表达。为提高ADC对高度增殖性B细胞恶性肿瘤的选择性,我们选择拓扑异构酶I(TOP1)抑制剂作为载荷,因为TOP1在侵袭性淋巴瘤中高表达,而在健康供者PBMC中检测不到。基于这些前提,我们构建了SLV-404,这是一种由针对RYK胞外域的嵌合抗体、可裂解连接子和强效TOP1抑制剂德鲁替康(DXd)组成的ADC。在淋巴瘤细胞系以及来自RT患者来源异种移植(RT-PDX)的细胞中进行的体外研究一致显示,SLV-404处理后能强烈诱导凋亡,而正常PBMC完全耐药。随后,我们在皮下和静脉RT-PDX模型中证实了SLV-404的体内抗肿瘤活性。接受治疗的动物生存期显著延长,肿瘤生长和肿瘤负荷明显降低。总之,这些发现将RYK确定为侵袭性RT的治疗靶点,并强调SLV-404作为基于ADC的策略用于治疗侵袭性淋巴瘤的潜力。
Smart medicine IF 12.8 2026-10 PMID: 42824273
Chemotherapy and photothermal therapy (PTT) are recognized as effective strategies in cancer treatment. However, the challenge remains in effectively targeting these therapeutic modalities to the tumor site to improve therapeutic effects. Here, a novel hierarchical cascade-activated microneedle (MN) patch (MNDOX@MICG) for photothermal and bioorthogonal chemotherapy was developed. The MN patch was fabricated by integrating hydrogel microspheres (MICG) containing tetrazine-functionalized indocyanine green (Tz-ICG) into the MN arrays. Upon irradiation with near-infrared light, Tz-ICG with high photothermal conversion efficiency can elevate the temperature of MN, facilitate PTT, and trigger the release of trans-cyclooctene-conjugated doxorubicin (TCO-DOX) encapsulated in MN. Then, the gradually released Tz-ICG from MICG can react with TCO-DOX via a specific inverse electron-demand Diels-Alder bioorthogonal reaction, thereby restoring the anticancer activity of DOX. Consequently, MNDOX@MICG can efficiently eradicate tumor cells in vitro and significantly inhibit the growth of postsurgical melanoma by combining PTT with bioorthogonal chemotherapy. These findings highlight the practical value of such a hierarchical cascade-activated MN patch for versatile drug delivery and biomedical applications.
中文摘要:化疗和光热治疗(PTT)被认为是癌症治疗的有效策略。然而,如何有效地将这些治疗方式靶向到肿瘤部位以提高治疗效果仍然是一个挑战。在此,开发了一种新型的分级级联激活微针(MN)贴片(MNDOX@MICG),用于光热和生物正交化疗。该MN贴片通过将含有四嗪功能化吲哚菁绿(Tz-ICG)的水凝胶微球(MICG)整合到MN阵列中而制备。在近红外光照射下,具有高光热转换效率的Tz-ICG可升高MN的温度,促进PTT,并触发包载于MN中的反式环辛烯偶联多柔比星(TCO-DOX)释放。随后,从MICG中逐渐释放的Tz-ICG可通过特异性的逆电子需求Diels-Alder生物正交反应与TCO-DOX反应,从而恢复DOX的抗癌活性。因此,MNDOX@MICG通过将PTT与生物正交化疗相结合,可在体外有效根除肿瘤细胞,并显著抑制术后黑色素瘤的生长。这些发现突出了这种分级级联激活MN贴片在多功能药物递送和生物医学应用中的实用价值。
Biomarker research IF 14.6 2026-10-01 PMID: 42823715
Primary central nervous system lymphoma (PCNSL) is a rare aggressive extranodal non-Hodgkin's lymphoma which outcomes remain poor despite therapeutic advances. Recent improvements in our understanding of the molecular diversity of aggressive diffuse large B cell lymphomas suggest that the biological refinement of PCNSL diagnostics may be enabled by an integrated multi-modal approach, augmenting clinical data with modern minimally-invasive liquid biopsy-based assays and multi-omic molecular profiling. Single cell sequencing and spatial imaging technologies dissecting the immune microenvironmental architecture of PCNSL are anticipated to further refine future diagnostics. Concurrently, several innovative strategies featuring immunomodulatory agents, oncogenic kinase inhibitors and immunotherapies including chimeric antigen receptor (CAR) T-cell therapy have emerged. In this review, we provide an update of recent advances in the understanding of the pathobiology of PCNSL focusing on clinically relevant molecular subclassifications, highlight emerging therapeutics, and discuss the translational roadmap to clinical implementation of next-generation diagnostic platforms based on novel technologies.
中文摘要:原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见、侵袭性的结外非霍奇金淋巴瘤,尽管治疗有所进展,其结局仍不佳。近年来,我们对侵袭性弥漫大B细胞淋巴瘤分子多样性的认识有所提高,这提示通过整合多模式方法,即以现代微创液体活检为基础的检测和多组学分子谱分析补充临床数据,可能使PCNSL诊断在生物学上得到精细化。单细胞测序和解剖PCNSL免疫微环境结构的空间成像技术预计将进一步改进未来的诊断。与此同时,出现了若干创新策略,包括免疫调节剂、致癌激酶抑制剂以及嵌合抗原受体(CAR)T细胞疗法等免疫治疗。在这篇综述中,我们更新了对PCNSL病理生物学认识的近期进展,重点关注具有临床意义的分子亚分类,突出新兴治疗方法,并讨论基于新技术的下一代诊断平台走向临床转化的路线图。
Immunity IF 30.6 2026-10-01 PMID: 42822443
Accurate prediction of T cell receptor (TCR) reactivity is a long-standing goal in immunology. Here, we asked whether functional validation of TCR-peptide-major histocompatibility complex (MHC) (TCR-pMHC) pairs at scale alters performance estimates of TCR-pMHC reactivity prediction models. We developed a TCR rapid assembly platform (T-RAP) that allowed the generation of large and uniform TCR libraries. T-RAP enabled evaluation of TCR signaling or MHC multimer binding of thousands of previously reported TCR-pMHC pairs under standardized conditions. In this setting of systematic standardized evaluation, only ∼50% of these TCRs showed the previously reported TCR reactivity. Notably, AlphaFold3 structural predictions showed good performance in identifying reactive TCR-pMHC pairs within the set of TCRs that experimentally validated without any task-specific training. AlphaFold3 structural predictions could likewise be used to shortlist TCRs reactive to patient-specific cancer neoantigens. In silico prediction of TCR-pMHC reactivity thus has greater feasibility than previously assumed, with implications for basic research and clinical application.
中文摘要:准确预测T细胞受体(TCR)反应性一直是免疫学领域的长期目标。在此,我们探究对TCR-肽-主要组织相容性复合体(MHC)(TCR-pMHC)配对进行大规模功能验证是否会改变TCR-pMHC反应性预测模型的性能评估。我们开发了TCR快速组装平台(T-RAP),可生成大型且均一的TCR文库。T-RAP能够在标准化条件下评估数千个既往报道的TCR-pMHC配对的TCR信号传导或MHC多聚体结合。在这种系统化标准化评估中,仅约50%的TCR显示出既往报道的TCR反应性。值得注意的是,AlphaFold3结构预测在无需任何任务特异性训练的情况下,在经实验验证的TCR集合中识别反应性TCR-pMHC配对方面表现出良好性能。AlphaFold3结构预测同样可用于筛选对患者特异性癌症新抗原具有反应性的TCR。因此,TCR-pMHC反应性的计算机预测比此前认为的更具可行性,并对基础研究和临床应用具有重要意义。
Cell stem cell IF 23.3 2026-10-01 PMID: 42822433
Patient-derived models of diffuse midline gliomas (DMGs) remain challenging for interrogating tumor biology and investigating novel therapeutics. Xie et al. develop a robust patient-derived brainstem glioma organoid (BSGO) platform, reveal an Activin B-ACVR2A signaling pathway that promotes DMG growth, and identify a promising triple intrathecal therapy to inhibit it.
中文摘要:弥漫性中线胶质瘤(DMG)的患者来源模型在探究肿瘤生物学和研究新型治疗方面仍具挑战性。Xie等人开发了一个稳健的患者来源脑干胶质瘤类器官(BSGO)平台,揭示了一条促进DMG生长的Activin B-ACVR2A信号通路,并确定了一种有前景的三联鞘内治疗来抑制该通路。
Blood IF 23.9 2026-10-01 PMID: 42821740
Although intensified chemotherapy regimens have improved survival of T-cell acute lymphoblastic leukemia (T-ALL) patients, treatment-related toxicities and poor outcomes following relapse highlight the need for alternative therapeutics. Our previous studies showed that leukemia-associated myeloid cells support T-ALL progression, suggesting myeloid cells or associated signals could serve as therapeutic targets. It remains unknown whether leukemia-associated myeloid cells support multiple molecular subtypes of T-ALL, and if so, whether subtype-specific mechanisms are involved. We demonstrate that tumor-associated myeloid cells support survival of both Early T-cell Progenitor (ETP)-like and non-ETP-like T-ALL subtypes from the LMO2 mouse model in vitro and in vivo. Transcriptional profiling and in vitro assays of mouse and human T-ALL reveal that myeloid cells support distinct T-ALL subtypes via different signaling pathways: IL6ST/STAT3 signaling supports ETP-like T-ALL, while growth factor receptor signaling supports non-ETP-like T-ALL. Notably, both subtypes require AKT activation for myeloid-mediated support, and acute myeloid depletion in vivo induces a common metabolic shift towards oxidative phosphorylation (OxPhos). These findings suggest that myeloid cells promote T-ALL survival via subtype-specific signals that converge on a common pathway regulating metabolism. The shared metabolic adaptation to myeloid cell loss suggests a compensatory mechanism enabling T-ALL persistence under stress. Consistent with this possibility, combining myeloid depletion with OxPhos inhibition reduces survival of mouse and patient T-ALL cells and prolongs leukemic mouse survival more than either single treatment. Our data highlight unique and shared mechanisms by which myeloid cells support T-ALL subtypes and implicate tumor-myeloid interactions and downstream metabolic reprogramming as promising therapeutic targets.
中文摘要:尽管强化化疗方案改善了T细胞急性淋巴细胞白血病(T-ALL)患者的生存,但治疗相关毒性和复发后不良结局凸显了对替代治疗的需求。我们前期研究显示,白血病相关髓系细胞支持T-ALL进展,提示髓系细胞或相关信号可作为治疗靶点。目前尚不清楚白血病相关髓系细胞是否支持T-ALL的多种分子亚型,若支持,是否涉及亚型特异性机制。我们证明,来自LMO2小鼠模型的肿瘤相关髓系细胞在体外和体内支持早期T细胞前体(ETP)样和非ETP样T-ALL亚型的存活。对小鼠和人T-ALL的转录谱分析和体外实验显示,髓系细胞通过不同信号通路支持不同的T-ALL亚型:IL6ST/STAT3信号支持ETP样T-ALL,而生长因子受体信号支持非ETP样T-ALL。值得注意的是,两种亚型均需要AKT激活以实现髓系细胞介导的支持,并且体内急性髓系细胞清除诱导共同的代谢转变,转向氧化磷酸化(OxPhos)。这些发现提示,髓系细胞通过亚型特异性信号促进T-ALL存活,这些信号汇聚于调控代谢的共同通路。对髓系细胞丢失的共同代谢适应提示了一种补偿机制,使T-ALL在应激下得以持续存在。与这一可能性一致,将髓系细胞清除与OxPhos抑制联合,比任一单药治疗更能降低小鼠和患者T-ALL细胞的存活并延长白血病小鼠生存。我们的数据强调了髓系细胞支持T-ALL亚型的独特和共享机制,并提示肿瘤-髓系相互作用及下游代谢重编程是有前景的治疗靶点。
Protein & cell IF 18.2 2026-10-01 PMID: 42820819
Mosaic loss of the Y chromosome (mLOY) is a male‑specific somatic loss of the Y chromosome that is predominantly observed in peripheral blood leukocytes, but can also be found in other tissue types. It represents one of the most common male-specific somatic mutations, particularly prevalent in aging individuals. Accumulating evidence shows that mLOY markedly increases the incidence, progression, and adverse prognosis of multiple diseases, including, but not limited to, myocardial fibrosis, lung and bladder cancers, and Alzheimer's disease. Mechanistically, for extrinsic effects of mLOY, hematopoietic mLOY affect other cell populations, thereby promoting disease initiation and progression. From an intrinsic effects, mLOY within cells reprograms autosomal gene expression and reshapes interactions with the immune microenvironment, jointly driving malignant evolution. In this review, we summarize the current understanding of both intrinsic and extrinsic mLOY effects on immune regulation and disease pathogenesis, highlighting its multifaceted roles across cancer, cardiovascular disorders, infections, and other mLOY-associated conditions.
中文摘要:Y染色体镶嵌缺失(mLOY)是一种男性特有的Y染色体体细胞缺失,主要见于外周血白细胞,但也可见于其他组织类型。它是最常见的男性特异性体细胞突变之一,在衰老个体中尤为普遍。越来越多的证据表明,mLOY显著增加多种疾病的发生率、进展和不良预后,包括但不限于心肌纤维化、肺癌和膀胱癌以及阿尔茨海默病。在机制上,对于mLOY的外在效应,造血系统的mLOY影响其他细胞群体,从而促进疾病的发生和进展。从内在效应来看,细胞内的mLOY重编程常染色体基因表达,并重塑与免疫微环境的相互作用,共同驱动恶性演化。在这篇综述中,我们总结了目前对mLOY内在和外在效应在免疫调节和疾病发病机制中的理解,强调其在癌症、心血管疾病、感染及其他mLOY相关病症中的多方面作用。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42820763
Glioma-associated macrophages (GAMs) promote glioma progression, but the membrane-proximal mechanisms sustaining their tumor-supportive states remain poorly defined. Bulk and single-cell transcriptomic analyses, human glioma specimens, GAM models, and orthotopic glioma models were used to define the expression and function of NFAM1. Lipid-raft fractionation, co-immunoprecipitation, proximity ligation, domain-mutant rescue, IP3 and Ca²⁺ measurements, and NFAT1 nuclear translocation assays delineated its signaling mechanism. Pharmacological, macrophage-depletion/reconstitution, and inducible genetic models evaluated its therapeutic relevance. NFAM1 was enriched in monocyte-derived, M2-like GAMs and associated with higher glioma grade, IDH-wild-type status, and poor survival. NFAM1 promoted GAM migration and M2-like polarization, thereby enhancing mesenchymal plasticity of glioma stem cells (GSCs), angiogenesis, and glioma progression. Mechanistically, phosphorylated NFAM1 recruited DAPP1 and PLCG2 through ITAM-SH2-dependent interactions within lipid rafts, organizing a spatially coordinated and functionally ordered signaling module. DAPP1 acted upstream of PLCG2 to promote IP3 production, Ca²⁺ signaling, and NFAT1 nuclear translocation. Madecassoside showed ITAM-dependent cellular target engagement with NFAM1, disrupted this signaling module, suppressed tumor-supportive GAM phenotypes, reduced orthotopic tumor growth, and prolonged survival. Its antitumor activity was markedly diminished after peripheral macrophage depletion or reconstitution with NFAM1-deficient bone marrow-derived macrophages. Moreover, inducible NFAM1 knockdown in reconstituted BMDM-derived GAMs after tumor establishment reduced tumor burden and extended survival. NFAM1 spatially organizes lipid-raft-restricted DAPP1-PLCG2-Ca²⁺-NFAT1 signaling in monocyte-derived GAMs and represents a therapeutically targetable vulnerability in glioma.
中文摘要:胶质瘤相关巨噬细胞(GAM)促进胶质瘤进展,但维持其肿瘤支持状态的膜近端机制仍不清楚。采用bulk和单细胞转录组分析、人胶质瘤标本、GAM模型和原位胶质瘤模型来界定NFAM1的表达和功能。脂筏分级分离、共免疫沉淀、邻近连接、结构域突变体回补、IP3和Ca²⁺测定以及NFAT1核转位实验阐明了其信号机制。药理学、巨噬细胞清除/重建和诱导型遗传模型评估了其治疗相关性。NFAM1在单核细胞来源的M2样GAM中富集,并与更高的胶质瘤级别、IDH野生型状态和较差生存相关。NFAM1促进GAM迁移和M2样极化,从而增强胶质瘤干细胞(GSC)的间充质可塑性、血管生成和胶质瘤进展。机制上,磷酸化的NFAM1通过脂筏内ITAM-SH2依赖性相互作用招募DAPP1和PLCG2,组织成一个空间协调且功能有序的信号模块。DAPP1作用于PLCG2上游,促进IP3产生、Ca²⁺信号和NFAT1核转位。羟基积雪草苷表现出与NFAM1的ITAM依赖性细胞靶点结合,破坏该信号模块,抑制肿瘤支持性GAM表型,减少原位肿瘤生长,并延长生存。在清除外周巨噬细胞或用NFAM1缺陷的骨髓来源巨噬细胞重建后,其抗肿瘤活性显著减弱。此外,在肿瘤建立后对重建的BMDM来源GAM进行诱导性NFAM1敲低,可降低肿瘤负荷并延长生存。NFAM1在单核细胞来源的GAM中空间组织脂筏限制性的DAPP1-PLCG2-Ca²⁺-NFAT1信号,并代表胶质瘤中一个可治疗靶向的弱点。
MedComm IF 14.1 2026-10 PMID: 42819416
p62/SQSTM1 is a multifunctional adaptor protein that serves as a central hub integrating cellular stress responses, including selective autophagy, antioxidant defense, metabolism, and immune signaling. Its diverse functions are precisely orchestrated by a complex network of posttranslational modifications (PTMs) that dynamically regulate its conformation, protein interactions, stability, and subcellular localization. This review provides a comprehensive overview of the p62 PTMs landscape, encompassing phosphorylation, ubiquitination, acetylation, methylation, and emerging cysteine-based modifications. We first discuss how these PTMs coordinately maintain cellular homeostasis by fine-tuning autophagic flux, activating antioxidant programs, coordinating nutrient sensing, preserving genomic stability, and regulating immune responses. We then examine how dysregulation of this PTMs network drives pathogenesis in major diseases including cancer, neurodegenerative disorders, metabolic diseases, and infections, with emphasis on context-dependent molecular mechanisms. Furthermore, we summarize current preclinical evidence targeting p62 PTMs. Finally, we emphasize the critical need for advanced technologies to decipher PTMs crosstalk and dynamic regulation, coupled with the development of corresponding therapeutic strategies, to advance precision medicine. Understanding the p62 PTMs code offers promising opportunities for developing novel biomarkers and targeted therapies for human diseases.
中文摘要:p62/SQSTM1是一种多功能衔接蛋白,作为整合细胞应激反应的中枢枢纽,参与选择性自噬、抗氧化防御、代谢和免疫信号传导等过程。其多样化的功能由复杂的翻译后修饰(PTM)网络精确调控,该网络动态调节其构象、蛋白质相互作用、稳定性及亚细胞定位。本综述全面概述了p62的PTM图谱,涵盖磷酸化、泛素化、乙酰化、甲基化以及新兴的基于半胱氨酸的修饰。我们首先讨论这些PTM如何通过精细调节自噬流、激活抗氧化程序、协调营养感知、维持基因组稳定性以及调控免疫反应,共同维持细胞稳态。随后,我们探讨该PTM网络失调如何驱动包括癌症、神经退行性疾病、代谢性疾病和感染在内的重大疾病的发病机制,并重点关注具有情境依赖性的分子机制。此外,我们总结了目前靶向p62 PTM的临床前证据。最后,我们强调迫切需要先进技术来解析PTM之间的交互作用与动态调控,并结合相应治疗策略的开发,以推进精准医学。理解p62的PTM密码为开发人类疾病的新型生物标志物和靶向治疗提供了有前景的机遇。
ACS sensors IF 10.9 2026-10-01 PMID: 42817894
Selective molecular recognition of trace volatile biomarkers in humid breath remains a fundamental coordination challenge at graphene interfaces. While exhaled breath contains a complex matrix of more than 3500 volatile organic compounds, clinical transition has been largely challenged by the selectivity-humidity paradox. This review traces the evolution of graphene transduction platforms from fundamental quantum phenomena to coordination-governed interfacial engineering strategies enabling selective molecular recognition. It critically analyzes the atomic-level interactions governing the interface, specifically how sublattice symmetry breaking, metal-ligand interactions, competitive water coordination, and 1/f noise spectroscopy enable detection limits at the parts-per-trillion level. It details nanoengineering strategies for superior performance, tracing the shift from pristine graphene to 2D/2D heterostructures and organic-functionalized scaffolds that introduce defined coordination environments to regulate analyte binding and suppress humidity interference. These coordination-engineered platforms are linked with clinical targets such as oncology and metabolic disorders, while machine intelligence serves as a supporting analytical layer within the sensor intelligence paradigm. Crucially, it addresses the path to clinical translation, emphasizing first-in-human safety milestones, green synthesis, and economic scalability afforded by adopting laser-induced graphene. By unifying 2D-material physics, coordination-driven selectivity, and sensor intelligence, graphene breathomics provides a chemically grounded framework for decentralized, personalized diagnostic technologies.
中文摘要:在潮湿呼气中痕量挥发性生物标志物的选择性分子识别,仍是石墨烯界面面临的一项基础配位挑战。虽然呼出气包含由3500多种挥发性有机化合物组成的复杂基质,但其临床转化在很大程度上受到选择性-湿度悖论的挑战。本综述追溯了石墨烯换能平台从基础量子现象到配位主导的界面工程策略的演化,这些策略使选择性分子识别成为可能。它批判性地分析了支配界面的原子级相互作用,特别是亚晶格对称性破缺、金属-配体相互作用、竞争性水配位以及1/f噪声谱学如何实现万亿分之一水平的检测限。文中详述了实现优异性能的纳米工程策略,追溯了从原始石墨烯向2D/2D异质结构和有机功能化支架的转变,这些结构引入明确的配位环境以调控分析物结合并抑制湿度干扰。这些配位工程化平台与肿瘤学和代谢紊乱等临床靶标相关联,而机器智能则在传感器智能范式中作为支持性分析层。至关重要的是,本文论述了临床转化路径,强调首次人体安全性里程碑、绿色合成以及采用激光诱导石墨烯所带来的经济可扩展性。通过统一二维材料物理、配位驱动的选择性和传感器智能,石墨烯呼气组学为去中心化、个性化诊断技术提供了一个以化学为基础的框架。
Cancer discovery IF 29.5 2026-10-01 PMID: 42817713
Despite strong preclinical evidence, ferroptosis-based strategies have not yet translated into the clinic, in part due to the disconnect between conventional in vitro models and the complex tumor microenvironment. In this commentary, we consider ferroptosis as a microenvironmentally regulated process and call for multidisciplinary approaches that bridge foundational ferroptosis biology with clinically actionable interventions grounded in the context of the tumor microenvironment.
中文摘要:尽管有强有力的临床前证据,基于铁死亡的策略尚未转化为临床应用,部分原因是传统体外模型与复杂的肿瘤微环境之间脱节。在这篇评论中,我们将铁死亡视为一种受微环境调控的过程,并呼吁采用多学科方法,将基础铁死亡生物学与基于肿瘤微环境背景的、具有临床可操作性的干预措施相衔接。
Nature methods IF 28.3 2026-10 PMID: 42816645
Antibody-based single-cell technologies, such as flow cytometry, mass cytometry and CITE-seq, have become widely used in clinical diagnostics and basic research; however, their analysis is complicated by technical noise, batch effects, platform differences and restricted antibody panels. Here we present CytoVI, a probabilistic generative model for statistically rigorous unified analysis of antibody-based single-cell data. CytoVI generates informative cell embeddings, imputes missing measurements, performs differential protein expression testing and automates annotation of cells in a single probabilistic model. We applied CytoVI to build an integrated B cell maturation atlas spanning 350 proteins and identified proteins associated with immunoglobulin class-switching. In a cohort of patients with B cell non-Hodgkin lymphoma profiled by flow cytometry and CITE-seq, CytoVI uncovered disease-associated T cell states. CytoVI is available as open-source software at scvi-tools.org .
中文摘要:基于抗体的单细胞技术,如流式细胞术、质谱流式细胞术和CITE-seq,已广泛用于临床诊断和基础研究;然而,其分析受到技术噪声、批次效应、平台差异和抗体组合受限的困扰。在此,我们提出CytoVI,一种用于对抗体单细胞数据进行统计严谨的统一分析的概率生成模型。CytoVI可在单一概率模型中生成有信息量的细胞嵌入、填补缺失测量值、进行差异蛋白表达检验并自动注释细胞。我们应用CytoVI构建了覆盖350种蛋白的整合B细胞成熟图谱,并识别出与免疫球蛋白类别转换相关的蛋白。在一个通过流式细胞术和CITE-seq分析的B细胞非霍奇金淋巴瘤患者队列中,CytoVI揭示了与疾病相关的T细胞状态。CytoVI已在scvi-tools.org以开源软件形式提供。
Acta pharmacologica Sinica IF 10.4 2026-10-01 PMID: 42816565
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with limited therapeutic options and a high incidence in East Asia. Gain-of-function mutations in nuclear factor erythroid 2-related factor 2 (Nrf2) are a major driver of ESCC progression, however, pharmacological interventions capable of effectively suppressing mutant Nrf2 signaling are currently lacking. Here, we conducted a high-throughput screen of 2141 natural products using Nrf2 reporter assays, fluorescence polarization, and Nrf2-dependent assays, and identified gambogenic acid (GNA) as a Nrf2-targeted inhibitor that preferentially attenuates oncogenic signaling driven by Nrf2 gain-of-function mutations in ESCC. GNA exhibited preferential anti-tumor activity in Nrf2-mutant ESCC cells compared with wild-type controls, both in vitro and in vivo. GNA also enhanced the chemosensitivity of Nrf2-mutant ESCC to cisplatin. Mechanistically, GNA suppressed the expression of Nrf2-driven ARE genes and modulated amino acid metabolism and mRNA translation by promoting cysteine oxidation in translational regulatory proteins within Nrf2-mutant cells. Importantly, GNA induced polymerization of the Nrf2/MafG protein complex and promoted its ubiquitin-mediated proteasomal degradation, thereby uncovering a previously uncharacterized mechanism of inhibition targeting the Nrf2/MafG axis. Collectively, our study identifies GNA as a promising therapeutic candidate that preferentially suppresses mutant Nrf2 signaling and shows therapeutic potential in Nrf2-driven ESCC.
中文摘要:食管鳞状细胞癌(ESCC)是一种高度侵袭性的恶性肿瘤,治疗选择有限,在东亚地区发病率高。核因子E2相关因子2(Nrf2)的功能获得性突变是ESCC进展的主要驱动因素,然而目前仍缺乏能够有效抑制突变型Nrf2信号的药物干预手段。在本研究中,我们利用Nrf2报告基因实验、荧光偏振和Nrf2依赖性实验对2141种天然产物进行了高通量筛选,鉴定出新藤黄酸(GNA)作为一种Nrf2靶向抑制剂,可优先减弱由ESCC中Nrf2功能获得性突变驱动的致癌信号。在体外和体内实验中,与野生型对照相比,GNA在Nrf2突变型ESCC细胞中表现出优先的抗肿瘤活性。GNA还增强了Nrf2突变型ESCC对顺铂的化疗敏感性。在机制上,GNA抑制Nrf2驱动的ARE基因表达,并通过促进Nrf2突变细胞中翻译调控蛋白的半胱氨酸氧化,调节氨基酸代谢和mRNA翻译。重要的是,GNA诱导Nrf2/MafG蛋白复合物发生多聚化,并促进其经泛素介导的蛋白酶体降解,从而揭示了一种此前未被阐明的靶向Nrf2/MafG轴的抑制机制。总之,我们的研究确定GNA是一种有前景的治疗候选药物,可优先抑制突变型Nrf2信号,并在Nrf2驱动的ESCC中显示出治疗潜力。
MedComm IF 14.1 2026-10 PMID: 42812576
Glutamine, the most abundant nonessential amino acid in the blood and tissues, plays essential roles in cellular proliferation, immune regulation, acid-base homeostasis, and metabolic balance. Although traditionally classified as a nonessential amino acid, glutamine becomes conditionally essential under pathological conditions and physiological stress due to its critical role in supporting cellular adaptation. Under diverse pathological states, glutamine metabolism undergoes extensive reprogramming, and cancer cells exhibit a particularly high dependence on glutamine to sustain proliferation, redox balance, and biosynthetic demands. In this review, we summarize the multifaceted functions of glutamine metabolism in physiological and pathological processes. We first discuss the fundamental pathways of glutamine synthesis, transport, and utilization, followed by an overview of its regulatory roles in cellular responses to oxidative, nutritional, thermal, mechanical, DNA damage, and osmotic stresses. We further highlight the involvement of glutamine metabolism in cancer progression, immune regulation, metabolic plasticity, and therapeutic resistance. Finally, we summarize emerging glutamine-targeted therapeutic strategies, including metabolic inhibitors, combination therapies, and advanced technologies for metabolic imaging and single-cell analysis. This review provides a comprehensive perspective on glutamine metabolism and highlights its potential as a therapeutic target for cancer and other metabolic disorders.
中文摘要:谷氨酰胺是血液和组织中最丰富的非必需氨基酸,在细胞增殖、免疫调节、酸碱稳态和代谢平衡中发挥重要作用。尽管传统上被归类为非必需氨基酸,但由于其在支持细胞适应中的关键作用,谷氨酰胺在病理状态和生理应激下会变为条件必需氨基酸。在多种病理状态下,谷氨酰胺代谢发生广泛重编程,癌细胞对谷氨酰胺表现出特别高的依赖性,以维持增殖、氧化还原平衡和生物合成需求。在本综述中,我们总结了谷氨酰胺代谢在生理和病理过程中的多方面功能。我们首先讨论谷氨酰胺合成、转运和利用的基本途径,随后概述其在细胞应对氧化应激、营养应激、热应激、机械应激、DNA损伤和渗透应激中的调控作用。我们进一步强调谷氨酰胺代谢参与癌症进展、免疫调节、代谢可塑性和治疗耐药。最后,我们总结新兴的靶向谷氨酰胺的治疗策略,包括代谢抑制剂、联合治疗以及用于代谢成像和单细胞分析的先进技术。本综述为谷氨酰胺代谢提供了全面的视角,并强调其作为癌症和其他代谢性疾病治疗靶点的潜力。
MedComm IF 14.1 2026-10 PMID: 42780627
The Hippo pathway and its downstream effectors Yes-associated protein/transcriptional coactivator with PDZ-binding motif-TEA domain transcription factor (YAP/TAZ-TEAD) play critical roles in organ-size control, tissue homeostasis, regeneration, and stem-cell biology. Their aberrant activation drives malignancies, fibrosis, cardiovascular disease, and immune dysregulation. Once regarded undruggable, the YAP/TAZ-TEAD complex has become one of the most actively pursued target classes in oncology and beyond. In this review, we delineate the biological functions of the Hippo-YAP/TAZ-TEAD axis and integrate its pathway physiology with the structural basis of druggability, centered on the Ω-loop surface pocket and the buried palmitoylation-binding pocket (PBP) of TEAD, whose distinct geometries dictate the pharmacophoric requirements, paralog selectivity, and resistance liabilities of current agents. We then systematically compare mechanism-guided therapeutic modalities, encompassing direct protein-protein interaction disruptors, covalent and noncovalent PBP inhibitors, proteolysis-targeting chimeras (PROTACs), and cofactor-interface modulators. We also analyze the upstream kinase (MST1/2, LATS1/2) modulators, direct YAP/TAZ inhibitors and degraders, and emerging gene-, RNA-, antibody-, and cell-based therapies. We critically evaluate preclinical and early clinical performance across oncology, fibrosis, immunology, and regenerative medicine, distinguishing robust proof-of-concept from clinically meaningful benefit. We further dissect resistance mechanisms, on-target safety concerns, and the therapeutic-window limitations of pan-TEAD inhibition. Ultimately, we outline rational combination strategies, biomarker-guided patient selection, and future directions for paralog-selective and tissue-restricted Hippo-targeted therapeutics.
中文摘要:Hippo通路及其下游效应分子Yes相关蛋白/具有PDZ结合基序的转录共激活因子-TEA结构域转录因子(YAP/TAZ-TEAD)在器官大小控制、组织稳态、再生和干细胞生物学中发挥关键作用。其异常激活驱动恶性肿瘤、纤维化、心血管疾病和免疫失调。曾被视为不可成药的YAP/TAZ-TEAD复合物,现已成为肿瘤学及其他领域最活跃追求的靶点类别之一。在这篇综述中,我们阐述Hippo-YAP/TAZ-TEAD轴的生物学功能,并将其通路生理学与可成药性的结构基础相整合,核心是TEAD的Ω环表面口袋和埋藏型棕榈酰化结合口袋(PBP),二者不同的几何结构决定了当前药物的药效团要求、旁系同源选择性及耐药风险。随后,我们系统比较机制导向的治疗方式,包括直接蛋白-蛋白相互作用破坏剂、共价和非共价PBP抑制剂、蛋白水解靶向嵌合体(PROTAC)以及辅因子界面调节剂。我们还分析上游激酶(MST1/2、LATS1/2)调节剂、直接YAP/TAZ抑制剂和降解剂,以及新兴的基因、RNA、抗体和细胞疗法。我们批判性评估其在肿瘤学、纤维化、免疫学和再生医学中的临床前和早期临床表现,区分稳健的概念验证与具有临床意义的获益。我们进一步剖析耐药机制、靶向安全性问题以及泛TEAD抑制的治疗窗限制。最后,我们概述合理联合策略、生物标志物指导的患者选择,以及旁系同源选择性、组织限制性Hippo靶向治疗的未来方向。
Nature immunology IF 26.5 2026-10 PMID: 42773266
Antigen release is a critical step in initiating antitumor immune responses, yet its regulation during metastasis is not well understood. Here we show that circulating tumor cells undergoing vascular migration produce migrasomes that serve as a metastasis-specific mechanism of antigen release. These migrasomes are enriched in tumor-associated antigens, including cancer-testis and mutated antigens, and are captured efficiently by antigen-presenting cells in secondary lymphoid organs, where they undergo cross-presentation to elicit CD8+ T cell-mediated immune responses that constrain metastatic progression. Genetic inhibition of migrasome formation enhances metastasis, while administration of purified cancer-derived migrasomes restores immune-mediated suppression of metastatic growth. These findings show paradoxically that metastasis can enhance tumor immunogenicity through migrasome-mediated antigen release, highlighting a link between cancer dissemination and immune activation and establishing migrasomes as a distinct and potent platform for endogenous tumor antigen delivery.
中文摘要:抗原释放是启动抗肿瘤免疫应答的关键步骤,但其在转移过程中的调控机制尚不明确。本研究表明,经历血管迁移的循环肿瘤细胞会产生迁移体,这是一种转移特异性的抗原释放机制。这些迁移体富含肿瘤相关抗原,包括癌-睾丸抗原和突变抗原,并能被次级淋巴器官中的抗原呈递细胞高效捕获,在那里发生交叉呈递,从而引发CD8+ T细胞介导的免疫应答,限制转移进展。遗传学抑制迁移体形成会增强转移,而给予纯化的肿瘤来源迁移体则可恢复免疫介导的对转移生长的抑制。这些发现表明,转移可以通过迁移体介导的抗原释放看似矛盾地增强肿瘤免疫原性,凸显了癌症播散与免疫激活之间的联系,并将迁移体确立为一种独特且有效的内源性肿瘤抗原递送平台。
MedComm IF 14.1 2026-10 PMID: 42769371
Natural killer (NK) cells are innate lymphocytes that defend the host by directly killing virus-infected, stressed, and tumor cells. Their direct cytotoxic mechanisms include the release of cytotoxic granules, engagement of death receptor pathways, and mediation of antibody-dependent cellular cytotoxicity (ADCC). They can also eliminate targets indirectly via the secretion of proinflammatory cytokines. Importantly, recent studies show NK cells help limit autoimmunity by targeting autoreactive immune cells, highlighting their broader role in maintaining tissue homeostasis, including within the immune-privileged central nervous system (CNS). Both preclinical and clinical studies support the therapeutic potential of NK cell-based immunotherapies for neuroinflammatory, neurodegenerative, and neuro-oncologic diseases. A key challenge remains achieving sufficient specificity and efficacy within the CNS, which necessitates a more profound understanding of NK cell biology in the unique brain microenvironment. This review summarizes the fundamental biology of NK cells and their roles in CNS pathologies, with a focus on their interactions with the CNS niche. We also discuss recent advances, such as immune-engager strategies and adoptive NK cell therapies, aiming to provide insights to guide future therapeutic development for CNS disorders.
中文摘要:自然杀伤(NK)细胞是先天淋巴细胞,通过直接杀伤病毒感染细胞、应激细胞和肿瘤细胞来防御宿主。其直接细胞毒性机制包括释放细胞毒性颗粒、参与死亡受体通路以及介导抗体依赖性细胞介导的细胞毒性作用(ADCC)。它们还可通过分泌促炎细胞因子间接清除靶细胞。重要的是,近期研究表明,NK细胞通过靶向自身反应性免疫细胞帮助限制自身免疫,突显其在维持组织稳态中的更广泛作用,包括在免疫豁免的中枢神经系统(CNS)内。临床前和临床研究均支持基于NK细胞的免疫疗法对神经炎症性、神经退行性和神经肿瘤性疾病的治疗潜力。一个关键挑战仍是在CNS内实现足够的特异性和疗效,这需要更深入理解NK细胞在独特脑微环境中的生物学。本综述总结NK细胞的基础生物学及其在CNS病理中的作用,重点是其与CNS微环境的相互作用。我们还讨论近期进展,如免疫衔接策略和过继性NK细胞疗法,旨在为未来CNS疾病治疗开发提供见解。
MedComm IF 14.1 2026-10 PMID: 42769291
A major limitation in preventing cancer relapse is our incomplete understanding of therapy resistance and tumor dormancy, including the role of therapy-induced polyploidy in generating rapidly proliferating progeny that repopulate the tumor. In this context, polyploid giant cancer cells (PGCCs) are a unique subpopulation traditionally considered terminally senescent due to large size, abnormal DNA content, and inability to undergo mitosis. However, compelling evidence shows that PGCCs generate progeny via amitotic mechanisms (neosis), producing highly proliferative, chemo-resistant tumor-initiating cells that drive cancer relapse. Although metabolic adaptations and autophagy support PGCC formation and survival, the mechanisms underlying these processes and their contribution to tumor relapse remain poorly understood. This review explores the complex interplay between autophagy and metabolic adaptations in PGCCs, emphasizing their role in PGCC formation, long-term survival and dormancy, and in the generation of amitotic progeny that drive tumor regrowth and cancer relapse. Mechanistic insights into how autophagy and metabolic plasticity enable PGCCs to withstand stress, maintain energy homeostasis, and escape therapy are highlighted. Additionally, we discuss therapeutic approaches targeting PGCCs by disruption of autophagy and metabolic pathways, evaluating their potential to impair progeny formation, overcome therapy resistance, and prevent cancer recurrence.
中文摘要:防止癌症复发的一个主要限制在于我们对治疗耐药和肿瘤休眠的理解仍不完整,包括治疗诱导的多倍体在产生可快速增殖并重新填充肿瘤的子代中的作用。在这一背景下,多倍体巨癌细胞(PGCCs)是一个独特的亚群,传统上因其体积大、DNA含量异常以及无法进行有丝分裂而被认为是终末衰老的。然而,有力证据表明,PGCCs通过无丝分裂机制(neosis)产生子代,生成高度增殖、耐化疗的肿瘤起始细胞,从而驱动癌症复发。尽管代谢适应和自噬支持PGCC形成与存活,但这些过程的机制及其对肿瘤复发的贡献仍知之甚少。本综述探讨了PGCCs中自噬与代谢适应之间复杂的相互作用,强调它们在PGCC形成、长期存活和休眠,以及产生驱动肿瘤再生长和癌症复发的无丝分裂子代中的作用。文中重点介绍了关于自噬和代谢可塑性如何使PGCCs承受压力、维持能量稳态并逃逸治疗的机制见解。此外,我们还讨论了通过破坏自噬和代谢途径来靶向PGCCs的治疗方法,评估其削弱子代形成、克服治疗耐药和预防癌症复发的潜力。
Molecular cell IF 16.0 2026-10-01 PMID: 42748909
Faithful gene expression requires coordination between RNA polymerase II elongation and co-transcriptional RNA processing, yet the chromatin-associated assemblies supporting this coupling remain incompletely defined. Using native chromatin proteomics in human cells, we identify ECAS (elongation complex associated with splicing), a bipartite assembly linking an elongation module (AFF4-ELL2-EAF1) to a U2 snRNP-associated intron binding complex. ECAS occupies promoter-proximal chromatin and is molecularly distinct from canonical P-TEFb-containing super elongation complex (SEC). Acute perturbation of Aquarius (AQR)/XAB2-dependent ECAS functions impairs productive gene-body elongation without altering pause release, increases intron retention, and preferentially affects long genes. AQR loss also reduces capping-factor recruitment and nascent 5' capping and increases promoter-proximal accumulation of cleavage/polyadenylation and RNA exosome factors. In mouse hematopoietic cells, Aqr is highly expressed, and its perturbation profoundly impairs leukemia initiation, maintenance, and leukemia stem cell function in MLL-rearranged leukemia. Together, these findings establish ECAS as a chromatin-associated assembly that couples productive elongation with RNA processing.
中文摘要:忠实的基因表达需要 RNA 聚合酶 II 延伸与共转录 RNA 加工之间的协调,但支持这种偶联的染色质相关组装体仍未完全明确。我们在人类细胞中利用天然染色质蛋白质组学鉴定出 ECAS(与剪接相关的延伸复合物),这是一个二分组装体,将延伸模块(AFF4-ELL2-EAF1)与一个 U2 snRNP 相关的内含子结合复合物连接起来。ECAS 占据启动子近端染色质,并且在分子上不同于含经典 P-TEFb 的超延伸复合物(SEC)。急性扰动 Aquarius(AQR)/XAB2 依赖的 ECAS 功能会损害有效基因体延伸,而不改变暂停释放,增加内含子保留,并优先影响长基因。AQR 缺失还会减少加帽因子募集和新生成 5' 加帽,并增加切割/多聚腺苷酸化及 RNA 外切体因子在启动子近端的积累。在小鼠造血细胞中,Aqr 高表达,其扰动会深刻损害 MLL 重排白血病中的白血病起始、维持和白血病干细胞功能。总之,这些发现确立 ECAS 是一个将有效延伸与 RNA 加工偶联的染色质相关组装体。
Trends in pharmacological sciences IF 24.0 2026-10 PMID: 42716878
Drug discovery relies on cellular assays to determine whether a candidate produces a desired response, reveals its mechanism, or causes toxicity, but only a small fraction of compound-dose-time-context combinations can be measured experimentally. Recent perturbation atlases, single-cell and imaging technologies, and intervention-conditioned AI models now make prediction of unmeasured cellular responses a testable objective. AI virtual cells could therefore complement conventional discovery by prioritizing compounds, contexts, and follow-up experiments rather than replacing laboratory assays. Here, we review the resources and modeling advances supporting this capability, assess their value for mechanism-of-action analysis, efficacy, safety, resistance, and combination studies, and define evidence requirements for pharmacological use. Data coverage makes oncology, including immuno-oncology, plausible early proving grounds, with safety assessment as a crosscutting use case; broader deployment requires perturbation-specific, mechanistic, and decision-level validation.
中文摘要:药物发现依赖细胞实验来判断候选物是否产生预期应答、揭示其机制或导致毒性,但实验上只能测量一小部分化合物-剂量-时间-情境组合。近期的扰动图谱、单细胞与成像技术,以及以干预为条件的AI模型,使预测未测量的细胞应答成为一个可检验的目标。因此,AI虚拟细胞可通过优先选择化合物、情境和后续实验来补充常规发现,而非替代实验室实验。在此,我们综述支持这一能力的资源和建模进展,评估其在作用机制分析、疗效、安全性、耐药性和联合研究中的价值,并界定用于药理学用途的证据要求。数据覆盖度使肿瘤学(包括免疫肿瘤学)成为合理的早期试验场,安全性评估则是贯穿各领域的用例;更广泛的部署需要针对扰动的、机制性的和决策层面的验证。
Nature immunology IF 26.5 2026-10 PMID: 42711529
Immunotherapies putatively require tumor-specific T cells. Here we show how T cells can eliminate tumors without tumor specificity via paracrine signaling. Activating unexhausted bystander non-tumor-specific T cells within tumors resulted in tumor elimination without conventional recognition-dependent mechanisms and in the absence of any tumor-specific T cell receptor (TCR)αβ+ T cells. Robust T cell activation recruited immune cells, used innate leukocytes and triggered a tumoricidal combination of effector molecules and panoptotic pathways. Mechanistically, interferon-γ, tumor necrosis factor and nitric oxide induced caspase-dependent death, recapitulating melanoma clearance in mice or human melanoma cell death in vitro. Gene expression signatures associated with this response in mice were predictive of survival among human patients with melanoma. Thus, triggering productive T cell activation within tumors can be sufficient for immunotherapy, without needing to induce or rescue cancer-specific responses.
中文摘要:免疫疗法通常被认为需要肿瘤特异性T细胞。本研究表明,T细胞可通过旁分泌信号在缺乏肿瘤特异性的情况下清除肿瘤。在肿瘤内激活未耗竭的旁观者非肿瘤特异性T细胞,可在不依赖传统识别机制且不存在任何肿瘤特异性T细胞受体(TCR)αβ+ T细胞的情况下导致肿瘤消除。强烈的T细胞激活可招募免疫细胞,利用固有免疫白细胞,并触发由效应分子和泛凋亡通路组成的杀肿瘤组合。机制上,干扰素-γ、肿瘤坏死因子和一氧化氮诱导半胱天冬酶依赖性死亡,重现了小鼠黑色素瘤清除或体外人类黑色素瘤细胞死亡。小鼠中与该反应相关的基因表达特征可预测人类黑色素瘤患者的生存。因此,在肿瘤内触发有效的T细胞激活可能足以实现免疫治疗,而无需诱导或挽救癌症特异性反应。
Acta biomaterialia IF 10.4 2026-10 PMID: 42685888
Enzyme-powered micro/nanomotors (EMNMs) are a type of self-propelled devices that biologically convert chemical energy into mechanical work through enzyme-catalyzed reactions. Compared to conventional chemically driven counterparts, a significant advantage of these platforms lies in their utilization of endogenous substrates, such as glucose, urea, glycerides, and peptides, to achieve autonomous propulsion. Through the rational design and regulation of functional material components, EMNMs can efficiently perform tasks ranging from active target recognition to autonomous drug loading and controlled release for biomedical applications. Additionally, emerging therapeutic modalities, such as photothermal and starvation therapy integrated with EMNMs, have been extensively investigated for diverse clinical interventions. Up to date, several reviews have outlined general progress in the field, however, a comprehensive synthesis of fabrication strategies and their specific therapeutic applications remain relatively underexplored. To address this gap, this review comprehensively elucidates the design principles and construction strategies of EMNMs through enzyme selection, matrix materials, and morphological structures. Besides, the latest research advances in treating cardiovascular and cerebrovascular diseases, cancer, and urological disorders were also systematically summarized. Through further analyzing current bottlenecks and outlines future directions, this article might aim to providing a cornerstone reference and strategic guidance for future endeavors of EMNMs in related fields. STATEMENT OF SIGNIFICANCE: ∙The core design principles and fabrication methodologies of enzyme-powered micro/nanomotors (EMNMs) are comprehensively elucidated. ∙Systematic structure-activity correlations of EMNMs are established across three pivotal dimensions: enzyme screening, matrix scaffolds and morphological architectures. ∙State-of-the-art advances of EMNM platforms for therapeutic intervention against malignancies, cardiovascular and cerebrovascular pathologies, and urinary tract disorders are thoroughly summarized.
中文摘要:酶驱动的微/纳米马达(EMNMs)是一类自驱动装置,可通过酶催化反应将化学能生物转化为机械功。与传统化学驱动对应物相比,这些平台的一个显著优势在于利用内源性底物,如葡萄糖、尿素、甘油酯和肽,实现自主推进。通过合理设计和调控功能材料组分,EMNMs能够高效执行从主动靶标识别到自主载药和可控释放等生物医学应用任务。此外,与EMNMs整合的光热治疗和饥饿治疗等新兴治疗模式已被广泛研究用于多种临床干预。迄今为止,已有若干综述概述了该领域的总体进展,然而对制备策略及其具体治疗应用的综合梳理仍相对不足。为填补这一空白,本综述通过酶选择、基质材料和形态结构全面阐明EMNMs的设计原则与构建策略。此外,还系统总结了其在治疗心脑血管疾病、癌症和泌尿系统疾病方面的最新研究进展。通过进一步分析当前瓶颈并勾勒未来方向,本文旨在为EMNMs在相关领域的未来探索提供基石性参考和战略性指导。意义声明:全面阐明了酶驱动微/纳米马达(EMNMs)的核心设计原则和制备方法。在酶筛选、基质支架和形态架构三个关键维度上建立了EMNMs的系统性构效关系。全面总结了EMNM平台在恶性肿瘤、心脑血管病理和尿路疾病治疗干预方面的最新进展。
Nature methods IF 28.3 2026-10 PMID: 42680843
Cellular function depends on the spatial organization of cells and biomolecules within the tissue microenvironment. Advances in spatial omics have enabled profiling of molecular features such as transcriptome, proteome and epigenome, and there has been rapid progress of imaging-based approaches to study spatial three-dimensional (3D) genome organization. Here we present Spatial-ATAC-Hi-C, a microfluidic‑based platform for genome-wide, spatially resolved joint-profiling of 3D genome organization and chromatin accessibility on tissue slides. Applied to mouse and human brains, Spatial-ATAC-Hi-C revealed distinct chromatin architecture and gene regulatory programs in neuronal and non-neuronal populations in their native tissue context. In glioblastoma and astrocytoma samples, we detected spatially resolved 3D genome alterations, copy number variations and structural variations across tumor regions, revealing clinically relevant oncogenic events and clonal heterogeneity. By co-profiling of genome architecture and chromatin accessibility while preserving tissue architecture, Spatial-ATAC-Hi-C provides a powerful tool for studying spatial gene regulation in human biology and disease.
中文摘要:细胞功能取决于组织微环境中细胞和生物分子的空间组织。空间组学的进展使得能够对转录组、蛋白质组和表观基因组等分子特征进行图谱分析,并且基于成像研究空间三维(3D)基因组组织的方法也取得了快速进展。在此,我们提出 Spatial-ATAC-Hi-C,一种基于微流控的平台,可在组织切片上对3D基因组组织和染色质可及性进行全基因组、空间分辨的联合分析。将其应用于小鼠和人脑,Spatial-ATAC-Hi-C 揭示了在原生组织背景中神经元和非神经元群体的不同染色质构架和基因调控程序。在胶质母细胞瘤和星形细胞瘤样本中,我们检测到肿瘤区域间空间分辨的3D基因组改变、拷贝数变异和结构变异,揭示了具有临床相关性的致癌事件和克隆异质性。通过在保留组织结构的同时联合分析基因组构架和染色质可及性,Spatial-ATAC-Hi-C 为研究人类生物学和疾病中的空间基因调控提供了强大工具。
Pharmacological research IF 12.2 2026-10 PMID: 42679869
Intratumoral administration is widely used to achieve high local drug delivery while minimizing systemic toxicity. However, the fundamental assumption that locally injected agents remain within tumor tissue has rarely been quantitatively examined. Here, we show that drug leakage from the tumor surface can reduce leakage-adjusted local retention and limit therapeutic efficacy after intratumoral injection. Using multiple tumor models, conventional needle injection frequently resulted in drug escape from the tumor surface, leading to reduced leakage-adjusted retention and diminished therapeutic efficacy. Mechanical measurements revealed pronounced differences in tissue stiffness across tumor types, suggesting that tumor mechanical properties may contribute to differences in drug leakage and local retention. Histological analysis further showed that guided jet injection induces structural remodeling within tumor tissue, creating transient interstitial spaces that may facilitate intratumoral fluid propagation. Consistent with these structural observations, three-dimensional imaging demonstrated distinct cavity-formation patterns between conventional needle injection and guided jet delivery. Together, these findings indicate that drug leakage is an underrecognized physical limitation of intratumoral drug delivery and that tumor mechanical heterogeneity is associated with local retention. This study provides a rationale for improving local drug delivery through mechanically guided injection strategies.
中文摘要:肿瘤内给药被广泛用于实现高局部药物递送,同时尽量减少全身毒性。然而,局部注射的药物仍保留在肿瘤组织内这一基本假设很少被定量检验。在此,我们表明,肿瘤表面的药物泄漏可降低经泄漏校正的局部滞留,并限制肿瘤内注射后的治疗效果。使用多种肿瘤模型,传统针头注射常导致药物从肿瘤表面逸出,从而导致经泄漏校正的滞留降低和治疗效果减弱。力学测量显示,不同肿瘤类型之间组织硬度存在显著差异,提示肿瘤力学特性可能促成药物泄漏和局部滞留的差异。组织学分析进一步表明,引导式喷射注射可诱导肿瘤组织内结构重塑,形成短暂的间质空间,这可能促进肿瘤内液体传播。与这些结构观察一致,三维成像显示传统针头注射与引导式喷射递送之间具有不同的空腔形成模式。总之,这些发现表明,药物泄漏是肿瘤内药物递送中一个未被充分认识的物理限制,并且肿瘤力学异质性与局部滞留相关。本研究为通过力学引导的注射策略改善局部药物递送提供了依据。
Pharmacological research IF 12.2 2026-10 PMID: 42674125
Splicing dysregulation frequently occurs in cancers, yet the functional implications of most mis-spliced genes remain elusive. Through a comprehensive pan-cancer analysis of splicing dysregulation, we identified universally mis-spliced genes in cancers and were surprised to find their significant functional enrichment in cell migration. Interestingly, the STE20-like protein kinase (SLK) gene encoding a scaffold protein showed a significant splicing shift from SLK-S to SLK-L isoforms across various cancer types. Detailed studies demonstrated this splicing shift promoted cancer metastasis in cellular and animal models. Mechanistically, RNA-binding Fox-1 Homolog 2 (RBFOX2) protein was identified as a splicing factor that regulates SLK splicing. The two isoforms interact with occludin with different affinities, contributing to their unique activities in cancer metastasis. Notably, the antisense oligonucleotides designed to suppress SLK-L splicing effectively inhibited cancer migration and invasion. Collectively, this study shows a new splicing switch with a key role in controlling cancer metastasis, shedding light on new cancer therapy via splicing manipulation.
中文摘要:剪接失调在癌症中频繁发生,但大多数错误剪接基因的功能意义仍不清楚。通过对剪接失调进行全面的泛癌分析,我们鉴定出癌症中普遍存在的错误剪接基因,并意外发现这些基因在细胞迁移方面具有显著的功能富集。有趣的是,编码支架蛋白的STE20样蛋白激酶(SLK)基因在多种癌症类型中表现出从SLK-S向SLK-L异构体的显著剪接转换。详细研究表明,这种剪接转换在细胞和动物模型中促进癌症转移。机制上,RNA结合Fox-1同源物2(RBFOX2)蛋白被鉴定为调控SLK剪接的剪接因子。两种异构体以不同亲和力与occludin相互作用,从而促成它们在癌症转移中的独特活性。值得注意的是,为抑制SLK-L剪接而设计的反义寡核苷酸有效抑制了癌症迁移和侵袭。总之,本研究揭示了一个在控制癌症转移中起关键作用的新剪接开关,为通过剪接操控进行癌症治疗提供了新思路。
Pharmacological research IF 12.2 2026-10 PMID: 42668077
Small ubiquitin-like modifier (SUMO) conjugation, or SUMOylation, is a dynamic post-translational modification that regulates protein stability, localization, transcriptional activity, DNA damage response, and cellular stress adaptation. Increasing evidence indicates that dysregulated SUMOylation contributes to tumor progression, immune disorders, and neurodegenerative diseases, highlighting the SUMO pathway as a promising therapeutic target. However, despite extensive advances in SUMO biology, a comprehensive pharmacological assessment of SUMO pathway inhibitors, including their mechanisms of action, evidence quality, target engagement, and translational challenges, remains insufficient. This review presents an inhibitor-centered analysis of pharmacological strategies targeting the SUMOylation machinery. This review describes the molecular architecture of the SUMO conjugation cycle and identifies major druggable nodes, including the SUMO-activating enzyme (SAE), the SUMO-conjugating enzyme UBC9, SUMO-specific proteases (SENPs), and SUMO-dependent protein-protein interactions. It also examines the biological rationale for SUMO pathway inhibition in major disease contexts, with an emphasis on cancer, autoimmune disorders, and neurological diseases. Furthermore, SUMO pathway modulators are systematically classified according to their molecular targets and evidence maturity, including SAE inhibitors, UBC9-directed compounds, SENP inhibitors, direct SUMO binders, and natural product-derived modulators. Their mechanisms of action, biochemical potency, structural validation, cellular target engagement, in vivo efficacy, PK/PD properties, and developmental status are critically evaluated. Overall, this review provides a comprehensive pharmacological framework for understanding SUMO pathway inhibition and highlights key considerations for the development of next-generation SUMO-directed therapeutics.
中文摘要:小泛素样修饰蛋白(SUMO)偶联,即SUMO化,是一种动态的翻译后修饰,可调控蛋白质稳定性、定位、转录活性、DNA损伤应答以及细胞应激适应。越来越多的证据表明,SUMO化失调促进肿瘤进展、免疫紊乱和神经退行性疾病,凸显SUMO通路作为有前景的治疗靶点。然而,尽管SUMO生物学已取得广泛进展,针对SUMO通路抑制剂的全面药理学评估,包括其作用机制、证据质量、靶点结合和转化挑战,仍不充分。本综述以抑制剂为中心分析靶向SUMO化机制的药理学策略。本综述描述SUMO偶联循环的分子结构,并识别主要可成药节点,包括SUMO激活酶(SAE)、SUMO结合酶UBC9、SUMO特异性蛋白酶(SENP)以及SUMO依赖性蛋白-蛋白相互作用。它还探讨在主要疾病背景下抑制SUMO通路的生物学依据,重点为癌症、自身免疫性疾病和神经系统疾病。此外,SUMO通路调节剂根据其分子靶点和证据成熟度进行系统分类,包括SAE抑制剂、靶向UBC9的化合物、SENP抑制剂、直接SUMO结合剂和天然产物来源的调节剂。对其作用机制、生化效力、结构验证、细胞靶点结合、体内疗效、PK/PD特性和开发状态进行批判性评估。总体而言,本综述为理解SUMO通路抑制提供全面的药理学框架,并强调开发下一代靶向SUMO治疗药物的关键考量。
Nature IF 56.1 2026-10 PMID: 42649300
The genus Myotis is one of the largest clades of bats, and it exhibits some of the most extreme variation in lifespans among mammals, alongside unique adaptations to viral tolerance and immune defence1-3. Here, to study the evolution of these phenotypes, we generated cell lines and near-complete genome assemblies for eight closely related Myotis species. Using genome-wide screens of positive selection, analyses of structural variation and functional experiments in primary cells, we identify patterns of adaptation contributing to longevity, cancer resistance and viral interactions. We demonstrate distinct modes of adaptation to DNA and RNA viruses compared with all other mammals, with bats exhibiting genome-wide over-representation of positive selection for DNA-virus-interacting proteins and elevated rates of copy-number variation for RNA-virus-interacting proteins. Characterization of Myotis-specific duplications of the key immune factor EIF2AK2 (also known as PKR) reveals multiple ancient segregating trans-species copy-number polymorphisms. We show that the recurrent evolution of longevity seen in Myotis is associated with positive selection in cancer pathways, and demonstrate a unique response to DNA damage in primary cells of the long-lived Myotis lucifugus. Together, our results suggest that bats' remarkable longevity and immunity are linked through pleiotropic adaptations to viruses and ageing-related disease.
中文摘要:鼠耳蝠属是蝙蝠中最大的演化支之一,在哺乳动物中表现出一些最极端的寿命变异,并具有对病毒耐受和免疫防御的独特适应1-3。在此,为研究这些表型的演化,我们为八种密切相关的鼠耳蝠物种构建了细胞系和近乎完整的基因组组装。利用全基因组正选择筛选、结构变异分析以及原代细胞功能实验,我们识别出有助于长寿、癌症抵抗和病毒相互作用的适应模式。我们证明,与所有其他哺乳动物相比,蝙蝠对DNA病毒和RNA病毒具有不同的适应模式:蝙蝠在DNA病毒相互作用蛋白方面表现出全基因组范围的正选择过度代表,而RNA病毒相互作用蛋白则具有更高的拷贝数变异率。对关键免疫因子EIF2AK2(也称为PKR)在鼠耳蝠属中的特异性重复进行表征,揭示了多个古老的、分离的跨物种拷贝数多态性。我们表明,鼠耳蝠属中反复出现的长寿演化与癌症通路中的正选择相关,并证明长寿的小棕蝠(Myotis lucifugus)原代细胞对DNA损伤具有独特反应。总之,我们的结果表明,蝙蝠非凡的长寿和免疫力通过对病毒和衰老相关疾病的多效性适应而相互关联。
Cytokine & growth factor reviews IF 13.4 2026-10 PMID: 42632295
Interleukin-17 (IL-17) family cytokines drive protective mucocutaneous immunity and, when dysregulated, a broad spectrum of inflammatory and autoimmune disease; almost all IL-17 receptor signaling converges on a single cytoplasmic adaptor, TRAF3IP2 (Act1/CIKS). This 574-amino-acid protein and U-box E3 ubiquitin ligase couples the IL-17 receptor to NF-κB and mitogen-activated protein kinase activation and also integrates non-IL-17 inputs through TRAF6, TRAF2/TRAF5, and TRAF3. Human germline variation in TRAF3IP2 offers a natural dissection of this adaptor along its signaling modules. Common coding variants that weaken TRAF6 recruitment, mainly rs33980500 (p.Asp19Asn), increase susceptibility to psoriasis and psoriatic arthritis, whereas rare biallelic variants that abolish SEFIR-mediated IL-17 receptor coupling cause chronic mucocutaneous candidiasis; an intermediate SEFIR lesion produces discoid lupus erythematosus. Additional associations span systemic lupus erythematosus, inflammatory bowel disease, cardiovascular disease, and malignancy. Interpreting these alleles has been limited by the absence of a variant catalogue anchored to a single protein reference and by a +9-residue offset between the 574- and 565-amino-acid isoforms that has propagated numbering errors across the literature. Here we assemble a reference-aligned atlas of 17 functionally or clinically annotated TRAF3IP2 variants on the 574-amino-acid sequence (NP_671733.2) and map each to the signaling interaction it perturbs. The resulting domain-to-phenotype framework, advanced as hypothesis-generating rather than deterministic, organizes variant effects along the IL-17 signaling axis, distinguishing TRAF-recruitment perturbation from receptor-coupling failure, and identifies the adaptor surfaces whose selective pharmacologic disruption could attenuate IL-17-driven inflammation in cardiovascular and oncologic disease while sparing antifungal immunity.
中文摘要:白细胞介素-17(IL-17)家族细胞因子驱动保护性皮肤黏膜免疫,而一旦失调,则会导致广谱的炎症性和自身免疫性疾病;几乎所有IL-17受体信号均汇聚于单一胞质衔接蛋白TRAF3IP2(Act1/CIKS)。这种由574个氨基酸组成的蛋白以及U-box E3泛素连接酶,将IL-17受体与NF-κB和丝裂原活化蛋白激酶激活偶联,并通过TRAF6、TRAF2/TRAF5和TRAF3整合非IL-17输入信号。TRAF3IP2的人类种系变异为沿其信号模块剖析该衔接蛋白提供了天然工具。削弱TRAF6募集能力的常见编码变异,主要是rs33980500(p.Asp19Asn),增加银屑病和银屑病关节炎易感性;而废除SEFIR介导的IL-17受体偶联的罕见双等位基因变异则导致慢性皮肤黏膜念珠菌病;一种中间型SEFIR损伤可产生盘状红斑狼疮。其他关联涵盖系统性红斑狼疮、炎症性肠病、心血管疾病和恶性肿瘤。由于缺乏以单一蛋白参考序列为锚定的变异目录,以及574和565个氨基酸两种异构体之间存在+9个残基的偏移,导致文献中传播了编号错误,从而限制了对这些等位基因的解读。在此,我们构建了一个参考序列对齐的图谱,包含17个在574个氨基酸序列(NP_671733.2)上具有功能或临床注释的TRAF3IP2变异,并将每个变异映射到其所扰动的信号相互作用。由此产生的结构域到表型框架,作为产生假设而非确定性的框架提出,沿IL-17信号轴组织变异效应,区分TRAF募集扰动与受体偶联失败,并识别衔接蛋白表面;对这些表面的选择性药理学破坏可在心血管疾病和肿瘤疾病中减弱IL-17驱动的炎症,同时保留抗真菌免疫。
Molecular cell IF 16.0 2026-10-01 PMID: 42628532
Cancer cell proliferation requires a precise balance between biomass production and nutrient catabolism. The pyridine nucleotide cofactors nicotinamide adenine dinucleotide NAD(H) and NAD phosphate NADP(H) are central to this process, but their compartment-specific regulation is incompletely understood. Using in vivo isotope-labeled metabolite tracing in an orthotopic xenograft model, we find that human gliomas extensively synthesize proline, an amino acid previously associated with hypoxia tolerance. In glioma cells, we identify a hypoxia-enhanced proliferative sensitivity to environmental proline dependent on NADH to NADPH transhydrogenation from a spatially compartmentalized mitochondrial pool by the enzyme nicotinamide nucleotide transhydrogenase (NNT). We demonstrate NNT-dependent generation of mitochondrial NADPH is important for proline accumulation, maintenance of antioxidant systems, and reductive metabolism in hypoxic glioma cells in vitro and tumor progression in vivo. Collectively, these results highlight proline accumulation as a marker of mitochondrial NAD(P)(H) homeostasis and NNT as a specific metabolic dependency in human glioma.
中文摘要:癌细胞增殖需要在生物量产生与营养分解代谢之间保持精确平衡。吡啶核苷酸辅因子烟酰胺腺嘌呤二核苷酸NAD(H)和烟酰胺腺嘌呤二核苷酸磷酸NADP(H)在这一过程中居于核心地位,但它们在特定区室中的调控仍未完全阐明。利用原位异种移植模型中的体内同位素标记代谢物示踪,我们发现人胶质瘤会大量合成脯氨酸,这是一种此前与缺氧耐受相关的氨基酸。在胶质瘤细胞中,我们鉴定出缺氧增强的增殖对环境脯氨酸的敏感性,这种敏感性依赖于由烟酰胺核苷酸转氢酶(NNT)从空间区室化的线粒体池中进行的NADH向NADPH的转氢反应。我们证明,NNT依赖性的线粒体NADPH生成对于体外缺氧胶质瘤细胞中的脯氨酸积累、抗氧化系统维持和还原性代谢以及体内肿瘤进展具有重要作用。总体而言,这些结果突显了脯氨酸积累可作为线粒体NAD(P)(H)稳态的标志,并将NNT确定为人类胶质瘤中的一种特异性代谢依赖。
Acta biomaterialia IF 10.4 2026-10 PMID: 42624347
Silicone breast implants (SBIs) are among the most common surgically-implantable medical devices, but carry high complication rates, especially in the setting of post-oncologic breast reconstruction. These complications include capsular contracture, malposition, rupture, and breast implant-associated anaplastic large cell lymphoma. The development of SBI-associated complications is recognized to be multifactorial with the underlying mechanisms being poorly defined. Physical factors implicated in pathophysiology include gross mechanical stresses induced by the implant on surrounding tissue, the dissipation of friction stresses to local tissue by implant microtopography, and the incongruity of stiffness between local breast tissue, fibrous capsular tissue, and biomaterial, causing a significant gradient at the interface. Hypotheses of implicated (bio)chemical factors include direct adjuvant activity of the silicone material, the adsorption and persistence of pro-inflammatory factors at the interface, and the seeding of bacterial colonies. The current review explores in detail the physiology of the specific foreign body response to implanted materials associated with clinical SBIs, including the available evidence implicating both physical and chemical factors in the propagation of pathology. New advances in models and materials-based approaches to assessing and mitigating material-induced pathology are also reviewed. Finally, recommendations for SBI design, as well as further mechanistic work to address the pathophysiology underlying SBI-associated complications are outlined. STATEMENT OF SIGNIFICANCE: Treatment for breast cancer is associated with significant morbidity between surgical, radiotherapeutic, and systemic therapeutic approaches. Silicone breast reconstructive devices can allow for patients to regain confidence and personal efficacy after the trauma of cancer treatment. However, these devices are notorious for immune-mediated foreign body reactions, and patients can then suffer from painful or disfiguring fibrosis, and rarely a subtype of lymphoma or whole-body autoimmune reactions. Despite the ubiquity of these devices, the pathophysiological mechanisms underlying these complications are poorly understood. In this review, we review both clinical and fundamental approaches to understanding the development of pathology related to breast reconstructive devices, and discuss potential physicochemical approaches to device composition that may minimize these risks in the future.
中文摘要:硅胶乳房植入物(SBIs)是最常见的外科植入医疗器械之一,但其并发症发生率较高,尤其是在肿瘤术后乳房重建的情况下。这些并发症包括包膜挛缩、移位、破裂以及乳房植入物相关间变性大细胞淋巴瘤。目前认为SBI相关并发症的发生是多因素的,其潜在机制尚不明确。与病理生理相关的物理因素包括植入物对周围组织产生的大体机械应力、植入物微形貌将摩擦应力耗散至局部组织,以及局部乳房组织、纤维包膜组织与生物材料之间刚度不匹配,从而在界面处造成显著梯度。所涉及(生物)化学因素的假说包括硅胶材料的直接佐剂活性、促炎因子在界面的吸附与持续存在,以及细菌菌落的定植。本综述详细探讨了与临床SBI相关的植入材料特异性异物反应的生理学,包括提示物理和化学因素均参与病理进展的现有证据。还综述了评估和减轻材料诱导病理的模型及基于材料的方法的新进展。最后,概述了SBI设计建议,以及针对SBI相关并发症潜在病理生理机制的进一步机制研究建议。意义声明:乳腺癌治疗与外科、放疗和全身治疗方式相关的显著发病率有关。硅胶乳房重建装置可使患者在癌症治疗的创伤后重获自信和个人效能。然而,这些装置因免疫介导的异物反应而广为人知,患者随后可能遭受疼痛性或毁容性纤维化,罕见情况下还会发生淋巴瘤亚型或全身性自身免疫反应。尽管这些装置广泛使用,但其并发症背后的病理生理机制仍知之甚少。在本综述中,我们回顾了理解乳房重建装置相关病理发展的临床和基础方法,并讨论了未来可能最大限度降低这些风险的装置组成的潜在物理化学方法。
Molecular aspects of medicine IF 13.8 2026-10 PMID: 42623890
Cachexia, also known as wasting syndrome, is a complex metabolic syndrome triggered by cancer and a variety of severe chronic diseases, characterized by skeletal muscle depletion (with or without loss of adipose tissue) and frequently involving multiple systems. Although inflammation plays a pivotal role in its pathogenesis, the traditional inflammation-centric theory remains insufficient to fully account for the systemic pathological alterations in cachexia. In recent years, growing evidence has demonstrated that the gut microbiota interacts with the neuro-immune-metabolic network, leading to adipose tissue atrophy and muscle catabolism, thereby driving the onset and progression of cachexia. This review systematically delineates the alterations in gut microbiota dysbiosis across various etiologies of cachexia and the functional roles of their related metabolites. It further summarizes the mechanisms by which the gut microbiota regulates cachexia through the nervous system and explores its impact on immune homeostasis and systemic metabolic balance. Furthermore, we highlight current research on cachexia treatment and novel therapeutic strategies based on gut microbiota modulation, providing a theoretical foundation and research direction for the precise diagnosis and intervention of cachexia. This review is expected to offer theoretical support for an in-depth understanding of the multidimensional pathophysiology of cachexia and to promote innovation in clinical intervention strategies.
中文摘要:恶病质,又称消耗综合征,是一种由癌症及多种严重慢性疾病触发的复杂代谢综合征,以骨骼肌消耗(伴或不伴脂肪组织丢失)为特征,并常累及多个系统。尽管炎症在其发病机制中起关键作用,但传统的以炎症为中心的理论仍不足以完全解释恶病质的全身性病理改变。近年来,越来越多证据表明,肠道菌群与神经-免疫-代谢网络相互作用,导致脂肪组织萎缩和肌肉分解代谢,从而驱动恶病质的发生与进展。本综述系统阐述了不同病因恶病质中肠道菌群失调的改变及其相关代谢物的功能作用。文章进一步总结了肠道菌群通过神经系统调控恶病质的机制,并探讨了其对免疫稳态和全身代谢平衡的影响。此外,我们重点介绍了当前恶病质治疗研究以及基于肠道菌群调节的新型治疗策略,为恶病质的精准诊断和干预提供了理论基础与研究方向。本综述有望为深入理解恶病质的多维病理生理学提供理论支持,并促进临床干预策略的创新。
Nature IF 56.1 2026-10 PMID: 42618784
Accumulating evidence demonstrates that the central nervous system (CNS) is not disconnected from the peripheral immune system; however, precisely how the adaptive immune system surveils the CNS remains a critical question. Recent findings reveal that channels between the skull and the dura mater facilitate the exchange of cerebrospinal fluid and immune cells between the CNS and skull bone marrow of mice under both homeostatic and disease conditions1-6. Skull bone marrow functions as a source of immune cells for the CNS5, yet its role in CNS antigen-specific adaptive immune responses remains unclear. Here we identify lymphoid structures within the skull bone marrow, featuring germinal-centre-like formations and containing a distinct population of follicular-helper-like T cells that promote B cell activation and humoral immunity through CD40L, IL-21 and IFNγ signalling. Adaptive immune cells within these skull bone marrow lymphoid structures surveil and respond to CNS-derived antigens and contribute to anti-tumour immune responses in mouse brain cancer models. Together, our findings show that the skull bone marrow is a site of CNS immunosurveillance that may influence immune responses across diverse neurological diseases.
中文摘要:不断积累的证据表明,中枢神经系统(CNS)并非与外周免疫系统相互隔绝;然而,适应性免疫系统究竟如何监视CNS仍是一个关键问题。近期研究发现,在稳态和疾病条件下,小鼠颅骨与硬脑膜之间的通道促进脑脊液和免疫细胞在CNS与颅骨骨髓之间交换。颅骨骨髓是CNS免疫细胞的来源,但其在CNS抗原特异性适应性免疫应答中的作用仍不清楚。在此,我们在颅骨骨髓中鉴定出淋巴结构,其具有生发中心样结构,并包含一群独特的滤泡辅助性T细胞样细胞,这些细胞通过CD40L、IL-21和IFNγ信号促进B细胞活化和体液免疫。这些颅骨骨髓淋巴结构内的适应性免疫细胞监视并对CNS来源抗原作出应答,并在小鼠脑癌模型中参与抗肿瘤免疫应答。总之,我们的研究结果表明,颅骨骨髓是CNS免疫监视的一个部位,可能影响多种神经系统疾病中的免疫应答。
Nature chemical biology IF 15.8 2026-10 PMID: 42618629
Ras is a small GTPase that regulates cell growth and proliferation. Hyperactive Ras is prevalent in cancer and has been a therapeutic target for decades. Many lines of evidence have demonstrated that Ras signals from the plasma membrane as well as noncanonical compartments such as the Golgi, making live-cell biosensors for tracking the spatiotemporal dynamics of Ras activity a valuable approach for Ras studies. However, current biosensors are limited in their quantitative capacity for measuring endogenous Ras activity. Here we introduce a chemigenetic biosensor design, making use of circularly permuted HaloTag labeled with the fluorophore JF635, for detecting endogenous Ras activity. This HaloTag-based Ras Activity Reporter (HaloRasAR) revealed the spatiotemporal dynamics of Ras activity downstream of either growth factor signaling or protein kinase C activation. In addition, live-cell characterization of a Ras(G12C) inhibitor and a Ras GEF inhibitor revealed subcellular-specific inhibition profiles. HaloRasAR represents a major advance in spatiotemporal interrogation of Ras signaling and live-cell pharmacology.
中文摘要:Ras 是一种小型 GTP 酶,调节细胞生长和增殖。过度活跃的 Ras 在癌症中普遍存在,数十年来一直是治疗靶点。许多证据表明,Ras 可从质膜以及高尔基体等非经典区室发出信号,因此,用于追踪 Ras 活性时空动态的活细胞生物传感器成为 Ras 研究的重要方法。然而,当前生物传感器在定量测量内源性 Ras 活性方面能力有限。在此,我们介绍一种化学遗传学生物传感器设计,利用用荧光团 JF635 标记的环状排列 HaloTag 检测内源性 Ras 活性。这种基于 HaloTag 的 Ras 活性报告器(HaloRasAR)揭示了生长因子信号或蛋白激酶 C 激活下游 Ras 活性的时空动态。此外,对一种 Ras(G12C) 抑制剂和一种 Ras GEF 抑制剂的活细胞表征揭示了亚细胞特异性的抑制谱。HaloRasAR 代表了在时空探究 Ras 信号和活细胞药理学方面的重要进展。
Redox biology IF 16.2 2026-10 PMID: 42617573
Alkaloids from Macleaya cordata have demonstrated to possess anti-tumor effects against various cancer types, but their efficacy on GBM remains unexplored. In this study we investigated the anti-GBM activity of 6-Met and its underlying mechanisms. GBM cell proliferation was assessed using CCK-8, RTCA, and colony formation assays in vitro. A xenograft mode used to investigate the anti-tumor efficacy of 6-Met. Apoptosis and ROS were quantified by Flow cytometry. GSH content was determined using a commercial GSH/GSSG assay kit. In parallel, the activities of GSS, GCLC, and GR, were quantified by corresponding commercial assay kits. Cellular bioenergetics was evaluated by Seahorse XFe96 analyzer. Ubiquitination analysis was conducted by immunoprecipitation (IP) using an anti-ubiquitin antibody. Finally, expression changes were analyzed by Western blotting and quantitative reverse transcription PCR. Our results revealed that 6-Met significantly suppressed GBM cell growth in vitro and transplanted tumor growth in vivo. Additionally, 6-Met induced caspase-dependent apoptosis in GBM cells. Mechanistically, 6-ME suppressed GSS expression by enhancing its ubiquitination, resulting in impaired GSH synthesis and subsequent ROS accumulation. The elevated ROS levels further disrupted mitochondrial function by damaging Fe-S clusters, as evidenced by reduced expression of Fe-S cluster-associated proteins, ultimately impairing mitochondrial respiration. Concurrently, ROS activation suppressed the mTOR signaling via modulation of its phosphorylation. Notably, exogenous GSH supplementation and ectopic GSS expression mitigates 6-Met cytotoxicity in GBM cells. Furthermore, exogenous expression of GSS abrogated 6-Met-induced transplanted tumor growth inhibition in vivo. Clinically, we observed that GSS expression was significantly elevated in GBM tissues compared to normal brain tissues, and lower GSS expression correlated with better patient prognosis, highlighting its potential as a prognostic marker. Collectively, these findings establish that 6-Met inhibits GBM tumor growth by disrupting GSS-dependent glutathione synthesis, thereby promoting oxidative stress, impairing mitochondrial respiration and mTOR signaling, and ultimately triggering apoptosis.
中文摘要:博落回中的生物碱已被证明对多种癌症具有抗肿瘤作用,但其对胶质母细胞瘤(GBM)的疗效尚未被探索。本研究探讨了6-Met的抗GBM活性及其潜在机制。在体外使用CCK-8、RTCA和集落形成实验评估GBM细胞增殖。使用异种移植模型研究6-Met的体内抗肿瘤疗效。通过流式细胞术定量凋亡和ROS。使用商业GSH/GSSG检测试剂盒测定GSH含量。同时,使用相应商业检测试剂盒定量GSS、GCLC和GR活性。使用Seahorse XFe96分析仪评估细胞生物能量学。使用抗泛素抗体通过免疫沉淀(IP)进行泛素化分析。最后,通过Western blotting和定量逆转录PCR分析表达变化。我们的结果揭示,6-Met在体外显著抑制GBM细胞生长,并在体内抑制移植瘤生长。此外,6-Met在GBM细胞中诱导caspase依赖性凋亡。在机制上,6-Met通过增强GSS的泛素化抑制GSS表达,导致GSH合成受损和随后的ROS积累。升高的ROS水平通过破坏Fe-S簇进一步扰乱线粒体功能,表现为Fe-S簇相关蛋白表达降低,最终损害线粒体呼吸。同时,ROS激活通过调节mTOR磷酸化抑制mTOR信号传导。值得注意的是,外源性GSH补充和异位GSS表达减轻了6-Met对GBM细胞的细胞毒性。此外,GSS的外源性表达在体内消除了6-Met诱导的移植瘤生长抑制。在临床方面,我们观察到与正常脑组织相比,GBM组织中GSS表达显著升高,且较低的GSS表达与更好的患者预后相关,突显其作为预后标志物的潜力。总之,这些发现确立6-Met通过破坏GSS依赖性谷胱甘肽合成来抑制GBM肿瘤生长,从而促进氧化应激、损害线粒体呼吸和mTOR信号传导,并最终触发凋亡。
Molecular aspects of medicine IF 13.8 2026-10 PMID: 42617280
Gestational diabetes mellitus (GDM) and cancer develop in distinct clinical and biological contexts; however, both conditions expose tissues to chronic metabolic stress, hypoxia, inflammation, and vascular remodelling. In this review, we advance the hypothesis that GDM and cancer share conserved endothelial adaptive response mechanisms, particularly within the placental and tumour-associated vasculature, without implying malignant transformation or direct oncogenic causation. Common alterations in nitric oxide signalling, mitochondrial metabolic programming, intracellular pH regulation, and redox homeostasis are highlighted. A central shared feature is dysregulation of purinergic signalling, whereby increased extracellular adenosine, driven by altered nucleoside transport and ectonucleotidase activity, including CD73, acts as an immunometabolic modulator. Engagement of A2A and A2B adenosine receptors on endothelial and immune cells suppress effector immune activation, favour myeloid immunoregulatory phenotypes, and promote vascular adaptation in tumours, while contributing to inflammatory persistence and endothelial dysfunction in GDM. These effects intersect with preserved signalling networks, including PI3K/AKT/mTOR, AMPK, MAPK/ERK, NF-κB, and hypoxia-inducible pathways, which regulate endothelial plasticity and survival across both diseases. We further propose that epigenetic stabilisation of these shared signalling states, mediated by DNA methylation, histone modifications, microRNA networks, and dysregulation of imprinted loci such as the insulin-like growth factor 2 gene, may extend the impact of gestational metabolic stress beyond pregnancy. Rather than conferring oncogenic risk per se, these mechanisms likely reflect common adaptive vascular programs reused across pathological settings. This comparative pattern can identify shared immunometabolic signalling nodes and provides a basis for understanding how gestational metabolic environments shape long-term vascular health.
中文摘要:妊娠期糖尿病(GDM)与癌症发生于不同的临床和生物学背景中;然而,这两种情况都使组织暴露于慢性代谢应激、缺氧、炎症和血管重塑。在这篇综述中,我们提出一个假说:GDM与癌症共享保守的内皮适应性反应机制,尤其是在胎盘和肿瘤相关血管系统中,但这并不意味着恶性转化或直接致癌因果关系。我们重点讨论一氧化氮信号、线粒体代谢编程、细胞内pH调节和氧化还原稳态中的共同改变。一个核心的共同特征是嘌呤能信号失调,其中由核苷转运改变和外核苷酸酶活性(包括CD73)驱动的细胞外腺苷增加,发挥免疫代谢调节因子的作用。内皮细胞和免疫细胞上A2A和A2B腺苷受体的参与抑制效应免疫激活,促进髓系免疫调节表型,并促进肿瘤中的血管适应,同时在GDM中促成炎症持续和内皮功能障碍。这些效应与保守的信号网络相交,包括PI3K/AKT/mTOR、AMPK、MAPK/ERK、NF-κB和缺氧诱导通路,这些通路调节两种疾病中的内皮可塑性和存活。我们进一步提出,这些共享信号状态的表观遗传稳定,由DNA甲基化、组蛋白修饰、microRNA网络以及诸如胰岛素样生长因子2基因等印记位点失调所介导,可能将妊娠期代谢应激的影响延伸至妊娠之后。这些机制本身可能并不赋予致癌风险,而更可能反映在不同病理环境中被重复利用的共同适应性血管程序。这种比较模式可以识别共享的免疫代谢信号节点,并为理解妊娠期代谢环境如何塑造长期血管健康提供基础。
Nature immunology IF 26.5 2026-10 PMID: 42613461
The limited effectiveness of chimeric antigen receptor macrophage (CAR-M) therapy is largely due to poor tumor infiltration, reduced effector function and immune escape of target antigen-low tumors. Here we developed syncytial CAR-Ms (S-CAR-M) by fusing CAR-Ms with neutrophils. S-CAR-Ms accumulated in tumors more than conventional CAR-Ms because of chemokine-driven migration. By releasing neutrophil extracellular traps and reactive oxygen species inherited from neutrophils, S-CAR-Ms increased PtdSer exposure on tumor cells, leading to efficient phagocytosis of tumor debris through both the scFv-antigen and PtdSer-MerTK pathways. Thus, a single dose of S-CAR-Ms can reduce tumor burden, limit metastasis and prevent tumor recurrence in syngeneic and xenograft mouse models. Additionally, S-CAR-M therapy triggered antigen spreading, minimizing escape by target antigen-low tumor cells. S-CAR-Ms overcome limitations of conventional CAR-Ms toward solid tumors.
中文摘要:嵌合抗原受体巨噬细胞(CAR-M)疗法效果有限,主要归因于肿瘤浸润差、效应功能降低以及靶抗原低表达肿瘤的免疫逃逸。在此,我们通过将CAR-M与中性粒细胞融合,开发了合胞体CAR-M(S-CAR-M)。由于趋化因子驱动的迁移,S-CAR-M在肿瘤中的蓄积多于常规CAR-M。通过释放继承自中性粒细胞的中性粒细胞胞外诱捕网和活性氧,S-CAR-M增加了肿瘤细胞上PtdSer的暴露,从而通过scFv-抗原和PtdSer-MerTK两条通路高效吞噬肿瘤碎片。因此,单剂S-CAR-M即可在同基因和异种移植小鼠模型中减轻肿瘤负荷、限制转移并预防肿瘤复发。此外,S-CAR-M疗法触发了抗原扩散,从而最大限度减少靶抗原低表达肿瘤细胞的逃逸。S-CAR-M克服了常规CAR-M针对实体瘤的局限性。
Nature neuroscience IF 20.3 2026-10 PMID: 42608571
Aging-associated loss of chromatin compaction is linked to derepression of retrotransposable elements (RTEs) in mouse and human tissues. Whether such RTE transcription contributes to the microglia activation that is common in aged brains is unknown. Here, we show that DAXX, a histone chaperone and RTE repressor, is downregulated during aging, preserves microglia homeostasis and inhibits cellular senescence. Loss of Daxx in young-adult microglia drives a reactive phenotype marked by chromatin decompaction at RTEs, loss of homeostatic markers, cell cycle re-entry and behavioral changes. This state leads to DNA damage and microglial depletion, followed by replacement with DAXX-deficient/Apoehigh microglia displaying features of senescence. Sustained induction of senescence relies on promyelocytic leukemia protein, a DAXX-interacting factor and interferon target. Together, these findings highlight the importance of heterochromatin maintenance in preserving adult microglial identity and plasticity, with broader implications for brain homeostasis, healthy aging and behavior.
中文摘要:衰老相关的染色质压缩丧失与小鼠和人类组织中逆转录转座元件(RTE)的去抑制有关。这种RTE转录是否促成衰老大脑中常见的小胶质细胞激活尚不清楚。在此,我们表明,DAXX——一种组蛋白伴侣和RTE抑制因子——在衰老过程中下调,可维持小胶质细胞稳态并抑制细胞衰老。年轻成年小胶质细胞中Daxx缺失会驱动一种反应性表型,其特征是RTE处染色质解聚、稳态标志物丢失、细胞周期重新进入以及行为改变。这种状态导致DNA损伤和小胶质细胞耗竭,随后被具有衰老特征的DAXX缺陷/Apoe高表达小胶质细胞替代。衰老的持续诱导依赖于早幼粒细胞白血病蛋白,这是一种与DAXX相互作用的因子,也是干扰素靶点。总之,这些发现强调了异染色质维持对于保留成体小胶质细胞身份和可塑性的重要性,并对脑稳态、健康衰老和行为具有更广泛的意义。
Redox biology IF 16.2 2026-10 PMID: 42607497
Resistance to tyrosine kinase inhibitors (TKIs) severely limits their long-term efficacy in renal cell carcinoma (RCC). Here, we identify prolyl 4-hydroxylase subunit alpha 3 (P4HA3) as a critical driver of TKI resistance and elucidate its underlying mechanism. P4HA3 was markedly upregulated in TKI-resistant RCC cells, and its overexpression promoted proliferation and resistance to sunitinib and axitinib, whereas P4HA3 depletion restored drug sensitivity and suppressed tumor growth in vitro and in vivo. Mechanistically, P4HA3 inhibited ferroptosis by stabilizing the cystine transporter SLC7A11, thereby maintaining redox homeostasis and suppressing lipid peroxidation. P4HA3 directly interacted with SLC7A11 and induced hydroxyproline modification at residues P153 and P161, which attenuated NEDD4-mediated ubiquitination and proteasomal degradation of SLC7A11. Moreover, a hydroxylase-inactive P4HA3 mutant failed to stabilize SLC7A11, suppress ferroptosis, or promote TKI resistance, demonstrating the essential role of P4HA3 enzymatic activity. Importantly, pharmacological inhibition of P4HA3 using Tubuloside A or 1,4-DPCA disrupted the P4HA3-SLC7A11 axis and significantly enhanced TKI efficacy across RCC cell lines, patient-derived organoids, and xenograft models. Together, these findings establish a hydroxylation-dependent P4HA3-SLC7A11-NEDD4 axis that drives ferroptosis evasion and TKI resistance in RCC and highlight P4HA3 as a promising therapeutic target.
中文摘要:酪氨酸激酶抑制剂(TKI)耐药严重限制了其在肾细胞癌(RCC)中的长期疗效。在此,我们确定脯氨酰4-羟化酶α3亚基(P4HA3)是TKI耐药的关键驱动因子,并阐明其潜在机制。P4HA3在TKI耐药的RCC细胞中显著上调,其过表达促进增殖以及对舒尼替尼和阿昔替尼的耐药,而P4HA3耗竭则恢复药物敏感性并在体外和体内抑制肿瘤生长。机制上,P4HA3通过稳定胱氨酸转运体SLC7A11抑制铁死亡,从而维持氧化还原稳态并抑制脂质过氧化。P4HA3直接与SLC7A11相互作用,并诱导P153和P161残基处的羟脯氨酸修饰,从而减弱NEDD4介导的SLC7A11泛素化和蛋白酶体降解。此外,羟化酶失活的P4HA3突变体无法稳定SLC7A11、抑制铁死亡或促进TKI耐药,表明P4HA3酶活性不可或缺。重要的是,使用Tubuloside A或1,4-DPCA对P4HA3进行药理学抑制,破坏了P4HA3-SLC7A11轴,并在RCC细胞系、患者来源类器官和异种移植模型中显著增强TKI疗效。总之,这些发现确立了一种依赖羟化的P4HA3-SLC7A11-NEDD4轴,其驱动RCC中的铁死亡逃逸和TKI耐药,并突出P4HA3作为有前景的治疗靶点。
Cytokine & growth factor reviews IF 13.4 2026-10 PMID: 42594808
Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy in which inflammatory signaling plays a pivotal role in disease pathogenesis. The dysregulation of the cytokine network leads to an increased abundance of pro-inflammatory mediators, such as IL-1β, TNF-α and IL-6, relative to anti-inflammatory cytokines like TGF-β and CXCL12. This disbalance in cytokine levels is closely associated with tumor development and fosters a pro-tumorigenic microenvironment by facilitating leukemic cell proliferation, reducing survival rates, and promoting drug resistance. In addition, inflammatory cytokines have been shown to preferentially support hematopoietic stem and progenitor cell populations harboring mutations associated with clonal hematopoiesis. This review summarizes the current knowledge on inflammatory cytokines and signaling pathways in AML, focusing on: (i) their mechanisms of action and implications for immune tolerance and clonal hematopoiesis and (ii) the emerging therapeutic strategies targeting these pathways to improve clinical outcomes for patients with AML.
中文摘要:急性髓系白血病(AML)是一种高度侵袭性的血液系统恶性肿瘤,其中炎症信号在疾病发病机制中起着关键作用。细胞因子网络的失调导致促炎介质(如IL-1β、TNF-α和IL-6)相对于抗炎细胞因子(如TGF-β和CXCL12)的丰度增加。细胞因子水平的这种失衡与肿瘤发展密切相关,并通过促进白血病细胞增殖、降低生存率以及促进耐药性,培育出促肿瘤的微环境。此外,炎症细胞因子已被证明优先支持携带与克隆性造血相关突变的造血干/祖细胞群体。本综述总结了目前关于AML中炎症细胞因子及信号通路的认识,重点关注:(i)它们的作用机制及其对免疫耐受和克隆性造血的影响,以及(ii)针对这些通路的新兴治疗策略,以改善AML患者的临床结局。
Carbohydrate polymers IF 13.2 2026-10-01 PMID: 42586674
Nanocarriers based on chitosan have become effective and biocompatible delivery systems for anticancer drugs that are poorly soluble. Recent developments in the design of amphiphilic chitosan derivatives modified with hydrophobic moieties, including fatty acids, cholesterol, bile acids, and functional ligands, are systematically compiled in this study. Such modifications allow for spontaneous self-assembly into micelles or nanoparticles that can encapsulate various hydrophobic drugs, including doxorubicin, paclitaxel, derivatives of camptothecin, and natural bioactives. The links between structure and properties that control drug loading, release kinetics, cellular uptake, and targeting efficiency are highlighted. In the context of tumor-specific microenvironments, pH-responsive behavior, ligand-mediated active targeting, and improved intracellular delivery are examined. Additionally, in vitro and in vivo data are used to critically assess strategies for enhancing bioavailability, overcoming multidrug resistance, and lowering systemic toxicity. To offer a comprehensive comparative overview of carrier design concepts, this paper schematically illustrates the synthesis methods and architectural diversity of several lipid-conjugated amphiphilic chitosan-based systems. All things considered, chitosan-derived amphiphilic nanocarriers are a promising and versatile family of drug delivery vehicles for enhancing the therapeutic efficacy of anticancer drugs.
中文摘要:基于壳聚糖的纳米载体已成为难溶性抗癌药物的有效且生物相容的递送系统。本研究系统梳理了近年来通过疏水基团(包括脂肪酸、胆固醇、胆汁酸和功能性配体)修饰的两亲性壳聚糖衍生物的设计进展。此类修饰使其能够自发自组装成胶束或纳米颗粒,从而包载多种疏水性药物,包括多柔比星、紫杉醇、喜树碱衍生物和天然生物活性物。文中重点阐述了控制载药量、释放动力学、细胞摄取和靶向效率的结构与性质之间的关系。在肿瘤特异性微环境背景下,本文考察了pH响应行为、配体介导的主动靶向以及改善的胞内递送。此外,本文利用体外和体内数据,批判性评估了提高生物利用度、克服多药耐药和降低全身毒性的策略。为对载体设计理念提供全面的比较性概述,本文以示意图展示了若干脂质偶联两亲性壳聚糖基体系的合成方法和结构多样性。总体而言,壳聚糖衍生的两亲性纳米载体是一类有前景且多功能的药物递送载体,可增强抗癌药物的治疗效果。
Carbohydrate polymers IF 13.2 2026-10-01 PMID: 42586625
The incorporation of metal-coordination chemistry into chitosan (CS)-based nanocarriers has expanded possibilities in the domain of intelligent drug delivery systems. CS serves as an optimal foundation for developing multifunctional carriers that enable targeted and stimuli-responsive drug release. This study emphasizes current progress in the design and use of metal-coordinated CS nanocarriers, concentrating on their coordination processes, drug loading techniques and controlled release characteristics. Special emphasis is placed on systems that include transition metals like Zn2+, Fe3+ and Cu2+, which improve structural integrity, facilitate environmentally induced release and sometimes provide further therapeutic benefits. Case studies illustrate the effectiveness of zinc-based CS nanocarriers integrated with mesoporous silica and biotin surface modification in tumor-targeted administration, pH-responsive release and selective cytotoxicity. Notwithstanding encouraging preclinical results, obstacles such as coordination bond stability, physiological interference, long-term safety and regulatory ambiguity continue to pose significant impediments to clinical translation. Proposed future paths include the advancement of theranostic platforms, multi-metallic systems and artificial intelligence (AI)-driven design tools. Metal-coordinated CS nanocarriers are a versatile and effective approach for precision nanomedicine with considerable promise in cancer, infectious disorders and regenerative medicine.
中文摘要:将金属配位化学引入壳聚糖(CS)基纳米载体,拓展了智能药物递送系统的可能性。CS是开发能够实现靶向和刺激响应性药物释放的多功能载体的理想基础。本研究强调金属配位CS纳米载体在设计和使用方面的当前进展,重点关注其配位过程、载药技术和控释特性。特别关注包含Zn2+、Fe3+和Cu2+等过渡金属的系统,这些系统可提高结构完整性、促进环境诱导释放,有时还提供额外的治疗益处。案例研究说明了将锌基CS纳米载体与介孔二氧化硅和生物素表面修饰相结合在肿瘤靶向给药、pH响应释放和选择性细胞毒性方面的有效性。尽管临床前结果令人鼓舞,但配位键稳定性、生理干扰、长期安全性和监管模糊性等障碍仍对临床转化构成重大阻碍。提出的未来路径包括治疗诊断平台、多金属系统和人工智能(AI)驱动的设计工具的发展。金属配位CS纳米载体是一种用于精准纳米医学的多功能且有效的方法,在癌症、感染性疾病和再生医学中具有相当大的前景。
Redox biology IF 16.2 2026-10 PMID: 42585793
Lung adenocarcinoma (LUAD) continues to be one of the top causes of cancer-associated deaths worldwide. TAR DNA-binding protein 43 (TDP-43) has been linked to several tumor-related biological processes, yet its specific role in LUAD growth remains poorly understood. Ferroptosis, an iron-dependent regulated cell death, is increasingly recognized as a key process affecting tumor development. Here, we report that TDP-43 acts as a key ferroptosis regulator facilitating LUAD growth. TDP-43 is upregulated in LUAD tissues and positively correlates with poor patient prognosis. Functionally, TDP-43 silencing impairs LUAD cell proliferation and promotes cell death, whereas TDP-43 overexpression exerts the opposite effects. Consistently, TDP-43 knockdown markedly suppresses xenograft tumor growth in vivo. Whole transcriptome sequencing combined with subsequent validation assays revealed that TDP-43 is capable of suppressing ferroptosis in LUAD cells. Accordingly, TDP-43 silencing sensitizes cells to erastin/RSL3-induced ferroptosis. Mechanistically, TDP-43 exerts its effects through two distinct pathways: it interacts with transcription factor VDR via its C-terminal domain to activate PCBP1 transcription, while directly binding to the UG-rich motif within the 3'UTR of PCBP2 mRNA to stabilize its transcript. Upregulation of iron chaperones PCBP1 and PCBP2 alleviates intracellular Fe2+ overload and lipid peroxidation, allowing LUAD cells to escape ferroptosis and support tumor growth. These results highlight TDP-43's pivotal role in regulating LUAD ferroptosis and offer promising directions for LUAD treatment.
中文摘要:肺腺癌(LUAD)仍然是全球癌症相关死亡的主要原因之一。TAR DNA结合蛋白43(TDP-43)已与多种肿瘤相关生物学过程有关,但其在LUAD生长中的具体作用仍知之甚少。铁死亡是一种铁依赖性的调节性细胞死亡,日益被认为是影响肿瘤发展的关键过程。在此,我们报道TDP-43作为关键的铁死亡调控因子促进LUAD生长。TDP-43在LUAD组织中上调,并与患者不良预后正相关。功能上,沉默TDP-43会损害LUAD细胞增殖并促进细胞死亡,而过表达TDP-43则产生相反效应。与此一致,敲低TDP-43可显著抑制体内异种移植瘤生长。全转录组测序结合后续验证实验显示,TDP-43能够抑制LUAD细胞中的铁死亡。因此,沉默TDP-43使细胞对erastin/RSL3诱导的铁死亡敏感。机制上,TDP-43通过两条不同途径发挥效应:它通过其C端结构域与转录因子VDR相互作用以激活PCBP1转录,同时直接结合PCBP2 mRNA 3'UTR内富含UG的基序以稳定其转录本。铁伴侣蛋白PCBP1和PCBP2上调减轻细胞内Fe2+超载和脂质过氧化,使LUAD细胞得以逃逸铁死亡并支持肿瘤生长。这些结果突显了TDP-43在调控LUAD铁死亡中的关键作用,并为LUAD治疗提供了有前景的方向。
Redox biology IF 16.2 2026-10 PMID: 42567042
Selenoprotein F (SELENOF) is one of the 25 human selenoproteins that is highly sensitive to fluctuations in bioavailable selenium, an essential micronutrient. Although SELENOF has been implicated in cancer etiology, its precise role remains unclear. To define its contribution to carcinogenesis, Selenof knockout (KO) mice were exposed to the potent carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) and fed a high-fat, high-calorie Western diet. All Selenof KO mice developed tumors and did so more rapidly, whereas only 30% of wild-type mice developed tumors. This effect was further exacerbated by the Western diet regardless of Selenof status. Notably, the majority of DMBA-induced tumors in KO mice were skin lesions, predominantly cutaneous squamous cell carcinomas (SCCs) and benign papillomas. These tumors occurred at a four-fold higher frequency in KO mice than in wild-type controls, establishing SELENOF as a key tumor suppressor in the skin. To assess the relevance of these findings to human disease, we analyzed a skin cancer microarray containing patient samples of SCC, basal cell carcinoma, melanomas, and matched adjacent normal tissue. SELENOF expression was dramatically reduced across all tumor types relative to normal skin. Although the skin of Selenof KO mice appears histologically normal, transcriptomic profiling followed by enrichment analysis revealed significant downregulation of pathways related to epidermal development and keratinocyte differentiation as well as the upregulation of oxidative phosphorylation and mitochondrial metabolic pathways. Collectively, these findings support a causal link between SELENOF loss and skin cancer development and highlight a previously unrecognized role for SELENOF in safeguarding against skin carcinogenesis. Significance: Skin cancers are the most common human malignancies. SELENOF levels are significantly reduced in skin cancers, and experimental evidence establishes a critical tumor-suppressive role for SELENOF in the skin.
中文摘要:硒蛋白F(SELENOF)是25种人类硒蛋白之一,对生物可利用硒的波动高度敏感,而硒是一种必需微量营养素。尽管SELENOF被认为与癌症病因有关,但其确切作用仍不清楚。为明确其在癌变中的作用,将Selenof基因敲除(KO)小鼠暴露于强效致癌物7,12-二甲基苯并[a]蒽(DMBA),并喂食高脂高热量西方饮食。所有Selenof KO小鼠均发生肿瘤,且发生速度更快,而野生型小鼠中仅30%发生肿瘤。无论Selenof状态如何,西方饮食均进一步加剧了这种效应。值得注意的是,KO小鼠中大多数DMBA诱导的肿瘤为皮肤病变,主要为皮肤鳞状细胞癌(SCC)和良性乳头状瘤。这些肿瘤在KO小鼠中的发生率是野生型对照的四倍,从而确立SELENOF是皮肤中的关键肿瘤抑制因子。为评估这些发现与人类疾病的相关性,我们分析了包含SCC、基底细胞癌、黑色素瘤患者样本及匹配的邻近正常组织的皮肤癌微阵列。与正常皮肤相比,所有肿瘤类型中SELENOF表达均显著降低。尽管Selenof KO小鼠的皮肤在组织学上看似正常,但转录组分析及富集分析显示,与表皮发育和角质形成细胞分化相关的通路显著下调,而氧化磷酸化和线粒体代谢通路则上调。总体而言,这些发现支持SELENOF缺失与皮肤癌发生之间的因果联系,并突显了SELENOF在防御皮肤癌发生中此前未被认识的作用。意义:皮肤癌是人类最常见的恶性肿瘤。皮肤癌中SELENOF水平显著降低,实验证据确立了SELENOF在皮肤中关键的肿瘤抑制作用。
Nature IF 56.1 2026-10 PMID: 42557318
A rational design for facilitating innovative cell death modes can substantially aid advances in antitumour therapy1,2. Here we design and implement a unique mode of immunogenic membranolytic cell death (mLCD) in tumour cells, characterized by time-lagged rupture from the lysosomal to plasma membranes; this approach was found to robustly potentiate immune checkpoint blockade therapy. This mode of mLCD was induced by the synthetic-acid-responsive membranolytic peptide (aMP) aMPC16-CA50, which exhibits hierarchical responsiveness to the decreasing pH associated with the tumour extracellular environment and lysosomes. aMPC16-CA50 activated an inflammatory transcriptional program in tumour cells, potentiating their ability to induce antigen presentation on class I major histocompatibility complex molecules on dendritic cells and the subsequent activation of T cells. The pH-responsive kinetics and membranolytic activity of the membranolytic peptides had a critical role in enhancing the immunogenicity of lytic tumour cells through the spatiotemporal regulation of the membrane-rupture processes. Furthermore, aMPC16-CA50 exhibited a considerable advantage in enhancing the antitumour efficacy of immune checkpoint blockade therapy through the promotion of antitumour immune response. Moreover, its systemic administration was well tolerated in mice. Overall, we successfully programmed a unique mode of immunogenic mLCD in tumour cells through the spatiotemporal regulation of membrane-rupture processes using a synthetic pH-responsive membranolytic peptide amenable to manipulation.
中文摘要:促进创新性细胞死亡模式的合理设计可极大推动抗肿瘤治疗的进展1,2。在此,我们设计并实现了一种独特的肿瘤细胞免疫原性膜溶解性细胞死亡(mLCD)模式,其特征为从溶酶体膜到质膜的时间滞后性破裂;该策略被发现可稳健增强免疫检查点阻断治疗。这种mLCD模式由合成酸响应性膜溶解肽(aMP)aMPC16-CA50诱导,该肽对肿瘤细胞外环境及溶酶体相关的pH降低表现出层级响应性。aMPC16-CA50激活肿瘤细胞中的炎症转录程序,增强其诱导树突状细胞I类主要组织相容性复合体分子抗原呈递以及随后T细胞激活的能力。膜溶解肽的pH响应动力学和膜溶解活性通过时空调控膜破裂过程,在增强裂解肿瘤细胞的免疫原性中发挥关键作用。此外,aMPC16-CA50通过促进抗肿瘤免疫应答,在增强免疫检查点阻断治疗的抗肿瘤疗效方面显示出显著优势。而且,其全身给药在小鼠中耐受良好。总体而言,我们利用一种易于操控的合成pH响应性膜溶解肽,通过时空调控膜破裂过程,成功在肿瘤细胞中编程了一种独特的免疫原性mLCD模式。
Food chemistry IF 10.4 2026-10-01 PMID: 42520606
Chemical composition, oxidative stability, and biological activity of cold-pressed pomegranate (PG), blackcurrant (BC), and prickly pear (PP) seed oils were investigated. Oils were characterised for fatty acids and minor constituents, and oxidative stability was assessed by differential scanning calorimetry (DSC). Biological activity was evaluated in colon cancer (LoVo, LoVo/Dx) and non-tumorigenic (CCD 841 CoTr) cells using viability, apoptosis, ROS generation, and Rhodamine 123 accumulation assays. PG exhibited the highest PUFA content (90.0%) and the lowest lipophilic antioxidant-to-PUFA ratio (5.92), whereas BC (32.00) and PP (8.78) showed greater antioxidant balance. BC contained the highest tocopherol (1649 mg/kg) and carotenoid levels, while PG contained the highest amount of quantified phenolic and phenolic-related compounds. PP showed the greatest oxidative stability at 100 °C, whereas BC was the most stable at higher temperatures and PG was the least stable. All oils reduced cancer cell viability and induced apoptosis, with PG showing the strongest pro-oxidant activity. The results suggest that the balance between lipophilic antioxidants, fatty acid composition, and the native oil matrix influences oxidative stability and may contribute to the observed biological activity.
中文摘要:研究了冷榨石榴(PG)、黑加仑(BC)和仙人掌果(PP)籽油的化学组成、氧化稳定性及生物活性。对油中的脂肪酸和次要成分进行了表征,并通过差示扫描量热法(DSC)评估氧化稳定性。利用活力、凋亡、ROS生成和罗丹明123蓄积实验,在结肠癌细胞(LoVo、LoVo/Dx)和非致瘤性细胞(CCD 841 CoTr)中评估了生物活性。PG的多不饱和脂肪酸含量最高(90.0%),亲脂性抗氧化剂与多不饱和脂肪酸比值最低(5.92),而BC(32.00)和PP(8.78)表现出更好的抗氧化平衡。BC的生育酚(1649 mg/kg)和类胡萝卜素水平最高,而PG中已定量的酚类及酚类相关化合物含量最高。PP在100 °C时氧化稳定性最好,BC在更高温度下最稳定,PG最不稳定。所有油均降低癌细胞活力并诱导凋亡,其中PG表现出最强的促氧化活性。结果表明,亲脂性抗氧化剂、脂肪酸组成与天然油基质之间的平衡会影响氧化稳定性,并可能促成所观察到的生物活性。
Redox biology IF 16.2 2026-10 PMID: 42501697
Myocardial ischemia-reperfusion injury (MIRI) is an inevitable pathophysiological response during the revascularization process following myocardial ischemia. Despite its clinical significance, effective targeted therapies for MIRI remain an unmet medical need. Mixed-lineage leukemia 4 (MLL4), a member of the SET family of histone methyltransferases, exhibits particular methyltransferase action toward histone H3 lysine 4 (H3K4). This study establishes a protective role for MLL4 in MIRI pathogenesis. Utilizing cardiomyocyte-specific Mll4 knockout mice and an in vivo ischemia-reperfusion (I/R) model induced by left anterior descending coronary artery ligation, we observed significant upregulation of MLL4 expression in cardiac tissue following I/R. Genetic ablation of Mll4 in cardiomyocytes markedly exacerbated both acute and chronic phases of MIRI. In vitro, Mll4 knockdown in neonatal rat cardiomyocytes (NRCMs) amplified mitochondrial dysfunction and apoptosis under hypoxia/reoxygenation (H/R) conditions. Integrated analysis of Cleavage Under Targets and Tagmentation sequencing (CUT&Tag-seq) and RNA sequencing (RNA-seq) revealed that Mll4 deficiency induces a pronounced reduction in H3K4 monomethylation (H3K4me1) and histone H3 lysine 27 acetylation (H3K27ac) enrichment at the Stat3 genomic locus. Mechanistically, MLL4 functions as a transcriptional activator of Stat3 by depositing H3K4me1 and H3K27ac, thereby facilitating STAT3 transcription. This regulatory cascade ultimately governs STAT3-dependent mitochondrial homeostasis. Collectively, these findings identify MLL4 as a critical epigenetic regulator of MIRI and suggest its therapeutic targeting may offer a promising strategy for mitigating reperfusion injury.
中文摘要:心肌缺血再灌注损伤(MIRI)是心肌缺血后血运重建过程中不可避免的病理生理反应。尽管具有重要临床意义,针对MIRI的有效靶向治疗仍是未被满足的医疗需求。混合谱系白血病4(MLL4)是SET家族组蛋白甲基转移酶成员,对组蛋白H3第4位赖氨酸(H3K4)具有特异的甲基转移酶活性。本研究确立了MLL4在MIRI发病中的保护作用。利用心肌细胞特异性Mll4敲除小鼠以及左前降支冠状动脉结扎诱导的体内缺血再灌注(I/R)模型,我们观察到I/R后心脏组织中MLL4表达显著上调。心肌细胞中Mll4的基因敲除显著加重了MIRI的急性期和慢性期损伤。体外实验中,新生大鼠心肌细胞(NRCMs)中敲低Mll4在缺氧/复氧(H/R)条件下加剧了线粒体功能障碍和凋亡。对靶向切割与转座测序(CUT&Tag-seq)和RNA测序(RNA-seq)的整合分析显示,Mll4缺失导致Stat3基因组位点上H3K4单甲基化(H3K4me1)和组蛋白H3第27位赖氨酸乙酰化(H3K27ac)富集显著减少。机制上,MLL4通过沉积H3K4me1和H3K27ac作为Stat3的转录激活因子,从而促进STAT3转录。这一调控级联最终控制STAT3依赖的线粒体稳态。总之,这些发现表明MLL4是MIRI的关键表观遗传调控因子,并提示靶向其治疗可能为减轻再灌注损伤提供有前景的策略。
Ageing research reviews IF 15.5 2026-10 PMID: 42492808
Tumor senescence is a durable cell-cycle arrest triggered by oncogenic signalling, DNA damage and therapeutic stress. Although senescence can restrain malignant expansion, heterogeneous senescence-associated secretory programs can also promote tumor progression, immune evasion and treatment resistance. Crucially, the composition, magnitude and persistence of these secretory programs vary across cell types, microenvironmental niches and treatment phases, making binary detection of "senescent cells" insufficient for deciding whether specific populations should be eliminated, modulated or preserved. This review synthesizes the molecular determinants of functional, temporal and spatial heterogeneity in tumor senescence and consolidates them into an operational state space to support phase-aware intervention logic. It further evaluates how artificial intelligence, combined with single-cell and spatial profiling, imaging and circulating readouts, can enable state-resolved mapping, stratification and monitoring of senescence contexts, thereby generating testable therapeutic window hypotheses and guiding the development of staged precision senotherapies.
中文摘要:肿瘤衰老是由致癌信号、DNA损伤和治疗应激触发的一种持久性细胞周期停滞。尽管衰老能够抑制恶性扩增,但异质性的衰老相关分泌程序也可促进肿瘤进展、免疫逃逸和治疗耐药。至关重要的是,这些分泌程序的组成、强度及持续性会因细胞类型、微环境生态位和治疗阶段而异,因此对「衰老细胞」的二元检测不足以决定特定细胞群体应被清除、调控还是保留。本综述整合了肿瘤衰老在功能、时间和空间异质性方面的分子决定因素,并将其归纳为一个可操作的状态空间,以支持分期感知的干预逻辑。文章还评估了人工智能如何结合单细胞与空间图谱、成像及循环读数,实现对衰老情境的状态解析式定位、分层和监测,从而生成可检验的治疗窗口假设,并指导分阶段精准衰老疗法的开发。
Nature chemistry IF 24.5 2026-10 PMID: 42486949
Chemically modified nucleic acids such as antisense oligonucleotides, small interfering RNA and CRISPR guide RNA have emerged as transformative modalities in modern medicine, providing new strategies for the treatment of genetic and metabolic disorders, viral infections and cancer. However, their application is limited by challenges related to intracellular delivery and targeting, advances in which would benefit from a broader range of methods for chemical functionalization. Here we describe a streamlined approach using inexpensive, bench-stable alcohols or nucleosides that enables site-selective modification at the 5' and 3' termini and at internal sites of synthetic oligonucleotides. Our strategy offers a conceptually straightforward solution to this problem through the in situ generation of phosphoramidites on the solid-supported oligonucleotide. The methodology displays high coupling efficiency, high functional-group compatibility with azides, amines and thiols, and efficient recovery of excess alcohols/monomers, thus offering a robust platform for advancing and diversifying therapeutic oligonucleotide modification.
中文摘要:化学修饰核酸,如反义寡核苷酸、小干扰RNA和CRISPR引导RNA,已成为现代医学中的变革性模式,为遗传和代谢性疾病、病毒感染和癌症的治疗提供了新策略。然而,其应用受限于细胞内递送和靶向相关的挑战,而这些方面的进展将受益于更广泛的化学功能化方法。在此,我们描述了一种简化方法,使用廉价、台面稳定的醇或核苷,能够在合成寡核苷酸的5'和3'末端以及内部位点进行位点选择性修饰。我们的策略通过在固相支持的寡核苷酸上原位生成亚磷酰胺,为这一问题提供了概念上直接的解决方案。该方法显示出高偶联效率、对叠氮化物、胺和硫醇的高官能团兼容性,以及过量醇/单体的有效回收,从而为推进和多样化治疗性寡核苷酸修饰提供了一个稳健平台。
Ageing research reviews IF 15.5 2026-10 PMID: 42480622
Changes in the gut microbiota occur throughout the human lifespan, and maintaining microbial homeostasis plays a critical role in promoting healthy aging. In recent years, substantial progress has been made in elucidating the mechanistic links between aging and microbiota remodeling, highlighting the central role of microbiota-host interactions in regulating immune responses and maintaining metabolic homeostasis. These findings provide new potential targets for the precision prevention and treatment of age-related diseases. This review systematically summarizes the patterns of gut microbiota succession across different stages of the human life cycle, including infancy, adolescence, adulthood, and old age, as well as the mechanisms through which the microbiota regulates immune and metabolic functions. Furthermore, the role of the gut microbiota as a key mediator linking aging with an increased risk of chronic inflammation, cardiovascular disease, cognitive impairment, neurodegenerative disorders, and cancer was explored. In addition, this review evaluates the therapeutic potential of microbiota-targeted interventions, such as dietary modification, probiotic and prebiotic supplementation, fecal microbiota transplantation (FMT), and lifestyle interventions-in maintaining microbiome homeostasis and mitigating age-related diseases. The feasibility of personalized microbiota-based intervention strategies is also discussed. Finally, we highlight the current challenges and limitations in this field and outline future research directions. In particular, integrating multi-omics approaches with metagenomic sequencing, including emerging spatial and spatiotemporal multi-omics technologies, is crucial for advancing our understanding of the complex interactions within the gut microbiome. These insights provide a theoretical framework for optimizing anti-aging therapeutic strategies and promoting healthy lifespan extension.
中文摘要:肠道微生物群的变化贯穿人类整个生命周期,维持微生物稳态在促进健康衰老中发挥关键作用。近年来,在阐明衰老与微生物群重塑之间的机制联系方面已取得重大进展,凸显了微生物群-宿主相互作用在调节免疫反应和维持代谢稳态中的核心作用。这些发现为年龄相关疾病的精准预防和治疗提供了新的潜在靶点。本综述系统总结了人类生命周期不同阶段(包括婴儿期、青春期、成年期和老年期)肠道微生物群的演替模式,以及微生物群调节免疫和代谢功能的机制。此外,还探讨了肠道微生物群作为连接衰老与慢性炎症、心血管疾病、认知障碍、神经退行性疾病和癌症风险增加的关键介质的作用。另外,本综述评估了微生物群靶向干预措施(如饮食调整、益生菌和益生元补充、粪菌移植(FMT)以及生活方式干预)在维持微生物组稳态和减轻年龄相关疾病方面的治疗潜力。还讨论了基于微生物群的个性化干预策略的可行性。最后,我们强调了该领域当前的挑战和局限性,并概述了未来的研究方向。特别是,将多组学方法与宏基因组测序相结合,包括新兴的空间和时空多组学技术,对于促进我们对肠道微生物组内复杂相互作用的理解至关重要。这些见解为优化抗衰老治疗策略和促进健康寿命延长提供了理论框架。
Cytokine & growth factor reviews IF 13.4 2026-10 PMID: 42475758
Death receptors (DRs) are a subset of the tumor necrosis factor receptor (TNFR) superfamily with a protein interaction motif called the death domain. DRs, particularly TNFR1, FAS and TRAIL-Rs, mediate critical cellular outcomes, including apoptosis, necroptosis, inflammation, survival, and proliferation. Phosphorylation is a rapid, reversible post-translational modification, and therefore might alter the downstream fate decisions in signal transduction pathways. Like most cytokines, death ligands activate a wide range of tyrosine kinases. However, our understanding of whether these tyrosine kinases phosphorylate DRs and modulate downstream signaling is limited. Depending on the cell type, several different tyrosine kinases, including Src family members, JAKs and EGFR have been demonstrated to be activated upon death ligand exposure. All three of these kinase families have the potential to phosphorylate DRs, as reviewed here, and these phosphorylation events create a bias towards proinflammatory and proliferative pathways over cell death. Since these kinases are frequently hyperactivated in cancer, this bias may sustain tumor cell survival and resistance to death receptor-targeted therapies, marking the responsible kinases and their opposing phosphatases as candidate therapeutic targets.
中文摘要:死亡受体(DRs)是肿瘤坏死因子受体(TNFR)超家族的一个亚群,具有称为死亡结构域的蛋白相互作用基序。DRs,尤其是TNFR1、FAS和TRAIL-Rs,介导关键的细胞结局,包括凋亡、坏死性凋亡、炎症、存活和增殖。磷酸化是一种快速、可逆的翻译后修饰,因此可能改变信号转导通路中的下游命运决定。与大多数细胞因子一样,死亡配体激活多种酪氨酸激酶。然而,关于这些酪氨酸激酶是否磷酸化DRs并调控下游信号,我们的了解仍然有限。根据细胞类型的不同,已证明在死亡配体暴露后,包括Src家族成员、JAKs和EGFR在内的几种不同酪氨酸激酶会被激活。正如本文所综述,这三个激酶家族都有磷酸化DRs的潜力,而这些磷酸化事件造成偏向促炎和增殖通路而非细胞死亡的偏倚。由于这些激酶在癌症中频繁过度激活,这种偏倚可能维持肿瘤细胞存活以及对死亡受体靶向治疗的抵抗,从而使负责的激酶及其相反的磷酸酶成为候选治疗靶点。
Cancer discovery IF 29.5 2026-10-01 PMID: 42474324
Combination therapies involving vascular targeting drugs have shown promise in overcoming resistance to immunotherapy. However, the prerequisite for vascular modulation to evoke an effective antitumor T-cell response remains elusive. Tracing the transcriptional response of liver metastasis-associated peritumoral and tumor endothelial cells (TEC) to T-cell intervention, we discovered an immunomodulatory TEC subpopulation that highly expressed lipoprotein lipase (LPL). LPL+ TECs facilitated intratumoral homing of activated antitumor CD8+ T cells driving liver metastatic regression. Mechanistically, LPL enhanced MHC-I-dependent cross-presentation of tumor antigens on TECs for T-cell trafficking. Consequently, LPL+ TECs were recognized and targeted by T cells, further aiding antitumor response. Corresponding analyses of human liver metastasis samples identified a significant correlation between the presence of intratumoral LPL+ blood vessels and the accumulation of T cells. Altogether, the study identifies a decisive role of TECs in orchestrating an effective T-cell response by overcoming tumor's intrinsic insufficient antigen presentation. The study identifies LPL+ TECs as orchestrators of activated CD8+ T-cell homing into immunologically cold tumors with low baseline MHC-I expression. Enhancing tumor antigen exposure by MHC-I cross-presentation in TECs presents a promising approach to compensate the intrinsic inability of tumor cells and boost antitumor immunotherapy.
中文摘要:涉及血管靶向药物的联合治疗在克服免疫治疗耐药方面已显示出前景。然而,血管调控若要引发有效的抗肿瘤T细胞应答,其先决条件仍不清楚。通过追踪肝转移相关瘤周和肿瘤内皮细胞(TEC)对T细胞干预的转录应答,我们发现了一个高表达脂蛋白脂肪酶(LPL)的免疫调节性TEC亚群。LPL+ TEC促进活化的抗肿瘤CD8+ T细胞在瘤内归巢,从而驱动肝转移消退。机制上,LPL增强TEC上MHC-I依赖的肿瘤抗原交叉呈递,以促进T细胞运输。因此,LPL+ TEC被T细胞识别并靶向,进一步辅助抗肿瘤应答。对人类肝转移样本的相应分析发现,瘤内LPL+血管的存在与T细胞积聚显著相关。总之,该研究确定了TEC在通过克服肿瘤内在抗原呈递不足来协调有效T细胞应答中的决定性作用。该研究将LPL+ TEC确定为活化的CD8+ T细胞归巢进入基线MHC-I表达低下的免疫冷肿瘤的协调者。通过TEC中的MHC-I交叉呈递增强肿瘤抗原暴露,为补偿肿瘤细胞的内在缺陷并增强抗肿瘤免疫治疗提供了一种有前景的方法。
Advanced drug delivery reviews IF 21.0 2026-10 PMID: 42472603
In recent years, heavy-atom-free photosensitizers have been recognized as an important class of agents for photodynamic therapy (PDT). In particular, redox-activated heavy-atom-free photosensitizers inspired by the redox imbalance of the tumor microenvironment are emerging as a promising strategy to improve the specificity and therapeutic efficiency of PDT. This review highlights design strategies of redox-activated heavy-atom-free photosensitizers (PSs), including donor-acceptor-based frameworks, thionation, aggregation-induced emission (AIE) driven intersystem crossing enhancement, and the integration of responsive moieties for reactive oxygen species (ROS), glutathione (GSH), cysteine (Cys), and hydrogen sulfide (H₂S). In addition, recent advances in the development of redox-activated heavy-atom-free PSs over the past three years are summarized. Finally, main challenges, including hypoxic tumors, limited tumor-targeting efficiency, and limited light penetration into deep-seated tumors, as well as future prospects for this field, are discussed.
中文摘要:近年来,无重原子光敏剂已被公认为光动力治疗(PDT)的重要一类试剂。特别是受肿瘤微环境氧化还原失衡启发而设计的氧化还原激活型无重原子光敏剂,正逐渐成为提高PDT特异性和治疗效率的一种有前景的策略。本综述重点介绍了氧化还原激活型无重原子光敏剂(PSs)的设计策略,包括基于供体-受体的框架、硫代化、聚集诱导发光(AIE)驱动的系间窜越增强,以及针对活性氧(ROS)、谷胱甘肽(GSH)、半胱氨酸(Cys)和硫化氢(H₂S)的响应性基团的整合。此外,还总结了过去三年中氧化还原激活型无重原子PSs开发的最新进展。最后,讨论了主要挑战,包括乏氧肿瘤、有限的肿瘤靶向效率以及光对深部肿瘤穿透有限,并展望了该领域的未来前景。
Pharmacology & therapeutics IF 13.5 2026-10 PMID: 42463065
Beyond their canonical role in bioenergetics, mitochondria are now recognized as critical signaling platforms that orchestrate innate immune responses. Central to this function is mitochondrial dynamics-the controlled equilibrium between fission and fusion-which serves as a critical structural and thermodynamic checkpoint for cellular fate and immunological status. A substantial body of evidence indicates that pathological mitochondrial fission, frequently driven by Dynamin-related protein 1 (Drp1), is a hallmark of numerous inflammatory conditions. Mechanistically, fragmented mitochondria release damage-associated molecular patterns (DAMPs) and induce acute ATP suppression, metabolically "licensing" NLRP3 activation by collapsing the ATP hydrolysis potential (ΔGATP). Recent breakthroughs have redefined this axis, distinguishing between physical damage and metabolic triggers, such as pyrimidine imbalance via the YME1L-SLC25A33 axis. Furthermore, the immunogenicity of DAMPs is strictly context-dependent; oxidized or "fragile" mtDNA containing ribonucleotides act as hyper-immunogenic ligands for cytosolic sensors like cGAS-STING. Emerging evidence further highlights that endosomal-mitochondrial crosstalk, intercellular mitochondrial transfer, and lipid-driven metabolic rewiring profoundly govern macrophage polarization and tissue homeostasis. Conversely, promoting mitochondrial fusion and robust quality control preserves organellar integrity and attenuates inflammatory cascades. This review critically synthesizes current literature, deconstructing the molecular linkages between organelle structure and metabolic signaling. By exploring the consequences in sepsis, neuroinflammation, osteoarthritis, and cancer, this treatise evaluates the pharmacological potential of modulating mitochondrial dynamics-ranging from direct Drp1 inhibitors and unfractionated heparin to metabolic stabilizers (e.g., GLP-1 receptor agonists), multi-pronged disruptors (e.g., Antimycin A), targeted nanomedicine, and communication-driven mitochondrial transplantation-positioning this axis as a promising frontier for precision pharmacology.
中文摘要:线粒体除在生物能量学中发挥经典作用外,现已被认为是协调先天免疫应答的关键信号平台。该功能的核心是线粒体动力学,即裂变与融合之间的受控平衡,它作为细胞命运和免疫状态的重要结构与热力学检查点。大量证据表明,病理性线粒体裂变通常由动力相关蛋白1(Drp1)驱动,是众多炎症性疾病的标志。机制上,碎片化线粒体释放损伤相关分子模式(DAMPs),并诱导急性ATP抑制,通过瓦解ATP水解电位(ΔGATP)在代谢上「许可」NLRP3激活。近期突破重新定义了该轴线,区分了物理损伤与代谢触发因素,例如经YME1L-SLC25A33轴引起的嘧啶失衡。此外,DAMPs的免疫原性严格依赖背景;含有核糖核苷酸的氧化或「脆弱」mtDNA可作为胞质传感器如cGAS-STING的高免疫原性配体。新出现的证据进一步强调,内体-线粒体串扰、细胞间线粒体转移以及脂质驱动的代谢重编程深刻调控巨噬细胞极化和组织稳态。相反,促进线粒体融合和稳健的质量控制可维持细胞器完整性并减弱炎症级联反应。本综述批判性整合当前文献,解构细胞器结构与代谢信号之间的分子联系。通过探讨其在脓毒症、神经炎症、骨关节炎和癌症中的后果,本文评估调节线粒体动力学的药理学潜力,涵盖直接Drp1抑制剂、普通肝素、代谢稳定剂(如GLP-1受体激动剂)、多途径干扰剂(如抗霉素A)、靶向纳米药物以及通讯驱动的线粒体移植,并将该轴线定位为精准药理学一个有前景的前沿。
Nature chemical biology IF 15.8 2026-10 PMID: 42443598
Site-level resolution of protein phosphorylation remains a central challenge in decoding cellular signaling and conventional global phosphoproteomics is limited in its ability to detect low-abundance peptides and resolve positional isomers. Here we introduce sequence-selective synthetic receptors based on imprinted polymers for targeted enrichment of defined phosphopeptide motifs from complex cancer cell proteomes. By encoding local sequence context into the binding interface, these receptors enable selective capture of closely related phosphorylation sites with high specificity. Using the T cell kinase ZAP70 as a model, we resolve phosphorylation at adjacent tyrosine residues (pY492 and pY493) within a regulatory motif, overcoming a long-standing limitation in site discrimination. Integrated with liquid chromatography-mass spectrometry workflows, this enables sensitive detection of low-abundance and isomeric phosphopeptides that evade conventional enrichment strategies. More broadly, our findings establish molecular imprinting as a programmable chemical platform for site-resolved phosphoproteomics, opening new avenues to interrogate signaling networks with molecular precision.
中文摘要:蛋白质磷酸化的位点级解析仍是解码细胞信号转导的核心挑战之一,而常规全局磷酸化蛋白质组学在检测低丰度肽段和区分位置异构体方面能力有限。在此,我们引入基于印迹聚合物的序列选择性合成受体,用于从复杂癌细胞蛋白质组中靶向富集特定磷酸肽基序。通过将局部序列上下文编码到结合界面中,这些受体能够以高特异性选择性捕获密切相关的磷酸化位点。以T细胞激酶ZAP70为模型,我们解析了调控基序内相邻酪氨酸残基(pY492和pY493)的磷酸化,克服了位点区分方面长期存在的局限。与液相色谱-质谱工作流程整合后,该方法能够灵敏检测常规富集策略难以捕获的低丰度和异构磷酸肽。更广泛地说,我们的发现确立了分子印迹作为一种可编程化学平台,用于位点分辨的磷酸化蛋白质组学,为以分子精度探究信号网络开辟了新途径。
Cancer letters IF 11.8 2026-10-01 PMID: 42435930
Docetaxel remains first-line chemotherapy for advanced prostate cancer (PCa), but acquired resistance severely limits durable clinical responses. While long non-coding RNAs (lncRNAs) are established as critical regulators of tumor chemoresistance, the specific mechanisms driving docetaxel resistance in PCa remain poorly understood. Here, we functionally characterized a novel docetaxel resistance-associated lncRNA in PCa. Through comparative transcriptome sequencing of isogenic docetaxel-sensitive and resistant PCa cell lines, we identified an uncharacterized lncRNA (RP11-151G14.2), termed HUDRPC, which was significantly upregulated in resistant cells and patient-derived tumor tissues. Loss-of-function validation confirmed that HUDRPC was required to maintain docetaxel resistance both in vitro and in vivo. Mechanistically, HUDRPC promoted docetaxel resistance by directly inhibiting ferroptosis. CRISPR-Cas9 knockout of HUDRPC markedly augmented docetaxel-induced reactive oxygen species accumulation, lipid peroxidation and iron overload, and sensitized resistant PCa cells and xenografts to docetaxel treatment. We further demonstrated that HUDRPC directly bound the RNA helicase DDX5, and recruited DDX5 to the DDIT3 promoter, thereby enhancing DDIT3 transcription in a DDX5-dependent manner. Clinically, high DDIT3 expression correlated with poorer overall survival and inferior docetaxel response in PCa patients. Rescue experiments showed that forced DDIT3 overexpression reversed HUDRPC depletion-induced ferroptosis and docetaxel sensitization, confirming DDIT3 as the key downstream effector of HUDRPC. Collectively, our findings identify the HUDRPC-DDX5- DDIT3 axis as a critical regulator of docetaxel resistance, highlighting HUDRPC as a promising prognostic biomarker and therapeutic target to overcome chemoresistance in advanced PCa.
中文摘要:多西他赛仍是晚期前列腺癌(PCa)的一线化疗药物,但获得性耐药严重限制了持久的临床缓解。尽管长链非编码RNA(lncRNA)已被确立为肿瘤化疗耐药的关键调控因子,但驱动PCa多西他赛耐药的具体机制仍知之甚少。在此,我们对PCa中一种新型多西他赛耐药相关lncRNA进行了功能表征。通过对同基因型多西他赛敏感和耐药PCa细胞系进行比较转录组测序,我们鉴定出一种未表征的lncRNA(RP11-151G14.2),命名为HUDRPC,其在耐药细胞和患者来源肿瘤组织中显著上调。功能缺失验证证实,HUDRPC在体外和体内均为维持多西他赛耐药所必需。机制上,HUDRPC通过直接抑制铁死亡促进多西他赛耐药。CRISPR-Cas9敲除HUDRPC显著增强多西他赛诱导的活性氧积累、脂质过氧化和铁过载,并使耐药PCa细胞和异种移植瘤对多西他赛治疗敏感。我们进一步证明,HUDRPC直接结合RNA解旋酶DDX5,并将DDX5招募到DDIT3启动子,从而以DDX5依赖的方式增强DDIT3转录。临床上,DDIT3高表达与PCa患者更差的总生存期和更差的多西他赛反应相关。救援实验显示,强制DDIT3过表达可逆转HUDRPC耗竭诱导的铁死亡和多西他赛增敏,证实DDIT3是HUDRPC的关键下游效应因子。总之,我们的研究结果确定HUDRPC-DDX5-DDIT3轴是多西他赛耐药的关键调控因子,突出HUDRPC作为有前景的预后生物标志物和治疗靶点,以克服晚期PCa的化疗耐药。
Advanced drug delivery reviews IF 21.0 2026-10 PMID: 42425318
Redox-responsive lipid nanoparticles (LNPs) are emerging as a powerful platform for precision nanomedicine by exploiting disease-associated redox imbalances, such as elevated glutathione and reactive oxygen species, to trigger controlled cargo release and structural activation. This strategy is of great importance for developing gene-based therapeutics, where efficient cytosolic delivery is essential. In addition to nucleic acids, redox-responsive LNPs have also been explored in delivering small molecules, proteins, and theranostic agents, broadening their potential in both cancer and non-cancer diseases. This review summarizes the biological basis of redox responsiveness, key design principles for responsive chemical structures, and major advances in payload delivery and targeting capability of LNP carriers. Moreover, some major bottlenecks, including redox heterogeneity, stability, responsiveness trade-offs, and translational complexity, are critically discussed. Future directions are also highlighted, particularly for organ-selective delivery, multifunctional theranostics, and clinically translatable LNP-based medicines.
中文摘要:氧化还原响应型脂质纳米颗粒(LNPs)正成为精准纳米医学的强大平台,它利用疾病相关的氧化还原失衡,例如谷胱甘肽升高和活性氧增多,来触发负载物的受控释放和结构激活。该策略对于开发基于基因的治疗药物尤为重要,因为高效的胞质递送至关重要。除核酸外,氧化还原响应型LNPs也被探索用于递送小分子、蛋白质和治疗诊断剂,拓宽了其在癌症和非癌症疾病中的潜力。本综述总结了氧化还原响应性的生物学基础、响应性化学结构的关键设计原则,以及LNP载体在负载物递送和靶向能力方面的主要进展。此外,还批判性地讨论了一些主要瓶颈,包括氧化还原异质性、稳定性、响应性权衡以及转化复杂性。未来方向也被重点强调,特别是器官选择性递送、多功能诊疗和可临床转化的基于LNP的药物。
Cancer letters IF 11.8 2026-10-01 PMID: 42425190
Glioblastoma (GBM) exhibits marked spatial and cellular heterogeneity, driving aggressive progression and therapy resistance. Utilizing multifocal GBM as a unique model of tumor evolution, we integrated multi-omics including scRNA-seq, scATAC-seq, and spatial transcriptomics (ST). This revealed a subcluster of bone marrow-derived macrophages (BMDMs), NUPR1+ myeloid-derived suppressor cells (MDSCs), enriched in peri-necrotic niches and higher-evolution lesions. Supported by multiplex immunofluorescence (mIF) and ultrastructural analyses, these MDSCs spatially co-localized and actively engaged in functional crosstalk with mesenchymal-like (MES) tumor cells. NUPR1+ MDSCs upregulated hypoxia and ferroptosis-resistance pathways and expressed a core Spatial-MDSC-Ferroptosis (SMF) program that independently predicted poor survival, irrespective of hypoxia, and correlated with a reduced response to neoadjuvant anti-PD-1 therapy. Epigenetic profiling revealed CEBPA as a core transcriptional regulator orchestrating the SMF program. In vitro, ferroptosis induction in macrophages promoted migration and mesenchymal transition of co-cultured GBM cells, phenotypes that were effectively reversed by ferrostatin-1 (Fer-1) and pazopanib. These findings reveal a spatially defined, ferroptosis-resistant myeloid niche driving MES tumor progression, providing mechanistic insights into myeloid-tumor interactions and identifying the myeloid compartment as a potential therapeutic target in GBM.
中文摘要:胶质母细胞瘤(GBM)表现出显著的空间和细胞异质性,驱动侵袭性进展和治疗耐药。利用多灶性GBM作为肿瘤进化的独特模型,我们整合了单细胞RNA测序、单细胞ATAC测序和空间转录组学(ST)等多组学数据。这揭示了一个骨髓来源巨噬细胞(BMDMs)亚群,即NUPR1+髓源性抑制细胞(MDSCs),富集于坏死周边微环境和更高进化程度的病灶中。多重免疫荧光(mIF)和超微结构分析支持,这些MDSCs与间质样(MES)肿瘤细胞在空间上共定位,并积极发生功能串扰。NUPR1+ MDSCs上调缺氧和抗铁死亡通路,并表达核心的空间-MDSC-铁死亡(SMF)程序,该程序独立预测不良生存,且与缺氧无关,并与新辅助抗PD-1治疗反应降低相关。表观遗传分析显示CEBPA是调控SMF程序的核心转录调节因子。体外实验中,诱导巨噬细胞铁死亡可促进共培养GBM细胞的迁移和间质转化,这些表型可被ferrostatin-1(Fer-1)和帕唑帕尼有效逆转。这些发现揭示了一个空间限定的、抗铁死亡的髓系龛驱动MES肿瘤进展,为髓系-肿瘤相互作用提供了机制见解,并将髓系区室确定为GBM的潜在治疗靶点。
Cancer letters IF 11.8 2026-10-01 PMID: 42379261
Ampullary adenocarcinoma (AMPAC) is a rare and heterogeneous malignancy with markedly variable clinical outcomes, underscoring the urgent need for molecularly informed classification and personalized therapeutic strategies. Current AMPAC classification relies primarily on morphological and immunohistochemical criteria, which lack prognostic accuracy and fail to capture the underlying molecular and tumor microenvironment heterogeneity. In this study, we integrated bulk RNA sequencing, single-cell RNA sequencing (scRNA-seq), and clinicopathological data to elucidate the molecular architecture of AMPAC and introduced a transcriptomic-based molecular classification (AMS). The AMS categorized patients into two molecular subtypes: mesenchymal AMPAC (AMS-M) and classical AMPAC (AMS-C). The AMS-M demonstrated increased epithelial-mesenchymal transition (EMT) and stromal activation, correlating with basal-like subtypes associated with unfavorable prognosis. In contrast, AMS-C tumors exhibited metabolic and differentiation programs with relatively preserved immune infiltration. Importantly, we identified MUC16 as a pivotal biomarker specifically overexpressed in AMS-M tumors. MUC16 knockout markedly reversed EMT, attenuated invasive and migratory capacities, and restored chemosensitivity in both cell lines and their xenograft models. Collectively, our findings establish AMS as a prognostically and therapeutically informative molecular classification framework for AMPAC, unveil the critical role of the tumor microenvironment in AMPAC heterogeneity, and provide a translational foundation for precision oncology in this rare tumor.
中文摘要:壶腹腺癌(AMPAC)是一种罕见且异质性高的恶性肿瘤,临床结局差异显著,凸显了基于分子信息的分类和个体化治疗策略的迫切需求。当前AMPAC分类主要依赖形态学和免疫组化标准,这些标准缺乏预后准确性,且未能捕捉潜在的分子和肿瘤微环境异质性。在本研究中,我们整合了bulk RNA测序、单细胞RNA测序(scRNA-seq)和临床病理数据,以阐明AMPAC的分子结构,并提出了基于转录组的分子分类(AMS)。AMS将患者分为两种分子亚型:间质型AMPAC(AMS-M)和经典型AMPAC(AMS-C)。AMS-M表现出上皮-间质转化(EMT)和基质活化增加,与预后不良的基底样亚型相关。相比之下,AMS-C肿瘤表现出代谢和分化程序,并具有相对保留的免疫浸润。重要的是,我们确定MUC16是AMS-M肿瘤中特异性过表达的关键生物标志物。在细胞系及其异种移植模型中,MUC16敲除显著逆转EMT、减弱侵袭和迁移能力,并恢复化疗敏感性。总体而言,我们的发现确立了AMS作为AMPAC具有预后和治疗信息价值的分子分类框架,揭示了肿瘤微环境在AMPAC异质性中的关键作用,并为这一罕见肿瘤的精准肿瘤学提供了转化基础。
Water research IF 12.8 2026-10-01 PMID: 42378972
The Fukushima Daiichi Nuclear Power Plant (FDNPP) accident has raised wide concerns about radioactive contamination in the aquatic environments of Japan while the long-lived and highly radiotoxic neptunium-237 (237Np) and Pu isotopes (239+240Pu) in the surface and drinking waters remain unexplored. For the first time, we revealed their activity levels in Japanese surface and drinking waters. The results showed that 237Np was detected in all the samples (0.004 to 0.116 μBq l-1), while 239Pu was only detected in twenty percent of the samples and 240Pu was not detected at all. The persistence of 237Np in aquatic environments was attributed to its high mobility and solubility. Although 237Np is ubiquitous in the water environments, the global fallout is identified as the main contributor. Our findings indicate that current drinking water purification techniques cannot effectively remove 237Np from natural waters. The annual effective ingestion doses from ingesting 237Np in the drinking water for different age groups were 7-8 orders of magnitude lower than the threshold (0.1 mSv yr-1). Besides, the mortality and morbidity cancer risks were also much lower than the acceptable risk for the public. These estimates indicated that the health risks of 237Np in drinking water were neglectable. Despite of this, its persistence emphasizes the necessity to monitor these long-lived and highly-soluble actinides after a nuclear accident to protect the public from excessive internal exposure.
中文摘要:福岛第一核电站(FDNPP)事故引发了人们对日本水生环境中放射性污染的广泛担忧,而表层水和饮用水中长寿命且具有高放射毒性的镎-237(237Np)和钚同位素(239+240Pu)仍未被探索。我们首次揭示了它们在日本表层水和饮用水中的活度水平。结果表明,237Np在所有样本中均被检出(0.004至0.116 μBq l-1),而239Pu仅在20%的样本中检出,240Pu则完全未检出。237Np在水生环境中的持久性归因于其高迁移性和溶解性。尽管237Np在水环境中普遍存在,但全球沉降被确定为主要贡献者。我们的发现表明,当前饮用水净化技术无法有效去除天然水中的237Np。不同年龄组通过饮用水中237Np摄入的年有效摄入剂量比阈值(0.1 mSv yr-1)低7-8个数量级。此外,癌症死亡率和发病率风险也远低于公众可接受风险。这些估计表明,饮用水中237Np的健康风险可忽略不计。尽管如此,其持久性强调了在核事故后监测这些长寿命且高溶解性锕系元素以保护公众免受过量内照射的必要性。
Blood IF 23.9 2026-10-01 PMID: 42378251
Primary cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of extranodal non-Hodgkin lymphomas. Outcomes for patients with advanced-stage disease are suboptimal, because few complete and durable responses are achieved with currently available therapeutic agents. However, improved understanding of oncogenic transcriptional programs in malignant T cells and their engagement with the tumor microenvironment (TME) may unveil therapeutic vulnerabilities. Therefore, we have compiled the largest available single-cell RNA-sequencing CTCL atlas that includes >2 million skin and blood cells from 116 individual patients. We identified recurrent transcriptional programs in malignant T cells, a subset of which are associated with GATA binding protein 3-dependent transcriptional programs, especially in the setting of large cell transformation and advanced-stage disease. Many of the transcriptional programs identified are therapeutically targetable with clinically available agents, including HDAC, XPO1, CDK9, JAK/CSF1R, and IKZF1/IKZF3 antagonists. The CTCL TME is dominated by infiltrating and exhausted effector and cytotoxic T cells that are restrained by a robust infiltrate of regulatory T cells, transcriptionally polarized monocytes/macrophages, and cancer-associated fibroblasts. Collectively, these findings have significant implications for the rational design of combinatorial strategies targeting immune checkpoints, including programmed cell death protein 1. We have identified transcriptional programs, driven by oncogenic transcription factors, and constituents of the TME as therapeutic vulnerabilities in CTCL, and hope that the CTCL atlas constructed will provide a valuable resource for future studies exploiting these therapeutic vulnerabilities.
中文摘要:原发性皮肤T细胞淋巴瘤(CTCL)是一组异质性的结外非霍奇金淋巴瘤。晚期患者的结局不理想,因为现有治疗药物很少能获得完全且持久的缓解。然而,进一步理解恶性T细胞中的致癌转录程序及其与肿瘤微环境(TME)的相互作用,可能揭示治疗脆弱性。因此,我们构建了目前可用的最大单细胞RNA测序CTCL图谱,包含来自116例个体患者的超过200万个皮肤和血液细胞。我们在恶性T细胞中识别出反复出现的转录程序,其中一部分与GATA结合蛋白3依赖性转录程序相关,尤其是在大细胞转化和晚期疾病情况下。识别出的许多转录程序可用临床可用药物进行治疗性靶向,包括HDAC、XPO1、CDK9、JAK/CSF1R和IKZF1/IKZF3拮抗剂。CTCL的TME以浸润性和耗竭性效应T细胞及细胞毒性T细胞为主,这些细胞受到大量调节性T细胞、转录极化的单核细胞/巨噬细胞和癌症相关成纤维细胞的抑制。总体而言,这些发现对合理设计靶向免疫检查点(包括程序性细胞死亡蛋白1)的联合策略具有重要意义。我们确定了由致癌转录因子驱动的转录程序以及TME的组成部分作为CTCL的治疗脆弱性,并希望所构建的CTCL图谱能为未来利用这些治疗脆弱性的研究提供宝贵资源。
Cancer letters IF 11.8 2026-10-01 PMID: 42372590
Recurrent glioblastoma (rGBM) exhibits aggressive progression and therapeutic resistance. However, how mechanical cues within the tumor microenvironment contribute to stemness and chemoresistance through mechanotransductive and epigenetic regulation remains incompletely understood. GBM tissues and derived cell models were systematically characterized to examine how defined matrix mechanical conditions are associated with stemness and chemoresistance. Multivalent VCAM1-Fc decoys were engineered to modulate ITGA4-associated mechanosensing, and mechanistic pathways connecting metabolism to mechanotransduction were interrogated using targeted perturbations. rGBM tissues exhibited elevated stiffness and extracellular matrix (ECM) remodeling, which were associated with enhanced stemness and temozolomide resistance alongside increased H3K18 histone lactylation. Stiffness-associated temozolomide (TMZ) resistance manifested as a pre-activated resistance state prior to TMZ exposure and a shielding effect under high-stiffness conditions that further attenuated TMZ efficacy. ITGA4 was identified as a mechanosensing-associated node, and engineered multivalent VCAM1-Fc decoys mediated valency-dependent, reversible competitive inhibition at cell-surface ITGA4, attenuating mechanosensing-associated stemness and chemoresistance without inducing non-specific cytotoxicity. ECM stiffening is linked to stemness maintenance and temozolomide resistance in recurrent GBM through H3K18la-associated epigenetic regulation, while ITGA4/YAP-related mechanosensing provides a membrane-proximal axis that can be attenuated by multivalent VCAM1-Fc. Multivalent VCAM1-Fc may therefore reduce stiffness-associated malignant phenotypes by limiting ITGA4-dependent mechanotransduction.
中文摘要:复发性胶质母细胞瘤(rGBM)表现出侵袭性进展和治疗耐药。然而,肿瘤微环境中的机械线索如何通过机械转导和表观遗传调控促进干性和化疗耐药,仍不完全清楚。我们系统表征了GBM组织和衍生细胞模型,以考察确定的基质机械条件如何与干性和化疗耐药相关。我们工程化构建了多价VCAM1-Fc诱饵以调节ITGA4相关机械感知,并使用靶向扰动探究了连接代谢与机械转导的机制通路。rGBM组织表现出硬度升高和细胞外基质(ECM)重塑,这与干性增强和替莫唑胺耐药相关,同时H3K18组蛋白乳酸化增加。硬度相关的替莫唑胺(TMZ)耐药表现为TMZ暴露前已存在的预激活耐药状态,以及高硬度条件下的屏蔽效应,该效应进一步削弱TMZ疗效。ITGA4被鉴定为机械感知相关节点,工程化多价VCAM1-Fc诱饵在细胞表面ITGA4处介导价态依赖的、可逆的竞争性抑制,减弱机械感知相关的干性和化疗耐药,而不诱导非特异性细胞毒性。ECM硬化通过H3K18la相关表观遗传调控与复发性GBM中的干性维持和替莫唑胺耐药相关,而ITGA4/YAP相关机械感知提供了一个可被多价VCAM1-Fc减弱的膜近端轴。因此,多价VCAM1-Fc可能通过限制ITGA4依赖的机械转导来减少硬度相关的恶性表型。
Blood IF 23.9 2026-10-01 PMID: 42371796
Mixed lineage leukemia (MLL)-rearranged (MLLr) acute myeloid leukemia (AML) and acute lymphoid leukemia involve reciprocal translocations of the KMT2A (MLL1) gene with various translocation partner genes, yielding oncogenic chimeric MLL1 fusion proteins (MLL-FPs). Menin, the protein product of the MEN1 gene, is essential for the leukemogenic activity of MLL-FPs. Revumenib is a small-molecule inhibitor that selectively disrupts the menin-MLL interaction, and it is now in clinical use for treatment of MLLr and NPM1-mutated acute leukemia. Notably, menin also interacts with the JUND, a member of the activator protein 1 transcription factor family, through a conserved protein sequence in the MLL1/2 binding pocket of menin. Despite this structural similarity, the impact of menin-MLL inhibitors on JUND function has remained unexplored. In this study, we investigated the influence of menin-MLL inhibitors on JUND activity. Quantitative mass spectrometry analysis of MLLr leukemic cells demonstrated that menin-MLL inhibitors also disrupt menin-JUND interactions. Furthermore, CRISPR-mediated inactivation of JUND or pharmacologic inhibition using c-Jun N-terminal kinase inhibitors synergistically enhanced the antileukemic effects of menin-MLL inhibitors, leading to reduced cell proliferation, cell cycle arrest, and apoptosis. RNA sequencing and chromatin-binding assays revealed that menin-MLL inhibitor treatment increased JUND chromatin occupancy, leading to the upregulation of target genes and contributing to resistance against menin-MLL inhibitors. Immunocompromised mice engrafted with JUND-deficient leukemia cells exhibited reduced tumor burden compared with control mice engrafted with wild-type leukemic cells. These findings reveal a role for JUND in MLLr-AML and suggest that targeting JUND transcription factor activity may enhance the efficacy of menin-MLL inhibitors toward MLLr leukemic cells.
中文摘要:混合谱系白血病(MLL)重排(MLLr)急性髓系白血病(AML)和急性淋巴细胞白血病涉及KMT2A(MLL1)基因与多种易位伙伴基因的相互易位,产生致癌性嵌合MLL1融合蛋白(MLL-FPs)。Menin是MEN1基因的蛋白产物,对MLL-FPs的白血病发生能力至关重要。Revumenib是一种小分子抑制剂,可选择性破坏menin-MLL相互作用,目前已在临床用于治疗MLLr和NPM1突变急性白血病。值得注意的是,menin还可通过其MLL1/2结合口袋中一段保守蛋白序列与活化蛋白1转录因子家族成员JUND相互作用。尽管存在这种结构相似性,menin-MLL抑制剂对JUND功能的影响仍未被探索。在本研究中,我们研究了menin-MLL抑制剂对JUND活性的影响。对MLLr白血病细胞的定量质谱分析表明,menin-MLL抑制剂也可破坏menin-JUND相互作用。此外,CRISPR介导的JUND失活或使用c-Jun N末端激酶抑制剂的药理抑制可协同增强menin-MLL抑制剂的抗白血病作用,导致细胞增殖减少、细胞周期停滞和凋亡。RNA测序和染色质结合实验显示,menin-MLL抑制剂处理增加了JUND的染色质占据,导致靶基因上调,并促进对menin-MLL抑制剂的耐药。移植了JUND缺陷白血病细胞的免疫缺陷小鼠与移植了野生型白血病细胞的对照小鼠相比,肿瘤负荷降低。这些发现揭示了JUND在MLLr-AML中的作用,并提示靶向JUND转录因子活性可能增强menin-MLL抑制剂对MLLr白血病细胞的疗效。
Blood IF 23.9 2026-10-01 PMID: 42360909
Nonhematopoietic stromal cells are essential regulators of hematopoiesis; however, their contribution to leukemogenesis and immune dysfunction remains poorly defined. In this study, we identified fibroblast-derived fibroblast growth factor 18 (FGF18) as a novel stromal cytokine that reprograms leukemia-immune interactions. Single-cell RNA sequencing of the bone marrow niche in acute myeloid leukemia (AML) revealed the upregulation of Fgf18 in stromal fibroblasts. Administration of recombinant FGF18 accelerated AML progression, whereas fibroblast-specific Fgf18 depletion markedly delayed disease development and improved the survival of mice. We performed a pooled CRISPR-Cas9 screen in AML cells and identified FGF receptor 3 (FGFR3) signaling as a critical mediator of leukemic fitness in the FGF18-rich microenvironment. Genetic loss of Fgfr3 in AML cells recapitulated the effects of FGF18 deficiency and limited leukemic expansion in vivo. Mechanistically, FGF18 binds to its receptor, FGFR3, on AML cells, activating the protein kinase B (AKT)-mechanistic target of rapamycin (mTOR) (AKT-mTOR) signaling pathway and inducing interleukin-6 (IL-6) production. IL-6 acts autocrinely to reinforce leukemic signaling and paracrinely to activate fibroblast JAK-STAT3 signaling, thereby amplifying stromal fibroblast FGF18 expression and forming a feed-forward loop that suppresses CD8+ T-cell effector function and weakens antileukemic immunity. Clinically, elevated FGF18 expression correlates with poor prognosis in patients with AML. To therapeutically target this malignant cross talk, we generated an FGF18-neutralizing antibody that disrupted the stromal-leukemia feedback loop, restored CD8+ T cell effector function, and synergized with anti-PD-1 therapy to elicit durable antileukemic immunity in vivo. Collectively, these findings identify an FGF18-dependent stromal-leukemia cross talk axis that drives AML progression and immune dysfunction, highlighting FGF18 neutralization as a potential therapeutic strategy.
中文摘要:非造血基质细胞是造血的重要调控者;然而,它们在白血病发生和免疫功能障碍中的作用仍不明确。在本研究中,我们鉴定出成纤维细胞来源的成纤维细胞生长因子18(FGF18)是一种新型基质细胞因子,可重编程白血病-免疫相互作用。对急性髓系白血病(AML)骨髓微环境的单细胞RNA测序显示,基质成纤维细胞中Fgf18表达上调。给予重组FGF18加速了AML进展,而成纤维细胞特异性Fgf18缺失显著延缓疾病发展并改善小鼠生存。我们在AML细胞中进行了混合CRISPR-Cas9筛选,鉴定出FGF受体3(FGFR3)信号是FGF18富集微环境中白血病细胞适应性的关键介质。AML细胞中Fgfr3的基因缺失重现了FGF18缺陷的效应,并限制了体内白血病扩增。机制上,FGF18与其在AML细胞上的受体FGFR3结合,激活蛋白激酶B(AKT)-雷帕霉素机制靶点(mTOR)(AKT-mTOR)信号通路,并诱导白细胞介素-6(IL-6)产生。IL-6以自分泌方式强化白血病信号,并以旁分泌方式激活成纤维细胞JAK-STAT3信号,从而放大基质成纤维细胞FGF18表达,形成一个前馈环路,抑制CD8+ T细胞效应功能并削弱抗白血病免疫。临床上,FGF18表达升高与AML患者不良预后相关。为从治疗上靶向这种恶性交互,我们制备了一种FGF18中和抗体,其可破坏基质-白血病反馈环路,恢复CD8+ T细胞效应功能,并与抗PD-1治疗协同,在体内诱导持久的抗白血病免疫。总之,这些发现鉴定出一条依赖FGF18的基质-白血病交互轴,其驱动AML进展和免疫功能障碍,突出了FGF18中和作为一种潜在治疗策略。
Biotechnology advances IF 14.1 2026-10 PMID: 42349764
Extrachromosomal circular DNA (eccDNA) is a class of circular DNA molecules that exists independently of chromosomes and plays critical roles in genome plasticity, cancer progression, drug resistance, and adaptive evolution. Recent advances in high-throughput sequencing, computational tools, and CRISPR-based genome editing have revolutionized the detection and functional characterization of eccDNAs. The emergence of single-molecule real-time and Nanopore sequencing technologies has further enabled the investigation of eccDNA at the cellular level. The rapid development of eccDNA research has revealed previously unrecognized dimensions of genome organization and function. In this review, we provide a systematic evaluation of current high-throughput sequencing-based methods for eccDNA detection, discussing their technical principles, strengths, limitations, and applications. Finally, we propose novel visualization strategies to improve data interpretation and highlight future research directions incorporating multi-omics integration and single-cell approaches. This review offers a comprehensive resource and presents an updated perspective for researchers interested in eccDNA biology.
中文摘要:染色体外环状DNA(eccDNA)是一类独立于染色体存在的环状DNA分子,在基因组可塑性、癌症进展、耐药性和适应性进化中发挥关键作用。近年来,高通量测序、计算工具和基于CRISPR的基因组编辑的进展,彻底改变了eccDNA的检测和功能表征。单分子实时测序和纳米孔测序技术的出现,进一步使在细胞水平研究eccDNA成为可能。eccDNA研究的快速发展揭示了基因组组织与功能中此前未被认识到的维度。在本综述中,我们系统评估了当前基于高通量测序的eccDNA检测方法,讨论其技术原理、优势、局限性和应用。最后,我们提出新的可视化策略以改善数据解读,并强调结合多组学整合和单细胞方法的未来研究方向。本综述为对eccDNA生物学感兴趣的研究人员提供了全面的资源和更新的视角。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42337054
G1 to S phase transition 1 (GSPT1) represents a promising yet historically challenging therapeutic target for MYC-driven malignancies. Herein, we identified XYD113, a potent and highly selective GSPT1-targeting molecular glue degrader. XYD113 exhibits significant antiproliferative activity (IC50 < 100 nM) against multiple MYC-overexpressing cancer cell lines (22Rv1, MV4-11, MOLM-16, Calu-1, HS-SY-II), and induces GSPT1 degradation in a dose- and time-dependent manner, with potency comparable to that of the clinical candidate MRT-2359. It also exhibits excellent selectivity without degrading common glutarimide analog substrates (such as SALL4, IKZF1/2/3, or CK1α). Mechanistically, XYD113 acts as a molecular glue to facilitate CRBN-GSPT1 ternary complex formation, mediating GSPT1 degradation via the UPS in a CRBN-dependent manner. Additionally, XYD113 demonstrates favorable stability in liver microsomes. Notably, XYD113 effectively downregulates the expression of genes critical for the initiation and progression of prostate cancer. In vivo, oral administration of XYD113 (5 mg/kg, daily for 21 days) significantly inhibited 22Rv1 xenograft growth (TGI = 46%) and showed a favorable safety profile in BALB/c-nude mice. Together, these findings highlight XYD113 as a promising therapeutic degrader worthy of further development for the treatment of MYC-driven cancers.
中文摘要:G1到S期转换1(GSPT1)是MYC驱动恶性肿瘤中一个有前景但历史上具有挑战性的治疗靶点。在此,我们发现了XYD113,一种强效且高选择性的靶向GSPT1的分子胶降解剂。XYD113对多种MYC过表达癌细胞系(22Rv1、MV4-11、MOLM-16、Calu-1、HS-SY-II)表现出显著的抗增殖活性(IC50 < 100 nM),并以剂量和时间依赖的方式诱导GSPT1降解,其效力与临床候选药物MRT-2359相当。它还表现出优异的选择性,不降解常见的戊二酰亚胺类似底物(如SALL4、IKZF1/2/3或CK1α)。机制上,XYD113作为分子胶促进CRBN-GSPT1三元复合物形成,以CRBN依赖的方式通过UPS介导GSPT1降解。此外,XYD113在肝微粒体中表现出良好的稳定性。值得注意的是,XYD113有效下调对前列腺癌发生和进展至关重要的基因表达。在体内,口服给予XYD113(5 mg/kg,每日一次,持续21天)显著抑制22Rv1异种移植瘤生长(TGI = 46%),并在BALB/c裸鼠中表现出良好的安全性。总之,这些发现凸显XYD113是一种有前景的治疗性降解剂,值得进一步开发用于治疗MYC驱动的癌症。
Cancer letters IF 11.8 2026-10-01 PMID: 42336095
Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma, remains difficult to treat in relapsed, metastatic, or refractory disease. Chimeric antigen receptor (CAR) T cell therapy has demonstrated promising results in hematological diseases, but its application to solid tumors including RMS is limited by antigen heterogeneity, on-target/off-tumor toxicity, and insufficient activity against moderate antigen density. We investigated L1 cell adhesion molecule (L1CAM) as a candidate CAR T cell target in RMS by profiling expression in cell lines, patient-derived xenografts, and healthy tissues. Using the CE7-derived single-chain variable fragment, we engineered and compared L1CAM-CAR constructs differing in hinge and costimulatory domains, including the clinically tested 4-1BB-based CE7-CAR configuration. Functional activity was assessed across fusion-positive and fusion-negative RMS models in vitro and in orthotopic mouse models, with B7-H3-CAR T cells included as a benchmark. L1CAM was expressed at variable but specific levels across RMS models, with more prominent expression in fusion-positive RMS and limited expression in healthy tissues. Among constructs, the CD28-based L1CAM.III-CAR showed the strongest cytotoxicity and IFN-γ release, including partial activity in a low-L1CAM model. In vivo, L1CAM.III-CAR T cells improved expansion, delayed tumor progression, and prolonged survival compared with the clinical-reference L1CAM.CT construct, although responses were incomplete and less pronounced than those achieved with B7-H3-CAR T cells. These findings support L1CAM as a rational target for L1CAM-positive RMS cases and demonstrate that CAR optimization can enhance activity against moderate-density antigens. The potent antitumor activity and favorable selectivity profile of L1CAM.III-CAR T cells support their development for pediatric sarcoma immunotherapy.
中文摘要:横纹肌肉瘤(RMS)是儿童最常见的软组织肉瘤,复发、转移或难治性疾病仍难以治疗。嵌合抗原受体(CAR)T细胞疗法在血液系统疾病中已显示出有希望的结果,但其应用于包括RMS在内的实体瘤受到抗原异质性、靶向/脱靶毒性以及对中等抗原密度活性不足的限制。我们通过分析细胞系、患者来源异种移植瘤和健康组织中的表达,研究了L1细胞黏附分子(L1CAM)作为RMS候选CAR T细胞靶点。使用CE7来源的单链可变片段,我们构建并比较了在铰链区和共刺激域上不同的L1CAM-CAR结构,包括已进入临床测试的基于4-1BB的CE7-CAR构型。在体外融合阳性与融合阴性RMS模型以及原位小鼠模型中评估功能活性,并以B7-H3-CAR T细胞作为基准。L1CAM在RMS模型中呈可变但特异的表达,在融合阳性RMS中表达更突出,在健康组织中表达有限。在各构建体中,基于CD28的L1CAM.III-CAR表现出最强的细胞毒性和IFN-γ释放,包括在低L1CAM模型中具有部分活性。在体内,与临床参考L1CAM.CT构建体相比,L1CAM.III-CAR T细胞改善了扩增、延缓肿瘤进展并延长生存,尽管反应不完整且不如B7-H3-CAR T细胞所达到的效果明显。这些发现支持L1CAM作为L1CAM阳性RMS病例的合理靶点,并证明CAR优化可增强针对中等密度抗原的活性。L1CAM.III-CAR T细胞强效的抗肿瘤活性和良好的选择性特征支持其用于儿童肉瘤免疫治疗的发展。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42332029
O-GlcNAcylation is a dynamic, reversible post-translational modification that attaches N-acetylglucosamine (GlcNAc) to the serine or threonine residues of intracellular proteins. Catalysed by O-GlcNAc transferase and removed by O-GlcNAcase, this modification acts as a key nutrient and stress sensor. Although cell adhesion is fundamental to tissue architecture and mechanotransduction, emerging evidence has shown that O-GlcNAcylation profoundly orchestrates these processes. By modulating the composition and signalling of adhesion complexes, O-GlcNAcylation regulates both cell-cell and cell-matrix interactions. Through crosstalk with phosphorylation, this modification drives cellular adhesion plasticity, with broad implications for development, immunity, and diseases, such as cancer and neurodegeneration. Recent advances revealed that O-GlcNAcylation fine-tunes key regulators, including Focal Adhesion Kinase (FAK), Zyxin, and integrins, to control focal adhesion turnover. These mechanistic insights pave the way for novel therapeutic strategies targeting glycosylation-dependent adhesion signalling.
中文摘要:O-GlcNAcylation是一种动态、可逆的翻译后修饰,可将N-乙酰葡糖胺(GlcNAc)连接到细胞内蛋白的丝氨酸或苏氨酸残基上。该修饰由O-GlcNAc转移酶催化,并由O-GlcNAcase去除,充当关键的营养和应激传感器。尽管细胞黏附是组织结构与机械转导的基础,但新出现的证据表明,O-GlcNAcylation深刻调控这些过程。通过调节黏附复合物的组成与信号传导,O-GlcNAcylation调节细胞间及细胞与基质间的相互作用。通过与磷酸化的串扰,该修饰驱动细胞黏附可塑性,并对发育、免疫以及癌症和神经退行性疾病等具有广泛意义。近期进展揭示,O-GlcNAcylation精细调节关键调控因子,包括黏着斑激酶(FAK)、Zyxin和整合素,以控制黏着斑周转。这些机制性见解为靶向糖基化依赖性黏附信号的新型治疗策略铺平了道路。
Cancer letters IF 11.8 2026-10-01 PMID: 42320877
Tumor resistance to radiotherapy continues to be a significant problem in improving cancer patient outcomes. To overcome radioresistance, drugs that sensitize cancer cells to ionizing radiation (IR) have been tested. In theory, radiosensitizers should increase irradiated tumor kill and improve patient outcomes. However, in practice, the clinical utility of such drugs is curtailed by radiosensitization of peri-tumoral normal tissues causing toxicities. To target radiosensitizer delivery to tumors, we developed an activatable cell penetrating peptide (ACPP) drug conjugate for spatially tumor-restricted delivery of the potent ataxia-telangiectasia mutated kinase inhibitor (ATMi) AZD0156. The ACPP scaffold cloaks a cell penetrating peptide-drug conjugate until it is unmasked within tumors through tumor-associated matrix metalloproteinase thus promoting preferential tumor uptake. Using clinically validated antibody-drug conjugate linker chemistry, we conjugated AZD0156 to ACPP (ACPP-AZD0156) and evaluated its immune stimulating and therapeutic activity with IR in immune-competent murine cancer models. Transcriptomic profiling revealed combining ACPP-AZD0156 with IR enhanced radiation-induced immune activation programs, including type I interferon signaling and leukocyte activation network. Importantly, ACPP-AZD0156 combined with IR stimulated intratumoral CD8+ T cell infiltration and improved tumor control compared to non-targeted ATM inhibitor. Mechanistically, the therapeutic effect of ACPP-AZD0156 + IR was abrogated by CD8+ T-cell depletion, establishing a role for adaptive immunity engagement by ACPP-AZD0156 radiosensitization. Finally, the combination of IR and ACPP-AZD0156 with PD-1 blockade resulted in durable tumor control and long-term survival. Taken together, these data provide a basis for tumor-targeted ATMi delivery as a precision oncology based immunogenic radiosensitization strategy.
中文摘要:肿瘤对放疗的抵抗仍然是改善癌症患者预后的一大难题。为了克服放射抵抗,已测试了使癌细胞对电离辐射(IR)敏感的药物。理论上,放射增敏剂应增加受照射肿瘤的杀伤并改善患者预后。然而在实践中,此类药物的临床效用受到肿瘤周围正常组织放射增敏导致毒性的限制。为了将放射增敏剂靶向递送至肿瘤,我们开发了一种可激活的细胞穿透肽(ACPP)药物偶联物,用于在空间上限制于肿瘤地递送强效的共济失调毛细血管扩张突变激酶抑制剂(ATMi)AZD0156。ACPP支架遮蔽细胞穿透肽-药物偶联物,直至其在肿瘤内被肿瘤相关基质金属蛋白酶揭开,从而促进优先的肿瘤摄取。利用经临床验证的抗体-药物偶联物连接子化学,我们将AZD0156与ACPP偶联(ACPP-AZD0156),并在免疫健全的小鼠癌症模型中评估其与IR联合的免疫刺激和治疗活性。转录组分析显示,ACPP-AZD0156与IR联合增强了辐射诱导的免疫激活程序,包括I型干扰素信号传导和白细胞激活网络。重要的是,与非靶向ATM抑制剂相比,ACPP-AZD0156联合IR刺激了瘤内CD8+ T细胞浸润并改善了肿瘤控制。机制上,ACPP-AZD0156 + IR的治疗效果被CD8+ T细胞清除所消除,确立了ACPP-AZD0156放射增敏对适应性免疫参与的作用。最后,IR与ACPP-AZD0156联合PD-1阻断实现了持久的肿瘤控制和长期生存。总之,这些数据为肿瘤靶向ATMi递送作为基于精准肿瘤学的免疫原性放射增敏策略提供了依据。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42298205
Chronic pain has emerged as the third leading health issue, following cardiovascular and cerebrovascular diseases and cancer. Clinically, patients with chronic pain often exhibit comorbid depression-like behaviors. However, the underlying mechanisms of chronic pain-related depression remain unclear. In this study, a chronic pain-related depression model was established in C57BL/6J, Vgat-Cre, and TH-Cre mice through sciatic nerve ligation (SNI) surgery. Viral-mediated DNA methyltransferase 1 (DNMT1) knockdown, optogenetic/chemogenetic modulation, electrophysiological recordings and molecular biology techniques were used to investigate the role of DNMT1 in regulating the projection from central amygdala GABAergic neurons (CeAGABA) to locus coeruleus noradrenergic neurons (LCNA) and its impact on chronic pain-related depression-like behaviors. Viral tracing identified LC as a major downstream target of the CeA. Immunohistochemical staining and electrophysiological recordings confirmed the functional synaptic connection between CeA-GABAergic neurons and LC-NAergic neurons. Behavioral assays showed the bidirectional modulation of pain-related depression phenotypes through LC-NAergic system: activation of LC-NAergic neurons induced depression-like behaviors, whereas their inhibition improved SNI-induced depression-like behaviors. Notably, CeA-GABAergic neurons were found to specifically innervate LC-NAergic neurons in mediating chronic pain-related depression-like behaviors. Furthermore, inhibition of the CeAGABA → LCNA circuit abolished the improvement of depressive behaviors in DNMT1 knockdown SNI mice, establishing DNMT1 as a key epigenetic regulator of this pathway. Taken together, our findings suggest that DNMT1 may suppress the GABAergic projections from the CeA to LC-NAergic neurons, thereby contributing to chronic pain-related depression-like behaviors. These findings provide novel insight into the circuit-related epigenetic basis of pain-depression comorbidity.
中文摘要:慢性疼痛已成为继心脑血管疾病和癌症之后的第三大健康问题。临床上,慢性疼痛患者常表现出共病抑郁样行为。然而,慢性疼痛相关抑郁的潜在机制仍不清楚。本研究通过坐骨神经结扎(SNI)手术在C57BL/6J、Vgat-Cre和TH-Cre小鼠中建立慢性疼痛相关抑郁模型。采用病毒介导的DNA甲基转移酶1(DNMT1)敲低、光遗传学/化学遗传学调控、电生理记录和分子生物学技术,探讨DNMT1在调节中央杏仁核GABA能神经元(CeAGABA)向蓝斑去甲肾上腺素能神经元(LCNA)投射中的作用及其对慢性疼痛相关抑郁样行为的影响。病毒示踪确定LC是CeA的主要下游靶点。免疫组化染色和电生理记录证实了CeA GABA能神经元与LC NA能神经元之间的功能性突触连接。行为学实验显示LC NA能系统对疼痛相关抑郁表型具有双向调节作用:激活LC NA能神经元可诱导抑郁样行为,而抑制其活动则可改善SNI诱导的抑郁样行为。值得注意的是,CeA GABA能神经元被发现特异性支配LC NA能神经元,从而介导慢性疼痛相关抑郁样行为。此外,抑制CeAGABA→LCNA环路可消除DNMT1敲低SNI小鼠抑郁行为的改善,表明DNMT1是该通路的关键表观遗传调控因子。综上,我们的研究结果提示,DNMT1可能抑制CeA向LC NA能神经元的GABA能投射,从而促进慢性疼痛相关抑郁样行为。这些发现为疼痛-抑郁共病的环路相关表观遗传基础提供了新的见解。
Nature protocols IF 18.4 2026-10 PMID: 42260234
Structural variants (SVs) are the most common nucleotide alteration per human genome compared to other variant types and have profound implications in evolution, diseases and regulation of genes. Sniffles2 (v2.6.3) is an open-source software for reliable detection of SVs ranging from 50 bp and upward across deletions, duplications, insertions, inversions and translocations, based on long-read sequencing. The tool is commonly used for various species and has identified multiple causative mutations in human diseases, key alleles in cancer progression. Here this protocol describes how to fully use Sniffles2 to accurately identify germline and mosaic SVs. The latter are low-variant allele fraction SVs (5-22% VAF) of parts of cells. We further provide detailed instruction for SV joint calling within Sniffles2 to enable tumor/normal calling or family trio analysis, which can scale up into large-scale population studies. Sniffles2 has been benchmarked and compared to currently available tools and has the highest precision while also being very fast, able to call SVs for a 40× human genome in ~34 CPU min (~8.5 min wall clock with the default four threads). It is designed to be easy to use for researchers with basic knowledge of Linux operating systems and the terminal.
中文摘要:结构变异(SVs)是每个人类基因组中相比其他变异类型最常见的核苷酸改变,对进化、疾病和基因调控具有深远影响。Sniffles2(v2.6.3)是一款开源软件,基于长读长测序,可可靠检测从50 bp及以上的结构变异,涵盖缺失、重复、插入、倒位和易位。该工具常用于多种物种,并已鉴定出人类疾病中的多个致病突变以及癌症进展中的关键等位基因。本协议描述了如何充分利用 Sniffles2 准确识别种系和嵌合 SVs。后者是部分细胞中低变异等位基因分数 SVs(5-22% VAF)。我们进一步提供 Sniffles2 内 SV 联合调用的详细说明,以实现肿瘤/正常调用或家族三人组分析,并可扩展至大规模人群研究。Sniffles2 已经过基准测试并与现有工具进行比较,具有最高精度,同时也非常快速,能够在约34 CPU分钟内对40×人类基因组进行 SV 调用(默认四线程时约8.5分钟墙钟时间)。其设计便于具备 Linux 操作系统和终端基础知识的研究人员使用。
Cancer letters IF 11.8 2026-10-01 PMID: 42217563
Nucleophosmin 1-mutant (NPM1MU) acute myeloid leukemia (AML) represents a distinct molecular subtype, yet the mechanisms underlying NPM1 mutation-driven malignant transformation remain incompletely understood. Here, we find prevalent copy number variations (CNVs) of N6-methyladenosine (m6A) key regulators in NPM1 wild-type (NPM1WT) AML patients, whereas such alterations are rarely detected in NPM1MU subgroup. Moreover, a reduction in m6A modification is observed in leukemic cells overexpressing NPM1MU protein, concomitant with an increase in FTO expression. Co-immunoprecipitation shows that NPM1MU protein mislocates in the cytoplasm and binds to FTO to block its ubiquitin-proteasome degradation through K422 specific site. Of note, creatine metabolism-related signaling and FTO-mediated macrophage M2 polarization signaling are enriched in NPM1MU patients according to TCGA data analysis. Indeed, FTO promotes creatine anabolism in NPM1MU leukemic cells by stabilizing the mRNA of GAMT, a key enzyme in the creatine synthesis pathway. Creatine facilitates macrophage M2 polarization, as evidenced by the upregulation of M2 polarization-related genes (CD206, CCL2, IL-10 and CXCL13). This effect is abrogated upon FTO knockdown in leukemic cells. Selinexor, an exportin 1 inhibitor to impede NPM1MU export from nucleus, enhances FTO degradation and reduces macrophage M2 polarization. This work reveals that FTO-creatine signaling plays an oncogenic role in NPM1MU AML, guiding more effective therapy strategies and clinical benefits for this distinctly leukemic entity.
中文摘要:核磷蛋白1突变型(NPM1MU)急性髓系白血病(AML)是一种独特的分子亚型,但NPM1突变驱动恶性转化的机制仍不完全清楚。在这里,我们发现N6-甲基腺苷(m6A)关键调控因子在NPM1野生型(NPM1WT)AML患者中普遍存在拷贝数变异(CNVs),而在NPM1MU亚组中很少检测到此类改变。此外,在过表达NPM1MU蛋白的白血病细胞中观察到m6A修饰减少,同时FTO表达增加。免疫共沉淀显示,NPM1MU蛋白错误定位于细胞质,并与FTO结合,通过K422特定位点阻断其泛素-蛋白酶体降解。值得注意的是,根据TCGA数据分析,肌酸代谢相关信号和FTO介导的巨噬细胞M2极化信号在NPM1MU患者中富集。事实上,FTO通过稳定肌酸合成通路关键酶GAMT的mRNA,促进NPM1MU白血病细胞中的肌酸合成代谢。肌酸促进巨噬细胞M2极化,表现为M2极化相关基因(CD206、CCL2、IL-10和CXCL13)上调。在白血病细胞中敲低FTO后,这种效应被消除。Selinexor是一种exportin 1抑制剂,可阻止NPM1MU从细胞核输出,其增强FTO降解并减少巨噬细胞M2极化。这项工作揭示,FTO-肌酸信号在NPM1MU AML中发挥致癌作用,为这一独特的白血病实体指导更有效的治疗策略和临床获益。
Autophagy IF 18.6 2026-10 PMID: 42212595
Influenza A virus (IAV) remains a major threat to global public health, causing seasonal epidemics and occasional pandemics with significant morbidity and mortality. M2 (matrix protein 2), a key IAV envelope protein with ion channel activity, is critical for viral uncoating, genome release, and virion assembly. Here, we identified FKBP8 (FK506 binding protein 8) as a host restriction factor targeting IAV. Overexpression of FKBP8 inhibited IAV replication, while FKBP8 knockdown/knockout enhanced viral susceptibility. Mechanistically, FKBP8 interacted with M2 from diverse IAV strains via high-affinity binding between its tetratricopeptide repeat (TPR) domain and the LC3-interacting region (LIR) of M2, inhibiting viral entry. Importantly, FKBP8 mediated M2 degradation through the lysosomal pathway, not via translational inhibition, as shown by cycloheximide and lysosomal inhibitor (BafA1 and CQ) experiments. FKBP8 recruited RAB7A and LAMP1 to form a FKBP8-RAB7A-LAMP1-M2 complex, facilitating M2 transport to lysosomes. Additionally, FKBP8 interacted with envelope proteins of other enveloped RNA viruses, suggesting broad-spectrum antiviral potential. Our findings reveal FKBP8 as a conserved IAV restriction factor and its mechanism, providing insights for antiviral drug development.Abbreviations: AA: amino acids; AP-MS: affinity tag purification-mass spectrometry; BCL2: B cell leukemia/lymphoma 2; BafA1: bafilomycin A1; MbFKBP8: Myotis brandtii FK506 binding protein 8; CHX: cycloheximide; CQ: chloroquine; CTD: cytoplasmic tail domain; ED: ectodomain; EV: empty vector; FKBP8: FK506 binding protein 8; FL: full length; HCIPs: high-confidence interacting proteins; HsFKBP8: Homo sapiens FKBP prolyl isomerase 8; IAV: influenza A virus; LIR: LC3-interacting region; LAMP1: lysosomal-associated membrane protein 1; M2: matrix protein 2; MOI: multiplicity of infection; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MmFKBP8: Mus musculus FK506 binding protein 8; NP: nucleoprotein; PA: polymerase acidic; PB1: polymerase basic 1; PB2: polymerase basic 2; PPIase: peptidyl-prolyl cis-trans isomerase; KO: knockout; RdRps: RNA-dependent RNA polymerases; RAB7A: RAB7, member RAS oncogene family; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; TRIM41: tripartite motif-containing 41; TMD: transmembrane domain; vRNP: viral ribonucleoprotein.
中文摘要:甲型流感病毒(IAV)仍然是对全球公共卫生的重大威胁,可导致季节性流行和偶发大流行,并造成显著发病率和死亡率。M2(基质蛋白2)是一种具有离子通道活性的关键IAV包膜蛋白,对病毒脱壳、基因组释放和病毒粒子组装至关重要。在此,我们鉴定FKBP8(FK506结合蛋白8)为靶向IAV的宿主限制因子。FKBP8过表达抑制IAV复制,而FKBP8敲低/敲除则增强病毒易感性。机制上,FKBP8通过其三十四肽重复(TPR)结构域与M2的LC3相互作用区(LIR)之间的高亲和力结合,与来自不同IAV毒株的M2相互作用,从而抑制病毒进入。重要的是,如放线菌酮和溶酶体抑制剂(BafA1和CQ)实验所示,FKBP8通过溶酶体途径介导M2降解,而非通过翻译抑制。FKBP8招募RAB7A和LAMP1形成FKBP8-RAB7A-LAMP1-M2复合物,促进M2转运至溶酶体。此外,FKBP8与其他包膜RNA病毒的包膜蛋白相互作用,提示其具有广谱抗病毒潜力。我们的发现揭示FKBP8是一种保守的IAV限制因子及其机制,为抗病毒药物开发提供见解。缩写:AA:氨基酸;AP-MS:亲和标签纯化-质谱;BCL2:B细胞白血病/淋巴瘤2;BafA1:巴弗洛霉素A1;MbFKBP8:布氏鼠耳蝠FK506结合蛋白8;CHX:放线菌酮;CQ:氯喹;CTD:胞质尾结构域;ED:胞外域;EV:空载体;FKBP8:FK506结合蛋白8;FL:全长;HCIPs:高置信度相互作用蛋白;HsFKBP8:人FKBP脯氨酰异构酶8;IAV:甲型流感病毒;LIR:LC3相互作用区;LAMP1:溶酶体相关膜蛋白1;M2:基质蛋白2;MOI:感染复数;MAP1LC3/LC3:微管相关蛋白1轻链3;MmFKBP8:小鼠FK506结合蛋白8;NP:核蛋白;PA:聚合酶酸性;PB1:聚合酶碱性1;PB2:聚合酶碱性2;PPIase:肽基脯氨酰顺反异构酶;KO:敲除;RdRps:RNA依赖性RNA聚合酶;RAB7A:RAB7,RAS癌基因家族成员;SARS-CoV-2:严重急性呼吸综合征冠状病毒2;TRIM41:三基序包含41;TMD:跨膜结构域;vRNP:病毒核糖核蛋白。
Autophagy IF 18.6 2026-10 PMID: 42171217
It is well established that the function of DCs (dendritic cells) is impaired during malaria infection; however, the underlying mechanisms responsible for this impairment remain poorly understood. In this study, we found that ATG5 (autophagy related 5) deficiency in DCs significantly suppressed the growth of malaria blood-stage parasites, and this effect was independent of both canonical and non-canonical macroautophagy/autophagy pathways in these cells. The reduced parasite growth observed in atg5f/f Itgax/Cd11c-Cre+ mice was associated with an enhanced parasite-specific CD4+ T cell response, which provided crucial support for the functional activation of Plasmodium-specific CD8+ T cells. Mechanistically, ATG5 deficiency led to a marked increase in the expression of the phagocytic receptor CD209A/DC-SIGN on conventional DCs (cDCs), thereby enhancing their capacity to activate Plasmodium-specific CD4+ T cell responses. Furthermore, the expression of CD209A was mediated by the TLR2 (toll-like receptor 2) signaling pathway, which was significantly augmented in the absence of ATG5. Thus, we reveal a novel role for ATG5 in modulating anti-malarial cellular immune responses by influencing TLR2-mediated CD209A expression in cDCs. These findings not only enhance our understanding of impaired DC function during malaria infection but also provide valuable insights for the design of more effective malaria vaccines.Abbreviations: ATG5: autophagy related 5; cDCs: conventional dendritic cells; CFSE: carboxyfluorescein succinimidyl ester; DC-SIGN: dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; IFNG/IFN-γ: interferon gamma; LAP: LC3-associated phagocytosis; MAPK: mitogen-activated protein kinase; NFKB1/NF-κB: nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105; pRBCs: parasitized red blood cells; PRRs: pattern recognition receptors; TLR2: toll-like receptor 2; TNF/TNF-α: tumor necrosis factor.
中文摘要:已知在疟疾感染期间树突状细胞(DC)的功能会受损,但导致这种受损的潜在机制仍知之甚少。在本研究中,我们发现DC中ATG5(自噬相关5)缺陷可显著抑制疟疾红内期寄生虫的生长,并且这种效应独立于这些细胞中的经典和非经典巨自噬/自噬途径。在atg5f/f Itgax/Cd11c-Cre+小鼠中观察到的寄生虫生长减少与增强的寄生虫特异性CD4+ T细胞反应相关,后者为疟原虫特异性CD8+ T细胞的功能活化提供了关键支持。机制上,ATG5缺陷导致常规树突状细胞(cDC)上吞噬受体CD209A/DC-SIGN表达显著增加,从而增强其激活疟原虫特异性CD4+ T细胞反应的能力。此外,CD209A的表达由TLR2(Toll样受体2)信号通路介导,而该通路在缺乏ATG5时显著增强。因此,我们揭示了ATG5通过影响cDC中TLR2介导的CD209A表达来调节抗疟细胞免疫反应的新作用。这些发现不仅加深了我们对疟疾感染期间DC功能受损的理解,也为设计更有效的疟疾疫苗提供了宝贵见解。缩写:ATG5:自噬相关5;cDCs:常规树突状细胞;CFSE:羧基荧光素琥珀酰亚胺酯;DC-SIGN:树突状细胞特异性细胞间黏附分子3捕获非整合素;IFNG/IFN-γ:干扰素γ;LAP:LC3相关吞噬作用;MAPK:丝裂原活化蛋白激酶;NFKB1/NF-κB:B细胞中κ轻多肽基因增强子核因子1,p105;pRBCs:寄生红细胞;PRRs:模式识别受体;TLR2:Toll样受体2;TNF/TNF-α:肿瘤坏死因子。
Physiological reviews IF 35.7 2026-10-01 PMID: 42155599
A-kinase anchoring proteins (AKAPs) received their name based on their ability to bind protein kinase A (PKA). Now, AKAPs have grown to a diverse family of more than 50 proteins, coordinating molecules far beyond PKA and the PKA signaling pathway. AKAPs are scaffolding proteins spanning in size between 15 and several hundred kilodaltons and can directly engage in protein interactions with other signaling proteins, their upstream regulators, and their downstream effectors. AKAPs possess unique targeting domains directing them to defined cellular compartments to coordinate cellular signaling spatially and temporally. A few AKAPs possess their own catalytic activity. AKAPs are crucial in directing cAMP signaling locally and in mediating cross talk with other second messenger systems. This review introduces individual AKAPs and their physiological functions in their respective cellular compartments and illustrates how they organize local signal transduction. The crucial role of AKAPs in coordinating cAMP responses to extracellular cues and how they facilitate specific responses to each stimulus will be exemplified. Dysregulation of AKAPs is associated with or causes disease. We will examine the pathophysiological roles of AKAPs in inherited and noninherited noncommunicable diseases, such as cardiovascular diseases and cancer. Due to the lack of understanding of molecular mechanisms underlying most of these diseases, the available therapeutic approaches often only slow progression and cause side effects. This review will discuss the unique opportunities AKAPs provide to address the medical need for novel therapeutic concepts. Finally, gaps in our knowledge about AKAPs will be outlined, and future directions in AKAP research will be suggested.
中文摘要:A激酶锚定蛋白(AKAPs)因其结合蛋白激酶A(PKA)的能力而得名。如今,AKAPs已发展为一个多样化的蛋白家族,包含50多种蛋白,其协调的分子远不止PKA和PKA信号通路。AKAPs是支架蛋白,大小介于15至数百千道尔顿之间,可直接与其他信号蛋白、其上游调节因子和下游效应器发生蛋白相互作用。AKAPs具有独特的靶向结构域,将其导向特定的细胞区室,从而在空间和时间上协调细胞信号传导。少数AKAPs自身具有催化活性。AKAPs在引导局部cAMP信号传导以及介导与其他第二信使系统的交互对话中至关重要。本综述介绍各个AKAPs及其在各自细胞区室中的生理功能,并阐明它们如何组织局部信号转导。文中将举例说明AKAPs在协调细胞对胞外线索的cAMP反应中的关键作用,以及它们如何促进对每种刺激的特异性反应。AKAPs的失调与疾病相关或导致疾病。我们将探讨AKAPs在遗传性和非遗传性非传染性疾病(如心血管疾病和癌症)中的病理生理作用。由于对其中大多数疾病的分子机制缺乏了解,现有治疗方法往往只能延缓进展并引起副作用。本综述将讨论AKAPs为解决新型治疗概念这一医学需求所提供的独特机会。最后,将概述我们在AKAPs知识方面的空白,并提出AKAP研究的未来方向。
Autophagy IF 18.6 2026-10 PMID: 42153663
Abnormal mechanical stress is closely linked to intervertebral disc degeneration (IVDD). Iron homeostasis disorder occurs in various degenerative diseases, including IVDD. PIEZO1 serves as a mechanosensitive cation channel, involving in multiple physiological and pathological processes; however, its potential association with iron homeostasis and IVDD remain to be elucidated. Here, it is discovered that PIEZO1 accumulates in cartilage endplate (CEP) during IVDD, accompanied by intensive ferritinophagy. Specific activation of PIEZO1 or NCOA4 (nuclear receptor coactivator 4) aggravates CEP degeneration. Conversely, chondrocyte-specific knockout of Piezo1 mitigates CEP degeneration by restoring the labile iron pool and stabilizing the mitochondrial genome. Mechanistically, PIEZO1-mediated nuclear translocation of YAP1 (Yes1 associated transcriptional regulator) enhances NCOA4-dependent ferritinophagy by promoting extracellular Ca2+ influx under oxidative stress. Moreover, ferritinophagy induces in the accumulation and release of Z-form mitochondrial DNA (Z-mtDNA), resulting in the activation of ZBP1 (Z-DNA binding protein 1), ultimately leading to NFKB-dependent inflammatory cascade. Therapeutically, blocking PIEZO1-mediated calcium influx or suppressing YAP1 activation alleviates ferritinophagy. Additionally, Ncoa4 silencing attenuates Z-mtDNA-ZBP1-NFKB axis-driven IVDD. Collectively, our findings suggest that mechanical overload induces ferritinophagy-dependent CEP degeneration via PIEZO1 activation and subsequent upregulation of the Z-mtDNA-ZBP1-NFKB axis, which might furnish a therapeutic target for IVDD.Abbreviation: AAV: adeno-associated virus; ALP: alkaline phosphatase; ARS: alizarin red S; BV:TV: bone volume:total volume; CAMK2/CaMKII: calcium/calmodulin dependent protein kinase II; CEP: cartilage endplate; CEPCs: cartilage endplate chondrocytes; ChIP: chromatin immunoprecipitation; CKO: conditional knockout; CsA: cyclosporin A; Co-IP: co-immunoprecipitation; DHI: disc height index; ECM: extracellular matrix; EtBr: ethidium bromide; HIF: hypoxia inducible factor; IVDD: intervertebral disc degeneration; KD: knockdown; LAT: large tumor suppressor kinase; LSI: lumbar spine instability; MDA: malondialdehyde; Mito-ROS: mitochondrial reactive oxygen species; MRI: magnetic resonance imaging; mtDNA: mitochondrial DNA; NCOA4: nuclear receptor coactivator 4; PCBP: poly(rC) binding protein; ROS: reactive oxygen species; RT-qPCR: real-time quantitative reverse transcription; SOFG: safranin O and fast green; WWTR1/TAZ: WW domain containing transcription regulator 1; TEAD1: TEA domain transcription factor 1; TEM: transmission electron microscopy; YAP1: Yes1 associated transcriptional regulator; ZBP1: Z-DNA binding protein 1; Z-DNA: Z-form DNA; Z-mtDNA: Z-form mitochondrial DNA.
中文摘要:异常的机械应力与椎间盘退变(IVDD)密切相关。铁稳态紊乱发生于多种退行性疾病,包括IVDD。PIEZO1是一种机械敏感阳离子通道,参与多种生理和病理过程;然而,其与铁稳态及IVDD的潜在关联仍有待阐明。本研究发现,在IVDD过程中PIEZO1在软骨终板(CEP)中积聚,并伴随强烈的铁蛋白自噬。特异性激活PIEZO1或NCOA4(核受体共激活因子4)会加重CEP退变。相反,软骨细胞特异性敲除Piezo1可通过恢复不稳定铁池和稳定线粒体基因组来减轻CEP退变。机制上,在氧化应激下,PIEZO1介导的YAP1(Yes1相关转录调节因子)核转位通过促进细胞外Ca2+内流增强NCOA4依赖性铁蛋白自噬。此外,铁蛋白自噬诱导Z型线粒体DNA(Z-mtDNA)的积累和释放,导致ZBP1(Z-DNA结合蛋白1)激活,最终引起NFKB依赖性炎症级联反应。在治疗方面,阻断PIEZO1介导的钙内流或抑制YAP1激活可减轻铁蛋白自噬。此外,沉默Ncoa4可减弱Z-mtDNA-ZBP1-NFKB轴驱动的IVDD。总之,我们的研究结果表明,机械超负荷通过PIEZO1激活以及随后上调Z-mtDNA-ZBP1-NFKB轴诱导铁蛋白自噬依赖性CEP退变,这可能为IVDD提供治疗靶点。
Nature protocols IF 18.4 2026-10 PMID: 42129485
Spatial cues and cell-cell interactions within in vivo tissue architecture generate physical signals that regulate cell behavior. These mechanical interactions drive processes such as morphogenesis, homeostasis, regeneration and disease progression. To recapitulate these spatial niches in vitro, lithographic micropatterning allows for precise control over the geometry, composition, topography and mechanics of cell-adhesive substrates. Micropatterned cultures have been essential in uncovering key mechanotransduction mechanisms, including YAP/TAZ-mediated signaling, mechanoregulation in cancer, aging and early embryonic development. However, accessible and adaptable micropatterning protocols for conventional cell biology laboratories remain limited. In this protocol, we present a comprehensive procedure for generating flexible, high-resolution micropatterns (down to 10 × 10 µm2), optimized for high-magnification confocal imaging, long-term cell culture, customizable functionalization (proteins, peptides or both) and extended shelf life. This versatile and convenient procedure can be performed by trained PhD students or postdoctoral researchers, does not require prior expertise in photolithography and can be completed within 2 d. In addition, we provide a step-by-step guide to study mechanotransduction using YAP/TAZ functional readouts that can be completed within 5 d. This protocol offers an affordable and scalable solution applicable to a wide range of biological questions, allowing for diverse experimental needs, and represents a valuable tool for advancing mechanobiology and other areas of cell biology.
中文摘要:体内组织架构中的空间线索和细胞间相互作用会产生调控细胞行为的物理信号。这些力学相互作用驱动形态发生、稳态、再生和疾病进展等过程。为了在体外重现这些空间微环境,光刻微图案化技术可精确控制细胞黏附基底的几何形状、组成、形貌和力学性质。微图案化培养对于揭示关键力转导机制至关重要,包括YAP/TAZ介导的信号、癌症、衰老和早期胚胎发育中的力学调控。然而,适用于常规细胞生物学实验室的易获取且可调整的微图案化方案仍然有限。在本方案中,我们提出了一套生成柔性高分辨率微图案(低至10 × 10 µm²)的综合流程,该流程针对高倍共聚焦成像、长期细胞培养、可定制功能化(蛋白质、肽或两者)以及延长保存期限进行了优化。这一通用且便捷的流程可由受过训练的博士生或博士后研究人员执行,不需要先前具备光刻专业知识,并可在2天内完成。此外,我们提供了使用YAP/TAZ功能性读出研究力转导的分步指南,可在5天内完成。该方案提供了一种经济且可扩展的解决方案,适用于广泛的生物学问题,可满足多样化实验需求,并且是推动力学生物学及细胞生物学其他领域发展的有价值的工具。
Annual review of cell and developmental biology IF 12.5 2026-10 PMID: 42127136
Small proteins, known as microproteins, typically consisting of fewer than 150 amino acids, have recently emerged as a previously unrecognized class of functional proteins in biology. Advances in ribosome profiling, proteogenomics, and genome-wide functional screens have revealed that thousands of small open reading frames are actively translated, producing microproteins, some of which regulate essential processes in metabolism, immunity, cancer, and neurodegeneration. These discoveries have challenged long-held assumptions that gene function is confined to large, conserved proteins and have underscored microproteins as critical modulators. Dysregulation or mutation of small open reading frame-encoding microproteins contributes to a diverse range of biology, and in some cases links the noncanonical proteome to pathophysiological biology. In this review, we summarize current knowledge of microprotein discovery and function, describe key examples connecting microproteins to human disease, and discuss the opportunities and challenges that define this rapidly evolving field.
中文摘要:小蛋白,即微蛋白,通常由少于150个氨基酸组成,近年来作为生物学中一类此前未被认识的功能蛋白而出现。核糖体图谱分析、蛋白质基因组学和全基因组功能筛选的进展揭示,数千个短开放阅读框被积极翻译,产生微蛋白,其中一些调控代谢、免疫、癌症和神经退行性变中的基本过程。这些发现挑战了长期存在的假设,即基因功能仅限于大型、保守的蛋白质,并强调微蛋白是关键的调节因子。短开放阅读框编码的微蛋白失调或突变促成多种生物学过程,在某些情况下将非经典蛋白质组与病理生理学联系起来。在这篇综述中,我们总结目前关于微蛋白发现和功能的知识,描述将微蛋白与人类疾病联系起来的关键例子,并讨论界定这一快速发展的领域的机遇和挑战。
Cancer discovery IF 29.5 2026-10-01 PMID: 42126225
Muscle-invasive bladder cancer (MIBC) is clinically heterogeneous, and current molecular subtyping does not capture the spatial organization of tumor states and microenvironmental context. In this study, we construct a spatial atlas of MIBC by integrating spatial transcriptomics from 22 tumors with matched bulk RNA and whole-exome sequencing data. We identify a continuous, spatially organized luminal-to-basal axis within individual tumors that is associated with greater chromosomal instability and transcriptional plasticity. Luminal tumor cores are enriched for FGFR3 and NECTIN4, whereas basal-like states localize toward invasive margins and are associated with elevated EGFR signaling, epithelial-mesenchymal transition, genomic instability, immune infiltration, and greater chemotherapy sensitivity. Spatial analyses further reveal lineage- and location-associated differences in tertiary lymphoid structure states. Pan-cohort analyses across more than 3,000 tumors confirm conserved FGFR3-EGFR lineage exclusivity and associated immune programs. Together, these findings define a spatial framework for understanding lineage states, immune architecture, and therapeutic vulnerabilities in MIBC. MIBC is clinically heterogeneous, yet current classification lacks spatial context for therapeutic guidance. This study establishes a spatial framework linking luminal and basal lineage states to distinct immune phenotypes and therapeutic vulnerabilities, providing a foundation for biomarker development and more precise, spatially informed, lineage-guided treatment strategies.
中文摘要:肌层浸润性膀胱癌(MIBC)在临床上具有异质性,当前的分子分型未能捕捉肿瘤状态与微环境背景的空间组织。本研究通过整合22个肿瘤的空间转录组学数据与匹配的批量RNA及全外显子组测序数据,构建了MIBC的空间图谱。我们在单个肿瘤内识别出一条连续的、空间组织的管腔样至基底样轴,该轴与更高的染色体不稳定性和转录可塑性相关。管腔样肿瘤核心富含FGFR3和NECTIN4,而基底样状态定位于侵袭边缘,并与EGFR信号升高、上皮-间质转化、基因组不稳定性、免疫浸润以及更高的化疗敏感性相关。空间分析进一步揭示了三级淋巴结构状态中与谱系和位置相关的差异。跨超过3000个肿瘤的泛队列分析证实了保守的FGFR3-EGFR谱系互斥性及相关免疫程序。总之,这些发现为理解MIBC中的谱系状态、免疫结构和治疗脆弱性定义了一个空间框架。MIBC在临床上具有异质性,但当前分类缺乏用于治疗指导的空间背景。本研究建立了一个空间框架,将管腔样和基底样谱系状态与不同的免疫表型及治疗脆弱性联系起来,为生物标志物开发以及更精确、具有空间信息、由谱系指导的治疗策略提供了基础。
Bioactive materials IF 23.6 2026-10 PMID: 42093838
Glioblastoma (GBM) currently still faces the challenges of limited chemotherapy efficacy and high risk of postoperative recurrence, despite the implementation of multimodal treatment approaches. Glioblastoma stem cells (GSCs), characterized by multidirectional differentiation and potent tumorigenic potential, represent the "tumor seeds" contributing to these challenges. The therapeutic bottleneck for GSCs lies in the lack of drugs and treatment strategies that can simultaneously cross the blood-brain barrier (BBB) and target GSCs. In this study, we modified Fe3+ onto the surface of red blood cell nanovesicles (RNVs) to hijack transferrin (Tf) in the blood. The hijacked Tf recognizes Tf receptors highly expressed on brain microvascular endothelial cells and GSCs, thereby simultaneously enabling nanovesicle crossing of the BBB and targeting of GSCs. Fe3+ interacts with endogenous Fe2+ released from hemoglobin in RNVs to create a feedback loop that amplifies ferroptosis effects, enhancing the chemotherapeutic efficacy of temozolomide against GSCs. This Tf-hijacking nanovesicle enables GSC tumoricidal treatment and provides a novel approach for GBM postoperative recurrence inhibition.
中文摘要:胶质母细胞瘤(GBM)尽管已采用多模式治疗,目前仍面临化疗疗效有限和术后复发风险高的挑战。胶质母细胞瘤干细胞(GSCs)具有多向分化和强致瘤潜能,是导致上述挑战的「肿瘤种子」。GSCs的治疗瓶颈在于缺乏能够同时跨越血脑屏障(BBB)并靶向GSCs的药物和治疗策略。在本研究中,我们将Fe3+修饰到红细胞纳米囊泡(RNVs)表面,以劫持血液中的转铁蛋白(Tf)。被劫持的Tf可识别脑微血管内皮细胞和GSCs上高表达的Tf受体,从而同时使纳米囊泡跨越BBB并靶向GSCs。Fe3+与RNVs中血红蛋白释放的内源性Fe2+相互作用,形成反馈环路以放大铁死亡效应,增强替莫唑胺对GSCs的化疗疗效。这种劫持Tf的纳米囊泡能够实现对GSCs的杀瘤治疗,并为抑制GBM术后复发提供了一种新方法。
Cancer discovery IF 29.5 2026-10-01 PMID: 42059863
Developing chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) has been challenging due to a lack of known AML-associated antigens that spare normal hematopoietic precursor cells. In this study, we reasoned that donor autoantibodies from AML recipients cured following allogeneic transplant and responsible for the graft-versus-leukemia effect could be engineered to create effective CAR T cells. We generated CAR T cells against one such antigen-U5 snRNP200, an RNA helicase localized to the AML cell surface and absent from normal hematopoietic precursors. Anti-U5 snRNP200 CAR T cells were effective in human and syngeneic models of AML as well as B-cell acute lymphoblastic leukemia, a setting where surface U5 snRNP200 is also present. Armoring CAR T cells with IL-18 led to antigen gain on AML, durable remission, and protection from AML rechallenge. These data thereby identify a CAR T-cell platform that addresses prior limitations in tumor selectivity and safety for patients with acute leukemias. A major hurdle in developing cell therapies for patients with AML has been that there are few antigens that discriminate AML from vital normal hematopoiesis. In this study, we harnessed alloantibodies from patients with AML who were cured following allotransplant targeting a cell surface RNA-binding protein to create an effective cell therapy for acute leukemias.
中文摘要:开发用于急性髓系白血病(AML)的嵌合抗原受体(CAR)T细胞一直具有挑战性,因为缺乏已知的AML相关抗原能够不损伤正常造血前体细胞。在本研究中,我们推测,来自异基因移植后治愈且与移植物抗白血病效应相关的AML受者的供者自身抗体,可被工程化改造以创建有效的CAR T细胞。我们针对这样一种抗原——U5 snRNP200——生成了CAR T细胞;U5 snRNP200是一种RNA解旋酶,定位于AML细胞表面,而在正常造血前体细胞中缺失。抗U5 snRNP200 CAR T细胞在AML的人源和同基因模型中有效,在B细胞急性淋巴细胞白血病中也有效,后者同样存在表面U5 snRNP200。用IL-18武装CAR T细胞导致AML中抗原增加、持久缓解,并防止AML再攻击。这些数据由此确定了一个CAR T细胞平台,可解决急性白血病患者在肿瘤选择性和安全性方面的既往局限。为AML患者开发细胞疗法的一个主要障碍是,很少有抗原能将AML与重要的正常造血区分开来。在本研究中,我们利用来自异基因移植后治愈的AML患者的同种抗体,靶向一种细胞表面RNA结合蛋白,以创建针对急性白血病的有效细胞疗法。
Nature protocols IF 18.4 2026-10 PMID: 42045563
Mapping complex biological systems and tracking disease progression at high resolution across the entire mammalian body has remained technically challenging. Here, to address this, we present wildDISCO (immunolabeling of wild-type mice and DISCO clearing), a comprehensive protocol for whole-body immunolabeling, optical clearing and imaging of mice at cellular resolution using standard IgG antibodies. This protocol optimizes tissue permeabilization using cyclodextrin as a potent enhancer of cholesterol extraction and membrane permeabilization, enabling deep antibody penetration across all organs. We detail procedures for sample preparation, tissue decolorization and decalcification, whole-body immunostaining, clearing, and subsequent 3D imaging, virtual reality visualization and whole-mouse atlas construction. The method allows comprehensive mapping of neuronal, vascular, lymphatic and immune systems, as well as systemic studies in disease models, including cancer and microbiome-host interaction studies. We anticipate that wildDISCO will serve as a broadly applicable platform for generating whole-body cellular atlases, enabling systems-level investigations of health and disease. Only standard immunohistochemistry facilities are required, but successful implementation may require initial technical training, particularly for researchers with limited prior experience in tissue clearing or 3D imaging workflows. From start to finish, the procedure takes 4 weeks.
中文摘要:在哺乳动物全身范围内以高分辨率绘制复杂生物系统并追踪疾病进展一直存在技术挑战。为此,我们在此提出wildDISCO(野生型小鼠免疫标记与DISCO透明化),这是一种使用标准IgG抗体对小鼠进行全身免疫标记、光学透明化和细胞分辨率成像的综合方案。该方案利用环糊精作为胆固醇去除和膜透化的强效增强剂来优化组织透化,从而使抗体能够深入渗透至所有器官。我们详细介绍了样本制备、组织脱色和脱钙、全身免疫染色、透明化以及后续3D成像、虚拟现实可视化和全鼠图谱构建的流程。该方法能够全面绘制神经元、血管、淋巴和免疫系统,并可用于疾病模型的系统性研究,包括癌症和微生物组-宿主相互作用研究。我们预期wildDISCO将作为一个广泛适用的平台,用于生成全身细胞图谱,从而实现对健康和疾病的系统级研究。仅需标准免疫组织化学设施,但成功实施可能需要初始技术培训,尤其是对于在组织透明化或3D成像工作流程方面经验有限的研究人员。从开始到结束,该流程需要4周。
Biomaterials IF 13.6 2026-10 PMID: 42033989
The clinical translation of nucleic acid delivery systems demands the development of vectors that are not only efficient but also amenable to scalable production and safe for high-dose administration. Herein, we report a quaternary ammonium chitosan derivative (QCS)​ synthesized via a straightforward and scalable​ one-step amine-epoxy ring-opening reaction. This modification enhanced QCS's water solubility, DNA condensation capability and proton buffering capacity, facilitating efficient endo/lysosome escape. The optimal QCS3 formulation achieved transfection efficiency comparable to polyethyleneimine (PEI) but with dramatically reduced cytotoxicity and exceptional hemocompatibility. This superior safety profile enabled high-dose intravenous gene delivery, a regime severely limited by the toxicity of standard cationic polymers like PEI. ​In tumor-bearing mice, QCS3-mediated delivery of high-dose p53 plasmid effectively suppressed tumor growth, outperforming PEI, which was constrained to low, sub-therapeutic doses. Furthermore, leveraging the same QCS3 platform without modification, delivery of a plasmid encoding growth factor in a rat skin-defect model accelerated wound healing through robust endogenous factor expression. This work highlights QCS as a safe, efficient, and multifunctional gene delivery platform​ with high clinical potential for diverse applications.
中文摘要:核酸递送系统的临床转化要求开发不仅高效,而且适合规模化生产并可安全用于高剂量给药的载体。在此,我们报道了一种通过简便且可规模化的胺-环氧开环一步反应合成的季铵化壳聚糖衍生物(QCS)。该修饰增强了QCS的水溶性、DNA凝聚能力和质子缓冲能力,促进了高效的内体/溶酶体逃逸。最优的QCS3制剂实现了与聚乙烯亚胺(PEI)相当的转染效率,但细胞毒性显著降低,且具有优异的血液相容性。这种更优的安全性使其能够进行高剂量静脉基因递送,而该方案此前因PEI等标准阳离子聚合物的毒性而受到严重限制。在荷瘤小鼠中,QCS3介导的高剂量p53质粒递送有效抑制了肿瘤生长,优于仅能使用低剂量、亚治疗剂量的PEI。此外,无需进一步修饰,利用同一QCS3平台在大鼠皮肤缺损模型中递送编码生长因子的质粒,可通过强烈的内源性因子表达加速伤口愈合。这项工作凸显了QCS作为一种安全、高效且多功能的基因递送平台,在多种应用中具有很高的临床潜力。
Biomaterials IF 13.6 2026-10 PMID: 42033988
Rational design of nanocarriers as specific multidrug co-delivery systems to overcome the complex disease microenvironment still remains a critical challenge in precision nanomedicine. In this study, using dicarboxyl-functionalized indocyanine green (Bis-COOH-ICG) as an auxiliary ligand coordinated with Zr6 clusters, a defect-engineered and functionalized metal-organic framework (Fun-MOF) with hierarchically micro/mesoporous architectures was successfully developed for tumor photothermal/photodynamic combination therapy (PTT/PDT) as well as photoacoustic/fluorescence dual-modal imaging (PAI/FI). And, the hierarchical Fun-MOF enables efficient co-encapsulation of HSP90 inhibitor 17-AAG and catalase (CAT), thus receiving potent antitumor therapy by inhibiting HSP90 overexpression and scavenging hydrogen peroxide to remodel the hypoxic tumor microenvironment. Additionally, owing to the robust coordination chemistry between Zr6 clusters and carboxyl groups, the defective Fun-MOF also can incorporate other carboxyl-containing small-molecule therapeutics during MOF preparation, making it a universal platform for diverse theranostic applications.
中文摘要:合理设计作为特定多药共递送系统的纳米载体以克服复杂疾病微环境,仍是精准纳米医学中的关键挑战。本研究以二羧基功能化吲哚菁绿(Bis-COOH-ICG)作为辅助配体与Zr6簇配位,成功构建了一种具有分级微孔/介孔结构的缺陷工程化功能化金属有机框架(Fun-MOF),用于肿瘤光热/光动力联合治疗(PTT/PDT)以及光声/荧光双模态成像(PAI/FI)。该分级Fun-MOF能够高效共包封HSP90抑制剂17-AAG和过氧化氢酶(CAT),从而通过抑制HSP90过表达和清除过氧化氢以重塑缺氧肿瘤微环境,实现强效抗肿瘤治疗。此外,由于Zr6簇与羧基之间稳健的配位化学作用,该缺陷型Fun-MOF还可在MOF制备过程中纳入其他含羧基小分子治疗药物,使其成为适用于多种诊疗一体化应用的通用平台。
Biomaterials IF 13.6 2026-10 PMID: 42025046
Two-dimensional (2D) metal-organic framework (MOF) nanosheets have emerged as a promising class of functional materials. Nevertheless, the fabrication of MOF nanosheets with well-defined uniformity and ultrathin thickness via traditional synthetic strategies still remains a great challenge. Herein, we report that ultrasonic treatment plays a crucial regulatory role in the bottom-up assembly of MOF nanosheets. This innovative synthetic protocol enables the precise preparation of Co-Mn-TCPP nanosheets with a uniform thickness of ∼1.82 nm. Notably, the as-synthesized Co-Mn-TCPP nanosheets exhibit an ultrahigh longitudinal relaxivity (r1) of 12.05 mM-1s-1. A combination of theoretical calculations and experimental characterizations reveals that the exceptional relaxivity of Co-Mn-TCPP nanosheets stems predominantly from their unique 2D square lattice structure, which imposes a strong restriction on molecular motion and thus prolongs the rotational correlation time (τᵣ). Furthermore, this single-unit-cell 2D MOF demonstrates remarkable magnetic resonance imaging (MRI) contrast enhancement efficacy across multiple tumor models. More importantly, it can effectively assist in MRI-guided precise resection of small tumors. This work not only showcases the great versatility of ultrasound as a powerful tool for the synthesis of high-quality MOF nanosheets but also provides a new strategy for the design of high-relaxivity MRI contrast agents by capitalizing on specific 2D topological features.
中文摘要:二维(2D)金属有机框架(MOF)纳米片已成为一类前景广阔的功能材料。然而,通过传统合成策略制备具有良好均匀性和超薄厚度的MOF纳米片仍然是一项巨大挑战。在此,我们报道超声处理在MOF纳米片的自下而上组装过程中发挥着关键的调控作用。这一创新性合成方案能够精确制备厚度均匀约为1.82 nm的Co-Mn-TCPP纳米片。值得注意的是,所合成的Co-Mn-TCPP纳米片表现出高达12.05 mM-1s-1的超高纵向弛豫率(r1)。理论计算与实验表征相结合表明,Co-Mn-TCPP纳米片优异的弛豫率主要源于其独特的二维正方形晶格结构,该结构对分子运动产生强烈限制,从而延长旋转相关时间(τᵣ)。此外,这种单晶胞二维MOF在多种肿瘤模型中均表现出显著的磁共振成像(MRI)对比增强效果。更重要的是,它能够有效辅助MRI引导下小肿瘤的精准切除。这项工作不仅展示了超声作为合成高质量MOF纳米片的强大工具所具有的广泛适用性,也提供了一种利用特定二维拓扑特征设计高弛豫率MRI造影剂的新策略。
Biomaterials IF 13.6 2026-10 PMID: 41990418
Acute myeloid leukemia (AML) is an aggressive bone marrow disease, characterized by increased levels of bone morphogenetic proteins (BMPs). In this study, the impact of the BMP-enriched leukemia environment was determined on surrounding cells, notably mesenchymal stem cells (MSC). BMP-2, 4, 7, 9, and TGFβ1 were presented via a biomimetic extracellular matrix to healthy and AML-MSC. We have previously shown the existence of a bidirectional cross-talk between BMP receptors and integrins, which tightly connect cell adhesion to cell differentiation. In this study, we investigated how BMPRs and integrins are regulated in the AML microenvironment, in particular in the context of MSC adhesion and differentiation. Smad phosphorylation and cell adhesive responses were assessed for MSC cultured on biomimetic materials with matrix-bound BMPs/TGFβ1 using a recently-developed high-content immunofluorescence method. The specific role of BMP receptors and of integrin beta chains in the activation of pSmad signal, cell adhesion and cell spreading was studied using silencing RNA. 33% of the AML-MSCs exhibited increased receptor levels, with higher variability for BMPR2, β1 and β5 receptors. Notably, AML-MSC exhibited an upregulated and sustained pSmad signaling, associated to ALK5, ALK6 and BMPR2 dysfunctions. AML-MSC adhesion was strongly impaired, associated with a loss of cooperation between BMPR and β integrins. Unexpectedly, β integrins inhibited AML-MSC adhesion, while BMPRI receptors promoted it, notably ALK5. Furthermore, we proved that MSCs from AML patients exhibit an impaired differentiation into osteogenic, chondrogenic and adipogenic lineage. For the first time, we proved here that MSCs present in the AML microenvironment present an altered adhesion and differentiation, due to an altered cross-talk between BMPRs and integrins. This paves the way for future therapeutic strategies taking into account ALK5 and integrin beta chains in AML disease.
中文摘要:急性髓系白血病(AML)是一种侵袭性骨髓疾病,其特征是骨形态发生蛋白(BMP)水平升高。本研究确定了富含BMP的白血病环境对周围细胞,尤其是间充质干细胞(MSC)的影响。BMP-2、4、7、9和TGFβ1通过仿生细胞外基质呈递给健康MSC和AML-MSC。我们此前已证明BMP受体与整合素之间存在双向对话,这种对话将细胞黏附与细胞分化紧密联系起来。在本研究中,我们探讨了AML微环境中BMPR和整合素如何受到调控,特别是在MSC黏附和分化背景下。使用最近开发的高内涵免疫荧光方法,评估了在具有基质结合BMP/TGFβ1的仿生材料上培养的MSC的Smad磷酸化和细胞黏附反应。使用沉默RNA研究了BMP受体和整合素β链在pSmad信号激活、细胞黏附和细胞铺展中的特定作用。33%的AML-MSC表现出受体水平升高,其中BMPR2、β1和β5受体的变异性更高。值得注意的是,AML-MSC表现出上调且持续的pSmad信号,与ALK5、ALK6和BMPR2功能障碍相关。AML-MSC黏附受到严重损害,与BMPR和β整合素之间协同作用丧失相关。出乎意料的是,β整合素抑制AML-MSC黏附,而BMPRI受体促进黏附,尤其是ALK5。此外,我们证明AML患者的MSC向成骨、软骨和脂肪谱系分化受损。我们在此首次证明,AML微环境中的MSC由于BMPR与整合素之间的对话异常而表现出黏附和分化改变。这为未来在AML疾病中考虑ALK5和整合素β链的治疗策略开辟了道路。
Biomaterials IF 13.6 2026-10 PMID: 41962274
Calcium ions (Ca2+) serve as a pivotal intracellular second messenger, participating in core physiological processes including cell proliferation, neurotransmission, and apoptosis. The maintenance of calcium homeostasis depends on the precise interplay of plasma membrane channels and intracellular organelle stores. Dysregulation of calcium signaling is implicated in the pathogenesis of multiple diseases, including Alzheimer's disease, cancer, and cardiovascular disorders. Conventional pharmacological interventions are limited by off-target effects, insufficient bioavailability, and a lack of temporal and spatial control. Ca2+-regulated nanoplatform achieves spatiotemporally controlled drug release and responsive calcium level modulation through advanced surface engineering and stimulus-responsive design, substantially improving therapeutic precision and efficacy. Furthermore, nanoprobes permit real-time monitoring of calcium dynamics with high sensitivity and resolution. This comprehensive review systematically summarizes and highlights significant advances in engineering versatile nanoplatforms for calcium homeostasis modulation, focusing on constructed nanocarriers for drug delivery, functional nano-regulators for calcium flux intervention, and sensitive nanoprobes for real-time calcium imaging and quantification. Current challenges and future directions are also discussed to inspire the development of next-generation nanotheranostic platforms for precise diagnosis and treatment of calcium homeostasis-related diseases.
中文摘要:钙离子(Ca2+)作为关键的细胞内第二信使,参与细胞增殖、神经传递和凋亡等核心生理过程。钙稳态的维持依赖于质膜通道与细胞内细胞器储存之间的精确相互作用。钙信号失调与多种疾病的发病机制有关,包括阿尔茨海默病、癌症和心血管疾病。传统药物干预受到脱靶效应、生物利用度不足以及缺乏时间和空间控制的限制。Ca2+调控纳米平台通过先进的表面工程和刺激响应设计,实现时空可控的药物释放和响应性钙水平调节,显著提高治疗精准度和疗效。此外,纳米探针能够以高灵敏度和高分辨率实时监测钙动态。这篇综合性综述系统总结并强调了工程化多功能纳米平台用于钙稳态调控的重要进展,重点关注用于药物递送的构建纳米载体、用于钙流干预的功能性纳米调节剂,以及用于实时钙成像和定量的灵敏纳米探针。文中还讨论了当前挑战和未来方向,以启发用于钙稳态相关疾病精准诊断和治疗的下一代纳米诊疗平台的发展。
Biomaterials IF 13.6 2026-10 PMID: 41946315
Nanoparticle (NP)-based cancer vaccine therapies conventionally incorporate tumor-associated antigens or neoantigens that are major histocompatibility complex (MHC) class I-restricted, an approach that educates cytotoxic CD8+ T cells to respond to tumors. Helper CD4+ T cells can support CD8+ T cell-mediated responses and are activated by MHC class II-presented peptides. However, strategies to deliver MHC class I and II antigens using NPs as vehicles have not been systematically examined for anti-cancer immunity. In melanoma and colon carcinoma murine models, we evaluated the effects of transporting MHC class I and class II antigens using different NP-based approaches, with the NPs being within the optimal size range for uptake by antigen-presenting dendritic cells. We found that co-delivering MHC class I and II peptides on dual-antigen NPs increased proliferation of cytotoxic and helper T cells relative to single-antigen NPs alone (i.e., either MHC class I or II peptide on a NP) and to mixtures of the single-antigen NPs. For both tumor models, dual-antigen NPs also elicited higher antigen-specific Th1 responses, including up to 8-fold higher interferon (IFN)-γ secretion. Significantly, immunization with the dual-antigen NPs prolonged survival, with 40% of melanoma- and 71% of colon carcinoma-bearing mice surviving, compared to 0% and 13%, respectively, of those treated with component- and dose-equivalent mixtures of single-antigen NPs. This highlights the importance of the antigen delivery strategy and locale with respect to the NP, with the simultaneous co-delivery of both MHC class I and II antigens on the same NP being critical for anti-tumor potency.
中文摘要:基于纳米颗粒(NP)的癌症疫苗疗法通常纳入受主要组织相容性复合体(MHC)I类限制的肿瘤相关抗原或新抗原,这一方法可教育细胞毒性CD8+ T细胞对肿瘤产生应答。辅助性CD4+ T细胞可支持CD8+ T细胞介导的应答,并由MHC II类呈递的肽激活。然而,利用NP作为载体递送MHC I类和II类抗原的策略尚未在抗肿瘤免疫中被系统研究。在黑色素瘤和结肠癌小鼠模型中,我们评估了采用不同基于NP的方法递送MHC I类和II类抗原的效果,所用NP的尺寸处于被抗原呈递树突状细胞摄取的最佳范围内。我们发现,与单独的单抗原NP(即NP上仅含MHC I类或II类肽)以及单抗原NP的混合物相比,在双抗原NP上共递送MHC I类和II类肽可增加细胞毒性T细胞和辅助性T细胞的增殖。对于两种肿瘤模型,双抗原NP还引发更高的抗原特异性Th1应答,包括干扰素(IFN)-γ分泌高达8倍的增加。重要的是,用双抗原NP免疫可延长生存期,黑色素瘤和结肠癌荷瘤小鼠的存活率分别为40%和71%,而接受组分和剂量等同的单抗原NP混合物治疗者分别为0%和13%。这突显了抗原递送策略以及抗原相对于NP的位置的重要性,其中在同一NP上同时共递送MHC I类和II类抗原对抗肿瘤效力至关重要。
Biomaterials IF 13.6 2026-10 PMID: 41934818
Non-alcoholic fatty liver disease (NAFLD) is an obesity or drug injury-induced chronic disease characterized by abnormal lipid deposition in the liver. For drug-induced non-obese NAFLD patients, timely theranostic intervention is crucial to prevent progression towards liver cancer. An intrinsically fluorescent anti-NAFLD drug with hepatic fat-targeting capability could provide an integrated theranostic solution to enable simultaneous diagnosis, treatment, and real-time efficacy monitoring in NAFLD patients. Herein, we developed a nanodrug-LIGHT (lipid droplet-guiding and hepatotropic targeting) with high affinity for intracellular lipid droplets and rapid hepatotropic accumulation following intravenous administration. LIGHT reduced lipid deposition in free fatty acids (FFAs)-induced steatosis hepatocyte model. For NAFLD mice model, LIGHT enabled real-time monitoring of the lesion site changes accompanied by restoring fatty liver to normal morphology and function. The integrated strategy of "target-image-therapy" simplifies theranostic operation and improves the efficacy in NAFLD treatment.
中文摘要:非酒精性脂肪性肝病(NAFLD)是一种由肥胖或药物损伤诱导的慢性疾病,以肝脏脂质异常沉积为特征。对于药物诱导的非肥胖NAFLD患者,及时进行诊疗一体化干预对于防止向肝癌进展至关重要。一种具有肝内脂肪靶向能力且本身具有荧光的抗NAFLD药物,可提供整合式诊疗一体化方案,从而实现对NAFLD患者的同步诊断、治疗和实时疗效监测。在此,我们开发了一种纳米药物LIGHT(脂滴引导和肝趋向靶向),其对细胞内脂滴具有高亲和力,并在静脉给药后快速在肝脏趋向性蓄积。LIGHT减少了游离脂肪酸(FFAs)诱导的脂肪变性肝细胞模型中的脂质沉积。在NAFLD小鼠模型中,LIGHT能够实时监测病变部位变化,同时使脂肪肝恢复正常形态和功能。「靶向-成像-治疗」的整合策略简化了诊疗一体化操作并提高了NAFLD治疗疗效。
Trends in biotechnology IF 16.6 2026-10 PMID: 41820175
Engineering bacteria as cancer therapeutics is gaining mounting attention due to the remarkable success in recent preclinical studies against several solid tumor models. Among the bacteria used, Salmonella stands out due to its inherent tumor localization ability, potential to activate the immune system, and ability to cause tumor regression, while having an easily editable genetic system. Here, we gather information on the mechanisms that enable Salmonella to stimulate the immune system and exert antitumor effects. We also address the genetic manipulation approaches adopted to reduce virulence, enhance tumor colonization, and equip Salmonella with the ability to deliver immunotherapeutic payloads, along with recent advances made in tumor metabolome rewiring. Finally, we propose the challenges associated with bacteria-based cancer therapy.
中文摘要:由于在针对若干实体瘤模型的临床前研究中取得了显著成功,将细菌工程化为癌症治疗手段正受到越来越多的关注。在所用的细菌中,沙门氏菌因其固有的肿瘤定位能力、激活免疫系统的潜力以及引起肿瘤消退的能力而脱颖而出,同时其遗传系统易于编辑。在此,我们汇集了关于沙门氏菌能够刺激免疫系统并发挥抗肿瘤作用的机制的信息。我们还讨论了为降低毒力、增强肿瘤定植以及使沙门氏菌具备递送免疫治疗有效载荷能力而采用的基因操作方法,并介绍了在肿瘤代谢组重编程方面取得的最新进展。最后,我们提出了基于细菌的癌症治疗所面临的挑战。
Nature chemical biology IF 15.8 2026-10 PMID: 41714721
Chimeric antigen receptor (CAR) T cell therapy is constrained by on-target, off-tumor toxicities and cellular exhaustion because of chronic antigen exposure. CARs incorporating small-molecule controlled on- and off-switches can enhance both safety and therapeutic efficacy but their design is limited by the scarcity of nonimmunogenic protein elements responsive to nonimmunosuppressive, clinically approved drugs with favorable pharmacodynamics. Here we combine rational design and library-based optimization of a protein-protein interaction (PPI) of human origin to develop venetoclax-controlled drug-regulated off-switch PPI (DROP)-CARs. DROP-CARs enable dose-dependent release of the tumor-targeting scFv and consequent reduction in T cell binding to the tumor cell. Additionally, we present proof of concept for a dual DROP-CAR controlled by different small molecules, as well as for logic-gated synthetic receptors enabling STAT3 signaling. We demonstrate in vitro and in vivo function of DROP-CAR T cells and conclude that the approach holds promise for clinical application.
中文摘要:嵌合抗原受体(CAR)T细胞治疗受到在靶、脱瘤毒性以及因慢性抗原暴露导致的细胞耗竭的限制。整合小分子控制的开启和关闭开关的CAR可提高安全性和治疗效力,但其设计受到缺乏非免疫原性蛋白元件的限制,这些元件需能响应具有良好药代动力学的非免疫抑制性、临床获批药物。在此,我们结合理性设计和基于文库的优化,针对一种人源蛋白质-蛋白质相互作用(PPI),开发了维奈克拉控制的药物调节关闭开关PPI(DROP)-CAR。DROP-CAR能够剂量依赖性地释放肿瘤靶向scFv,并因此减少T细胞与肿瘤细胞的结合。此外,我们提出了由不同小分子控制的双重DROP-CAR的概念验证,以及可实现STAT3信号传导的逻辑门控合成受体的概念验证。我们展示了DROP-CAR T细胞的体外和体内功能,并得出结论:该方法有望用于临床应用。
Journal of advanced research IF 17.1 2026-10 PMID: 41558606
Ovarian cancer (OC) is a leading cause of gynecologic cancer-related mortality, primarily due to frequent therapy resistance and disease recurrence. Growing evidence indicates that metabolic reprogramming serves as a critical adaptive mechanism, allowing cancer cells to survive therapeutic stress. This review aims to decode the interplay between nutrient adaptation and therapy resistance in OC. It examines how alterations in key metabolic pathways contribute to treatment resilience and disease progression, and explores the potential of targeting metabolic vulnerabilities to improve therapeutic outcomes. We discuss how OC cells utilize metabolic pathways-including glycolysis, OXPHOS, glutamine metabolism, and lipid utilization-to promote survival, DNA repair, and immune evasion. Metabolic plasticity enables shifts between nutrient sources, driving resistance to platinum-based agents, PARP inhibitors, and anti-angiogenic therapies. These adaptations vary across subtypes, such as high-grade serous and clear cell carcinomas, and are influenced by specific mutations. Targeting metabolic enzymes-such as GLS, CPT1, OXPHOS complexes, or NAD+ synthesis-offers a promising strategic direction. Metabolic profiling may allow stratification of OC patients and pave the way for precision medicine approaches to overcome treatment resistance.
中文摘要:卵巢癌(OC)是妇科癌症相关死亡的主要原因,主要归因于频繁的治疗耐药和疾病复发。越来越多证据表明,代谢重编程是关键适应性机制,使癌细胞能够在治疗应激下存活。本综述旨在解析OC中营养适应与治疗耐药之间的相互作用。文章审视关键代谢通路改变如何促进治疗耐受和疾病进展,并探讨靶向代谢脆弱性以改善治疗结局的潜力。我们讨论OC细胞如何利用代谢通路——包括糖酵解、OXPHOS、谷氨酰胺代谢和脂质利用——来促进存活、DNA修复和免疫逃逸。代谢可塑性使细胞能够在营养来源之间转换,从而驱动对铂类药物、PARP抑制剂和抗血管生成治疗的耐药。这些适应在不同亚型间存在差异,例如高级别浆液性和透明细胞癌,并受特定突变影响。靶向代谢酶——如GLS、CPT1、OXPHOS复合物或NAD+合成——提供了有前景的战略方向。代谢谱分析可能有助于对OC患者进行分层,并为克服治疗耐药的精准医学方法铺平道路。
Journal of advanced research IF 17.1 2026-10 PMID: 41558600
Deoxyribozyme (DNAzyme) with RNA cleavage activity, including a DNAzyme walker, has been extensively explored as the tool for cancer diagnosis and therapy due to its excellent programmability, stability, and activity. However, the precise control over the directionality and progressivity of molecular movement towards its predetermined destination remains a formidable challenge. We aim to construct a three-dimensional DNA walker capable of addressing the uncertainty of motion direction because of the deviation from the predesignated track in uniform solutions. The cleavage sequence of substrates by DNAzyme was explored through gel electrophoresis analysis . Gel electrophoresis analyses show that DNAzyme cleaves the substrates in a sequential manner and preferentially digests the ones in the shortest spatial distance regardless of their nature, indicating a distance-dependent cleavage process. Moreover, the substrate stands freely moving in a homogenous solution (not confined onto DNA scaffold) cannot be cleaved, implying that the derailment of DNAzmye walker from the tri-prism scaffold is completely circumvented. When the adjacent substrates were removed to leave the vacant sites, the cleavage order of substrates is changed, indicating that the controllability of cleavage behavior of DNAzyme is realized. DNA triangular prism-controlled DNAzyme walker circumvents the intractable derailment event and has several advantages, such as low cost, programmability, high cleavage specificity and directional controllability, showing great potential applications in biosensing, cancer, diagnosis and therapy.
中文摘要:脱氧核酶(DNAzyme)具有RNA切割活性,包括DNAzyme步行器,因其优异的可编程性、稳定性和活性,已被广泛探索作为癌症诊断和治疗的工具有。然而,对其分子运动朝向预定目的地方向性和渐进性的精确控制仍然是一项艰巨挑战。我们旨在构建一种三维DNA步行器,能够解决在均相溶液中因偏离预设轨道而导致的运动方向不确定性问题。通过凝胶电泳分析探究了DNAzyme对底物的切割序列。凝胶电泳分析表明,DNAzyme以顺序方式切割底物,并优先消化空间距离最短的底物,而不管其性质如何,表明切割过程具有距离依赖性。此外,在均相溶液中自由移动(未限制在DNA支架上)的底物不能被切割,这意味着DNAzyme步行器从三棱柱支架上脱轨的情况被完全规避。当移除相邻底物以留下空位时,底物的切割顺序发生改变,表明DNAzyme切割行为的可控性得以实现。DNA三角棱柱控制的DNAzyme步行器规避了难以处理的脱轨事件,并具有低成本、可编程性、高切割特异性和方向可控性等优点,在生物传感、癌症诊断和治疗中显示出巨大的应用潜力。
Journal of advanced research IF 17.1 2026-10 PMID: 41558599
Chimeric antigen receptor (CAR) technology represents a groundbreaking advancement in gene therapy. While CAR-T cells are approved for specific types of leukemia, the therapeutic potential of CAR-macrophages remains largely unexplored. Additionally, potentially synergistic effects between CAR-T cells and CAR-macrophages in cancer cell clearance are still elusive. This study aimed to investigate the efficiency and mechanisms of human CAR-T cells and CAR-macrophages for clearing cancer cells using co-culture experiments. We encapsulated a second generation CD19 CAR mRNA or enhanced green fluorescent protein (Egfp) encoding control mRNA into lipid nanoparticles (LNP) using different methods. We transfected human primary T cells or macrophages with these LNP and studied their CAR expression using flow cytometry or confocal microscopy. Killing and phagocytosis assays were conducted to evaluate the impact of CAR-T cells and CAR-macrophages on CD19+ NALM6 leukemia and CD19- control cells. Motility analyses of macrophages, T cells, and cancer cells were done using live-cell imaging. Activated T cells upregulated the low-density lipoprotein receptor (LDLR), resulting in higher CAR surface expression post-transfection than in non-activated T cells. CAR-T cells efficiently induced death of lymphoma cells. CAR-macrophages cleared cancer cells mainly via phagocytosis and CAR mRNA altered the expression of both M1 and M2-associated genes. Interestingly, CAR macrophages also upregulated the Signal regulatory protein alpha (SIRPA), a receptor of the CD47 ligand expressed by cancer cells, and knockdown of SIRPA by siRNA efficiently counteracted this phenomenon. We noted a decrease in the motility of macrophages, T cells, and cancer cells in co-cultures containing CAR-transfected effector cells. Co-culturing CAR-T cells with CAR-macrophages synergistically enhanced tumor cell eradication. Our findings underscore the superior cancer cell-killing capability of CAR-T cells. Additionally, CAR-macrophages play a crucial role in clearing cancer cells through phagocytosis, thereby synergistically supporting the activity of CAR-T cells.
中文摘要:嵌合抗原受体(CAR)技术代表基因治疗的一项突破性进展。虽然CAR-T细胞已被批准用于特定类型的白血病,但CAR-巨噬细胞的治疗潜力仍在很大程度上尚未被探索。此外,CAR-T细胞与CAR-巨噬细胞在清除癌细胞中的潜在协同效应仍不明确。本研究旨在通过共培养实验,探究人CAR-T细胞和CAR-巨噬细胞清除癌细胞的效率与机制。我们采用不同方法,将第二代CD19 CAR mRNA或编码增强型绿色荧光蛋白(Egfp)的对照mRNA封装到脂质纳米颗粒(LNP)中。我们用这些LNP转染人原代T细胞或巨噬细胞,并通过流式细胞术或共聚焦显微镜研究其CAR表达。我们进行了杀伤和吞噬实验,以评估CAR-T细胞和CAR-巨噬细胞对CD19+ NALM6白血病细胞及CD19-对照细胞的影响。我们使用活细胞成像对巨噬细胞、T细胞和癌细胞的运动性进行分析。活化的T细胞上调低密度脂蛋白受体(LDLR),导致转染后CAR表面表达高于未活化T细胞。CAR-T细胞有效诱导淋巴瘤细胞死亡。CAR-巨噬细胞主要通过吞噬作用清除癌细胞,并且CAR mRNA改变了M1和M2相关基因的表达。有趣的是,CAR-巨噬细胞还上调了信号调节蛋白α(SIRPA),这是癌细胞所表达CD47配体的受体,而通过siRNA敲低SIRPA可有效抵消这一现象。我们注意到,在含有CAR转染效应细胞的共培养体系中,巨噬细胞、T细胞和癌细胞的运动性降低。将CAR-T细胞与CAR-巨噬细胞共培养可协同增强肿瘤细胞清除。我们的发现强调了CAR-T细胞优越的癌细胞杀伤能力。此外,CAR-巨噬细胞通过吞噬作用在清除癌细胞中发挥关键作用,从而协同支持CAR-T细胞的活性。

2肿瘤免疫/微环境 (139篇)

临床研究 (22篇)

Journal of hematology & oncology IF 47.8 2026-10-07 PMID: 42844630
Adoptive cellular therapies (ACT) have reshaped the treatment landscape of hematologic malignancies and are increasingly being explored in solid tumors. Key approaches include chimeric antigen receptor T-cell (CAR-T) therapy, which targets tumor-associated surface antigens in an HLA-independent manner, and T-cell receptor-engineered T-cell (TCR-T) therapy, which enables recognition of intracellular tumor antigens presented by major histocompatibility complex molecules. However, the application of CAR-T and TCR-T in solid tumors remains limited by antigen heterogeneity, an immunosuppressive tumor microenvironment, manufacturing complexity, and safety concerns related to on-target/off-tumor effects and cytokine-mediated toxicities. The American Society for Clinical Oncology (ASCO) Annual Meeting is a key platform for the presentation of cutting-edge clinical data, and in this brief correspondence, we summarize the principal early-phase clinical trials with CAR-T and TCR-T for solid tumors reported at the 2026 meeting.
中文摘要:过继性细胞疗法(ACT)已经重塑了血液系统恶性肿瘤的治疗格局,并正在实体瘤中日益受到探索。关键方法包括嵌合抗原受体T细胞(CAR-T)疗法,其以不依赖HLA的方式靶向肿瘤相关表面抗原;以及T细胞受体工程化T细胞(TCR-T)疗法,其能够识别由主要组织相容性复合体分子呈递的胞内肿瘤抗原。然而,CAR-T和TCR-T在实体瘤中的应用仍受限于抗原异质性、免疫抑制性肿瘤微环境、生产复杂性,以及与靶向/脱靶效应和细胞因子介导毒性相关的安全性问题。美国临床肿瘤学会(ASCO)年会是展示前沿临床数据的重要平台,在这篇简短通讯中,我们总结了2026年年会上报道的CAR-T和TCR-T治疗实体瘤的主要早期临床试验。
Journal for immunotherapy of cancer IF 11.7 2026-10-07 PMID: 42843925
CD6 is a promising target in cancer immunotherapy, with preclinical evidence supporting its role in modulating immune responses. This warrants further investigation into current CD6-targeting treatments, which could lead to new anti-tumor therapies. However, the clinical effects of targeting CD6 in solid tumors remain unexplored. This proof-of-concept study is the first in-human evaluation of the safety and early effectiveness of anti-CD6 monoclonal antibody itolizumab in patients with advanced, highly heterogeneous solid tumors. Treatment had two phases: induction and maintenance. In induction, group A received 100 mg weekly for nine doses; group B received 200 mg biweekly for five doses. After completing induction, patients moved to maintenance 21 days later, receiving 100 mg every 21 days for up to six doses. The primary endpoint was safety; secondary objectives included disease control, survival, and exploratory molecular mechanisms and blood biomarkers. Itolizumab demonstrated a favorable safety profile, with no safety-related treatment discontinuations, no related serious adverse events, and no unexpected toxicities. In this heavily treated, non-biomarker-selected population, disease control was achieved in 25% in group A and 20% in group B, and the 1-year survival rate was 26% in group A and 15% in group B. Mechanistically, ex vivo analysis demonstrated that itolizumab downregulates CD6, increasing soluble CD6 levels and promoting a cytotoxic phenotype on CD8 and NK cells. Additionally, patient-derived peripheral blood mononuclear cells demonstrated boosted in vitro killing capacity specifically against CD318+ cancer cells. The antibody also modulates PD-1 expression in peripheral lymphocytes, promoting NK cell activity while maintaining inhibitory signals on CD8+ T cells and decreasing T helper overactivation. These findings support the dual role of itolizumab, enhancing anti-tumor responses while preventing autoimmune-like effects by reducing off-target inflammation and avoiding immune-related adverse effects associated with immune checkpoint therapies. Overall, these findings support further development of itolizumab as a rational immunomodulatory strategy with a favorable safety profile for advanced solid tumors, particularly in CD318-expressing tumors and as part of rational combination regimens. RPCEC00000444.
中文摘要:CD6是癌症免疫治疗中有前景的靶点,临床前证据支持其在调节免疫应答中的作用。这值得进一步研究当前靶向CD6的治疗,可能带来新的抗肿瘤疗法。然而,靶向CD6在实体瘤中的临床效果尚未被探索。本概念验证研究是首个在晚期、高度异质性实体瘤患者中评估抗CD6单克隆抗体itolizumab安全性和早期有效性的首次人体研究。治疗分为两个阶段:诱导期和维持期。诱导期中,A组接受100 mg每周一次,共9剂;B组接受200 mg每两周一次,共5剂。完成诱导期后,患者于21天后进入维持期,每21天接受100 mg,最多6剂。主要终点为安全性;次要目标包括疾病控制、生存以及探索性分子机制和血液生物标志物。Itolizumab表现出良好的安全性特征,未发生与安全性相关的治疗中止、相关严重不良事件或非预期毒性。在这一接受过大量治疗且未根据生物标志物选择的人群中,A组和B组的疾病控制率分别为25%和20%,1年生存率分别为26%和15%。在机制上,离体分析表明itolizumab下调CD6,增加可溶性CD6水平,并促进CD8和NK细胞的细胞毒性表型。此外,患者来源的外周血单个核细胞显示出增强的体外杀伤能力,且特异性针对CD318+癌细胞。该抗体还调节外周淋巴细胞中PD-1的表达,促进NK细胞活性,同时维持CD8+ T细胞上的抑制性信号,并减少T辅助细胞过度活化。这些发现支持itolizumab的双重作用,即在增强抗肿瘤应答的同时,通过减少脱靶炎症和避免与免疫检查点治疗相关的免疫相关不良事件来预防自身免疫样效应。总体而言,这些发现支持进一步开发itolizumab,作为一种具有良好安全性特征的合理免疫调节策略,用于晚期实体瘤,特别是CD318表达的肿瘤,并作为合理联合方案的一部分。RPCEC00000444。
Journal for immunotherapy of cancer IF 11.7 2026-10-07 PMID: 42843924
Identifying robust predictive biomarkers for immune checkpoint blockade (ICB) remains a challenge. While alternative splicing (AS) shapes tumor immunity, the lack of large-scale, consensus-based datasets constrains the characterization of ICB-specific splicing landscapes. We developed TCASIA (the Cancer Alternative Splicing Immunotherapy Atlas), harmonizing >4000 samples across 29 cohorts. A rigorous "2-out-of-4" multi-algorithm consensus framework (rMATS, MAJIQ, SUPPA2, and SplAdder) with a fuzzy matching strategy was used to establish a high-confidence AS landscape. TCASIA provides a robust toolkit linking splicing perturbations with clinical phenotypes (response, survival, and immune infiltration). Using this platform, we recapitulated the established FAS exon 6 skipping mechanism and identified IL7R exon 6 skipping as a functionally supported candidate associated with reduced CD8+ T-cell infiltration and poor survival in melanoma. TCASIA provides an analytical atlas for investigating splicing-mediated immune evasion and prioritizing isoform-specific candidates for further functional and clinical validation in the context of ICB treatment.
中文摘要:寻找免疫检查点阻断(ICB)可靠的预测性生物标志物仍然是一项挑战。尽管可变剪接(AS)塑造肿瘤免疫,但缺乏大规模、基于共识的数据集限制了对ICB特异性剪接景观的刻画。我们开发了TCASIA(癌症可变剪接免疫治疗图谱),整合了29个队列中的4000余份样本。采用严格的「2-out-of-4」多算法共识框架(rMATS、MAJIQ、SUPPA2和SplAdder)并结合模糊匹配策略,建立了高置信度的AS景观。TCASIA提供了一个稳健的工具包,将剪接扰动与临床表型(应答、生存和免疫浸润)联系起来。利用该平台,我们重现了已建立的FAS外显子6跳跃机制,并鉴定出IL7R外显子6跳跃是一个有功能支撑的候选事件,与黑色素瘤中CD8+ T细胞浸润减少和生存不良相关。TCASIA提供了一个分析图谱,用于研究剪接介导的免疫逃逸,并优先筛选异构体特异性候选,以便在ICB治疗背景下进行进一步的功能和临床验证。
Clinical and molecular hepatology IF 21.7 2026-10-07 PMID: 42843419
The treatment strategy for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial because of its the dismal prognosis. This study aimed to evaluate the safety and efficacy of immune checkpoint inhibitors (ICIs) plus molecular-targeted agents (MTA) with or without hepatic arterial infusion chemotherapy (HAIC) as a first-line treatment for HCC with PVTT. This nationwide retrospective cohort study utilized a target trial emulation framework with a clone-censor-weighting (CCW) approach and was conducted in 36 centers across China. The study population comprised patients diagnosed with HCC and PVTT who received HAIC in combination with ICIs and MTA (HAIC-ICIs-MTA) or ICIs plus MTA (ICIs-MTA) from June 2018 to December 2024. The primary endpoint was overall survival (OS), which was evaluated through restricted mean survival time (RMST) with bootstrapping. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety profiles. This study included a total of 1649 HCC patients (614 in the HAIC-ICIs-MTA group and 1035 in the ICIs-MTA group). After CCW, the median OS of the HAIC-ICIs-MTA group was 23.3 months, whereas that of the ICIs-MTA group was 16.4 months. The difference in RMST for OS was 7.4 months (95% confidence interval [CI]: 3.5-11.7, bootstrapped P<0.001). The HAIC-ICIs-MTA group also had a significantly longer median PFS (8.7 months vs. 6.2 months, bootstrapped P=0.002) with an RMST of 2.6 months (95% CI: 0.9-4.5), and a higher ORR (38.9% vs. 22.7%, P<0.001) as per the Response Evaluation Criteria in Solid Tumors Version 1.1. Grade ≥3 treatment-related adverse events occurred in 243 patients in the HAIC-ICIs-MTA group (39.6%) and 335 patients in the ICIs-MTA group (32.4%). HAIC in combination with ICIs and MTA is associated with improved survival and an acceptable safety profile compared to ICIs plus MTA alone, supporting this regimen as a promising treatment strategy for HCC patients with PVTT that warrants further prospective validation.
中文摘要:肝细胞癌(HCC)合并门静脉癌栓(PVTT)因预后极差,其治疗策略仍存在争议。本研究旨在评估免疫检查点抑制剂(ICIs)联合分子靶向药物(MTA)联合或不联合肝动脉灌注化疗(HAIC)作为HCC合并PVTT一线治疗的安全性和有效性。这项全国性回顾性队列研究采用目标试验模拟框架和克隆-删失-加权(CCW)方法,在中国36个中心开展。研究人群包括2018年6月至2024年12月期间接受HAIC联合ICIs和MTA(HAIC-ICIs-MTA)或ICIs联合MTA(ICIs-MTA)治疗的HCC合并PVTT患者。主要终点为总生存期(OS),通过限制性平均生存时间(RMST)并结合自举法进行评估。次要终点包括无进展生存期(PFS)、客观缓解率(ORR)和安全性特征。本研究共纳入1649例HCC患者(HAIC-ICIs-MTA组614例,ICIs-MTA组1035例)。经CCW后,HAIC-ICIs-MTA组的中位OS为23.3个月,而ICIs-MTA组为16.4个月。OS的RMST差异为7.4个月(95%置信区间[CI]:3.5-11.7,自举法P<0.001)。HAIC-ICIs-MTA组的中位PFS也显著更长(8.7个月 vs. 6.2个月,自举法P=0.002),RMST为2.6个月(95%CI:0.9-4.5),并且根据实体瘤疗效评价标准1.1版,ORR更高(38.9% vs. 22.7%,P<0.001)。HAIC-ICIs-MTA组有243例患者(39.6%)发生≥3级治疗相关不良事件,ICIs-MTA组有335例(32.4%)。与单用ICIs联合MTA相比,HAIC联合ICIs和MTA与生存改善及可接受的安全性特征相关,支持该方案作为HCC合并PVTT患者有前景的治疗策略,值得进一步前瞻性验证。
Gut IF 24.6 2026-10-07 PMID: 41980760
Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, with clinical progress limited by intratumoural cellular diversity and the absence of robust, informative markers. Leveraging the heterogeneity of cancer-associated fibroblasts (CAFs) within the tumour microenvironment, this study aims to identify and evaluate candidate biomarkers to support patient stratification and improve prediction of therapeutic responses. We applied a multiomic approach integrating single-cell RNA sequencing, computational cell deconvolution and protein-level assessment from patient tumours, complemented by in vitro and in vivo preclinical models, to characterise stromal populations linked to CRC progression and treatment resistance. Retrospective analysis of over 3000 patient samples across multiple cohorts identified a distinct subset of CAFs expressing collagen triple helix repeat containing 1 (CTHRC1). CTHRC1(+) CAFs were associated with increased transforming growth factor-beta (TGF-beta) signalling and poor clinical outcomes in early and advanced disease stages. CTHRC1(+) CAFs enabled stratification of both mismatch repair-deficient/microsatellite instability (dMMR/MSI) and mismatch repair-proficient/microsatellite stability (pMMR/MSS) tumours into immune-inflamed and poorly immunogenic subtypes. Retrospective analysis of several clinical trials revealed that CTHRC1(+) CAFs are linked to resistance to immune checkpoint inhibitors in MSI and MSS tumours, suggesting therapeutic potential for combining TGF-beta blockade with immunotherapy. CTHRC1-expressing CAFs represent clinically relevant biomarkers that link molecular profiling with diagnostic pathology. Our findings support the potential incorporation of CTHRC1(+) CAF assessment into routine histopathological workflows, pending prospective validation, and suggest a framework for stroma-informed CRC stratification, particularly in patients with stroma-rich, treatment-resistant tumours and pMMR/MSS with limited therapeutic options.
中文摘要:结直肠癌(CRC)仍是全球癌症死亡的主要原因之一,其临床进展受限于肿瘤内细胞多样性以及缺乏稳健且具有信息量的标志物。利用肿瘤微环境中癌症相关成纤维细胞(CAF)的异质性,本研究旨在识别并评估候选生物标志物,以支持患者分层并改善治疗反应预测。我们采用多组学方法,整合单细胞RNA测序、计算性细胞解卷积以及来自患者肿瘤的蛋白水平评估,并辅以体外和体内临床前模型,以刻画与CRC进展和治疗耐药相关的基质细胞群体。对多个队列中3000余例患者样本的回顾性分析发现,一类独特的CAF亚群表达胶原三螺旋重复序列包含蛋白1(CTHRC1)。CTHRC1(+) CAF与转化生长因子-β(TGF-β)信号增强以及早期和晚期疾病阶段的不良临床结局相关。CTHRC1(+) CAF能够将错配修复缺陷/微卫星不稳定(dMMR/MSI)和错配修复正常/微卫星稳定(pMMR/MSS)肿瘤分层为免疫炎症型和免疫原性低下亚型。对若干临床试验的回顾性分析显示,CTHRC1(+) CAF与MSI和MSS肿瘤中对免疫检查点抑制剂的耐药相关,提示将TGF-β阻断与免疫治疗联合具有治疗潜力。表达CTHRC1的CAF代表了具有临床相关性的生物标志物,将分子谱分析与诊断病理学联系起来。我们的发现支持在常规组织病理学工作流程中纳入CTHRC1(+) CAF评估的潜力(尚待前瞻性验证),并提出了一种基于基质信息的CRC分层框架,尤其适用于基质丰富、治疗耐药且治疗选择有限的pMMR/MSS患者。
Gut IF 24.6 2026-10-07 PMID: 41748160
In the past 5 years, clinical trials on immune checkpoint inhibitors (ICIs) for the treatment of locally advanced rectal cancer (LARC) have flourished globally, and China has become one of the leading regions in this field. In response to the breakthrough progress and accumulation of evidence from key clinical trials, the Chinese Society of Colorectal Surgery has recognised the need for updated consensus guidance on the development of perioperative and organ-preserving treatment strategies for LARC. This expert consensus guidance provided unified standards for the indications, medication regimens, efficacy evaluations and follow-up of ICIs in this population, with a focus mainly on perioperative management and organ-sparing strategies. The diagnostic part of this consensus guidance is based on the internationally recognised definition of mismatch repair/microsatellite instability detection and emphasises the importance of multidisciplinary teams in treatment decision-making. In terms of treatment, based on the results of key trials that have changed clinical practice in the past 5 years, this expert consensus provides graded recommendations for the duration of preoperative immunotherapy and the necessity of postoperative adjuvant therapy, local resection and organ preservation strategies. Moreover, we refined the management process for the safety of perioperative immunotherapy. This document aims to provide a reference for surgeons; internal medicine, radiation therapy, pathology and imaging physicians; patients and nursing staff involved in the treatment of LARC, as well as health policy makers.
中文摘要:过去5年,针对局部晚期直肠癌(LARC)治疗的免疫检查点抑制剂(ICIs)临床试验在全球蓬勃发展,中国已成为该领域的领先地区之一。针对关键临床试验取得的突破性进展和不断积累的证据,中华医学会外科学分会结直肠外科学组认识到有必要就LARC围手术期及器官保留治疗策略的制定更新共识指导。该专家共识指导为该人群中ICIs的适应证、用药方案、疗效评估和随访提供了统一标准,主要关注围手术期管理和器官保留策略。本共识指导的诊断部分基于国际公认的错配修复/微卫星不稳定性检测定义,并强调多学科团队在治疗决策中的重要性。在治疗方面,基于过去5年改变临床实践的关键试验结果,该专家共识对术前免疫治疗的持续时间、术后辅助治疗的必要性、局部切除和器官保留策略提供了分级推荐。此外,我们细化了围手术期免疫治疗安全性的管理流程。本文件旨在为外科医生;内科、放射治疗、病理和影像科医生;参与LARC治疗的患者和护理人员以及卫生政策制定者提供参考。
Gut IF 24.6 2026-10-07 PMID: 41667242
The gut microbiota plays a crucial role in regulating host immunity, metabolism and inflammation, with accumulating evidence linking its composition and function to the development and progression of cancers in the reproductive tract. Patients with ovarian, endometrial and cervical cancers exhibit distinct alterations in their gut microbiota, characterised by reduced microbial diversity and shifts towards taxa associated with dysbiosis and chronic inflammation. Mechanistically, gut-derived metabolites and microbial translocation appear to influence systemic immune responses and oestrogen metabolism, thereby fostering a tumour microenvironment conducive to cancer growth. Beyond its role in tumourigenesis, the gut microbiota also affects treatment outcomes. Dysbiosis can reduce sensitivity to chemotherapy and alter immunotherapy responses, while antibiotic use during cancer treatment has been linked to poorer prognosis. Clinically, these insights highlight emerging applications of microbiome modulation as biomarkers for patient stratification and as adjuvant approaches to enhance therapeutic efficacy in gynaecological oncology, underscoring the therapeutic potential of targeting the microbiota-through dietary interventions, probiotics or faecal microbiota transplantation-to improve cancer treatment outcomes. However, most of these applications remain investigational, and current evidence is limited by heterogeneity across study designs, patient cohorts and cancer subtypes. This review summarises current understanding of gut microbiota profiles in reproductive tract cancers, examines potential mechanisms by which the microbiota influences malignancy, discusses its impact on therapy response and explores its emerging role in precision oncology.
中文摘要:肠道微生物群在调节宿主免疫、代谢和炎症中发挥关键作用,越来越多的证据将其组成和功能与生殖道癌症的发生和发展联系起来。卵巢癌、子宫内膜癌和宫颈癌患者表现出独特的肠道微生物群改变,其特征是微生物多样性降低以及向与菌群失调和慢性炎症相关的类群转变。在机制上,肠道来源的代谢物和微生物易位似乎影响全身免疫反应和雌激素代谢,从而形成有利于癌症生长的肿瘤微环境。除了在肿瘤发生中的作用外,肠道微生物群还影响治疗结果。菌群失调可降低化疗敏感性并改变免疫治疗反应,而癌症治疗期间使用抗生素与较差的预后相关。在临床上,这些见解突出了微生物组调节作为患者分层生物标志物以及作为增强妇科肿瘤治疗疗效的辅助方法的新兴应用,强调了通过饮食干预、益生菌或粪菌移植靶向微生物群以改善癌症治疗结果的治疗潜力。然而,这些应用大多仍处于研究阶段,当前证据受到研究设计、患者队列和癌症亚型异质性的限制。本综述总结了目前对生殖道癌症肠道微生物群特征的理解,探讨了微生物群影响恶性肿瘤的潜在机制,讨论了其对治疗反应的影响,并探索了其在精准肿瘤学中的新兴作用。
Journal for immunotherapy of cancer IF 11.7 2026-10-05 PMID: 42833860
Immune checkpoint blockade (ICB) improved survival outcomes for patients with metastatic melanoma. Yet up to 65% of patients experience primary resistance and nearly half of initial responders acquire resistance. The clinical utility of ICB is further tempered by frequent immune-related adverse events (irAEs), which increase in severity and frequency with prolonged treatment duration. Hence, a pivotal challenge is to identify clinically accessible markers to predict durable ICB responses. While prior reports indicate that the development of cutaneous irAEs may reflect robust antitumor immune responses, there is limited evidence linking specific types of cutaneous irAEs to clinical ICB benefit. In this retrospective multicenter study, we investigated a cohort of 741 patients diagnosed with non-resectable stage III/IV melanoma who were treated with ICB between April 2012 and August 2025. Patient demographics, tumor characteristics, treatment regimens and survival outcomes were collected within six German skin cancer centers. We stratified patients by the type of cutaneous AE into such with whitening of the body skin (vitiligo), hair (poliosis) or other cutaneous AE. Primary endpoints included progression-free survival (PFS) and objective response rates (ORR). Among 741 eligible patients, 221 developed cutaneous irAE within the median follow-up period of 48 months. Thereof, we observed tumor recurrences in 17.2% of patients with poliosis, 57.7% of patients developing vitiligo and 60.0% of patients with other cutaneous irAE. In line, we detected a significantly enhanced ORR (93.1% vs 58.8% vs 38.8%, p<0.001), prolonged PFS (Not reached, NR, vs 31 months vs 9 months, p<0.001) and overall survival (NR vs NR vs 69 months, p<0.001) in poliosis patients. Critically, enhanced tumor control in poliosis patients was seen regardless of initial tumor burden, treatment duration or the presence of melanoma brain metastases. While other AE usually arise early on ICB start, poliosis was a late event that occurred at a median of 6 months. Our study identifies poliosis as a distinct and immunologically-informed marker linked to strong and durable ICB responses easily applicable in a routine clinical setting. Detection of poliosis may complement radiographic imaging for clinical decision-making on ICB treatment duration and early cessation and provides a window for translational investigations harnessing epitope-specific T-cell responses to melanoma antigens.
中文摘要:免疫检查点抑制剂(ICB)改善了转移性黑色素瘤患者的生存结局。然而,高达65%的患者出现原发性耐药,且近一半初始缓解者获得性耐药。ICB的临床效用还受到频繁免疫相关不良事件(irAE)的限制,随着治疗时间延长,irAE的严重程度和频率增加。因此,一个关键挑战是识别可临床获取的标志物以预测持久的ICB缓解。既往报道提示,皮肤irAE的发生可能反映强健的抗肿瘤免疫反应,但将特定类型皮肤irAE与ICB临床获益联系起来的证据有限。在这项回顾性多中心研究中,我们纳入2012年4月至2025年8月期间接受ICB治疗的741例诊断为不可切除III/IV期黑色素瘤患者队列。在德国六家皮肤肿瘤中心收集患者人口学资料、肿瘤特征、治疗方案和生存结局。我们按皮肤AE类型将患者分层为体表皮肤变白(白癜风)、毛发变白(白发症)或其他皮肤AE。主要终点包括无进展生存期(PFS)和客观缓解率(ORR)。在741例符合条件患者中,221例在中位48个月随访期内发生皮肤irAE。其中,我们在白发症患者中观察到17.2%肿瘤复发,白癜风患者为57.7%,其他皮肤irAE患者为60.0%。一致地,我们检测到白发症患者ORR显著提高(93.1% vs 58.8% vs 38.8%,p<0.001)、PFS延长(未达到,NR,vs 31个月 vs 9个月,p<0.001)和总生存期延长(NR vs NR vs 69个月,p<0.001)。关键的是,无论初始肿瘤负荷、治疗持续时间或黑色素瘤脑转移存在与否,白发症患者均可见增强的肿瘤控制。其他AE通常在ICB开始早期出现,而白发症是晚期事件,发生中位时间为6个月。我们的研究确定白发症是一个独特且具免疫学信息的标志物,与强烈而持久的ICB缓解相关,易于在常规临床环境中应用。检测白发症可能补充影像学检查,用于关于ICB治疗持续时间和早期停药的临床决策,并为利用黑色素瘤抗原表位特异性T细胞反应的转化研究提供窗口。
Signal transduction and targeted therapy IF 81.2 2026-10-05 PMID: 42830288
Neuroendocrine cervical carcinoma (NECC) is an aggressive and rare malignancy comprising 0.9-1.5% of cervical cancers. Its molecular basis remains poorly understood, limiting treatment options. A national multicenter cohort survival analysis showed that NECC patients had a 5.17-fold higher death risk than non-NECC patients and demonstrated broad chemotherapy resistance, which was further validated in both NECC cell lines and patient-derived organoids. To identify therapeutic targets, multi‑omics profiling of NECC tumors and matched normal adjacent tissues revealed pronounced DNA replication stress and hyperactivation of homologous recombination repair (HRR). These findings were validated in cells and patient-derived organoids using DR-GFP reporter and pRPA32 assays, suggesting that NECC may be susceptible to PARP inhibitor therapy. NECC cells exhibited moderate PARP inhibitor sensitivity, greater than that of resistant non‑NECC lines but less than that of highly sensitive A2780 cells. However, combining PARP inhibitors with cisplatin/carboplatin did not enhance efficacy, prompting the exploration of alternative combinatorial targets. Multi-omics analysis and in vitro validation identified Bloom syndrome helicase (BLM) as a key factor overexpressed in NECC that modulates PARP inhibitor sensitivity. Further in vitro and in vivo experiments confirmed that combining PARP and BLM inhibitors achieved potent anticancer effects. Mechanistically, cancer-associated fibroblasts (CAFs) infiltration in the tumor microenvironment upregulated the transcription factor E2F1 via IL6, with ChIP‒qPCR verifying that activated E2F1 directly binds the BLM promoter (hg38, chr15:90,715,346-90,717,346) to drive its expression, suppressing PARP inhibitor sensitivity. Our findings establish dual PARP and BLM inhibition as a promising therapeutic strategy for NECC by blocking HRR pathway compensation.
中文摘要:神经内分泌宫颈癌(NECC)是一种侵袭性强且罕见的恶性肿瘤,占宫颈癌的0.9-1.5%。其分子基础仍知之甚少,限制了治疗选择。一项全国多中心队列生存分析显示,NECC患者的死亡风险是非NECC患者的5.17倍,并表现出广泛的化疗耐药性,这一现象在NECC细胞系和患者来源类器官中得到了进一步验证。为了确定治疗靶点,对NECC肿瘤及匹配的癌旁正常组织进行多组学分析,揭示了显著的DNA复制压力和同源重组修复(HRR)的过度激活。这些发现通过DR-GFP报告基因和pRPA32检测在细胞和患者来源类器官中得到验证,提示NECC可能对PARP抑制剂治疗敏感。NECC细胞表现出中等的PARP抑制剂敏感性,高于耐药的非NECC细胞系,但低于高度敏感的A2780细胞。然而,将PARP抑制剂与顺铂/卡铂联合并未增强疗效,促使我们探索替代的联合靶点。多组学分析和体外验证确定Bloom综合征解旋酶(BLM)是NECC中过表达的关键因子,可调节PARP抑制剂敏感性。进一步的体外和体内实验证实,联合PARP和BLM抑制剂可产生强效抗癌作用。机制上,肿瘤微环境中癌症相关成纤维细胞(CAFs)的浸润通过IL6上调转录因子E2F1,ChIP-qPCR验证了激活的E2F1直接结合BLM启动子(hg38, chr15:90,715,346-90,717,346)以驱动其表达,从而抑制PARP抑制剂敏感性。我们的研究结果确立了双重PARP和BLM抑制通过阻断HRR通路补偿,作为NECC的一种有前景的治疗策略。
EClinicalMedicine IF 12.8 2026-10 PMID: 42830853
Tumour-agnostic immunotherapy has reshaped precision oncology by showing that treatment benefit can, in selected settings, be predicted by a shared biological state rather than anatomical origin. Microsatellite instability-high or mismatch repair-deficient cancer is the clearest example, with durable responses across diverse malignancies. By contrast, broader biomarkers show that pan-cancer applicability cannot be inferred from a measurable molecular feature alone. Tumour lineage, antigen presentation, immune microenvironment, prior therapy, and health-system context all influence whether a tumour-agnostic indication translates into real-world benefit. We examine the biological principles that distinguish robust from context-dependent immunotherapy biomarkers, the uncertainty created by rare cancers and incomplete evidence, and the implementation challenges that arise when therapeutic access outpaces biomarker infrastructure. Using Australia's broad reimbursement of immune checkpoint inhibitors for immunotherapy-sensitive advanced cancers as a case study, we consider implications for emerging pan-tumour platforms. We argue for biologically informed access embedded within learning health systems.
中文摘要:不计癌种免疫治疗已重塑精准肿瘤学,其表明在特定情况下,治疗获益可由共同的生物学状态而非解剖来源来预测。微卫星高度不稳定或错配修复缺陷癌症是最清晰的例子,在多种恶性肿瘤中均可产生持久缓解。相比之下,更广泛的生物标志物表明,泛癌适用性不能仅凭可测量的分子特征推断。肿瘤谱系、抗原呈递、免疫微环境、既往治疗及卫生系统背景均影响不计癌种适应症能否转化为真实世界获益。我们审视区分稳健与依赖情境的免疫治疗生物标志物的生物学原理、罕见癌症和不完整证据带来的不确定性,以及当治疗可及性超前于生物标志物基础设施时出现的实施挑战。以澳大利亚对免疫治疗敏感的晚期癌症广泛报销免疫检查点抑制剂作为案例研究,我们思考对新兴泛肿瘤平台的意义。我们主张将基于生物学信息的可及性嵌入学习型卫生系统之中。
EClinicalMedicine IF 12.8 2026-10 PMID: 42830785
Novel therapies are needed for advanced endometrial cancer (aEC) that recurs after chemotherapy + immunotherapy. Lenvatinib has antitumour activity in patients with aEC after platinum-based chemotherapy and is approved in combination with pembrolizumab for aEC following prior systemic therapy. E7386, an oral anticancer agent, inhibits the interaction between β-catenin and CREB-binding protein (CBP). Preliminary results of a dose expansion cohort of Study 102 (n = 16) showed manageable safety and promising antitumour activity of E7386 + lenvatinib in aEC that progressed after platinum-based chemotherapy and anti-programmed cell death (ligand) 1, including responses in patients with prior lenvatinib. We report safety and antitumour activity for this complete dose expansion cohort. In a dose expansion cohort of Study 102 (NCT04008797), patients with aEC that progressed after platinum-based chemotherapy and immunotherapy received E7386 120 mg twice daily plus lenvatinib 14 mg once daily (amended from 20 mg during enrolment). The primary endpoint was safety; secondary endpoints included objective response rate (ORR), duration of response, clinical benefit rate, and progression-free survival by investigator per RECIST v1·1). Thirty patients were enrolled; 16 (53·3%) previously received lenvatinib. By data cut-off (4 June, 2025), five (16·7%) patients had treatment ongoing. All patients experienced treatment-emergent adverse events (TEAEs), most commonly vomiting (n = 22, 73·3%). Nineteen (63·3%) patients had grade 3 TEAEs, most frequently diarrhoea (n = 4). No grade 4-5 AEs were observed. TEAEs led to withdrawal of lenvatinib and/or E7386 in two patients. Overall, 11 patients (three with prior lenvatinib) had a confirmed response (one complete, ten partial) for an ORR of 36·7% (95% CI: 19·9-56·1). In patients without prior lenvatinib (n = 14), the ORR was 57·1% (95% CI: 28·9-82·3). E7386 + lenvatinib showed promising antitumour activity with a manageable safety profile in heavily pretreated patients with aEC following platinum-based chemotherapy + immunotherapy. The dose-optimisation phase of Study 102 (E7386 + lenvatinib in patients with advanced endometrial carcinoma) is currently enrolling (NCT04008797). Eisai Inc., Nutley, NJ, USA.
中文摘要:对于在化疗加免疫治疗后复发的晚期子宫内膜癌(aEC),需要新的疗法。仑伐替尼对铂类化疗后的aEC患者具有抗肿瘤活性,并已获批与帕博利珠单抗联合用于既往接受过全身治疗的aEC。E7386是一种口服抗癌药,可抑制β-catenin与CREB结合蛋白(CBP)之间的相互作用。研究102剂量扩展队列(n=16)的初步结果显示,E7386+仑伐替尼在铂类化疗和抗程序性细胞死亡(配体)1治疗后进展的aEC中安全性可控且具有有前景的抗肿瘤活性,包括既往接受过仑伐替尼患者的缓解。我们报告该完整剂量扩展队列的安全性和抗肿瘤活性。在研究102(NCT04008797)的剂量扩展队列中,铂类化疗和免疫治疗后进展的aEC患者接受E7386 120 mg每日两次加仑伐替尼14 mg每日一次(入组期间从20 mg修订)。主要终点为安全性;次要终点包括研究者按RECIST v1·1评估的客观缓解率(ORR)、缓解持续时间、临床获益率和无进展生存期。共入组30例患者;16例(53·3%)既往接受过仑伐替尼。截至数据截止日期(2025年6月4日),5例(16·7%)患者仍在治疗中。所有患者均发生治疗中出现的不良事件(TEAE),最常见为呕吐(n=22,73·3%)。19例(63·3%)患者发生3级TEAE,最常见为腹泻(n=4)。未观察到4-5级AE。TEAE导致2例患者停用仑伐替尼和/或E7386。总体而言,11例患者(其中3例既往接受过仑伐替尼)达到确认缓解(1例完全缓解,10例部分缓解),ORR为36·7%(95% CI:19·9-56·1)。在既往未接受过仑伐替尼的患者中(n=14),ORR为57·1%(95% CI:28·9-82·3)。E7386+仑伐替尼在铂类化疗+免疫治疗后接受过多线治疗的aEC患者中显示出有前景的抗肿瘤活性,且安全性可控。研究102的剂量优化阶段(E7386+仑伐替尼治疗晚期子宫内膜癌患者)目前正在入组(NCT04008797)。日本卫材株式会社,美国新泽西州纳特利。
Nature medicine IF 52.5 2026-10-01 PMID: 42823486
Neoadjuvant immune checkpoint inhibitors (ICIs) are standard of care for resectable stage IIIB-D melanoma, but knowledge gaps remain regarding optimal treatment type, long-term survival, postsurgical management and clinical, histopathological or molecular subgroups. We analyzed 1,038 patients treated with neoadjuvant ICIs (n = 735), BRAF and MEK inhibitors (BRAF/MEKis; n = 119) or ICI plus any targeted therapy (ICI + TT; n = 184) from 26 international sites in both trial (755, 72.7%) and nontrial (283, 27.3%) settings. ICI regimens included anti-programmed cell death protein 1 (PD-1) alone (PD-1 alone; n = 242) and anti-PD-1 plus other immuno-oncology agent(s) (PD-1 + IO; n = 489). Outcomes included major pathological response (MPR), recurrence-free survival (RFS) and overall survival (OS). An MPR was achieved in 57.8% of patients with ICIs, 51.4% with BRAF/MEKis and 44.6% with ICI + TT. PD-1 + IO elicited higher MPR rates than PD-1 alone (61.4% versus 49.5%). The 5-year RFS rate was 61.0% with PD-1 alone, 73.9% with PD-1 + IO, 37.4% with BRAF/MEKis and 76.4% with ICI + TT; the 5-year OS rates were 83.3%, 87.5%, 69.8% and 83.9%, respectively. ICI-treated patients with MPR had 5-year OS rates of 98.8% with PD-1 alone and 97.9% with PD-1 + IO and gained no benefit from continuing ICIs into the adjuvant setting. Neoadjuvant ICIs were active in BRAF-mutant melanoma (MPR, 46.3%), acral melanoma (38.1%), in-transit metastases (66.7%) and oligometastases (41.2%), although subgroup sizes and relative effectiveness varied. Survival outcomes were excellent with neoadjuvant ICIs, particularly in patients achieving MPR, but poor with BRAF/MEKis and mixed with ICI + TT. Predictive biomarker-driven trials, effective adjuvant strategies and subgroup-specific research are needed for nonresponders.
中文摘要:新辅助免疫检查点抑制剂(ICIs)是可切除IIIB-D期黑色素瘤的标准治疗,但在最佳治疗类型、长期生存、术后管理以及临床、组织病理学或分子亚组方面仍存在知识空白。我们分析了来自26个国际中心的1,038例接受新辅助ICIs(n=735)、BRAF和MEK抑制剂(BRAF/MEKis;n=119)或ICI联合任何靶向治疗(ICI+TT;n=184)治疗的患者,这些患者来自临床试验(755例,72.7%)和非临床试验(283例,27.3%)环境。ICI方案包括单用抗程序性细胞死亡蛋白1(PD-1)(单用PD-1;n=242)和抗PD-1联合其他免疫肿瘤药物(PD-1+IO;n=489)。结局包括主要病理缓解(MPR)、无复发生存(RFS)和总生存(OS)。达到MPR的患者比例在ICIs组为57.8%,BRAF/MEKis组为51.4%,ICI+TT组为44.6%。PD-1+IO的MPR率高于单用PD-1(61.4%对49.5%)。5年RFS率在单用PD-1组为61.0%,PD-1+IO组为73.9%,BRAF/MEKis组为37.4%,ICI+TT组为76.4%;5年OS率分别为83.3%、87.5%、69.8%和83.9%。接受ICI治疗且达到MPR的患者中,单用PD-1的5年OS率为98.8%,PD-1+IO为97.9%,并且未从辅助治疗阶段继续使用ICIs中获益。新辅助ICIs在BRAF突变黑色素瘤(MPR,46.3%)、肢端黑色素瘤(38.1%)、移行转移(66.7%)和寡转移(41.2%)中具有活性,尽管亚组样本量和相对有效性存在差异。新辅助ICIs的生存结局极佳,尤其是在达到MPR的患者中,但BRAF/MEKis组较差,ICI+TT组结果不一。针对无应答者,需要预测性生物标志物驱动的试验、有效的辅助策略以及亚组特异性研究。
JAMA oncology IF 23.9 2026-10-01 PMID: 42821287
Despite the integration of bevacizumab and poly(ADP-ribose) polymerase inhibitors into first-line treatment of advanced high-grade serous ovarian cancer, survival remains poor for the substantial subset of patients whose tumors respond insufficiently to platinum-based chemotherapy and who, therefore, frequently do not achieve complete cytoreductive surgery (the 2 red flags population). This Review examines the rationale, current evidence, and emerging strategies for systemic treatment intensification-or chemosensitization-aimed at improving tumor response before initiating maintenance therapy. Achieving minimal residual disease before maintenance depends on 2 key determinants: surgical completeness and intrinsic tumor chemosensitivity. Pragmatic indicators of chemosensitivity-KELIM (modeled cancer antigen 125 elimination rate constant K), pathological chemotherapy response score, and radiologic response-are now cited in European Society for Medical Oncology-European Society of Gynaecological Oncology and American Society of Clinical Oncology guidelines, while BRCA/homologous recombination deficiency status may not reliably predict neoadjuvant carboplatin-paclitaxel response. Across post hoc analyses of phase 3 trials (ICON-7, GOG-0218, ICON-8, ICON-8B, VELIA, and IMagyn050), patients with poorly chemosensitive disease may have derived greater benefit from intensification strategies. Weekly dose-dense paclitaxel was associated with improved survival in the 2 red flags subgroup of ICON-8. Bevacizumab, added either to standard postoperative chemotherapy or to neoadjuvant dose-dense chemotherapy, showed signals of greater benefit on both progression-free and overall survival in high-risk and poorly chemosensitive subsets. In contrast, poly(ADP-ribose) polymerase inhibitor and immune checkpoint inhibitor combinations showed meaningful activity only in selected subgroups, supporting further evaluation of innovative DNA repair-targeting agents and immunotherapeutic approaches in these populations. Early identification of poorly chemosensitive advanced high-grade serous ovarian cancer enables a response-adapted first-line strategy in which treatment intensification is selectively offered to patients most likely to benefit-an approach now being prospectively evaluated in the phase 3 SALVOVAR and phase 1/2 RegeNovar trials. This framework provides a clinically actionable platform to test novel therapies aimed at increasing complete interval cytoreduction rates and improving survival in a population with otherwise limited options.
中文摘要:尽管贝伐珠单抗和聚(ADP-核糖)聚合酶抑制剂已整合进晚期高级别浆液性卵巢癌的一线治疗,但对于相当一部分肿瘤对铂类化疗反应不足、因此常无法达到完全细胞减灭术的患者(即2 red flags人群),生存仍然很差。本综述探讨旨在在开始维持治疗前提高肿瘤反应的全身治疗强化——或化疗增敏——的理论依据、当前证据和新策略。在维持治疗前达到最小残留病灶取决于两个关键决定因素:手术彻底性和肿瘤内在化疗敏感性。化疗敏感性的实用指标——KELIM(模型化的癌抗原125消除速率常数K)、病理化疗反应评分和影像学反应——现已被欧洲肿瘤内科学会-欧洲妇科肿瘤学会(ESMO-ESGO)和美国临床肿瘤学会(ASCO)指南引用,而BRCA/同源重组修复缺陷状态可能无法可靠预测新辅助卡铂-紫杉醇治疗反应。在3期试验(ICON-7、GOG-0218、ICON-8、ICON-8B、VELIA和IMagyn050)的事后分析中,化疗敏感性差的患者可能从强化策略中获得更大获益。每周剂量密集紫杉醇与ICON-8中2 red flags亚组生存改善相关。贝伐珠单抗,无论是加入标准术后化疗还是新辅助剂量密集化疗,在高危和化疗敏感性差的亚组中均显示出在无进展生存和总生存方面更大获益的信号。相反,PARP抑制剂和免疫检查点抑制剂联合方案仅在特定亚组中显示出有意义的活性,支持在这些人群中进一步评估创新的DNA修复靶向药物和免疫治疗策略。早期识别化疗敏感性差的晚期高级别浆液性卵巢癌,可实现反应适应的一线策略,即选择性地向最可能获益的患者提供治疗强化——这种方法目前正在3期SALVOVAR试验和1/2期RegeNovar试验中前瞻性评估。该框架提供了一个临床可操作的平台,用于测试旨在提高完全间歇性细胞减灭率并改善这一原本选择有限人群生存的新疗法。
Journal of hepatology IF 40.1 2026-10 PMID: 42744526
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with most patients requiring systemic therapy at diagnosis or during disease progression. Immune checkpoint inhibitor (ICI)-based combinations have transformed the therapeutic landscape and are now the standard first-line treatment, demonstrating improved survival and higher response rates compared with earlier tyrosine kinase inhibitor-based approaches. Attempts to further improve outcomes through triplet immunotherapy strategies have so far failed to show clear clinical benefit and are often associated with increased toxicity. Emerging therapeutic approaches - including bispecific antibodies, cellular therapies, cancer vaccines, oncolytic viruses, and novel molecularly targeted agents - are currently under clinical investigation. However, the biological heterogeneity of HCC and the lack of robust predictive biomarkers remain major challenges. This review summarises current systemic therapies for advanced stages of HCC and discusses emerging strategies and biomarker approaches that may enable more precise and effective treatment selection in the future.
中文摘要:肝细胞癌(HCC)仍是全球癌症相关死亡的主要原因之一,多数患者在诊断时或疾病进展过程中需要接受系统性治疗。基于免疫检查点抑制剂(ICI)的联合方案已经改变了治疗格局,目前已成为标准一线治疗,与既往以酪氨酸激酶抑制剂为基础的治疗相比,显示出生存改善和更高的缓解率。迄今为止,通过三药免疫治疗策略进一步改善预后的尝试未能显示明确的临床获益,且常与毒性增加相关。新兴治疗方法——包括双特异性抗体、细胞疗法、癌症疫苗、溶瘤病毒以及新型分子靶向药物——目前正在进行临床研究。然而,HCC的生物学异质性以及缺乏可靠的预测性生物标志物仍是主要挑战。本综述总结了晚期HCC当前的系统性治疗,并讨论了可能在未来实现更精准、更有效治疗选择的新兴策略和生物标志物方法。
Journal of hepatology IF 40.1 2026-10 PMID: 42744525
The treatment of advanced primary liver cancer has seen major improvement in recent years. In hepatocellular carcinoma (HCC), immunotherapy has improved both survival and quality of life. In biliary tract cancers (BTC), immunotherapy has shown modest benefits, while molecular targeted therapies have had a major impact in selected populations defined by molecular alterations. These advances are now being tested at earlier disease stages. In this review, we first discuss the challenges in designing trials that combine local and systemic treatment at earlier stages, and the different endpoints that might be used. We then present the available data on the combination of intra-arterial and systemic treatments in HCC. We continue with a discussion of the available data on adjuvant and neoadjuvant systemic treatment in HCC. Finally, we review recent developments in the adjuvant and neoadjuvant settings for BTC. While promising data exist across these settings, uncertainties remain regarding whether these strategies will become standard of care in the coming years.
中文摘要:晚期原发性肝癌的治疗近年来取得了重大进展。在肝细胞癌(HCC)中,免疫治疗改善了生存率和生活质量。在胆道癌(BTC)中,免疫治疗显示出适度获益,而分子靶向治疗在由分子改变定义的特定人群中产生了重大影响。这些进展目前正在更早期疾病阶段进行测试。在这篇综述中,我们首先讨论在早期阶段联合局部和系统治疗时试验设计所面临的挑战,以及可能使用的不同终点。随后,我们介绍肝细胞癌中动脉内治疗与系统治疗联合的现有数据。接着讨论肝细胞癌辅助和新辅助系统治疗的现有数据。最后,我们回顾胆道癌辅助和新辅助治疗的最新进展。尽管这些背景下存在有希望的数据,但这些策略是否会在未来几年成为标准治疗仍存在不确定性。
Journal of hepatology IF 40.1 2026-10 PMID: 42744523
Liver transplantation (LT) remains the most effective curative-intent surgical approach for selected patients with primary hepatic malignancies, owing to its ability to completely replace the diseased liver and address both the tumour and the underlying liver disease. Rather than being determined solely by technical feasibility, transplant candidacy is defined by a dynamic "window of eligibility" based on predicted overall survival and transplant benefit, with repeated assessment of tumour burden, biology, and response to therapy. LT should therefore be viewed as a complex, multi-step process encompassing patient selection, neoadjuvant treatment, graft procurement, surgery, and long-term postoperative management. Neoadjuvant strategies, including bridging, downstaging, and conversion therapies, have become central to patient selection and have expanded transplant eligibility for selected patients with advanced disease through combinations of systemic and locoregional treatments. Following transplantation, minimisation of immunosuppression is essential to balance graft preservation against tumour immune surveillance, although the persistence of antitumour immunity after pre-transplant immunotherapy remains uncertain. Emerging biomarkers, including circulating tumour DNA, circulating tumour cells, and microRNAs, have the potential to improve candidate selection, detect minimal residual disease, and enable earlier, biology-driven identification of recurrence, thereby supporting a more personalised approach to LT in primary liver cancers.
中文摘要:肝移植(LT)仍是部分原发性肝脏恶性肿瘤患者最有效的以治愈为目的的手术方式,因为它能够完全替换病变肝脏,并同时处理肿瘤和基础肝病。移植候选资格并非仅由技术可行性决定,而是由基于预测总生存和移植获益的动态「合格窗口」界定,并需反复评估肿瘤负荷、生物学特征和治疗反应。因此,LT应被视为一个复杂、多步骤的过程,涵盖患者选择、新辅助治疗、移植物获取、手术和长期术后管理。新辅助策略,包括桥接治疗、降期治疗和转化治疗,已成为患者选择的核心,并通过系统治疗与局部区域治疗的联合,扩大了部分晚期疾病患者的移植资格。移植后,最小化免疫抑制对平衡移植物保护与肿瘤免疫监视至关重要,尽管移植前免疫治疗后抗肿瘤免疫的持久性仍不确定。新兴生物标志物,包括循环肿瘤DNA、循环肿瘤细胞和微小RNA,有潜力改善候选者选择、检测微小残留病,并实现更早、由生物学驱动的复发识别,从而支持原发性肝癌LT的更个体化方法。
Cancer discovery IF 29.5 2026-10-01 PMID: 42627109
The new AI model Oncoformer can predict whether patients are likely to develop cancer within the next year, diagnose existing tumors, forecast responses to treatments, and stage tumors. The model makes conclusions and predictions from electronic health records and chest X-rays. Trained and tested with information from Chinese patients, the model also delivered accurate results for a cohort of patients in the UK.
中文摘要:新型人工智能模型Oncoformer能够预测患者在未来一年内是否可能患癌,诊断已有肿瘤,预测对治疗的反应,并对肿瘤进行分期。该模型基于电子健康记录和胸部X光片得出结论并做出预测。该模型使用中国患者的信息进行训练和测试,同时也在英国一个患者队列中得出了准确结果。
European urology IF 29.1 2026-10 PMID: 42457459
This publication represents a summary of the updated 2026 European Association of Urology (EAU) Guidelines for nonmuscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC, with a focus on clinical presentation. For the 2026 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included MEDLINE, EMBASE, and the Cochrane Library. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately. Key updates in the 2026 NMIBC Guidelines summary include: the addition of two new tables addressing risk factors for bladder cancer and prognostic factors for progression in subtypes; the addition of two new tables summarising the treatment options for Bacillus Calmette-Guérin (BCG)-unresponsive tumours; inclusion of a new section addressing the addition of immune checkpoint inhibitors to BCG in selected high- and very high-risk NMIBC BCG-NAÏVE patients; a new table addressing the role of urinary markers in follow-up; and the addition of a new section on pragmatic de-intensification strategy for NMIBC. This overview of the 2026 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. They are designed for effective integration into clinical practice. The EAU has issued updated clinical practice guidelines on NMIBC. The guidelines provide recommendations for diagnosis, treatment, and follow-up, with a particular focus on quality of life for patients.
中文摘要:本出版物是2026年更新版欧洲泌尿外科学会(EAU)非肌层浸润性膀胱癌(NMIBC),即TaT1和原位癌(CIS)指南的摘要。除另有说明外,本文信息仅限于尿路上皮癌。其目的是提供关于NMIBC临床管理的实用建议,并重点关注临床表现。针对2026年NMIBC指南,通过结构化文献评估识别、整理和评价了新的相关证据。检索数据库包括MEDLINE、EMBASE和Cochrane Library。指南中的建议由专家组制定,以优先考虑临床重要的诊疗决策。每条建议的强度根据替代管理策略的可取与不良后果之间的平衡、证据质量(包括估计值的确定性)以及患者价值观和偏好的性质与变异性来确定。关键建议强调对NMIBC患者进行彻底诊断、治疗和随访的重要性。指南强调明确患者风险分层并给予适当治疗的重要性。2026年NMIBC指南摘要的关键更新包括:新增两个表格,分别讨论膀胱癌风险因素和亚型进展的预后因素;新增两个表格,总结对卡介苗(BCG)无应答肿瘤的治疗选择;新增一个章节,讨论在选定的高危和极高危、未接受过BCG的NMIBC患者中,将免疫检查点抑制剂加入BCG治疗;新增一个表格,讨论尿液标志物在随访中的作用;并新增一个章节,讨论NMIBC的务实降阶梯策略。这份2026年EAU指南概览为NMIBC的风险因素、诊断、分类、预后因素、治疗和随访提供了有价值的见解。这些指南旨在有效整合到临床实践中。EAU发布了更新的NMIBC临床实践指南。指南提供了诊断、治疗和随访建议,并特别关注患者的生活质量。
Cancer letters IF 11.8 2026-10-01 PMID: 42431392
Immune checkpoint blockade (ICB) is regarded as a major breakthrough in lung cancer treatment. However, the limited response rates and immune-related adverse events associated with ICB present major challenges in clinical practice. To predict the immunotherapy response, we developed the CCCNP signature comprising 5 immune checkpoint molecules (CD226, CD276, CTLA-4, Nectin-2, and PD-L1) in "driver gene-negative" lung adenocarcinoma (LUAD). Immune checkpoint signatures were identified from large, retrospectively collected tumor cohorts by testing how their immunohistochemical characteristics influence patient survival. The predictive performance of the CCCNP signature was evaluated in a prospective cohort of 34 patients treated with anti-PD-1/PD-L1 therapy. It achieved a numerically higher accuracy of AUC (0.803, 95% CI: 0.661-0.945) compared to clinically used PD-L1, tumor mutational burden (TMB), and microsatellite instability (MSI). When applied to a newly enrolled exploratory cohort with 146 patients, the CCCNP signature could stratify a high-risk subgroup that derived statistically significant clinical benefit from the addition of immunotherapy. Overall, we present a new framework for risk stratification and support precise immunotherapy decision-making in "driver gene-negative" LUAD.
中文摘要:免疫检查点阻断(ICB)被认为是肺癌治疗的一项重大突破。然而,ICB有限的应答率和免疫相关不良事件在临床实践中构成重大挑战。为预测免疫治疗应答,我们在「驱动基因阴性」肺腺癌(LUAD)中开发了包含5种免疫检查点分子(CD226、CD276、CTLA-4、Nectin-2和PD-L1)的CCCNP特征。通过检测免疫组化特征如何影响患者生存,从大型回顾性收集的肿瘤队列中鉴定出免疫检查点特征。CCCNP特征的预测性能在34例接受抗PD-1/PD-L1治疗患者的前瞻性队列中进行了评估。与临床使用的PD-L1、肿瘤突变负荷(TMB)和微卫星不稳定性(MSI)相比,其AUC准确率在数值上更高(0.803,95% CI:0.661-0.945)。当应用于新入组的146例患者探索性队列时,CCCNP特征可分层出一个高危亚组,该亚组从加入免疫治疗中获得具有统计学显著性的临床获益。总体而言,我们提出了一种新的风险分层框架,并支持「驱动基因阴性」LUAD的精准免疫治疗决策。
European urology IF 29.1 2026-10 PMID: 42362411
Histological subtypes and divergent differentiation are common in bladder cancer. Each subtype has distinct biology and clinical features. We aim to summarize pathology, molecular features, and outcomes of the most common bladder cancer subtypes to guide management. We performed a narrative review of cohort studies, clinical trials, and population-based analyses assessing morphology, immunophenotype, genomic alterations, and outcomes following various localized and systemic therapies in patients with bladder cancer subtypes. Histological subtypes are often understaged on transurethral resection of bladder tumor and commonly demonstrate lymph node metastasis, supporting early radical cystectomy (RC) even for certain clinically non-muscle-invasive bladder cancers. Small cell urothelial carcinoma (UC) consistently benefits from platinum/etoposide-based chemotherapy regimens, whereas predominant squamous, plasmacytoid, sarcomatoid, and micropapillary tumors demonstrate variable response rates to systemic therapies used in conventional UC. Trimodality therapy may approximate RC in locoregional control for small cell UC and appears inferior in cases with predominant squamous and adenocarcinoma. Genomic profiling highlights actionable alterations, albeit with unclear clinical implications. Immune checkpoint blockade and antibody-drug conjugates have been used sparingly against subtype bladder cancers and have anecdotally demonstrated activity across several subtypes. Histological subtypes and divergent differentiation of UC represent high-risk yet biologically distinct disease phenotypes that may not conform to the current "one-size-fits-all" treatment paradigm. More in-depth clinical and translational analyses with robust, adequately powered cohorts are required to further understand the clinical behavior of each unique bladder cancer subtype and to customize the optimal therapeutic strategies.
中文摘要:组织学亚型和异向分化在膀胱癌中常见。每个亚型都具有独特的生物学和临床特征。我们旨在总结最常见膀胱癌亚型的病理学、分子特征和结局,以指导管理。我们对评估膀胱癌亚型患者形态学、免疫表型、基因组改变以及接受各种局部和全身治疗后结局的队列研究、临床试验和基于人群的分析进行了叙述性综述。组织学亚型在经尿道膀胱肿瘤电切术中常被低估分期,并常显示淋巴结转移,支持即使对于某些临床非肌层浸润性膀胱癌也早期行根治性膀胱切除术(RC)。小细胞尿路上皮癌(UC)始终受益于以铂类/依托泊苷为基础的化疗方案,而以鳞状、浆细胞样、肉瘤样和微乳头状成分为主的肿瘤对传统UC所用全身治疗的反应率不一。对于小细胞UC,三联疗法在局部区域控制方面可能接近RC,而在以鳞状和腺癌为主的情况下似乎较差。基因组分析突出了可干预的改变,尽管其临床意义尚不明确。免疫检查点阻断和抗体药物偶联物在亚型膀胱癌中应用较少,并有个案显示在若干亚型中具有活性。UC的组织学亚型和异向分化代表高风险但生物学上不同的疾病表型,可能不符合当前「一刀切」的治疗范式。需要更深入的临床和转化分析,以及稳健且效能充分的队列,以进一步了解每种独特膀胱癌亚型的临床行为,并制定最佳治疗策略。
Cancer letters IF 11.8 2026-10-01 PMID: 42309220
Immune checkpoint blockade (ICB) therapy has demonstrated promising efficacy in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). However, a substantial proportion of these patients remain resistant to treatment. This study aims to investigate the mechanisms underlying ICB resistance in dMMR/MSI-H CRCs. We analyzed single-cell transcriptomic data from 34 CRC patients treated with ICB and integrated ten spatial transcriptomic datasets to compare the tumor microenvironment (TME) features between responders and non-responders. Our analysis identified a distinct subset of tumor-associated fibroblasts (CAFs), marked by elevated POSTN expression (POSTN + CAFs), which was significantly enriched in non-responders. These cells encapsulate tumor cell aggregates and contribute to extensive extracellular matrix (ECM) remodeling, forming a dense, fortress-like stromal architecture at tumor periphery. Notably, cytotoxic T cells including CXCL13+CD8+ T cells were enriched in the ECM surrounding POSTN + CAF regions but were largely excluded from the adjacent tumor core, suggesting that POSTN + CAFs function as a physical and biochemical barrier to T cell infiltration. Differentiation trajectory analyses revealed that POSTN + CAFs originate from precursor CAFs (PI16+ CAFs and SFRP2+ CAFs), potentially driven by malignant cell-derived cues. Specifically, we identified GDF15 as key tumor-cell ligands that may interact with precursor CAFs to promote POSTN + CAF differentiation. Our findings uncover a stromal mechanism of ICB resistance in dMMR/MSI-H CRC mediated by POSTN + CAFs and highlight novel therapeutic strategies to enhance immunotherapy efficacy.
中文摘要:免疫检查点阻断(ICB)治疗已在错配修复缺陷(dMMR)或微卫星高度不稳定(MSI-H)结直肠癌(CRC)患者中展现出良好疗效。然而,仍有相当一部分此类患者对治疗耐药。本研究旨在探讨dMMR/MSI-H CRC中ICB耐药的机制。我们分析了34例接受ICB治疗的CRC患者的单细胞转录组数据,并整合了10个空间转录组数据集,以比较应答者与非应答者之间的肿瘤微环境(TME)特征。我们的分析鉴定出一类独特的肿瘤相关成纤维细胞(CAF)亚群,其以POSTN表达升高为标志(POSTN+ CAF),并在非应答者中显著富集。这些细胞包裹肿瘤细胞聚集体,并参与广泛的细胞外基质(ECM)重塑,在肿瘤周边形成致密、堡垒样的基质结构。值得注意的是,包括CXCL13+CD8+ T细胞在内的细胞毒性T细胞富集于POSTN+ CAF区域周围的ECM中,但在邻近肿瘤核心中大多被排除,提示POSTN+ CAF作为T细胞浸润的物理和生化屏障发挥作用。分化轨迹分析显示,POSTN+ CAF起源于前体CAF(PI16+ CAF和SFRP2+ CAF),可能由恶性细胞来源的信号驱动。具体而言,我们鉴定出GDF15是关键肿瘤细胞配体,可能与前体CAF相互作用以促进POSTN+ CAF分化。我们的发现揭示了dMMR/MSI-H CRC中由POSTN+ CAF介导的ICB耐药基质机制,并突出了增强免疫治疗疗效的新治疗策略。
Journal of the American Academy of Dermatology IF 12.3 2026-10 PMID: 42285257
Immune checkpoint inhibitors (ICIs) have markedly advanced oncology by enhancing the immune system's ability to combat malignancies. However, their use is increasingly associated with immune-related adverse events, including immunobullous dermatoses. These disorders, such as bullous pemphigoid, pemphigus vulgaris, linear immunoglobulin A bullous dermatosis, mucous membrane pemphigoid, paraneoplastic pemphigus, dermatitis herpetiformis, and lichen planus pemphigoides present significant diagnostic and therapeutic challenges. This clinical review explores the pathogenesis, clinical presentation, diagnosis, and management strategies of immunobullous dermatoses triggered by ICIs, highlighting the complex relationship between effective cancer treatment and immune regulation. ICI-induced immunobullous dermatoses closely mimic their conventional autoimmune counterparts but often have unique clinical considerations, such as delayed onset, mucosal predilection, and persistence post-discontinuation of medication. Diagnostic evaluation relies on clinical suspicion, histopathology, direct and indirect immunofluorescence, and enzyme-linked immunosorbent assays. Management typically involves corticosteroids and immunosuppressants, with biologics such as rituximab, dupilumab and omalizumab reserved for refractory cases. Decisions regarding the continuation of ICIs require individualized assessment, balancing cancer control with autoimmune toxicity. Dermatologic and oncologic teams must navigate dual priorities of mitigating autoimmune toxicity and preserving oncologic benefit.
中文摘要:免疫检查点抑制剂(ICIs)通过增强免疫系统对抗恶性肿瘤的能力,显著推动了肿瘤学进展。然而,其使用与免疫相关不良事件(包括免疫性大疱性皮肤病)的关联日益增多。这些疾病,如大疱性类天疱疮、寻常型天疱疮、线状免疫球蛋白A大疱性皮病、黏膜类天疱疮、副肿瘤性天疱疮、疱疹样皮炎和扁平苔藓样类天疱疮,给诊断和治疗带来了重大挑战。本临床综述探讨了ICIs诱发的免疫性大疱性皮肤病的发病机制、临床表现、诊断和管理策略,强调有效癌症治疗与免疫调节之间的复杂关系。ICI诱发的免疫性大疱性皮肤病与其传统自身免疫性对应疾病高度相似,但常具有独特的临床考量,如起病延迟、黏膜倾向以及停药后持续存在。诊断评估依赖于临床怀疑、组织病理学、直接和间接免疫荧光以及酶联免疫吸附试验。管理通常包括糖皮质激素和免疫抑制剂,利妥昔单抗、度普利尤单抗和奥马珠单抗等生物制剂保留用于难治性病例。关于是否继续使用ICIs的决策需要个体化评估,在癌症控制与自身免疫毒性之间取得平衡。皮肤科和肿瘤科团队必须应对双重优先事项:减轻自身免疫毒性并保留肿瘤学获益。

基础研究 (117篇)

Science advances IF 13.9 2026-10-09 PMID: 42842669
Exploiting macrophages as cell-autonomous reporters of their polarization states represents a promising strategy for interrogating tumor-associated macrophage (TAM) phenotypes in cancer. Here, we develop a macrophage-based sensing platform, termed eMφ. This platform is created by engineering macrophages with a modular and multiplexable DNA origami nanodevice to report TAM polarization states within the tumor microenvironment. Upon tumor infiltration, microenvironmental cues drive macrophage polarization, triggering the engineered system to convert endogenous signals (e.g., Arg1 or iNOS mRNA) into distinct, state-specific reporter outputs. The integration of local and circulating reporters enables compartment-resolved, multiscale readouts of macrophage state. Following intravenous administration, eMφ facilitates tumor detection across multiple murine models, including B16F10 melanoma and lung metastasis, and enables precise evaluation of macrophage-reprogramming immunotherapy. Overall, this work establishes DNA nanodevice-programmed macrophages as a novel class of synthetic-living hybrid systems, paving the way for programmable and precise immune-state diagnostics and therapy.
中文摘要:将巨噬细胞用作其极化状态的细胞自主报告器,代表了一种有前景的策略,可用于探究癌症中的肿瘤相关巨噬细胞(TAM)表型。在此,我们开发了一种基于巨噬细胞的传感平台,称为eMφ。该平台通过用模块化且可多重化的DNA折纸纳米器件工程化改造巨噬细胞而构建,用于报告肿瘤微环境中的TAM极化状态。在肿瘤浸润后,微环境线索驱动巨噬细胞极化,触发工程化系统将内源性信号(例如Arg1或iNOS mRNA)转化为不同的、状态特异性的报告输出。局部和循环报告器的整合使得能够对巨噬细胞状态进行区室分辨、多尺度读取。静脉给药后,eMφ促进了多种小鼠模型中的肿瘤检测,包括B16F10黑色素瘤和肺转移,并能够精确评估巨噬细胞重编程免疫疗法。总体而言,这项工作确立了DNA纳米器件编程的巨噬细胞作为一类新型合成-活体混合系统,为可编程且精确的免疫状态诊断和治疗开辟了道路。
Science advances IF 13.9 2026-10-09 PMID: 42842645
Tumor metabolic programs shape immune evasion; however, the mechanism by which nutrient-transport systems rewire tumor-immune cell interactions remains unknown. We integrated bulk multi-omics, single-cell transcriptomics, spatial profiling, and functional assays for colorectal cancer-associated zinc-driven immunosuppressive circuit identification. Multi-omics analysis of 258 patients revealed three solute carrier transporter-centered archetypes, with an SLC39-enriched subtype aligned with consensus molecular subtype 2-like immune-desert tumors. SLC39-mediated zinc influx activated CDX2, which engaged a distal enhancer to induce tumor cell-specific CD24 expression. CD24+ tumor cells formed spatial niches with SIGLEC10-expressing monocyte-derived macrophages, dendritic cells, and resident macrophages, activating pleiotropic programs that suppress phagocytosis and remodel adhesion. SLC39 overexpression increased intracellular zinc and CD24 levels and reduced macrophage-mediated engulfment, whereas CD24 blockade restored phagocytosis. The zinc-CDX2-CD24-SIGLEC10 axis defined a terminal cancer cell state associated with poor survival and immune checkpoint blockade resistance. A seven-gene signature predicted immunotherapy responses across five colorectal cancer cohorts, identifying SLC39-driven zinc influx as a metabolic checkpoint governing immune exclusion.
中文摘要:肿瘤代谢程序塑造免疫逃逸;然而,营养转运系统重编程肿瘤-免疫细胞相互作用的机制仍不清楚。我们整合了批量多组学、单细胞转录组学、空间图谱和功能实验,以识别结直肠癌相关的锌驱动免疫抑制回路。对258例患者的多组学分析揭示了三种以溶质载体转运体为中心的原型,其中富含SLC39的亚型与共识分子亚型2样免疫荒漠型肿瘤一致。SLC39介导的锌内流激活CDX2,后者结合远端增强子诱导肿瘤细胞特异性CD24表达。CD24+肿瘤细胞与表达SIGLEC10的单核细胞衍生巨噬细胞、树突状细胞和驻留巨噬细胞形成空间生态位,激活抑制吞噬作用并重塑黏附的多效性程序。SLC39过表达增加细胞内锌和CD24水平,并减少巨噬细胞介导的吞噬,而CD24阻断恢复了吞噬作用。锌-CDX2-CD24-SIGLEC10轴定义了一种与不良生存和免疫检查点阻断耐药相关的终末癌细胞状态。一个七基因特征在五个结直肠癌队列中预测免疫治疗反应,确定SLC39驱动的锌内流是控制免疫排斥的代谢检查点。
Advanced healthcare materials IF 11.0 2026-10-07 PMID: 42844646
Lung cancer imposes the highest cancer-related mortality burden worldwide, while its responsiveness to immunotherapy is often constrained by the immunosuppressive pulmonary tumor microenvironment (TME) and tumor adaptations that buffer oxidative stress. Pyroptosis, a highly immunogenic form of programmed cell death that can be activated through mechanisms not strictly dependent on exogenous reactive oxygen species (ROS), offers a promising alternative for immune activation but remains challenging to induce effectively in vivo. Here, we report an inhalable fluorinated polymer nanoplatform (PFAP) that triggers mitochondrial dysfunction to initiate pyroptosis and thereby elicits potent antitumor immunity in the lung. PFAP integrates perfluoroalkyl segments with cationic domains to enhance interactions with mitochondrial membranes, while a detachable polyethylene glycol shell preserves nanoparticle stability during aerosolization and facilitates penetration of pulmonary barriers. Upon exposure to the acidic TME, PFAP restores membrane-disruptive activity, leading to mitochondrial depolarization, Cyto C release, caspase-3 activation, GSDME cleavage, and pyroptosis induction. In orthotopic and metastatic lung cancer models, inhaled PFAP achieves efficient lung delivery, elicits robust antitumor immunity, and suppresses tumor progression without detectable systemic toxicity. This work provides a nanomaterial-based approach for inducing pyroptosis in lung cancer and highlights the potential of inhalable polymer systems for localized cancer immunotherapy.
中文摘要:肺癌在全球范围内造成最高的癌症相关死亡负担,而其对免疫治疗的应答常受免疫抑制性肺部肿瘤微环境(TME)以及肿瘤用以缓冲氧化应激的适应机制所限制。焦亡是一种高度免疫原性的程序性细胞死亡形式,可通过不严格依赖外源性活性氧(ROS)的机制被激活,为免疫激活提供了有前景的替代策略,但在体内有效诱导仍具挑战。在此,我们报道一种可吸入的含氟聚合物纳米平台(PFAP),其可触发线粒体功能障碍以启动焦亡,从而在肺部激发强效抗肿瘤免疫。PFAP将全氟烷基片段与阳离子结构域整合,以增强与线粒体膜的相互作用,同时可脱落的聚乙二醇外壳在雾化过程中保持纳米颗粒稳定性,并促进其穿透肺部屏障。在暴露于酸性TME后,PFAP恢复膜破坏活性,导致线粒体去极化、细胞色素C释放、caspase-3激活、GSDME切割以及焦亡诱导。在原位和转移性肺癌模型中,吸入PFAP可实现高效的肺部递送,激发强健的抗肿瘤免疫,并抑制肿瘤进展,且未检测到全身毒性。该工作提供了一种基于纳米材料在肺癌中诱导焦亡的方法,并凸显了可吸入聚合物系统用于局部癌症免疫治疗的潜力。
Trends in pharmacological sciences IF 24.0 2026-10-07 PMID: 42844037
Antimetabolites have been used to treat cancer since the 1950s, yet how tumors survive remains unclear. Two studies by Moss and colleagues and Witus and colleagues show that surviving cells recycle nucleotides and reshape mitochondria, revealing a shared resistance program. Because this program is measurable, it could identify, before treatment, which patients would benefit from drugs that block it.
中文摘要:抗代谢药物自20世纪50年代以来一直用于治疗癌症,但肿瘤如何存活仍不清楚。Moss及其同事以及Witus及其同事的两项研究表明,存活下来的细胞会回收核苷酸并重塑线粒体,揭示出一个共有的耐药程序。由于该程序可被测量,它有可能在治疗前识别出哪些患者会受益于阻断该程序的药物。
Journal for immunotherapy of cancer IF 11.7 2026-10-07 PMID: 42843926
Interleukin-7 receptor (IL7R) signaling is critical for T-cell survival, homeostasis, and immune function, but the therapeutic potential of increasing IL7R expression through messenger RNA (mRNA) delivery remains poorly defined. We investigated whether IL7R mRNA therapy could enhance antitumor immunity and improve tumor control in preclinical cancer models. IL7R mRNA formulated in lipid nanoparticles (LNPs) was administered by combined intratumoral and intravenous injection in syngeneic B16 melanoma and Lewis lung carcinoma (LLC) models, with empty LNPs included as vehicle controls. Therapeutic efficacy, IL7R expression, immune responses, transcriptomic remodeling, T-cell receptor (TCR) repertoire changes, and treatment tolerability were evaluated using complementary molecular, immunological, and sequencing approaches. IL7R mRNA treatment increased IL7R transcript and protein levels in tumor-bearing mice, whereas empty LNPs did not produce comparable increases. Treatment increased tumor-infiltrating CD8 T-cell frequencies, suppressed tumor growth and prolonged survival in both B16 and LLC models; empty LNP controls did not reproduce the therapeutic effect. Cytokine and transcriptomic analyses showed treatment-associated activation of inflammatory, T-cell, interferon, and antigen-receptor signaling programs. TCR sequencing further demonstrated increased repertoire diversity and reduced clonal dominance following IL7R mRNA treatment. No obvious body-weight loss or marked changes in serum alanine aminotransferase, aspartate aminotransferase, or creatinine were observed under the tested conditions. IL7R mRNA therapy increases IL7R expression and is associated with enhanced T-cell antitumor responses, tumor growth suppression, improved survival, and remodeling of the tumor immune environment. These findings support further mechanistic and preclinical evaluation of IL7R mRNA-based cancer immunotherapy.
中文摘要:白细胞介素-7受体(IL7R)信号对T细胞存活、稳态和免疫功能至关重要,但通过信使RNA(mRNA)递送提高IL7R表达的治疗潜力仍未被充分明确。我们研究了IL7R mRNA疗法是否能在临床前癌症模型中增强抗肿瘤免疫并改善肿瘤控制。在同基因B16黑色素瘤和Lewis肺癌(LLC)模型中,将配制于脂质纳米颗粒(LNP)中的IL7R mRNA通过瘤内和静脉联合注射给药,并设置空LNP作为载体对照。采用互补的分子、免疫学和测序方法评估了治疗效果、IL7R表达、免疫应答、转录组重塑、T细胞受体(TCR)谱变化以及治疗耐受性。IL7R mRNA治疗提高了荷瘤小鼠中的IL7R转录本和蛋白水平,而空LNP未产生可比增加。治疗增加了肿瘤浸润CD8 T细胞频率,在B16和LLC模型中均抑制肿瘤生长并延长生存;空LNP对照未重现治疗效果。细胞因子和转录组分析显示,治疗相关地激活了炎症、T细胞、干扰素和抗原受体信号程序。TCR测序进一步表明,IL7R mRNA治疗后TCR库多样性增加、克隆优势降低。在所测试条件下,未观察到明显的体重下降或血清丙氨酸氨基转移酶、天冬氨酸氨基转移酶或肌酐的显著变化。IL7R mRNA疗法提高了IL7R表达,并与增强的T细胞抗肿瘤应答、肿瘤生长抑制、生存改善以及肿瘤免疫环境重塑相关。这些发现支持对基于IL7R mRNA的癌症免疫疗法开展进一步的机制和临床前评价。
Cancer letters IF 11.8 2026-10-07 PMID: 42843584
Glioma progression is driven by both tumor-intrinsic genetics and tumor microenvironment (TME) heterogeneity. Although tumor-intrinsic heterogeneity has been widely explored, the understanding of the isocitrate dehydrogenase (IDH)-associated TME in glioma remains less clear. In this study, therefore, we integrated bulk and single-cell transcriptomics, spatial transcriptomics, and proteomic data from glioma tissues and patient blood samples to characterize TME composition, subtype-associated molecular patterns, and their prognostic relevance. The data showed that IDH-wildtype (IDH-WT) glioma exhibited complicated TME, enriched in pericytes and immune cells, whereas IDH-mutant (IDH-MU) glioma displayed a TME dominated by oligodendrocytes and neurons. From a TME-related geneset, we identified four subtype-associated gene patterns: 179 genes in IDH-WT (WT-179) associated with extracellular matrix remodeling and angiogenesis; 68 genes in IDH-MU (MU-68) linked to neuronal and synaptic pathways; 30 genes in IDH-MU with chromosome 1p/19q-non-codeletion (M-N-30) enriched in RNA/protein binding; and 83 genes in IDH-MU with chromosome 1p/19q-codeletion (M-C-83) involved in neurodevelopmental processes. Single-cell transcriptomics profiled contributions of pericyte, myeloid, and lymphocyte subpopulations to these patterns, revealing distinct developmental trajectories and functional programs across glioma subtypes. Glioma tissue and serum proteomics detected WT-179-associated proteins and identified POSTN, LTF, PLA2G2A, and ANXA1 as candidate protein markers associated with the IDH-WT TME program. Taken together, this study provided novel insights into the cellular and molecular features of the TME across glioma molecular subtypes and implied TME as a promising therapeutic target for developing novel treatment strategies.
中文摘要:胶质瘤的进展既由肿瘤内在遗传学驱动,也受肿瘤微环境(TME)异质性驱动。尽管肿瘤内在异质性已被广泛探索,但胶质瘤中与异柠檬酸脱氢酶(IDH)相关的TME仍认识不足。因此,本研究整合了来自胶质瘤组织和患者血液样本的批量与单细胞转录组学、空间转录组学和蛋白质组学数据,以刻画TME组成、亚型相关分子模式及其预后相关性。数据表明,IDH野生型(IDH-WT)胶质瘤表现出复杂的TME,富含周细胞和免疫细胞,而IDH突变型(IDH-MU)胶质瘤则呈现以少突胶质细胞和神经元为主的TME。从一个TME相关基因集中,我们鉴定出四种亚型相关基因模式:IDH-WT中的179个基因(WT-179)与细胞外基质重塑和血管生成相关;IDH-MU中的68个基因(MU-68)与神经元和突触通路相关;伴染色体1p/19q非共缺失的IDH-MU中的30个基因(M-N-30)富集于RNA/蛋白质结合;伴染色体1p/19q共缺失的IDH-MU中的83个基因(M-C-83)参与神经发育过程。单细胞转录组学刻画了周细胞、髓系和淋巴细胞亚群对这些模式的贡献,揭示了不同胶质瘤亚型中不同的发育轨迹和功能程序。胶质瘤组织和血清蛋白质组学检测到WT-179相关蛋白,并鉴定出POSTN、LTF、PLA2G2A和ANXA1作为与IDH-WT TME程序相关的候选蛋白质标志物。总之,本研究为胶质瘤分子亚型间TME的细胞和分子特征提供了新见解,并提示TME可作为开发新型治疗策略的有前景的治疗靶点。
Clinical and molecular hepatology IF 21.7 2026-10-07 PMID: 42843420
Immune checkpoint inhibitors (ICIs) have reshaped systemic therapy for hepatocellular carcinoma (HCC), but durable benefit remains limited to a subset of patients because of tumor-intrinsic and microenvironmental mechanisms of immune resistance. Canonical epigenetic and epitranscriptomic alterations, including DNA methylation, histone modifications and chromatin remodeling, and epitranscriptomic RNA modifications, can influence tumor immune visibility by regulating antigen presentation, interferon responses, chemokine production, T-cell recruitment and function, and immunosuppressive programs in myeloid and stromal cells. This review critically evaluates HCC-specific evidence linking these regulatory mechanisms to immune checkpoint responsiveness. Emphasis is placed on crosstalk among DNA methylation, histone/chromatin regulation, and N6-methyladenosine (m6A)-dependent pathways; transcriptional-epigenetic stabilization of T-cell dysfunction; and epigenetic or epitranscriptomic remodeling of myeloid and stromal compartments, including cancer-associated fibroblasts. We further evaluate candidate therapeutic targets using a tiered evidence framework that integrates molecular association, mechanistic validation, pharmacologic validation, evidence from ICI-combination studies, and clinical validation. We assess therapeutic targets by evidence maturity and discuss emerging combination strategies and HCC-specific translational challenges, including chronic liver disease, limited hepatic reserve, and biomarker-guided patient selection. Although preclinical studies support several candidate mechanisms for modulating ICI responsiveness, mature clinical evidence for epigenetic-ICI combinations in HCC remains limited. These strategies should therefore be regarded as mechanistically compelling but clinically unproven and require rigorously designed, biomarker-integrated HCC trials with pharmacodynamic confirmation of immune reprogramming and careful safety evaluation.
中文摘要:免疫检查点抑制剂(ICIs)重塑了肝细胞癌(HCC)的系统治疗格局,但由于肿瘤内在及微环境介导的免疫抵抗机制,持久获益仍局限于部分患者。经典的表观遗传学和表观转录组学改变,包括DNA甲基化、组蛋白修饰和染色质重塑,以及表观转录组RNA修饰,可通过调控抗原呈递、干扰素反应、趋化因子产生、T细胞募集与功能,以及髓系和基质细胞中的免疫抑制程序,影响肿瘤的免疫可见性。本综述批判性评估了将上述调控机制与免疫检查点反应性联系起来的HCC特异性证据。重点关注DNA甲基化、组蛋白/染色质调控与N6-甲基腺苷(m6A)依赖性通路之间的交互作用;T细胞功能障碍的转录-表观遗传稳定化;以及髓系和基质区室(包括癌相关成纤维细胞)的表观遗传或表观转录组重塑。我们进一步采用分层证据框架评估候选治疗靶点,该框架整合了分子关联、机制验证、药理学验证、ICI联合研究证据和临床验证。我们根据证据成熟度评估治疗靶点,并讨论新兴联合策略及HCC特异性转化挑战,包括慢性肝病、有限肝脏储备和生物标志物指导的患者选择。尽管临床前研究支持若干调节ICI反应性的候选机制,但表观遗传-ICI联合治疗在HCC中的成熟临床证据仍然有限。因此,这些策略应被视为机制上具有吸引力但临床尚未证实,需要严格设计、整合生物标志物的HCC试验,并进行免疫重编程的药效学确认和谨慎的安全性评估。
Science translational medicine IF 15.6 2026-10-07 PMID: 42842723
Instead of asking what nerves do to cancer, my work reveals how cancer injures and reprograms peripheral nerves to drive immune evasion and how targeting this process restores immunotherapy responses.
中文摘要:与其追问神经对癌症做了什么,我的工作揭示了癌症如何损伤并重编程外周神经以驱动免疫逃逸,以及靶向这一过程如何恢复免疫治疗反应。
Cancer research IF 22.6 2026-10-07 PMID: 42841543
A substantial proportion of treatment-naive lung adenocarcinoma (LUAD) patients exhibit intrinsic resistance to neoadjuvant chemoimmunotherapy, highlighting the need for mechanism-driven therapeutic strategies. Here, we performed integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics on clinical specimens from the CheckMate 816 trial to define the tumor immune microenvironment (TIME) dynamics associated with therapy resistance. The scRNA-seq data revealed distinct TIME features in non-responders to neoadjuvant chemoimmunotherapy, characterized by the upregulation of CHCHD3. Mechanistically, CHCHD3 acted as a negative regulator of innate immunity by sequestering cGAS in mitochondria. This interaction between the CHCHD3 domain and the cGAS catalytic core reduced the cytosolic cGAS pool, thereby blunting STING-dependent signaling. Consequently, CHCHD3 knockout restored CXCL5/CXCL1 production, reduced M2-like tumor-associated macrophages, and promoted CD8+ T cell infiltration. Integrated virtual and functional drug screening identified TN4510 as a small molecule that disrupts the CHCHD3-cGAS interface. TN4510 treatment effectively restored STING signaling and synergized with chemoimmunotherapy to suppress tumor growth in preclinical models. Together, these findings reveal that CHCHD3 drives chemoimmunotherapy resistance by sequestering cGAS to limit STING activation. Targeting CHCHD3 with TN4510 restores antitumor immunity, offering a translatable strategy to overcome treatment resistance in LUAD.
中文摘要:相当一部分初治肺腺癌(LUAD)患者对新辅助化疗联合免疫治疗存在固有耐药,凸显了以机制为导向的治疗策略的必要性。本研究对来自CheckMate 816试验的临床标本进行了单细胞RNA测序(scRNA-seq)与空间转录组学的整合分析,以明确与治疗耐药相关的肿瘤免疫微环境(TIME)动态变化。scRNA-seq数据显示,新辅助化疗联合免疫治疗无应答者具有独特的TIME特征,表现为CHCHD3表达上调。在机制上,CHCHD3通过将cGAS滞留于线粒体而充当天然免疫的负调控因子。CHCHD3结构域与cGAS催化核心之间的这种相互作用减少了胞质cGAS库,从而削弱了依赖STING的信号传导。因此,敲除CHCHD3可恢复CXCL5/CXCL1的产生,减少M2样肿瘤相关巨噬细胞,并促进CD8+ T细胞浸润。整合虚拟筛选与功能药物筛选鉴定出TN4510是一种可破坏CHCHD3-cGAS相互作用界面的小分子。TN4510处理有效恢复了STING信号,并与化疗联合免疫治疗协同抑制临床前模型中的肿瘤生长。综上,这些发现揭示CHCHD3通过滞留cGAS以限制STING激活,从而驱动化疗联合免疫治疗耐药。以TN4510靶向CHCHD3可恢复抗肿瘤免疫,为克服LUAD治疗耐药提供了一种可转化的策略。
Trends in molecular medicine IF 18.1 2026-10-06 PMID: 42838763
The unfolded protein response (UPR) is a fundamental stress pathway coopted in cancer, and it is thought to drive adaptation, tumor progression, and therapeutic resistance. While the analysis of 'single-effector' biomarkers within the tumor microenvironment often fails to capture its spatial, temporal, and cellular complexity, recent advances in high-resolution spatial transcriptomics and single-cell multiomics may enable a shift from static readouts toward more comprehensive multigene UPR signatures. This could help resolve proteostatic heterogeneity at unprecedented resolution. In this review, we provide a pan-cancer perspective on using these quantitative signatures to map proteostatic states. By combining cell biology, mechanobiology, and computational pathology, our proposed translational framework blends morphological hallmarks with multiomic UPR signatures. Although still requiring prospective clinical validation, this approach could improve patient stratification and treatment decisions, advancing the field of precision oncology.
中文摘要:未折叠蛋白反应(UPR)是癌症中常被劫持的基本应激通路,被认为可驱动适应性、肿瘤进展和治疗耐药。尽管对肿瘤微环境中「单一效应因子」生物标志物的分析往往无法捕捉其空间、时间和细胞层面的复杂性,但高分辨率空间转录组学和单细胞多组学的最新进展,可能推动从静态读数转向更全面的多基因UPR特征。这有望以前所未有的分辨率解析蛋白质稳态异质性。在本综述中,我们从泛癌视角出发,探讨如何利用这些定量特征来绘制蛋白质稳态状态。通过结合细胞生物学、力学生物学和计算病理学,我们提出的转化框架将形态学标志与多组学UPR特征相融合。尽管仍需前瞻性临床验证,但该方法可能改善患者分层和治疗决策,推动精准肿瘤学领域的发展。
Cancer letters IF 11.8 2026-10-06 PMID: 42838218
Lymph node metastasis (LNM) is a major determinant of staging and outcome in cholangiocarcinoma (CCA), yet its mechanisms, biomarkers, anatomical heterogeneity, and treatment evidence remain insufficiently integrated. This review develops an LNM-centered framework in which lymphatic invasion, lymphangiogenesis, genomic alterations and metabolic reprogramming, and reciprocal tumor microenvironment remodeling interact to shape CCA LNM by enabling lymphatic entry, dissemination, immune evasion, tumor-cell survival, and nodal colonization. A subtype-aware synthesis distinguishes small-duct-type and large-duct-type intrahepatic CCA, positions the latter as a biological bridge to perihilar and distal CCA, and maps subtype-associated lymphangiogenic, matrix-remodeling, metabolic, stromal, and immune programs. Translationally, serum ANGPTL4 and exosomal TTN-AS1 are prioritized as candidate adjuncts to preoperative radiologic nodal assessment and CA19-9, whereas tissue ITGB6 represents a comparatively well-characterized candidate for postoperative or biopsy-integrated LNM risk assessment. For node-positive CCA requiring systemic therapy, PD-1/PD-L1 blockade plus gemcitabine-cisplatin provides the first-line backbone. Additional opportunities include intensified chemoimmunotherapy and antiangiogenic combinations, postoperative and locoregional multimodal treatment, genotype-directed or cellular therapies, and mechanism-informed targeting of chemoresistance, oncogenic and lymphangiogenic signaling, stromal and immune niches, and metabolic adaptation. Epigenetic circuitry and post-transcriptional regulation represent emerging regulatory layers, while microbiome-immune interactions provide testable hypotheses for LNM. We propose spatial multi-omics across paired primary tumors, pathologically negative tumor-draining nodes, and metastatic nodes, integrated with pathology-validated liquid biopsy, to identify where metastatic competence emerges and how nodal niches are conditioned. Together, this mechanism-to-clinic synthesis provides a subtype-aware roadmap for biomarker validation, LNM-specific endpoints, and rational therapeutic intervention.
中文摘要:淋巴结转移(LNM)是胆管癌(CCA)分期和结局的主要决定因素,但其机制、生物标志物、解剖异质性及治疗证据仍整合不足。本综述构建了一个以LNM为核心的框架,其中淋巴管侵犯、淋巴管生成、基因组改变与代谢重编程以及肿瘤微环境的相互重塑共同作用,通过促进淋巴管进入、播散、免疫逃逸、肿瘤细胞存活和淋巴结定植来塑造CCA的LNM。基于亚型的综合梳理区分了小胆管型和大胆管型肝内胆管癌,将后者定位为通向肝门部胆管癌和远端胆管癌的生物学桥梁,并绘制了与亚型相关的淋巴管生成、基质重塑、代谢、间质和免疫程序。在转化层面,血清ANGPTL4和外泌体TTN-AS1被优先作为术前影像学淋巴结评估和CA19-9的候选辅助指标,而组织ITGB6则是相对研究较充分的候选标志物,可用于术后或整合活检的LNM风险评估。对于需要全身治疗的淋巴结阳性CCA,PD-1/PD-L1阻断联合吉西他滨-顺铂构成一线骨干方案。其他机会包括强化化疗免疫治疗和抗血管生成联合方案、术后及局部区域多模式治疗、基因型导向或细胞治疗,以及基于机制靶向化疗耐药、致癌和淋巴管生成信号、基质和免疫微环境以及代谢适应。表观遗传回路和转录后调控是新兴的调控层面,而微生物组-免疫相互作用为LNM提供了可检验的假说。我们提出对配对的原发肿瘤、病理阴性肿瘤引流淋巴结和转移淋巴结开展空间多组学,并与经病理学验证的液体活检整合,以识别转移能力在何处出现以及淋巴结微环境如何被塑造。总之,这一从机制到临床的综合梳理为生物标志物验证、LNM特异性终点和合理治疗干预提供了具有亚型意识的路线图。
Cancer letters IF 11.8 2026-10-06 PMID: 42838217
An aberrant mechanical microenvironment is a major driver of malignant tumor progression. Its effects are not limited to the immediate regulation of tumor cell behavior. Through mechanotransduction-mediated epigenetic remodeling, external physical cues can also be converted into persistent malignant programs. Mechanical alterations in the physical tumor microenvironment, including increased matrix stiffness, compressive stress, fluid shear stress, and spatial confinement, can be sensed by integrin adhesion complexes, mechanosensitive ion channels, and the nucleo-cytoskeletal system. These signals are then transmitted to the nucleus through multiple pathways, leading to systematic remodeling of multilayered epigenetic networks, including DNA methylation, histone modifications, chromatin accessibility, and RNA modifications. Notably, some mechanically induced nuclear alterations can be retained even after the original stimulus is attenuated, thereby forming "mechanical memory." This enables tumor cells to maintain malignant phenotypes such as invasion, metastasis, stem-like states, and therapeutic resistance during transitions between distinct microenvironments. In this review, we systematically summarize the key mechanisms by which mechanical signals regulate epigenetic processes across multiple epigenetic layers, with a particular focus on the basis and functional significance of mechanical memory. We also discuss therapeutic strategies targeting mechano-epigenetic coupling nodes and highlight recent advances in clinical translation. A deeper understanding of how mechanical cues are epigenetically written into and maintained as stable malignant states will provide new theoretical insights and potential therapeutic targets for the precision treatment of solid tumors.
中文摘要:异常的力学微环境是恶性肿瘤进展的主要驱动因素。其影响不仅限于对肿瘤细胞行为的即时调控。通过机械转导介导的表观遗传重塑,外部物理线索还可被转化为持续性的恶性程序。物理性肿瘤微环境中的力学改变,包括基质硬度增加、压缩应力、流体剪切应力和空间限制,可由整合素黏附复合体、机械敏感离子通道及核-细胞骨架系统感知。这些信号随后经多条途径传递至细胞核,导致多层表观遗传网络的系统性重塑,包括DNA甲基化、组蛋白修饰、染色质可及性和RNA修饰。值得注意的是,某些机械诱导的核内改变即使在原始刺激减弱后仍可保留,从而形成「机械记忆」。这使肿瘤细胞能够在不同微环境之间转换时维持恶性表型,如侵袭、转移、干细胞样状态和治疗耐药。在本综述中,我们系统总结机械信号在多个表观遗传层面调控表观遗传过程的关键机制,特别关注机械记忆的基础及其功能意义。我们还讨论靶向机械-表观遗传耦合节点的治疗策略,并强调临床转化中的最新进展。更深入理解力学线索如何以表观遗传方式被写入并维持为稳定的恶性状态,将为实体瘤的精准治疗提供新的理论见解和潜在治疗靶点。
Cell IF 45.1 2026-10-06 PMID: 42838046
Metabolic competition between tumors and T cells drives immune evasion, but the transporters and mechanisms remain largely elusive. Here, we establish the CareSLCs platform and identify that SLC52A3-mediated vitamin B2 (VB2) uptake is indispensable for T cell antitumor immunity. Mechanistically, VB2 deficiency impairs mitochondrial respiration and glutathione regeneration, leading to mitophagy, labile iron accumulation, and lipid peroxidation that trigger T cell ferroptosis. Unexpectedly, tumors preferentially employ SLC52A2, not SLC52A3, to scavenge VB2 and outcompete T cells. Tumor SLC52A2 ablation enhances T cell function in immunocompetent hosts without appreciably affecting intrinsic tumor growth. Clinically, high tumoral SLC52A2 correlates with T cell dysfunction and poor survival, whereas dietary VB2 intake is associated with reduced cancer risks. Thus, VB2 supplementation or SLC52A3 overexpression augments CAR-T cell antitumor efficacy. Our results suggest that tumoral VB2 competition establishes a metabolic checkpoint driving T cell ferroptosis and that enhancing VB2 uptake reinvigorates T cells to improve cancer immunotherapy.
中文摘要:肿瘤与T细胞之间的代谢竞争会驱动免疫逃逸,但相关转运蛋白及机制仍大多不明。在此,我们建立了CareSLCs平台,并发现SLC52A3介导的维生素B2(VB2)摄取对T细胞抗肿瘤免疫不可或缺。机制上,VB2缺乏会损害线粒体呼吸和谷胱甘肽再生,导致线粒体自噬、不稳定铁蓄积和脂质过氧化,从而触发T细胞铁死亡。出乎意料的是,肿瘤优先使用SLC52A2而非SLC52A3来清除VB2,并以此在与T细胞的竞争中胜出。在免疫功能正常的宿主中,敲除肿瘤SLC52A2可增强T细胞功能,而对肿瘤自身生长没有明显影响。临床上,肿瘤SLC52A2高表达与T细胞功能障碍和较差生存相关,而膳食VB2摄入则与癌症风险降低相关。因此,补充VB2或过表达SLC52A3可增强CAR-T细胞的抗肿瘤疗效。我们的结果提示,肿瘤对VB2的竞争建立了一个驱动T细胞铁死亡的代谢检查点,而增强VB2摄取可使T细胞恢复活力,从而改善癌症免疫治疗。
Cell IF 45.1 2026-10-06 PMID: 42838045
Sex differences in cancer therapy response remain poorly understood. Using a "phase II-like preclinical trial" across 55 CLDN18.2+ pancreatic cancer patient-derived xenografts, we identify marked female-biased resistance to CLDN18.2-targeted antibody-drug conjugate (ADC) therapy despite equivalent antigen expression. Mechanistically, estrogen signals through GPER1 to upregulate TRAF6, redirecting tumor-intrinsic STING signaling from IRF3-mediated interferon production toward nuclear factor κB (NF-κB) activation. This drives CXCL1 secretion, neutrophil recruitment, and neutrophil extracellular trap (NET) formation. NETs form a charged extracellular network that restricts antibody access to tumor-cell-surface antigens-a mechanism we term functional antigen shielding-reducing ADC cytotoxicity independently of antigen expression. The NET burden also correlated with poorer responses to trastuzumab, cetuximab, and enfortumab vedotin across three clinical cohorts. Pharmacologic NET disruption with sivelestat restored ADC efficacy in female mice. These findings reveal an estrogen-driven resistance mechanism with broad implications for antibody-based cancer therapy.
中文摘要:癌症治疗反应中的性别差异仍未被充分理解。我们在55例CLDN18.2阳性胰腺癌患者来源异种移植瘤中开展了一项「II期临床试验样临床前试验」,发现尽管抗原表达相当,仍存在显著女性偏向的对CLDN18.2靶向抗体药物偶联物(ADC)治疗的耐药性。机制上,雌激素通过GPER1信号上调TRAF6,使肿瘤内在STING信号从IRF3介导的干扰素产生转向核因子κB(NF-κB)激活。这驱动CXCL1分泌、中性粒细胞募集和中性粒细胞胞外诱捕网(NET)形成。NET形成带电荷的细胞外网络,限制抗体接近肿瘤细胞表面抗原——我们将这一机制称为「功能性抗原屏蔽」——从而在不依赖抗原表达的情况下降低ADC细胞毒性。NET负荷还与三个临床队列中曲妥珠单抗、西妥昔单抗和维恩妥尤单抗(enfortumab vedotin)较差的反应相关。使用西维来司他进行药理学NET破坏可恢复雌性小鼠中的ADC疗效。这些发现揭示了一种由雌激素驱动的耐药机制,对基于抗体的癌症治疗具有广泛意义。
Cell metabolism IF 37.0 2026-10-06 PMID: 42838033
In a recent issue of Nature, Desharnais and colleagues show that diet-dependent remodeling of the gut microbiome promotes anti-tumor immunity and may explain the enhanced efficacy of immune checkpoint blockade observed in obesity. Their study identifies dietary intervention as a promising strategy to optimize the host for cancer immunotherapy.
中文摘要:在近期一期的《自然》中,Desharnais及其同事表明,饮食依赖性的肠道微生物组重塑可促进抗肿瘤免疫,并可能解释在肥胖中观察到的免疫检查点阻断疗效增强。他们的研究将饮食干预确定为优化宿主以进行癌症免疫治疗的一种有前景的策略。
Cancer research IF 22.6 2026-10-06 PMID: 42836774
Immune checkpoint blockade (ICB) has shown limited efficacy in metastatic breast cancer. Resistance mechanisms involve suppressive myeloid and stromal populations in the tumor microenvironment (TME). In this issue of Cancer Research, Gonzalez and colleagues integrate single-cell transcriptomics, spatial proteomics, functional immunology, and mathematical modeling to dissect how combined treatment with the histone deacetylase (HDAC) inhibitor entinostat and anti-PD-1/anti-CTLA-4 blockade (EPC) sensitizes these refractory tumors. Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression (via ICAM-1 and IFNγ signaling) along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation. Some of these findings are further validated in biospecimens from patients on a phase Ib trial treated with the EPC combination treatment. Mathematical modeling formalizes this insight, demonstrating that simultaneous modulation of T-cell activation and myeloid suppression, rather than either alone, is required to drive tumor eradication in silico. This work highlights the increasingly accepted idea that the answer to how current treatments modify and shape tumors is multifactorial. Thus, diversified strategies that include comprehensive analysis of the TME, mathematical modeling tools, and validation in human specimens are required to optimize treatment efficacy. See related article by Gonzalez et al., p. XX .
中文摘要:免疫检查点阻断(ICB)在转移性乳腺癌中疗效有限。耐药机制涉及肿瘤微环境(TME)中具有抑制作用的髓系和基质细胞群体。在本期《Cancer Research》中,Gonzalez及其同事整合单细胞转录组学、空间蛋白质组学、功能免疫学和数学建模,剖析组蛋白去乙酰化酶(HDAC)抑制剂恩替诺特联合抗PD-1/抗CTLA-4阻断(EPC)如何使这些难治性肿瘤敏感。使用转移性小鼠模型的研究表明,抗肿瘤反应是多因素的,包括下调髓系介导的CD8+ T细胞抑制(通过ICAM-1和IFNγ信号通路),同时增加B细胞和浆细胞活化、抗体产生以及三级淋巴结构(TLS)成熟。其中一些发现在接受EPC联合治疗的一项Ib期试验患者的生物标本中得到进一步验证。数学建模将这一见解形式化,表明在计算机模拟中,需要同时调节T细胞活化和髓系抑制,而非单独调节其中任一者,才能推动肿瘤清除。这项工作强调了日益被接受的观点:当前治疗如何改变和塑造肿瘤的答案是多因素的。因此,需要包括对TME的全面分析、数学建模工具以及在人类标本中的验证在内的多样化策略,以优化治疗疗效。参见Gonzalez等人的相关文章,第XX页。
Cell metabolism IF 37.0 2026-10-06 PMID: 42664974
Cancer progression is systemically influenced by distant organ dysfunction induced by primary tumors, yet how long-distance tumor-organ crosstalk regulates antitumor immunity remains unclear. Here, we identify host metadherin (MTDH) as a critical regulator of tumor-induced immunosuppression and metabolic reprogramming via tumor-liver interactions. Using Mtdh knockout mouse models, we show that concurrent MTDH loss in hepatocytes and CD8+ T cells enhances effector T cell function and suppresses tumor growth and metastasis. Mechanistically, tumor-derived extracellular vesicles and particles (EVPs) activate Kupffer cells to secrete tumor necrosis factor α (TNF-α) and TGF-β, which suppress hepatic PPARα-mediated lipid oxidation via nuclear factor κB (NF-κB) signaling. MTDH loss restores hepatic lipid catabolism, reduces systemic lipid levels, and promotes mitochondrial metabolic reprogramming in CD8+ T cells under lipid-reduced conditions, thereby boosting antitumor immunity. Genetic or pharmacological targeting of MTDH synergizes with anti-PD-1 therapy. These findings establish host MTDH as a key mediator of tumor-liver crosstalk through metabolic and immune interactions, driving systemic cancer progression.
中文摘要:癌症进展会受到原发肿瘤诱导的远处器官功能障碍的系统性影响,但远距离肿瘤-器官串扰如何调控抗肿瘤免疫仍不清楚。在此,我们发现宿主metadherin(MTDH)是通过肿瘤-肝脏相互作用介导肿瘤诱导的免疫抑制和代谢重编程的关键调控因子。利用Mtdh敲除小鼠模型,我们表明肝细胞和CD8+ T细胞中同时缺失MTDH可增强效应T细胞功能,并抑制肿瘤生长和转移。机制上,肿瘤来源的细胞外囊泡和颗粒(EVPs)激活Kupffer细胞分泌肿瘤坏死因子α(TNF-α)和TGF-β,后者通过核因子κB(NF-κB)信号通路抑制肝脏PPARα介导的脂质氧化。MTDH缺失可恢复肝脏脂质分解代谢,降低全身脂质水平,并促进脂质减少条件下CD8+ T细胞的线粒体代谢重编程,从而增强抗肿瘤免疫。遗传或药理学靶向MTDH可与抗PD-1治疗协同。这些发现确立宿主MTDH作为肿瘤-肝脏串扰通过代谢和免疫相互作用的关键介质,驱动系统性癌症进展。
Advanced healthcare materials IF 11.0 2026-10-05 PMID: 42834743
Lactate, as a key metabolite in the tumor microenvironment (TME), has been reported to inhibit the stimulator of interferon genes (STING) pathway and contribute to immunosuppression and tumor progression. Here, we develop a dual-enzyme delivery system (Fuc@ZIF-GOx-LOx, FZGL) that is coated with fucoidan (Fuc) and loaded with glucose oxidase (GOx) and lactate oxidase (LOx) based on zinc imidazolate framework-90 (ZIF-90), to inhibit breast cancer metastasis by "source interception and downstream blockade" of lactate. FZGL targets tumor cells via Fuc and releases GOx and LOx by the ATP-responsive degradation of ZIF-90. GOx rapidly consumes glucose to block lactate generation from the source ("source interception") and induces disulfidptosis in tumor cells. LOx degrades accumulated lactate ("downstream blockade") to alleviate immunosuppression. FZGL activates the cGAS-STING pathway by damaging mitochondria and inducing mitochondrial DNA (mtDNA) release. Furthermore, lactate depletion can relieve lactate-mediated inhibition of STING signaling, thereby enhancing the anti-tumor immune response. In vivo experiments demonstrate that FZGL significantly promotes T cell infiltration and M1 macrophage polarization, and effectively inhibits the growth and lung metastasis of breast cancer. Our study provides a new approach for metastatic breast cancer treatment through lactate metabolism intervention.
中文摘要:乳酸作为肿瘤微环境(TME)中的关键代谢物,已被报道可抑制干扰素基因刺激因子(STING)通路,并促进免疫抑制和肿瘤进展。在此,我们开发了一种双酶递送系统(Fuc@ZIF-GOx-LOx,FZGL),其基于锌咪唑酯骨架-90(ZIF-90),表面包覆岩藻多糖(Fuc),并负载葡萄糖氧化酶(GOx)和乳酸氧化酶(LOx),通过乳酸的「源头拦截和下游阻断」来抑制乳腺癌转移。FZGL通过Fuc靶向肿瘤细胞,并借助ZIF-90的ATP响应性降解释放GOx和LOx。GOx迅速消耗葡萄糖,从源头阻断乳酸生成(「源头拦截」),并诱导肿瘤细胞发生二硫死亡。LOx降解蓄积的乳酸(「下游阻断」),从而缓解免疫抑制。FZGL通过损伤线粒体并诱导线粒体DNA(mtDNA)释放来激活cGAS-STING通路。此外,乳酸耗竭可解除乳酸对STING信号传导的抑制,从而增强抗肿瘤免疫应答。体内实验表明,FZGL显著促进T细胞浸润和M1巨噬细胞极化,并有效抑制乳腺癌生长和肺转移。我们的研究通过干预乳酸代谢,为转移性乳腺癌治疗提供了一种新方法。
Journal for immunotherapy of cancer IF 11.7 2026-10-05 PMID: 42833861
KRAS-mutant lung adenocarcinoma (LUAD) shows limited benefit from immune checkpoint blockade (ICB), and the mechanisms by which oncogenic KRAS signaling promotes immune resistance remain poorly understood. Here, we sought to identify tumor-intrinsic mediators of KRAS-driven immune evasion and therapeutic resistance in LUAD. Integrated analyses of human LUAD cohorts, genetically engineered mouse models, tumor cell models, and patient-derived organoids were performed to define the role of PRTN3 in immune regulation. PRTN3 regulation and function were investigated using transcriptional analyses, chromatin immunoprecipitation assays, biochemical cleavage assays, and immune cell co-culture systems. The therapeutic effect of PRTN3 inhibition was evaluated using flow cytometric immune profiling, functional immune assays, and syngeneic tumor models. We identified PRTN3 as a downstream effector of KRAS signaling that promotes immune evasion in LUAD. Mechanistically, KRAS signaling transcriptionally upregulated PRTN3 through c-Myc activation. Secreted PRTN3 directly cleaved and inactivated CXCL9 in the tumor microenvironment, disrupting CXCL9/CXCR3 signaling and impairing the recruitment and activation of cytotoxic CD8+ T cells and natural killer cells. In patients with LUAD, elevated PRTN3 expression was associated with reduced cytotoxic immune signatures and decreased CXCL9 activity. Genetic inhibition of PRTN3 enhanced antitumor immunity and improved responses to anti-programmed cell death protein 1 therapy in vivo. Furthermore, a hydrolysis-resistant CXCL9 variant restored cytotoxic lymphocyte activation and enhanced immune-mediated tumor cell killing in patient-derived organoids. Our findings reveal a KRAS/c-Myc/PRTN3 axis that promotes immune suppression through extracellular proteolytic inactivation of CXCL9. Targeting PRTN3-mediated immune evasion may represent a promising strategy to enhance ICB efficacy in KRAS-driven LUAD.
中文摘要:KRAS突变肺腺癌(LUAD)从免疫检查点阻断(ICB)中获益有限,而致癌KRAS信号促进免疫抵抗的机制仍知之甚少。在此,我们试图确定LUAD中KRAS驱动免疫逃逸和治疗抵抗的肿瘤内在介质。我们对人类LUAD队列、基因工程小鼠模型、肿瘤细胞模型和患者来源类器官进行了整合分析,以界定PRTN3在免疫调节中的作用。我们利用转录分析、染色质免疫沉淀试验、生化切割试验和免疫细胞共培养系统研究了PRTN3的调控和功能。我们使用流式细胞术免疫分析、功能性免疫试验和同基因肿瘤模型评估了抑制PRTN3的治疗效果。我们发现PRTN3是KRAS信号的下游效应因子,可促进LUAD免疫逃逸。机制上,KRAS信号通过c-Myc激活在转录水平上调PRTN3。分泌的PRTN3直接切割并灭活肿瘤微环境中的CXCL9,破坏CXCL9/CXCR3信号,并损害细胞毒性CD8+ T细胞和自然杀伤细胞的招募与激活。在LUAD患者中,PRTN3表达升高与细胞毒性免疫特征减少和CXCL9活性降低相关。在体内,对PRTN3进行基因抑制可增强抗肿瘤免疫并改善对抗程序性细胞死亡蛋白1治疗的反应。此外,一种抗水解的CXCL9变体恢复了细胞毒性淋巴细胞激活,并增强了患者来源类器官中免疫介导的肿瘤细胞杀伤。我们的发现揭示了一条KRAS/c-Myc/PRTN3轴,其通过细胞外蛋白水解灭活CXCL9促进免疫抑制。靶向PRTN3介导的免疫逃逸可能是增强KRAS驱动LUAD中ICB疗效的一种有前景的策略。
Cancer research IF 22.6 2026-10-05 PMID: 42832699
Clinical outcomes are often suboptimal in colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy (NAC). A key determinant of the response to NAC is the functional state of tumor-infiltrating immune cells. Understanding how NAC reshapes the immunological landscape will be essential for refining patient stratification and identifying effective combination treatment strategies. Here, we analyzed paired samples before and after NAC treatment by single-cell RNA sequencing, revealing that NAC treatment significantly reshaped the immune microenvironment. Tumors from NAC non-responders featured increased immunosuppressive M2-like macrophage infiltration, which correlated with elevated phosphatidylserine-specific phospholipase A1 (PLA1A). Mechanistically, PLA1A hydrolyzed phosphatidylserine (PS) exposed by chemotherapy to elevate lysophosphatidylserine (LysoPS), which activated the P2ry10 receptor and downstream signaling to promote M2-like macrophage polarization. Importantly, pharmacological inhibition of PLA1A by cilengitide synergized with chemoimmunotherapy to suppress tumor progression in murine models. Clinically, high plasma PLA1A levels negatively correlated with responses to chemoimmunotherapy. Collectively, these findings reveal a chemotherapy-driven metabolic axis that induces an immunosuppressive milieu by increasing lysoPS release. This axis highlights PLA1A as a therapeutic target to mitigate immunosuppression and improve chemoimmunotherapy efficacy.
中文摘要:接受新辅助化疗(NAC)的结直肠癌(CRC)患者临床结局往往不理想。NAC疗效的关键决定因素是肿瘤浸润免疫细胞的功能状态。理解NAC如何重塑免疫景观对于优化患者分层和确定有效的联合治疗策略至关重要。在此,我们通过单细胞RNA测序分析了NAC治疗前后的配对样本,揭示NAC治疗显著重塑了免疫微环境。NAC无应答者的肿瘤表现为免疫抑制性M2样巨噬细胞浸润增加,这与磷脂酰丝氨酸特异性磷脂酶A1(PLA1A)升高相关。机制上,PLA1A水解化疗暴露的磷脂酰丝氨酸(PS)以升高溶血磷脂酰丝氨酸(LysoPS),后者激活P2ry10受体及下游信号,促进M2样巨噬细胞极化。重要的是,西仑吉肽对PLA1A的药理学抑制与化疗免疫治疗协同抑制了小鼠模型中的肿瘤进展。临床上,高血浆PLA1A水平与化疗免疫治疗应答呈负相关。总之,这些发现揭示了一条化疗驱动的代谢轴,其通过增加LysoPS释放诱导免疫抑制微环境。该轴凸显PLA1A作为减轻免疫抑制并提高化疗免疫治疗疗效的治疗靶点。
Cancer research IF 22.6 2026-10-05 PMID: 42832697
Despite the clinical success of programmed cell death protein 1 (PD-1) checkpoint blockade in many cancer types, its efficacy in glioblastoma remains notably limited, underscoring the critical need to uncover primary resistance mechanisms and identify synergistic therapeutic targets. To discover genes modulating αPD-1 immunotherapy response, we performed an in vivo CRISPR-Cas9 screen in immunocompetent mice bearing glioblastoma, which prioritized the glutamine (Gln) transporter SLC38A5 as a candidate modulator of αPD-1 immunotherapy efficacy. In human glioblastoma, SLC38A5 was significantly upregulated compared with normal brain tissue. Ablation of SLC38A5 did not impair glioblastoma cell intrinsic growth but profoundly sensitized glioblastoma to αPD-1 therapy in a CD8+ T cell-dependent manner, leading to enhanced anti-tumor immunity and tumor control. Mechanistically, SLC38A5 deficiency created a Gln-enriched tumor microenvironment by impairing Gln uptake of glioblastoma cells. This metabolic rewiring enhanced CD8+ T cell function via SLC1A5-dependent Gln utilization and promoted MHC-I-mediated antigen presentation in glioblastoma cells through a Gln-glutathione (GSH)-reactive oxygen species (ROS) axis. Furthermore, an SLC38A5-targeting nanobody was developed that efficiently accumulated in orthotopic glioblastoma and potentiated αPD-1 therapy to suppress brain tumor growth in vivo. Overall, this study establishes SLC38A5 as a metabolic immune regulator in glioblastoma and presents a promising Nb-based strategy for overcoming αPD-1 immunotherapy resistance.
中文摘要:尽管程序性细胞死亡蛋白1(PD-1)检查点阻断在许多癌症类型中取得临床成功,但其在胶质母细胞瘤中的疗效仍显著有限,这凸显了揭示原发性耐药机制并确定协同治疗靶点的迫切需求。为了发现调节αPD-1免疫治疗应答的基因,我们在荷胶质母细胞瘤的免疫健全小鼠中进行了体内CRISPR-Cas9筛选,该筛选将谷氨酰胺(Gln)转运体SLC38A5列为αPD-1免疫治疗疗效的候选调节因子。在人类胶质母细胞瘤中,SLC38A5较正常脑组织显著上调。敲除SLC38A5并不损害胶质母细胞瘤细胞的内在生长,但以CD8+ T细胞依赖的方式使胶质母细胞瘤对αPD-1治疗深度敏感,从而增强抗肿瘤免疫和肿瘤控制。机制上,SLC38A5缺失通过损害胶质母细胞瘤细胞对Gln的摄取,构建了富含Gln的肿瘤微环境。这种代谢重编程通过SLC1A5依赖的Gln利用增强CD8+ T细胞功能,并通过Gln-谷胱甘肽(GSH)-活性氧(ROS)轴促进胶质母细胞瘤细胞中MHC-I介导的抗原呈递。此外,开发了一种靶向SLC38A5的纳米抗体,其可在原位胶质母细胞瘤中有效蓄积,并增强αPD-1治疗以在体内抑制脑肿瘤生长。总体而言,本研究确立SLC38A5为胶质母细胞瘤中的代谢免疫调节因子,并提出了一种有前景的基于纳米抗体的策略,用于克服αPD-1免疫治疗耐药。
Cancer research IF 22.6 2026-10-05 PMID: 42831539
Fibroblast activation and extracellular matrix stiffening are hallmarks of the fibrotic tumor microenvironment. Fibrotic microenvironmental remodeling is also linked to immune exclusion and evasion, suggesting that common microenvironmental signals might coordinate both fibrotic and inflammatory outputs. Here, we identified methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) as a redox-sensitive metabolic regulator linking TGF-β-driven fibroblast activation to inflammatory signaling in lung adenocarcinoma (LUAD). MTHFD2 was elevated in cancer-associated fibroblasts across multiple scRNA-seq datasets, and TGF-β induced MTHFD2 even under compliant matrix conditions, with matrix stiffening further enhancing its expression. Notably, while MTHFD2 knockdown suppressed both myofibroblastic and inflammatory programs, enforced expression was sufficient to drive inflammatory cytokine production even in the absence of TGF-β, and this response was further amplified by concomitant TGF-β signaling. These MTHFD2-mediated responses depended on redox perturbation rather than biosynthetic one-carbon metabolism, as they resisted formate supplementation but responded to pro-oxidants. Mechanistically, MTHFD2-driven redox imbalance promoted mitochondrial stress, cytosolic mitochondrial DNA accumulation, and activation of the cGAS-STING-NF-κB pathway, resulting in IL-6 and IL-8 production. Fibroblast-specific MTHFD2 knockdown suppressed paracrine PD-L1 induction in tumor cells and inhibited tumor growth in vivo in an immune-dependent manner. Clinically, high stromal MTHFD2 correlated with epithelial PD-L1 expression and poor LUAD prognosis. Together, these findings identify stromal MTHFD2 as a redox-sensitive metabolic checkpoint linking fibrotic remodeling to immune evasion.
中文摘要:成纤维细胞活化和细胞外基质硬化是纤维化肿瘤微环境的标志。纤维化微环境重塑也与免疫排斥和免疫逃逸相关,提示共同的微环境信号可能协调纤维化和炎症两种输出。在此,我们将亚甲基四氢叶酸脱氢酶2(MTHFD2)鉴定为一种氧化还原敏感的代谢调节因子,将TGF-β驱动的成纤维细胞活化与肺腺癌(LUAD)中的炎症信号联系起来。在多个scRNA-seq数据集中,MTHFD2在癌相关成纤维细胞中升高;即使在顺应性基质条件下,TGF-β也可诱导MTHFD2,而基质硬化进一步增强其表达。值得注意的是,虽然敲低MTHFD2可抑制肌成纤维细胞和炎症程序,但强制表达足以在缺乏TGF-β的情况下驱动炎症细胞因子产生,并且同时存在的TGF-β信号可进一步放大该反应。这些由MTHFD2介导的反应依赖于氧化还原扰动而非生物合成性一碳代谢,因为它们对甲酸盐补充具有抵抗性,但对促氧化剂有反应。机制上,MTHFD2驱动的氧化还原失衡促进线粒体应激、胞质线粒体DNA累积以及cGAS-STING-NF-κB通路活化,导致IL-6和IL-8产生。成纤维细胞特异性敲低MTHFD2可抑制肿瘤细胞中旁分泌诱导的PD-L1,并以免疫依赖方式在体内抑制肿瘤生长。临床上,高基质MTHFD2与上皮PD-L1表达和较差的LUAD预后相关。总之,这些发现将基质MTHFD2鉴定为一种氧化还原敏感的代谢检查点,将纤维化重塑与免疫逃逸联系起来。
Advanced healthcare materials IF 11.0 2026-10-05 PMID: 42831290
The tumor microenvironment (TME) is a complex and heterogeneous milieu encompassing biological and biochemical events and diverse physical, chemical, and mechanical interactions between tumor and stromal cells. This heterogeneity plays a pivotal role in regulating tumor progression, metastasis, and resistance to therapy. In breast cancer, cancer-associated fibroblasts, adipocytes, endothelial cells, and immune cells all contribute to this intricate environment, necessitating precise spatial and cellular modeling to better replicate physiological conditions. Moreover, angiogenesis and metastasis are key contributors to breast cancer mortality. Therefore, three-dimensional (3D) models that incorporate co-cultures of cancer and stromal cells are essential for recreating realistic TMEs. This review highlights the advances in 3D bioprinting technologies for modeling the breast cancer TME. We discuss their potential in drug screening, explore their advantages and limitations, and outline future directions to enhance their fidelity and translational relevance.
中文摘要:肿瘤微环境(TME)是一个复杂且异质的微环境,涵盖生物学和生物化学事件,以及肿瘤细胞与基质细胞之间多种物理、化学和机械相互作用。这种异质性在调控肿瘤进展、转移和治疗耐药中发挥关键作用。在乳腺癌中,癌相关成纤维细胞、脂肪细胞、内皮细胞和免疫细胞均参与构成这一复杂环境,因此需要精确的空间和细胞建模以更好地再现生理条件。此外,血管生成和转移是导致乳腺癌死亡的关键因素。因此,纳入癌细胞与基质细胞共培养的三维(3D)模型对于重建逼真的TME至关重要。本综述重点介绍用于构建乳腺癌TME模型的3D生物打印技术的进展。我们讨论其在药物筛选中的潜力,探讨其优势与局限性,并概述提高其保真度和转化相关性的未来方向。
Molecular biomedicine IF 13.0 2026-10-05 PMID: 42830367
Neoadjuvant chemotherapy (NAC) for colorectal cancer liver metastasis (CRLM) remains a major clinical challenge, with outcomes varying widely among patients, yet the mechanisms that drive therapeutic resistance remain incompletely understood. In this study, we integrated single‑cell RNA‑sequencing and spatial transcriptomics of patient tumor specimens to dissect the interplay between the hepatic tumor microenvironment and chemotherapy resistance. We identified a specific macrophage subpopulation marked by elevated expression of Secreted Phosphoprotein 1 (SPP1) that is significantly enriched in insufficient responders to NAC. Mechanistically, these SPP1 + macrophages exhibit a pro‑tumoral transcriptomic profile and directly suppress CD8 + T cell cytotoxic function through the SPP1‑CD44 signaling axis, as demonstrated by in vitro co‑culture assays, a large‑scale tissue microarray, and multiple syngeneic mouse models. Spatially, they are scattered throughout the tumour and form dense barriers that sequester CD8 + T cells and drive their exhaustion. Strikingly, this spatial configuration inversely correlates with cytotoxic activity and adaptive immune signatures and thereby reinforces a local immunosuppressive niche that sustains chemoresistance. These data provide the missing link: effective chemotherapy requires an immune‑active hepatic microenvironment, and SPP1 + macrophage infiltration actively disrupts this state, which in turn promotes clinical resistance. In a preclinical CRLM model, SPP1 blockade synergised with anti‑PD‑1, inducing significant tumour regression and restoring T‑cell function. Collectively, our findings position SPP1 + macrophages as central drivers of NAC resistance in CRLM and highlight the spatial immune barrier they create as a promising therapeutic target for overcoming chemoresistance and improving immunotherapy responses.
中文摘要:结直肠癌肝转移(CRLM)的新辅助化疗(NAC)仍是一项重大临床挑战,患者结局差异很大,而驱动治疗耐药性的机制仍未完全阐明。在本研究中,我们整合了患者肿瘤标本的单细胞RNA测序和空间转录组学,以解析肝脏肿瘤微环境与化疗耐药之间的相互作用。我们鉴定出一个以分泌型磷蛋白1(SPP1)表达升高为标志的特定巨噬细胞亚群,该亚群在NAC应答不足者中显著富集。在机制上,这些SPP1+巨噬细胞表现出促肿瘤转录组特征,并通过SPP1-CD44信号轴直接抑制CD8+ T细胞的细胞毒功能,这一点已由体外共培养实验、大规模组织芯片和多种同基因小鼠模型所证实。在空间上,它们散布于整个肿瘤中,并形成致密屏障,将CD8+ T细胞隔离并驱动其耗竭。引人注目的是,这种空间构型与细胞毒活性和适应性免疫特征呈负相关,从而强化了一个维持化疗耐药的局部免疫抑制生态位。这些数据提供了缺失的环节:有效的化疗需要免疫活跃的肝脏微环境,而SPP1+巨噬细胞浸润会主动破坏这种状态,进而促进临床耐药。在临床前CRLM模型中,阻断SPP1与抗PD-1协同作用,诱导显著肿瘤消退并恢复T细胞功能。总体而言,我们的发现将SPP1+巨噬细胞定位为CRLM中NAC耐药的核心驱动因素,并突出其形成的空间免疫屏障作为克服化疗耐药和改善免疫治疗应答的有前景的治疗靶点。
MedComm IF 14.1 2026-10 PMID: 42830947
Immune-cell dynamics within the tumor microenvironment (TME) determine whether immune cells can reach, recognize, and sustain antitumor function against malignant cells under suppressive pressure. These dynamics are shaped by hypoxia, nutrient stress, cytokine and chemokine signaling, stromal architecture, vascular access, and multicellular crosstalk, and are further regulated by transcriptional and epigenetic programs. In this review, we organize TME immunity around four major barriers to effective therapy: failed immune access, defective antigen visibility and priming, failure to sustain effector function, and suppressive tissue remodeling. We use FOSL2/Fra-2, a component of activator protein-1 (AP-1) transcription factor complexes, as an example of how local signals can produce distinct regulatory effects in malignant, immune, and stromal compartments. FOSL2-associated programs have been linked to differentiation, plasticity, myeloid and stromal remodeling, stress adaptation, and selected immune-regulatory processes; however, the strength and direction of these associations vary by lineage, tumor type, model system, and level of functional evidence. We distinguish perturbation-supported mechanisms from correlative state signatures and identify the need for spatial validation, functional perturbation, and biomarker validation. This perspective supports biomarker-guided TME-directed therapy matched to the dominant immune barrier.
中文摘要:肿瘤微环境(TME)中的免疫细胞动态决定免疫细胞能否在抑制性压力下到达、识别恶性细胞并维持抗肿瘤功能。这些动态受到缺氧、营养应激、细胞因子和趋化因子信号、基质结构、血管通路以及多细胞间串扰的影响,并进一步受到转录和表观遗传程序的调控。在这篇综述中,我们围绕有效治疗的四大障碍来组织TME免疫:免疫进入失败、抗原可见性和致敏缺陷、效应功能维持失败以及抑制性组织重塑。我们以FOSL2/Fra-2——激活蛋白-1(AP-1)转录因子复合物的一个组分——为例,说明局部信号如何在恶性、免疫和基质区室中产生不同的调控效应。FOSL2相关程序已被与分化、可塑性、髓系和基质重塑、应激适应以及部分免疫调控过程联系起来;然而,这些关联的强度和方向因谱系、肿瘤类型、模型系统及功能证据水平而异。我们区分扰动实验支持的机制与相关性状态特征,并指出需要进行空间验证、功能性扰动和生物标志物验证。这一观点支持根据主要免疫障碍匹配生物标志物指导的TME靶向治疗。
MedComm IF 14.1 2026-10 PMID: 42830873
Colorectal cancer (CRC) remains one of the most frequently diagnosed malignancies worldwide, and colorectal cancer liver metastasis (CRLM) represents a major cause of CRC-related mortality. The liver provides a highly specialized environment that can be remodeled into a metastatic niche, where anatomical structure, metabolic properties, and immunological landscape collectively influence tumor cell survival, colonization, and outgrowth. Increasing evidence indicates that CRLM development is driven by dynamic interactions between tumor intrinsic programs and the hepatic tumor microenvironment(TME), involving epithelial plasticity, intercellular communication, stromal remodeling, and immune regulation. However, an integrated understanding that links metastatic initiation, hepatic niche formation, immune escape, and therapeutic intervention remain lacking. This review examines recent advances in the multistage progression of CRLM and discusses how immune tolerance, lymphocyte dysfunction, and suppressive cellular networks contribute to the establishment and maintenance of the CRLM. Finally, we review current clinical management strategies and emerging approaches, immunotherapy, and biomarker-guided precision treatment. By integrating mechanistic insights with clinical perspectives, this review aims to provide a conceptual framework for understanding CRLM progression and to identify potential directions for improving individualized therapeutic strategies.
中文摘要:结直肠癌(CRC)仍是全球诊断最频繁的恶性肿瘤之一,而结直肠癌肝转移(CRLM)是CRC相关死亡的主要原因。肝脏提供了高度特殊的环境,可被重塑为转移生态位,其中解剖结构、代谢特性和免疫景观共同影响肿瘤细胞的存活、定植和生长。越来越多证据表明,CRLM的发生由肿瘤内在程序与肝脏肿瘤微环境(TME)之间的动态相互作用驱动,涉及上皮可塑性、细胞间通讯、基质重塑和免疫调节。然而,将转移起始、肝脏生态位形成、免疫逃逸和治疗干预联系起来的整合性认识仍然缺乏。本综述审视CRLM多阶段进展的最新进展,并讨论免疫耐受、淋巴细胞功能障碍和抑制性细胞网络如何促进CRLM的建立和维持。最后,我们回顾当前临床管理策略以及新兴方法、免疫治疗和生物标志物指导的精准治疗。通过整合机制认识与临床视角,本综述旨在为理解CRLM进展提供概念框架,并确定改善个体化治疗策略的潜在方向。
Cancer letters IF 11.8 2026-10-03 PMID: 42829067
Single-pathway targeted therapy is often insufficient to control malignant glioma progression, and the blood-brain barrier (BBB) remains a major obstacle to effective drug delivery. Therefore, discovering multifunctional target molecules and corresponding drugs that can penetrate the BBB can provide new strategies for targeted glioma therapy. Analysis of public databases and 179 clinical samples showed that solute carrier family 35 member F6 (SLC35F6) was upregulated in gliomas and associated with poorer clinical outcomes. Proteomic analyses and functional validation identified PIK3R2 as a potential downstream mediator of SLC35F6. Mechanistically, SLC35F6 knockdown reduced the abundance of the p85β-p110β complex and promoted proteasome-dependent degradation of p85β (encoded by PIK3R2). These findings support a model in which SLC35F6 maintains p85β stability, at least in part, by preserving the p85β-p110β association, with PIK3R2-associated PI3K/AKT signaling contributing to aerobic glycolysis, glioma cell proliferation, and reduced sensitivity to temozolomide (TMZ). In parallel, SLC35F6 promoted macrophage polarization toward the M2-like phenotype, with evidence supporting the involvement of the macrophage migration inhibitory factor (MIF)/CD74 axis, thereby contributing to an immunosuppressive tumor microenvironment. Leveraging these mechanisms, we developed a dual-ligand nanoplatform designed to facilitate trans-BBB delivery of siSLC35F6, TMZ, and an anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibody (α-PD-L1). SLC35F6 knockdown suppressed glycolytic reprogramming and induced changes in macrophage polarization consistent with a less immunosuppressive immune microenvironment, thereby enhancing glioma sensitivity to both TMZ and α-PD-L1. Collectively, this study identifies SLC35F6 as a potential therapeutic target for glioma and provides a rationale for further preclinical development of BBB-crossing combinatorial therapeutic approaches.
中文摘要:单通路靶向治疗往往不足以控制恶性胶质瘤进展,而血脑屏障(BBB)仍是有效药物递送的主要障碍。因此,发现能够穿透BBB的多功能靶点分子及相应药物,可为胶质瘤靶向治疗提供新策略。对公共数据库和179例临床样本的分析显示,溶质载体家族35成员F6(SLC35F6)在胶质瘤中上调,并与较差的临床结局相关。蛋白质组学分析和功能验证确定PIK3R2是SLC35F6的潜在下游介质。在机制上,敲低SLC35F6降低了p85β-p110β复合物的丰度,并促进p85β(由PIK3R2编码)的蛋白酶体依赖性降解。这些发现支持这样一种模型:SLC35F6至少部分通过维持p85β-p110β结合来维持p85β稳定性,而PIK3R2相关的PI3K/AKT信号传导促进有氧糖酵解、胶质瘤细胞增殖以及降低对替莫唑胺(TMZ)的敏感性。同时,SLC35F6促进巨噬细胞向M2样表型极化,并有证据支持巨噬细胞迁移抑制因子(MIF)/CD74轴的参与,从而促成免疫抑制性肿瘤微环境。基于这些机制,我们开发了一种双配体纳米平台,旨在促进siSLC35F6、TMZ和抗程序性死亡配体1(anti-PD-L1)单克隆抗体(α-PD-L1)的跨BBB递送。敲低SLC35F6抑制糖酵解重编程,并诱导与免疫抑制性较低的免疫微环境一致的巨噬细胞极化变化,从而增强胶质瘤对TMZ和α-PD-L1的敏感性。总体而言,本研究将SLC35F6确定为胶质瘤的潜在治疗靶点,并为进一步开展跨越BBB的联合治疗策略的临床前开发提供了依据。
MedComm IF 14.1 2026-10 PMID: 42827714
Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that couples B-cell receptor (BCR) signaling to broader immune-cell activation. By integrating signals from BCR, Toll-like receptors, chemokine receptors, Fc receptors, and BAFF receptors, BTK governs B-cell development, immune-cell migration, innate immunity, and inflammation. Inhibition of BTK has transformed the treatment landscape of B-cell malignancies, while the development of covalent, noncovalent, dual-target inhibitors, and BTK degraders has expanded therapeutic opportunities. However, the mechanisms of action, resistance patterns, and expanding therapeutic applications of BTK inhibitors (BTKis) across malignant and nonmalignant diseases have yet to be comprehensively integrated. This review outlines BTK structure and signaling pathways, BTKi classification, resistance mechanisms, and emerging therapeutic strategies with emphasis on monotherapy in B-cell malignancies and combination strategies involving CAR-T therapy, immune checkpoint inhibitors, CD20-targeted antibodies, BCL2 inhibitors, and hematopoietic stem cell transplantation. Mechanistically, these combinations enhance T-cell function, attenuate immune checkpoint signaling, and remodel the tumor microenvironment (TME). We further discuss BTKis in solid tumors, autoimmune diseases, and chronic inflammatory disorders. Collectively, this review integrates current advances in BTK-targeted therapy and highlights opportunities for precision treatment across oncology and immune-mediated diseases.
中文摘要:布鲁顿酪氨酸激酶(BTK)是一种非受体酪氨酸激酶,可将B细胞受体(BCR)信号与更广泛的免疫细胞激活耦合起来。通过整合来自BCR、Toll样受体、趋化因子受体、Fc受体和BAFF受体的信号,BTK调控B细胞发育、免疫细胞迁移、固有免疫和炎症。BTK抑制已改变了B细胞恶性肿瘤的治疗格局,而共价、非共价、双靶点抑制剂以及BTK降解剂的发展则拓展了治疗机会。然而,BTK抑制剂(BTKis)在恶性和非恶性疾病中的作用机制、耐药模式及不断扩展的治疗应用尚未得到全面整合。本综述概述了BTK的结构与信号通路、BTKi分类、耐药机制以及新兴治疗策略,重点讨论其在B细胞恶性肿瘤中的单药治疗,以及涉及CAR-T治疗、免疫检查点抑制剂、CD20靶向抗体、BCL2抑制剂和造血干细胞移植的联合策略。在机制上,这些联合方案可增强T细胞功能、减弱免疫检查点信号并重塑肿瘤微环境(TME)。我们进一步讨论了BTKis在实体瘤、自身免疫性疾病和慢性炎症性疾病中的应用。总之,本综述整合了BTK靶向治疗的当前进展,并强调了在肿瘤学和免疫介导性疾病中实现精准治疗的机会。
Journal of advanced research IF 17.1 2026-10-02 PMID: 42826900
Accumulating evidence demonstrates that antibody-dependent cellular phagocytosis (ADCP), mediated by tumor-associated macrophages via Fcγ receptors (FcγR), represents a key Fc-dependent effector mechanism for selected antitumor monoclonal antibodies, including rituximab in B-cell malignancies, trastuzumab in HER2-positive cancers, cetuximab in EGFR-expressing tumors, and daratumumab in multiple myeloma. Beyond direct tumor cell clearance, macrophage-driven ADCP acts as a critical innate-adaptive immune bridge by facilitating antigen processing, intercellular immune crosstalk and downstream adaptive immune activation. However, ADCP is not uniformly beneficial. Depending on target antigen properties, macrophage functional state, and tumor microenvironmental cues, excessive or dysregulated ADCP may instead drive macrophage dysfunction, immunosuppressive remodeling, adaptive resistance, and dose-limiting toxicities. These observations highlight the need for a more selective and mechanistically informed framework for understanding and therapeutically harnessing ADCP in cancer immunotherapy. This review summarizes the molecular regulation of ADCP, including FcγR signaling, cytoskeletal dynamics, phagosome formation and maturation, and phagocytosis checkpoint control, and discusses how these mechanisms shape phagocytic quality and therapeutic outcomes. We propose a conceptual shift from phagocytosis maximization to phagocytosis optimization and highlight strategies to improve the efficacy and safety of ADCP-based cancer immunotherapy. This review emphasizes four key concepts. First, it outlines the molecular cascade governing ADCP from FcγR-mediated signaling to phagosome maturation and degradation. Second, it highlights the dual roles of ADCP in tumor immunity, showing that productive ADCP promotes tumor clearance and immune priming, whereas dysregulated ADCP drives immunosuppression and toxicity. Third, it proposes that therapeutic ADCP should be defined by tumor selectivity and durable immune activation rather than engulfment alone. Fourth, it summarizes six major strategies to enhance beneficial ADCP, including Fc engineering, antigen-binding optimization, FcγRIIb blockade, targeting "don't-eat-me" signals, macrophage reprogramming, and combination with immune checkpoint inhibitors.
中文摘要:越来越多证据表明,由肿瘤相关巨噬细胞通过Fcγ受体(FcγR)介导的抗体依赖性细胞吞噬作用(ADCP)是多种抗肿瘤单克隆抗体的关键Fc依赖性效应机制,包括用于B细胞恶性肿瘤的利妥昔单抗、用于HER2阳性癌症的曲妥珠单抗、用于表达EGFR肿瘤的西妥昔单抗以及用于多发性骨髓瘤的达雷妥尤单抗。除直接清除肿瘤细胞外,巨噬细胞驱动的ADCP还通过促进抗原加工、细胞间免疫串扰和下游适应性免疫激活,充当先天性与适应性免疫之间的关键桥梁。然而,ADCP并非总是有益。取决于靶抗原特性、巨噬细胞功能状态和肿瘤微环境线索,过度或失调的ADCP反而可能驱动巨噬细胞功能障碍、免疫抑制性重塑、适应性耐药和剂量限制性毒性。这些观察凸显了需要一个更具选择性和机制导向的框架来理解并在癌症免疫治疗中治疗性利用ADCP。本综述总结了ADCP的分子调控,包括FcγR信号、细胞骨架动力学、吞噬体形成与成熟以及吞噬检查点控制,并讨论这些机制如何塑造吞噬质量和治疗结局。我们提出从吞噬最大化向吞噬优化的概念转变,并强调提高基于ADCP的癌症免疫治疗疗效和安全性的策略。本综述强调四个关键概念。第一,概述了从FcγR介导的信号到吞噬体成熟与降解的ADCP分子级联。第二,强调ADCP在肿瘤免疫中的双重作用,表明有效ADCP促进肿瘤清除和免疫致敏,而失调ADCP则驱动免疫抑制和毒性。第三,提出治疗性ADCP应由肿瘤选择性和持久免疫激活来定义,而不仅是吞噬本身。第四,总结了增强有益ADCP的六项主要策略,包括Fc工程、抗原结合优化、FcγRIIb阻断、靶向「不要吃我」信号、巨噬细胞重编程以及与免疫检查点抑制剂联合。
Cancer cell IF 56.1 2026-10-02 PMID: 42826713
Therapeutic cancer vaccines are increasingly tested in clinical settings alongside standard-of-care treatments that often include chemotherapy, yet whether chemotherapy synergizes with cancer vaccines remains unclear. Here, we tested heterologous prime-boost viral vector vaccines in combination with various chemotherapy regimens. Both carboplatin plus paclitaxel (CarboTaxol) and cyclophosphamide improve vaccine efficacy and enhance antigen-specific CD8+ T cell responses. These chemotherapies act as immunological adjuvants independently of tumor presence. Mechanistically, CarboTaxol induces an early, antigen-independent expansion of stem-like T cell factor 1 (TCF1)+CD8+ T cells, an effect also observed in patients with different cancer types. Genetic or pharmacological disruption of TCF1 impairs the immunological adjuvant effect of CarboTaxol. Adding programmed cell death 1 (PD-1) blockade to viral vector vaccines and CarboTaxol further improves tumor control and survival. Together, these findings identify a TCF1-dependent mechanism underlying the immune adjuvant effect of chemotherapy and provide a rationale for clinical evaluation of this triple combination therapy.
中文摘要:治疗性癌症疫苗正越来越多地在临床环境中与常包括化疗的标准治疗一同进行测试,但化疗是否能与癌症疫苗协同作用仍不清楚。在此,我们测试了异源初免-加强病毒载体疫苗与多种化疗方案的联合应用。卡铂联合紫杉醇(CarboTaxol)以及环磷酰胺均能提高疫苗效力,并增强抗原特异性CD8+ T细胞应答。这些化疗药物作为免疫佐剂发挥作用,且不依赖于肿瘤的存在。在机制上,CarboTaxol可诱导早期、抗原非依赖性的干细胞样T细胞因子1(TCF1)+CD8+ T细胞扩增,这一效应也在不同癌症类型的患者中观察到。对TCF1进行遗传或药理学破坏会削弱CarboTaxol的免疫佐剂效应。在病毒载体疫苗和CarboTaxol基础上加入程序性细胞死亡1(PD-1)阻断可进一步改善肿瘤控制与生存。总之,这些发现确定了化疗免疫佐剂效应背后一种依赖TCF1的机制,并为该三联联合疗法的临床评估提供了依据。
Seminars in immunology IF 11.5 2026-10-02 PMID: 42826468
IL-1 signaling is a central regulator of inflammation and immune responses within the tumor microenvironment, with IL-1α and IL-1β acting as key mediators. Tumors exploit IL-1 signaling through complex autocrine and paracrine interactions among malignant cells, immune cells, and cancer-associated fibroblasts (CAFs) to promote growth and progression. CAFs comprise a heterogeneous population of stromal cells with critical roles in extracellular matrix remodeling, angiogenesis, and immune response modulation. Within the broader spectrum of CAFs exhibiting inflammatory and immunomodulatory programs, inflammatory CAFs (iCAFs) represent a distinct and well-characterized polarized fibroblast state. IL-1 is a key driver of iCAF polarization, acting primarily through NF-κB and JAK/STAT3 signaling to promote the secretion of pro-inflammatory cytokines and chemokines. These factors can enhance malignant tumor-cell phenotypes and establish self-reinforcing stromal-immune circuits that foster immunosuppression and treatment resistance. Although IL-1 signaling represents an attractive therapeutic target, the clinical efficacy of IL-1-targeted approaches has been variable. These divergent outcomes may reflect differences in tumor and patient context, treatment timing, and the functional heterogeneity of the CAF compartment, in which distinct CAF states may differentially contribute to tumor-promoting activities and responses to IL-1 inhibition. Here, we discuss the spatiotemporal dynamics of IL-1 signaling across the tumor-immune-CAF axis and evaluate emerging therapeutic strategies targeting IL-1 signaling and pro-tumorigenic CAF states to overcome immunosuppression and treatment resistance in cancer.
中文摘要:IL-1信号是肿瘤微环境中炎症和免疫反应的核心调控因子,其中IL-1α和IL-1β是关键介质。肿瘤通过恶性细胞、免疫细胞和癌相关成纤维细胞(CAFs)之间复杂的自分泌和旁分泌相互作用来利用IL-1信号,从而促进生长和进展。CAFs由异质性基质细胞群体组成,在细胞外基质重塑、血管生成和免疫反应调节中发挥关键作用。在表现出炎症和免疫调节程序的更广泛CAFs谱系中,炎性CAFs(iCAFs)代表一种独特且已被充分表征的极化成纤维细胞状态。IL-1是iCAF极化的关键驱动因素,主要通过NF-κB和JAK/STAT3信号发挥作用,促进促炎细胞因子和趋化因子的分泌。这些因子可增强恶性肿瘤细胞表型,并建立自我强化的基质-免疫回路,从而促成免疫抑制和治疗耐药。尽管IL-1信号是有吸引力的治疗靶点,但靶向IL-1方法的临床疗效并不一致。这些不同结局可能反映了肿瘤和患者背景、治疗时机以及CAF区室功能异质性的差异,其中不同CAF状态可能对促肿瘤活性和IL-1抑制反应有不同贡献。在此,我们讨论IL-1信号在肿瘤-免疫-CAF轴中的时空动态,并评估靶向IL-1信号和促肿瘤CAF状态的新兴治疗策略,以克服癌症中的免疫抑制和治疗耐药。
Science advances IF 13.9 2026-10-02 PMID: 42814835
This study investigates the transcriptional impact of Q901, a highly selective cyclin-dependent kinase 7 (CDK7) inhibitor in clinical development. Q901 primarily disrupted MYC and E2F-dependent transcription programs, down-regulating cell cycle control and DNA damage repair pathways. CDK7 binding at the promoter-proximal regions was markedly stabilized by Q901, leading to reduced occupancy of MYC, E2F, and RNA polymerase II (RNAPII). These findings offered a novel therapeutic strategy to enhance cancer susceptibility to topoisomerase I (TOP1) DNA-protein cross-links (TOP1-DPCs) induced by TOP1 inhibitors. Resistance to TOP1 inhibitors arises through activation of DNA repair pathways when elongating RNAPII encounters TOP1-DPCs. By suppressing RNAPII transition from initiation to elongation and DNA repair pathways, Q901 stabilizes TOP1-DPCs and sensitizes tumors to TOP1 inhibitors. Preclinical studies demonstrated enhanced tumor suppression when combining Q901 with TOP1 inhibitor-based antibody-drug conjugates (TOP1i-ADCs), highlighting its potential as a therapeutic option for cancers resistant to TOP1i-ADC therapy.
中文摘要:本研究探讨了Q901的转录影响,Q901是一种处于临床开发阶段的高选择性细胞周期蛋白依赖性激酶7(CDK7)抑制剂。Q901主要破坏MYC和E2F依赖性转录程序,下调细胞周期控制和DNA损伤修复通路。Q901显著稳定了CDK7在启动子近端区域的结合,导致MYC、E2F和RNA聚合酶II(RNAPII)占据减少。这些发现提供了一种新的治疗策略,以增强癌症对拓扑异构酶I(TOP1)抑制剂诱导的TOP1 DNA-蛋白质交联(TOP1-DPCs)的敏感性。当延伸中的RNAPII遇到TOP1-DPCs时,DNA修复通路的激活会导致TOP1抑制剂耐药。通过抑制RNAPII从起始到延伸的转变以及DNA修复通路,Q901稳定TOP1-DPCs并使肿瘤对TOP1抑制剂敏感。临床前研究表明,将Q901与基于TOP1抑制剂的抗体药物偶联物(TOP1i-ADCs)联用可增强肿瘤抑制,突显其作为对TOP1i-ADC治疗耐药的癌症的潜在治疗选择。
Cancer research IF 22.6 2026-10-02 PMID: 42545372
Immune evasion remains a major barrier to effective immunotherapy in cancer. Coordinated activation of different immune cell types shapes immune responses within the tumor microenvironment (TME). In this study, we uncovered a spatiotemporal synergy between cytotoxic T lymphocytes (CTL) and natural killer (NK) cells in tumors with low T-cell infiltration. An integrative multiomics approach combining spatial transcriptomics, single-cell RNA sequencing, and high-dimensional flow cytometry demonstrated that vaccination, capable of activating both innate and adaptive immunity, rapidly reshapes the TME. Early infiltration of IRF8+KLRG1+ NK cells established a chemokine-rich niche together with myeloid cells that promoted the recruitment of antigen-primed CXCR3+ CTLs. The accompanying inflammatory monocyte recruitment and dendritic cell activation led to the coordinated structural and chemotactic remodeling of the TME. Functionally, NK-CTL clustering at the tumor margin was associated with enhanced cytotoxic activity and sustained immune engagement. These spatially organized immune interactions involved CCR5-CCL5 and CXCR3-CXCL9 signaling pathways that coordinate communication between innate and adaptive immune compartments. Together, these findings reveal a previously unrecognized NK-CTL cooperative program that promotes the transition of poorly infiltrated tumors toward an inflamed, immune-responsive state. More broadly, this study illustrates how spatially resolved multiomics approaches can uncover immune interactions and provides a conceptual framework for designing next-generation immunotherapies that mobilize coordinated innate and adaptive immunity. Early infiltration of NK cells followed by T-cell accumulation reshapes the tumor microenvironment to promote antitumor immunity following vaccination, providing a mechanistic rationale for the development of effective vaccine-based immunotherapy strategies.
中文摘要:免疫逃逸仍是癌症有效免疫治疗的主要障碍。不同免疫细胞类型的协同激活塑造了肿瘤微环境(TME)内的免疫应答。在本研究中,我们揭示了在T细胞浸润较低的肿瘤中,细胞毒性T淋巴细胞(CTL)与自然杀伤(NK)细胞之间存在时空协同作用。整合空间转录组学、单细胞RNA测序和高维流式细胞术的多组学方法表明,能够同时激活固有免疫和适应性免疫的疫苗接种可迅速重塑TME。IRF8+KLRG1+ NK细胞的早期浸润与髓系细胞共同建立了富含趋化因子的生态位,促进抗原致敏的CXCR3+ CTL的募集。伴随的炎性单核细胞募集和树突状细胞激活导致TME在结构和趋化性上发生协同重塑。在功能上,NK-CTL在肿瘤边缘的聚集与细胞毒性活性增强和持续的免疫参与相关。这些空间组织的免疫相互作用涉及CCR5-CCL5和CXCR3-CXCL9信号通路,协调固有免疫与适应性免疫区室之间的通讯。总之,这些发现揭示了一个此前未被识别的NK-CTL协同程序,可促进低浸润肿瘤向炎症性、免疫应答状态转变。更广泛地说,本研究展示了空间分辨多组学方法如何揭示免疫相互作用,并为设计动员固有免疫和适应性免疫协同作用的下一代免疫疗法提供了概念框架。NK细胞早期浸润随后T细胞积聚重塑肿瘤微环境,从而在疫苗接种后促进抗肿瘤免疫,为开发有效的疫苗免疫治疗策略提供了机制依据。
Cancer research IF 22.6 2026-10-02 PMID: 42467549
Poly (ADP-ribose) polymerase inhibitors (PARPi) are a first-line treatment for patients with epithelial ovarian cancer (EOC), but the development of resistance limits long-term therapeutic efficacy. Tumor acidosis is a hallmark of the tumor microenvironment (TME) that has been shown to promote resistance to cancer therapies, suggesting that it may affect PARPi responses. In this study, we demonstrated that the acidic TME drives a p300-dependent mechanism of PARPi resistance in EOC. Pathologically acidic pH enhanced DNA damage repair, reduced PARPi-induced PARP1 trapping, and attenuated the antitumor efficacy of PARPis. A CRISPR-Cas9 screen identified p300 as a druggable mediator of acidosis-induced PARPi resistance. Mechanistically, acidic pH activated an ERK-p300-PARP1 signaling axis that acetylated PARP1 at lysine 505 (PARP1 K505Ac), thereby alleviating PARPi-mediated PARP1 trapping and DNA damage. Elevated PARP1 K505Ac was associated with clinical resistance to PARPis and poor overall survival. In patient-derived and syngeneic EOC models, pharmacologic inhibition of p300 synergized with PARPis to suppress tumor growth. Together, these findings identify p300 as a key mediator of acidosis-induced PARPi resistance and a promising therapeutic target to enhance PARPi efficacy. Tumor acidosis drives PARP inhibitor resistance by promoting p300-dependent acetylation of PARP1, which can be effectively targeted in preclinical models to reverse resistance and improve the therapeutic efficacy of PARP inhibitors.
中文摘要:聚(ADP-核糖)聚合酶抑制剂(PARPi)是上皮性卵巢癌(EOC)患者的一线治疗药物,但耐药的发生限制了长期疗效。肿瘤酸中毒是肿瘤微环境(TME)的一个标志,已被证明可促进癌症治疗耐药,提示其可能影响PARPi反应。在本研究中,我们证明酸性TME驱动了EOC中一种依赖p300的PARPi耐药机制。病理性酸性pH增强了DNA损伤修复,减少了PARPi诱导的PARP1捕获,并削弱了PARPi的抗肿瘤疗效。一项CRISPR-Cas9筛选鉴定出p300是酸性诱导PARPi耐药的可成药介质。在机制上,酸性pH激活ERK-p300-PARP1信号轴,使PARP1在赖氨酸505位点发生乙酰化(PARP1 K505Ac),从而减轻PARPi介导的PARP1捕获和DNA损伤。PARP1 K505Ac升高与PARPi临床耐药和较差的总生存期相关。在患者来源和同基因EOC模型中,药理学抑制p300与PARPi协同抑制肿瘤生长。总之,这些发现确定p300是酸中毒诱导PARPi耐药的关键介质,也是增强PARPi疗效的有前景的治疗靶点。肿瘤酸中毒通过促进p300依赖的PARP1乙酰化驱动PARP抑制剂耐药,在临床前模型中可有效靶向该过程以逆转耐药并提高PARP抑制剂的治疗疗效。
Cancer research IF 22.6 2026-10-02 PMID: 42461083
Colorectal cancer with microsatellite instability (MSI) is often treated with immune checkpoint inhibitors (ICI), such as anti-PD-1 antibodies. However, a substantial fraction of MSI colorectal cancers do not respond to ICIs. Recent studies have identified the DNA helicase Werner (WRN) as a synthetic lethal target in MSI cancer cells, leading to the development of several small-molecule WRN inhibitors that are currently in clinical trials. In this study, we found that targeting WRN in MSI colorectal cancer cells triggered a robust antitumor immune response. Cell death induced by WRN inhibition was selective in MSI colorectal cancer cells and led to the release of extrachromosomal circular DNA (eccDNA), which directly stimulated immune cell activation and cytokine production. The deletion of nuclear ligase LIG3, a key mediator of eccDNA biogenesis, abolished the antitumor and immunogenic effects of WRN inhibition in MSI colorectal cancer cells and tumors. Furthermore, WRN inhibition potentiated anti-PD-1 therapy in MSI colorectal cancer models, including syngeneic mouse tumors and patient-derived tumor organoids. Together, these results reveal the eccDNA-mediated immunogenic effects of WRN inhibition in MSI colorectal cancer, further strengthening the rationale for combining WRN inhibitors with ICIs. Extrachromosomal circular DNA release induced by WRN inhibition in colorectal cancer cells with microsatellite instability stimulates immune cell activation and cytokine production, which can be leveraged to enhance the efficacy of immunotherapy.
中文摘要:微卫星不稳定(MSI)结直肠癌通常使用免疫检查点抑制剂(ICI)治疗,例如抗PD-1抗体。然而,相当一部分MSI结直肠癌对ICI无应答。近期研究已确定DNA解旋酶Werner(WRN)是MSI癌细胞中的合成致死靶点,推动了数种小分子WRN抑制剂的开发,这些抑制剂目前正处于临床试验中。在本研究中,我们发现靶向MSI结直肠癌细胞中的WRN可触发强烈的抗肿瘤免疫应答。WRN抑制诱导的细胞死亡在MSI结直肠癌细胞中具有选择性,并导致染色体外环状DNA(eccDNA)释放,后者可直接刺激免疫细胞活化和细胞因子产生。核连接酶LIG3是eccDNA生物发生的关键介质,缺失LIG3可消除WRN抑制在MSI结直肠癌细胞和肿瘤中的抗肿瘤及免疫原性效应。此外,WRN抑制可增强MSI结直肠癌模型中的抗PD-1治疗,包括同基因小鼠肿瘤和患者来源肿瘤类器官。总之,这些结果揭示了WRN抑制在MSI结直肠癌中由eccDNA介导的免疫原性效应,进一步强化了将WRN抑制剂与ICI联合使用的依据。WRN抑制在微卫星不稳定结直肠癌细胞中诱导的染色体外环状DNA释放可刺激免疫细胞活化和细胞因子产生,这一效应可用于增强免疫治疗的疗效。
Cancer research IF 22.6 2026-10-02 PMID: 42446901
The proto-oncogene MYC acts as a master regulator of diverse metabolic programs that fuel tumor initiation and progression, but the exact programs it activates depend heavily on context, tissue type, accompanying mutations, and the tumor microenvironment (TME). Furthermore, extrinsic influences, including diet and systemic metabolism, interact with MYC to reshape tumor and stromal cell metabolism, revealing a multifaceted metabolic landscape governed by MYC. This review focuses on MYC-driven in vivo metabolic addictions and discusses tissue-specific programs, TME interactions, and systemic influences to illustrate how MYC-driven metabolic reprogramming creates context-dependent vulnerabilities. These insights may uncover actionable targets and guide precision therapeutic strategies for MYC-driven cancers.
中文摘要:原癌基因MYC是驱动肿瘤发生和进展的多种代谢程序的主调控因子,但其激活的具体程序在很大程度上取决于背景、组织类型、伴随突变以及肿瘤微环境(TME)。此外,包括饮食和全身代谢在内的外在影响会与MYC相互作用,重塑肿瘤细胞和基质细胞的代谢,揭示出由MYC调控的多层面代谢格局。本综述聚焦于MYC驱动的体内代谢依赖性,并讨论组织特异性程序、TME相互作用和全身性影响,以阐明MYC驱动的代谢重编程如何产生依赖背景的脆弱性。这些见解可能发现可操作靶点,并指导针对MYC驱动癌症的精准治疗策略。
Cancer research IF 22.6 2026-10-02 PMID: 42418705
Cancer-associated fibroblasts (CAF) play a crucial role in the tumor microenvironment (TME) by influencing tumor progression, metastasis, and therapy resistance. Accumulating evidence suggests that CAFs undergo senescence, which can affect their effects on the TME. In this study, we developed a machine learning-based prediction model, the cellular senescence prediction model, to accurately identify senescent CAFs (sCAF) based on single-cell RNA sequencing data. In colorectal cancer, the abundance of sCAFs strongly correlated with impaired chemotherapy responsiveness and poor prognosis. In preclinical models, including subcutaneous tumors, patient-derived organoids (PDO), PDO xenografts, and orthotopic tumors, sCAFs mediated chemoresistance through the senescence-associated secretory phenotype (SASP), with IL6 and CXCL12 being key contributors. Macrophage-derived IL1B triggered CAF senescence through the IL1B-IL1R1 interaction, promoting the accumulation of sCAFs in tumors. Spatial transcriptomics and multiplex immunohistochemistry revealed the colocalization of IL1B+ macrophages and IL1R1+ sCAFs in the tumor stroma. Functional studies using fibroblast-specific Il1r1 knockout mice further confirmed that macrophage-derived IL1B induces CAF senescence via IL1R1, leading to SASP-driven chemotherapy resistance. These findings highlight the critical role of sCAFs in colorectal cancer chemoresistance and suggest that targeting the IL1B-IL1R1 axis may offer a promising strategy to enhance chemotherapy efficacy in colorectal cancer. Senescent cancer-associated fibroblasts induced by IL1B-IL1R1 signaling mediated by macrophages secrete SASP factors that impair chemotherapy responsiveness in colorectal cancer, suggesting that stromal senescence could be a therapeutic target.
中文摘要:癌相关成纤维细胞(CAF)通过影响肿瘤进展、转移和治疗耐药,在肿瘤微环境(TME)中发挥关键作用。越来越多的证据表明,CAF会发生衰老,从而影响其对TME的作用。在本研究中,我们开发了一种基于机器学习的预测模型,即细胞衰老预测模型,以基于单细胞RNA测序数据准确识别衰老CAF(sCAF)。在结直肠癌中,sCAF的丰度与化疗反应受损和不良预后密切相关。在临床前模型中,包括皮下肿瘤、患者来源类器官(PDO)、PDO异种移植瘤和原位肿瘤,sCAF通过衰老相关分泌表型(SASP)介导化疗耐药,其中IL6和CXCL12是关键贡献因子。巨噬细胞来源的IL1B通过IL1B-IL1R1相互作用触发CAF衰老,促进肿瘤中sCAF的积累。空间转录组学和多重心免疫组织化学显示,IL1B+巨噬细胞与IL1R1+ sCAF在肿瘤间质中共定位。使用成纤维细胞特异性Il1r1敲除小鼠进行的功能研究进一步证实,巨噬细胞来源的IL1B通过IL1R1诱导CAF衰老,导致SASP驱动的化疗耐药。这些发现强调了sCAF在结直肠癌化疗耐药中的关键作用,并提示靶向IL1B-IL1R1轴可能为增强结直肠癌化疗疗效提供有前景的策略。巨噬细胞介导的IL1B-IL1R1信号诱导的衰老癌相关成纤维细胞分泌SASP因子,损害结直肠癌的化疗反应,提示间质衰老可能成为治疗靶点。
Trends in pharmacological sciences IF 24.0 2026-10-01 PMID: 42823199
Immune checkpoint blockade has revolutionized cancer therapy, but durable benefit remains limited by immune-cold tumor states, poor antigen presentation, T cell exhaustion, and adaptive resistance. Recent studies position lysine-specific demethylase 1 (LSD1) as a druggable epigenetic regulator that links these barriers across tumor and immune cells. Emerging evidence shows that targeting LSD1 can restore major histocompatibility complex class I antigen presentation, activate viral mimicry and interferon programs, modulate programmed death-ligand 1 in a context-dependent manner, influence CD8+ T cell state transitions, and restrain tumor plasticity. In this review, we feature these mechanistic advances, compare evolving drug classes, and outline biomarker-guided strategies that may support the rational development of next-generation combination immunotherapy.
中文摘要:免疫检查点阻断已经彻底改变了癌症治疗,但持久获益仍受限于免疫冷肿瘤状态、抗原提呈不佳、T细胞耗竭和适应性耐药。近期研究将赖氨酸特异性去甲基化酶1(LSD1)定位为一种可成药的表观遗传调控因子,它在肿瘤细胞和免疫细胞之间连接了这些障碍。新出现的证据表明,靶向LSD1可以恢复主要组织相容性复合体I类抗原提呈,激活病毒模拟和干扰素程序,以环境依赖的方式调节程序性死亡配体1,影响CD8+ T细胞状态转换,并限制肿瘤可塑性。在这篇综述中,我们重点介绍这些机制进展,比较不断演变的药物类别,并概述可能支持下一代联合免疫治疗合理开发的生物标志物指导策略。
Journal for immunotherapy of cancer IF 11.7 2026-10-01 PMID: 42823087
Short-chain fatty acids (SCFAs) produced by the gut microbiota are increasingly recognized as regulators of host immunity, yet the role of individual SCFAs in shaping the tumor immune microenvironment in colorectal cancer (CRC) remains poorly defined. This study aims to investigate the role of propionate in antitumor immunity and immunotherapy responsiveness in CRC. SCFA levels, systemic inflammatory cytokine levels, and immune cell subsets were quantified in peripheral blood and tumor tissues from patients with CRC and healthy controls. Syngeneic microsatellite instability-high (MSI-H) and microsatellite stable (MSS) murine CRC models were used to evaluate the therapeutic efficacy of propionate alone and in combination with anti-programmed death-ligand 1 (PD-L1) blockade. CD8+ T-cell infiltration, activation status, and cytotoxic function were assessed by flow cytometry, immunohistochemistry, and single-cell RNA sequencing. Mechanistic investigations included acetylation-dependent protein modification analyses. Molecular analyses of signaling pathways were performed to delineate the regulatory axis underlying propionate-mediated immune modulation. Propionate levels were inversely associated with systemic inflammation and positively correlated with intratumoral CD8+ T-cell infiltration. Propionate supplementation enhanced CD8+ T-cell cytotoxicity, promoted CD8+ T-cell tumor infiltration and suppressed tumor growth in both MSI-H and MSS mouse models. Notably, propionate significantly potentiated the efficacy of PD-L1 blockade and restored immunotherapy sensitivity in otherwise resistant MSS tumors. Mechanistically, propionate induced acetyl-CoA acetyltransferase 1-dependent acetylation and proteasomal degradation of argininosuccinate synthase 1 (ASS1), resulting in activation of signal transducer and activator of transcription 1 signaling and upregulation of the T cell-recruiting chemokine C-X-C motif chemokine ligand 9. In clinical samples, low ASS1 expression was associated with high CD8+ T-cell infiltration. This study revealed the role of propionate in regulating the tumor immune microenvironment in CRC, suggesting propionate as a promising strategy to overcome immune exclusion and enhance the efficacy of immunotherapy.
中文摘要:由肠道微生物群产生的短链脂肪酸(SCFAs)日益被认为是宿主免疫的调节因子,但单个SCFA在塑造结直肠癌(CRC)肿瘤免疫微环境中的作用仍不明确。本研究旨在探讨丙酸在CRC抗肿瘤免疫和免疫治疗反应性中的作用。我们对CRC患者和健康对照者外周血及肿瘤组织中的SCFA水平、全身炎症细胞因子水平和免疫细胞亚群进行了定量。使用同基因微卫星高度不稳定(MSI-H)和微卫星稳定(MSS)小鼠CRC模型,评估单独使用丙酸以及与抗程序性死亡配体1(PD-L1)阻断联合使用的治疗效果。通过流式细胞术、免疫组织化学和单细胞RNA测序评估CD8+ T细胞浸润、活化状态和细胞毒性功能。机制研究包括乙酰化依赖性蛋白修饰分析。对信号通路进行分子分析,以阐明丙酸介导免疫调节的调控轴。丙酸水平与全身炎症呈负相关,并与瘤内CD8+ T细胞浸润呈正相关。补充丙酸增强了CD8+ T细胞细胞毒性,促进了CD8+ T细胞肿瘤浸润,并在MSI-H和MSS小鼠模型中抑制了肿瘤生长。值得注意的是,丙酸显著增强了PD-L1阻断的疗效,并恢复了原本耐药的MSS肿瘤的免疫治疗敏感性。在机制上,丙酸诱导乙酰辅酶A乙酰转移酶1依赖的乙酰化以及精氨基琥珀酸合成酶1(ASS1)的蛋白酶体降解,导致信号转导和转录激活因子1信号激活,并上调T细胞招募趋化因子C-X-C基序趋化因子配体9。在临床样本中,低ASS1表达与高CD8+ T细胞浸润相关。本研究揭示了丙酸在调节CRC肿瘤免疫微环境中的作用,提示丙酸是一种有前景的策略,可克服免疫排斥并增强免疫治疗的疗效。
Journal for immunotherapy of cancer IF 11.7 2026-10-01 PMID: 42823086
Combining immunotherapy with endocrine therapy and/or chemotherapy promotes prognosis in patients with estrogen receptor-positive/HER2-negative (ER+HER2-) breast cancer; however, the unclear underlying mechanisms limit their widespread application in clinical practice. This study aimed to investigate how ER signaling regulates antitumor immunity and influences responses to chemoimmunotherapy. We evaluated pathological complete response rates between ER-positive and ER-negative breast cancer patients across internal and external cohorts treated with immunotherapy and neoadjuvant chemotherapy. Mechanistic studies were conducted to explore the crosstalk between ER and immunogenic cell death (ICD) through high mobility group box 1 (HMGB1) SUMOylation. The therapeutic potential of chemoimmunotherapy regimens was assessed using immunocompetent mouse models of ER+ breast cancer. Patients with ER- breast cancer had higher pathological complete response rates after immunotherapy and neoadjuvant chemotherapy compared with those with ER+ breast cancer in both internal and external cohorts. Enhanced immune responses were observed in ER- breast cancer after chemotherapy, which was attributed to the induction of ICD via the release of HMGB1. Mechanistically, ER inhibits HMGB1 release by directly interacting with the HMG Box B domain and suppressing its SUMOylation at the K114 site, thereby suppressing the antitumor immune response. Therapeutically, combining ER antagonist with chemotherapy potentiated the efficacy of PD-1 blockade through HMGB1 in an immunocompetent mice model. These findings provide new mechanistic insights and clinical strategies for addressing immunotherapy resistance in ER+ breast cancer patients.
中文摘要:将免疫治疗与内分泌治疗和/或化疗联合可改善雌激素受体阳性/HER2阴性(ER+HER2-)乳腺癌患者的预后;然而,其潜在机制尚不明确,限制了这些方案在临床实践中的广泛应用。本研究旨在探讨ER信号如何调控抗肿瘤免疫并影响化疗免疫治疗的应答。我们在接受免疫治疗和新辅助化疗的内部和外部队列中,评估了ER阳性与ER阴性乳腺癌患者的病理完全缓解率。并开展机制研究,探索ER与免疫原性细胞死亡(ICD)之间通过高迁移率族蛋白B1(HMGB1)SUMO化修饰的交互作用。我们利用免疫功能健全的ER+乳腺癌小鼠模型评估了化疗免疫治疗方案的潜在疗效。在内部和外部队列中,ER阴性乳腺癌患者在接受免疫治疗和新辅助化疗后的病理完全缓解率均高于ER阳性乳腺癌患者,且在化疗后ER阴性乳腺癌中观察到更强的免疫应答,这归因于HMGB1释放所诱导的ICD。机制上,ER通过与HMG Box B结构域直接相互作用并抑制HMGB1在K114位点的SUMO化修饰,从而抑制HMGB1释放,进而抑制抗肿瘤免疫应答。在治疗层面,在免疫功能健全的小鼠模型中,将ER拮抗剂与化疗联合可通过HMGB1增强PD-1阻断的疗效。这些发现为解决ER+乳腺癌患者免疫治疗耐药提供了新的机制见解和临床策略。
Journal for immunotherapy of cancer IF 11.7 2026-10-01 PMID: 42823085
PTPN22, a protein tyrosine phosphatase (PTP) family member, has recently emerged as an intracellular regulator in adaptive immune cells. However, its function in natural killer (NK) cells remains unclear despite its high expression in innate immune cells. We analyzed single-cell RNA-sequencing (scRNA-seq) datasets and The Cancer Genome Atlas (TCGA) to evaluate PTPN22 expression in NK cells and its association with clinical outcomes. We established a CRISPR-mediated PTPN22 knockout platform for NK cell gene editing and evaluated PTPN22 function using both genetic deletion and pharmacological inhibition across multiple NK cell platforms. Cytotoxicity and cytokine production were assessed against hematologic and solid tumor targets, including CD19+ and mesothelin-positive (MSLN+) cancer cells. PTPN22 knockout (PTPN22KO) anti-CD19/CAR-NK92 cells were tested in Nalm6 xenograft models. Published scRNA-seq datasets showed that PTPN22 was highly expressed in tumor-infiltrating NK cells. PTPN22high NK cells exhibited stress and dysfunction signatures within inflammatory and immunosuppressive tumor microenvironments (TME), with elevated PTPN22 expression in TCGA associated with poorer patient survival. Genetic deletion of PTPN22 or pharmacological inhibition enhanced NK-cell cytotoxicity and pro-inflammatory cytokine release and improved the antitumor activity of chimeric antigen receptor (CAR)-NK cells against CD19+ and MSLN+ targets. PTPN22KO preserved CAR-NK cell function under cytokine-based TME-like conditions and improved the functional persistence of primary anti-CD19 CAR-NK cells during prolonged tumor exposure. PTPN22KO NK and CAR-NK cells showed increased or preserved signal transducer and activator of transcription 3 (STAT3) phosphorylation and reduced FAS expression under inflammatory conditions. Notably, PTPN22KO anti-CD19/CAR-NK92 cells demonstrated superior anti-leukemic activity and significantly prolonged survival compared with non-knockout controls in vivo. These findings identify PTPN22 as a novel intracellular checkpoint that limits NK and CAR-NK cell function. Targeted deletion of PTPN22 represents a promising strategy to enhance the therapeutic efficacy and persistence of both unmodified and CAR-engineered NK cells for cancer immunotherapy.
中文摘要:PTPN22 是蛋白酪氨酸磷酸酶(PTP)家族成员,最近作为适应性免疫细胞中的细胞内调节因子出现。然而,尽管其在先天免疫细胞中高表达,其在自然杀伤(NK)细胞中的功能仍不清楚。我们分析了单细胞 RNA 测序(scRNA-seq)数据集和癌症基因组图谱(TCGA),以评估 PTPN22 在 NK 细胞中的表达及其与临床结局的关联。我们建立了 CRISPR 介导的 PTPN22 敲除平台用于 NK 细胞基因编辑,并利用基因缺失和药理抑制在多个 NK 细胞平台中评估 PTPN22 功能。针对血液和实体瘤靶点,包括 CD19+ 和间皮素阳性(MSLN+)癌细胞,评估了细胞毒性和细胞因子产生。在 Nalm6 异种移植模型中测试了 PTPN22 敲除(PTPN22KO)抗 CD19/CAR-NK92 细胞。已发表的 scRNA-seq 数据集显示,PTPN22 在肿瘤浸润 NK 细胞中高表达。PTPN22 高表达 NK 细胞在炎症和免疫抑制肿瘤微环境(TME)中表现出应激和功能障碍特征,TCGA 中 PTPN22 表达升高与患者生存较差相关。PTPN22 的基因缺失或药理抑制增强了 NK 细胞毒性和促炎细胞因子释放,并改善了嵌合抗原受体(CAR)-NK 细胞针对 CD19+ 和 MSLN+ 靶点的抗肿瘤活性。PTPN22KO 在基于细胞因子的 TME 样条件下保留了 CAR-NK 细胞功能,并在长期肿瘤暴露期间改善了原代抗 CD19 CAR-NK 细胞的功能持久性。PTPN22KO NK 和 CAR-NK 细胞在炎症条件下显示信号转导和转录激活因子 3(STAT3)磷酸化增加或保留,并降低 FAS 表达。值得注意的是,PTPN22KO 抗 CD19/CAR-NK92 细胞在体内表现出优于非敲除对照的抗白血病活性,并显著延长生存期。这些发现表明 PTPN22 是一种限制 NK 和 CAR-NK 细胞功能的新型细胞内检查点。靶向删除 PTPN22 代表了一种有前景的策略,可增强未修饰和 CAR 工程化 NK 细胞在癌症免疫治疗中的疗效和持久性。
Immunity IF 30.6 2026-10-01 PMID: 42822444
Surgical removal of tumor-draining lymph nodes (tdLNs) is commonly performed in cancer patients. Here, we investigated whether immune checkpoint blockade (ICB) responses persist after resection of tdLNs, important sites for the initiation and maintenance of anti-cancer immunity. Melanoma patients remained responsive to programmed death 1 (PD-1) blockade after regional LN dissection. Similarly, ICB efficacy persisted after tdLN resection in orthotopic murine melanoma and mammary carcinoma models. Following tdLN removal, interstitial fluid containing soluble antigen was diverted through interstitial spaces across lymphosome boundaries to distant LNs, wherein cancer-derived antigen was acquired and presented to T cells by LN-resident type I conventional dendritic cells. These responses persisted after primary tumor resection and supported ICB-induced systemic immunity. Locoregional delivery of ICB to compensatory LNs enhanced anti-cancer responses after tdLN resection. Consistently, ICB responses in head and neck cancer patients were associated with reactive LNs at distant sites. Thus, antigen rerouting enables distant LNs to compensate for resected tdLNs and sustain anti-cancer immunity, including responses enhanced by immunotherapy.
中文摘要:肿瘤患者常接受肿瘤引流淋巴结(tdLN)的手术切除。在本研究中,我们探讨了切除tdLN后免疫检查点阻断(ICB)反应是否持续存在,tdLN是启动和维持抗肿瘤免疫的重要部位。黑色素瘤患者在区域淋巴结清扫后仍对程序性死亡1(PD-1)阻断有反应。同样,在原位小鼠黑色素瘤和乳腺癌模型中,切除tdLN后ICB疗效仍然持续。切除tdLN后,含有可溶性抗原的组织间液通过间质间隙跨越淋巴体边界被分流至远处淋巴结,在此处癌症来源抗原被淋巴结驻留的I型常规树突状细胞获取并呈递给T细胞。这些反应在原发肿瘤切除后仍持续存在,并支持ICB诱导的全身免疫。将ICB局部递送至代偿性淋巴结可增强tdLN切除后的抗肿瘤反应。与此一致,头颈部癌症患者的ICB反应与远处部位的反应性淋巴结相关。因此,抗原改道使远处淋巴结能够代偿被切除的tdLN,并维持抗肿瘤免疫,包括由免疫治疗增强的反应。
Immunity IF 30.6 2026-10-01 PMID: 42822442
T helper 9 (Th9) cells show promise for adoptive cell therapy (ACT) against solid tumors. However, clinical application faces challenges regarding their persistence in the tumor microenvironment (TME). We observed that tumor growth gradually reduced glucose concentrations in the TME, accompanied by a decline in transferred Th9 cells and their effector functions, due to Th9 cell senescence. Restoring glucose concentrations suppressed Th9 cell senescence, thereby improving their persistence. Mechanistically, glucose-deprivation-activated AMP-activated protein kinase (AMPK), triggering downstream leucine-zipper and sterile-α motif kinase (ZAK)-nuclear factor κB (NF-κB)-inducing kinase (NIK) cascades that suppressed noncanonical NF-κB signaling and interleukin (IL)-9 production, ultimately driving Th9 cell senescence. ZAK-associated chimeric antigen receptor (CAR)-T cell senescence was linked to compromised therapeutic efficacy in human cancers. Targeting ZAK rejuvenated Th9 cells and enhanced CAR-Th9 cell efficacy against solid tumors. Our study uncovers a mechanism by which nutrient deprivation promotes Th9 cell senescence to compromise persistence, highlights the potential of targeting ZAK to rejuvenate CAR-Th9 cells for solid tumor therapy.
中文摘要:辅助性T细胞9(Th9)细胞在针对实体瘤的过继细胞治疗(ACT)中显示出前景。然而,其在肿瘤微环境(TME)中的持续性面临挑战。我们观察到肿瘤生长逐渐降低TME中的葡萄糖浓度,伴随转移的Th9细胞及其效应功能下降,这是由于Th9细胞衰老所致。恢复葡萄糖浓度可抑制Th9细胞衰老,从而提高其持续性。机制上,葡萄糖剥夺激活AMP活化蛋白激酶(AMPK),触发下游亮氨酸拉链和无菌α基序激酶(ZAK)-核因子κB(NF-κB)诱导激酶(NIK)级联反应,抑制非经典NF-κB信号传导和白细胞介素(IL)-9产生,最终驱动Th9细胞衰老。ZAK相关的嵌合抗原受体(CAR)-T细胞衰老与人类癌症治疗疗效受损相关。靶向ZAK可使Th9细胞恢复活力,并增强CAR-Th9细胞对抗实体瘤的疗效。我们的研究揭示了一种营养剥夺促进Th9细胞衰老从而损害持续性的机制,并强调了靶向ZAK以使CAR-Th9细胞恢复活力用于实体瘤治疗的潜力。
Molecular cell IF 16.0 2026-10-01 PMID: 42822413
In this issue of Molecular Cell, Chu et al.1 describe that cancers with increased cyclin E-CDK2 activity suppress responses to immunotherapy through phosphorylation of BRD4, resulting in downregulation of interferon-stimulated genes. Their findings suggest approaches to enhance immunotherapy responses.
中文摘要:在本期《Molecular Cell》中,Chu等人描述,cyclin E-CDK2活性升高的癌症通过磷酸化BRD4抑制免疫治疗反应,导致干扰素刺激基因下调。他们的发现提示了增强免疫治疗反应的方法。
Cancer discovery IF 29.5 2026-10-01 PMID: 42817715
Genomic instability manifests in two distinct ways based on DNA alteration scale, differentially affecting the tumor-immune microenvironment. Mutational instability involves excessive accumulation of small-scale alterations, such as substitutions and indels, from defective DNA repair or aberrant mutagenic processes, generating neoantigens and increased immunogenicity. Chromosomal instability encompasses large-scale alterations in which cells gain, lose, or rearrange chromosomes, resulting in aneuploidy and immune evasion through chronic innate activation and myeloid remodeling. This review outlines differences between mutational and chromosomal instability and discuss how their interplay shapes tumor immunogenicity and response to immunotherapy. Understanding these opposing mechanisms could inform immunotherapeutic approaches in cancer. Mutational and chromosomal alterations exert opposing effects on antitumor immunity. Hypermutated tumors can generate abundant neoantigens that prime adaptive immunity and sensitize tumors to checkpoint blockade. In contrast, chromosomal instability triggers chronic innate immune signaling that is paradoxically immunosuppressive, in part through myeloid cell and T-cell dysfunction. Integrating both processes into a unified framework could help uncover mechanisms of immune evasion and guide personalized immunotherapeutic strategies.
中文摘要:基因组不稳定性根据DNA改变规模表现为两种不同形式,并差异性地影响肿瘤免疫微环境。突变不稳定性涉及由DNA修复缺陷或异常致突变过程导致的小规模改变(如替换和插入缺失)的过度积累,从而产生新抗原并增加免疫原性。染色体不稳定性则包括大规模改变,即细胞获得、丢失或重排染色体,导致非整倍体,并通过慢性固有免疫激活和髓系重塑实现免疫逃逸。本综述概述了突变不稳定性与染色体不稳定性之间的差异,并讨论二者的相互作用如何塑造肿瘤免疫原性和对免疫治疗的应答。理解这些相反的机制可能为癌症免疫治疗策略提供信息。突变和染色体改变对抗肿瘤免疫产生相反影响。超突变肿瘤可产生丰富的新抗原,启动适应性免疫并使肿瘤对检查点阻断敏感。相比之下,染色体不稳定性触发慢性固有免疫信号,这种信号矛盾地具有免疫抑制作用,部分通过髓系细胞和T细胞功能障碍实现。将这两种过程整合到一个统一框架中,可能有助于揭示免疫逃逸机制并指导个性化免疫治疗策略。
Journal of extracellular vesicles IF 21.7 2026-10 PMID: 42814771
Breast cancer is the most commonly diagnosed cancer worldwide and a leading cause of cancer-related mortality in women. Despite therapeutic advances, treating advanced or recurrent cases is substantially hampered by drug resistance and the immunosuppressive tumor microenvironment (TME). Here, we report a breakthrough immunotherapeutic strategy using dual-targeted extracellular vesicles from pro-inflammatory M1 macrophages, hyaluronic acid (HA), and cyclic RGD (M1EV_HA/cRGD), which function as molecular bridges to physically link natural killer (NK) cells with cancer cells. Our platform simultaneously reprograms the hostile TME while activating potent antitumor immunity. HA is incorporated to engage CD44 receptors on NK cells and cRGD peptides to bind tumor-overexpressing integrins, establishing precision dual-targeting. M1EV_HA/cRGD could physically tether NK cells directly to tumors, and deliver inflammatory cytokines and miRNAs that transform the immunosuppressive TME into a pro-inflammatory battlefield, substantially amplifying immune activation. In vitro and in vivo studies demonstrate that M1EV_HA/cRGD significantly enhances NK cell clustering at tumor sites, activation status, and cytotoxic killing of breast cancer cells. Unlike single-targeted approaches, this dual-targeting mechanism achieves simultaneous TME reprogramming and enhanced immune-tumor engagement. M1EV_HA/cRGD is a paradigm shift in solid tumor immunotherapy that directly addresses breast cancer treatment failure, can overcome therapeutic resistance, and substantially improve patient survival outcomes.
中文摘要:乳腺癌是全球诊断最常见的癌症,也是女性癌症相关死亡的主要原因之一。尽管治疗取得进展,晚期或复发病例的治疗仍因耐药和免疫抑制性肿瘤微环境(TME)而受到显著阻碍。在此,我们报告一种突破性免疫治疗策略,使用来自促炎性M1巨噬细胞的双靶向细胞外囊泡、透明质酸(HA)和环状RGD(M1EV_HA/cRGD),其作为分子桥将自然杀伤(NK)细胞与癌细胞物理连接。我们的平台在重编程敌对TME的同时激活强效抗肿瘤免疫。HA被引入以结合NK细胞上的CD44受体,cRGD肽结合肿瘤高表达的整合素,从而建立精准双靶向。M1EV_HA/cRGD可将NK细胞直接物理系连至肿瘤,并递送炎症细胞因子和miRNA,将免疫抑制性TME转化为促炎战场,从而大幅放大免疫激活。体外和体内研究证明,M1EV_HA/cRGD显著增强NK细胞在肿瘤部位的聚集、活化状态以及对乳腺癌细胞的细胞毒性杀伤。与单靶向策略不同,这种双靶向机制实现同时的TME重编程和增强的免疫-肿瘤相互作用。M1EV_HA/cRGD是实体瘤免疫治疗的范式转变,直接针对乳腺癌治疗失败,可克服治疗耐药,并显著改善患者生存结局。
MedComm IF 14.1 2026-10 PMID: 42802858
Chimeric antigen receptor T-cell (CAR-T) therapy is a transformative tumor immunotherapy that redirects autologous T cells to eliminate malignant cells. However, its broader clinical translation is constrained by complex and costly ex vivo manufacturing, variable product quality, and limited control over in vivo activity. In vivo CAR-T engineering enables direct T-cell programming in the body, reducing reliance on ex vivo manufacturing while improving T-cell fitness and antitumor efficacy. This approach also enables flexible dosing and may obviate lymphodepletion. This review first summarizes recent advances in in vivo CAR-T engineering and the evolution of CAR architectures. We then examine viral and non-viral delivery systems, including lentiviral vectors (LVs), adeno-associated virus (AAV) vectors, lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and emerging platforms, highlighting their distinct advantages and limitations. We further evaluate strategies to facilitate clinical translation, focusing on safety and efficacy. Finally, we discuss emerging opportunities enabled by biomaterials and artificial intelligence to improve scalability and accessibility while broadening therapeutic applications. This review provides a framework for understanding in vivo CAR-T engineering and highlights key strategies for overcoming translational barriers and advancing next-generation CAR-T therapies.
中文摘要:嵌合抗原受体T细胞(CAR-T)疗法是一种变革性的肿瘤免疫治疗,可将自体T细胞重定向以清除恶性细胞。然而,其更广泛的临床转化受到复杂且昂贵的体外制造、产品质量不稳定以及对体内活性控制有限等因素制约。体内CAR-T工程化能够在体内直接编程T细胞,减少对体外制造的依赖,同时改善T细胞适应性和抗肿瘤疗效。该方法还支持灵活给药,并可能无需淋巴细胞清除。本综述首先总结体内CAR-T工程化的最新进展以及CAR架构的演变。随后,我们审视病毒性和非病毒性递送系统,包括慢病毒载体(LV)、腺相关病毒(AAV)载体、脂质纳米颗粒(LNP)、聚合物纳米颗粒(PNP)及新兴平台,强调其各自独特的优势与局限。我们进一步评估促进临床转化的策略,重点关注安全性和有效性。最后,我们讨论生物材料与人工智能带来的新兴机会,以改善可扩展性和可及性,同时拓宽治疗应用。本综述为理解体内CAR-T工程化提供了框架,并强调克服转化障碍、推进下一代CAR-T疗法的关键策略。
MedComm IF 14.1 2026-10 PMID: 42798800
Cancer remains a major global health burden despite recent advances in early diagnosis and novel therapeutics. The cytoskeleton is a dynamic filamentous network that controls cell morphology, motility, and intracellular trafficking; in normal cells, its activity is tightly regulated, whereas in cancer, it undergoes aberrant remodeling that fuels uncontrolled proliferation, metastatic dissemination, resistance to apoptosis, and epithelial-mesenchymal transition. These pathological changes are associated with Rho guanosine triphosphatases (Rho GTPases) cascades, Hippo/Yes-associated protein (YAP) signaling, and other mechanosensitive pathways. However, a comprehensive understanding of how cytoskeletal dynamics integrate with these signaling networks and the tumor microenvironment to drive malignant progression and modulate treatment responses is still lacking. This review systematically addresses this gap by dissecting the diverse contributions of the cytoskeleton to tumor proliferation, invasion, programmed cell death, and angiogenesis, and by clarifying how mechanical signals synergize with cytoskeletal rearrangements to enhance aggressive behaviors. It further evaluates the modulatory effects of cytoskeletal components on the efficacy of conventional chemotherapy, immunotherapy, and molecular targeted therapy, and summarizes the clinical evidence for microtubule‑stabilizing and destabilizing drugs. Taken together, this study offers fresh perspectives on the intricate interplay between the cytoskeleton and cancer, and provides an important reference for the current field of cancer research.
中文摘要:尽管早期诊断和新疗法近期取得进展,癌症仍是全球主要健康负担。细胞骨架是一种动态的丝状网络,控制细胞形态、运动和细胞内运输;在正常细胞中,其活动受到严格调控,而在癌症中,细胞骨架发生异常重塑,促进不受控制的增殖、转移播散、凋亡抵抗和上皮-间质转化。这些病理变化与Rho鸟苷三磷酸酶(Rho GTPases)级联、Hippo/Yes相关蛋白(YAP)信号及其他机械敏感通路相关。然而,目前仍缺乏对细胞骨架动力学如何与这些信号网络及肿瘤微环境整合,从而驱动恶性进展并调节治疗反应的全面理解。本综述通过剖析细胞骨架对肿瘤增殖、侵袭、程序性细胞死亡和血管生成的多方面贡献,并阐明机械信号如何与细胞骨架重排协同增强侵袭性行为,系统性地填补了这一空白。文章进一步评估了细胞骨架组分对传统化疗、免疫治疗和分子靶向治疗疗效的调节作用,并总结了微管稳定药物和微管去稳定药物的临床证据。总之,本研究为细胞骨架与癌症之间复杂的相互作用提供了新视角,并为当前癌症研究领域提供了重要参考。
MedComm IF 14.1 2026-10 PMID: 42798783
Cancer remains a critical global health concern due to late detection, drug resistance, and high mortality. Mesothelin (MSLN) is a glycoprotein highly expressed on the surface of various cancer cells, including those of ovarian, pancreatic, and gastric cancers. Thus, it could be a valuable target for both as a biomarker and for immunotherapy. This review summarizes MSLN biology in cancer, current immunotherapeutic strategies targeting MSLN, associated clinical challenges, and emerging avenues to enhance immunotherapy efficacy. During cancer progression, MSLN acts as a cellular accelerator, promoting cell division and survival. It activates several critical signaling pathways, including nuclear factor k-light-chain-enhancer of activated B cells (NF-κB), interleukin-6 and its soluble receptor (IL-6/sIL-6R), and c-Jun N-terminal kinase (JNK), thereby promoting epithelial-mesenchymal transition and angiogenesis. Various MSLN-targeting immunotherapies, including monoclonal antibodies, chimeric antigen receptor-T cells, cytokine therapies, and vaccines, have shown preclinical and early clinical efficacy. However, immune evasion, an immunosuppressive tumor microenvironment, antigen heterogeneity, tumor immune escape, and off-tumor toxicities continue to hinder the broad clinical success of these modalities. Nonetheless, rational combinations of MSLN-directed therapies with other immunomodulatory strategies, optimized patient stratification, and advances in vaccine and adoptive cell therapy design hold promise for overcoming resistance and improving patient outcomes.
中文摘要:癌症由于发现晚、耐药和高死亡率,仍然是全球重大健康问题。间皮素(MSLN)是一种在多种癌细胞表面高表达的糖蛋白,包括卵巢癌、胰腺癌和胃癌细胞。因此,它可能作为生物标志物和免疫治疗的有价值靶点。本综述总结了MSLN在癌症中的生物学、当前靶向MSLN的免疫治疗策略、相关临床挑战以及提高免疫治疗疗效的新兴途径。在癌症进展过程中,MSLN充当细胞加速器,促进细胞分裂和存活。它激活若干关键信号通路,包括核因子κB(NF-κB)、白细胞介素-6及其可溶性受体(IL-6/sIL-6R)和c-Jun氨基末端激酶(JNK),从而促进上皮-间质转化和血管生成。多种靶向MSLN的免疫疗法,包括单克隆抗体、嵌合抗原受体T细胞、细胞因子疗法和疫苗,已显示出临床前和早期临床疗效。然而,免疫逃逸、免疫抑制性肿瘤微环境、抗原异质性、肿瘤免疫逃逸和脱靶毒性继续阻碍这些疗法的广泛临床成功。尽管如此,将MSLN导向疗法与其他免疫调节策略合理联合、优化患者分层以及疫苗和过继细胞治疗设计的进步,有望克服耐药并改善患者结局。
MedComm IF 14.1 2026-10 PMID: 42781243
The DNA damage response (DDR) is increasingly recognized not only as a genome-maintenance network and source of synthetic-lethal vulnerabilities, but also as a regulator of tumor immunity. DDR defects and pharmacologic inhibition can increase neoantigen formation, generate micronuclei and cytosolic nucleic acids, activate cGAS-STING, DNA-PK-NF-κB, and ERV-driven RIG-I/MDA5-MAVS signaling, and alter antigen presentation and immune checkpoint expression. However, the same processes may also promote chronic interferon tolerance, PD-L1 induction, lymphocyte stress, myeloid suppression, extracellular cGAMP degradation, stromal exclusion, and treatment resistance. This review frames DDR targeting around damage-to-immunity conversion, asking when DNA damage becomes a productive antitumor immune signal and when it does not. We summarize targetable DDR modules across cancer types, examine tumor-intrinsic and host-cell sensing mechanisms, and discuss antigen-processing defects, STING regulation, and microenvironmental barriers that shape divergent outcomes. We further review PARP, ATR, WEE1, ATM, and DNA-PK inhibitor combinations with immunotherapy and other treatment modalities, emphasizing clinical evidence, scheduling, and host-cell toxicity. Finally, we propose a modular biomarker framework integrating genomic, functional, immune-context, spatial and dynamic readouts to guide patient selection, treatment adaptation, and precision therapeutic decision-making.
中文摘要:DNA损伤应答(DDR)日益被认为不仅是基因组维持网络和合成致死脆弱性的来源,也是肿瘤免疫的调节因子。DDR缺陷和药物抑制可增加新抗原形成,产生微核和胞质核酸,激活cGAS-STING、DNA-PK-NF-κB以及ERV驱动的RIG-I/MDA5-MAVS信号,并改变抗原呈递和免疫检查点表达。然而,这些相同过程也可能促进慢性干扰素耐受、PD-L1诱导、淋巴细胞应激、髓系抑制、细胞外cGAMP降解、基质排斥和治疗耐药。本综述围绕损伤向免疫转化来构建DDR靶向治疗框架,探讨DNA损伤何时成为有效的抗肿瘤免疫信号、何时不能。我们总结跨癌种的可靶向DDR模块,审视肿瘤内在和宿主细胞感知机制,并讨论抗原加工缺陷、STING调控和塑造不同结局的微环境屏障。我们进一步综述PARP、ATR、WEE1、ATM和DNA-PK抑制剂与免疫治疗及其他治疗方式的联合,强调临床证据、给药安排和宿主细胞毒性。最后,我们提出一个模块化生物标志物框架,整合基因组、功能、免疫背景、空间和动态读数,以指导患者选择、治疗调整和精准治疗决策。
Cell stem cell IF 23.3 2026-10-01 PMID: 42748922
Brainstem gliomas, particularly H3K27M-mutant diffuse midline gliomas (DMGs), lack effective therapies owing to anatomic inaccessibility, intact blood-brain barrier, and treatment resistance. Conventional models have low establishment rates and fail to preserve the native tumor microenvironment, limiting translational study for this rare disease. Here, we established a patient-derived brainstem glioma organoid (BSGO) platform with high success, faithfully recapitulating parental tumor features. Multi-omics and functional assays revealed that DMGs maintain oligodendrocyte precursor cell (OPC) stemness by dysregulating ACTIVIN signaling. To overcome delivery barriers and target stemness, we conducted an intrathecal drug screening and identified triple intrathecal therapy (methotrexate + cytarabine + dexamethasone, TIT) as a potent regimen against DMGs. In DMG patients, organoid-avatar guided personalized therapy induced sustained responses, with TIT-associated reductions in OPC markers reliably tracked by cerebrospinal fluid (CSF) proteomic profiling. Together, our study provides an organoid-based platform for mechanistic investigation and personalized intrathecal therapy screening and proposes TIT as a promising translational strategy for DMG.
中文摘要:脑干胶质瘤,尤其是H3K27M突变的弥漫性中线胶质瘤(DMG),由于解剖位置难以到达、血脑屏障完整以及治疗耐药,缺乏有效疗法。传统模型的建立成功率低,且无法保留原发肿瘤微环境,限制了针对这一罕见疾病的转化研究。在此,我们建立了一个高成功率的患者来源脑干胶质瘤类器官(BSGO)平台,能够忠实再现亲本肿瘤特征。多组学和功能实验显示,DMG通过失调ACTIVIN信号维持少突胶质前体细胞(OPC)干性。为克服递送屏障并靶向干性,我们进行了鞘内药物筛选,并确定三联鞘内治疗(甲氨蝶呤+阿糖胞苷+地塞米松,TIT)是抗DMG的有效方案。在DMG患者中,类器官替身指导的个体化治疗诱导了持续缓解,且TIT相关的OPC标志物降低可通过脑脊液(CSF)蛋白质组学分析可靠追踪。总之,我们的研究提供了一个基于类器官的平台,用于机制探究和个体化鞘内治疗筛选,并提出TIT作为DMG有前景的转化策略。
Nature immunology IF 26.5 2026-10 PMID: 42728401
CD8+ T cell dysfunction is a major obstacle to hepatitis B virus (HBV) clearance and antitumor immunity. Here, using a humanized mouse model, we identify a T cell receptor targeting a clinically relevant HBV epitope and reveal ANKRD11 as a key epigenetic regulator of CD8+ T cell dysfunction in chronic infection and tumors. Ankrd11 knockout in CD8+ T cells enhances HBV-specific T cell proliferation and effector differentiation, especially under immunosuppressive conditions, via AP-1 family gene upregulation. Loss of Ankrd11 both drives the conversion of progenitor exhausted T cells into terminally exhausted T cells, and reprograms PD-1-TOX- tolerant cells into functional effectors, improving antiviral and antitumor responses. Ankrd11-deficient T cells show increased granzyme and superior effector function, enhancing viral control and tumor regression. These findings position ANKRD11 as a promising immunotherapy target for chronic HBV infection and cancer.
中文摘要:CD8+ T细胞功能障碍是乙型肝炎病毒(HBV)清除和抗肿瘤免疫的主要障碍。在此,我们利用人源化小鼠模型,鉴定出一个靶向临床相关HBV表位的T细胞受体,并揭示ANKRD11是慢性感染和肿瘤中CD8+ T细胞功能障碍的关键表观遗传调控因子。在CD8+ T细胞中敲除Ankrd11可通过上调AP-1家族基因增强HBV特异性T细胞增殖和效应分化,尤其是在免疫抑制条件下。Ankrd11缺失既驱动祖细胞耗竭T细胞向终末耗竭T细胞转化,又将PD-1-TOX-耐受细胞重编程为功能性效应细胞,从而改善抗病毒和抗肿瘤应答。Ankrd11缺陷T细胞显示颗粒酶增加和更优的效应功能,增强病毒控制和肿瘤消退。这些发现将ANKRD11定位为慢性HBV感染和癌症的有前景的免疫治疗靶点。
Cellular & molecular immunology IF 23.9 2026-10 PMID: 42722716
Cytokines are powerful modulators of antitumor immunity, but their clinical use is limited by structural instability, short half-life, poor drug-like properties, and severe systemic toxicity. Antibody-based cytokine mimetics have recently emerged to activate immune cells in vitro, but whether these mimetics can overcome the shortcomings of cytokines and exert therapeutic efficacy in vivo remains unclear. Here, we engineered bispecific antibody-based IL-15 mimetics using immunized Alpaca-derived phage display coupled with AlphaFold3-assisted structural screening and comparative screening of multiple formats to identify tandem IL-15 mimetics with strong in vitro bioactivity. Importantly, tandem IL-15R agonistic bispecifics, which simultaneously engage IL-15Rβ and γc, clearly demonstrated antitumor activity in vivo. To better target tumor-infiltrating lymphocytes (TILs), we incorporated a high-affinity anti-TIGIT antibody to guide tandem IL-15Rβγ agonists. This tri-antibody design, αTIGIT-αIL-15Rβγ, resulted in a striking improvement in antitumor activity without detectable systemic toxicity even at high doses. Mechanistically, αTIGIT-αIL-15Rβγ enhanced CD8⁺ T effector function and expanded the number of intratumoral stem-like T cells. Our study highlights a strategy to use TIL-targeted cytokine mimetics to overcome the limitations of native cytokines and enable dose pairing with immune checkpoint blockade (ICB), offering a path toward safer and more effective cytokine immunotherapy.
中文摘要:细胞因子是抗肿瘤免疫的强大调节因子,但其临床应用受到结构不稳定、半衰期短、成药性差以及严重全身毒性的限制。基于抗体的细胞因子模拟物近来已被用于在体外激活免疫细胞,但这些模拟物能否克服细胞因子的缺点并在体内发挥治疗疗效仍不清楚。在此,我们利用免疫羊驼来源的噬菌体展示,结合AlphaFold3辅助的结构筛选以及对多种形式的比较筛选,设计了基于双特异性抗体的IL-15模拟物,以鉴定具有强体外生物活性的串联IL-15模拟物。重要的是,同时结合IL-15Rβ和γc的串联IL-15R激动性双特异性抗体在体内明确显示出抗肿瘤活性。为了更好地靶向肿瘤浸润淋巴细胞(TILs),我们引入高亲和力抗TIGIT抗体来引导串联IL-15Rβγ激动剂。这种三抗体设计αTIGIT-αIL-15Rβγ,即使在高中剂量下也可显著改善抗肿瘤活性,且未检测到全身毒性。机制上,αTIGIT-αIL-15Rβγ增强了CD8⁺ T效应功能,并增加了瘤内干细胞样T细胞的数量。我们的研究强调了一种策略,即利用靶向TIL的细胞因子模拟物来克服天然细胞因子的局限性,并实现与免疫检查点阻断(ICB)的剂量配对,为更安全、更有效的细胞因子免疫治疗提供了路径。
Nature IF 56.1 2026-10 PMID: 42717091
Systemic anti-tumour immunity results from T cell priming in tumour-draining lymph nodes (TDLNs)1-4. Although the suppression of T cells in tumours is well characterized5-8, whether this occurs in TDLNs-and if so, through which mechanisms-remains poorly understood. Here, using imaging mass cytometry of TDLNs from patients with melanoma, we identify a spatial neighbourhood in the TDLN paracortex that is linked to the development of distant metastases. Targeted spatial transcriptomics of cells inside this neighbourhood revealed activated CD8+ T cells engaging with myeloid cells that expressed high levels of the immunosuppressive secretory phospholipase PLA2G2D. PLA2G2D+ myeloid cells were substantially more abundant in TDLNs than they were in primary tumours or metastases. Genetic loss-of-function or antibody-mediated inhibition of PLA2G2D reduced tumour growth markedly, and single-cell transcriptomics in melanoma-bearing mice revealed that expression of Pla2g2d is confined to lymph-node macrophages. Mechanistically, PLA2G2D directly suppressed the early proliferation of T cells in vitro, and inhibiting PLA2G2D resulted in an expansion of tumour-specific T cells in TDLNs, leading to an increase in these T cells in the circulation and subsequently in tumours. Notably, PLA2G2D and PD-1 act as non-redundant immune checkpoints, with combination treatment showing additive or synergistic efficacy in humanized mice treated with human-specific antibodies. Collectively, our in-depth spatial profiling identifies PLA2G2D as a TDLN-centred targetable immune checkpoint for cancer immunotherapy.
中文摘要:系统性抗肿瘤免疫源于肿瘤引流淋巴结(TDLNs)中的T细胞致敏。尽管肿瘤内T细胞抑制已被充分描述,但这种抑制是否发生在TDLNs中,若发生又通过何种机制,仍知之甚少。本研究利用黑色素瘤患者TDLNs的成像质谱流式细胞术,鉴定出TDLN副皮质区中一个与远处转移发生相关的空间邻域。对该邻域内细胞进行靶向空间转录组学分析显示,活化的CD8+ T细胞与表达高水平免疫抑制性分泌型磷脂酶PLA2G2D的髓系细胞相互作用。PLA2G2D+髓系细胞在TDLNs中的丰度显著高于原发肿瘤或转移灶。PLA2G2D的基因功能缺失或抗体介导的抑制可显著减缓肿瘤生长,而对荷黑色素瘤小鼠的单细胞转录组学分析显示,Pla2g2d的表达局限于淋巴结巨噬细胞。在机制上,PLA2G2D在体外直接抑制T细胞的早期增殖,而抑制PLA2G2D可导致TDLNs中肿瘤特异性T细胞扩增,进而使这些T细胞在循环中增加,并随后在肿瘤内增加。值得注意的是,PLA2G2D与PD-1作为非冗余免疫检查点,在用人特异性抗体治疗的人源化小鼠中,联合治疗显示出相加或协同疗效。总体而言,我们深入的空间图谱分析将PLA2G2D确定为以TDLN为中心、可用于癌症免疫治疗的可靶向免疫检查点。
Pharmacological research IF 12.2 2026-10 PMID: 42716237
Metabolic reprogramming and resistance to regulated cell death (RCD) are central features of the tumor microenvironment (TME) that drive therapeutic failure. Emerging evidence indicates that neurotransmitter signaling networks-including glutamate, dopamine, 5-hydroxytryptamine (5-HT), and norepinephrine-extend beyond neural communication to function as critical regulators of tumor metabolism, immune modulation, and cell fate. These neurotransmitters influence multiple RCD modalities, such as ferroptosis, cuproptosis, and PANoptosis, through interconnected metabolic and signaling mechanisms. Glutamate is explicitly resolved by compartment and route: high extracellular glutamate inhibits System Xc⁻, restricts cystine uptake and glutathione synthesis, and promotes ferroptosis, whereas intracellular glutamate production, glutaminolysis, SLC7A11-coupled glutamate export, and receptor-mediated signaling have distinct, context-dependent consequences. Dopamine and 5-HT exert context-dependent effects through receptor subtype-specific metabolic rewiring. Sympathetic neurotransmitters, including norepinephrine, enhance glycolysis and lactate-driven immunosuppression through β₂-adrenergic signaling. In parallel, the gut-brain axis modulates tumor susceptibility to RCD by shaping the availability of microbiota-derived neurotransmitter precursors and metabolites. Mechanistically, neurotransmitter signaling converges on RCD programs by regulating redox homeostasis, lipid peroxidation, mitochondrial vulnerability, and inflammatory signaling. Integrating these observations, this review proposes a conceptual framework termed the "Neurotransmitter-Novel Cell Death-Gut-Brain Axis," which links neural signaling, microbial metabolism, and tumor cell death decisions. Building on this framework, we highlight therapeutic strategies combining receptor-subtype-specific neurotransmitter modulation with selective induction of RCD pathways to overcome metabolic plasticity, immune evasion, and therapy resistance. Targeting this integrated neuro-metabolic-death network may offer a clinically actionable avenue to enhance tumor sensitivity to existing and emerging anticancer therapies.
中文摘要:代谢重编程和对调节性细胞死亡(RCD)的抵抗是肿瘤微环境(TME)驱动治疗失败的核心特征。新出现的证据表明,神经递质信号网络——包括谷氨酸、多巴胺、5-羟色胺(5-HT)和去甲肾上腺素——的作用超出神经通讯,成为肿瘤代谢、免疫调节和细胞命运的关键调控者。这些神经递质通过相互关联的代谢和信号机制影响多种RCD模式,如铁死亡、铜死亡和PANoptosis。谷氨酸的作用因区室和途径而异:高细胞外谷氨酸抑制System Xc⁻,限制胱氨酸摄取和谷胱甘肽合成,并促进铁死亡;而细胞内谷氨酸生成、谷氨酰胺分解、SLC7A11偶联的谷氨酸外排以及受体介导的信号传导则具有不同的、依赖于情境的后果。多巴胺和5-HT通过受体亚型特异性的代谢重编程发挥依赖于情境的效应。交感神经递质,包括去甲肾上腺素,通过β₂肾上腺素能信号增强糖酵解和乳酸驱动的免疫抑制。与此同时,肠-脑轴通过塑造微生物群来源的神经递质前体和代谢物的可利用性,调节肿瘤对RCD的易感性。在机制上,神经递质信号通过调节氧化还原稳态、脂质过氧化、线粒体脆弱性和炎症信号,汇聚于RCD程序。整合这些观察,本综述提出一个称为「神经递质-新型细胞死亡-肠-脑轴」的概念框架,将神经信号、微生物代谢和肿瘤细胞死亡决策联系起来。基于此框架,我们强调将受体亚型特异性神经递质调节与选择性诱导RCD通路相结合的治疗策略,以克服代谢可塑性、免疫逃逸和治疗耐药。靶向这一整合的神经-代谢-死亡网络可能提供一条临床可行的途径,以增强肿瘤对现有和新兴抗癌疗法的敏感性。
Pharmacological research IF 12.2 2026-10 PMID: 42705426
Despite the transformative advances that have been made in cancer immunotherapy, primary and acquired resistance remain prevalent, limiting durable clinical benefits. Mechanistic studies on immunotherapeutic resistance have largely focused on genetic, transcriptional, signaling, and metabolic programs within tumor and immune cells, with organelle physical routes and metabolic exchange across the tumor-host interface remaining relatively underexplored. Tunneling nanotubes (TNTs), membranous conduits that mediate long-range intercellular exchange, are increasingly implicated in tumor microenvironment remodeling. Thus, TNT-mediated mitochondrial transfer may represent an underexplored intercellular communication axis that can potentially influence tumor adaptation and immunotherapeutic responses. By enabling tumor cells to acquire functional mitochondria from neighboring stromal or immune cells, TNT-associated transfer may reinforce oxidative metabolism, redox homeostasis, and survival under immune and therapeutic pressure. Conversely, although the functional consequences of mitochondrial exchange are strongly dependent on the donor-recipient context, the transfer of tumor-derived mitochondria may result in the reprogramming of recipient immune or stromal cells and favor immunosuppressive states. However, direct evidence establishing TNT-mediated mitochondrial transfer as a causal determinant of immunotherapeutic resistance remains limited and varies significantly across therapeutic modalities. This review discusses the molecular mechanisms governing TNT formation and mitochondrial trafficking, examines the metabolic and immunological consequences of bidirectional tumor-host mitochondrial exchange, critically evaluates evidence linking these processes to distinct immunotherapeutic modalities, and discusses strategies and experimental priorities for their therapeutic translation.
中文摘要:尽管癌症免疫治疗已取得变革性进展,但原发性和获得性耐药仍然普遍存在,限制了持久的临床获益。关于免疫治疗耐药的机制研究在很大程度上集中于肿瘤细胞和免疫细胞内部的遗传、转录、信号传导和代谢程序,而跨肿瘤-宿主界面的细胞器物理途径和代谢交换仍相对未被充分探索。隧道纳米管(TNTs)是介导长距离细胞间交换的膜性管道,越来越多地被牵涉到肿瘤微环境重塑中。因此,TNT介导的线粒体转移可能代表一种尚未被充分探索的细胞间通讯轴,可能影响肿瘤适应和免疫治疗反应。通过使肿瘤细胞从邻近的基质细胞或免疫细胞获得功能性线粒体,TNT相关转移可能增强氧化代谢、氧化还原稳态以及在免疫和治疗压力下的存活。相反,尽管线粒体交换的功能后果强烈依赖于供体-受体背景,但肿瘤来源线粒体的转移可能导致受体免疫细胞或基质细胞重编程,并促进免疫抑制状态。然而,确立TNT介导的线粒体转移作为免疫治疗耐药的因果决定因素的直接证据仍然有限,并且在不同治疗方式之间存在显著差异。本综述讨论了调控TNT形成和线粒体运输的分子机制,审视了双向肿瘤-宿主线粒体交换的代谢和免疫学后果,批判性评估了将这些过程与不同免疫治疗方式联系起来的证据,并讨论了其治疗转化的策略和实验优先事项。
Pharmacological research IF 12.2 2026-10 PMID: 42704980
Precision oncology faces three systemic bottlenecks: static molecular snapshots fail to capture tumor dynamics, patient‑derived organoids lack physiological reconstruction of the tumor microenvironment (TME), and artificial intelligence (AI) remains a "black box" in clinical decision‑making. This review aims to propose an integrated closed‑loop framework that addresses these challenges by combining dynamic multi‑omics monitoring, next‑generation bioengineered models, and explainable AI. This review synthesizes recent advances in microfluidics, organoid technology, CRISPR screening, and multimodal data integration and, more importantly, proposes a closed-loop framework that distinguishes itself from existing approaches by explicitly linking dynamic monitoring, functional organoid testing, and explainable AI into an iterative decision cycle. Liquid biopsy enables longitudinal tracking of tumor evolution, while vascularized organoids and organ‑on‑chip systems reconstruct key TME features such as oxygen gradients, shear stress, and immune‑stromal interactions. These models serve as "therapeutic sandboxes" for functional drug testing and resistance mechanism elucidation. Concurrently, explainable AI (XAI) techniques-including feature perturbation, knowledge graph embedding, and dynamic Bayesian networks-provide interpretable predictions of treatment response. We outline a closed‑loop paradigm where dynamic monitoring data inform organoid‑based assays, XAI translates experimental evidence into clinical decisions, and real‑world outcomes continuously refine the models. Technical challenges such as multi‑scale data integration, vascularization fidelity, and AI transparency are discussed, along with emerging solutions including federated learning, 3D bioprinting, and standardized quality control pathways. Integrating dynamic monitoring, physiologically relevant organoid models, and explainable AI establishes a convergent precision oncology ecosystem that shifts the field from static biopsy‑based decisions toward adaptive, closed‑loop personalized therapy. This paradigm holds promise for overcoming tumor heterogeneity, predicting drug resistance, and improving clinical outcomes, while also providing a roadmap for future translational research and regulatory harmonization.
中文摘要:精准肿瘤学面临三个系统性瓶颈:静态分子快照无法捕捉肿瘤动态,患者来源类器官缺乏对肿瘤微环境(TME)的生理性重建,人工智能(AI)在临床决策中仍是一个「黑箱」。本综述旨在提出一个整合性闭环框架,通过结合动态多组学监测、下一代生物工程模型和可解释AI来应对这些挑战。本综述综合了微流控、类器官技术、CRISPR筛选和多模态数据整合方面的最新进展,更重要的是,提出了一个闭环框架;该框架通过将动态监测、功能性类器官检测和可解释AI明确连接为迭代决策循环,从而区别于现有方法。液体活检能够纵向追踪肿瘤演化,而血管化类器官和器官芯片系统可重建关键TME特征,如氧梯度、剪切应力和免疫-基质相互作用。这些模型可作为「治疗沙盒」,用于功能性药物测试和耐药机制阐明。同时,可解释AI(XAI)技术——包括特征扰动、知识图谱嵌入和动态贝叶斯网络——可提供治疗反应的可解释预测。我们概述了一种闭环范式:动态监测数据为基于类器官的检测提供信息,XAI将实验证据转化为临床决策,真实世界结局持续改进模型。我们讨论了多尺度数据整合、血管化保真度和AI透明度等技术挑战,以及包括联邦学习、3D生物打印和标准化质量控制路径在内的新兴解决方案。整合动态监测、生理相关类器官模型和可解释AI,可建立一个趋同的精准肿瘤学生态系统,推动该领域从基于静态活检的决策转向适应性闭环个体化治疗。这一范式有望克服肿瘤异质性、预测耐药并改善临床结局,同时也为未来转化研究和监管协调提供路线图。
Pharmacological research IF 12.2 2026-10 PMID: 42702340
Cancer neuroscience has expanded the conceptual landscape of tumor biology by revealing that nerves are not passive bystanders within malignant tissues, but active regulators of tumor progression, immune surveillance, and therapeutic response. Among neural components of the tumor microenvironment, nociceptive sensory neurons have emerged as critical interfaces between tissue injury, inflammation, cancer-associated pain, and immune regulation. This review proposes that nociceptive neuron-driven immune escape represents a tissue-level pathological process positioned at the intersection of cancer neuroscience, tumor immunology, and immunometabolism. We discuss how tumor-associated inflammatory mediators, extracellular acidosis, mechanical stress, metabolic perturbations, and axon-guidance programs activate nociceptors and induce the release of calcitonin gene-related peptide (CGRP) and related neuropeptides. Through receptor activity-modifying protein 1-containing receptor complexes, CGRP can suppress CD8⁺ T-cell receptor signaling, promote exhaustion-associated transcriptional and metabolic programs, impair dendritic cell function, and reinforce suppressive myeloid and regulatory immune compartments. We further examine how tumor cells may co-opt the ATF4-SLIT2-CGRP axis to establish cross-organ neuroimmune circuits extending to tumor-draining lymph nodes, thereby weakening antigen presentation, T-cell priming, and responsiveness to immune checkpoint blockade. Finally, we consider lactate accumulation and extracellular acidification as parallel immunometabolic pressures that may consolidate nociceptor-associated immune dysfunction by constraining T-cell bioenergetic fitness, promoting suppressive immune states, and potentially modulating sensory-neuron activity. Rather than defining a fixed linear pathway, we conceptualize the nociceptor-CGRP-lactate axis as an integrative neuroimmune-metabolic framework in which partially independent neural and metabolic processes converge on shared mechanisms of immune escape. This framework provides a translational rationale for evaluating combined neural, metabolic, and immune checkpoint-directed interventions in cancers characterized by neural involvement, metabolic suppression, and immunotherapy resistance.
中文摘要:癌症神经科学通过揭示神经并非恶性组织中的被动旁观者,而是肿瘤进展、免疫监视和治疗反应的主动调节者,拓展了肿瘤生物学的概念图景。在肿瘤微环境的神经成分中,伤害性感受器感觉神经元已成为组织损伤、炎症、癌症相关疼痛和免疫调节之间的关键接口。本综述提出,伤害性神经元驱动的免疫逃逸是一种组织水平的病理过程,位于癌症神经科学、肿瘤免疫学和免疫代谢的交叉点。我们讨论肿瘤相关炎症介质、细胞外酸中毒、机械应激、代谢紊乱和轴突导向程序如何激活伤害性感受器,并诱导降钙素基因相关肽(CGRP)及相关神经肽的释放。通过含受体活性修饰蛋白1的受体复合物,CGRP可抑制CD8⁺ T细胞受体信号传导,促进耗竭相关的转录和代谢程序,损害树突状细胞功能,并强化抑制性髓系和调节性免疫区室。我们进一步探讨肿瘤细胞如何可能利用ATF4-SLIT2-CGRP轴,建立延伸至肿瘤引流淋巴结的跨器官神经免疫回路,从而削弱抗原呈递、T细胞致敏以及对免疫检查点阻断的反应性。最后,我们将乳酸积累和细胞外酸化视为并行的免疫代谢压力,它们可能通过限制T细胞生物能量适应性、促进抑制性免疫状态以及潜在调节感觉神经元活动,来巩固与伤害性感受器相关的免疫功能障碍。我们并非定义一个固定的线性通路,而是将伤害性感受器-CGRP-乳酸轴概念化为一个整合性神经免疫代谢框架,其中部分独立的神经和代谢过程汇聚于共同的免疫逃逸机制。该框架为在以神经受累、代谢抑制和免疫治疗耐药为特征的癌症中评估神经、代谢和免疫检查点联合干预提供了转化依据。
Pharmacological research IF 12.2 2026-10 PMID: 42692375
Upper tract urothelial carcinoma (UTUC) is characterized by a high incidence of muscle invasion and distinct molecular heterogeneity, with tumor microenvironment (TME) heterogeneity playing a pivotal role in its malignant progression. However, the spatial distribution patterns of functional cell populations in UTUC and their regulatory mechanisms driving high-grade (HG) and muscle-invasive (MI) progression remain largely unelucidated. Herein, we integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptome sequencing (ST-seq) to systematically characterize the cellular landscape, spatial molecular network, and intercellular communication profile of UTUC tissues. Six tumor cell subpopulations were identified in UTUC, among which SLC14A1⁺ tumor cells were correlated with favorable clinical prognosis, whereas S100A8/9⁺ tumor cells were associated with poor clinical outcomes. Mechanistically, SLC14A1⁺ tumor cells decelerated UTUC progression via modulating cell apoptosis mediated by the FASLG-TNFRSF10B ligand-receptor pair. In contrast, S100A8/9⁺ tumor cells promoted the malignant progression of UTUC by regulating extracellular matrix remodeling and epithelial-mesenchymal transition (EMT) via the CCL19-CCR7, CCN2-EGFR, ADAM28-ITGA4 and CD14-ITGB2 ligand-receptor pairs. Collectively, our study uncovers the cellular and spatial heterogeneity of the UTUC TME, identifies SLC14A1⁺ tumor cells as a tumor-suppressive subpopulation and S100A8/9⁺ tumor cells as a key driver of UTUC malignant progression, and further delineates the core spatial signaling pathways underlying HG and MI progression of UTUC. These findings provide novel prognostic biomarkers and potential therapeutic targets for UTUC, and advance our mechanistic understanding of spatial TME regulation in urothelial carcinoma.
中文摘要:上尿路尿路上皮癌(UTUC)以肌层浸润发生率高和显著的分子异质性为特征,其中肿瘤微环境(TME)异质性在其恶性进展中发挥关键作用。然而,UTUC中功能性细胞群的空间分布模式及其驱动高级别(HG)和肌层浸润(MI)进展的调控机制在很大程度上仍未被阐明。在此,我们整合单细胞RNA测序(scRNA-seq)和空间转录组测序(ST-seq),系统刻画了UTUC组织的细胞图谱、空间分子网络和细胞间通讯特征。我们在UTUC中鉴定出六个肿瘤细胞亚群,其中SLC14A1⁺肿瘤细胞与良好临床预后相关,而S100A8/9⁺肿瘤细胞与不良临床结局相关。机制上,SLC14A1⁺肿瘤细胞通过FASLG-TNFRSF10B配体-受体对调控细胞凋亡,从而减缓UTUC进展。相反,S100A8/9⁺肿瘤细胞通过CCL19-CCR7、CCN2-EGFR、ADAM28-ITGA4和CD14-ITGB2配体-受体对调控细胞外基质重塑和上皮-间质转化(EMT),从而促进UTUC恶性进展。总之,我们的研究揭示了UTUC TME的细胞和空间异质性,确定SLC14A1⁺肿瘤细胞为抑瘤亚群,S100A8/9⁺肿瘤细胞为UTUC恶性进展的关键驱动因素,并进一步阐明了UTUC HG和MI进展的核心空间信号通路。这些发现为UTUC提供了新的预后生物标志物和潜在治疗靶点,并推进了我们对尿路上皮癌空间TME调控机制的理解。
Molecular cell IF 16.0 2026-10-01 PMID: 42685699
The cyclin E-cyclin-dependent kinase 2 (CDK2) complex is a component of mammalian cell-cycle machinery that drives cell division. Hyperactivation of cyclin E-CDK2 is frequent in human cancers. Small-molecule CDK2 inhibitors are tested in clinical trials for cancer patients. Here, we report that cyclin E-CDK2 has a cell-cycle-independent function in regulating the global transcriptional program of cancer cells. CDK2 phosphorylates bromodomain-containing protein-4 (BRD4) and regulates its chromatin association. Overexpression of cyclin E and the resulting activation of CDK2 in cancer cells alter the cancer cell transcriptome, repress the expression of interferon-stimulated genes, and confer resistance to immunotherapy. Conversely, CDK2 inhibition has the opposite effect and augments the efficacy of immune checkpoint blockade. CDK2 inhibition also increases tumor infiltration by dendritic cells (DCs) and enhances antigen cross-presentation to CD8 T cells. These studies reveal an additional function of cyclin E-CDK2 in tumorigenesis and identify inhibition of CDK2 with clinically available compounds as a strategy for enhancing immune checkpoint blockade.
中文摘要:细胞周期蛋白E-细胞周期蛋白依赖性激酶2(CDK2)复合物是驱动细胞分裂的哺乳动物细胞周期机器的组成部分。细胞周期蛋白E-CDK2的过度激活在人类癌症中常见。小分子CDK2抑制剂正在癌症患者临床试验中测试。在这里,我们报道细胞周期蛋白E-CDK2在调节癌细胞全局转录程序方面具有不依赖细胞周期的功能。CDK2磷酸化含溴结构域蛋白4(BRD4)并调节其染色质关联。癌细胞中细胞周期蛋白E过表达及由此导致的CDK2激活会改变癌细胞转录组,抑制干扰素刺激基因表达,并赋予免疫治疗耐药性。相反,CDK2抑制具有相反效应,并增强免疫检查点阻断的疗效。CDK2抑制还增加树突状细胞(DC)对肿瘤的浸润,并增强向CD8 T细胞的抗原交叉呈递。这些研究揭示了细胞周期蛋白E-CDK2在肿瘤发生中的额外功能,并确定用临床可用化合物抑制CDK2是增强免疫检查点阻断的一种策略。
Acta biomaterialia IF 10.4 2026-10 PMID: 42669342
Selecting effective chemotherapy after immunotherapy remains a major clinical challenge in advanced gastric cancer because patient responses are highly heterogeneous. A major obstacle is the lack of personalized preclinical models that faithfully recapitulate the immune-activated tumor microenvironment (TME) following immunotherapy and enable evaluation of subsequent chemotherapy responses while preserving immune-tumor interactions. Here, we developed an immune-activated co-culture model comprising patient-derived gastric cancer organoids and autologous peripheral blood mononuclear cells (PBMCs). Immune activation was achieved using anti-PD-1-loaded gold nanocages (aPD-1@Au NCs), which integrate near-infrared-triggered photothermal tumor ablation with sustained anti-PD-1-mediated immune modulation. The resulting model recapitulates key features of the post-immunotherapy TME, including enhanced immune-cell infiltration, increased tumor-cell apoptosis, and CD8+ T-cell activation. We then applied this model to evaluate five clinically relevant chemotherapeutic agents, including oxaliplatin, irinotecan, fluorouracil, doxorubicin, and docetaxel, for personalized chemotherapy screening after immunotherapy. Compared with monoculture organoids or non-activated co-cultures, the immune-activated model revealed drug-specific differences in tumor-killing efficacy, immune-mediated chemosensitization, and PBMC toxicity. Among the tested agents, oxaliplatin showed the strongest immune-mediated chemosensitization, whereas docetaxel achieved favorable tumor cell killing with relatively low immunotoxicity. These findings demonstrate that chemotherapy responses after immune activation are highly drug-specific, underscoring the importance of personalized chemotherapy selection following immunotherapy. As a proof-of-concept study, this work establishes an immune-activated patient-derived gastric cancer organoid-PBMC co-culture model that partially recapitulates the post-immunotherapy TME. This model provides a promising framework for developing personalized chemotherapy screening strategies after immunotherapy. STATEMENT OF SIGNIFICANCE: Selecting effective chemotherapy after immunotherapy remains a major challenge in advanced gastric cancer because of substantial interpatient heterogeneity. Progress in personalized treatment is limited by the lack of preclinical models that faithfully recapitulate the post-immunotherapy tumor microenvironment (TME). Here, we developed an immune-activated co-culture model integrating patient-derived gastric cancer organoids with autologous peripheral blood mononuclear cells (PBMCs). Immune activation was achieved using anti-PD-1-loaded gold nanocages (aPD-1@Au NCs), which combine near-infrared-triggered photothermal tumor ablation with sustained aPD-1-mediated immune modulation. This platform preserves patient-specific tumor characteristics while capturing key immune-tumor interactions following immunotherapy. Using this model, we evaluated five clinically relevant chemotherapeutic agents and identified distinct drug-specific differences in tumor-killing efficacy, immune-mediated chemosensitization, and immunotoxicity. As a proof-of-concept study, this work establishes a promising framework for personalized chemotherapy screening after immunotherapy and supports the development of precision treatment strategies for gastric cancer.
中文摘要:在晚期胃癌中,免疫治疗后选择有效的化疗仍是一项重大临床挑战,因为患者反应高度异质。一个主要障碍是缺乏个体化临床前模型,这些模型需忠实再现免疫治疗后的免疫激活肿瘤微环境(TME),并在保留免疫-肿瘤相互作用的同时评估后续化疗反应。在此,我们构建了一个免疫激活共培养模型,由患者来源的胃癌类器官和自体外周血单个核细胞(PBMC)组成。免疫激活通过负载抗PD-1的金纳米笼(aPD-1@Au NCs)实现,该体系将近红外触发的光热肿瘤消融与持续的抗PD-1介导免疫调节相结合。所得模型再现了免疫治疗后TME的关键特征,包括免疫细胞浸润增强、肿瘤细胞凋亡增加和CD8+ T细胞活化。随后,我们将该模型用于评估五种临床相关化疗药物,包括奥沙利铂、伊立替康、氟尿嘧啶、多柔比星和多西他赛,以进行免疫治疗后的个体化化疗筛选。与单培养类器官或未激活共培养相比,免疫激活模型揭示了在肿瘤杀伤效力、免疫介导的化疗增敏和PBMC毒性方面存在药物特异性差异。在受试药物中,奥沙利铂表现出最强的免疫介导化疗增敏,而多西他赛在相对较低的免疫毒性下实现了良好的肿瘤细胞杀伤。这些发现表明,免疫激活后的化疗反应具有高度药物特异性,凸显了免疫治疗后个体化化疗选择的重要性。作为一项概念验证研究,本工作建立了一个免疫激活的患者来源胃癌类器官-PBMC共培养模型,该模型部分再现了免疫治疗后的TME。该模型为开发免疫治疗后的个体化化疗筛选策略提供了一个有前景的框架。意义声明:由于患者间存在显著异质性,免疫治疗后选择有效的化疗仍是晚期胃癌的重大挑战。个体化治疗的进展受限于缺乏忠实再现免疫治疗后肿瘤微环境(TME)的临床前模型。在此,我们构建了一个免疫激活共培养模型,将患者来源的胃癌类器官与自体外周血单个核细胞(PBMC)整合。免疫激活通过负载抗PD-1的金纳米笼(aPD-1@Au NCs)实现,其将近红外触发的光热肿瘤消融与持续的抗PD-1介导免疫调节相结合。该平台在保留患者特异性肿瘤特征的同时,捕捉了免疫治疗后的关键免疫-肿瘤相互作用。利用该模型,我们评估了五种临床相关化疗药物,并识别出在肿瘤杀伤效力、免疫介导的化疗增敏和免疫毒性方面存在明显的药物特异性差异。作为一项概念验证研究,本工作为免疫治疗后的个体化化疗筛选建立了一个有前景的框架,并支持胃癌精准治疗策略的发展。
Cell stem cell IF 23.3 2026-10-01 PMID: 42641609
Autologous-derived dendritic cells (DCs) are a promising source for cell-based cancer vaccines. However, their therapeutic potential is challenged by the number and quality produced and the diversity of antigens presented. To address these limitations, we present an approach that involves differentiating universal MHC-deficient human-induced pluripotent stem cells (hiPSCs) into CCR7+ migratory DCs. These DCs are subsequently "dressed" with the full repertoire of MHC-antigen complexes derived from tumor cell membranes, transforming an allogeneic substrate into a personalized cancer vaccine product. The resulting "TumorDressed" DCs effectively activate T cells against tumor antigens. Their function is diminished when CD80/86 is deleted but significantly enhanced by the loss of PD-L1/2. PD-L1/2-null TumorDressed DCs demonstrate robust priming of anti-tumor T cell-mediated cytotoxicity both in vitro and in vivo, including against primary hematologic and solid tumors with matching patient T cells. These findings provide proof of concept for a universal, scalable, adaptable, and off-the-shelf DC cancer vaccine platform.
中文摘要:自体来源的树突状细胞(DC)是基于细胞的癌症疫苗的一个有前景的来源。然而,其治疗潜力受到所产生细胞的数量和质量以及所呈递抗原多样性的挑战。为解决这些局限,我们提出一种方法,即将通用的MHC缺陷型人诱导多能干细胞(hiPSCs)分化为CCR7+迁移性DC。随后,这些DC被「穿戴」上源自肿瘤细胞膜的完整MHC-抗原复合物库,从而将一种异体基质转化为个性化的癌症疫苗产品。由此产生的「TumorDressed」DC能有效激活针对肿瘤抗原的T细胞。当CD80/86被删除时,其功能减弱,但PD-L1/2缺失则显著增强其功能。PD-L1/2缺失的TumorDressed DC在体外和体内均显示出强大的抗肿瘤T细胞介导细胞毒性致敏作用,包括针对原发血液肿瘤和实体瘤,并与匹配的患者T细胞共同作用。这些发现为一种通用、可扩展、可适配且即用型DC癌症疫苗平台提供了概念验证。
Acta biomaterialia IF 10.4 2026-10 PMID: 42617782
Cancer immunotherapy has substantially advanced cancer treatment; however, durable responses remain uncommon in tumors with low immunogenicity and strongly suppressive tumor microenvironments (TME). Among innate immune pathways, cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling has attracted considerable attention because of its ability to initiate broad antitumor immune responses. Despite this promise, the therapeutic use of STING agonists is limited by rapid systemic clearance, insufficient tumor accumulation, and dose-limiting inflammatory toxicity. Simultaneously, metabolic adaptations within tumors, including elevated glycolytic flux, lactate enrichment, and redox imbalance, continue to undermine immune cell function and restrict treatment efficacy. Zn-based nanoplatforms have recently emerged as versatile systems capable of simultaneously addressing both challenges. Controlled intracellular release of Zn2+ can potentiate cGAS activity and strengthen downstream STING signaling, whereas oxidative stress induced by these nanomaterials promotes DNA damage, cytosolic DNA leakage, and immunogenic cell death. These effects are not limited to the activation of innate immunity. Several Zn-containing nanoplatforms reshape the metabolic landscape of the TME by lowering lactate accumulation and partially restoring immune cell activity. Consequently, dendritic cell (DC) maturation and antigen presentation are enhanced, leading to more effective T cell-driven antitumor responses. This review examines the emerging role of Zn2+ in regulating the immune and metabolic pathways relevant to cancer therapy. We discuss current strategies for designing Zn-based nanoplatforms, with particular emphasis on the mechanisms linking metabolic intervention to cGAS-STING activation. Dedicated sections examine Zn-based platforms for drug delivery and photodynamic and sonodynamic therapies, as well as their capacity to promote DC activation and combination immunotherapy. Finally, we consider the major barriers to clinical translation, including biosafety, delivery efficiency, and large-scale manufacturing, and outline the directions for the development of next-generation Zn-based immunotherapeutic systems. STATEMENT OF SIGNIFICANCE: This review provides a comprehensive, mechanistically integrated perspective on Zn-based nanoplatforms as multifunctional immunotherapeutic systems that bridge tumor metabolic reprogramming and cGAS-STING-mediated innate and adaptive immune activation. Unlike previous reviews that primarily focused on STING agonists or Zn-based nanomaterials independently, this study highlights how tumor-responsive Zn²⁺ release, oxidative stress, DNA damage, and metabolic remodeling collectively enhance antitumor immunity. This review critically compares the design principles, therapeutic mechanisms, and translational potential of diverse Zn-based nanoplatforms and discusses the key challenges in biosafety, manufacturing, and clinical translation. This review offers a conceptual framework to guide the rational development of next-generation Zn-based nanomedicines for precision cancer immunotherapy.
中文摘要:癌症免疫治疗已显著推进了癌症治疗;然而,在免疫原性低且肿瘤微环境(TME)具有强抑制性的肿瘤中,持久缓解仍不常见。在先天免疫通路中,环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子(cGAS-STING)信号因能启动广泛的抗肿瘤免疫应答而备受关注。尽管前景可观,STING激动剂的治疗应用仍受限于快速全身清除、肿瘤蓄积不足以及剂量限制性炎症毒性。同时,肿瘤内的代谢适应,包括糖酵解通量升高、乳酸富集和氧化还原失衡,持续削弱免疫细胞功能并限制治疗效果。锌基纳米平台近来作为多功能系统出现,能够同时应对这两类挑战。受控的细胞内Zn2+释放可增强cGAS活性并强化下游STING信号,而这些纳米材料诱导的氧化应激可促进DNA损伤、胞质DNA泄漏和免疫原性细胞死亡。这些效应不仅限于激活先天免疫。若干含锌纳米平台通过降低乳酸积累并部分恢复免疫细胞活性来重塑TME的代谢格局。因此,树突状细胞(DC)成熟和抗原呈递得到增强,从而产生更有效的T细胞驱动的抗肿瘤应答。本综述探讨Zn2+在调节与癌症治疗相关的免疫和代谢通路中的新兴作用。我们讨论当前设计锌基纳米平台的策略,尤其强调将代谢干预与cGAS-STING激活联系起来的机制。专门章节考察用于药物递送以及光动力和声动力治疗的锌基平台,以及它们促进DC激活和联合免疫治疗的能力。最后,我们考虑临床转化的主要障碍,包括生物安全性、递送效率和大规模制造,并概述下一代锌基免疫治疗系统的发展方向。意义声明:本综述提供了关于锌基纳米平台作为多功能免疫治疗系统的全面且机制整合的视角,该系统桥接肿瘤代谢重编程与cGAS-STING介导的先天性和适应性免疫激活。与既往主要独立关注STING激动剂或锌基纳米材料的综述不同,本研究强调肿瘤响应性Zn2+释放、氧化应激、DNA损伤和代谢重塑如何共同增强抗肿瘤免疫。本综述批判性地比较了多种锌基纳米平台的设计原则、治疗机制和转化潜力,并讨论了生物安全性、制造和临床转化方面的关键挑战。本综述为合理开发用于精准癌症免疫治疗的下一代锌基纳米药物提供了概念框架。
Acta biomaterialia IF 10.4 2026-10 PMID: 42612942
The immunosuppressive tumor microenvironment (TME) remains a major challenge to effective cancer immunotherapy. We hypothesized that combining dendritic cell (DC) maturation with immunogenic cell death (ICD) could enhance antitumor immunity by simultaneously providing immune-activating signals and tumor-associated antigens. To achieve this, we developed a dual-nanocarrier utilizing distinct nanoparticles: surface-modified magnetic nanoparticles (MNPs) for CpG oligodeoxynucleotide (CpG ODN) delivery and metal-organic frameworks (MOFs) for doxorubicin (DOX) encapsulation. Separate carriers of the two agents enabled independent control of their delivery functions. CpG-pMNPs promoted DC maturation more effectively than an equivalent dose of free CpG ODN, whereas DOX@UiO-67 induced ICD. In breast tumor model, the combined treatment markedly suppressed tumor growth and prolonged survival. Immune profiling further showed increased matured DC in tumor-draining lymph nodes, enhanced tumor infiltration of T cells and cytotoxic T lymphocytes, and modulation of immunosuppressive immune populations. In the spleen, the combination treatment reduced regulatory T cells and increased the proportion of CD8+ effector memory T cells. Collectively, current research demonstrates that separate delivery of CpG ODN and DOX through optimized nanocarriers effectively remodels the local TME and improves therapeutic efficacy. This dual-carrier strategy provides a practical approach for combining therapeutic agents with contrasting physicochemical properties in cancer chemo-immunotherapy. STATEMENT OF SIGNIFICANCE: Cancer immunotherapy is often limited by an immunosuppressive tumor microenvironment (TME) that restricts effective immune activation. Chemo-immunotherapy combining CpG oligodeoxynucleotides (CpG ODN) with doxorubicin (DOX) may address this limitation by coupling dendritic cell (DC) maturation with immunogenic cell death in tumor. Here, we developed a dual-nanocarrier strategy in which CpG ODN and DOX were separately formulated in functionalized magnetic nanoparticles and metal-organic frameworks, respectively. This carrier-level separation enabled independent optimization of each therapeutic component while preserving their complementary functions within the tumor site. The combined treatment promoted DC maturation, remodeled the local TME, suppressed tumor growth, and prolonged survival in a murine breast cancer model. This work provides a practical method for combining physicochemically incompatible therapeutic agents in cancer chemo-immunotherapy.
中文摘要:免疫抑制性肿瘤微环境(TME)仍是有效癌症免疫治疗的主要挑战。我们假设,将树突状细胞(DC)成熟与免疫原性细胞死亡(ICD)相结合,可通过同时提供免疫激活信号和肿瘤相关抗原来增强抗肿瘤免疫。为实现这一点,我们开发了一种双纳米载体,利用不同纳米颗粒:表面修饰的磁性纳米颗粒(MNPs)用于递送CpG寡脱氧核苷酸(CpG ODN),金属有机框架(MOFs)用于包封多柔比星(DOX)。两种药物的载体分离使得可独立控制其递送功能。CpG-pMNPs比等剂量游离CpG ODN更有效地促进DC成熟,而DOX@UiO-67诱导ICD。在乳腺肿瘤模型中,联合治疗显著抑制肿瘤生长并延长生存期。免疫分析进一步显示,肿瘤引流淋巴结中成熟DC增加,T细胞和细胞毒性T淋巴细胞向肿瘤浸润增强,并调节免疫抑制性免疫细胞群。在脾脏中,联合治疗减少了调节性T细胞并增加了CD8+效应记忆T细胞比例。总体而言,当前研究表明,通过优化的纳米载体分别递送CpG ODN和DOX可有效重塑局部TME并提高治疗效果。这种双载体策略为在癌症化学免疫治疗中联合具有相反理化性质的治疗药物提供了一种实用方法。意义声明:癌症免疫治疗常受到免疫抑制性肿瘤微环境(TME)的限制,后者制约有效的免疫激活。将CpG寡脱氧核苷酸(CpG ODN)与多柔比星(DOX)联合的化学免疫治疗,可能通过将树突状细胞(DC)成熟与肿瘤中的免疫原性细胞死亡偶联来解决这一限制。在此,我们开发了一种双纳米载体策略,其中CpG ODN和DOX分别被配制于功能化磁性纳米颗粒和金属有机框架中。这种载体水平的分离使得能够独立优化每种治疗组分,同时在肿瘤部位保留其互补功能。联合治疗促进了DC成熟,重塑了局部TME,抑制了肿瘤生长,并在小鼠乳腺癌模型中延长了生存期。这项工作为在癌症化学免疫治疗中联合物理化学性质不相容的治疗药物提供了一种实用方法。
Pharmacological research IF 12.2 2026-10 PMID: 42612932
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have transformed the realm of cancer treatment. Nevertheless, fewer than one in five patients derive durable benefit, and a substantial proportion of initial responders eventually relapse, reflecting a heterogeneous milieu of intrinsic and acquired mechanisms of resistance. Resistance to ICIs can arise from impaired neoantigen generation and presentation (low tumor mutational burden, loss of functional HLA class I and β2-microglobulin), defective IFN-γ/JAK-STAT signaling, co-expression of alternative checkpoints (LAG-3, TIM-3, TIGIT, CTLA-4), an immunosuppressive and metabolically hostile "cold" tumor microenvironment enriched in regulatory T cells, myeloid-derived suppressor cells, and M2-polarized macrophages, and clonal immunoediting. In this review, we synthesize the current landscape of PD-1/PD-L1-directed ICIs, dissect the molecular and cellular determinants of intrinsic and acquired resistance, and discuss emerging pharmacological strategies to overcome them, including next-generation checkpoint combinations (anti-LAG-3, anti-TIGIT), bispecific antibodies (e.g., PD-1/VEGF, PD-L1/TGF-β), antibody-drug conjugates, targeted-therapy and epigenetic combinations, innate immune agonists, oncolytic viruses, gut microbiome modulation, and biomarker-guided patient selection, with the goal of informing rational combination regimens capable of extending the benefit of checkpoint blockade to a substantially broader patient population.
中文摘要:靶向PD-1/PD-L1轴的免疫检查点抑制剂(ICIs)已改变癌症治疗格局。然而,不足五分之一的患者可获得持久获益,且相当一部分初始应答者最终复发,这反映了原发性和获得性耐药机制的异质性环境。ICI耐药可由新抗原生成和呈递受损(低肿瘤突变负荷、功能性HLA I类和β2-微球蛋白缺失)、IFN-γ/JAK-STAT信号缺陷、替代检查点共表达(LAG-3、TIM-3、TIGIT、CTLA-4)、富含调节性T细胞、髓源性抑制细胞和M2极化巨噬细胞的免疫抑制且代谢不利的「冷」肿瘤微环境以及克隆性免疫编辑引起。在这篇综述中,我们综合了PD-1/PD-L1导向ICIs的当前格局,剖析原发性和获得性耐药的分子与细胞决定因素,并讨论克服耐药的新兴药理策略,包括下一代检查点联合方案(抗LAG-3、抗TIGIT)、双特异性抗体(如PD-1/VEGF、PD-L1/TGF-β)、抗体药物偶联物、靶向治疗与表观遗传联合方案、固有免疫激动剂、溶瘤病毒、肠道微生物组调控以及生物标志物指导的患者选择,旨在为合理联合方案提供依据,从而将检查点阻断的获益扩展至更广泛的患者群体。
Cytokine & growth factor reviews IF 13.4 2026-10 PMID: 42612451
Cancer immunotherapy has substantially improved the management of solid tumors and hematologic malignancies; however, durable clinical benefit remains limited by primary and acquired therapeutic resistance, immune-related toxicities, and considerable interpatient heterogeneity. Although cytokines, chemokines, and growth factors have been extensively investigated as predictive and prognostic biomarkers, their coordinated functions within dynamic immune networks remain insufficiently integrated into current translational and clinical frameworks. The purpose of this review is to critically evaluate emerging evidence supporting cytokine network dynamics and to introduce adaptive cytokine circuitries as a conceptual framework for understanding how interconnected cytokine signaling regulates therapeutic response, resistance, and toxicity across immune checkpoint blockade, chimeric antigen receptor T-cell therapy, T-cell receptor-engineered therapies, bispecific antibodies, and emerging cellular immunotherapies. Current evidence indicates that cytokine interactions operate through spatially and temporally organized signaling networks that influence T-cell functional states, myeloid cell reprogramming, immune escape, and tissue-specific inflammatory responses, while highlighting important biological uncertainties and the need for prospective clinical validation. The review further examines the translational potential of longitudinal immune monitoring, multiplex cytokine profiling, spatial and single-cell multi-omic technologies, computational network reconstruction, and biomarker-guided patient stratification for precision immunotherapy. Collectively, the available evidence supports a transition from static cytokine measurements toward dynamic cytokine network analysis while underscoring the scientific and clinical challenges that must be addressed before cytokine circuitry-informed strategies can be implemented in precision immuno-oncology.
中文摘要:癌症免疫治疗已显著改善实体瘤和血液系统恶性肿瘤的管理;然而,持久临床获益仍受原发性与获得性治疗耐药、免疫相关毒性以及相当大的患者间异质性限制。尽管细胞因子、趋化因子和生长因子已作为预测性和预后性生物标志物得到广泛研究,但它们在动态免疫网络中的协同功能仍未充分整合到当前的转化和临床框架中。本综述旨在批判性评估支持细胞因子网络动态的新兴证据,并引入适应性细胞因子回路这一概念框架,以理解相互连接的细胞因子信号如何在免疫检查点阻断、嵌合抗原受体T细胞治疗、T细胞受体工程化治疗、双特异性抗体以及新兴细胞免疫治疗中调控治疗应答、耐药和毒性。当前证据表明,细胞因子相互作用通过空间和时间上组织化的信号网络发挥作用,影响T细胞功能状态、髓系细胞重编程、免疫逃逸和组织特异性炎症反应,同时凸显了重要的生物学不确定性以及开展前瞻性临床验证的必要性。本综述进一步探讨纵向免疫监测、多重细胞因子谱分析、空间和单细胞多组学技术、计算网络重建以及生物标志物指导的患者分层在精准免疫治疗中的转化潜力。总体而言,现有证据支持从静态细胞因子测量转向动态细胞因子网络分析,同时强调在精准免疫肿瘤学中实施细胞因子回路指导策略之前必须解决的科学和临床挑战。
Pharmacological research IF 12.2 2026-10 PMID: 42595201
Systemic administration of bispecific T‑cell engagers (BiTEs) targeting CEACAM6 has shown therapeutic potential but is limited by on‑target/off‑tumor toxicity and short serum half‑life. To overcome these challenges, we engineered an oncolytic herpes simplex virus (oHSV) that delivers and locally produces anti‑CEACAM6/CD3 BiTE directly within the tumor microenvironment (oHSV‑anti‑CEA6/CD3). In immunocompetent mouse models of colon (CT26) and breast (4T1) cancer, a single intratumoral injection of oHSV‑anti‑CEA6/CD3 promoted tumor regression, increased infiltration of CD8⁺CD44⁺ T cells both locally and systemically, and induced durable antitumor immunity. When combined with PD‑1 blockade, this localized BiTE‑arming strategy synergistically enhanced therapeutic efficacy, leading to superior tumor control and long‑term immunological memory without additional toxicity. Mechanistically, the virus exerts a dual action: direct oncolysis and sustained in situ BiTE production, enabling targeted T‑cell activation and tumor elimination while limiting systemic BiTE exposure. Unlike previous reports of BiTE‑armed oncolytic viruses or simple combinations with immune checkpoint inhibitors, our approach leverages the oHSV platform to achieve spatiotemporally controlled T‑cell redirection coupled with virus‑mediated innate immune stimulation. This work provides a safe, effective, and readily translatable strategy for solid tumor immunotherapy.
中文摘要:全身给予靶向CEACAM6的双特异性T细胞衔接器(BiTEs)已显示出治疗潜力,但受限于靶向/瘤外毒性和较短的血清半衰期。为克服这些挑战,我们工程化了一种溶瘤单纯疱疹病毒(oHSV),其可在肿瘤微环境内直接递送并局部产生抗CEACAM6/CD3 BiTE(oHSV-anti-CEA6/CD3)。在结肠癌(CT26)和乳腺癌(4T1)免疫健全小鼠模型中,单次瘤内注射oHSV-anti-CEA6/CD3可促进肿瘤消退,增加局部和全身CD8⁺CD44⁺ T细胞浸润,并诱导持久抗肿瘤免疫。与PD-1阻断联合时,这种局部BiTE武装策略协同增强治疗效果,导致更优的肿瘤控制和长期免疫记忆,且未增加毒性。机制上,该病毒发挥双重作用:直接溶瘤和持续原位产生BiTE,从而实现靶向T细胞激活和肿瘤清除,同时限制全身BiTE暴露。与既往关于BiTE武装溶瘤病毒或与免疫检查点抑制剂简单联合的报道不同,我们的方法利用oHSV平台实现时空可控的T细胞重定向,并结合病毒介导的先天免疫刺激。这项工作为实体瘤免疫治疗提供了一种安全、有效且易于转化的策略。
Redox biology IF 16.2 2026-10 PMID: 42594485
Hypoxia-induced reprogramming of glutamine metabolism and ferroptosis resistance serve as pivotal factors that drive the progression of solid tumors and contribute to therapeutic resistance. However, the potential interaction between these processes remains inadequately understood. Elucidating the regulatory mechanisms linking these pathways is essential for developing effective therapies for solid tumors. This study demonstrated that HIF-1α promotes the expression of UBASH3B in hepatocellular carcinoma (HCC), resulting in ferroptosis resistance mediated by glutamine metabolism. Mechanistically, HIF-1α-driven UBASH3B dephosphorylated MYBL2 at Y15, leading to MYBL2 stabilization and a reprogramming of glutamine metabolism that modulates ferroptosis resistance. Specifically, MYBL2 augmented the transcriptional activity of SPSB4, which facilitated the K48-linked polyubiquitination and degradation of GLUD1, a key enzyme in glutamine metabolism, at residue K191. This degradation inhibited glutamine-driven oxidative phosphorylation (OXPHOS). Furthermore, UBASH3B played a crucial role in macrophage polarization and T-cell inhibition by promoting CXCL8 expression, which contributed to immunosuppression. Finally, we found that targeting UBASH3B in HCC cells using ZIF-8-Cu@siRNA@HA nanoparticles (ZCSH NPs) enhanced the efficacy of anti-PD-1 in combination with lenvatinib treatment. In summary, our study uncovers a novel interaction between hypoxia, glutamine metabolic reprogramming, and immune suppression in HCC progression, positioning UBASH3B as a promising therapeutic target for overcoming hypoxia-induced treatment resistance.
中文摘要:缺氧诱导的谷氨酰胺代谢重编程和铁死亡抵抗是驱动实体瘤进展并导致治疗耐药的关键因素。然而,这些过程之间潜在的相互作用仍未得到充分理解。阐明连接这些通路的调控机制对于开发有效的实体瘤疗法至关重要。本研究表明,HIF-1α促进肝细胞癌(HCC)中UBASH3B的表达,从而导致由谷氨酰胺代谢介导的铁死亡抵抗。在机制上,HIF-1α驱动的UBASH3B使MYBL2在Y15位点去磷酸化,导致MYBL2稳定以及谷氨酰胺代谢重编程,进而调节铁死亡抵抗。具体而言,MYBL2增强了SPSB4的转录活性,SPSB4促进谷氨酰胺代谢关键酶GLUD1在第K191位点发生K48连接的多聚泛素化并降解。这种降解抑制了谷氨酰胺驱动的氧化磷酸化(OXPHOS)。此外,UBASH3B通过促进CXCL8表达在巨噬细胞极化和T细胞抑制中发挥关键作用,从而促进免疫抑制。最后,我们发现使用ZIF-8-Cu@siRNA@HA纳米颗粒(ZCSH NPs)靶向HCC细胞中的UBASH3B,可增强抗PD-1联合仑伐替尼治疗的疗效。总之,我们的研究揭示了缺氧、谷氨酰胺代谢重编程和免疫抑制在HCC进展中的一种新型相互作用,将UBASH3B定位为克服缺氧诱导的治疗耐药的有前景的治疗靶点。
Carbohydrate polymers IF 13.2 2026-10-01 PMID: 42586689
Cancer vaccines aim to elicit durable, antigen-specific antitumour immunity, yet clinical translation remains constrained by inefficient antigen retention, weak innate immune activation, and poor spatiotemporal coordination of immune priming. Biomaterial-based vaccine depots, particularly hydrogels incorporating natural polysaccharides, can address these barriers by creating immune-instructive microenvironments that support localised and sustained antigen delivery. Polysaccharide-based hydrogels combine structural support, tuneable release kinetics, and intrinsic immunomodulatory properties through direct engagement with antigen-presenting cells. This review analyses their development as cancer vaccine depots. Alginate-based cryogels and microporous scaffolds are discussed as platforms that promote antigen-presenting cell recruitment, activation, and prolonged local antigen presentation, supporting durable adaptive responses. Hyaluronic acid hydrogels, deployed as injectable or implantable systems, are highlighted for sustaining antigen delivery and modulating the tumor-immune interface to limit recurrence. Hybrid platforms combining alginate or hyaluronic acid with synthetic polymers, proteins, or immunostimulatory cargos are examined as strategies to optimize mechanics, release, and immunogenicity. Emerging polysaccharides, including chitosan, fucoidan, pullulan, mannan, dextran, β-glucans, and cellulose derivatives, are evaluated as immunomodulatory components, despite more limited validation in cancer vaccination. Finally, translational challenges related to reproducibility, sterilization, scalability, and regulation are discussed, defining a framework for clinically relevant hydrogel vaccine depots.
中文摘要:癌症疫苗旨在引发持久、抗原特异性的抗肿瘤免疫,但其临床转化仍受限于抗原滞留效率低、先天免疫激活弱以及免疫启动的时空协调不佳。基于生物材料的疫苗储库,尤其是掺入天然多糖的水凝胶,可通过创建具有免疫指导作用的微环境来支持局部且持续的抗原递送,从而应对这些障碍。基于多糖的水凝胶兼具结构支撑、可调释放动力学以及通过与抗原呈递细胞直接相互作用而产生的固有免疫调节特性。本综述分析其作为癌症疫苗储库的发展。海藻酸盐基冷冻凝胶和微孔支架被讨论为可促进抗原呈递细胞募集、激活和延长局部抗原呈递,从而支持持久适应性反应的平台。透明质酸水凝胶作为可注射或可植入系统,因能够维持抗原递送并调节肿瘤-免疫界面以限制复发而受到重点关注。将海藻酸盐或透明质酸与合成聚合物、蛋白质或免疫刺激载荷相结合的杂化平台,被审视作为优化力学性能、释放和免疫原性的策略。新兴多糖,包括壳聚糖、岩藻多糖、普鲁兰多糖、甘露聚糖、右旋糖酐、β-葡聚糖和纤维素衍生物,尽管在癌症疫苗接种中的验证较为有限,仍被评估为免疫调节组分。最后,讨论了与可重复性、灭菌、规模化及监管相关的转化挑战,从而为临床相关的水凝胶疫苗储库界定了一个框架。
Redox biology IF 16.2 2026-10 PMID: 42541911
The NADPH oxidase (NOX) enzymes are major sources of reactive oxygen species (ROS) involved in redox signaling and inflammation. However, the specific contribution of individual NOX isoforms to the pathophysiology of acute pancreatitis remains unclear. Here, we investigated the roles of NOX1 and NOX2 in ROS generation in vivo during experimental acute pancreatitis in mice as well as their impact on the regulation of the inflammatory cascade. We confirmed NOX1 expression in the exocrine compartment of the pancreas where it acts as the early and primary source of superoxide in acute pancreatitis. However, both NOX1 and DUOX were expressed in infiltrating neutrophils, suggesting disease-associated reprogramming of these cells within the inflamed pancreas. NOX1 deficiency largely restrained immune cell recruitment, whereas the absence of NOX2 resulted in marked upregulation of pro-inflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin 6, reduced protein phosphatase 2A (PP2A) levels, and enhanced MAPK signaling. In addition, pancreatitis in obese mice induced decreased NOX2 expression in pancreatic macrophages, together with an impaired phagocytic profile in both macrophages and neutrophils. In conclusion, our findings reveal opposing roles of NOX1 and NOX2 in acute pancreatitis, with NOX1 promoting neutrophil recruitment and their inflammation-dependent reprogramming, whereas NOX2 restrains the inflammatory response through PP2A.
中文摘要:NADPH氧化酶(NOX)是活性氧(ROS)的主要来源,参与氧化还原信号传导和炎症。然而,各NOX亚型在急性胰腺炎病理生理中的具体贡献仍不清楚。在此,我们研究了NOX1和NOX2在小鼠实验性急性胰腺炎体内ROS生成中的作用,以及它们对炎症级联调控的影响。我们证实NOX1在胰腺外分泌区表达,并在急性胰腺炎中作为超氧化物的早期和主要来源。然而,NOX1和DUOX均在浸润的中性粒细胞中表达,提示这些细胞在炎症胰腺内发生了疾病相关重编程。NOX1缺陷在很大程度上抑制了免疫细胞募集,而NOX2缺失则导致促炎细胞因子肿瘤坏死因子-α、白介素-1β和白介素-6显著上调,蛋白磷酸酶2A(PP2A)水平降低,并增强MAPK信号传导。此外,肥胖小鼠的胰腺炎诱导胰腺巨噬细胞中NOX2表达下降,同时巨噬细胞和中性粒细胞的吞噬功能谱受损。总之,我们的研究结果揭示了NOX1和NOX2在急性胰腺炎中的相反作用:NOX1促进中性粒细胞募集及其炎症依赖性重编程,而NOX2通过PP2A抑制炎症反应。
Redox biology IF 16.2 2026-10 PMID: 42537477
Abnormal lipid accumulation in the tumor microenvironment (TME) promotes lipid peroxidation in tumor-infiltrating CD8+T cells (CD8+TILs), driving their dysfunction and impairing antitumor immunity in ovarian cancer (OC). To elucidate the underlying immunosuppressive mechanisms, we integrated clinical specimens, mouse models, and in-vitro validation. Notably, CD8+TILs from OC patients exhibited pronounced lipid peroxidation signatures. Elevated oxidized low-density lipoprotein (oxLDL) levels were detected in ovarian tumor interstitial fluid (TIF), tumor mass-derived supernatants, and tissue sections, correlating with accelerated peroxidation phenotype in CD8+TILs. Bulk RNA sequencing and experimental validation revealed LOX-1 as the dominant oxLDL receptor in CD8+TILs, where its expression was positively correlated with peroxidation levels and negatively linked to PRF1, GZMB, and IFNG expression. In ID8 mouse OC models, LOX-1 expression and lipid peroxidation in CD8+TILs increased with tumor progression, and LOX-1-neutralizing antibody treatment partially reversed these changes and restored T-cell function. In vitro, LOX-1 blockade reduced oxLDL-induced lipid peroxidation, restored IFN-γ and GZMB production, and downregulated PD-1 expression, whereas LOX-1 overexpression exerted the opposite effects. Notably, the antioxidants, not ferroptosis inhibitors, restored CD8+T cell effector function by suppressing peroxidation. Mechanistically, oxLDL/LOX-1 signaling activated the transcription factor ELF3, which subsequently bound to the PDCD1 promoter to drive PD-1 expression. Together, this study demonstrates that in CD8+TILs, LOX-1-mediated uptake of oxLDL induced lipid peroxidation via oxidative stress and establish the oxLDL/LOX-1 axis as a pivotal pathway through which lipid peroxidation impairs CD8+TILs function in OC. Targeting LOX-1 or employing antioxidants restored the antitumor capacity of CD8+TILs, providing a mechanistic basis for metabolically modulating T cell-based cancer immunotherapy.
中文摘要:肿瘤微环境(TME)中异常的脂质积累促进肿瘤浸润CD8+ T细胞(CD8+TILs)发生脂质过氧化,驱动其功能障碍并损害卵巢癌(OC)的抗肿瘤免疫。为阐明潜在免疫抑制机制,我们整合了临床标本、小鼠模型和体外验证。值得注意的是,OC患者的CD8+TILs表现出显著的脂质过氧化特征。在卵巢肿瘤间质液(TIF)、肿瘤组织来源上清液和组织切片中检测到氧化低密度脂蛋白(oxLDL)水平升高,并与CD8+TILs过氧化表型加速相关。批量RNA测序和实验验证揭示,LOX-1是CD8+TILs中主要的oxLDL受体,其表达与过氧化水平正相关,并与PRF1、GZMB和IFNG表达负相关。在ID8小鼠OC模型中,CD8+TILs中的LOX-1表达和脂质过氧化随肿瘤进展而增加,LOX-1中和抗体治疗部分逆转了这些变化并恢复了T细胞功能。体外实验中,阻断LOX-1减少了oxLDL诱导的脂质过氧化,恢复了IFN-γ和GZMB产生,并下调了PD-1表达,而LOX-1过表达则产生相反效应。值得注意的是,抗氧化剂而非铁死亡抑制剂通过抑制过氧化恢复了CD8+ T细胞效应功能。机制上,oxLDL/LOX-1信号激活转录因子ELF3,后者随后结合PDCD1启动子以驱动PD-1表达。总之,本研究表明,在CD8+TILs中,LOX-1介导的oxLDL摄取通过氧化应激诱导脂质过氧化,并确立oxLDL/LOX-1轴是脂质过氧化损害OC中CD8+TILs功能的关键通路。靶向LOX-1或使用抗氧化剂可恢复CD8+TILs的抗肿瘤能力,为通过代谢调节T细胞为基础的癌症免疫治疗提供了机制基础。
Redox biology IF 16.2 2026-10 PMID: 42520384
Colorectal cancer (CRC) exhibits significant heterogeneity in response to immunotherapy that cannot be fully explained by microsatellite status alone. Although elevated bile acid levels are recognized as an important risk factor for CRC, their impact on immunotherapy responsiveness remains poorly understood. Here, we demonstrate that high bile acid levels profoundly impair anti-PD-1 efficacy in both CRC patient cohort and mouse models, accompanied by reduced infiltration and functional impairment of tumor-infiltrating CD8+ T cells. Bile acid profiling identified deoxycholic acid (DCA) as the key bile acid species mediating this immunosuppressive effect. In vitro and in vivo studies have shown that DCA not only suppressed CD8+ T cell effector function but also drove them toward terminal exhaustion, thereby limiting responsiveness to anti-PD-1. Mechanistically, DCA disrupted mitochondrial fitness in CD8+ T cells by suppressing oxidative phosphorylation and inducing excessive mitochondrial reactive oxygen species (mtROS) production. In parallel, DCA enhanced ubiquitination-dependent degradation of Parkin, thereby inhibiting mitophagy and causing the accumulation of damaged mitochondria. These convergent defects in mitochondrial homeostasis ultimately promoted CD8+ T cell dysfunction and terminal exhaustion. Notably, pharmacological reactivation of mitophagy via Urolithin A reversed these defects and restored the antitumor efficacy of anti-PD-1 in vivo. Collectively, our findings identified a DCA-Parkin-mitophagy axis that drives CD8+ T cell terminal exhaustion and compromises immunotherapy efficacy, providing a potential metabolic intervention strategy to improve immunotherapy responses in CRC patients with elevated bile acid levels.
中文摘要:结直肠癌(CRC)对免疫治疗的反应存在显著异质性,仅凭微卫星状态无法完全解释。尽管胆汁酸水平升高被认为是CRC的重要危险因素,但其对免疫治疗反应性的影响仍知之甚少。在此,我们证明高胆汁酸水平在CRC患者队列和小鼠模型中均显著损害抗PD-1疗效,并伴随肿瘤浸润CD8+ T细胞浸润减少和功能受损。胆汁酸谱分析确定脱氧胆酸(DCA)是介导这种免疫抑制效应的关键胆汁酸种类。体外和体内研究表明,DCA不仅抑制CD8+ T细胞的效应功能,还驱动其向终末耗竭发展,从而限制对抗PD-1的反应。机制上,DCA通过抑制氧化磷酸化并诱导线粒体活性氧(mtROS)过度产生,破坏CD8+ T细胞的线粒体适应性。同时,DCA增强Parkin的泛素化依赖性降解,从而抑制线粒体自噬并导致受损线粒体积累。这些线粒体稳态的汇聚性缺陷最终促进CD8+ T细胞功能障碍和终末耗竭。值得注意的是,通过尿石素A药理学重新激活线粒体自噬可逆转这些缺陷,并在体内恢复抗PD-1的抗肿瘤疗效。总体而言,我们的研究确定了DCA-Parkin-线粒体自噬轴驱动CD8+ T细胞终末耗竭并损害免疫治疗疗效,为改善胆汁酸水平升高的CRC患者的免疫治疗反应提供了潜在的代谢干预策略。
Pharmacology & therapeutics IF 13.5 2026-10 PMID: 42498155
The cGAS-STING pathway serves as a central hub for DNA-triggered innate immune activation in tumors. Nevertheless, the clinical translation of stimulator of interferon genes (STING) agonists remains hindered by challenges such as rapid in vivo degradation, inefficient cytosolic delivery, and the risk of systemic inflammation. Inorganic nanomaterials, leveraging their high specific surface area, tunable size and morphology, and unique surface chemical properties, provide an ideal platform for the precise delivery and spatiotemporally controlled release of STING agonists. Furthermore, these materials can induce the release of double-stranded DNA (dsDNA) to activate STING while also synergistically potentiating STING activation through the induction of immunogenic cell death or the release of specific metal ions. This review highlights that the application of inorganic nanomaterials in STING pathway activation extends beyond simple agonist delivery to encompass precise spatiotemporal control and modulation of signal intensity. We systematically outline design strategies for inorganic platforms that facilitate agonist protection and stimuli-responsive release. Furthermore, we discuss their synergistic integration with therapeutic modalities, including radiosensitization, reactive oxygen species (ROS) induced DNA damage, and immunogenic cell death (e.g., pyroptosis and ferroptosis), ultimately contributing to the establishment of a cGAS-STING amplification immune circuit. By achieving synergistic integration of delivery, activation, and potentiation, inorganic nanomaterials enhance both the efficacy and safety of STING-targeted immunotherapy, realizing the integrated functional advantage of "carrier-adjuvant-inducer" and offering a new paradigm for cancer immunotherapy.
中文摘要:cGAS-STING通路是肿瘤中DNA触发的先天免疫激活的中枢枢纽。然而,干扰素基因刺激因子(STING)激动剂的临床转化仍受到诸如体内快速降解、胞质递送效率低以及全身性炎症风险等挑战的阻碍。无机纳米材料凭借其高比表面积、可调控的尺寸与形貌以及独特的表面化学性质,为STING激动剂的精准递送和时空可控释放提供了理想平台。此外,这些材料可诱导双链DNA(dsDNA)释放以激活STING,同时还能通过诱导免疫原性细胞死亡或释放特定金属离子来协同增强STING激活。本综述强调,无机纳米材料在STING通路激活中的应用已超越简单的激动剂递送,涵盖对信号强度的精准时空控制和调控。我们系统概述了促进激动剂保护和刺激响应释放的无机平台设计策略。此外,我们讨论了其与治疗方式的协同整合,包括放射增敏、活性氧(ROS)诱导的DNA损伤和免疫原性细胞死亡(如细胞焦亡和铁死亡),最终有助于建立cGAS-STING放大免疫回路。通过实现递送、激活和增强的协同整合,无机纳米材料提高了STING靶向免疫治疗的疗效和安全性,实现了「载体-佐剂-诱导剂」一体化功能优势,并为癌症免疫治疗提供了新范式。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42479151
Glioblastoma (GBM) progression is driven by intricate interactions between neoplastic cells and immune populations within the tumor microenvironment (TME), yet the temporal organization of these processes remains insufficiently defined. While tumor-associated macrophages (TAMs), composed of microglia and monocyte-derived macrophages, constitute a major immune population in GBM, microglia play a prominent role in shaping local immunosuppressive niches, thereby limiting cytotoxic lymphocyte infiltration. However, static co-culture models constrain interrogation of dynamic tumor-immune signaling. We utilized a programmable multi-inlet microfluidic platform that allows sequential, order-specific introduction of immune cells into GBM constructs, enabling controlled interrogation of MG- and natural killer (NK)-mediated interactions under defined temporal conditions. Bulk transcriptomic profiling and single-cell analyses were used to characterize tumor- and immune-associated pathways elicited by distinct temporal configurations. In triculture constructs containing identical populations of GBM cells, microglia, and NK cells, MG-first delivery preferentially activated STAT3-associated immunoregulatory transcriptional programs, whereas NK-first delivery induced cytotoxic and interferon-related gene expression profiles. IL12A expression was selectively increased under NK-first conditions and correlated with immune-active GBM states in patient datasets. STAT3 inhibition reduced MG-associated suppression, increased IL12A expression, and enhanced the response to temozolomide. This programmable spheroid platform not only recapitulates hallmark features of the GBM immune microenvironment but also uncovers temporally regulated pathways arising from sequential cellular interactions. By enabling controlled reconstruction of dynamic tumor-immune signaling, this system offers a versatile strategy for mechanistic investigation and provides a foundation for evaluating immune-modulatory approaches and microenvironment-targeted interventions in GBM and other malignancies.
中文摘要:胶质母细胞瘤(GBM)的进展由肿瘤微环境(TME)中肿瘤细胞与免疫群体之间复杂的相互作用所驱动,但这些过程的时间组织仍未被充分界定。由小胶质细胞和单核细胞来源巨噬细胞组成的肿瘤相关巨噬细胞(TAM)是GBM中的主要免疫群体,其中小胶质细胞在塑造局部免疫抑制微环境方面发挥突出作用,从而限制细胞毒性淋巴细胞浸润。然而,静态共培养模型限制了对动态肿瘤-免疫信号的研究。我们利用可编程多入口微流控平台,可将免疫细胞按顺序、且依赖次序地引入GBM构建体中,从而在确定的时间条件下可控地探究小胶质细胞(MG)和自然杀伤(NK)细胞介导的相互作用。我们使用批量转录组分析和单细胞分析来表征不同时间配置所引发的肿瘤和免疫相关通路。在包含相同数量GBM细胞、小胶质细胞和NK细胞的三培养构建体中,先递送MG优先激活STAT3相关免疫调节转录程序,而先递送NK则诱导细胞毒性和干扰素相关基因表达谱。IL12A表达在NK先递送条件下选择性增加,并与患者数据集中免疫活跃的GBM状态相关。抑制STAT3可减少MG相关抑制,增加IL12A表达,并增强对替莫唑胺的响应。这种可编程球体平台不仅重现了GBM免疫微环境的标志性特征,还揭示了由顺序细胞相互作用产生的时间调控通路。通过实现动态肿瘤-免疫信号的可控重建,该系统为机制研究提供了一种通用策略,并为评估GBM及其他恶性肿瘤中的免疫调节方法和微环境靶向干预奠定了基础。
Redox biology IF 16.2 2026-10 PMID: 42476006
Ovarian cancer (OC) is highly lethal, with late diagnosis and frequent treatment resistance. Tumor-associated macrophage (TAM) are key immunosuppressive cells whose metabolic state critically influences redox homeostasis and immune function in the tumor microenvironment (TME). Here, we show that STXBP6 expression is elevated in OC TAMs. Mechanistically, STXBP6 promotes cPLA2-mediated arachidonic acid release and PKCβ-dependent nuclear translocation and activation of arachidonate 5-lipoxygenase (ALOX5), driving alterations in arachidonic acid metabolism and downstream 5-HETE production. Lipidomics, transcriptomics, and functional assays demonstrated that STXBP6 regulates lipid droplet formation, lipid peroxidation, and TAM polarization, linking redox-regulated lipid metabolism to immunosuppressive phenotypes. Using in vitro TAM models and in vivo OC models, including TAMs-OC co-implantation, we further confirmed that the STXBP6/cPLA2/ALOX5/5-HETE axis enhances tumor growth, metastasis, and the establishment of an immunosuppressive microenvironment. These findings reveal a previously unrecognized mechanism by which STXBP6 drives TAM metabolic reprogramming and immune modulation in OC, highlighting STXBP6 as a potential target for immunometabolic therapy.
中文摘要:卵巢癌(OC)致死性高,诊断晚且常出现治疗耐药。肿瘤相关巨噬细胞(TAM)是关键免疫抑制细胞,其代谢状态严重影响肿瘤微环境(TME)中的氧化还原稳态和免疫功能。本研究表明,STXBP6在OC的TAM中表达升高。机制上,STXBP6促进cPLA2介导的花生四烯酸释放以及PKCβ依赖的核转位和花生四烯酸5-脂氧合酶(ALOX5)激活,从而驱动花生四烯酸代谢改变及下游5-HETE生成。脂质组学、转录组学和功能实验表明,STXBP6调控脂滴形成、脂质过氧化和TAM极化,将氧化还原调节的脂质代谢与免疫抑制表型联系起来。利用体外TAM模型和体内OC模型(包括TAM与OC共植入),我们进一步证实STXBP6/cPLA2/ALOX5/5-HETE轴增强肿瘤生长、转移以及免疫抑制微环境的建立。这些发现揭示了STXBP6驱动OC中TAM代谢重编程和免疫调节的既往未被认识机制,突显STXBP6作为免疫代谢治疗潜在靶点。
Trends in cell biology IF 25.3 2026-10 PMID: 42469035
Long noncoding RNAs (lncRNAs) regulate the tumor microenvironment (TME), yet their cell-intrinsic roles within immune populations of the TME remain underappreciated. In this review, we shift focus from the cancer cell to the immune compartment, systematically reviewing how immune cell-intrinsic lncRNAs govern CD8+ T cell exhaustion, CD4+ T cell polarization, NK cell cytotoxicity, dendritic cell antigen presentation, and macrophage inflammatory programming. We highlight lncRNAs that function as molecular switches-tipping immune cells between antitumor effector and immunosuppressive states-and examine how exosomal lncRNAs extend these regulatory circuits across cellular boundaries within the TME. Finally, we evaluate opportunities for lncRNA-based biomarkers and therapies designed to target the immune landscape, outlining a framework for integrating immune-intrinsic lncRNA biology into precision immuno-oncology.
中文摘要:长非编码RNA(lncRNAs)调控肿瘤微环境(TME),但其在TME免疫细胞群体中的细胞内在作用仍被低估。在这篇综述中,我们将焦点从癌细胞转向免疫细胞区室,系统回顾免疫细胞内在lncRNAs如何调控CD8+ T细胞耗竭、CD4+ T细胞极化、NK细胞细胞毒性、树突状细胞抗原呈递以及巨噬细胞炎症编程。我们重点介绍作为分子开关的lncRNAs——使免疫细胞在抗肿瘤效应状态与免疫抑制状态之间转换——并探讨外泌体lncRNAs如何将这些调控回路扩展至TME内跨越细胞边界。最后,我们评估基于lncRNA的生物标志物和旨在靶向免疫景观的治疗机会,并概述将免疫内在lncRNA生物学整合到精准免疫肿瘤学中的框架。
Cancer letters IF 11.8 2026-10-01 PMID: 42442600
Peripheral nerves contribute to tumor progression, but the mechanisms by which neural signals regulate cancer cell plasticity and immune resistance remain unclear. Using a paired murine model of intraneural and nonintraneural tumor growth with single-cell RNA sequencing, we identified a nerve-associated cancer cell state marked by increased expression of secretory leukocyte protease inhibitor (SLPI). SLPI was elevated in intraneural tumors and in human tumors with perineural invasion. Sensory neuron-derived substance P (SP) induced SLPI secretion through tumor cell TACR1, whereas sensory denervation or TACR1 blockade reduced SLPI production. SLPIhigh cancer cells were enriched for WNT/β-catenin and stemness programs. Consistent with this, SLPI increased β-catenin and c-MYC expression, expanded ALDH+ stem-like cells, and enhanced mammosphere formation, whereas Slpi deletion reduced stemness and impaired tumor growth in vivo. SLPI also limited immune-mediated tumor cell killing. Proteomic and biochemical analyses identified granzyme B as a direct SLPI-binding partner, and SLPI inhibited granzyme B-dependent cleavage of caspase-3 and gasdermin E, thereby reducing cytotoxic lymphocyte-induced cell death. In immunocompetent mouse models, pharmacologic inhibition of the upstream SP-TACR1 pathway with aprepitant synergized with anti-PD-1 therapy. In clinical datasets, high SLPI expression was associated with residual disease after immunotherapy, poor response, and adverse outcome. Together, these findings identify the SP-TACR1-SLPI axis as a neural pathway linking cancer stemness to immune escape and nominate this pathway as a target for combination immunotherapy.
中文摘要:外周神经促进肿瘤进展,但神经信号调控癌细胞可塑性和免疫抵抗的机制仍不清楚。我们利用神经内和非神经内肿瘤生长的配对小鼠模型,结合单细胞RNA测序,鉴定出一种与神经相关的癌细胞状态,其特征是分泌型白细胞蛋白酶抑制剂(SLPI)表达升高。SLPI在神经内肿瘤以及伴有神经周围侵犯的人类肿瘤中升高。感觉神经元来源的P物质(SP)通过肿瘤细胞TACR1诱导SLPI分泌,而感觉神经去支配或TACR1阻断则减少SLPI产生。SLPI高表达的癌细胞富集WNT/β-catenin和干性程序。与此一致,SLPI增加β-catenin和c-MYC表达,扩增ALDH+干细胞样细胞,并增强乳腺球形成,而Slpi缺失降低干性并损害体内肿瘤生长。SLPI还限制免疫介导的肿瘤细胞杀伤。蛋白质组学和生化分析鉴定出颗粒酶B是SLPI的直接结合伴侣,SLPI抑制颗粒酶B依赖的caspase-3和gasdermin E切割,从而减少细胞毒性淋巴细胞诱导的细胞死亡。在免疫健全小鼠模型中,用阿瑞匹坦对上游SP-TACR1通路进行药理抑制,与抗PD-1治疗产生协同作用。在临床数据集中,高SLPI表达与免疫治疗后残留病灶、不良反应和不良结局相关。总之,这些发现将SP-TACR1-SLPI轴确定为连接癌症干性与免疫逃逸的神经通路,并提名该通路作为联合免疫治疗的靶点。
Cancer letters IF 11.8 2026-10-01 PMID: 42442599
Although immune checkpoint blockade has offered new hope to patients with bladder cancer, its overall response rate remains modest. In this setting, the quantity and functional status of CD8+T cells largely dictate therapeutic efficacy. Integrative bioinformatics analyses, validated in our institutional tissue cohort, we demonstrated that histone deacetylase 10 (HDAC10) was markedly up-regulated in bladder cancer and inversely correlated with CD8+T cells infiltration. In vivo experiments, using Hdac10-KO cell line, we revealed that Hdac10-KO significantly inhibited tumour growth and promoted the infiltration and activity of CD8+T cells. Mechanically, HDAC10 deacetylated the K342 site of interleukin enhancer-binding factor 3 (ILF3), thereby inducing the ubiquitination and degradation of it by WWP2. This reduced the stability regulation of CXCL9 mRNA by ILF3, decreasing CXCL9 expression and weakening CD8+T cell infiltration and activation. Notably, we found that the probiotic Clostridium butyricum (C.B.) can inhibit the expression of HDAC10 by increasing the short-chain fatty acid butyric acid, thereby sensitizing immunotherapy for bladder cancer in mouse models. This study revealed the specific mechanism by which HDAC10 led to immunotherapy resistance in bladder cancer and proposed potential combined treatment strategies.
中文摘要:尽管免疫检查点阻断为膀胱癌患者带来了新希望,但其总体缓解率仍较低。在此背景下,CD8+ T细胞的数量和功能状态在很大程度上决定治疗效果。我们通过整合生物信息学分析,并在本机构组织队列中验证,发现组蛋白去乙酰化酶10(HDAC10)在膀胱癌中显著上调,且与CD8+ T细胞浸润呈负相关。在体内实验中,我们使用Hdac10敲除细胞系发现,Hdac10敲除显著抑制肿瘤生长,并促进CD8+ T细胞的浸润和活性。在机制上,HDAC10使白细胞介素增强子结合因子3(ILF3)的K342位点去乙酰化,从而诱导WWP2介导其泛素化与降解。这降低了ILF3对CXCL9 mRNA的稳定性调控,导致CXCL9表达减少,并削弱CD8+ T细胞浸润与活化。值得注意的是,我们发现益生菌丁酸梭菌(C.B.)可通过增加短链脂肪酸丁酸来抑制HDAC10表达,从而在小鼠模型中使膀胱癌免疫治疗增敏。本研究揭示了HDAC10导致膀胱癌免疫治疗耐药的具体机制,并提出了潜在的联合治疗策略。
Pharmacology & therapeutics IF 13.5 2026-10 PMID: 42413882
Multispecific antibodies (MsAbs), capable of targeting multiple antigens simultaneously, are regarded as the 2.0 version of monoclonal antibodies (mAbs), providing therapeutic benefits that significantly exceed those of mAbs. This enhanced functionality makes MsAbs a particularly promising strategy for treating solid tumors. In this comprehensive review, we summarize diverse targeting strategies, clinical trial outcomes, and existing hurdles, while proposing novel directions to enhance the development of MsAbs for overcoming the immunosuppressive tumor microenvironment (TME). Based on their therapeutic mechanisms, we categorize their actions into six principles: 1) blocking various oncogenic signaling pathways; 2) activating and redirecting cytotoxic immune cells toward tumor cells; 3) enhancing macrophage-mediated phagocytosis; 4) targeting immune checkpoints to alleviate immunosuppression; 5) modulating matrix components within the immunosuppressive TME; and 6) promoting immune cell infiltration and localized cytokine signaling. In addition, the integration of MsAbs with sophisticated technologies has opened new avenues for enhancing therapeutic efficacy. These approaches include antibody-degrader conjugates, chimeric antigen receptor T cell (CAR-T) therapies, antibody-oncolytic virus combinations, nanomaterial-based delivery systems, and messenger RNA (mRNA)-based technologies. Such innovative strategies highlight the transformative potential of MsAbs, positioning them at the forefront of next-generation cancer immunotherapies.
中文摘要:多特异性抗体(MsAbs)能够同时靶向多种抗原,被视为单克隆抗体(mAbs)的2.0版本,其提供的治疗获益显著超过mAbs。这种增强的功能使MsAbs成为治疗实体瘤特别有前景的策略。在这篇综合性综述中,我们总结了多种靶向策略、临床试验结果和现有障碍,同时提出了新方向以促进MsAbs的开发,从而克服免疫抑制性肿瘤微环境(TME)。基于其治疗机制,我们将其作用归纳为六项原则:1)阻断多种致癌信号通路;2)激活并重定向细胞毒性免疫细胞以靶向肿瘤细胞;3)增强巨噬细胞介导的吞噬作用;4)靶向免疫检查点以减轻免疫抑制;5)调节免疫抑制性TME中的基质成分;6)促进免疫细胞浸润和局部细胞因子信号传导。此外,MsAbs与先进技术的整合为增强治疗效果开辟了新途径。这些方法包括抗体-降解剂偶联物、嵌合抗原受体T细胞(CAR-T)疗法、抗体-溶瘤病毒组合、基于纳米材料的递送系统以及基于信使RNA(mRNA)的技术。此类创新策略凸显了MsAbs的变革潜力,使其处于下一代癌症免疫治疗的前沿。
Cancer letters IF 11.8 2026-10-01 PMID: 42413814
Tertiary lymphoid structures (TLS) are essential immune components within the tumor microenvironment. The cellular composition, heterogeneity, and maturity of TLS are closely associated with tumor progression, response to therapy, and patient prognosis. Although numerous studies have highlighted the antitumor potential of TLS, their role can vary-either inhibiting or promoting tumor growth-depending on the specific microenvironment or disease stage. Hepatocellular carcinoma (HCC), the most common and aggressive primary liver cancer, frequently resists immune checkpoint therapy. In this context, inducing antitumor TLS has emerged as a key strategy to remodel the immune microenvironment, overcome drug resistance, and enhance the effectiveness of HCC immunotherapy. This review outlines the cellular composition and formation process of TLS, compares TLS in liver cancer with those in other cancer types, and explores their roles in HCC pathogenesis, progression, and treatment. These findings are expected to provide novel therapeutic strategies for enhancing the efficacy of immunotherapy in liver cancer.
中文摘要:三级淋巴结构(TLS)是肿瘤微环境中的重要免疫组分。TLS的细胞组成、异质性及成熟度与肿瘤进展、治疗反应及患者预后密切相关。尽管大量研究强调了TLS的抗肿瘤潜力,但其作用可能因特定微环境或疾病阶段而异,既可抑制也可促进肿瘤生长。肝细胞癌(HCC)是最常见且侵袭性强的原发性肝癌,常对免疫检查点治疗产生耐药。在此背景下,诱导抗肿瘤TLS已成为重塑免疫微环境、克服耐药并增强HCC免疫治疗疗效的关键策略。本文综述了TLS的细胞组成及形成过程,比较了肝癌与其他癌种中的TLS,并探讨了其在HCC发病机制、进展及治疗中的作用。这些发现有望为提升肝癌免疫治疗疗效提供新的治疗策略。
Cytokine & growth factor reviews IF 13.4 2026-10 PMID: 42413190
Macrophage Migration Inhibitory Factor (MIF) is a structurally conserved yet functionally versatile cytokine that possesses enzymatic activity and can trigger downstream signaling through multiple receptors (such as CD74/CD44 and CXCR2/4/7). MIF participates in tumor cell survival, metabolic reprogramming, extracellular matrix remodeling, and treatment resistance. It also shapes the tumor immune microenvironment by regulating innate and adaptive immunity. Recent evidence suggests that the biological effects of MIF are not uniform but are shaped by both molecular states and the local tumor microenvironment. At the molecular level, MIF exists in reduced and oxidized forms, exhibits distinct subcellular localizations, and is associated with different signaling profiles and functional characteristics. Its expression and biological activity are further influenced by organ-specific niches. Although high MIF expression is often associated with invasive disease and a poor prognosis in most studies, its clinical significance can vary significantly depending on the type of tumor, disease stage, subcellular localization, and detection method. Due to this complex heterogeneity, the clinical translation of MIF as a biomarker and therapeutic target faces multiple challenges. This review systematically summarizes the structural basis, regulatory mechanisms, and multifunctional properties of MIF in tumors, with a particular focus on elucidating its functional heterogeneity in different TME contexts. Clarifying the context-dependent functions of MIF will provide a theoretical framework for its clinical application as a stratified biomarker and the development of precise intervention strategies.
中文摘要:巨噬细胞移动抑制因子(MIF)是一种结构保守但功能多样的细胞因子,具有酶活性,并可通过多种受体(如CD74/CD44和CXCR2/4/7)触发下游信号传导。MIF参与肿瘤细胞存活、代谢重编程、细胞外基质重塑和治疗抵抗。它还通过调节固有免疫和适应性免疫塑造肿瘤免疫微环境。近期证据提示,MIF的生物学效应并非单一不变,而是受到分子状态和局部肿瘤微环境的共同塑造。在分子层面,MIF以还原型和氧化型存在,具有不同的亚细胞定位,并与不同的信号谱和功能特征相关。其表达和生物学活性进一步受器官特异性微环境的影响。尽管在多数研究中,MIF高表达常与侵袭性疾病和不良预后相关,但其临床意义可因肿瘤类型、疾病分期、亚细胞定位和检测方法的不同而存在显著差异。由于这种复杂的异质性,MIF作为生物标志物和治疗靶点的临床转化面临多重挑战。本综述系统总结了MIF在肿瘤中的结构基础、调控机制和多功能特性,并特别关注阐明其在不同肿瘤微环境背景下的功能异质性。明确MIF依赖背景的功能将为将其作为分层生物标志物进行临床应用以及制定精准干预策略提供理论框架。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42410247
Cellular metabolism critically influences tumor resistance. Biophysical stimulations such as mechanical vibration and electrical pulses can reprogram mesenchymal stem cells (MSCs) and T cells into tumor-suppressive states. Here, we investigated whether optical pulses (OP) could similarly promote an anti-tumor microenvironment. Using mechanical and electrical stimulation as controls, we examined optically stimulated MSCs and T cells and their conditioned medium (CM) in breast cancer and osteoclast models. OP elicited color-specific effects: blue light induced direct tumor cell death, whereas green and red light converted MSCs into induced tumor-suppressing (iTS) cells. This conversion was mediated by OPN4, independent of the Piezo1 pathway engaged by mechanical and electrical cues. Green/red pulses enhanced nucleosome scattering, increased the NAD⁺/NADH ratio, reduced the repressive histone mark H3K9me3, and activated demethylases KDM3A/KDM4. Proteomic profiling revealed enrichment of transferrin receptor (TFRC) and Annexin A2 (ANXA2) in CM, which may suppress tumors via CD44 interaction and are associated with reduced immune-evasive signaling, including Programmed Death-Ligand 1 (PD-L1). These findings demonstrate that visible light pulses can epigenetically reprogram MSCs and T cells, offering a potential therapeutic strategy for breast cancer and bone metastasis.
中文摘要:细胞代谢对肿瘤耐药具有关键影响。机械振动和电脉冲等生物物理刺激可将间充质干细胞(MSCs)和T细胞重编程为肿瘤抑制状态。在此,我们探究光学脉冲(OP)是否也能类似地促进抗肿瘤微环境。以机械和电刺激作为对照,我们检测了光刺激后的MSCs和T细胞及其条件培养基(CM)在乳腺癌和破骨细胞模型中的作用。OP呈现颜色特异性效应:蓝光诱导直接的肿瘤细胞死亡,而绿光和红光将MSCs转化为诱导型肿瘤抑制(iTS)细胞。这种转化由OPN4介导,不依赖于机械和电刺激所涉及的Piezo1通路。绿/红脉冲增强核小体散射,提高NAD⁺/NADH比值,降低抑制性组蛋白标记H3K9me3,并激活去甲基化酶KDM3A/KDM4。蛋白质组学分析显示,CM中富含转铁蛋白受体(TFRC)和膜联蛋白A2(ANXA2),它们可能通过CD44相互作用抑制肿瘤,并与免疫逃逸信号减少相关,包括程序性死亡配体1(PD-L1)。这些发现表明,可见光脉冲可对MSCs和T细胞进行表观遗传重编程,为乳腺癌和骨转移提供潜在治疗策略。
Cancer letters IF 11.8 2026-10-01 PMID: 42409257
FGFR2 fusion is a common alteration in malignancies, including intrahepatic cholangiocarcinoma (iCCA). While FGFR2 fusion has oncogenic properties, iCCA patients harboring this alteration demonstrate favorable prognosis, remaining a paradox. Here, we delineated the transcriptomic landscape of FGFR2 fusion-positive iCCA. We observed transcriptional features related to PI3K-AKT signaling in tumor cells and reduced neutrophil infiltration, particularly of the PD-L1+ neutrophil subtype. Mechanistically, FGFR2 fusion was associated with reduced H3K27ac enrichment at the CXCL3 promoter and decreased CXCL3 expression in tumor cells, which may contribute to impaired neutrophil recruitment to tumor tissues. In preclinical models, pharmacological FGFR inhibition increased CXCL3 levels and neutrophil infiltration. Combining neutrophil blockade with clinically available FGFR inhibitors enhanced antitumor activity. In conclusion, this study provides mechanistic insights into the paradox between the oncogenic properties of FGFR2 fusion and favorable clinical outcomes in FGFR2 fusion-positive iCCA, and suggests a potential strategy to optimize FGFR2-targeted therapies.
中文摘要:FGFR2融合是包括肝内胆管癌(iCCA)在内的恶性肿瘤中常见的改变。尽管FGFR2融合具有致癌特性,但携带该改变的iCCA患者却表现出良好的预后,这一现象一直是一个悖论。在此,我们描绘了FGFR2融合阳性iCCA的转录组图谱。我们观察到肿瘤细胞中与PI3K-AKT信号相关的转录特征,以及中性粒细胞浸润减少,尤其是PD-L1+中性粒细胞亚型。在机制上,FGFR2融合与CXCL3启动子处H3K27ac富集减少以及肿瘤细胞中CXCL3表达降低相关,这可能导致了中性粒细胞向肿瘤组织募集受损。在临床前模型中,药物性FGFR抑制增加了CXCL3水平和中性粒细胞浸润。将中性粒细胞阻断与临床可用的FGFR抑制剂联合使用增强了抗肿瘤活性。总之,本研究为FGFR2融合阳性iCCA中FGFR2融合的致癌特性与良好临床结局之间的悖论提供了机制性见解,并提出了优化FGFR2靶向治疗的潜在策略。
Cancer letters IF 11.8 2026-10-01 PMID: 42401334
Given the high heterogeneity and immunosuppressive nature of glioblastoma (GBM), standard monotherapies such as chemotherapy, radiotherapy, and immunotherapy show limited efficacy. Therefore, urgent combined treatment strategies-like immunostimulatory recombinant proteins-are needed. Compared to interleukin-2 (IL-2), IL-15 is a promising agent without the drawback of activation-induced cell death (AICD). We engineered a recombinant human IL-15 fused with an albumin-binding domain (hIL-15-ABD) to prolong IL-15's half-life and enhance blood-brain barrier penetration. We evaluated whether hIL-15-ABD could boost the efficacy of immune checkpoint inhibitors (ICIs) in a GBM model. Our findings indicate that hIL-15-ABD significantly improves the anti-GBM effects of anti-PD-L1 and anti-PD-1 therapies by increasing M1 macrophage populations, activating cytotoxic T cells, and promoting natural killer cell responses in an orthotopic GBM model. hIL-15-ABD enhanced the efficacy of both anti-PD-L1 (10 F.9G2) in C57BL/6 mice and anti-PD-1 (nivolumab) in a GL261 model using humanized PD1+/+ mice. Notably, hIL-15-ABD not only boosts immunostimulation but also reduces the proportions of immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), in the tumor microenvironment. Additionally, hIL-15-ABD appears to target FGF-2 and its receptors, inactivating the FGF-2/FGFR1/2 pathways. In summary, hIL-15-ABD shows potential as an immunostimulatory agent for ICIs in GBM treatment.
中文摘要:胶质母细胞瘤(GBM)具有高度异质性和免疫抑制特性,标准化单药治疗如化疗、放疗和免疫治疗疗效有限。因此,亟需联合治疗策略,例如免疫刺激性重组蛋白。与白细胞介素-2(IL-2)相比,IL-15是一种有前景的药物,没有活化诱导的细胞死亡(AICD)这一缺点。我们设计了一种与白蛋白结合结构域融合的重组人IL-15(hIL-15-ABD),以延长IL-15的半衰期并增强血脑屏障穿透能力。我们在GBM模型中评估了hIL-15-ABD是否能增强免疫检查点抑制剂(ICIs)的疗效。我们的研究结果表明,在原位GBM模型中,hIL-15-ABD通过增加M1巨噬细胞群体、激活细胞毒性T细胞并促进自然杀伤细胞反应,显著提高了抗PD-L1和抗PD-1治疗的抗GBM效果。hIL-15-ABD增强了抗PD-L1(10 F.9G2)在C57BL/6小鼠中的疗效,以及抗PD-1(nivolumab)在人源化PD1+/+小鼠GL261模型中的疗效。值得注意的是,hIL-15-ABD不仅增强免疫刺激,还降低了肿瘤微环境中免疫抑制细胞的比例,包括调节性T细胞(Tregs)和髓系来源抑制细胞(MDSCs)。此外,hIL-15-ABD似乎靶向FGF-2及其受体,使FGF-2/FGFR1/2通路失活。总之,hIL-15-ABD显示出作为GBM治疗中ICIs免疫刺激剂的潜力。
Cancer letters IF 11.8 2026-10-01 PMID: 42398852
Cancer-associated fibroblasts (CAFs) are key regulators of the tumor microenvironment (TME), shaping immune surveillance, stromal architecture, metastatic progression, and therapeutic resistance across solid tumors. Although traditionally classified into heterogeneous subtypes, emerging evidence indicates that CAF phenotypes are not fixed lineages, but dynamic stress-adaptive states continuously reshaped by hypoxia, oxidative stress, nutrient deprivation, metabolic pressure, and therapy-induced injury. These pressures reprogram CAFs transcriptional, metabolic, and secretory programs, enabling CAFs to amplify tumor-promoting signals that reinforce immunosuppression, extracellular matrix (ECM) remodeling, metastatic niche formation, and treatment resistance. Viewing CAF biology through this stress-adaptation framework provides a mechanistic explanation for the limited success of indiscriminate stromal depletion strategies and highlights the need for more selective, context-aware therapeutic intervention. In this review, we examine how microenvironmental and therapeutic stress rewires CAF identity and function across tumor progression, integrating insights from single-cell, spatial, and translational evidence. We further discuss emerging strategies aimed at disrupting stress-adaptive CAF programs, including modulation of inflammatory signaling, stromal mechanotransduction, metabolic dependencies, and senescence-associated secretory phenotypes. Reframing CAFs as dynamic stress-responsive hubs rather than static stromal subtypes may provide a conceptual foundation for next-generation stromal-targeted therapies designed to overcome immunosuppression and therapeutic resistance.
中文摘要:癌症相关成纤维细胞(CAFs)是肿瘤微环境(TME)的关键调控者,在实体瘤中塑造免疫监视、基质结构、转移进展和治疗耐药。尽管传统上将其分为异质性亚型,新出现的证据表明CAF表型并非固定谱系,而是由缺氧、氧化应激、营养剥夺、代谢压力和治療诱导损伤不断重塑的动态应激适应状态。这些压力重编程CAF的转录、代谢和分泌程序,使CAF能够放大促瘤信号,从而强化免疫抑制、细胞外基质(ECM)重塑、转移龛形成和治疗耐药。通过这一应激适应框架审视CAF生物学,可为不加区分的基质耗竭策略收效有限提供机制解释,并凸显更选择性、情境感知治疗干预的必要性。在本综述中,我们考察微环境和治疗压力如何在肿瘤进展过程中重连CAF身份与功能,并整合单细胞、空间和转化证据的见解。我们进一步讨论旨在破坏应激适应性CAF程序的新兴策略,包括调节炎症信号、基质机械转导、代谢依赖性和衰老相关分泌表型。将CAF重新定义为动态应激响应枢纽而非静态基质亚型,或可为旨在克服免疫抑制和治疗耐药的下一代基质靶向治疗提供概念基础。
Cytokine & growth factor reviews IF 13.4 2026-10 PMID: 42385401
Traditional tumor immunology research has predominantly focused on circulating recruited immune cells. In contrast, tissue-resident immune cells-a unique subset that stably resides in normal tissues and the tumor microenvironment (TME) for extended periods without entering the systemic circulation-exhibit distinct transcriptional, epigenetic and functional profiles, and their roles in tumor initiation, progression and therapeutic response remain incompletely elucidated. Focusing on the representative subsets of resident T cells, natural killer (NK) cells and macrophages, this review defines the origins of tissue-resident immune cells and elucidates the transcriptional regulatory networks (including TGF-β/IL-33 and RUNX3) that control their differentiation, maintenance, and tissue retention. Meanwhile, we systematically compare tissue-resident immune cells with recruited immune cells and summarize the canonical cell surface markers of resident cells such as CD69 and CD49a. We further reveal the bidirectional plasticity between tissue-resident and recruited immune cells: circulating T cells and monocytes can differentiate into resident subsets under the influence of local cytokine signals such as TGF-β and IFN-γ, while a fraction of tissue-resident immune cells retain the capacity to re-enter the circulation and migrate to distant tissues under inflammatory conditions. On this basis, we dissect the molecular mechanisms underlying the dual pro-tumor and anti-tumor effects exerted by the tissue-resident immune cells in the TME, which are mediated through cytokine regulation, direct contact-mediated cytotoxicity, and indirect modulation of recruited immune cells. Finally, we summarize the multifaceted impacts of conventional cancer therapies (radiotherapy, chemotherapy and targeted therapy) on tissue-resident immune cells, propose innovative therapeutic strategies targeting tissue-resident immune cells, and outline the directions for the development of next-generation molecular targeted anticancer agents. Collectively, this comprehensive review clarifies the mechanistic basis of the dual roles of tissue-resident immune cells in tumor immunity, uncovers their functional plasticity and co-evolutionary mechanisms with the TME, and provides a theoretical framework and novel therapeutic targets for overcoming immune escape in cold tumors.
中文摘要:传统肿瘤免疫学研究主要聚焦于循环中招募而来的免疫细胞。相比之下,组织驻留免疫细胞——一种稳定存在于正常组织和肿瘤微环境(TME)中较长时间且不进入体循环的独特亚群——表现出不同的转录、表观遗传和功能特征,而其在肿瘤发生、进展和治疗反应中的作用仍未完全阐明。本文以组织驻留T细胞、自然杀伤(NK)细胞和巨噬细胞等代表性亚群为切入点,界定组织驻留免疫细胞的来源,并阐明控制其分化、维持和组织滞留的转录调控网络(包括TGF-β/IL-33和RUNX3)。同时,我们系统比较组织驻留免疫细胞与招募免疫细胞,并总结驻留细胞的经典细胞表面标志物,如CD69和CD49a。我们进一步揭示组织驻留免疫细胞与招募免疫细胞之间的双向可塑性:循环T细胞和单核细胞可在TGF-β和IFN-γ等局部细胞因子信号影响下分化为驻留亚群,而一部分组织驻留免疫细胞在炎症条件下仍保留重新进入循环并迁移至远处组织的能力。在此基础上,我们剖析组织驻留免疫细胞在TME中发挥促肿瘤和抗肿瘤双重效应的分子机制,这些效应由细胞因子调控、直接接触介导的细胞毒作用以及对招募免疫细胞的间接调节所介导。最后,我们总结传统癌症治疗(放疗、化疗和靶向治疗)对组织驻留免疫细胞的多方面影响,提出靶向组织驻留免疫细胞的创新治疗策略,并概述下一代分子靶向抗癌药物的发展方向。总之,这篇综述阐明了组织驻留免疫细胞在肿瘤免疫中双重作用的机制基础,揭示其功能可塑性及其与TME的共进化机制,并为克服冷肿瘤免疫逃逸提供理论框架和新的治疗靶点。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42366227
Emerging evidence underscores the pivotal role of CD4+ effector T cells in antitumor immunity, yet their full therapeutic potential remains underexplored. This study investigates the impact of targeting the Wnt coactivators B-cell lymphoma 9 and B-cell lymphoma 9-like (BCL9/BCL9L) on CD4+ T cell-mediated antitumor immunity. We demonstrate that either genetic deletion or pharmacological inhibition of BCL9/BCL9L suppresses tumor progression and increases CD4+ T cell activation in the tumor microenvironment (TME). Critically, loss of Bcl9/Bcl9l skews CD4+ T cell differentiation toward a Th1 phenotype at the expense of Th2, Th17, and Treg lineages, thereby establishing a Th1-dominant TME and unleashing a direct cytotoxic program in these Th1 cells. Mechanistically, BCL9/BCL9L inhibition promotes Th1 polarization by suppressing TCF4-mediated regulation of PIAS family genes and enhancing STAT1/STAT4 activation, thereby driving a potent Th1-mediated antitumor response. Collectively, our findings identify BCL9/BCL9L as critical negative regulators of CD4+ T cell antitumor immunity and establish them as promising therapeutic targets for reprogramming the TME toward a Th1-supportive state.
中文摘要:新出现的证据强调了CD4+效应T细胞在抗肿瘤免疫中的关键作用,但其完整的治疗潜力仍未被充分探索。本研究探讨靶向Wnt共激活因子B细胞淋巴瘤9和B细胞淋巴瘤9样蛋白(BCL9/BCL9L)对CD4+ T细胞介导的抗肿瘤免疫的影响。我们证明,遗传性缺失或药理学抑制BCL9/BCL9L均可抑制肿瘤进展,并增加肿瘤微环境(TME)中CD4+ T细胞的活化。关键的是,Bcl9/Bcl9l缺失使CD4+ T细胞分化向Th1表型偏移,同时减少Th2、Th17和Treg谱系,从而建立一个Th1占优势的TME,并在这些Th1细胞中释放直接细胞毒性程序。机制上,抑制BCL9/BCL9L通过抑制TCF4介导的对PIAS家族基因的调控并增强STAT1/STAT4活化来促进Th1极化,从而驱动强效的Th1介导抗肿瘤反应。总体而言,我们的发现确定BCL9/BCL9L是CD4+ T细胞抗肿瘤免疫的关键负性调节因子,并将其确立为有前景的治疗靶点,可将TME重编程为支持Th1的状态。
Cancer letters IF 11.8 2026-10-01 PMID: 42365891
The design of antigen-binding domains (binders) is emerging as a decisive frontier in chimeric antigen receptor (CAR)-T cell engineering. Rather than serving as passive recognition elements, binders actively shape antigen selectivity, signaling thresholds, exhaustion propensity, persistence, and toxicity. We propose that optimal CAR performance requires a multidimensional design strategy. Success cannot be achieved by maximizing a single variable like affinity. Designers must instead integrate epitope position, binding kinetics, avidity, molecular geometry, and biophysical stability. In this review, we synthesize recent advances showing how these parameters collectively govern immunological synapse formation, antigen-density discrimination, and functional durability. Importantly, we highlight that the consequences of binder design are increasingly evident not only in mechanistic and preclinical studies, but also in real-world clinical translation and commercial trajectories. We further examine how the binder landscape has expanded beyond conventional scFvs to include VHHs, monobodies, DARPins, D-domains, peptides, natural ligands, TCR-mimic binders, and de novo AI-designed proteins. Together, these advances support a shift from empirical binder selection to rational binder orchestration as a foundational principle for next-generation CAR-T immunotherapy.
中文摘要:抗原结合域(结合子)的设计正在成为嵌合抗原受体(CAR)-T细胞工程中一个具有决定性意义的前沿。结合子并非被动识别元件,而是主动塑造抗原选择性、信号阈值、耗竭倾向、持久性和毒性。我们提出,最佳的CAR性能需要多维设计策略。仅通过最大化亲和力等单一变量无法取得成功。设计者必须转而整合表位位置、结合动力学、亲合力、分子几何构型和生物物理稳定性。在本综述中,我们综合近期进展,展示这些参数如何共同决定免疫突触形成、抗原密度辨别和功能持久性。重要的是,我们强调结合子设计的后果不仅日益体现在机制和临床前研究中,也体现在真实世界临床转化和商业发展轨迹中。我们进一步探讨结合子版图如何超越传统scFv,扩展至VHH、monobody、DARPin、D结构域、肽、天然配体、TCR模拟结合子以及AI从头设计的蛋白质。总之,这些进展支持从经验性结合子选择转向理性结合子编排,并将其作为下一代CAR-T免疫治疗的基础原则。
Cancer letters IF 11.8 2026-10-01 PMID: 42362103
Glypican-3 (GPC3) is highly expressed in most hepatocellular carcinomas (HCCs) and hepatoblastoma, shows minimal expression in non-tumor adult tissues, and is also detected in several other malignancies, making it an ideal target for anticancer immunotherapy. We previously demonstrated in clinical trials that GPC3 peptide vaccination can induce durable antitumor immunity in patients with HCC and pediatric hepatoblastoma and established human leukocyte antigen (HLA)-A∗02:01-restricted GPC3-specific cytotoxic T lymphocyte (CTL) clones. In this study, we isolated high-avidity T-cell receptors (TCRs) from CTL clones established from a pediatric hepatoblastoma patient who achieved long-term recurrence-free survival for more than 10 years after surgical resection of pulmonary metastases followed by GPC3 peptide vaccination. Using a retroviral vector incorporating endogenous TCR suppression, these TCR genes were introduced into primary human T cells to generate GPC3-specific TCR-engineered T cells (TCR-T cells). These TCR-T cells exhibited GPC3-specific recognition and significant cytotoxicity against GPC3-positive tumor cells in vitro, while showing minimal activity against GPC3-negative targets. Moreover, GPC3-specific TCR-T cells migrated to tumor sites, resulting in the prevention of tumor engraftment as well as tumor growth suppression and stabilization in xenograft models. GPC3-targeted TCR-T cells derived from CTLs induced by GPC3 peptide vaccination demonstrated potent antitumor activity against HLA-A∗02-positive and GPC3-positive cancers. These findings provide an important rationale for Phase I clinical trials of GPC3-targeted TCR-T cells as a promising therapeutic strategy for GPC3-expressing solid tumors, including HCC and refractory hepatoblastoma.
中文摘要:磷脂酰肌醇蛋白聚糖3(GPC3)在大多数肝细胞癌(HCC)和肝母细胞瘤中高表达,在成人非肿瘤组织中表达极低,并且也在其他几种恶性肿瘤中检测到,使其成为抗癌免疫治疗的理想靶点。我们先前在临床试验中证明,GPC3肽疫苗可在HCC和儿童肝母细胞瘤患者中诱导持久的抗肿瘤免疫,并建立了人类白细胞抗原(HLA)-A*02:01限制性GPC3特异性细胞毒性T淋巴细胞(CTL)克隆。在本研究中,我们从一名儿童肝母细胞瘤患者的CTL克隆中分离出高亲和力T细胞受体(TCR),该患者在接受肺转移灶手术切除后接种GPC3肽疫苗,获得了超过10年的长期无复发生存。使用包含内源性TCR抑制的逆转录病毒载体,将这些TCR基因导入原代人T细胞,以生成GPC3特异性TCR工程化T细胞(TCR-T细胞)。这些TCR-T细胞在体外表现出GPC3特异性识别和对GPC3阳性肿瘤细胞的显著细胞毒性,而对GPC3阴性靶标活性极低。此外,GPC3特异性TCR-T细胞迁移至肿瘤部位,在异种移植模型中预防肿瘤植入以及抑制和稳定肿瘤生长。由GPC3肽疫苗诱导的CTL衍生的GPC3靶向TCR-T细胞,对HLA-A*02阳性和GPC3阳性癌症表现出强效抗肿瘤活性。这些发现为GPC3靶向TCR-T细胞的I期临床试验提供了重要依据,作为GPC3表达实体瘤(包括HCC和难治性肝母细胞瘤)的有前景的治疗策略。
Cancer letters IF 11.8 2026-10-01 PMID: 42362102
Oncolytic virotherapy has emerged as a promising strategy for cancer immunotherapy; however, its immunomodulatory mechanisms in colorectal cancer remain incompletely understood. Here, we evaluated the therapeutic effects of the oncolytic virus VG161 in murine colorectal cancer models (CT26.WT and MC38) and systematically characterized the associated tumor microenvironment (TME) remodeling. Using single-cell RNA sequencing, flow cytometry, and multiplex immunohistochemistry, we identified a distinct population of CD3+ macrophages that was markedly expanded following VG161 treatment. Functional analyses suggested that these cells exhibit enhanced phagocytic capacity and immunostimulatory properties, including the recruitment of CCL5high CD8+ effector memory T cells (Tem). Mechanistically, VG161-infected tumor cells were found to secrete complement-related factors, including complement factor B (CFB) and complement component 3 (C3), which may contribute to CD3 upregulation and the emergence of a CD3+ macrophage-associated state. These findings suggest that complement signaling may contribute to CD3 upregulation in macrophages, although the downstream mechanisms remain to be elucidated. Furthermore, VG161 treatment enhanced systemic antitumor immunity and improved responsiveness to immune checkpoint blockade. Collectively, these findings reveal a potential role for VG161 in orchestrating innate-adaptive immune interactions and provide a rationale for targeting macrophage-mediated pathways to improve colorectal cancer immunotherapy.
中文摘要:溶瘤病毒治疗已成为癌症免疫治疗的一种有前景的策略;然而,其在结直肠癌中的免疫调节机制仍未完全阐明。在此,我们在小鼠结直肠癌模型(CT26.WT和MC38)中评估了溶瘤病毒VG161的治疗效果,并系统表征了相关的肿瘤微环境(TME)重塑。利用单细胞RNA测序、流式细胞术和多色免疫组织化学,我们鉴定出一群独特的CD3+巨噬细胞,其在VG161治疗后显著扩增。功能分析提示,这些细胞表现出增强的吞噬能力和免疫刺激特性,包括招募CCL5高表达的CD8+效应记忆T细胞(Tem)。在机制上,发现VG161感染的肿瘤细胞分泌补体相关因子,包括补体因子B(CFB)和补体成分3(C3),这可能有助于CD3上调以及CD3+巨噬细胞相关状态的出现。这些发现提示,补体信号可能促进巨噬细胞中CD3上调,尽管下游机制仍有待阐明。此外,VG161治疗增强了全身抗肿瘤免疫,并改善了对免疫检查点阻断的应答。总体而言,这些发现揭示了VG161在协调固有免疫与适应性免疫相互作用中的潜在作用,并为靶向巨噬细胞介导的通路以改善结直肠癌免疫治疗提供了依据。
Biotechnology advances IF 14.1 2026-10 PMID: 42229669
Immunotherapy has transformed the landscape of cancer treatment, driving sustained innovation and investment across the biotechnology sector. Among the most prominent advances, CAR-T cell therapy and cancer nanovaccines have emerged as powerful and potentially complementary strategies with the capacity to reshape clinical practice. Despite their promise, each approach presents distinct strengths and limitations, as demonstrated across preclinical and clinical studies. This review provides a comparative analysis of these platforms, examining their underlying mechanisms, technological features, and recent developments aimed at improving therapeutic efficacy. Particular attention is given to the key challenges that continue to limit their broader clinical translation, including barriers associated with solid tumors, safety, scalability, and the durability of immune responses. We further integrate these discussions into translational clinical decision-making insights intended to support context-dependent patient stratification, therapeutic selection, and rational design of combination immunotherapies. By integrating these perspectives, this work offers an updated overview of CAR-T cell therapies and nanovaccines, emphasizing convergent and divergent features while outlining strategic directions to guide future research and translational development.
中文摘要:免疫疗法已经改变了癌症治疗的格局,推动了生物技术领域的持续创新和投资。在最突出的进展中,CAR-T细胞疗法和癌症纳米疫苗已成为强大且可能互补的策略,有能力重塑临床实践。尽管前景广阔,但正如临床前和临床研究所显示的,这两种方法各自具有不同的优势和局限性。本综述对这两个平台进行了比较分析,考察了其基本机制、技术特征以及旨在提高治疗效果的最新进展。特别关注了继续限制其更广泛临床转化的关键挑战,包括与实体瘤相关的障碍、安全性、可扩展性以及免疫应答持久性。我们进一步将这些讨论整合为转化临床决策方面的见解,旨在支持依赖具体情境的患者分层、治疗选择以及合理设计联合免疫疗法。通过整合这些观点,本工作提供了关于CAR-T细胞疗法和纳米疫苗的最新概述,强调了其趋同和趋异的特征,同时概述了指导未来研究和转化开发的战略方向。
Bioactive materials IF 23.6 2026-10 PMID: 42211722
Postoperative management of osteosarcoma remains hindered by several critical challenges, including platinum-based chemoresistance, insufficient antitumor immune responses, and the difficulty of synchronously repairing large bone defects. Addressing these issues requires strategies capable of coordinating tumor eradication, immune modulation, and bone regeneration within the dynamic postoperative microenvironment. In this study, we developed a near-infrared (NIR)-responsive intelligent composite bone scaffold that integrates a reducible platinum (IV) prodrug (Pt (IV)) and cucurbitacin B (CuB) via hollow mesoporous silica and polydopamine interfacial engineering, enabling dual responsiveness to tumor-associated cues and exogenous photonic stimulation. Mechanistically, controlled CuB release suppresses DNA damage repair, amplifies Pt (IV)-induced DNA damage, and reverses platinum resistance, while the combined action of Pt (IV) and CuB induces immunogenic cell death and activates the cGAS-STING pathway, thereby remodeling an antitumor immune microenvironment. Concurrently, sustained Si4+ release and CuB synergistically promote angiogenesis and osteogenic differentiation, establishing a regenerative niche for bone reconstruction. In vivo studies further demonstrate that the scaffold exhibits microenvironment-responsive and externally triggered regulatory capability. During the tumor suppression phase, the acidic tumor microenvironment and NIR stimulation enhance the release of Pt (IV) and CuB, leading to effective inhibition of drug-resistant osteosarcoma. As the local microenvironment progressively normalizes, the system supports osteogenesis and vascularization, ultimately achieving substantial new bone formation and bone bridging without observable systemic toxicity. Taken together, this work presents a multifunctional composite scaffold strategy characterized by microenvironment responsiveness, functional integration, and multi-pathway coordination. This approach provides an integrated solution for postoperative treatment and bone repair in drug-resistant osteosarcoma.
中文摘要:骨肉瘤的术后管理仍受到若干关键挑战的阻碍,包括铂类化疗耐药、抗肿瘤免疫应答不足以及同步修复大段骨缺损的困难。解决这些问题需要能够在动态术后微环境中协调肿瘤清除、免疫调节和骨再生的策略。在本研究中,我们开发了一种近红外(NIR)响应型智能复合骨支架,通过中空介孔二氧化硅和聚多巴胺界面工程整合可还原的铂(IV)前药(Pt(IV))和葫芦素B(CuB),从而实现对肿瘤相关线索和外源性光刺激的双重响应。在机制上,CuB的受控释放抑制DNA损伤修复,放大Pt(IV)诱导的DNA损伤,并逆转铂耐药;同时Pt(IV)和CuB的联合作用诱导免疫原性细胞死亡并激活cGAS-STING通路,从而重塑抗肿瘤免疫微环境。与此同时,Si4+的持续释放和CuB协同促进血管生成和成骨分化,为骨重建建立再生微环境。体内研究进一步表明,该支架具有微环境响应性和外部触发调控能力。在肿瘤抑制阶段,酸性肿瘤微环境和NIR刺激增强Pt(IV)和CuB的释放,从而有效抑制耐药骨肉瘤。随着局部微环境逐步正常化,该系统支持成骨和血管化,最终实现大量新骨形成和骨桥接,且未观察到明显全身毒性。综上所述,这项工作提出了一种多功能复合支架策略,其特征为微环境响应性、功能整合和多通路协调。该方法为耐药骨肉瘤的术后治疗和骨修复提供了一种整合解决方案。
Nature chemical biology IF 15.8 2026-10 PMID: 42204309
Understanding of the metabolic determinants influencing immunotherapy responsiveness remains limited. Here we performed a multiomics analysis of tumor biopsies from patients with hepatocellular carcinoma (HCC) treated with immune checkpoint blockade (ICB) and revealed that heightened expression of OXCT1, a rate-limiting enzyme in ketone body metabolism, was negatively correlated with ICB efficacy, whereas its metabolic substrate, β-hydroxybutyrate (BHB), displayed an opposite effect. Mechanistically, glucose deprivation in HCC cells promotes AMPK-mediated OXCT1 S113 phosphorylation, which exposes the nuclear localization sequence of OXCT1 to trigger its nuclear translocation. Nucleus-translocated OXCT1 associates with IRF1 to locally consume BHB and suppress histone H3K9 BHB at the major histocompatibility complex class I (MHC-I) and chemokine gene loci, leading to repressed transcription of these immune genes. Targeting the AMPK-OXCT1-IRF1 axis sensitizes tumor cells to ICB upon ketogenic diet. These findings reveal a mechanism by which a non-canonical function of nuclear OXCT1 coordinates the interplay between ketone body metabolic reprogramming and immunotherapy responsiveness.
中文摘要:影响免疫治疗反应性的代谢决定因素仍所知有限。在此,我们对接受免疫检查点阻断(ICB)治疗的肝细胞癌(HCC)患者的肿瘤活检进行了多组学分析,发现酮体代谢限速酶OXCT1表达升高与ICB疗效负相关,而其代谢底物β-羟基丁酸(BHB)则表现出相反效应。机制上,HCC细胞中的葡萄糖剥夺促进AMPK介导的OXCT1 S113磷酸化,从而暴露OXCT1的核定位序列并触发其核转位。核转位后的OXCT1与IRF1结合,在局部消耗BHB并抑制主要组织相容性复合体I类(MHC-I)和趋化因子基因位点处的组蛋白H3K9 β-羟基丁酰化,导致这些免疫基因转录受抑。靶向AMPK-OXCT1-IRF1轴可在生酮饮食下使肿瘤细胞对ICB敏感。这些发现揭示了一种机制,即核内OXCT1的非经典功能协调酮体代谢重编程与免疫治疗反应性之间的相互作用。
Gastroenterology IF 29.7 2026-10 PMID: 42191046
Oncogenic de novo mucins (oncoMUCs; MUC4, MUC16, and MUC5AC) are progressively upregulated in pancreatic ductal adenocarcinoma (PDA). Although their individual cell-intrinsic roles have been investigated, their collective impact on PDA progression and the tumor microenvironment (TME) remains unclear. Evaluating the patient-centric impact of oncoMUCs on the TME will inform diagnostic and therapeutic strategies. Integration of single-cell RNA sequencing (n = 34), multiplex/sequential immunostaining, and murine models characterized the oncomucinome. Immune suppression was investigated using NanoString profiling and gene silencing. Pharmacologic oncoMUC targeting (Istradefylline) was evaluated in combination with K-rasG12D inhibitor in a syngeneic murine model. OncoMUCs showed extensive clonal diversity and survival disadvantage (P = .00013) in PDA. OncoMUC4 and oncoMUC16 subpopulations were enriched after stage IIA/B, and their deletion significantly reduced immune checkpoints (ICs) expression (V-domain immunoglobulin suppressor of T-cell activation [VISTA]: P < .0001, .001; T-cell immunoglobulin and mucin domain-containing protein 3 [TIM3]: P < .0001, .001), and increased CD8+ T-cell (P = .0087) and antigen-presenting cell infiltration (macrophages: P < .004; dendritic cells: P = .021) in tumors of PDA autochthonous models. Mechanistically, these subpopulations potentiate epidermal growth factor receptor (EGFR) and Unc-5 Netrin Receptor B (UNC5B) signaling, which collaboratively upregulate ICs, VISTA, and programmed death ligand 1 ([PD-L1] P < .0001). As KrasG12D inhibition (MRTX1133) upregulated oncoMuc4 and oncoMuc16 expression, pharmacological targeting of oncoMUCs enhanced the efficacy of MRTX1133, as indicated by reduced tumor burden (P = .034), ICs (local, [P range 0.03-0.009] and systemic VISTA and TIM3 [P = .024, .014]), and Unc5b (P = .048) expression. Transmembrane oncoMUCs promote immune evasion in PDA through EGFR/UNC5B signaling, and their targeting enhances the efficacy of K-rasG12D inhibition, suggesting oncoMUCs as novel immune regulators and therapeutic targets in PDA.
中文摘要:致癌性从头合成的黏蛋白(oncoMUCs;MUC4、MUC16和MUC5AC)在胰腺导管腺癌(PDA)中逐步上调。尽管其各自的细胞内在作用已被研究,但它们对PDA进展和肿瘤微环境(TME)的总体影响仍不清楚。评估oncoMUCs对TME以患者为中心的影响将为诊断和治疗策略提供信息。整合单细胞RNA测序(n = 34)、多重/序贯免疫染色和小鼠模型,对oncomucinome进行了表征。使用NanoString谱分析和基因沉默研究免疫抑制。在同基因小鼠模型中评估了药理oncoMUC靶向药物(Istradefylline)与K-rasG12D抑制剂的联合应用。OncoMUCs在PDA中显示出广泛的克隆多样性和生存劣势(P = .00013)。OncoMUC4和oncoMUC16亚群在IIA/B期后富集,其缺失显著降低了免疫检查点(ICs)表达(V域免疫球蛋白抑制T细胞活化因子[VISTA]:P < .0001,.001;含T细胞免疫球蛋白和黏蛋白结构域蛋白3[TIM3]:P < .0001,.001),并增加了PDA自发模型肿瘤中的CD8+ T细胞(P = .0087)和抗原呈递细胞浸润(巨噬细胞:P < .004;树突状细胞:P = .021)。机制上,这些亚群增强表皮生长因子受体(EGFR)和Unc-5 Netrin受体B(UNC5B)信号,二者协同上调ICs、VISTA和程序性死亡配体1([PD-L1] P < .0001)。由于KrasG12D抑制(MRTX1133)上调oncoMuc4和oncoMuc16表达,药理靶向oncoMUCs增强了MRTX1133的疗效,表现为肿瘤负荷降低(P = .034)、ICs(局部,[P范围0.03-0.009]以及全身VISTA和TIM3[P = .024,.014])和Unc5b(P = .048)表达降低。跨膜oncoMUCs通过EGFR/UNC5B信号促进PDA免疫逃逸,靶向其可增强K-rasG12D抑制的疗效,提示oncoMUCs是PDA中新型免疫调节因子和治疗靶点。
Cancer discovery IF 29.5 2026-10-01 PMID: 42188872
Although genetic sequencing is routine in cancer care, translating a tumor's complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is pretrained on a large corpus of genomic alterations across more than 30,000 tumors, integrated with extensive molecular knowledge. The resulting projection reveals a tumor's altered molecular pathways, facilitating model interpretation, and it accurately reconstructs held-out mutations, demonstrating model generalization. When applied to predict immunotherapy or chemotherapy resistance across multiple cancer types and cohorts, MutationProjector achieves or exceeds state-of-the-art performance in all contexts. It identifies unexpected biomarkers, including KMT2D mutation in immunotherapy sensitivity and joint alteration of SMARCA4 and STK11 in immunotherapy resistance. These results establish a unifying framework for connecting tumor genotypes to biological mechanisms and therapeutic outcomes. This work describes MutationProjector, a tumor genomic foundation model pretrained on more than 30,000 tumors. It maps mutations to biological states for diagnosis and treatment, achieving state-of-the-art performance in predicting therapy resistance and identifying biomarkers such as KMT2D (sensitivity) and SMARCA4/STK11 coalterations (resistance).
中文摘要:尽管基因测序在肿瘤诊疗中已属常规,但将肿瘤复杂的突变谱转化为可操作的治疗决策仍是一项核心挑战。MutationProjector 在涵盖 3 万余个肿瘤的基因组变异大型语料库上进行预训练,并整合了广泛的分子知识。由此产生的投影可揭示肿瘤中发生改变的分子通路,促进模型解释,并能准确重建留出的突变,证明模型具有泛化能力。当用于预测多种癌症类型和队列中的免疫治疗或化疗耐药时,MutationProjector 在所有情境中均达到或超越当前最佳性能。它识别出意料之外的生物标志物,包括免疫治疗敏感性中的 KMT2D 突变,以及免疫治疗耐药中的 SMARCA4 和 STK11 联合改变。这些结果建立了一个连接肿瘤基因型与生物学机制及治疗结局的统一框架。本工作介绍了 MutationProjector,一种在 3 万余个肿瘤上预训练的肿瘤基因组基础模型。它将突变映射到生物学状态,用于诊断和治疗,在预测治疗耐药方面达到当前最佳性能,并识别出如 KMT2D(敏感性)以及 SMARCA4/STK11 联合改变(耐药)等生物标志物。
Bioactive materials IF 23.6 2026-10 PMID: 42181167
Postoperative immune suppression, driven by transforming growth factor β (TGFβ)-mediated dendritic cell (DC) dysfunction, significantly impairs antigen-specific T cell responses and elevates cancer recurrence risk. A key mechanism is TGFβ-mediated lysosomal incompetence in DCs, resulting from loss of lysosomal prosaposin (pSAP). Herein, we developed an in vivo-generated DC vaccine, BAIT (boosting antigen-delivering immunovaccine for T cell priming), which integrated DC recruitment, antigen delivery, and immune activation within a single platform. Inspired by arginine metabolism-driven lysosomal biogenesis and acidification, BAITs were designed with an arginine-enriched self-assembling peptide backbone, in which tumor lysate antigens and CCL20 co-assembled via coordination interactions. When administered early post-surgery, BAITs recruited DCs, promoted antigen internalization, and activated the mTOR pathway to upregulate pSAP expression. This BAIT-driven DC modulation reversed TGFβ-induced impairments in antigen digestion and MHC-peptide complex formation. To optimize precision immunotherapy, we employed a functional precision medicine approach by customizing tumor lysate preparations induced via ferroptosis, necroptosis, or apoptosis. In a murine postoperative cancer model, Apo-BAITs formulated with apoptotic lysates achieved an 85.5% reduction in tumor burden. These findings demonstrate that BAITs target the lysosomal mTOR-pSAP axis to restore DC function, providing a personalized postoperative cancer vaccine strategy to counter surgery-induced immune suppression.
中文摘要:术后免疫抑制由转化生长因子β(TGFβ)介导的树突状细胞(DC)功能障碍所驱动,会显著损害抗原特异性T细胞应答并提高癌症复发风险。一个关键机制是TGFβ介导的DC溶酶体功能缺陷,其源于溶酶体prosaposin(pSAP)的缺失。在此,我们开发了一种体内生成的DC疫苗BAIT(用于T细胞致敏的增强抗原递送免疫疫苗),其在单一平台中整合了DC募集、抗原递送和免疫激活。受精氨酸代谢驱动的溶酶体生物发生和酸化启发,BAIT被设计为富含精氨酸的自组装肽骨架,其中肿瘤裂解物抗原和CCL20通过配位相互作用共组装。在术后早期给药时,BAIT募集DC,促进抗原内化,并激活mTOR通路以上调pSAP表达。这种BAIT驱动的DC调节逆转了TGFβ诱导的抗原消化和MHC-肽复合物形成障碍。为优化精准免疫治疗,我们采用功能性精准医学方法,通过铁死亡、坏死性凋亡或凋亡诱导定制肿瘤裂解物制剂。在小鼠术后癌症模型中,用凋亡裂解物配制的Apo-BAIT使肿瘤负荷减少85.5%。这些发现表明,BAIT靶向溶酶体mTOR-pSAP轴以恢复DC功能,提供了一种个性化的术后癌症疫苗策略,以对抗手术诱导的免疫抑制。
Cancer letters IF 11.8 2026-10-01 PMID: 42140344
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy; however, primary and acquired resistance, driven largely by tumor cell-mediated remodeling of the immunosuppressive tumor microenvironment (TME), limit durable responses in most patients. The cohesin subunit RAD21 exhibits frequent copy number variation (CNV) across human cancers, yet its role in modulating tumor immunity remains poorly defined. Here, we identify RAD21 as a frequently amplified oncogene that promotes tumor cell proliferation and metastasis and whose elevated expression correlates with poor patient survival. Mechanistically, RAD21 drives M2-like polarization of tumor-associated macrophages (TAMs) via upregulation of CSF1 signaling, thereby fostering an immunologically "cold" tumor and conferring resistance to anti-PD-1 therapy. RAD21 depletion reverses this immunosuppressive phenotype and, when combined with anti-PD-1 blockade, achieves maximal tumor regression. Our findings unveil a previously unrecognized oncogenic mechanism wherein RAD21 orchestrates immune evasion through activation of CSF1 signaling and position RAD21 as a promising therapeutic target to overcome resistance to anti-PD-1 blockade.
中文摘要:免疫检查点抑制剂(ICIs)已彻底改变癌症治疗;然而,主要由肿瘤细胞介导的免疫抑制性肿瘤微环境(TME)重塑所驱动的原发性和获得性耐药,限制了大多数患者的持久缓解。黏连蛋白亚基RAD21在人类癌症中频繁发生拷贝数变异(CNV),但其在调节肿瘤免疫中的作用仍不明确。在此,我们将RAD21鉴定为一个频繁扩增的癌基因,其促进肿瘤细胞增殖和转移,且其高表达与患者生存不良相关。机制上,RAD21通过上调CSF1信号驱动肿瘤相关巨噬细胞(TAMs)向M2样极化,从而促进形成免疫学「冷」肿瘤并导致抗PD-1治疗耐药。RAD21缺失可逆转这种免疫抑制表型,并且与抗PD-1阻断联合时可实现最大程度的肿瘤消退。我们的研究揭示了一种此前未被认识的致癌机制,即RAD21通过激活CSF1信号协调免疫逃逸,并将RAD21定位为克服抗PD-1阻断耐药的有前景的治疗靶点。
Cancer discovery IF 29.5 2026-10-01 PMID: 42126206
Although microsatellite-instable (MSI) colorectal cancers, reflecting mismatch repair (MMR) deficiency, often respond to immune checkpoint inhibitors, microsatellite-stable (MSS) tumors remain largely resistant. This disparity is typically attributed to differences in neoantigen load. However, whether antigen-independent mechanisms contribute to immune evasion in MSS colorectal cancer remains unclear. To address this, we engineered a model in which MSI and MSS colorectal cancer cells express identical levels of a defined antigen recognized by T-cell receptor-engineered T cells. Despite equivalent antigen presentation, MSS tumors exhibited impaired T-cell activation, reduced cytotoxicity, and resistance to killing. We linked this immune evasion to the MSS tumor secretome, which suppressed immune responses even in immunogenic MSI cells by impairing immune synapse formation. Surfaceome profiling by mass spectrometry identified glycosylation-dependent alterations that impair immune recognition. Our findings demonstrate that MSS colorectal cancer evades immune attack via intrinsic secretome-driven mechanisms, independent of antigenicity. Targeting glycosylation-linked suppressive pathways may restore T-cell responsiveness and improve immunotherapy efficacy in MSS colorectal cancer. This study reveals that MMR-proficient colorectal cancers resist T-cell attack not only due to low neoantigen load but also through glycosylation-dependent, secretome-mediated immunosuppression. These findings uncover a previously unrecognized immune evasion mechanism and identify actionable pathways to restore immunotherapy responsiveness in resistant colorectal tumors.
中文摘要:尽管反映错配修复(MMR)缺陷的微卫星不稳定(MSI)结直肠癌通常对免疫检查点抑制剂有反应,但微卫星稳定(MSS)肿瘤仍大多耐药。这种差异通常被归因于新抗原负荷不同。然而,抗原非依赖性机制是否参与MSS结直肠癌的免疫逃逸仍不清楚。为解决这一问题,我们构建了一个模型,使MSI和MSS结直肠癌细胞表达相同水平的、由T细胞受体工程化T细胞识别的特定抗原。尽管抗原呈递相当,MSS肿瘤仍表现出T细胞激活受损、细胞毒性降低以及对杀伤的抵抗。我们将这种免疫逃逸与MSS肿瘤分泌组联系起来,后者即使对免疫原性MSI细胞也可通过损害免疫突触形成来抑制免疫应答。通过质谱进行的表面蛋白质组分析鉴定出损害免疫识别的糖基化依赖性改变。我们的发现表明,MSS结直肠癌通过内在分泌组驱动的机制逃避免疫攻击,且不依赖于抗原性。靶向糖基化相关的抑制通路可能恢复T细胞反应性并改善MSS结直肠癌的免疫治疗疗效。本研究揭示,错配修复功能完整的结直肠癌抵抗T细胞攻击不仅由于新抗原负荷低,还通过糖基化依赖的、分泌组介导的免疫抑制。这些发现揭示了一种此前未被认识的免疫逃逸机制,并确定了可操作的途径,以恢复耐药结直肠肿瘤的免疫治疗反应性。
Bioactive materials IF 23.6 2026-10 PMID: 42099773
Although nanovaccines hold promise for cancer immunotherapy, the engineering platforms that respond to tumor-specific cues and activate antitumor immunity remains challenging. Herein, a glutathione (GSH)-responsive immunogenic nanovaccine (SHINE) is developed, integrating immunogenic cell death (ICD)-inducing chemodynamic therapy (CDT) with immunotherapy to elicit synergistic in situ antitumor immunity. Constructed from a hollow MnO2 nanostructure, SHINE selectively degrades in GSH-enriched tumors, depleting intracellular GSH while releasing Mn2+ to catalyze Fenton-like reactive oxygen species generation. Concurrently, SHINE facilitates the controlled release of the TLR7/8 agonist R848 and, through surface-conjugated anti-PD-L1 antibodies, enables immune checkpoint blockade and enhances active tumor targeting. This design integrates CDT as the "initiator" and R848/anti-PD-L1 as dual immune "boosters," thereby eliciting a synergistic cascade that drives potent ICD and promotes dendritic cell maturation and T cell priming. Transcriptomics confirms robust immune activation, while in vivo SHINE suppresses both primary tumor growth and lung metastasis. Remarkably, SHINE establishes durable immune memory, characterized by elevated effector memory T cells and upregulation of memory T cell-related genes, thereby conferring rechallenge protection and preventing tumor recurrence. Collectively, SHINE represents a robust in situ cancer nanovaccine for systemic, long-term tumor control.
中文摘要:尽管纳米疫苗在肿瘤免疫治疗中具有前景,但能够响应肿瘤特异性信号并激活抗肿瘤免疫的工程化平台仍具挑战性。在此,开发了一种谷胱甘肽(GSH)响应性免疫原性纳米疫苗(SHINE),将诱导免疫原性细胞死亡(ICD)的化学动力学治疗(CDT)与免疫治疗整合,以激发协同的原位抗肿瘤免疫。SHINE由中空MnO2纳米结构构建,在富含GSH的肿瘤中选择性降解,耗竭细胞内GSH,同时释放Mn2+以催化类Fenton反应产生活性氧。同时,SHINE促进TLR7/8激动剂R848的控释,并通过表面偶联的抗PD-L1抗体实现免疫检查点阻断并增强主动肿瘤靶向。该设计将CDT作为「启动器」,R848/抗PD-L1作为双重免疫「增强剂」,从而引发协同级联反应,驱动强效ICD并促进树突状细胞成熟和T细胞致敏。转录组学证实了强烈的免疫激活,而体内实验中SHINE抑制原发肿瘤生长和肺转移。值得注意的是,SHINE建立了持久免疫记忆,其特征为效应记忆T细胞升高和记忆T细胞相关基因上调,从而提供再攻击保护和防止肿瘤复发。总体而言,SHINE代表一种稳健的原位癌症纳米疫苗,用于系统性、长期肿瘤控制。
Bioactive materials IF 23.6 2026-10 PMID: 42093837
This review presents an innovative "three-axis synergy" immunotherapeutic strategy for malignant bone tumors, combining natural bioactives with bioactive materials to overcome the challenges posed by the immunosuppressive microenvironment (IME) of tumors. Malignant bone tumors create an IME characterized by immune evasion, bone destruction, and physicochemical dysregulation, which limits the effectiveness of conventional therapies. Natural bioactives, known for their immunomodulatory effects, can potentially reprogram the IME, but their clinical application is hindered by low bioavailability and limited targeting efficiency. Bioactive materials, such as scaffolds and nanoparticles, can improve the delivery, retention, and targeted release of these bioactives, while also supporting bone regeneration. By combining natural bioactives with bioactive materials, this synergistic approach offers a dual-functional therapeutic platform that not only targets immune suppression but also promotes bone repair. This strategy addresses the key barriers of the IME, including immune imbalance, bone resorption, and physicochemical abnormalities. Although challenges remain in the clinical translation of these natural bioactives, their integration with bioactive materials provides a promising direction for improving treatment outcomes of malignant bone tumors. This approach offers new insights into the future of cancer immunotherapy and bone regeneration.
中文摘要:本综述提出了一种针对恶性骨肿瘤的创新性「三轴协同」免疫治疗策略,将天然生物活性物质与生物活性材料相结合,以克服肿瘤免疫抑制微环境(IME)带来的挑战。恶性骨肿瘤形成以免疫逃逸、骨破坏和理化失调为特征的IME,限制了常规疗法的效果。天然生物活性物质因其免疫调节作用而受到关注,有可能重编程IME,但其临床应用受到低生物利用度和有限靶向效率的阻碍。生物活性材料,如支架和纳米颗粒,可以改善这些生物活性物质的递送、滞留和靶向释放,同时支持骨再生。通过将天然生物活性物质与生物活性材料相结合,这种协同策略提供了一个双功能治疗平台,不仅靶向免疫抑制,还能促进骨修复。该策略针对IME的关键障碍,包括免疫失衡、骨吸收和理化异常。尽管这些天然生物活性物质的临床转化仍面临挑战,但它们与生物活性材料的整合为改善恶性骨肿瘤的治疗结局提供了有前景的方向。这种方法为癌症免疫治疗和骨再生的未来提供了新的见解。
Bioactive materials IF 23.6 2026-10 PMID: 42088559
Sonogenetics represents a non-invasive and precise strategy for cancer therapy by coupling ultrasound (US) with genetic engineering. However, achieving efficient deep-tumor delivery and profound immune activation remains challenging. Herein, we developed a novel sonogenetic nanogel system (NGs@pDNA) designed to trigger a potent systemic antitumor immune response via US-induced calcium (Ca2+) overload. These nanogels feature flexible mechanical properties and glutathione (GSH) responsiveness, facilitating deep tumor penetration and the targeted delivery of plasmids encoding the mechanosensitive channel MscL. Upon US irradiation, the activated MscL channels drive a massive influx of endogenous Ca2+ (5.8 ± 0.6-fold increase), disrupting intracellular homeostasis and provoking a synergistic cascade of oxidative endoplasmic reticulum (ER) stress and mitochondrial dysfunction efficiently triggering immunogenic cell death (ICD). Further, ICD promotes dendritic cell (DC) maturation and reprograms pro-tumoral M2 macrophages into the anti-tumoral M1 phenotype. Whole-genome transcriptomic sequencing reveals the significant enrichment of pathways related to Ca2+ homeostasis, oxidative stress-induced apoptosis, and antigen processing. In vivo studies further demonstrated this sonogenetic platform effectively eradicated primary tumors and suppressed distant metastases by activating a robust systemic immune response. Overall, this study establishes a spatiotemporally controllable therapeutic paradigm by integrating sonogenetic modulation, nanogel delivery, and Ca2+ overload-induced ICD to overcome tumor immunosuppression and enhance systemic antitumor immunity.
中文摘要:声遗传学通过将超声(US)与基因工程相偶联,为癌症治疗提供了一种无创且精准的策略。然而,实现高效的深部肿瘤递送与充分的免疫激活仍具挑战性。在此,我们开发了一种新型声遗传纳米凝胶系统(NGs@pDNA),旨在通过超声诱导的钙(Ca2+)超载触发强效的全身抗肿瘤免疫应答。该纳米凝胶具有柔性的力学性质和谷胱甘肽(GSH)响应性,有利于深部肿瘤穿透以及编码机械敏感通道MscL的质粒的靶向递送。在超声照射下,被激活的MscL通道驱动内源性Ca2+大量内流(增加5.8 ± 0.6倍),破坏细胞内稳态,并引发氧化性内质网(ER)应激与线粒体功能障碍的协同级联反应,从而高效触发免疫原性细胞死亡(ICD)。此外,ICD促进树突状细胞(DC)成熟,并将促肿瘤的M2型巨噬细胞重编程为抗肿瘤的M1型。全基因组转录组测序显示,与Ca2+稳态、氧化应激诱导的凋亡以及抗原加工相关的通路显著富集。体内研究进一步表明,该声遗传平台通过激活强效的全身免疫应答,有效根除原发肿瘤并抑制远处转移。总体而言,本研究通过整合声遗传调控、纳米凝胶递送与Ca2+超载诱导的ICD,建立了一种时空可控的治疗范式,以克服肿瘤免疫抑制并增强全身抗肿瘤免疫。
Trends in biotechnology IF 16.6 2026-10 PMID: 42062180
Oligoclonal VHH mixtures targeting distinct epitopes offer therapeutic benefits in mitigating complex diseases, including cancer, infectious diseases, and snakebite envenoming. However, current production strategies rely on separate expression and purification of individual VHHs, followed by downstream mixing, resulting in high costs. We present a cocultivation approach for producing an experimental recombinant antivenom using growth-decoupled Escherichia coli strains. Six different cell lines were generated by transforming the same host with different VHH genes. The cell lines displayed high-yield extracellular secretion in microtiter plate and 1-l bioreactor cultivations, and cocultivation at defined inoculation ratios yielded oligoclonal VHH mixtures approaching target compositions. This strategy enables one-pot manufacturing with minimal downstream processing and predictable composition. A techno-economic assessment based on obtained titers and two-step purification indicates reduced per-treatment costs compared with Chinese Hamster Ovary cells produced IgG-based antivenoms. Our findings offer an alternative to conventional oligoclonal VHH production for multivalent therapeutics requiring broad neutralization, including recombinant antivenoms.
中文摘要:靶向不同表位的寡克隆VHH混合物在缓解复杂疾病方面具有治疗益处,包括癌症、感染性疾病和蛇咬伤中毒。然而,当前的生产策略依赖于分别表达和纯化单个VHH,随后进行下游混合,导致成本高昂。我们提出了一种共培养方法,利用生长解偶联的大肠杆菌菌株生产实验性重组抗蛇毒血清。通过用不同VHH基因转化同一宿主,生成了六种不同的细胞系。这些细胞系在微孔板和1 L生物反应器培养中表现出高产量胞外分泌,并且按确定的接种比例进行共培养可产生接近目标组成的寡克隆VHH混合物。该策略能够实现一锅法制造,下游处理最少且组成可预测。基于所获得的滴度和两步纯化的技术经济评估表明,与中国仓鼠卵巢细胞生产的基于IgG的抗蛇毒血清相比,每次治疗成本降低。我们的发现为需要广泛中和的多价疗法(包括重组抗蛇毒血清)提供了一种替代传统寡克隆VHH生产的方法。
Biomaterials IF 13.6 2026-10 PMID: 42048842
Sonodynamic therapy (SDT) is a non-invasive cancer treatment that uses ultrasound to activate sonosensitizers and generate reactive oxygen species (ROS), offering the distinct advantage of penetrating deep tumor tissues. However, SDT efficacy is hindered by tumor hypoxia and strong antioxidant defenses. Glutathione (GSH), the central ROS scavenger, depends on cysteine (Cys) for synthesis, and tumor cells elevate Cys uptake to preserve redox balance and counter oxidative stress, thereby weakening SDT responsiveness. To address these challenges, we present a multifunctional nanoplatform, NBD-B-T/TiO2@Lip, integrating organic and inorganic sonosensitizers within liposomes to optimize solubility, biocompatibility, and ROS production for enhanced sonodynamic therapy. The BODIPY-based NBD-B-T generates oxygen-independent ROS and selectively binds intracellular cysteine, enabling real-time fluorescence imaging while depleting cysteine, disrupting GSH biosynthesis, and perturbing redox homeostasis to trigger ferroptosis. Upon ultrasound activation, the platform synergistically amplifies ROS generation and cysteine depletion, intensifying oxidative stress and ferroptotic cell death in the tumor microenvironment. In vivo, it achieves potent tumor suppression, durable therapeutic efficacy, and minimal systemic toxicity. This strategy establishes a precise, high-efficacy SDT paradigm by uniting oxygen-independent ROS production with targeted redox modulation.
中文摘要:声动力治疗(SDT)是一种非侵入性肿瘤治疗方法,利用超声激活声敏剂产生活性氧(ROS),具有可穿透深部肿瘤组织的独特优势。然而,肿瘤缺氧和强抗氧化防御会限制SDT疗效。谷胱甘肽(GSH)是核心ROS清除剂,其合成依赖半胱氨酸(Cys),肿瘤细胞通过增强Cys摄取来维持氧化还原平衡并对抗氧化应激,从而削弱SDT响应性。为应对这些挑战,我们提出一种多功能纳米平台NBD-B-T/TiO2@Lip,将有机与无机声敏剂整合于脂质体中,以优化溶解度、生物相容性和ROS生成,从而增强声动力治疗。基于BODIPY的NBD-B-T可产生不依赖氧的ROS,并选择性结合细胞内半胱氨酸,在耗竭半胱氨酸的同时实现实时荧光成像,破坏GSH生物合成并扰动氧化还原稳态,从而触发铁死亡。超声激活后,该平台协同放大ROS生成和半胱氨酸耗竭,加剧肿瘤微环境中的氧化应激和铁死亡性细胞死亡。在体内,它实现了强效肿瘤抑制、持久治疗效果和极低的全身毒性。该策略通过将不依赖氧的ROS产生与靶向氧化还原调控相结合,建立了一种精准、高效的SDT范式。
Biomaterials IF 13.6 2026-10 PMID: 42025044
Mitochondrial damage in tumor cells has recently emerged as a mechanism of immunogenic cell death, with precise triggers acting as potent antitumor immunostimulants. Here, we developed PyTPAMa, an asymmetric AIE-active photosensitizer that selectively accumulates in mitochondria and binds mitochondrial DNA (mtDNA) and induces mitochondrial fragmentation to trigger strong immunostimulation. Upon light activation, PyTPAMa generates a spatially confined, hybrid Type I/II ROS burst that disrupts the mitochondrial network, causing mitochondrial fragmentation, opening the mitochondrial permeability transition pore, and releasing mtDNA into the cytosol. This activates the NLRP3-GSDMD inflammasome, initiating pyroptosis and orchestrating systemic antitumor immunity. RNA sequencing reveals widespread silencing of mitochondrial genes and reprogramming of the NLRP3 inflammasome and antigen-presentation pathways. As a programmable immune ignition switch, PyTPAMa induces immunogenic cell death in vitro, transforms distant "cold" tumors into immune-infiltrated lesions in vivo, and achieves 96% suppression of bilateral 4T1 tumors without systemic toxicity. This work establishes mitochondrial fragmentation as a programmable immune switch and validates PyTPAMa for fragmentation-driven cancer immunotherapy.
中文摘要:肿瘤细胞中的线粒体损伤近来已成为一种免疫原性细胞死亡机制,精准的触发因素可作为强效抗肿瘤免疫刺激剂。在此,我们开发了PyTPAMa,一种不对称AIE活性光敏剂,可选择性蓄积于线粒体并结合线粒体DNA(mtDNA),诱导线粒体碎片化,从而触发强烈的免疫刺激。光激活后,PyTPAMa产生空间受限的I/II型混合ROS爆发,破坏线粒体网络,导致线粒体碎片化、开放线粒体通透性转换孔,并将mtDNA释放到胞质中。这会激活NLRP3-GSDMD炎性小体,启动细胞焦亡并协调全身抗肿瘤免疫。RNA测序显示线粒体基因广泛沉默,以及NLRP3炎性小体和抗原呈递通路重编程。作为一种可编程的免疫点火开关,PyTPAMa在体外诱导免疫原性细胞死亡,在体内将远端「冷」肿瘤转化为免疫浸润病灶,并在无明显全身毒性情况下实现对双侧4T1肿瘤96%的抑制。这项工作确立了线粒体碎片化作为一种可编程免疫开关,并验证了PyTPAMa用于碎片化驱动的癌症免疫治疗。
Biomaterials IF 13.6 2026-10 PMID: 42008884
Hepatocellular carcinoma(HCC) ranks among the leading causes of cancer-related mortality worldwide. In the treatment landscape of HCC, transarterial therapies plfan'yiay a crucial role. This review focuses on transarterial embolization for HCC, with particular emphasis on transarterial chemoembolization(TACE) and transarterial radioembolization(TARE), exploring their significant effects on the tumor microenvironment. TACE involves the liberation of tumor-derived antigens and damage-associated molecular patterns (DAMPs), while exerting direct modulatory influences on immune populations including tumor-infiltrating macrophages, cytotoxic T cells, and natural killer lymphocytes. This process, in turn, activates the local immune response while simultaneously inducing changes in the tumor's vascular environment. These changes have unveiled novel opportunities for immunotherapy and targeted therapy. Additionally, nanomaterials have emerged as a significant component in both HCC treatment and TACE therapy. Their unique properties facilitate improved drug delivery, precise modulation of the immune microenvironment, and ultimately, better treatment outcomes. They can targetedly ameliorate the hypoxic and acidic immunosuppressive tumor microenvironment. Furthermore, by activating immunogenic cell death and regulating immune cell infiltration, these materials can reverse immunosuppression. Looking ahead, elucidating the intricate mechanisms by which TACE modulates the immuno-tumor microenvironment and developing innovative therapeutics that specifically target the tumor microenvironment will remain key focal points in future HCC research.
中文摘要:肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一。在HCC的治疗格局中,经动脉治疗发挥关键作用。本综述聚焦于HCC的经动脉栓塞治疗,尤其强调经导管动脉化疗栓塞(TACE)和经导管动脉放射栓塞(TARE),探讨它们对肿瘤微环境的显著影响。TACE涉及肿瘤来源抗原和损伤相关分子模式(DAMPs)的释放,同时对包括肿瘤浸润巨噬细胞、细胞毒性T细胞和自然杀伤淋巴细胞在内的免疫细胞群产生直接调节作用。这一过程反过来激活局部免疫应答,同时诱导肿瘤血管环境的变化。这些变化为免疫治疗和靶向治疗揭示了新的机会。此外,纳米材料已成为HCC治疗和TACE治疗中的重要组成部分。其独特性质有助于改善药物递送、精准调节免疫微环境,并最终带来更好的治疗结局。它们能够靶向改善缺氧和酸性的免疫抑制性肿瘤微环境。此外,通过激活免疫原性细胞死亡和调节免疫细胞浸润,这些材料可以逆转免疫抑制。展望未来,阐明TACE调节免疫肿瘤微环境的复杂机制,以及开发特异性靶向肿瘤微环境的创新疗法,仍将是未来HCC研究的关键焦点。
Biomaterials IF 13.6 2026-10 PMID: 41999709
Recent advances in organ-on-a-chip (OOC) blood-brain barrier (BBB) models for oncology research have revealed key insights into the metastatic cascade. However, in most 3D BBB systems, type I collagen is commonly selected as the brain-side extracellular matrix (ECM) due to its ease of use and affordability. This selection overlooks the native ECM composition of the brain, which is primarily composed of hyaluronan/hyaluronic acid (HyA). Given that the ECM occupies approximately 20% of the brain volume and actively modulates tumor progression, substrate selection is an important yet frequently under-examined component in 3D BBB systems. Using our published blood-brain barrier niche (BBN), we compared HyA and type I collagen matrices to evaluate their impact on cancer cell phenotypes and the tumor microenvironment (TME) to establish which substrate affords the greatest versatility across different lines of investigation. Using a TA DHR-3 rheometer, we examined biophysical variations of these matrices in response to oscillatory shear. We then assessed phenotypic and migratory differences in human breast cancer cells, and their brain-seeking subclones in an ECM of HyA with media versus type I collagen, within our BBN device. Finally, ELISA analysis revealed significant matrix-dependent impact on key chemokine alterations, with collagen matrices promoting CXCL5 and DKK1 secretion across all conditions relative to HyA. We conclude that ECM selection to mimic the patient's brain microenvironment in OOC systems is a critical decision due to inherent substrate differences and either can be appropriate depending on the study goals.
中文摘要:近年来,用于肿瘤学研究的器官芯片(OOC)血脑屏障(BBB)模型进展揭示了转移级联的关键见解。然而,在大多数3D BBB系统中,由于I型胶原易于使用且成本较低,常被选作脑侧细胞外基质(ECM)。这一选择忽视了脑天然ECM组成,其主要由透明质酸(HyA)构成。鉴于ECM约占脑体积的20%,并主动调节肿瘤进展,基质选择是3D BBB系统中重要但常被忽视的组成部分。我们使用已发表的血脑屏障生态位(BBN),比较了HyA与I型胶原基质,以评估它们对癌细胞表型和肿瘤微环境(TME)的影响,从而确定哪种基质在不同研究方向中提供最大的通用性。我们使用TA DHR-3流变仪,检测了这些基质在振荡剪切下的生物物理变化。随后,在BBN装置中,我们评估了人乳腺癌细胞及其脑趋向性亚克隆在含培养基的HyA ECM与I型胶原ECM中的表型和迁移差异。最后,ELISA分析显示,基质对关键趋化因子变化具有显著依赖性影响;与HyA相比,胶原基质在所有条件下均促进CXCL5和DKK1分泌。我们得出结论:在OOC系统中,为模拟患者脑微环境而选择ECM是一个关键决定,因为基质本身存在差异,并且根据研究目标,两种基质均可适用。
Biomaterials IF 13.6 2026-10 PMID: 41999708
Immunotherapy efficacy is constrained by immunosuppressive features of the tumor microenvironment (TME) beyond canonical molecular checkpoints, including emerging extracellular ionic regulatory mechanisms that remain poorly characterized. Here, we identify potassium ion (K+) as a metabolically coupled ionic immune checkpoint that suppresses CD8+ T cell antitumor immunity. Using a murine melanoma model with an elevated-K+ microenvironment, we demonstrate that excess extracellular K+ profoundly impairs CD8+ T cell proliferation, activation, and effector function while promoting functional exhaustion without reducing T cell abundance. Mechanistically, K+-mediated immunosuppression is accompanied by restricted glucose uptake, suppressed glycolytic flux, and impaired mitochondrial fitness, establishing metabolic insufficiency as a key basis for ionic checkpoint-driven T cell dysfunction. To therapeutically target this extracellular and non-molecular suppressive mechanism, we develop a localized K+-depleting strategy by encapsulating the clinically approved potassium-binding agent sodium zirconium cyclosilicate (ZS-9) within a thermosensitive poly (lactide-co-glycolide)-polyethylene glycol-poly (lactide-co-glycolide) (PLGA-PEG-PLGA) hydrogel, forming a peritumoral K+-scavenging depot. This biomaterial platform efficiently remodels the ionic TME, restores CD8+ T cell metabolic fitness and effector function, alleviates T cell exhaustion, and significantly enhances the antitumor efficacy of adoptive cell therapy (ACT). Collectively, this work establishes extracellular ionic modulation as a metabolically grounded immune checkpoint mechanism and highlights biomaterials-based ionic remodeling as a translatable strategy to augment cancer immunotherapy.
中文摘要:免疫治疗疗效受到肿瘤微环境(TME)中超越经典分子检查点的免疫抑制特征限制,其中包括新出现的细胞外离子调控机制,而这类机制目前仍表征不足。在此,我们将钾离子(K+)鉴定为一种代谢偶联的离子免疫检查点,其可抑制CD8+ T细胞的抗肿瘤免疫。利用具有高K+微环境的小鼠黑色素瘤模型,我们证明细胞外过量K+会显著损害CD8+ T细胞的增殖、活化和效应功能,同时促进功能性耗竭,但不降低T细胞数量。机制上,K+介导的免疫抑制伴随葡萄糖摄取受限、糖酵解通量受抑和线粒体适应性受损,从而确立代谢不足是离子检查点驱动T细胞功能障碍的关键基础。为了从治疗上靶向这一细胞外且非分子的抑制机制,我们开发了一种局部耗竭K+的策略,即将临床批准的钾结合剂环硅酸锆钠(ZS-9)包裹于热敏性聚乳酸-羟基乙酸共聚物-聚乙二醇-聚乳酸-羟基乙酸共聚物(PLGA-PEG-PLGA)水凝胶中,形成瘤周K+清除储库。该生物材料平台有效重塑离子TME,恢复CD8+ T细胞代谢适应性和效应功能,减轻T细胞耗竭,并显著增强过继细胞治疗(ACT)的抗肿瘤疗效。总体而言,这项工作确立了细胞外离子调控作为一种具有代谢基础的免疫检查点机制,并凸显基于生物材料的离子重塑作为增强癌症免疫治疗的可转化策略。
Biomaterials IF 13.6 2026-10 PMID: 41955696
Epidermal Growth Factor Receptor (EGFR) is crucial for cell proliferation and survival, and has emerged as a promising therapeutic target for colorectal cancer (CRC). Anti-EGFR monoclonal antibodies (mAbs) have demonstrated success in various clinical practice in CRC patients. However, they are only effective in patients with RAS wild-type, and more importantly, most patients eventually develop resistance to anti-EGFR therapy due to the mutations of the effector molecules in EGFR downstream signaling pathways or/and the activation of compensatory feedback loop signaling, which limits the long-term efficacy of anti-EGFR mAbs. Advances in antibody engineering and nanotechnology have brought new hope for cancer treatment, particularly through bi-/tri-specific antibodies, antibody-drug conjugates(ADCs), and antibody-functionalized nanoparticles(AFNPs), which can simultaneously inhibit the activation of EGFR and its compensatory pathways-or even directly eradicate cancer cells bypassing EGFR-mediated signaling-these innovations hold promise for addressing drug resistance and leading to better response rates of EGFR-targeted therapy in CRC. In this review, we provide an overview of the design strategy of EGFR-targeted therapies based on antibody engineering and nanotechnology for CRC using a mechanistic framework, focusing on analyzing the optimization strategies for representative drugs or studies and their potential in overcoming heterogeneous drug resistance in CRC, in order to provide useful information for researchers developing EGFR-targeted drugs for CRC.
中文摘要:表皮生长因子受体(EGFR)对细胞增殖和存活至关重要,已成为结直肠癌(CRC)一个有前景的治疗靶点。抗EGFR单克隆抗体(mAbs)已在CRC患者的多种临床实践中显示出成功。然而,它们仅对RAS野生型患者有效,更重要的是,由于EGFR下游信号通路中效应分子的突变或/和代偿性反馈环路信号的激活,大多数患者最终会对anti-EGFR治疗产生耐药,这限制了抗EGFR单克隆抗体的长期疗效。抗体工程和纳米技术的进步为癌症治疗带来了新希望,特别是通过双/三特异性抗体、抗体药物偶联物(ADCs)和抗体功能化纳米颗粒(AFNPs),它们可以同时抑制EGFR及其代偿通路的激活,甚至绕过EGFR介导的信号直接根除癌细胞,这些创新有望解决耐药问题,并使CRC中EGFR靶向治疗的应答率提高。在这篇综述中,我们以机制框架概述基于抗体工程和纳米技术的CRC EGFR靶向治疗的设计策略,重点分析代表性药物或研究的优化策略及其在克服CRC异质性耐药方面的潜力,以期为开发CRC EGFR靶向药物的研究人员提供有用信息。
Biomaterials IF 13.6 2026-10 PMID: 41936184
This study developed a hypoxia-responsive N-803 nanogel (BiA-N-803 NG) for controlled release of an IL-15 superagonist to enhance CAR-T cell therapy in multiple myeloma. The nanogel was dual-targeted to CD138 and TIM-3 and exhibited stable, hypoxia-triggered release properties. In vitro analyses demonstrated that BiA-N-803 NG promoted CAR-T cell expansion, memory programming, and antitumor function, characterized by increased memory T-cell subsets and reduced exhaustion phenotypes. Transcriptomic profiling identified activation of the FOXO1 signaling axis as a key mechanism underlying CAR-T cell memory differentiation. In vivo studies further showed improved CAR-T cell persistence, enhanced NK cell recruitment, and reduced infiltration of immunosuppressive cells, collectively leading to a remodeled immune microenvironment and improved therapeutic durability in multiple myeloma.
中文摘要:本研究开发了一种缺氧响应性 N-803 纳米凝胶(BiA-N-803 NG),用于可控释放 IL-15 超激动剂,以增强多发性骨髓瘤中的 CAR-T 细胞治疗。该纳米凝胶双靶向 CD138 和 TIM-3,并表现出稳定的、由缺氧触发的释放特性。体外分析表明,BiA-N-803 NG 促进 CAR-T 细胞扩增、记忆程序化及抗肿瘤功能,表现为记忆 T 细胞亚群增加和耗竭表型减少。转录组分析确定 FOXO1 信号轴的激活是 CAR-T 细胞记忆分化的关键机制。体内研究进一步显示,CAR-T 细胞持久性提高、NK 细胞招募增强,以及免疫抑制性细胞浸润减少,共同导致免疫微环境重塑并在多发性骨髓瘤中改善治疗持久性。
Biomaterials IF 13.6 2026-10 PMID: 41934820
Ultrasound-activated sonodynamic therapy (SDT) is showing more potential in the treatment of deep-seated tumors such as renal cell carcinoma because of the high tissue-penetration depth. However, existing sonosensitizers lack active-targeting ability and often have "always on" characteristics, leading to potential accumulation in normal tissues and causing damage under US irradiation. Herein, we present for the first time the "sonodynamic passivation strategy" for sonosensitizers to prevent ROS-induced damage to normal cells. MnO2 nanoflowers with TME-responsive degradation features are utilized to load on the surface of Co3O4 sonozymes, realizing the passivation of sonodynamic and chemodynamic activities of Co3O4. In addition to the passivated sonozyme catalytic activity, MnO2@Co3O4 heterojunctions are capable of regulating the immunosuppressive tumor microenvironment (TME) by depleting GSH and alleviating hypoxia. Owing to the TME-responsive degradation of MnO2, the tumor-specific released Co3O4 sonozymes can restore their sonodynamic and chemodynamic activities, achieving the in-situ SDT/CDT and then realizing the trigger of ICD. Meanwhile, the released Mn ions can not only realize the cascade amplification of ROS production through Fenton-like reaction, GSH depletion, and hypoxia alleviation, but also activate cGAS-STING pathway for the augmentation of antitumor immune response. The activation of cGAS-STING pathway is further enhanced by the loading of STING agonist MSA-2 on the surface of Co3O4 before the coating of MnO2. MnO2@Co3O4/MSA-2-mediated TME-reactivated SDT/CDT/cGAS-STING-activation has shown significant antitumor efficacy, resulting in the eradication of primary tumors and the inhibition of distant tumor growth. Overall, this work offers hopeful insights into the modulation of the "on/off" function of sonosensitizer activity, ultimately enabling precise sonodynamic therapy for refractory renal cell carcinoma.
中文摘要:超声激活的声动力疗法(SDT)因具有较高的组织穿透深度,在肾细胞癌等深部肿瘤治疗中显示出更大潜力。然而,现有声敏剂缺乏主动靶向能力,且常具有「始终开启」的特性,导致其可能在正常组织中蓄积并在超声照射下造成损伤。在此,我们首次提出针对声敏剂的「声动力钝化策略」,以防止活性氧(ROS)诱导的正常细胞损伤。利用具有肿瘤微环境(TME)响应性降解特征的MnO2纳米花负载于Co3O4声酶表面,实现对Co3O4声动力和化学动力活性的钝化。除钝化声酶催化活性外,MnO2@Co3O4异质结还能通过消耗谷胱甘肽(GSH)和缓解缺氧来调节免疫抑制性肿瘤微环境(TME)。由于MnO2的TME响应性降解,肿瘤特异性释放的Co3O4声酶可恢复其声动力和化学动力活性,实现原位SDT/CDT,进而触发免疫原性细胞死亡(ICD)。同时,释放的Mn离子不仅可通过类Fenton反应、GSH消耗和缺氧缓解实现ROS产生的级联放大,还可激活cGAS-STING通路以增强抗肿瘤免疫应答。在包覆MnO2之前,将STING激动剂MSA-2负载于Co3O4表面,可进一步增强cGAS-STING通路的激活。MnO2@Co3O4/MSA-2介导的TME再激活SDT/CDT/cGAS-STING激活显示出显著抗肿瘤疗效,可根除原发肿瘤并抑制远端肿瘤生长。总体而言,这项工作为调控声敏剂活性的「开/关」功能提供了有希望的见解,最终有望实现针对难治性肾细胞癌的精准声动力治疗。
Biomaterials IF 13.6 2026-10 PMID: 41931965
Inadequate antigen presentation, driven by epigenetic repression of major histocompatibility complex class I (MHC-I), represents a fundamental barrier to effective cancer immunotherapy. Here, we identify polycomb group ring finger 1 (PCGF1) as a tumor cell-intrinsic epigenetic repressor of MHC-I through a genome-wide CRISPR screen. Genetic ablation of PCGF1 alone is sufficient to relieve repressive histone modifications (H2AK119ub and H3K27me3) at both the MHC-I gene cluster and its master regulator NLRC5, thereby restoring cell-surface antigen presentation and immunotherapy sensitivity. Building on this epigenetic foundation, we introduce modular engineering strategies to enhance translational robustness against tumor antigen heterogeneity. Specifically, CRISPR activation (CRISPRa) is used to broaden the repertoire of endogenous tumor antigens without altering the restored antigen presentation machinery. These epigenetically reprogrammed cells are subsequently cryoinactivated and formulated into an injectable thermosensitive chitosan-based hydrogel, in which manganese-mediated STING activation serves as an immunostimulatory adjuvant to amplify antigen capture and systemic T-cell priming.Collectively, this study establishes epigenetic reprogramming of antigen presentation as a foundational principle for whole-cell vaccine design and demonstrates how modular antigen and innate immune augmentation can enhance therapeutic robustness without obscuring the core mechanism. This platform offers a rational and adaptable framework for overcoming immune resistance in next-generation cancer immunotherapy.
中文摘要:抗原呈递不足由主要组织相容性复合体I类(MHC-I)的表观遗传抑制所驱动,是有效癌症免疫治疗的根本障碍。在此,我们通过全基因组CRISPR筛选鉴定出多梳组环指蛋白1(PCGF1)是肿瘤细胞内在的MHC-I表观遗传抑制因子。单独敲除PCGF1足以解除MHC-I基因簇及其主调控因子NLRC5上的抑制性组蛋白修饰(H2AK119ub和H3K27me3),从而恢复细胞表面抗原呈递和免疫治疗敏感性。在此基础上,我们引入模块化工程策略,以增强针对肿瘤抗原异质性的转化稳健性。具体而言,使用CRISPR激活(CRISPRa)拓宽内源性肿瘤抗原库,而不改变已恢复的抗原呈递机制。这些经过表观遗传重编程的细胞随后被冷冻灭活,并配制到可注射的温度敏感性壳聚糖基水凝胶中,其中锰介导的STING激活作为免疫刺激性佐剂,以放大抗原捕获和全身性T细胞启动。总之,本研究确立了抗原呈递的表观遗传重编程作为全细胞疫苗设计的基本原则,并证明模块化抗原增强和先天免疫增强如何在不妨碍核心机制的情况下提高治疗稳健性。该平台为克服下一代癌症免疫治疗中的免疫抵抗提供了一个合理且可适应的框架。
Cell death and differentiation IF 13.6 2026-10 PMID: 41857138
While immunotherapy based on immune checkpoint inhibitors (ICIs) shows limited efficacy in colorectal cancer (CRC) due to its immunosuppressive tumor microenvironment, strategies to activate innate immunity remain underexplored. Here, we identified wild-type p53-induced phosphatase 1 (WIP1/PPM1D) as a critical immunosuppressive driver in CRC, with its expression significantly upregulated in tumor tissues. Genetic or pharmacological inhibition of WIP1 robustly suppressed tumor growth by remodeling the tumor immune microenvironment, marked by increased infiltration of anti-tumor macrophages and cytotoxic T cells. Mechanistically, WIP1 inhibited type I interferon (IFN) signaling by reducing cytoplasmic dsDNA accumulation to inactivate the cGAS-STING-TBK1 axis, and by directly dephosphorylating TBK1 at Ser172 to suppress its kinase activity. Strikingly, combining a WIP1 inhibitor with a STING agonist synergistically enhanced anti-tumor efficacy by amplifying IFNβ production to activate anti-tumor immune response. This combination further potentiated anti-PD-1 immunotherapy. In summary, this study uncovers WIP1 as a pioneering dual-functional suppressor of tumor-intrinsic STING activation and establishes a rationally designed "STING-WIP1 co-targeting" strategy to reverse immunotherapy resistance. Our findings bridge genomic instability with adaptive immune evasion, offering a roadmap for precision immunotherapy in CRC.
中文摘要:尽管基于免疫检查点抑制剂(ICIs)的免疫治疗因结直肠癌(CRC)存在免疫抑制性肿瘤微环境而疗效有限,但激活固有免疫的策略仍未被充分探索。在此,我们鉴定野生型p53诱导的磷酸酶1(WIP1/PPM1D)是CRC中关键的免疫抑制驱动因子,其表达在肿瘤组织中显著上调。对WIP1进行遗传学或药理学抑制可通过重塑肿瘤免疫微环境而强烈抑制肿瘤生长,其标志为抗肿瘤巨噬细胞和细胞毒性T细胞浸润增加。机制上,WIP1通过减少胞质dsDNA积累以失活cGAS-STING-TBK1轴,并直接使TBK1在Ser172位点去磷酸化以抑制其激酶活性,从而抑制I型干扰素(IFN)信号。引人注目的是,将WIP1抑制剂与STING激动剂联用可通过放大IFNβ产生以激活抗肿瘤免疫应答,协同增强抗肿瘤疗效。该联合方案进一步增强了抗PD-1免疫治疗。总之,本研究揭示WIP1是肿瘤内在STING激活的双功能抑制因子,并建立了一种合理设计的「STING-WIP1共靶向」策略以逆转免疫治疗耐药。我们的发现将基因组不稳定性与适应性免疫逃逸联系起来,为CRC的精准免疫治疗提供了路线图。
Nature chemical biology IF 15.8 2026-10 PMID: 41826762
Reactive oxygen species (ROS) dynamics exhibits rhythmic oscillations in cancer cells but how this rhythm influences tumorigenesis and therapeutic responses remains unclear. Here we found coexistence of ROS rhythmicity and rhythm loss in tumor samples. Under low-ROS conditions, indoleamine 2,3-dioxygenase 1 (IDO1), an immune-checkpoint molecule, binds to KEAP1 for proteasomal degradation in the nucleus. In contrast, elevated ROS levels drive IDO1 translocation into the cytosol, where it binds mitochondria-released heme to form an active holoenzyme. This holoenzyme catalyzes tryptophan to kynurenine that allosterically activates glucose-6-phosphate dehydrogenase, enhancing NADPH production and promoting ROS clearance. However, in hypoxic tumor microenvironments, ROS rhythmicity is lost. Compensating for this, hypoxic tumor cells mobilize the sulfenylated aryl hydrocarbon receptor (AhR)-mediated glycogenolysis pathway to manage disordered ROS accumulation, maintaining elevated ROS levels that favor tumor growth. Dual inhibition of IDO1 and AhR significantly prolongs survival of NSG mice, highlighting enforced disruption of ROS rhythm as a common therapeutic strategy.
中文摘要:活性氧(ROS)动态在癌细胞中表现出节律性振荡,但这种节律如何影响肿瘤发生和治疗反应仍不清楚。本研究发现,肿瘤样本中ROS节律性与节律丧失并存。在低ROS条件下,免疫检查点分子吲哚胺2,3-双加氧酶1(IDO1)与KEAP1结合,并在细胞核内经蛋白酶体降解。相反,升高的ROS水平驱动IDO1转位至细胞质,在那里与线粒体释放的血红素结合形成活性全酶。该全酶催化色氨酸转化为犬尿氨酸,后者变构激活葡萄糖-6-磷酸脱氢酶,增强NADPH生成并促进ROS清除。然而,在缺氧肿瘤微环境中,ROS节律性丧失。为补偿这一点,缺氧肿瘤细胞动员亚磺酰化的芳香烃受体(AhR)介导的糖原分解途径,以应对紊乱的ROS积累,维持有利于肿瘤生长的高ROS水平。双重抑制IDO1和AhR可显著延长NSG小鼠生存期,突显强制破坏ROS节律是一种通用治疗策略。
Cell death and differentiation IF 13.6 2026-10 PMID: 41826729
Programmed cell death protein 1 (PD-1) and its ligand programmed cell death ligand-1 (PD-L1) are key mediators of immune checkpoint blockade therapy in clear cell renal cell carcinoma (RCC). However, immune evasion and primary resistance often limit their efficacy, highlighting the need for improved strategies. Here, we identified dipeptidyl peptidase 9 (DPP9) as a critical regulator of PD-L1 expression in ccRCC. Pharmacological inhibition of DPP9 with 1G244 restores T cell cytotoxicity and enhances checkpoint blockade efficacy. Mechanistically, DPP9 disrupts the BRISC-SHMT2 complex, enhancing BRISC-mediated deubiquitination and stabilization of IFNAR1, which activates the JAK/STAT pathway and drives PD-L1 transcription. 1G244 reverses this process by reducing DPP9 interacting with SHMT2, promoting IFNAR1 ubiquitination and degradation, thereby reducing PD-L1 levels and restoring T cell-mediated cytotoxicity. Moreover, the combination of 1G244 and anti-CTLA-4 therapy further enhanced antitumor immunity, highlighting a potential synergistic therapeutic strategy. Collectively, our findings define a novel DPP9-BRISC-SHMT2 regulatory axis in PD-L1 transcriptional control and identify 1G244 as an alternative combinatorial strategy to enhance the efficacy of cancer immunotherapy.
中文摘要:程序性细胞死亡蛋白1(PD-1)及其配体程序性细胞死亡配体1(PD-L1)是透明细胞肾细胞癌(RCC)免疫检查点阻断治疗的关键介质。然而,免疫逃逸和原发性耐药常限制其疗效,凸显了改进策略的必要性。在此,我们将二肽基肽酶9(DPP9)鉴定为ccRCC中PD-L1表达的关键调控因子。使用1G244对DPP9进行药理学抑制可恢复T细胞细胞毒性并增强检查点阻断疗效。机制上,DPP9破坏BRISC-SHMT2复合物,增强BRISC介导的IFNAR1去泛素化和稳定化,从而激活JAK/STAT通路并驱动PD-L1转录。1G244通过减少DPP9与SHMT2相互作用、促进IFNAR1泛素化和降解来逆转这一过程,从而降低PD-L1水平并恢复T细胞介导的细胞毒性。此外,1G244与抗CTLA-4治疗联合进一步增强了抗肿瘤免疫,凸显了一种潜在的协同治疗策略。总的来说,我们的发现定义了PD-L1转录控制中一个新的DPP9-BRISC-SHMT2调控轴,并确定1G244作为一种替代性联合策略以增强癌症免疫治疗疗效。
Journal of advanced research IF 17.1 2026-10 PMID: 41638631
Personalized nanovaccines represent advancing frontier in cancer immunotherapy by integrating patient-specific tumor antigens with biomimetic delivery systems to enhance immune activation, targeting precision and clinical efficacy. Biomimetic platforms including exosome-, red blood cell (RBC)-, and immune cell membrane-coated nanoparticles, as well as artificial antigen-presenting cell (aAPC) systems, recreate native biological interfaces to improve antigen presentation, macrophage polarization, and adaptive immune priming. Despite significant progress, major translational challenges remain, including incomplete mechanistic understanding, regulatory complexity, and manufacturing scalability. This review synthesizes recent advances in biomimetic and personalized nanovaccine design, highlighting clinical progress in lipid nanoparticle (LNP)-based vaccines such as BNT111 and mRNA-4157, emerging innate immune adjuvants including Toll-like receptor (TLR) and stimulator of interferon genes (STING) agonists, and rational combination strategies with immune checkpoint blockade. Key safety and quality consideration including immunotoxicity, off-target immune activation, and batch heterogeneity are critically evaluated alongside emerging engineering solutions. Finally, future directions integrating AI-guided neoantigen prediction, modular microfluidic manufacturing, and multi-omic biomarker frameworks are discussed to accelerate next generation cancer nanovaccine translation.
中文摘要:个体化纳米疫苗通过将患者特异性肿瘤抗原与仿生递送系统整合,增强免疫激活、靶向精准性和临床疗效,代表癌症免疫治疗中不断推进的前沿。仿生平台包括外泌体、红细胞(RBC)和免疫细胞膜包被的纳米颗粒,以及人工抗原提呈细胞(aAPC)系统,可重建天然生物界面,以改善抗原提呈、巨噬细胞极化和适应性免疫启动。尽管取得显著进展,仍存在重大转化挑战,包括机制理解不完整、监管复杂性和生产可扩展性。本综述综合了仿生和个体化纳米疫苗设计的最新进展,重点介绍了基于脂质纳米颗粒(LNP)的疫苗如BNT111和mRNA-4157的临床进展、包括Toll样受体(TLR)和干扰素基因刺激因子(STING)激动剂在内的新兴固有免疫佐剂,以及与免疫检查点阻断的合理联合策略。关键安全性和质量考量包括免疫毒性、脱靶免疫激活和批次异质性,并与新兴工程解决方案一起受到批判性评估。最后,讨论了整合人工智能引导的新抗原预测、模块化微流控制造和多组学生物标志物框架的未来方向,以加速下一代癌症纳米疫苗的转化。
Journal of advanced research IF 17.1 2026-10 PMID: 41592682
Trastuzumab profoundly improves outcomes of Her2+ breast cancer (BC) patients, but eventual drug resistance is inevitable. Therefore, new treatment options are urgently needed. Here, we modify extracellular vesicles (EVs) with a Her2 single-chain variable fragment of trastuzumab (EVs/Her2-scFv) to target Her2+ BC and found that EVs/Her2-scFv inhibit human Her2+ orthotopic BC comparable to trastuzumab and also uniquely suppress brain metastasies. Moreover, EVs/Her2-scFv loaded with rabeprazole (EVs/Her2-scFv/Rabe) effectively improve tumor immunosuppressive microenvironment and abnormal vasculature of Her2+ BC by reducing tumor EVs. When further anchored with CD8+ T cell chemotactic CXCL9, CXCL9-loaded EVs/Her2-scFv/Rabe (EVs/Her2-scFv/CXCL9/Rabe) facilitate CD8+ T cell recruitment and subsequent activation, thereby exhibiting immunotherapeutic effects on mouse Her2+ BC. In BC patient-derived tumor organoids (PDOs) and peripheral blood mononuclear cell coculture systems, EVs/Her2-scFv/CXCL9/Rabe limit PDO growth by blocking Her2 signaling and activating CD8+ T cells. Besides, EVs/Her2-scFv/CXCL9/Rabe are low-immunogenic with biosafety. Altogether, EVs/Her2-scFv/CXCL9/Rabe hold high potential in Her2+ BC therapy.
中文摘要:曲妥珠单抗显著改善了HER2阳性乳腺癌(BC)患者的结局,但最终耐药不可避免,因此亟需新的治疗选择。在此,我们用曲妥珠单抗的HER2单链可变区片段修饰细胞外囊泡(EVs/Her2-scFv),以靶向HER2阳性乳腺癌,并发现EVs/Her2-scFv能抑制人HER2阳性原位乳腺癌,其效果与曲妥珠单抗相当,且还能独特地抑制脑转移。此外,负载雷贝拉唑的EVs/Her2-scFv(EVs/Her2-scFv/Rabe)通过减少肿瘤EVs,有效改善HER2阳性乳腺癌的肿瘤免疫抑制微环境和异常血管。进一步锚定对CD8+ T细胞具有趋化作用的CXCL9后,负载CXCL9的EVs/Her2-scFv/Rabe(EVs/Her2-scFv/CXCL9/Rabe)促进CD8+ T细胞募集及其后续激活,从而对小鼠HER2阳性乳腺癌表现出免疫治疗效应。在乳腺癌患者来源肿瘤类器官(PDOs)与外周血单个核细胞共培养系统中,EVs/Her2-scFv/CXCL9/Rabe通过阻断HER2信号并激活CD8+ T细胞来限制PDO生长。此外,EVs/Her2-scFv/CXCL9/Rabe免疫原性低且具有生物安全性。总之,EVs/Her2-scFv/CXCL9/Rabe在HER2阳性乳腺癌治疗中具有很大潜力。
Journal of advanced research IF 17.1 2026-10 PMID: 41558601
Tumor-associated macrophages (TAMs) are a functionally heterogeneous population within the tumor microenvironments, exhibiting both anti-tumor and pro-tumor functions. Pro-tumorigenic TAMs can derive from peripheral monocytes or tissue-resident macrophages (TRMs). However, the epigenetic mechanisms driving the differentiation of these distinct cellular sources into specific TAM subtypes remain unclear. Here, we sought to define the epigenetic mechanisms that drive the divergent differentiation of monocyte and TRM-derived TAMs. Through a pan-cancer analysis, we map the regulatory cascade, from cis-regulatory elements and key transcription factors to the release of RNA Polymerase II (Pol II) pausing, that specifies TAM heterogeneity. We performed single-cell epigenetic profiling of macrophages derived from various human cancers, precancerous lesions, and healthy adult and fetal tissues using publicly available datasets, coupled with single-cell multi-omics integration. Key findings were validated through multi-omics analysis of mouse bone marrow-derived macrophage and CRISPR-based functional assays using in vitro human cell culture models. We delineated the distinct epigenetic developmental trajectories by which peripheral monocytes and TRMs give rise to SPP1+ and C1QC + TAM, respectively. Along the monocyte-to-SPP1+ TAM trajectories, we identified PPARG, NFAT5 and MECP2 as pivotal regulators that promote pro-tumorigenic polarization. Conversely, the differentiation of TRMs to C1QC + TAMs was associated with regulators MAF, HES1 and PRDM1. Furthermore, we discovered a core transcriptional signature regulated by SPP1+ TAM-specific super-enhancers that is significantly associated with poor prognosis across 18 cancer types. Mechanistically, we demonstrated that these enhancers, such as HIPK2 enhancers, establish the pro-tumorigenic TAM state primarily by modulating Pol II pausing rather than by altering promoter accessibility of their target genes. Our work delineates the epigenetic and transcriptional circuitry that establishes TAM heterogeneity as potential therapeutic levers to enhance cancer immunotherapy.
中文摘要:肿瘤相关巨噬细胞(TAMs)是肿瘤微环境中功能异质的群体,兼具抗肿瘤和促肿瘤功能。促肿瘤性TAMs可来源于外周单核细胞或组织驻留巨噬细胞(TRMs)。然而,驱动这些不同细胞来源分化为特定TAM亚型的表观遗传机制仍不清楚。在本研究中,我们试图定义驱动单核细胞来源和TRM来源TAMs差异分化的表观遗传机制。通过泛癌分析,我们绘制了从顺式调控元件和关键转录因子到RNA聚合酶II(Pol II)暂停释放的调控级联,该级联决定了TAM异质性。我们利用公开数据集,对来源于多种人类癌症、癌前病变以及健康成人和胎儿组织的巨噬细胞进行单细胞表观遗传分析,并结合单细胞多组学整合。关键发现通过小鼠骨髓来源巨噬细胞的多组学分析以及使用体外人类细胞培养模型的CRISPR功能实验得到验证。我们描绘了外周单核细胞和TRMs分别产生SPP1+和C1QC+ TAM的不同表观遗传发育轨迹。在单核细胞向SPP1+ TAM的轨迹中,我们确定PPARG、NFAT5和MECP2是促进促肿瘤极化的关键调控因子。相反,TRMs向C1QC+ TAMs的分化与调控因子MAF、HES1和PRDM1相关。此外,我们发现由SPP1+ TAM特异性超级增强子调控的核心转录特征,在18种癌症类型中与不良预后显著相关。机制上,我们证明这些增强子,例如HIPK2增强子,主要通过调节Pol II暂停而非改变其靶基因的启动子可及性来建立促肿瘤性TAM状态。我们的工作描绘了建立TAM异质性的表观遗传和转录回路,可作为增强癌症免疫治疗的潜在治疗杠杆。

3消化系统肿瘤 (73篇)

临床研究 (32篇)

Endoscopy IF 11.8 2026-10-07 PMID: 42843801
Underwater techniques are increasingly used in colorectal endoscopic submucosal dissection (ESD), but real-world data remain limited. We compared underwater and conventional colorectal ESD. This retrospective observational study included consecutive colorectal ESD lesions at a tertiary referral center between May 2010 and September 2024. The analysis used propensity score overlap weighting. Procedural outcomes included dissection speed, procedure time, resection outcomes, and adverse events. Intraoperative perforation and long-term outcomes were assessed descriptively. Among 1,649 lesions, 1,635 were included in the main analysis (conventional, 914; underwater, 721). Dissection speed was higher in the underwater group (speed ratio, 1.23; 95% CI, 1.14-1.32; p<0.001), whereas procedure time was similar. Failure to complete ESD was less frequent in the underwater group, with no clear differences in en bloc resection, R0 resection, or adverse events. Among 56 intraoperative perforation cases, all perforation sites were closed endoscopically, no emergent surgery was required, and short-term clinical outcomes showed no clear differences. Median survival follow-up was 3.09 [IQR, 0.48-7.39] and 2.10 [IQR, 0.56-3.72] years in the conventional and underwater groups, respectively; overall death occurred in 27/824 (3.3%) and 3/622 (0.5%) patients, with no colorectal cancer-related deaths. The underwater technique was associated with higher dissection speed, although this did not translate into a shorter procedure time or clear improvements in other procedural outcomes. These findings suggest a potential technical advantage during dissection, while its clinical relevance remains to be established.
中文摘要:水下技术正越来越多地用于结直肠内镜黏膜下剥离术(ESD),但真实世界数据仍有限。我们比较了水下结直肠ESD与传统结直肠ESD。这项回顾性观察性研究纳入了2010年5月至2024年9月期间在一家三级转诊中心连续接受结直肠ESD的病变。分析采用倾向性评分重叠权重。操作结局包括剥离速度、操作时间、切除结局和不良事件。术中穿孔和长期结局采用描述性评估。在1649个病变中,1635个纳入主分析(传统组914个;水下组721个)。水下组剥离速度更高(速率比1.23;95%CI 1.14-1.32;p<0.001),而操作时间相似。水下组未能完成ESD的情况较少,整块切除、R0切除或不良事件方面未见明显差异。在56例术中穿孔病例中,所有穿孔部位均经内镜下闭合,无需急诊手术,短期临床结局未见明显差异。传统组和水下组的中位生存随访分别为3.09[IQR,0.48-7.39]年和2.10[IQR,0.56-3.72]年;总体死亡分别发生于27/824(3.3%)和3/622(0.5%)例患者,无结直肠癌相关死亡。水下技术与更高的剥离速度相关,但这并未转化为更短的操作时间或其他操作结局的明显改善。这些发现提示其在剥离过程中可能具有技术优势,但其临床相关性仍有待确立。
Endoscopy IF 11.8 2026-10-07 PMID: 42843632
BACKGROUND : In Sweden, a nationwide colorectal cancer (CRC) screening program for individuals aged 60-74 started in 2021; to meet the increasing demand for colonoscopy, nurse endoscopists may play a key role - provided they maintain high technical quality. This observational study aimed to evaluate the nurse endoscopists' performance in the screening program, focusing on core quality indicators. METHODS : Data were extracted from the Swedish Quality Register for Colonoscopies and Colorectal Cancer Screening (SveReKKS), including all screening colonoscopies performed between 1 April 2019 and 31 August 2025. Key quality indicators - adenoma detection rate (ADR), cecal and ileal intubation rates, bowel preparation, sedation use, and complications - were compared between nurse and physician endoscopists using generalized linear mixed-effects models with a logit link. RESULTS : Of 27 978 colonoscopies, 42 % were performed by nurses. Nurses had a higher ADR (57 % vs. 46 %; odds ratio [OR] 1.55, 95 %CI 1.47-1.62), and 3.6 % of the nurses had an ADR < 25 %, compared with 11.2 % of the physicians. Nurses also had higher odds of ileal intubation (OR 1.2, 95 %CI 1.1-1.2) and longer withdrawal times. CONCLUSIONS : Nurse endoscopists demonstrated high quality colonoscopy performance in CRC screening and represent a valuable resource to meet increasing service demands without compromising clinical standards.
中文摘要:背景:瑞典于2021年启动了针对60-74岁人群的全国性结直肠癌(CRC)筛查项目;为满足日益增长的结肠镜检查需求,护士内镜医师可能发挥关键作用——前提是其保持高技术质量。本观察性研究旨在评估护士内镜医师在筛查项目中的表现,重点关注核心质量指标。方法:数据提取自瑞典结肠镜检查与结直肠癌筛查质量登记系统(SveReKKS),纳入2019年4月1日至2025年8月31日期间进行的所有筛查性结肠镜检查。采用带logit链接的广义线性混合效应模型,比较护士与医师内镜医师在关键质量指标上的差异,包括腺瘤检出率(ADR)、盲肠与回肠插管率、肠道准备、镇静使用及并发症。结果:在27 978例结肠镜检查中,42%由护士完成。护士的ADR更高(57% vs. 46%;比值比[OR] 1.55,95%CI 1.47-1.62),且3.6%的护士ADR<25%,而医师为11.2%。护士回肠插管的几率也更高(OR 1.2,95%CI 1.1-1.2),退镜时间更长。结论:护士内镜医师在CRC筛查中表现出高质量的结肠镜检查水平,是满足日益增长的服务需求且不降低临床标准的重要资源。
JAMA surgery IF 15.6 2026-10-07 PMID: 42842264
In the era of modern systemic chemotherapy, the optimal treatment strategy for gastric cancer with positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a) remains controversial. To explore the optimal treatment strategy for patients with gastric cancer with CY1 and/or P1a by comparing the outcomes of various therapeutic strategies. This cohort study was a retrospective multicenter study set in 48 institutions of the Stomach Cancer Study Group in the Japan Clinical Oncology Group. Participants were patients with gastric cancer with CY1 and/or P1a, but no other distant metastases, who were treated in 2016 to 2022. Data were analyzed from July 2025 to May 2026. Patients were stratified according to initial treatment: upfront gastrectomy (n = 838 [71%]) or upfront chemotherapy (n = 343 [29%]). The upfront chemotherapy group was further subdivided into chemotherapy alone (n = 205), gastrectomy after conversion to P0CY0 (n = 92), and nonconversion gastrectomy (n = 46) according to preoperative chemotherapy efficacy. The primary outcome was overall survival (OS), and secondary outcomes included progression-free survival. Among 1181 patients, the median (IQR) age was 72 (65-78) years; 725 patients (61%) were male and 456 (39%) were female. The overall 5-year OS rate was 25.0% (95% CI, 22.3%-28.0%), with a median survival time of 24.3 months. Upfront gastrectomy showed a significantly longer OS than upfront chemotherapy (5-year OS: 27.6% vs 19.0%; hazard ratio, 0.80; 95% CI, 0.69-0.93; P = .004). Among the multimodal treatment strategies, upfront chemotherapy followed by gastrectomy showed a significantly higher 5-year OS rate than upfront gastrectomy with postoperative chemotherapy (39.9%; 95% CI, 31.7%-50.2%, vs 31.4%; 95% CI, 27.6%-35.8%; P = .01). Gastrectomy alone and chemotherapy alone showed poor prognoses (10.3% and 3.2%, respectively). Notably, survival after gastrectomy following conversion to P0CY0 was the most favorable (5-year OS: 50.5%), whereas that without P0CY0 was modest (5-year OS: 17.2%). This study found that for gastric cancer with CY1 and/or P1a, upfront chemotherapy followed by gastrectomy resulted in a slightly higher 5-year OS rate than upfront gastrectomy followed by postoperative chemotherapy. Because gastrectomy after conversion to P0CY0 was associated with the most favorable survival, the development of more effective preoperative chemotherapy is warranted.
中文摘要:在当代全身化疗时代,对于腹腔灌洗细胞学阳性(CY1)和/或局限性腹膜转移(P1a)的胃癌,最佳治疗策略仍存在争议。本研究旨在通过比较各种治疗策略的结局,探索CY1和/或P1a胃癌患者的最佳治疗策略。这项队列研究是一项回顾性多中心研究,纳入日本临床肿瘤学组胃癌研究组48家机构。参与者为2016年至2022年接受治疗的CY1和/或P1a、但无其他远处转移的胃癌患者。数据分析时间为2025年7月至2026年5月。患者根据初始治疗分层:初始胃切除术(n=838[71%])或初始化疗(n=343[29%])。初始化疗组根据术前化疗疗效进一步分为单纯化疗(n=205)、转化为P0CY0后胃切除术(n=92)和未转化胃切除术(n=46)。主要结局为总生存期(OS),次要结局包括无进展生存期。在1181例患者中,中位(IQR)年龄为72(65-78)岁;725例(61%)为男性,456例(39%)为女性。总体5年OS率为25.0%(95%CI,22.3%-28.0%),中位生存时间为24.3个月。初始胃切除术的OS显著长于初始化疗(5年OS:27.6%vs19.0%;风险比,0.80;95%CI,0.69-0.93;P=.004)。在多模式治疗策略中,初始化疗后胃切除术的5年OS率显著高于初始胃切除术联合术后化疗(39.9%;95%CI,31.7%-50.2%vs31.4%;95%CI,27.6%-35.8%;P=.01)。单纯胃切除术和单纯化疗的预后较差(分别为10.3%和3.2%)。值得注意的是,转化为P0CY0后胃切除术的生存最为有利(5年OS:50.5%),而未达到P0CY0者为中等(5年OS:17.2%)。本研究发现,对于CY1和/或P1a胃癌,初始化疗后胃切除术的5年OS率略高于初始胃切除术后术后化疗。由于转化为P0CY0后胃切除术与最有利的生存相关,因此有必要开发更有效的术前化疗。
Gut IF 24.6 2026-10-07 PMID: 41791848
While colorectal cancer (CRC) has been linked to the gut microbiome, it remains unclear whether specific microbial signatures are detectable in precursor lesions such as adenomatous polyps, serrated lesions or sessile serrated lesions. To assess gut microbiome taxonomic and functional associations with colorectal neoplasia presence, severity (non-advanced, advanced and CRC) and subtype and evaluate predictive potential in high-risk neoplasia. Analysed cross-sectional stool metagenomes (pre-colonoscopy) from 1762 participants (97% White British) undergoing colonoscopy in the multicentre COLO-COHORT study. Neoplasia was classified per British Society of Gastroenterology surveillance guidelines. Linear mixed-effects models and random forest classifiers assessed taxonomic and functional associations, adjusting for dietary, clinical and lifestyle covariates. Gut microbiome composition differences between individuals with and without neoplasia were statistically significant but minimal (R2=0.0008, p=0.03). A small number of species, including Mediterraneibacter faecis and Pseudoruminococcus massiliensis, and microbial pathways, including amino acid biosynthesis and β-lactam resistance, were modestly linked to neoplasia, particularly early lesions (q value <0.05). Associations were generally weak and attenuated after covariate adjustment. Predictive models combining the microbiome with clinical/demographic features modestly improved high-risk neoplasia classification (area under the curve=0.64 vs 0.58 for clinical/demographic features alone). This large prospective cross-sectional study found weak and inconsistent associations between the gut microbiome and premalignant colorectal neoplasia, with no robust microbial signatures. Findings suggest that previously reported microbial shifts may emerge later in disease progression, potentially as a consequence rather than a cause of CRC. Longitudinal, multiomic studies disentangling temporal and causal pathways between the gut microbiome and neoplasia are required.
中文摘要:虽然结直肠癌(CRC)已与肠道微生物组相关联,但尚不清楚在腺瘤性息肉、锯齿状病变或无蒂锯齿状病变等前驱病变中是否能检测到特定的微生物特征。本研究旨在评估肠道微生物组分类和功能与结直肠肿瘤的存在、严重程度(非进展期、进展期和CRC)及亚型的关联,并评估其在高风险肿瘤中的预测潜力。研究分析了多中心COLO-COHORT研究中1762名接受结肠镜检查参与者(97%为英国白人)的横断面粪便宏基因组(结肠镜检查前)。肿瘤按照英国胃肠病学会监测指南进行分类。采用线性混合效应模型和随机森林分类器评估分类和功能关联,并校正饮食、临床和生活方式协变量。有和无肿瘤个体之间的肠道微生物组成差异具有统计学显著性但极微小(R2=0.0008,p=0.03)。少数物种,包括Mediterraneibacter faecis和Pseudoruminococcus massiliensis,以及微生物通路,包括氨基酸生物合成和β-内酰胺耐药,与肿瘤存在轻度关联,尤其是在早期病变中(q值<0.05)。这些关联总体上较弱,并在协变量校正后减弱。将微生物组与临床/人口学特征结合的预测模型轻度改善了高风险肿瘤的分类(曲线下面积=0.64,而仅用临床/人口学特征为0.58)。这项大型前瞻性横断面研究发现,肠道微生物组与癌前结直肠肿瘤之间的关联较弱且不一致,未发现稳健的微生物特征。研究结果提示,既往报道的微生物改变可能在疾病进展后期才出现,可能是CRC的结果而非原因。需要开展纵向、多组学研究,以厘清肠道微生物组与肿瘤之间的时间性和因果通路。
Gut IF 24.6 2026-10-07 PMID: 41151792
The impact of nucleos(t)ide analogues (NAs) therapy on the long-term outcomes in chronic HBV infection individuals outside 2025 European Association for the Study of the Liver (EASL) strongly recommended treatment indications remains uncertain. We aimed to assess the association between NAs therapy and the risks of cirrhosis and hepatocellular carcinoma (HCC) in Chinese chronic HBV infection individuals outside these criteria. We analysed data from 30 784 chronic HBV infection individuals across 12 centres in China. We categorised individuals outside 2025 EASL strongly recommended treatment criteria into four groups: (1) hepatitis B e antigen (HBeAg)-positive, high replicative (age <30, HBV DNA ≥8 log₁₀IU/mL, normal alanine aminotransferase (ALT), no/mild fibrosis, no family history of liver cancer); (2) HBeAg-positive, impending phase transition (typically age ≥30, HBV DNA ≥6 log₁₀IU/mL, normal ALT, no advanced fibrosis); (3) HBeAg-negative, low replicative (HBV DNA <3.3 log₁₀IU/mL, normal ALT, no/mild fibrosis); (4) HBeAg-negative, high replicative, low-risk (HBV DNA 3.3-4.3 log₁₀IU/mL, normal ALT, no/mild fibrosis). The primary endpoints were the incidence of cirrhosis and HCC. Up to 5 years of follow-up (117 814 person-years), we documented 635 incident cirrhosis and 164 HCC cases. In multivariable analyses, NA therapy significantly reduced risks of cirrhosis (HR 0.18, 95% CI 0.11 to 0.32) and HCC (HR 0.03, 95% CI 0.01 to 0.21) in Group 1, and cirrhosis (HR 0.50, 95% CI 0.41 to 0.61) and HCC (HR 0.25, 95% CI 0.16 to 0.41) in Group 2. No significant associations were observed in Groups 3 and 4. Findings were consistent in propensity score matching analyses. NAs therapy was associated with reduced risks of cirrhosis and HCC in HBeAg-positive individuals with high replicative or impending phase transition phenotypes, supporting the expansion of chronic HBV infection treatment criteria.
中文摘要:核苷(酸)类似物(NAs)治疗对2025年欧洲肝脏研究学会(EASL)强烈推荐治疗指征之外的慢性HBV感染者的长期结局影响仍不确定。我们旨在评估NAs治疗与中国慢性HBV感染者中不符合上述标准者的肝硬化和肝细胞癌(HCC)风险之间的关联。我们分析了中国12个中心30 784例慢性HBV感染者的数据。我们将不符合2025年EASL强烈推荐治疗标准者分为四组:(1)乙型肝炎e抗原(HBeAg)阳性、高复制期(年龄<30岁,HBV DNA ≥8 log₁₀IU/mL,丙氨酸氨基转移酶(ALT)正常,无/轻度纤维化,无肝癌家族史);(2)HBeAg阳性、即将进入阶段转换(通常年龄≥30岁,HBV DNA ≥6 log₁₀IU/mL,ALT正常,无进展期纤维化);(3)HBeAg阴性、低复制(HBV DNA <3.3 log₁₀IU/mL,ALT正常,无/轻度纤维化);(4)HBeAg阴性、高复制、低风险(HBV DNA 3.3-4.3 log₁₀IU/mL,ALT正常,无/轻度纤维化)。主要终点为肝硬化和HCC的发生率。在最长5年随访(117 814人年)期间,我们记录了635例新发肝硬化和164例HCC病例。在多变量分析中,NA治疗显著降低了第1组的肝硬化(HR 0.18,95%CI 0.11至0.32)和HCC(HR 0.03,95%CI 0.01至0.21)风险,以及第2组的肝硬化(HR 0.50,95%CI 0.41至0.61)和HCC(HR 0.25,95%CI 0.16至0.41)风险。第3组和第4组未观察到显著关联。倾向评分匹配分析中结果一致。NAs治疗与具有高复制期或即将进入阶段转换表型的HBeAg阳性个体肝硬化和HCC风险降低相关,支持扩大慢性HBV感染的治疗标准。
Gut IF 24.6 2026-10-06 PMID: 42838738
Individuals with diabetes are prioritised for pancreatic cancer screening. Tailored risk prediction models can improve stratification and screening efficiency. However, most existing predictive tools focus on new-onset diabetes, overlooking individuals with long-standing type 2 diabetes. To develop and validate a short-term pancreatic cancer risk prediction model applicable to both new-onset and long-standing type 2 diabetes. This retrospective longitudinal cohort study used two independent Chinese cohorts: the Tianjin Diabetes and Health Cohort (n=330 767, registration ID: NCT06913153) for derivation and internal validation, and the Xiamen Regional Electronic Health Record Database (n=105 537) for external validation. The Short-Term risk predictiOn of Pancreatic cancer in Diabetes Mellitus (STOP-DM) model was developed using a random forest algorithm and 11 routinely available clinical predictors to estimate pancreatic cancer risk at 6, 12, 24 and 36 months. Model performance was further evaluated in subgroups stratified by diabetes duration. The STOP-DM model exhibited the highest predictive performance at a 6-month time window, with the area under the receiver operating characteristic curve of 0.88 (95% CI 0.84 to 0.92) in the derivation cohort, 0.89 (0.83 to 0.94) in internal validation and 0.86 (0.83 to 0.89) in external validation. The top 5% high-risk group identified 59.37% and 48.03% of incident cases in the two validation cohorts and had 11.00-fold and 14.37-fold higher risk than the lowest-risk group. The model performed well in both new-onset and long-standing diabetes, and outperformed existing models for new-onset diabetes in sensitivity and positive predictive value. The STOP-DM model provides a practical approach to stratify pancreatic cancer risk and deliver targeted screening for individuals with type 2 diabetes, particularly those living with long-standing diabetes. Prospective validation and real-world implementation studies are warranted.
中文摘要:糖尿病患者被优先纳入胰腺癌筛查。个体化风险预测模型可改善风险分层和筛查效率。然而,现有大多数预测工具聚焦于新发糖尿病,忽视了长期2型糖尿病患者。为开发并验证一个适用于新发和长期2型糖尿病的短期胰腺癌风险预测模型,本回顾性纵向队列研究使用两个中国独立队列:天津糖尿病与健康队列(n=330 767,注册号:NCT06913153)用于开发与内部验证,厦门区域电子健康记录数据库(n=105 537)用于外部验证。采用随机森林算法和11个常规可获得的临床预测因子开发了糖尿病中胰腺癌短期风险预测(STOP-DM)模型,用于估计6、12、24和36个月时的胰腺癌风险。模型性能进一步在按糖尿病病程分层的亚组中评估。STOP-DM模型在6个月时间窗预测性能最高,其受试者工作特征曲线下面积在开发队列中为0.88(95%置信区间0.84至0.92),内部验证中为0.89(0.83至0.94),外部验证中为0.86(0.83至0.89)。最高5%高风险组在两个验证队列中分别识别出59.37%和48.03%的新发病例,其风险分别比最低风险组高11.00倍和14.37倍。该模型在新发糖尿病和长期糖尿病中均表现良好,并在灵敏度和阳性预测值方面优于现有针对新发糖尿病的模型。STOP-DM模型为2型糖尿病患者,尤其是长期糖尿病患者,提供了一种实用的胰腺癌风险分层和靶向筛查方法。有必要开展前瞻性验证和真实世界实施研究。
Journal of the American Academy of Dermatology IF 12.3 2026-10-05 PMID: 42833484
Systemic relapse after stage I melanoma is uncommon, but accounts for nearly one-third of metastatic melanoma cases. The prognostic impact of primary melanoma stage in advanced disease is unknown. Overall survival (OS) was analyzed in patients with advanced melanoma from the Spanish Melanoma Registry (2018-2024), stratified by primary stage. Among 365 patients with metastatic melanoma treated at first line, 58 had prior stage I, 32 IIA, 80 IIB/C, and 195 III. Median time to relapse was 52 months for stage I, 30 months in IIA, 27 months in IIB/C and 25 months in stage III (p=0.0001). At systemic relapse, patients with previous stage I more frequently had ≥3 metastatic sites (OR 1.89, 95% CI 1.06-3.35), brain metastases (OR 4.02, 95% CI 2.13-7.58), and elevated LDH (OR 2.19, 95% CI 1.18-4.04). Median OS was shorter for patients with prior stage I (19.8 m, 95% CI 12, 55.9) versus stage IIA (60.1 m, 95% CI 52.8, NR), IIB/C (32.6 m, 95% CI 18.9, NR), and III (43 m, 95% CI 25.5, 62.3) (p=0.024). Systemic relapse after stage I melanoma is associated with higher tumor burden and poorer survival than relapse after stage II/III.
中文摘要:I期黑色素瘤后全身性复发不常见,但占转移性黑色素瘤病例近三分之一。原发黑色素瘤分期对晚期疾病的预后影响尚不明确。研究分析了西班牙黑色素瘤登记处(2018-2024)晚期黑色素瘤患者的总生存期(OS),并按原发分期分层。在365例接受一线治疗的转移性黑色素瘤患者中,58例既往为I期,32例为IIA期,80例为IIB/C期,195例为III期。中位复发时间在I期为52个月,IIA期为30个月,IIB/C期为27个月,III期为25个月(p=0.0001)。全身性复发时,既往I期患者更常见≥3个转移部位(OR 1.89,95% CI 1.06-3.35)、脑转移(OR 4.02,95% CI 2.13-7.58)和LDH升高(OR 2.19,95% CI 1.18-4.04)。中位OS在既往I期患者中更短(19.8个月,95% CI 12-55.9),而IIA期为60.1个月(95% CI 52.8-NR)、IIB/C期为32.6个月(95% CI 18.9-NR)、III期为43个月(95% CI 25.5-62.3)(p=0.024)。I期黑色素瘤后全身性复发与较II/III期复发更高的肿瘤负荷和更差的生存相关。
Endoscopy IF 11.8 2026-10-02 PMID: 42826731
Evidence regarding the survival benefit of endobiliary radiofrequency ablation (RFA) in perihilar cholangiocarcinoma (CCA) remains limited. We evaluated the association between endobiliary RFA and overall survival in unresectable perihilar CCA, with a focus on the timing of exposure. This retrospective cohort study included 475 patients with unresectable perihilar CCA treated with endoscopic biliary drainage between 2015 and 2025 (90 with a single RFA session, 50 with two or more). RFA was modeled as a time-dependent cumulative count (0, 1, or ≥2 sessions), with landmark analyses of subsequent 6-month mortality at baseline and 3, 6, 9, and 12 months. Sensitivity analyses adjusted for stent type and calendar year. RFA within 7 days of drainage was associated with lower 6-month mortality (adjusted hazard ratio [aHR], 0.34; 95% CI, 0.16-0.70; P=0.004). At the 3-month landmark, two or more sessions were associated with lower mortality (aHR, 0.10; P=0.024); no association was seen at later landmarks. These estimates were unchanged after adjustment for stent type and calendar year. Over the entire follow-up, two or more sessions were associated with lower mortality (aHR, 0.59; P=0.007), but this association was attenuated after adjustment for calendar year (aHR, 0.77; P=0.209). Recurrent biliary obstruction was more frequent after RFA (37.9% vs. 22.1%; P<0.001), with the excess confined to non-tumor causes. Endobiliary RFA was associated with improved survival in unresectable perihilar CCA, with the benefit concentrated in the first three months after biliary drainage, at the cost of more frequent non-tumor biliary obstruction.
中文摘要:关于胆管内射频消融(RFA)在肝门部胆管癌(CCA)中生存获益的证据仍有限。我们评估了胆管内RFA与不可切除肝门部CCA总生存之间的关联,并重点关注暴露时机。这项回顾性队列研究纳入2015年至2025年间接受内镜胆道引流治疗的475例不可切除肝门部CCA患者(90例接受单次RFA,50例接受两次或以上)。RFA以时间依赖性累计次数建模(0、1或≥2次),并在基线及3、6、9、12个月进行界标分析,评估随后6个月死亡率。敏感性分析针对支架类型和日历年份进行调整。引流后7天内进行RFA与较低的6个月死亡率相关(校正风险比[aHR]为0.34;95%CI为0.16-0.70;P=0.004)。在3个月界标时,两次或以上RFA与较低死亡率相关(aHR为0.10;P=0.024);在更晚的界标时未见关联。这些估计值在调整支架类型和日历年份后未改变。在整个随访期间,两次或以上RFA与较低死亡率相关(aHR为0.59;P=0.007),但在调整日历年份后该关联减弱(aHR为0.77;P=0.209)。RFA后复发性胆道梗阻更常见(37.9% vs. 22.1%;P<0.001),且这种增加仅限于非肿瘤原因。胆管内RFA与不可切除肝门部CCA生存改善相关,获益集中在胆道引流后的前三个月,但代价是非肿瘤性胆道梗阻更频繁。
JAMA network open IF 11.7 2026-10-01 PMID: 42842249
American Indian and Alaska Native patients represent a uniquely vulnerable population in the US. Epidemiological studies have shown significant health disparities within this group. Contemporary outcomes and utilization studies of cancer in this population could aid in public health interventions in the future. To analyze utilization, spending, and mortality outcomes for American Indian and Alaska Native beneficiaries with cancer covered by traditional Medicare (TM). A multiyear cross-sectional analysis of a near population of TM beneficiaries in the US using Medicare beneficiary summary files and prescription drug event International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) linked claims from January 1, 2016 to December 31, 2023. TM coverage for American Indian and Alaska Native beneficiaries with cancer. Aggregate claims for care utilization and spending from Medicare Parts A, B, and D to assess cancer prevalence, care utilization (ie, inpatient, outpatient, and prescription usage), total spending, mortality and secondary outcomes (hospice usage, screening utilization, and out-of-pocket costs). A sample of 26 867 866 TM beneficiaries in 2023 had 123 597 (0.46%) identifying as American Indian and Alaska Native (69 294 [56%] female). In this American Indian and Alaska Native subpopulation, 10.8% (n = 13 291) had a cancer diagnosis, lower than the 19.4% (5 211 773) prevalence noted in the overall TM population. The annual all-cause mortality rate among American Indian and Alaska Native beneficiaries with cancer in 2023 was 12.4% (1643), nearly double the overall TM cancer population at 6.9% (358 049). American Indian and Alaska Native beneficiaries had elevated rates of renal, hepatocellular, and biliary carcinomas. The mean (SD) spending per American Indian and Alaska Native beneficiary with cancer spent was $32 775 ($58 089) annually whereas the mean (SD) spending per TM beneficiary was $25 073 ($47 226) annually. Annual uptake of breast and colorectal screenings were lowest among American Indian and Alaska Native beneficiaries. Finally, only 939 of 1642 American Indian and Alaska Native beneficiaries with cancer (57.2%) filed hospice claims near date of death, lower than the 234 809 of 357 941 in the overall TM population (65.6%). In this cross-sectional analysis the American Indian and Alaska Native cancer population experienced significant differences in spending and outcomes in TM from 2016 through 2023. American Indian and Alaska Native beneficiaries with cancer displayed the worst all-cause mortality across demographics, elevated total and out-of-pocket spending as well as lower rates of apparent access to preventive and hospice services. The magnitude of these differences is critical in formulating action plans to promote health and reduce cancer among American Indian and Alaska Native beneficiaries.
中文摘要:美国印第安人与阿拉斯加原住民患者是美国一个格外脆弱的群体。流行病学研究已显示该群体内存在显著的健康差异。针对该人群癌症的当代结局与利用研究可为未来的公共卫生干预提供帮助。旨在分析传统Medicare(TM)覆盖的、患有癌症的美国印第安人与阿拉斯加原住民受益人的医疗利用、支出和死亡结局。采用2016年1月1日至2023年12月31日期间Medicare受益人汇总文件以及处方药事件与《国际疾病分类第十次修订本》(ICD-10)关联索赔数据,对美国接近全体的TM受益人进行多年横断面分析。暴露为美国印第安人与阿拉斯加原住民癌症受益人获得TM覆盖。汇总Medicare A、B和D部分的医疗服务利用与支出索赔,以评估癌症患病率、医疗服务利用(即住院、门诊和处方使用)、总支出、死亡率及次要结局(临终关怀使用、筛查利用和自付费用)。2023年26 867 866名TM受益人样本中,有123 597人(0.46%)自认为美国印第安人与阿拉斯加原住民(69 294人[56%]为女性)。在该美国印第安人与阿拉斯加原住民亚人群中,10.8%(n=13 291)有癌症诊断,低于总体TM人群中观察到的19.4%(5 211 773)患病率。2023年美国印第安人与阿拉斯加原住民癌症受益人的年度全因死亡率为12.4%(1643人),几乎是总体TM癌症人群6.9%(358 049人)的两倍。美国印第安人与阿拉斯加原住民受益人肾癌、肝细胞癌和胆道癌发生率升高。美国印第安人与阿拉斯加原住民癌症受益人每年平均(标准差)支出为32 775美元(58 089美元),而每名TM受益人每年平均(标准差)支出为25 073美元(47 226美元)。乳腺和结直肠癌筛查的年度接受率在美国印第安人与阿拉斯加原住民受益人最低。最后,1642名美国印第安人与阿拉斯加原住民癌症受益人中有939人(57.2%)在死亡日期附近提交了临终关怀索赔,低于总体TM人群中357 941人中的234 809人(65.6%)。在这项横断面分析中,美国印第安人与阿拉斯加原住民癌症人群在2016年至2023年期间于TM中的支出和结局存在显著差异。美国印第安人与阿拉斯加原住民癌症受益人在不同人口统计学群体中全因死亡率最差,总支出和自付费用升高,且预防和临终关怀服务的可及性似乎较低。这些差异的幅度对于制定行动计划以促进美国印第安人与阿拉斯加原住民受益人的健康并减少癌症至关重要。
JAMA network open IF 11.7 2026-10-01 PMID: 42837155
Clinical trial enrollment is essential to advancing cancer care, yet participation among patients with advanced cancer remains low. While patient-level barriers are frequently cited, the role of health care delivery factors-specifically physician- and practice-level variation-has been poorly quantified. To quantify variation in clinical trial participation and identify associated delivery system factors among patients with advanced cancer. This cohort study included adults with advanced or metastatic cancers diagnosed and treated between January 1, 2011, and December 31, 2024, by 1664 physicians across 107 trial-available oncology practices across the US. Data were obtained from the Flatiron Health Research Database. Analyses were conducted between January and April 2025. Patient-level (eg, demographic characteristics, cancer type, and performance status), physician-level (eg, patient volume, subspecialization, and prior trial enrollment activity), and practice-level (eg, size, research engagement, and patient composition) factors. The primary outcome was clinical trial participation, defined as receipt of a clinical study drug. Mixed-effects logistic regression models were used to decompose the proportion of variation attributable to patient-, physician-, and practice-level factors. Multivariable logistic regression was used to identify characteristics associated with trial participation. Among the 205 743 patients with advanced or metastatic cancer (mean [SD] age at advanced cancer diagnosis, 67.5 [11.3]; 107 370 males [52.2%]), 10 785 (5.2%) participated in a clinical trial over the study period, increasing from 235 of 5964 (3.9%) in 2011 to 638 of 9336 (6.8%) in 2024. Participation remained highly concentrated: of 1664 physicians, 389 (23.4%) accounted for 9018 (83.6%) of all enrollments (10 785), while 21 of 107 practices (19.6%) accounted for 8686 (80.5%) of all enrolled patients. Additionally, 494 of 1664 physicians (29.7%) enrolled no patients. Physician-level (12.3%) and practice-level (15.1%) factors explained a greater share of variation in trial participation than observable patient-level characteristics (11.4%), with physician- and practice-level contributions increasing over time. Physician's subspecialization (treated 1-2 cancer groups: odds ratio [OR], 4.11 [95% CI, 2.53-6.68], P = .002; treated 3-4 cancer groups: OR, 2.38 [95% CI, 1.37-4.14], P < .001), physician's prior trial enrollment activity (enrolled patients in the 2 previous years: OR, 1.58; 95% CI, 1.43-1.76; P < .001), and practice's research engagement (OR, 2.68; 95% CI, 2.12-3.39; P < .001) were associated with higher odds of trial participation. In this cohort study of patients with advanced cancer, clinical trial participation increased moderately but remained low over the study period, with physician- and practice-level factors consistently accounting for a substantial share of participation variation. Improving trial accrual requires interventions targeting structural factors in enrollment, including research infrastructure and physician engagement.
中文摘要:临床试验入组对于推进癌症诊疗至关重要,但晚期癌症患者的参与率仍然较低。虽然患者层面的障碍常被提及,但医疗服务提供因素,特别是医生层面和执业机构层面的差异,其作用尚未得到充分量化。旨在量化晚期癌症患者临床试验参与情况的差异,并识别相关的医疗服务系统因素。这项队列研究纳入了2011年1月1日至2024年12月31日期间诊断并接受治疗的晚期或转移性癌症成人患者,涉及美国107家可开展试验的肿瘤执业机构中的1664名医生。数据来自Flatiron Health Research Database。分析于2025年1月至4月进行。变量包括患者层面(如人口学特征、癌症类型和体能状态)、医生层面(如患者量、亚专业化和既往试验入组活动)以及执业机构层面(如规模、研究参与度和患者构成)因素。主要结局为临床试验参与,定义为接受临床研究药物。采用混合效应logistic回归模型分解可归因于患者、医生和执业机构层面因素的变异比例。采用多变量logistic回归识别与试验参与相关的特征。在205743例晚期或转移性癌症患者中(晚期癌症诊断时平均[SD]年龄为67.5[11.3]岁;107370例男性[52.2%]),10785例(5.2%)在研究期间参与了临床试验,从2011年的5964例中235例(3.9%)增至2024年的9336例中638例(6.8%)。参与情况仍高度集中:1664名医生中,389名(23.4%)贡献了全部入组10785例中的9018例(83.6%),而107家执业机构中21家(19.6%)贡献了全部入组患者8686例(80.5%)。此外,1664名医生中有494名(29.7%)未入组任何患者。医生层面(12.3%)和执业机构层面(15.1%)因素解释的试验参与变异比例高于可观察的患者层面特征(11.4%),且医生和执业机构层面的贡献随时间增加。医生亚专业化(治疗1-2个癌种组:比值比[OR] 4.11[95% CI 2.53-6.68],P=.002;治疗3-4个癌种组:OR 2.38[95% CI 1.37-4.14],P<.001)、医生既往试验入组活动(前2年曾入组患者:OR 1.58;95% CI 1.43-1.76;P<.001)以及执业机构的研究参与度(OR 2.68;95% CI 2.12-3.39;P<.001)与更高的试验参与几率相关。在这项晚期癌症患者队列研究中,临床试验参与在研究期间适度增加但仍较低,医生和执业机构层面因素持续解释参与差异的相当大比例。改善试验招募需要针对入组结构性因素的干预,包括研究基础设施和医生参与。
Radiology IF 17.6 2026-10 PMID: 42836755
Background Previous studies on imaging of hepatocellular carcinoma (HCC) have shown inconsistency in the growth of tumor vascularity and gross morphologic features. Contrast-enhanced US (CEUS) is one of the few methods that can depict both features simultaneously, making it valuable for assessing this inconsistency and its potential clinical influence. Purpose To evaluate and establish a new CEUS feature representing inconsistency between vascularity and gross morphologic features (perfusion beyond margin [PBM]) and analyze its underlying biologic mechanisms and prognostic influence. Materials and Methods This multicenter retrospective study included patients with HCC from January 2015 to August 2023. Three radiologists (5-8 years of experience) measured tumor diameter using gray-scale US and CEUS. Mathematic, prognostic, and bioinformatics analyses were used to quantify the PBM diagnostic standard. Prognostic analysis included recurrence-free survival after laparoscopic hepatectomy and local tumor progression-free survival after thermal ablation. Bioinformatics analysis included pathologic and immunohistochemical evaluation and RNA sequencing. Results This study included 1076 patients (mean age ± SD, 60 years ± 10.5; 854 men, 1166 HCCs). PBM was defined as the tumor diameter on arterial phase exceeding that at gray-scale US by 5 mm. PBM was associated with worse recurrence-free survival (hazard ratio [HR], 1.76 [95% CI: 1.05, 2.94]; P = .03); worse local tumor progression-free survival (HR, 2.40 [95% CI: 1.84, 3.13]; P < .001); and higher rates of microvascular invasion (52.2% [12 of 23] vs 25.0% [29 of 116]; P = .02), cytokeratin-7 positivity (26.2% [11 of 42] vs 11.3% [14 of 124]; P = .04), and cytokeratin-19 positivity (26.9% [seven of 26] vs 8.8% [13 of 148]; P = .02) compared with the non-PBM group. PBM occurrence was related to upregulation of genes for angiogenesis (VEGA, PIGF), epithelial-mesenchymal transition (TGFB1, MMP2), and immunosuppressive tumor microenvironment (CD163). PBM was more common in patients with cirrhosis (26.8% [236 of 880]; P = .04; odds ratio, 1.41), recurrent tumors (28.4% [161 of 567]; P = .02; odds ratio, 1.38), and tumors greater than 3 cm (30.8% [92 of 298]; P = .01; odds ratio, 1.46). Conclusion Perfusion beyond margin, a new imaging feature, was identified through contrast-enhanced US in patients with hepatocellular carcinoma; it was associated with greater invasive potential and poorer prognosis. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Shafaat and Reis in this issue.
中文摘要:背景 既往关于肝细胞癌(HCC)影像学的研究显示,肿瘤血管生成与大体形态学特征的增长并不一致。对比增强超声(CEUS)是少数能同时显示这两种特征的方法之一,因此对于评估这种不一致及其潜在临床影响具有价值。目的 评估并建立一种新的CEUS特征,用以代表血管性与大体形态学特征之间的不一致(边缘外灌注[PBM]),并分析其潜在生物学机制及对预后的影响。材料与方法 这项多中心回顾性研究纳入2015年1月至2023年8月的HCC患者。三名放射科医师(经验5至8年)使用灰阶超声和CEUS测量肿瘤直径。采用数学、预后和生物信息学分析来量化PBM诊断标准。预后分析包括腹腔镜肝切除术后无复发生存期和热消融后局部肿瘤无进展生存期。生物信息学分析包括病理和免疫组织化学评估以及RNA测序。结果 本研究纳入1076例患者(平均年龄±标准差,60岁±10.5;854例男性,1166个HCC病灶)。PBM定义为动脉期肿瘤直径超过灰阶超声测量值5 mm。与非PBM组相比,PBM与更差的无复发生存期(风险比[HR],1.76[95%CI:1.05,2.94];P=0.03)、更差的局部肿瘤无进展生存期(HR,2.40[95%CI:1.84,3.13];P<0.001)以及更高的微血管侵犯发生率(52.2%[12/23] vs 25.0%[29/116];P=0.02)、细胞角蛋白7阳性率(26.2%[11/42] vs 11.3%[14/124];P=0.04)和细胞角蛋白19阳性率(26.9%[7/26] vs 8.8%[13/148];P=0.02)相关。PBM的发生与血管生成(VEGA、PIGF)、上皮-间质转化(TGFB1、MMP2)和免疫抑制性肿瘤微环境(CD163)相关基因上调有关。PBM在肝硬化患者(26.8%[236/880];P=0.04;比值比1.41)、复发性肿瘤(28.4%[161/567];P=0.02;比值比1.38)和大于3 cm的肿瘤(30.8%[92/298];P=0.01;比值比1.46)中更常见。结论 边缘外灌注是一种通过对比增强超声在肝细胞癌患者中发现的新影像学特征;它与更强的侵袭潜力和更差的预后相关。©RSNA,2026。本文有补充材料。另见本期Shafaat和Reis的社论。
JAMA network open IF 11.7 2026-10-01 PMID: 42826017
Sex is a well-recognized factor associated with hepatocellular carcinoma (HCC) incidence, but its association with mortality is unclear. To assess the association between sex and the risk of overall, liver-related, and non-liver-related mortality among patients with HCC. This retrospective cohort study was conducted among patients with HCC in 17 centers from 5 countries and regions (2000-2023). Male and female patients with HCC who had balanced baseline characteristics via inverse probability of treatment weighting (IPTW) were included, with a propensity score-matched cohort included for sensitivity analyses. Data were analyzed between July 10 and September 8, 2025. Male vs female sex. Overall, liver-related, and non-liver-related mortality. Among 8594 patients with HCC (mean [SD] age, 63.3 [10.9] years; 6214 male [72.3%]; 5644 Asian [65.7%], 458 Black [5.3%], 615 Hispanic [7.2%], and 1784 White [20.8%]), 4567 were from Asia (53.1%), 6327 had cirrhosis (73.6%), and 6617 had viral etiology (77.0%). In the unmatched cohort, males had a higher overall mortality rate per 100 person-years than females in the total cohort (15.9 [95% CI, 15.3-16.4] vs 13.3 [95% CI, 12.5-14.1]; P < .001) and in Asian (14.1 [95% CI, 13.5-14.7] vs 11.1 [95% CI, 10.3-12.0]; P < .001), Asia region (14.4 [95% CI, 13.6-15.2] vs 10.8 [95% CI, 9.9-11.8]; P < .001), cirrhosis (17.6 [95% CI, 16.9-18.3] vs 14.4 [95% CI, 13.5-15.4]; P < .001), and hepatitis B (13.6 [95% CI, 12.7-14.5] vs 10.0 [95% CI, 8.6-11.5]; P < .001) and C (15.8 [95% CI, 15.0-16.6] vs 13.4 [95% CI, 12.4-14.6]; P < .001) subgroups. In the IPTW-matched cohort, male sex was associated with increased overall mortality in the full cohort (adjusted hazard ratio [aHR], 1.14 [95% CI, 1.05-1.23]; P = .002) and in Asian (aHR, 1.22 [95% CI, 1.10-1.36]; P < .001), Asia region (aHR, 1.23 [95% CI, 1.09-1.39]; P < .001), cirrhosis (aHR, 1.18 [95% CI, 1.08-1.29]; P < .001), and viral (aHR, 1.15 [95% CI, 1.05-1.26]; P = .004) subgroups. Additionally, sex differences varied by liver disease etiology, with male sex having the highest aHR in the association with overall mortality among individuals with alcohol-associated liver disease (aHR, 1.90 [95% CI, 1.02-3.54]; P = .04), followed by those with hepatitis B (aHR, 1.22 [95% CI, 1.01-1.47]; P = .04) or C (aHR, 1.13 [95% CI, 1.02-1.26]; P = .03), but there was no association in patients with metabolic dysfunction-associated steatotic liver disease. There was no significant sex difference for non-liver-related mortality. In this study, sex disparities in HCC mortality existed but were heterogeneous across ethnic background and liver disease etiologies. These findings support incorporation of sex-based considerations in HCC management.
中文摘要:性别是公认与肝细胞癌(HCC)发病率相关的因素,但其与死亡率的关联尚不明确。本研究旨在评估性别与HCC患者总体死亡、肝脏相关死亡及非肝脏相关死亡风险之间的关联。这项回顾性队列研究纳入来自5个国家和地区17个中心的HCC患者(2000-2023年)。纳入通过逆概率处理加权(IPTW)实现基线特征平衡的男性和女性HCC患者,并纳入倾向评分匹配队列进行敏感性分析。数据分析时间为2025年7月10日至9月8日。暴露因素为男性与女性。结局为总体死亡、肝脏相关死亡和非肝脏相关死亡。在8594例HCC患者中(平均[标准差]年龄63.3[10.9]岁;男性6214例[72.3%];亚裔5644例[65.7%]、黑人458例[5.3%]、西班牙裔615例[7.2%]、白人1784例[20.8%]),4567例来自亚洲(53.1%),6327例有肝硬化(73.6%),6617例为病毒性病因(77.0%)。在未匹配队列中,男性每100人年的总体死亡率高于女性:总队列中为15.9(95%CI 15.3-16.4)对13.3(95%CI 12.5-14.1),P<.001;亚裔中为14.1(95%CI 13.5-14.7)对11.1(95%CI 10.3-12.0),P<.001;亚洲地区中为14.4(95%CI 13.6-15.2)对10.8(95%CI 9.9-11.8),P<.001;肝硬化中为17.6(95%CI 16.9-18.3)对14.4(95%CI 13.5-15.4),P<.001;乙型肝炎中为13.6(95%CI 12.7-14.5)对10.0(95%CI 8.6-11.5),P<.001;丙型肝炎中为15.8(95%CI 15.0-16.6)对13.4(95%CI 12.4-14.6),P<.001。在IPTW匹配队列中,男性与总体死亡风险增加相关:全队列中调整后风险比(aHR)为1.14(95%CI 1.05-1.23),P=.002;亚裔中aHR为1.22(95%CI 1.10-1.36),P<.001;亚洲地区中aHR为1.23(95%CI 1.09-1.39),P<.001;肝硬化中aHR为1.18(95%CI 1.08-1.29),P<.001;病毒性病因中aHR为1.15(95%CI 1.05-1.26),P=.004。此外,性别差异因肝病病因不同而异,在酒精相关性肝病患者中,男性与总体死亡风险相关的aHR最高(aHR为1.90,95%CI 1.02-3.54;P=.04),其次为乙型肝炎(aHR为1.22,95%CI 1.01-1.47;P=.04)或丙型肝炎(aHR为1.13,95%CI 1.02-1.26;P=.03),但在代谢功能障碍相关脂肪性肝病患者中未见此关联。非肝脏相关死亡方面未见显著性别差异。本研究中,HCC死亡存在性别差异,但该差异在不同种族背景和肝病病因间具有异质性。这些发现支持在HCC管理中纳入基于性别的考量。
Gut IF 24.6 2026-10-01 PMID: 42823331
The impact of circulating tumour DNA (ctDNA) detection, which informs minimal residual disease (MRD) after curative treatment, remains debated especially for stage IV patients. The study objectives were to evaluate the prognostic role of MRD and to estimate lead time (LT) at different timepoints when adopting longitudinal MRD testing. INTERCEPT, is a prospective, observational cohort study of stage II-IV patients with colorectal cancer receiving curative-intent treatment who are longitudinally monitored using tissue-informed MRD assays as part of routine clinical care. Study results confirm the prognostic value of MRD, also beyond 12 months from surgery, with higher recurrence incidence in MRD-positive stage II-III patients than in MRD-negative stage IV patients (p<0.0001). Adjuvant therapy in stage IV disease showed limited durable benefit in both MRD-positive and negative patients. Clinical management was associated with increased use of more intensive second-line imaging (MRI, positron emission tomography; p<0.0001) when ctDNA was detected. Concurrent macroscopic disease detection was observed in 26% of cases and when excluded, LT from MRD detection to radiographic recurrence varies during surveillance (p=0.007). Multitimepoint testing improves sensitivity for recurrence (79.9% vs 48.5%) and may enable earlier, potentially curative interventions. ctDNA testing provides a framework for risk stratification and defines temporal windows that may inform future interventional strategies. Prospective interventional studies are required to define clinical utility and optimal implementation.
中文摘要:循环肿瘤DNA(ctDNA)检测可用于判断根治性治疗后的微小残留病灶(MRD),但其影响仍存争议,尤其是在IV期患者中。本研究旨在评估MRD的预后作用,并估计在采用纵向MRD检测时不同时间点的提前时间(LT)。INTERCEPT是一项前瞻性观察性队列研究,纳入接受根治性治疗的II–IV期结直肠癌患者,并将基于组织信息的MRD检测作为常规临床照护的一部分进行纵向监测。研究结果证实了MRD的预后价值,且该价值在术后超过12个月时仍然存在,MRD阳性II–III期患者的复发发生率高于MRD阴性IV期患者(p<0.0001)。IV期疾病中的辅助治疗在MRD阳性和阴性患者中均显示出有限的持久获益。当检测到ctDNA时,临床管理与此后更频繁使用更强化的二线影像学检查(MRI、正电子发射断层扫描)相关(p<0.0001)。26%的病例同时发现肉眼可见的宏观病灶;在排除这些病例后,从MRD检测到影像学复发之间的LT在监测期间存在变化(p=0.007)。多时间点检测提高了复发检测灵敏度(79.9% vs 48.5%),并可能促成更早、潜在可根治的干预。ctDNA检测提供了风险分层框架,并界定了可能为未来干预策略提供信息的时间窗口。仍需开展前瞻性干预性研究以明确其临床效用和最佳实施方式。
JAMA oncology IF 23.9 2026-10-01 PMID: 42821267
In patients with hepatocellular carcinoma (HCC) that is initially beyond the Milan criteria, immune checkpoint inhibitor (ICI)-based regimens have been explored before liver transplant (LT) to improve tumor control as part of downstaging strategies that most often involve locoregional therapy, but associations with posttransplant oncologic and survival benefit remain uncertain. To evaluate the associations of an ICI-based multimodal pretransplant strategy with posttransplant oncologic outcomes and acute rejection among patients with HCC that was initially beyond the Milan criteria who underwent LT. This multicenter, retrospective, matched cohort study included adults (≥18 years) with HCC that was initially beyond the Milan criteria who underwent LT at 8 high-volume LT centers (>55 LTs annually) in China between January 2019 and December 2024. Propensity score matching balanced measured covariates between ICI and non-ICI groups. The data were analyzed in February 2026. ICI-based multimodal pretransplant strategy (typically combined with locoregional and/or targeted therapies) vs therapy without ICIs. Primary outcomes were overall survival (OS) and recurrence-free survival (RFS) from LT. Secondary outcomes were posttransplant recurrence and acute rejection within 90 days. Among 416 matched recipients, 208 (50.5%) received ICI-based multimodal therapy and 208 (50.0%) did not. The median age was 53 years (IQR, 46-59 years), 39 recipients (9.4%) were female, and 377 (90.6%) were male. Median OS was 4.57 years (95% CI, 4.34 to not estimable) in the ICI group and 2.53 years (95% CI, 2.17-3.10; P < .001) in the non-ICI group. Median RFS was 1.47 years (95% CI, 1.18-4.34) in the ICI group and 0.89 years (95% CI, 0.75-1.39; P = .02) in the non-ICI group. In multivariable Cox models, the ICI-based multimodal strategy was associated with better OS (hazard ratio [HR], 0.63; 95% CI, 0.43-0.92) and RFS (HR, 0.59; 95% CI, 0.44-0.80). In a Fine-Gray model, the ICI-based multimodal strategy was associated with lower posttransplant recurrence risk (subdistribution HR, 0.54; 95% CI, 0.40-0.72). Acute rejection within 90 days after transplant was more frequent in the ICI group (34 [16.3%] vs 17 [8.2%]; P = .01). The results of this cohort study suggest that an ICI-based multimodal pretransplant strategy was associated with better posttransplant oncologic outcomes and survival in selected patients with HCC that was initially beyond the Milan criteria, despite more frequent acute rejection.
中文摘要:在初诊超出米兰标准的肝细胞癌(HCC)患者中,已有研究探索在肝移植(LT)前使用以免疫检查点抑制剂(ICI)为基础的方案,作为通常包含局部区域治疗的降期策略的一部分,以改善肿瘤控制,但其与移植后肿瘤学结局和生存获益的关联仍不确定。本研究旨在评估以ICI为基础的多模式移植前策略与初诊超出米兰标准并接受LT的HCC患者移植后肿瘤学结局及急性排斥反应之间的关联。这项多中心、回顾性、匹配队列研究纳入了2019年1月至2024年12月期间在中国8个高手术量LT中心(每年>55例LT)接受LT、初诊超出米兰标准的成人(≥18岁)HCC患者。倾向性评分匹配平衡了ICI组与非ICI组之间已测量的协变量。数据于2026年2月进行分析。比较以ICI为基础的多模式移植前策略(通常联合局部区域治疗和/或靶向治疗)与不含ICI的治疗。主要结局为自LT起的总生存期(OS)和无复发生存期(RFS)。次要结局为移植后复发和90天内急性排斥反应。在416例匹配受者中,208例(50.5%)接受以ICI为基础的多模式治疗,208例(50.0%)未接受。中位年龄为53岁(IQR,46-59岁),39例受者(9.4%)为女性,377例(90.6%)为男性。ICI组的中位OS为4.57年(95% CI,4.34至不可估计),非ICI组为2.53年(95% CI,2.17-3.10;P < .001)。ICI组的中位RFS为1.47年(95% CI,1.18-4.34),非ICI组为0.89年(95% CI,0.75-1.39;P = .02)。在多变量Cox模型中,以ICI为基础的多模式策略与更好的OS(风险比[HR],0.63;95% CI,0.43-0.92)和RFS(HR,0.59;95% CI,0.44-0.80)相关。在Fine-Gray模型中,以ICI为基础的多模式策略与更低的移植后复发风险相关(亚分布HR,0.54;95% CI,0.40-0.72)。移植后90天内的急性排斥反应在ICI组中更常见(34例[16.3%] vs 17例[8.2%];P = .01)。这项队列研究的结果提示,以ICI为基础的多模式移植前策略与初诊超出米兰标准的部分HCC患者移植后更好的肿瘤学结局和生存相关,尽管急性排斥反应更常见。
MedComm IF 14.1 2026-10 PMID: 42780629
Breath analysis may improve the noninvasive triage of CT-detected pulmonary nodules. We prospectively evaluated two complementary breath platforms, an electronic nose (eNose) and gas chromatography-mass spectrometry (GC-MS), in patients with newly detected nodules. The eNose cohort included 89 participants (55 malignant and 34 benign), and the GC-MS cohort included 75 participants (52 malignant and 23 benign). For each platform, three logistic regression models were assessed: clinical-only, biomarker-only, and combined clinical + biomarker. For eNose, apparent discrimination improved from the clinical-only model (AUC 0.67; misclassification rate [MCR] 40.4%) to the sensor-only model (AUC 0.86; MCR 22.5%), with further improvement in the combined clinical + sensor model (AUC 0.88; MCR 22.5%). Internal validation showed attenuation, with the combined eNose model achieving a leave-one-out cross-validation (LOOCV) AUC of 0.67. For GC-MS, LASSO logistic regression showed strong apparent discrimination for the VOC-only (AUC 0.97; MCR 4%), although internal validation indicated attenuation of performance (bootstrap-corrected AUC 0.64; LOOCV AUC 0.65). The combined clinical + VOC model remained comparably high (AUC 0.96; MCR 8%), outperforming the clinical-only benchmark (AUC 0.73; MCR 32%). These findings support complementary, noninvasive breath-based approaches for pulmonary nodule triage and warrant larger multicenter validation studies.
中文摘要:呼气分析可能改善CT检出肺结节的无创分诊。我们前瞻性评估了两种互补的呼气平台,电子鼻(eNose)和气相色谱-质谱联用(GC-MS),用于新检出结节的患者。eNose队列包括89名参与者(55例恶性,34例良性),GC-MS队列包括75名参与者(52例恶性,23例良性)。对于每个平台,评估了三种逻辑回归模型:仅临床、仅生物标志物和临床+生物标志物联合。对于eNose,表观区分度从仅临床模型(AUC 0.67;误分类率[MCR] 40.4%)提高到仅传感器模型(AUC 0.86;MCR 22.5%),临床+传感器联合模型进一步提高(AUC 0.88;MCR 22.5%)。内部验证显示性能衰减,联合eNose模型达到留一法交叉验证(LOOCV)AUC 0.67。对于GC-MS,LASSO逻辑回归显示仅VOC(AUC 0.97;MCR 4%)具有很强的表观区分度,但内部验证表明性能衰减(bootstrap校正AUC 0.64;LOOCV AUC 0.65)。临床+VOC联合模型仍保持相当高(AUC 0.96;MCR 8%),优于仅临床基准(AUC 0.73;MCR 32%)。这些发现支持互补的、基于呼气的无创方法用于肺结节分诊,并值得开展更大规模的多中心验证研究。
EClinicalMedicine IF 12.8 2026-10 PMID: 42750940
Rare cancers account for approximately one quarter of cancer diagnoses in Europe, yet prevailing clinical trial governance frameworks were developed for common malignancies and conventional randomised designs. The 2024 WHO Guidance for best practices for clinical trials and ICH E6(R3) reframe trial quality around scientific validity, ethical proportionality, feasibility, equity, and meaningful patient engagement - principles that are structurally tested by rare cancer research. This narrative review examines how these principles are operationalised in representative sarcoma trials, where biological heterogeneity, low incidence, and international collaboration expose the limits of standard approaches. Drawing on examples from Bayesian designs, umbrella and platform trials, registry-based approaches, decentralised participation, and structured advocacy involvement, we identify recurring governance features associated with successful implementation in rare cancer settings. Patient-centred approaches - particularly early integration of patient-reported outcomes (PROs), risk-proportional oversight, and attention to participant burden - emerge as key determinants of feasibility, recruitment, retention, and interpretability. In rare cancers, patient-centred, fit-for-purpose governance is not an ethical adjunct but a structural determinant of operational validity. Lessons from sarcoma trials can be extended beyond rare cancers to molecularly stratified subsets of common malignancies. This work received no specific funding from public, commercial, or not-for-profit organisations.
中文摘要:罕见癌约占欧洲癌症诊断的四分之一,但现行临床试验治理框架是为常见恶性肿瘤和传统随机设计而制定的。2024年WHO临床试验最佳实践指南和ICH E6(R3)将试验质量重新围绕科学有效性、伦理相称性、可行性、公平性以及有意义的患者参与来界定——这些原则在罕见癌研究中受到结构性检验。本叙述性综述考察这些原则如何在具有代表性的肉瘤试验中得以实施,其中生物学异质性、低发病率以及国际合作暴露出标准方法的局限。借鉴贝叶斯设计、伞式试验和平台试验、基于登记的研究方法、去中心化参与以及结构化倡导参与等示例,我们识别出与罕见癌环境下成功实施相关的反复出现的治理特征。以患者为中心的方法——尤其是患者报告结局(PROs)的早期整合、与风险相称的监管以及关注受试者负担——成为可行性、招募、留存和可解释性的关键决定因素。在罕见癌中,以患者为中心、适合目的的治理并非伦理附加项,而是操作有效性的结构性决定因素。来自肉瘤试验的经验可以扩展到罕见癌之外,应用于常见恶性肿瘤的分子分层亚组。本工作未获得来自公共、商业或非营利组织的专项资助。
MedComm IF 14.1 2026-10 PMID: 42746058
Homologous recombination deficiency (HRD) in colorectal cancer (CRC) remains largely unexplored. In contrast, mismatch repair deficiency (dMMR) occurs in ∼15% of patients with CRC. Although HRD and dMMR have historically been regarded as mutually exclusive, emerging evidence suggests that this mutual exclusivity may not be absolute. Here, we conducted a retrospective cohort study utilizing genomic and transcriptomic data to define HRD status in a Chinese dMMR CRC cohort (n = 99). Multiple machine learning approaches were employed to analyze the expression profiles of these tumors and to develop a classifier distinguishing HRD from homologous recombination proficiency (HRP) in dMMR CRCs. In the Chinese dMMR CRC cohort, 66% of tumors were classified as HRD. Compared with the HRP group, the HRD group had a significantly higher tumor mutational burden and better outcomes. The derived expression signature, comprising eight genes, successfully predicted HRD status in dMMR tumors with high accuracy in the training set (AUC = 0.88, Naïve Bayes) and the test set (AUC = 0.87). In this study, a subset of dMMR CRC tumors with co-occurring HRD was identified, which may have potential implications for patient stratification and the application of targeted therapies, such as PARP inhibitors, in this molecular subgroup.
中文摘要:结直肠癌中的同源重组缺陷(HRD)在很大程度上尚未得到探索。相比之下,错配修复缺陷(dMMR)发生于约15%的结直肠癌患者中。尽管HRD和dMMR历来被认为互相排斥,但新出现的证据提示这种互斥性可能并非绝对。在此,我们开展了一项回顾性队列研究,利用基因组和转录组数据在一个中国dMMR结直肠癌队列(n=99)中界定HRD状态。我们采用多种机器学习方法分析这些肿瘤的表达谱,并开发了一个分类器,用于在dMMR结直肠癌中区分HRD与同源重组功能正常(HRP)。在中国dMMR结直肠癌队列中,66%的肿瘤被归类为HRD。与HRP组相比,HRD组具有显著更高的肿瘤突变负荷和更好的结局。所得到的由八个基因组成的表达特征在训练集(AUC=0.88,朴素贝叶斯)和测试集(AUC=0.87)中均能以高准确度成功预测dMMR肿瘤的HRD状态。在本研究中,我们识别出dMMR结直肠癌中一个同时存在HRD的亚群,这可能对该分子亚群的患者分层以及靶向治疗(如PARP抑制剂)的应用具有潜在意义。
Journal of hepatology IF 40.1 2026-10 PMID: 42744522
Liver cancer remains a major global health burden, with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA) accounting for the vast majority of primary liver malignancies. As most patients are diagnosed at advanced stages, imaging plays a central role across the entire care continuum - from surveillance and early detection to diagnosis, staging, prognostic stratification, and treatment response assessment. Recent advances in imaging technology, diagnostic frameworks, and computational analysis have substantially expanded the clinical value of liver imaging. This review summarises key developments in liver cancer imaging, beginning with technical innovations in ultrasound, multiphasic and spectral CT, MRI with hepatobiliary contrast agents, abbreviated MRI protocols, and evolving PET tracers such as FAPI. We then examine the convergence and remaining differences among major diagnostic guideline systems for HCC, including LI-RADS, EASL, AASLD, KLCA-NCC, and APASL, with emphasis on vascular hallmarks, hepatobiliary phase interpretation, and Kupffer-phase contrast-enhanced ultrasound criteria. We also discuss the concept of the HCC-iCCA biological continuum, and how imaging features can reflect this phenotypic spectrum. A major focus is the emerging concept of imaging-based prognostication of HCC, which captures biologically meaningful phenotypes such as proliferative class, macrotrabecular-massive subtype, microvascular invasion likelihood, immune microenvironment signatures, and VETC phenotype. We discuss how these imaging features reflect underlying molecular programmes and may inform treatment allocation beyond tumour size and number. In iCCA, advances in quantitative imaging and contrast-enhanced ultrasound perfusion enable differentiation of small-duct vs. large-duct subtypes and prediction of stromal-rich aggressive variants. Treatment response assessment criteria are reviewed, addressing challenges in evaluating locoregional therapies and immunotherapy. Finally, we examine the emerging roles of radiomics and artificial intelligence, focusing on current validation challenges. Together, these advances demonstrate the evolution of liver cancer imaging from a detection tool to a comprehensive platform for biological characterisation and personalised treatment guidance.
中文摘要:肝癌仍是全球重大健康负担,其中肝细胞癌(HCC)和肝内胆管癌(iCCA)占原发性肝脏恶性肿瘤的绝大多数。由于大多数患者在晚期才被诊断,影像学在整个诊疗连续过程中发挥核心作用——从监测和早期发现到诊断、分期、预后分层以及治疗反应评估。影像技术、诊断框架和计算分析的最新进展显著拓展了肝脏影像学的临床价值。本综述总结肝癌影像学的关键进展,首先介绍超声、多期和能谱CT、使用肝胆对比剂的MRI、简化MRI方案以及不断发展的PET示踪剂如FAPI的技术创新。随后,我们审视HCC主要诊断指南体系之间的趋同与尚存差异,包括LI-RADS、EASL、AASLD、KLCA-NCC和APASL,重点讨论血管性特征、肝胆期判读和Kupffer期超声造影标准。我们还讨论HCC-iCCA生物学连续体的概念,以及影像特征如何反映这一表型谱。一个主要关注点是HCC基于影像的预后评估这一新兴概念,它可捕捉具有生物学意义的表型,如增殖类、巨梁状-块状亚型、微血管侵犯可能性、免疫微环境特征和VETC表型。我们讨论这些影像特征如何反映潜在的分子程序,并可能超越肿瘤大小和数目来指导治疗分配。在iCCA中,定量影像和超声造影灌注的进展使得能够区分小胆管型与大管型亚型,并预测富含间质的侵袭性变异型。本文还回顾治疗反应评估标准,讨论评估局部区域治疗和免疫治疗的挑战。最后,我们探讨影像组学和人工智能的新兴作用,聚焦当前验证方面的挑战。总之,这些进展表明肝癌影像学已从检测工具演变为用于生物学表征和个体化治疗指导的综合平台。
Drugs IF 14.7 2026-10 PMID: 42730868
To summarise the literature regarding the safety of short-term use of the non-steroidal anti-inflammatory drug (NSAID) celecoxib. Systematic review with meta-analysis of randomised trials. Participants comprised individuals of all ages with acute non-cancer pain. Interventions included celecoxib at 200-400 mg/day for up to 10 days. The comparators were placebo, other NSAIDs (including cyclooxygenase-2 [COX-2] inhibitors and non-selective NSAIDS [nsNSAIDS]), or opioids. Five databases were searched from inception to April 2025: Embase, Web of Science, MEDLINE, Cochrane Central Register of Controlled Trials, and Scopus. Additionally, a registry was searched: ClinicalTrials.gov. Meta-analyses using Mantel-Haenszel and random-effects model were used to calculate risk ratios (RRs) and 95% confidence intervals (CIs) for severe cardiovascular, respiratory, and gastrointestinal adverse events and secondary outcomes. The Cochrane Risk of Bias Tool for randomised trials (RoB-2) was used to assess bias risk. The Grading of Recommendation Assessment, Development and Evaluation (GRADE) was conducted to assess the certainty of evidence of each reported outcome. Title/abstract and full text screening comprised 3976 and 273 studies, respectively. Fifty studies were included with 10,693 participants. The RRs for adverse events were no different between celecoxib and placebo for severe events (3 studies) (RR 0.44 [95% CI 0.10-2.03]), cardiovascular (3 studies) (RR 0.84 [95% CI 0.24-2.92]), respiratory (4 studies) (RR 1.23 [95% CI 0.29-5.26]), and gastrointestinal events (33 studies) (RR 0.96 [95% CI 0.64-1.43]). There was no difference between celecoxib and NSAIDS for gastrointestinal adverse events, RR 0.89 (95% CI 0.68-1.17). Celecoxib had a lower risk compared to opioids for gastrointestinal events, RR 0.34 (95% CI 0.14-0.86), and showed a lower risk of nausea compared with placebo, RR 0.75 (95% CI 0.60-0.93), and nsNSAIDS, RR 0.80 (95% CI 0.64-0.99). Most studies had some risk of bias concerns, and the overall certainty of evidence for most outcomes was very low. Celecoxib appears to be safe for acute non-cancer pain when compared to placebo, NSAIDS, and opioids. It had a lower risk compared to opioids for gastrointestinal adverse events in general, nausea and vomiting, as well as a lower risk for nausea adverse events when compared to placebo and nsNSAIDS. PROSPERO-CRD42025642152.
中文摘要:总结关于短期使用非甾体抗炎药塞来昔布安全性的文献。采用随机试验的系统评价与荟萃分析。参与者包括各年龄段急性非癌性疼痛患者。干预措施包括塞来昔布200-400 mg/天,最多10天。对照为安慰剂、其他非甾体抗炎药(包括环氧化酶-2[COX-2]抑制剂和非选择性非甾体抗炎药[nsNSAIDS])或阿片类药物。检索五个数据库自建库至2025年4月:Embase、Web of Science、MEDLINE、Cochrane Central Register of Controlled Trials和Scopus。此外,检索了一个注册库:ClinicalTrials.gov。使用Mantel-Haenszel法和随机效应模型进行荟萃分析,计算严重心血管、呼吸和胃肠道不良事件及次要结局的风险比(RR)和95%置信区间(CI)。使用Cochrane随机试验偏倚风险工具(RoB-2)评估偏倚风险。进行推荐分级的评估、制定与评价(GRADE)以评估每个报告结局的证据确定性。标题/摘要和全文筛选分别包括3976项和273项研究。共纳入50项研究,10693名参与者。塞来昔布与安慰剂相比,严重事件(3项研究)(RR 0.44 [95% CI 0.10-2.03])、心血管事件(3项研究)(RR 0.84 [95% CI 0.24-2.92])、呼吸事件(4项研究)(RR 1.23 [95% CI 0.29-5.26])和胃肠道事件(33项研究)(RR 0.96 [95% CI 0.64-1.43])的不良事件RR无差异。塞来昔布与非甾体抗炎药在胃肠道不良事件方面无差异,RR 0.89(95% CI 0.68-1.17)。与阿片类药物相比,塞来昔布胃肠道事件风险较低,RR 0.34(95% CI 0.14-0.86),并且与安慰剂相比恶心风险较低,RR 0.75(95% CI 0.60-0.93),与nsNSAIDS相比,RR 0.80(95% CI 0.64-0.99)。大多数研究存在一定偏倚风险担忧,大多数结局的总体证据确定性极低。与安慰剂、非甾体抗炎药和阿片类药物相比,塞来昔布在急性非癌性疼痛中似乎是安全的。总体上,与阿片类药物相比,其胃肠道不良事件、恶心和呕吐风险较低;与安慰剂和nsNSAIDS相比,其恶心不良事件风险也较低。PROSPERO-CRD42025642152。
Journal of hepatology IF 40.1 2026-10 PMID: 42684194
Primary liver cancers, including hepatocellular carcinoma and cholangiocarcinoma, represent a growing global health burden marked by rising incidence and high mortality. Clinical management requires integration of tumour stage, liver function, and patient-related factors to guide treatment decisions, yet current frameworks capture only a fraction of underlying disease complexity. In this setting, artificial intelligence (AI) is emerging as a key enabler of precision medicine in liver oncology. AI encompasses machine learning and deep learning approaches capable of identifying complex, non-linear patterns within large, high-dimensional datasets. These methods are increasingly applied across multimodal data inputs, including electronic health records, radiologic imaging, digital pathology, and omics profiling. In imaging, AI supports surveillance, lesion detection, characterisation, and prediction of recurrence, survival, and treatment response. In computational pathology, models are extending tissue analysis beyond description of morphology and marker expression toward prognostic modelling and inference of tumour biology. Integration of clinical, imaging, and pathological data in multimodal AI frameworks has shown superior performance compared with single-modality models for key outcomes such as recurrence and survival. Despite promising results, clinical translation remains limited by insufficient external and prospective validation, limited interpretability of complex models, and regulatory and workflow integration challenges. Addressing these barriers through federated learning strategies and the development of transparent, explainable systems is essential. If successfully implemented, AI-driven multimodal decision-support systems could substantially refine diagnosis, prognostication, and treatment selection in liver cancer, advancing personalised care in this biologically and clinically complex disease.
中文摘要:原发性肝癌,包括肝细胞癌和胆管癌,是一个日益加重的全球健康负担,其发病率上升且死亡率高。临床管理需要整合肿瘤分期、肝功能和患者相关因素以指导治疗决策,然而当前框架仅能捕捉潜在疾病复杂性的一小部分。在此背景下,人工智能(AI)正成为肝脏肿瘤学精准医疗的关键推动因素。AI涵盖机器学习和深度学习方法,能够在大规模、高维数据集中识别复杂的非线性模式。这些方法正越来越多地应用于多模态数据输入,包括电子健康记录、放射影像、数字病理和组学分析。在影像学中,AI支持监测、病灶检测、表征以及复发、生存和治疗反应的预测。在计算病理学中,模型正将组织分析从形态学和标志物表达的描述扩展到预后建模和肿瘤生物学推断。将临床、影像和病理数据整合到多模态AI框架中,在复发和生存等关键结局上已显示出优于单模态模型的性能。尽管结果令人鼓舞,但临床转化仍受限于外部验证和前瞻性验证不足、复杂模型可解释性有限,以及监管和工作流程整合方面的挑战。通过联邦学习策略以及开发透明、可解释的系统来解决这些障碍至关重要。如果能够成功实施,AI驱动的多模态决策支持系统可显著改进肝癌的诊断、预后判断和治疗选择,推动这种生物学和临床上均复杂的疾病的个性化诊疗。
JAMA surgery IF 15.6 2026-10-01 PMID: 42647021
The role of preoperative radiotherapy after neoadjuvant chemotherapy for pancreatic cancer remains controversial. To evaluate whether the addition of radiotherapy to chemotherapy is associated with improved oncologic outcomes in patients undergoing resection for pancreatic cancer. This was a retrospective propensity score-matched cohort study of patients undergoing pancreatic cancer resection between 2015 and 2023, with a median follow-up of 44 months. Patients were recruited from 2 high-volume referral centers. Of patients undergoing pancreatectomy after neoadjuvant treatment for pancreatic ductal adenocarcinoma, those treated with fluorouracil, leucovorin, irinotecan, and oxaliplatin or gemcitabine/nab-paclitaxel with or without preoperative radiation met eligibility criteria. Patients with metastatic disease, surgery-related mortality, or follow-up less than 12 months were excluded. Treatment groups were matched 1:1 on age, sex, comorbidity, tumor characteristics, baseline carbohydrate antigen 19-9 level, resectability status, and chemotherapy exposure. Neoadjuvant chemotherapy with or without radiotherapy. Event-free survival, pattern of recurrence, and overall survival. Of 1201 consecutive patients undergoing pancreatectomy after neoadjuvant treatment for pancreatic ductal adenocarcinoma, 869 met eligibility criteria. Among 800 included patients (median [IQR] age, 65 [58-71] years; 402 men [50.2%]), 438 received neoadjuvant chemotherapy and radiotherapy and 362 chemotherapy alone. After matching, 226 patients per group were analyzed; most had resectable (117 of 226 [51.1%]) or borderline-resectable (104 of 226 [46.5%]) disease. Radiotherapy was associated with higher rates of pathologic complete response (15 of 226 [6.6%] vs 10 of 226 [4.4%]), node-negative disease (139 of 226 [61.5%] vs 76 of 226 [33.6%]), and R0 resection (192 of 226 [85.0%] vs 118 of 226 [52.2%]). Recurrence patterns were similar, with distant recurrence as the predominant first site of failure in both groups (116 of 226 [51.3%] vs 109 of 226 [48.3%]). In competing risk analysis, the cumulative incidence of locoregional recurrence did not differ (subdistribution hazard ratio [HR], 0.90; 95% CI, 0.53-1.54; P = .71). Radiotherapy was not associated with improved event-free survival (HR, 1.10; 95% CI, 0.88-1.37; P = .38) or overall survival (HR, 1.02; 95% CI, 0.79-1.32; P = .84). Results of this cohort study suggest that although the addition of radiotherapy to neoadjuvant chemotherapy was associated with an improved pathologic response, it was not associated with survival benefit or reduced recurrence in resectable and borderline-resectable pancreatic cancer. These findings highlight the limited impact of locoregional control in a disease driven by systemic progression.
中文摘要:对于胰腺癌新辅助化疗后术前放疗的作用仍存在争议。旨在评估在因胰腺癌接受切除术的患者中,在化疗基础上加用放疗是否与肿瘤学结局改善相关。这是一项回顾性倾向评分匹配队列研究,纳入2015年至2023年间接受胰腺癌切除术的患者,中位随访44个月。患者来自2家高容量转诊中心。在接受新辅助治疗后行胰腺切除术的胰腺导管腺癌患者中,接受氟尿嘧啶、亚叶酸、伊立替康和奥沙利铂或吉西他滨/白蛋白结合型紫杉醇治疗、伴或不伴术前放疗者符合纳入标准。排除转移性疾病、手术相关死亡或随访不足12个月的患者。治疗组按年龄、性别、合并症、肿瘤特征、基线糖类抗原19-9水平、可切除状态和化疗暴露进行1:1匹配。新辅助化疗伴或不伴放疗。无事件生存期、复发模式及总生存期。在1201例连续接受新辅助治疗后行胰腺切除术的胰腺导管腺癌患者中,869例符合纳入标准。在纳入的800例患者中(中位[IQR]年龄65[58-71]岁;402例男性[50.2%]),438例接受新辅助化疗和放疗,362例仅接受化疗。匹配后,每组各分析226例患者;大多数为可切除(226例中117例[51.1%])或临界可切除(226例中104例[46.5%])疾病。放疗与更高的病理完全缓解率相关(226例中15例[6.6%] vs 226例中10例[4.4%])、淋巴结阴性疾病(226例中139例[61.5%] vs 226例中76例[33.6%])和R0切除(226例中192例[85.0%] vs 226例中118例[52.2%])。复发模式相似,两组首次失败部位均以远处复发为主(226例中116例[51.3%] vs 226例中109例[48.3%])。在竞争风险分析中,局部区域复发的累积发生率无差异(亚分布风险比[HR],0.90;95% CI,0.53-1.54;P = .71)。放疗与无事件生存期改善无关(HR,1.10;95% CI,0.88-1.37;P = .38)或总生存期改善无关(HR,1.02;95% CI,0.79-1.32;P = .84)。这项队列研究的结果提示,尽管在新辅助化疗基础上加用放疗与病理缓解改善相关,但在可切除和临界可切除胰腺癌中,其与生存获益或复发减少无关。这些发现凸显了在由全身进展驱动的疾病中局部区域控制的有限影响。
JAMA surgery IF 15.6 2026-10-01 PMID: 42584916
As cancer care becomes increasingly complex, patients may experience prolonged delays between diagnosis and definitive surgical management. While consolidation and expansion of health systems, along with centralization of care, may further amplify these delays, a comprehensive assessment of contemporary waiting times within cancer surgery care pathways in the US is lacking. To evaluate national trends and predictors of delays from diagnosis to initiation of first-course therapy among patients ultimately undergoing cancer surgery. This retrospective cohort study included patients with nonmetastatic, clinical stage I through III breast, colon, lung, pancreatic, gastric, or esophageal cancer in the National Cancer Database from January 2012 to December 2023 who underwent definitive surgical resection. Waiting time from diagnosis to first-course therapy, defined as up-front surgery or neoadjuvant therapy preceding surgery, was assessed. Data were analyzed from August 2025 to June 2026. The primary outcome was the waiting time from diagnosis to first-course therapy. Secondary outcomes included factors associated with prolonged (≥30 days) or extreme (≥60 days) delays. A total of 2 731 059 patients were identified. Mean (SD) patient age was 63.5 (12.8) years, and 2 325 110 patients (85%) were female. From 2012 to 2023, median (IQR) time from diagnosis to first-course therapy increased across all malignancies (breast: 34 days [22-50] in 2012-2015 to 45 days [32-64] in 2022-2023; colon: 20 days [7-34] to 31 days [15-49]; lung: 41 days [27-60] to 53 days [35-77]; pancreas: 23 days [14-35] to 32 days [22-44]; gastric: 35 days [21-51] to 49 days [33-70]; and esophageal: 38 days [27-54] to 48 days [35-66]; P value for trend <.001 for all) and among both patients undergoing up-front surgery and those receiving neoadjuvant therapy prior to surgery. Delays were more pronounced at academic compared with community hospitals and among patients referred for care. Predictors of longer waiting time included Medicaid insurance (5 of 6 cancers), lowest-quartile income (6 of 6 cancers), Black race (5 of 6 cancers), increased travel distance (4 of 6 cancers), care in the West region (6 of 6 cancers), and treatment at academic institutions (6 of 6 cancers). Receipt of robotic operations was linked with longer waiting times for nonbreast malignancies (5 of 5 cancers). Among patients undergoing cancer surgery, waiting times to initiation of first-course therapy have steadily increased since 2012, particularly at high-volume academic centers and among patients referred for definitive care. With continued consolidation and expansion of health systems, system-level strategies are urgently needed to monitor and mitigate delays in the delivery of surgical care for cancer.
中文摘要:随着癌症诊疗日益复杂,患者从确诊到接受根治性手术治疗之间可能出现较长的延迟。医疗系统的整合与扩张以及诊疗的集中化,可能进一步加剧这些延迟,但美国癌症外科治疗路径中当代等待时间的全面评估仍然缺乏。本研究旨在评估最终接受癌症手术的患者从确诊到开始首次治疗之间的延迟的国家趋势及其预测因素。这项回顾性队列研究纳入美国国家癌症数据库(National Cancer Database)中2012年1月至2023年12月期间临床分期为I至III期、无转移的乳腺癌、结肠癌、肺癌、胰腺癌、胃癌或食管癌并接受根治性手术切除的患者。研究评估了从确诊到首次治疗(定义为先行手术或术前新辅助治疗后手术)的等待时间。数据分析时间为2025年8月至2026年6月。主要结局为从确诊到首次治疗的等待时间。次要结局包括与延长延迟(≥30天)或极端延迟(≥60天)相关的因素。共纳入2 731 059例患者。患者平均(SD)年龄为63.5(12.8)岁,其中2 325 110例(85%)为女性。2012年至2023年间,所有癌种从确诊到首次治疗的中位(IQR)时间均有所增加(乳腺癌:2012-2015年为34天[22-50],2022-2023年为45天[32-64];结肠癌:20天[7-34]增至31天[15-49];肺癌:41天[27-60]增至53天[35-77];胰腺癌:23天[14-35]增至32天[22-44];胃癌:35天[21-51]增至49天[33-70];食管癌:38天[27-54]增至48天[35-66];所有癌种趋势P值均<.001),且在先行手术的患者与术前接受新辅助治疗的患者中均呈上升趋势。与社区医院相比,学术型医院的延迟更为明显,转诊接受治疗的患者亦然。等待时间延长的预测因素包括医疗补助保险(6种癌症中的5种)、最低四分位收入(6种癌症中的6种)、黑人种族(6种癌症中的5种)、出行距离增加(6种癌症中的4种)、西部地区接受诊疗(6种癌症中的6种)以及在学术机构接受治疗(6种癌症中的6种)。接受机器人手术与非乳腺恶性肿瘤的较长等待时间相关(5种癌症中的5种)。在接受癌症手术的患者中,自2012年以来开始首次治疗的等待时间持续增加,尤其是在高容量学术中心以及转诊接受根治性治疗的患者中。随着医疗系统持续整合与扩张,亟需系统层面的策略来监测并减少癌症外科治疗实施中的延迟。
European urology IF 29.1 2026-10 PMID: 42580957
As renal tumor classification continues to evolve and new hereditary entities emerge, accurate recognition of hereditary renal neoplasms is increasingly important. Advances in precision genomics, genetic testing, and international registries will improve early detection, risk stratification, and precision management.
中文摘要:随着肾肿瘤分类不断演变以及新的遗传性实体不断出现,准确识别遗传性肾肿瘤日益重要。精准基因组学、基因检测和国际注册登记系统的进展将改善早期发现、风险分层和精准管理。
Journal of hepatology IF 40.1 2026-10 PMID: 42550920
Biliary tract cancers (BTC), including cholangiocarcinoma, gallbladder cancer, and ampullary cancer, remain poor-prognosis tumours. Chemo-immunotherapy is now established as the first-line standard of care. In parallel, precision medicine is now well established in the form of targeted therapies. These have transformed outcomes for defined subgroups, particularly intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements, where pemigatinib and futibatinib provide meaningful response rates and durable disease control. On top of this, next-generation FGFR inhibitors aim to address secondary resistance. IDH1-mutant cholangiocarcinoma benefits from ivosidenib, with multiple combination strategies currently under investigation. HER2-directed therapies, including zanidatamab and trastuzumab deruxtecan, have shown promising efficacy in HER2-amplified or strongly overexpressing BTC, with ongoing clinical trials in the first-line setting. Tumour-agnostic targets (BRAF V600E, MSI-H/dMMR, RET/NTRK/NRG1 fusions) and other emerging therapies are further broadening therapeutic opportunities. However, key barriers to implementation include heterogeneous biomarker testing, limited tissue availability, the need for DNA/RNA hybrid-capture sequencing, and evolving resistance biology, underscoring the importance of optimised diagnostics and innovative trial designs to realise personalised care in BTC. This review provides detailed insights on these therapies, and most importantly a view to what the future may hold.
中文摘要:胆道癌(BTC)包括胆管癌、胆囊癌和壶腹癌,仍属预后不良的肿瘤。化疗联合免疫治疗现已成为一线标准治疗。与此同时,以靶向治疗为形式的精准医学也已牢固确立。这些治疗已改变特定亚组的结局,尤其是伴有FGFR2融合/重排的肝内胆管癌,其中培米替尼(pemigatinib)和福巴替尼(futibatinib)可带来有意义的缓解率和持久的疾病控制。在此基础上,下一代FGFR抑制剂旨在应对继发性耐药。IDH1突变胆管癌可从艾伏尼布(ivosidenib)获益,目前多种联合策略正在研究中。HER2靶向治疗,包括zanidatamab和德曲妥珠单抗(trastuzumab deruxtecan),在HER2扩增或强过表达的BTC中显示出有前景的疗效,一线治疗中的临床试验正在进行。肿瘤不可知靶点(BRAF V600E、MSI-H/dMMR、RET/NTRK/NRG1融合)及其他新兴疗法正在进一步拓宽治疗机会。然而,实施的主要障碍包括生物标志物检测异质性、组织可用性有限、需要DNA/RNA杂交捕获测序以及不断演变的耐药生物学,这凸显了优化诊断和创新试验设计以实现BTC个体化治疗的重要性。本综述对这些治疗提供了详细见解,最重要的是展望未来可能的发展方向。
Cell IF 45.1 2026-10-01 PMID: 42546689
Three-dimensional (3D) histology provides volumetric insights into tissue microarchitectures across entire specimens, holding great promise for more accurate prognostication. However, existing methods are too slow for intraoperative consultations. We present ULTRA (ultrarapid cleared stimulated Raman with AI), a label-free, stain-free, fixation-free, and section-free platform that leverages the chemical specificity of stimulated Raman scattering (SRS) microscopy for rapid 3D histological analysis. Through the synergistic development of a one-step tissue-clearing protocol and unsupervised learning algorithms, ULTRA delivers high-resolution, formalin-fixed, paraffin-embedded (FFPE)-grade deep 3D virtual histology within 30 min, covering orders of magnitude more tissue than slide-based methods. In human surgical glioma samples, ULTRA accurately resolves key histological features in 3D and delineates depth-dependent tumor infiltration margins at single-cell resolution. By compressing 3D histology from days or hours to an intraoperative timescale, ULTRA addresses a critical clinical gap and enables more informed surgical decision-making in the operating room.
中文摘要:三维(3D)组织学可对整个标本的组织微结构提供体积学见解,为更准确的预后判断带来巨大希望。然而,现有方法对于术中会诊而言过于缓慢。我们提出ULTRA(超快速透明化受激拉曼结合AI),一个无标记、无需染色、无需固定、无需切片的平台,利用受激拉曼散射(SRS)显微术的化学特异性进行快速3D组织学分析。通过一步组织透明化方案与无监督学习算法的协同开发,ULTRA可在30分钟内提供高分辨率、福尔马林固定石蜡包埋(FFPE)级深部3D虚拟组织学,覆盖的组织量比基于切片的方法多几个数量级。在人类外科胶质瘤样本中,ULTRA能在3D中准确解析关键组织学特征,并以单细胞分辨率描绘深度依赖的肿瘤浸润边缘。通过将3D组织学从数天或数小时压缩至术中时间尺度,ULTRA填补了一个关键临床空白,并能在手术室中实现更明智的手术决策。
Journal of hepatology IF 40.1 2026-10 PMID: 42542384
During the 21st century, the global burden of primary liver cancer has continued to rise, with the absolute numbers of incident cases and deaths increasing by 59.4% and 55.8%, respectively, between 2000 and 2023. Analysis of the GBD 2023 database shows that although age-standardised incidence and mortality rates declined from 2000, this favourable trend reversed around 2020, highlighting the need for continued surveillance. Viral hepatitis remains the leading cause of primary liver cancer worldwide, but its proportional contribution is decreasing. Notably, despite earlier gains from vaccination and antiviral therapies, hepatitis B- and hepatitis C-associated liver cancer incidence and mortality have rebounded globally since 2020. In contrast, metabolic dysfunction-associated steatotic liver disease has exhibited the fastest growth, with sustained increases in age-adjusted incidence and mortality across regions. Marked geographical variation persists in underlying aetiologies, with hepatitis B predominant in East Asia and Sub-Saharan Africa, hepatitis C in the Middle East, North Africa, the Americas, and alcohol-related disease in Europe and Australasia. Additionally, rising incidence and mortality of intrahepatic cholangiocarcinoma underscore the need for dedicated research beyond hepatocellular carcinoma. Collectively, these findings emphasise the urgency of sustained public health and clinical interventions targeting preventable and treatable liver diseases to curb future liver cancer burden.
中文摘要:在21世纪,原发性肝癌的全球负担持续上升,2000年至2023年间,新发病例和死亡的绝对数量分别增加了59.4%和55.8%。对GBD 2023数据库的分析显示,尽管年龄标化发病率和死亡率自2000年以来有所下降,但这一有利趋势在2020年前后发生逆转,凸显了持续监测的必要性。病毒性肝炎仍是全球原发性肝癌的主要原因,但其构成比例正在下降。值得注意的是,尽管疫苗接种和抗病毒治疗早期带来了收益,自2020年以来,与乙型肝炎和丙型肝炎相关的肝癌发病率和死亡率在全球范围内出现回升。相比之下,代谢功能障碍相关脂肪性肝病增长最快,各区域年龄调整后的发病率和死亡率持续上升。潜在病因仍存在显著地理差异,乙型肝炎在东亚和撒哈拉以南非洲占主导,丙型肝炎在中东、北非和美洲占主导,酒精相关疾病在欧洲和澳大拉西亚占主导。此外,肝内胆管癌发病率和死亡率上升,凸显了在肝细胞癌之外开展专门研究的必要性。总体而言,这些发现强调了针对可预防和可治疗肝病采取持续公共卫生和临床干预的紧迫性,以遏制未来的肝癌负担。
Journal of hepatology IF 40.1 2026-10 PMID: 42493369
Surgical resection is a cornerstone of curative therapy for hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), the two most common primary liver malignancies. In most patients with HCC, underlying cirrhosis is present, whereas in iCCA an identifiable risk factor is often absent. Regardless of tumour type, surgical planning must account for the future liver remnant to minimise the risk of post-hepatectomy liver failure, evaluating not only its volume but also its functional reserve. Furthermore, a deeper knowledge of surgical oncological principles combined with integrative strategies, including systemic and locoregional therapies, has enabled downstaging and conversion of initially unresectable liver malignancies, expanding surgical eligibility across a growing spectrum of hepatic tumoural conditions. Additionally, advances in the understanding of molecular biology and new treatment strategies, particularly in iCCA, have the potential to further extend the boundaries of resectability.
中文摘要:手术切除是肝细胞癌(HCC)和肝内胆管癌(iCCA)这两种最常见原发性肝脏恶性肿瘤根治性治疗的基石。在大多数HCC患者中,存在合并肝硬化;而在iCCA中,常缺乏可识别的危险因素。无论肿瘤类型如何,手术规划都必须考虑未来残肝,以尽量减少肝切除术后肝衰竭的风险,不仅评估其体积,也评估其功能储备。此外,对肿瘤外科原则更深入的认识,结合包括全身治疗和局部区域治疗在内的综合策略,使得初始不可切除的肝脏恶性肿瘤能够降期和转化,从而在越来越多的肝脏肿瘤情况下扩大手术适用范围。另外,对分子生物学的理解进展以及新的治疗策略,尤其是在iCCA中,有可能进一步拓展可切除性的边界。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42421219
Artificial intelligence (AI)-based models have shown initial promise in imaging brain metastasis; however, many lack validation against advanced imaging-informed datasets, precluding external validity and limiting widespread adoption. To overcome these limitations, we performed comprehensive performance testing against reference standard metrics and externally validated an AI algorithm. As part of its FDA-clearance process, performance testing of a previously developed U-Net-based AI model was conducted on a multi-institutional cohort with reference standard established via consensus review by 3 neuroradiologists. External validation was performed on patients imaged with dual sequences (augmented) as well as an open-access dataset (UCSF-BMSR). Evaluation metrics included sensitivity, false positive (FP) rate, positive predictive value (PPV), dice similarity coefficient (DSC), 95% Hausdorff distance, normalized surface distance, and qualitative physician assessment. In the FDA performance testing cohort, the AI algorithm achieved a sensitivity of 90.0% (95% CI: 87.0%-94.0%), DSC of 0.86 (95% CI: 0.83-0.89), and average FP rate of 0.57 lesions. In the augmented and open-access external validation cohorts, a sensitivity of 81.4% (95% CI: 73.7%-89.1%) and 85.2% (95% CI: 83.0%-87.4%) with an average number of 0.22 and 1.19 FP lesions and DSCs of 0.70 (95% CI: 0.66-0.73) and 0.78 (95% CI: 0.77-0.78) were calculated, respectively. In the augmented external validation cohort, 38.5% of contours were rated as requiring major revisions. This AI algorithm demonstrated promising performance via 3 unique datasets. However, given the notable rate of contour revisions, these findings support its clinical role not as an autonomous system but as a human-in-the-loop tool requiring physician oversight.
中文摘要:基于人工智能(AI)的模型在脑转移瘤影像中已显示出初步前景;然而,许多模型缺乏在先进影像信息数据集上的验证,因而无法保证外部有效性并限制其广泛采用。为克服这些局限,我们针对参考标准指标进行了全面的性能测试,并对外部验证了一种AI算法。作为其获得FDA批准过程的一部分,对一个先前开发的基于U-Net的AI模型在多机构队列中进行了性能测试,参考标准由3名神经放射科医生共识复核确立。外部验证在采用双序列(增强)成像的患者以及一个开放获取数据集(UCSF-BMSR)上进行。评估指标包括敏感性、假阳性(FP)率、阳性预测值(PPV)、Dice相似系数(DSC)、95% Hausdorff距离、归一化表面距离以及医生定性评估。在FDA性能测试队列中,AI算法达到90.0%的敏感性(95% CI:87.0%-94.0%)、0.86的DSC(95% CI:0.83-0.89)以及平均0.57个病灶的FP率。在增强和开放获取外部验证队列中,计算得到敏感性分别为81.4%(95% CI:73.7%-89.1%)和85.2%(95% CI:83.0%-87.4%),平均FP病灶数分别为0.22和1.19,DSC分别为0.70(95% CI:0.66-0.73)和0.78(95% CI:0.77-0.78)。在增强外部验证队列中,38.5%的轮廓被评定为需要重大修改。该AI算法通过3个独特数据集展现出有前景的性能。然而,鉴于轮廓修改率显著,这些发现支持其临床作用并非作为自主系统,而是作为需要医生监督的人在环路中工具。
Endoscopy IF 11.8 2026-10 PMID: 42314698
Colonoscopy is important for colorectal cancer screening, but real-world data on complications and their associated costs are limited. We assessed direct and indirect complications within 7 days after screening colonoscopy and estimated excess costs by complication type. We examined 365 685 individuals, aged 60-69, invited to screening in Region Stockholm, Sweden, from 2008 to 2021, to assess excess healthcare utilization after screening colonoscopy following a positive fecal occult blood test (FOBT). Healthcare events within 7 days postcolonoscopy were compared with 1 : 5 propensity score-matched controls, calculating between-group differences in healthcare utilization and costs. 11 177 screening colonoscopies were included. Bleeding occurred most frequently (47/10 000, relative risk [RR] 52.6, 95%CI 21.0-131.6), among the 86/10 000 individuals who had at least one healthcare event within 7 days postcolonoscopy. Compared with the propensity score-matched controls, the colonoscopy group had at least a threefold higher proportion of unplanned outpatient visits (RR 3.0, 95%CI 2.2-4.2) and hospital admissions (RR 4.2, 95%CI 3.0-5.8), driven by direct complications. No increase in indirect complications (e.g. cardiovascular or cerebrovascular) was observed. The excess cost was €32.88 per colonoscopy. Four patients died within 30 days of colonoscopy, with no increase in all-cause mortality compared with propensity score-matched controls (3.6 vs. 10.0 per 10 000; RR 0.4, 95%CI 0.1-1.0). Healthcare utilization and costs increased after screening colonoscopies compared with propensity score-matched controls, driven by direct complications. However, because few screened individuals undergo colonoscopy, and complications occur in fewer than 1% of procedures, excess costs are marginal relative to program expenditure.
中文摘要:结肠镜检查对结直肠癌筛查很重要,但关于并发症及其相关成本的现实世界数据有限。我们评估了筛查性结肠镜检查后7天内的直接和间接并发症,并按并发症类型估算了超额成本。我们检查了2008年至2021年瑞典斯德哥尔摩大区受邀参加筛查的365 685名60-69岁个体,以评估粪便隐血试验(FOBT)阳性后接受筛查性结肠镜检查后的超额医疗资源利用。将结肠镜检查后7天内的医疗事件与按1:5倾向评分匹配的对照进行比较,计算组间医疗资源利用和成本差异。共纳入11 177次筛查性结肠镜检查。在结肠镜检查后7天内至少发生一次医疗事件的86/10 000例个体中,出血最常见(47/10 000,相对危险度[RR] 52.6,95%CI 21.0-131.6)。与倾向评分匹配的对照相比,结肠镜组的非计划门诊就诊(RR 3.0,95%CI 2.2-4.2)和住院(RR 4.2,95%CI 3.0-5.8)比例至少高3倍,且主要由直接并发症驱动。未观察到间接并发症(如心血管或脑血管并发症)增加。每次结肠镜检查的超额成本为32.88欧元。4例患者在结肠镜检查后30天内死亡,与倾向评分匹配的对照相比,全因死亡率未增加(每10 000人3.6 vs. 10.0;RR 0.4,95%CI 0.1-1.0)。与倾向评分匹配的对照相比,筛查性结肠镜检查后医疗资源利用和成本增加,且由直接并发症驱动。然而,由于接受结肠镜检查的筛查个体较少,且并发症在不到1%的操作中发生,相对于项目支出,超额成本微乎其微。
Archives of toxicology IF 10.9 2026-10 PMID: 42228134
Per- and polyfluoroalkyl substances (PFAS) are persistent chemicals commonly found in consumer products. Despite growing concern over their health effects, their associations with chronic diseases in humans are still unclear. We included 10,093 participants to examine the associations between 8 PFAS and 40 chronic diseases. Multivariable logistic regression and restricted cubic spline (RCS) models were applied to evaluate linear and nonlinear associations, and mixture effects were further assessed using weighted quantile sum regression (WQS), quantile-based g-computation (q g‑comp), and Bayesian kernel machine regression (BKMR). Overall, we identified 16 significant PFAS-chronic disease associations after false discovery rate (FDR) correction, involving 7 PFAS and 6 chronic diseases. Specifically, each 1 ng/mL increase in perfluoroundecanoic acid (PFUnA) was associated with higher odds of heart attack (OR = 1.32, PFDR = 0.032), coronary heart disease (OR = 1.31, PFDR = 0.040), and non-melanoma cancer (OR = 1.22, PFDR = 0.046). Non-linear analyses showed that, 6 PFAS were significantly associated with colorectal cancer. PFAS mixture analyses consistently indicated increased risks of cardiovascular diseases, hypertension, high cholesterol, and metabolic dysfunction. Perfluorononanoic acid (PFNA) was identified as the dominant contributor to the positive mixture effect (31.8-52.7%), as evidenced by several machine learning methods. Our findings provide important evidence of associations between PFAS exposure and multiple chronic diseases, and may contribute to the development of precision management strategies for chronic diseases prevention.
中文摘要:全氟和多氟烷基物质(PFAS)是常见于消费品的持久性化学物质。尽管对其健康影响的担忧日益增加,但其与人类慢性疾病的关联仍不明确。我们纳入10,093名参与者,以探讨8种PFAS与40种慢性疾病之间的关联。采用多变量logistic回归和限制性立方样条(RCS)模型评估线性和非线性关联,并进一步使用加权分位数和回归(WQS)、基于分位数的g计算(q g-comp)和贝叶斯核机器回归(BKMR)评估混合效应。总体而言,在错误发现率(FDR)校正后,我们识别出16个显著的PFAS-慢性疾病关联,涉及7种PFAS和6种慢性疾病。具体而言,全氟十一烷酸(PFUnA)每增加1 ng/mL,与心脏病发作(OR=1.32,PFDR=0.032)、冠心病(OR=1.31,PFDR=0.040)和非黑色素瘤癌症(OR=1.22,PFDR=0.046)的较高几率相关。非线性分析显示,6种PFAS与结直肠癌显著相关。PFAS混合物分析一致表明,心血管疾病、高血压、高胆固醇和代谢功能障碍的风险增加。多种机器学习方法证明,全氟壬酸(PFNA)被确定为正向混合效应的主要贡献者(31.8-52.7%)。我们的研究结果为PFAS暴露与多种慢性疾病之间的关联提供了重要证据,并可能有助于制定慢性病预防的精准管理策略。
Ophthalmology IF 10.9 2026-10 PMID: 42203133
To investigate the potential impact of ocular inflammation on development of antiadalimumab antibodies (AAAs) in patients with systemic autoimmune diseases treated with adalimumab. Retrospective case-control study. Patients who were treated with adalimumab for various autoimmune conditions for at least 6 months and were tested for adalimumab levels, AAA, or both from June 2005 through May 2024. The Stanford Research Repository database, a clinical data warehouse that aggregates electronic health records from Stanford Health Care, Stanford Children's Health, and affiliated clinics, was used to identify eligible participants. Demographic data, systemic diagnoses, ocular involvement, and prior and concurrent treatment also were collected. Subsequently, univariable and multivariable logistic regression analyses were conducted to identify factors associated with AAA development. The correlation of AAAs with ocular inflammation and the proportion of patients with positive AAA findings in the study cohort. Among 704 patients, 151 patients (21.5%) demonstrated AAAs. The group was predominantly female compared with the AAA-negative group (60.9% vs. 47.0%; adjusted odds ratio [aOR], 1.75; 95% confidence interval [CI], 1.07-2.85; P = 0.024). On multivariable analysis, ocular inflammation (aOR, 2.19; 95% CI, 1.19-4.02; P = 0.011), female sex (aOR, 1.75; 95% CI, 1.08-2.85; P = 0.024), and adalimumab interruption (aOR, 1.74; 95% CI, 1.03-2.94; P = 0.038) remained independent risk factors for AAA formation. Prior biologic therapy other than tumor necrosis factor (TNF)-α inhibitors was protective (aOR, 0.27; 95% CI, 0.08-0.98; P = 0.046), although prior TNF-α inhibitor exposure remained a risk factor (aOR, 2.11; 95% CI, 1.25-3.55; P = 0.005). Ocular inflammation in patients with autoimmune disorders is associated with an increased risk of AAA formation, prospective studies are needed to determine whether this reflects a mechanistic relationship and whether therapeutic drug monitoring in this subgroup improves clinical outcomes. Notably, more than one-fifth of patients receiving adalimumab in this cohort demonstrated AAAs. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
中文摘要:探讨眼部炎症对接受阿达木单抗治疗的全身性自身免疫病患者产生抗阿达木单抗抗体(AAAs)的潜在影响。回顾性病例对照研究。纳入2005年6月至2024年5月期间因各种自身免疫性疾病接受阿达木单抗治疗至少6个月、并检测过阿达木单抗水平、AAA或两者均检测的患者。使用Stanford Research Repository数据库,这是一个汇总Stanford Health Care、Stanford Children's Health及附属诊所电子健康记录的临床数据仓库,用于识别符合条件的参与者。还收集了人口学数据、全身性诊断、眼部受累以及既往和同期治疗情况。随后进行单变量和多变量logistic回归分析,以识别与AAA产生相关的因素。研究队列中AAAs与眼部炎症的相关性及AAA阳性患者的比例。在704例患者中,151例(21.5%)检出AAAs。与AAA阴性组相比,该组以女性为主(60.9% vs. 47.0%;校正比值比[aOR],1.75;95%置信区间[CI],1.07-2.85;P = 0.024)。多变量分析显示,眼部炎症(aOR,2.19;95% CI,1.19-4.02;P = 0.011)、女性(aOR,1.75;95% CI,1.08-2.85;P = 0.024)和阿达木单抗中断(aOR,1.74;95% CI,1.03-2.94;P = 0.038)仍是AAA形成的独立危险因素。既往接受过肿瘤坏死因子(TNF)-α抑制剂以外的生物制剂具有保护作用(aOR,0.27;95% CI,0.08-0.98;P = 0.046),但既往暴露于TNF-α抑制剂仍是危险因素(aOR,2.11;95% CI,1.25-3.55;P = 0.005)。自身免疫性疾病患者的眼部炎症与AAA形成风险增加相关,需要前瞻性研究来确定这是否反映机制性关系,以及该亚组中的治疗药物监测是否改善临床结局。值得注意的是,该队列中超过五分之一的接受阿达木单抗治疗的患者检出AAAs。专有或商业披露可参见本文末尾的脚注和披露部分。
Biosensors & bioelectronics IF 11.8 2026-10-01 PMID: 42161118
Tumor-derived exosomes carry multidimensional molecular cargo, including surface proteins, microRNAs, and lipids that encode tumor identity and disease dynamics. These features support their application as biomarkers for liquid biopsy-based cancer diagnostics. Circulating tumor DNA undergoes rapid nuclease-mediated degradation, whereas exosomes retain stable molecular information that reflects the proteomic, transcriptomic, and metabolic states of parent tumor cells. However, clinical translation of exosome-based sensing remains limited by variability in isolation, biological heterogeneity, and the analytical difficulty of detecting low-abundance biomarkers in clinical samples. In this review, we examine cancer-specific exosomal signatures across breast, lung, colorectal, and gastric cancers and evaluate biosensing platforms for exosomal biomarker profiling. We integrate engineering principles, clinical performance metrics, and AI-assisted analysis across complementary biosensing modalities to establish a cross-platform analytical framework. We compare optical platforms based on surface plasmon resonance, localized surface plasmon resonance, and surface-enhanced Raman scattering with photoluminescence- and electrochemical-based platforms in terms of sensitivity, clinical compatibility, and translational potential. Furthermore, we examine artificial intelligence (AI)-assisted biosensing frameworks, including classical machine learning classifiers, deep convolutional networks, ensemble models, explainable AI methods, and large language model interfaces. We evaluate how each framework addresses high-dimensional spectral complexity, nonlinear relationships among signals, and inter-patient variability in exosomal data. Finally, we identify remaining challenges, such as the lack of standardized isolation protocols and the absence of large-scale clinical validation. We further highlight minimal residual disease monitoring and early-stage cancer detection as important and underexplored directions for AI-integrated exosomal biosensing in precision oncology.
中文摘要:肿瘤来源外泌体携带多维分子货物,包括表面蛋白、microRNA和脂质,这些分子编码肿瘤身份和疾病动态。这些特征支持其作为液体活检癌症诊断生物标志物的应用。循环肿瘤DNA会经历核酸酶介导的快速降解,而外泌体保留稳定的分子信息,反映亲本肿瘤细胞的蛋白质组、转录组和代谢状态。然而,基于外泌体的传感技术的临床转化仍受限于分离方法变异、生物学异质性以及检测临床样本中低丰度生物标志物的分析难度。在本综述中,我们考察乳腺癌、肺癌、结直肠癌和胃癌中癌症特异性外泌体特征,并评估用于外泌体生物标志物谱分析的生物传感平台。我们整合工程学原理、临床性能指标和AI辅助分析,涵盖互补的生物传感模式,以建立跨平台分析框架。我们比较基于表面等离子体共振、局域表面等离子体共振和表面增强拉曼散射的光学平台与光致发光和电化学平台在灵敏度、临床兼容性和转化潜力方面的表现。此外,我们考察人工智能(AI)辅助的生物传感框架,包括经典机器学习分类器、深度卷积网络、集成模型、可解释AI方法和大型语言模型接口。我们评估各框架如何应对外泌体数据中的高维光谱复杂性、信号间非线性关系以及患者间变异性。最后,我们指出仍存在的挑战,如缺乏标准化分离方案和缺乏大规模临床验证。我们进一步强调微小残留病监测和早期癌症检测是AI整合外泌体生物传感在精准肿瘤学中重要且探索不足的方向。

基础研究 (41篇)

Signal transduction and targeted therapy IF 81.2 2026-10-08 PMID: 42844247
Tumor metastasis is the leading cause of death for more than 90% of cancer patients, with colorectal cancer (CRC) mainly spreading to the liver. The colon and liver possess distinct nutritional microenvironments, yet how these differences shape the tumor immune landscape remains unclear. Using single-cell analysis of autologous samples from CRC patients with liver metastases, we identified a distinct CD177+GK+ regulatory T (Treg) cell subset in metastatic lesions. Spatial transcriptomics revealed that these GK+ Tregs localize at the tumor-adjacent interface and interact with immunosuppressive macrophages. Moreover, a selective clonal selection was observed in the metastatic niche, leading to the super-amplification of metastasis-associated clones of GK+ Tregs, suggesting a dominant role of these clones in metastatic immune evasion. Mechanistically, glycerol-derived lactate promotes H4K5 histone lactylation, which upregulates FOXP3 and subsequently GK expression, creating a positive feedback loop that amplifies Treg immunosuppressive activity. Blocking the glycerol metabolic pathway in Tregs combined with anti-PD-1 therapy synergistically curbs tumor progression. Pan-cancer analyses further confirm the potent suppressive activity of CD177+GK+ Tregs across multiple cancer types. Collectively, our findings highlight glycerol metabolism and histone lactylation as critical drivers of Treg-mediated immune evasion, offering new strategies to reprogram the immunosuppressive tumor microenvironment for enhanced cancer therapy.
中文摘要:肿瘤转移是超过90%癌症患者的主要死亡原因,其中结直肠癌(CRC)主要转移至肝脏。结肠和肝脏具有不同的营养微环境,但这些差异如何塑造肿瘤免疫景观仍不清楚。通过对伴有肝转移的CRC患者自体样本进行单细胞分析,我们在转移病灶中鉴定出一个独特的CD177+GK+调节性T(Treg)细胞亚群。空间转录组学显示,这些GK+ Treg定位于肿瘤邻近界面,并与免疫抑制性巨噬细胞相互作用。此外,在转移微环境中观察到选择性克隆选择,导致GK+ Treg的转移相关克隆超级扩增,提示这些克隆在转移免疫逃逸中起主导作用。机制上,甘油来源的乳酸促进H4K5组蛋白乳酸化,进而上调FOXP3并随后上调GK表达,形成一个正反馈回路,增强Treg的免疫抑制活性。阻断Treg中的甘油代谢通路联合抗PD-1治疗可协同抑制肿瘤进展。泛癌分析进一步证实CD177+GK+ Treg在多种癌症类型中具有强效抑制活性。总之,我们的研究结果强调甘油代谢和组蛋白乳酸化是Treg介导免疫逃逸的关键驱动因素,为重编程免疫抑制性肿瘤微环境以增强癌症治疗提供了新策略。
Cancer cell IF 56.1 2026-10-07 PMID: 42843336
Chromatin dynamics shape gastric cancer at every stage. In this issue of Cancer Cell, Wang et al. uncover a premalignant chromatin state primed for oncogenic activation alongside a pseudo-gastric subtype that hijacks acid secretion to evade antitumor immunity, revealing gastric proton pumps as a potential therapeutic target.
中文摘要:染色质动态在胃癌的每一个阶段都发挥作用。在本期《Cancer Cell》中,Wang等人揭示了一种为致癌激活做好准备的癌前染色质状态,以及一种劫持酸分泌以逃避免疫监视的假性胃亚型,表明胃质子泵是潜在的治疗靶点。
Gut IF 24.6 2026-10-07 PMID: 41663153
Liver metastasis is a common and fatal event for patients with pancreatic ductal adenocarcinoma (PDAC). Dysregulated mitochondrial dynamics reshape biological processes, including metabolism reprogramming, which disrupts immune cell function and promotes metastatic progression. To identify key drivers that reprogramme PDAC mitochondrial function and its role in remodelling the immunosuppressive tumour microenvironment (TME) during PDAC liver colonisation. Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) loss-of-function screening, in vivo mouse model screening and in vitro anoikis-resistant cell selection were employed to identify key drivers during PDAC liver colonisation. PDAC organoids, metabolic flux analysis, single-cell RNA sequencing, spatial metabolomics and glutathione S-transferase (GST) pull-down assay were used to explore the regulation of mitochondrial fission process protein 1 (MTFP1) on PDAC liver colonisation and unravel the underlying mechanism. We revealed MTFP1, a protein that plays an important role in cell viability and mitochondrial dynamics, as a driver of PDAC liver colonisation. Mechanistically, MTFP1 is recognised as a novel ATP synthase modulator through its interaction with numerous ATP synthase subunits, thereby enhancing oxidative phosphorylation (OXPHOS). Increased mitochondrial fission and subsequent redox signalling (ROS production) upregulates solute carrier family A1 member 5 (SLC1A5) expression by activating the PI3K/AKT/c-MYC pathway, competing for glutamine uptake and impaired antitumour responses of CD8+ T cells. By performing virtual screening, we identified KPT 9274 (ATG-019) as an effective inhibitor of MTFP1. Limitation of glutamine uptake in PDAC cells or MTFP1 inhibition reverses the immunosuppressive TME and reduces liver colonisation of PDAC. Our data demonstrate that the enhanced MTFP1 expression leads to an upregulated glutamine-OXPHOS axis in PDAC liver colonisation. This metabolic shift is triggered by the ROS/PI3K/AKT/c-MYC/SLC1A5 pathway. Targeting MTFP1 may be a potential therapeutic strategy for PDAC patients with liver metastasis.
中文摘要:肝转移是胰腺导管腺癌(PDAC)患者常见且致命的事件。线粒体动力学失调会重塑生物学过程,包括代谢重编程,进而破坏免疫细胞功能并促进转移进展。为识别重编程PDAC线粒体功能的关键驱动因素及其在PDAC肝脏定植过程中重塑免疫抑制性肿瘤微环境(TME)中的作用,我们采用了全基因组成簇规律间隔短回文重复序列(CRISPR)功能缺失筛选、体内小鼠模型筛选和体外失巢凋亡抵抗细胞选择来识别PDAC肝脏定植过程中的关键驱动因素。我们使用PDAC类器官、代谢流分析、单细胞RNA测序、空间代谢组学和谷胱甘肽S-转移酶(GST)pull-down实验来探究线粒体裂变过程蛋白1(MTFP1)对PDAC肝脏定植的调控并阐明其潜在机制。我们发现MTFP1——一种在细胞活力和线粒体动力学中发挥重要作用的蛋白——是PDAC肝脏定植的驱动因素。在机制上,MTFP1通过与众多ATP合酶亚基相互作用而被认为是一种新型ATP合酶调节因子,从而增强氧化磷酸化(OXPHOS)。线粒体裂变增加及随后的氧化还原信号(ROS产生)通过激活PI3K/AKT/c-MYC通路上调溶质载体家族A1成员5(SLC1A5)表达,竞争性摄取谷氨酰胺并损害CD8+ T细胞的抗肿瘤反应。通过进行虚拟筛选,我们鉴定出KPT 9274(ATG-019)是MTFP1的有效抑制剂。限制PDAC细胞中的谷氨酰胺摄取或抑制MTFP1可逆转免疫抑制性TME并减少PDAC肝脏定植。我们的数据表明,MTFP1表达增强导致PDAC肝脏定植中谷氨酰胺-OXPHOS轴上调。这种代谢转变由ROS/PI3K/AKT/c-MYC/SLC1A5通路触发。靶向MTFP1可能是伴有肝转移的PDAC患者的一种潜在治疗策略。
Gut IF 24.6 2026-10-07 PMID: 41494804
Over 90% pancreatic cancers harbour activating kirsten rat sarcoma viral oncogene homolog (KRAS)mutations. However, monotherapies targeting the KRAS vertical pathway, with recently developed KRAS inhibitors or rapidly accelerated fibrosarcoma (RAF)/MEK/ERK inhibitors, have demonstrated limited clinical benefit. Therefore, there is an urgent need to identify novel therapeutic targets and combination strategies with KRAS inhibition. This study aims to identify pharmaceutical targets whose inhibition suppresses pancreatic ductal adenocarcinoma (PDAC) or potentiates KRAS inhibition, focusing on molecular vulnerabilities specific to KRAS-mutant PDAC. We integrated genome-wide clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 (CRISPR-associated Protein 9) dropout screens, large-scale genomic dependency datasets and pharmacological screens to identify molecular vulnerabilities in KRAS-mutant PDAC. Conditional knockout mouse models were used to assess the essentiality of candidate genes in pancreatic cancer. RNA sequencing, metabolomics/proteomics analysis and stable isotopic tracing were employed to investigate mechanisms underlying inosine monophosphate dehydrogenase 2 (IMPDH2) vulnerability. Additionally, proteolysis-targeting chimaera compounds targeting IMPDH2 were developed and evaluated in patient-derived organoid and xenograft models. Integrated screens revealed de novo guanine nucleotide biosynthesis (DNGB) as a vulnerability in KRAS-mutant PDAC, with IMPDH2 being the critical gene. Unexpectedly, IMPDH2 expression and activity are not driven by the KRAS vertical pathway. Consequently, IMPDH2 inhibition induces irreversible guanine nucleotide depletion that cannot be compensated for by mutant KRAS. Inducing guanine nucleotide depletion via targeting IMPDH2 for degradation inhibits PDAC and augments KRAS inhibitor efficacy in vitro and in vivo. These findings provide a rationale for developing combination therapies targeting KRAS and DNGB, highlighting the potential of purine nucleotide imbalance as a biomarker to guide the application of these therapies.
中文摘要:超过90%的胰腺癌携带激活性Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)突变。然而,针对KRAS垂直通路的单药治疗,包括新近开发的KRAS抑制剂或快速加速纤维肉瘤(RAF)/MEK/ERK抑制剂,临床获益有限。因此,亟需发现新的治疗靶点以及与KRAS抑制联合的策略。本研究旨在识别其抑制可抑制胰腺导管腺癌(PDAC)或增强KRAS抑制效果的药物靶点,重点关注KRAS突变PDAC特异的分子脆弱性。我们整合了全基因组成簇规律间隔短回文重复序列(CRISPR)/Cas9(CRISPR相关蛋白9)敲除筛选、大规模基因组依赖性数据集和药理学筛选,以识别KRAS突变PDAC中的分子脆弱性。使用条件性敲除小鼠模型评估候选基因在胰腺癌中的必要性。采用RNA测序、代谢组学/蛋白质组学分析和稳定同位素示踪研究次黄嘌呤核苷酸脱氢酶2(IMPDH2)脆弱性的机制。此外,开发了靶向IMPDH2的蛋白水解靶向嵌合体化合物,并在患者来源的类器官和异种移植模型中进行了评估。整合筛选揭示从头鸟嘌呤核苷酸生物合成(DNGB)是KRAS突变PDAC的一种脆弱性,其中IMPDH2是关键基因。出乎意料的是,IMPDH2的表达和活性并非由KRAS垂直通路驱动。因此,抑制IMPDH2诱导不可逆的鸟嘌呤核苷酸耗竭,突变KRAS无法代偿。通过靶向IMPDH2使其降解来诱导鸟嘌呤核苷酸耗竭,可在体外和体内抑制PDAC并增强KRAS抑制剂的疗效。这些发现为开发靶向KRAS和DNGB的联合治疗提供了依据,并突出了嘌呤核苷酸失衡作为指导这些疗法应用的生物标志物的潜力。
Advanced healthcare materials IF 11.0 2026-10-06 PMID: 42839295
Accurate detection of myocardial injury (MI) biomarkers for assessing anticancer drug-induced cardiotoxicity has long been constrained by insufficient capture efficiency and limited assay sensitivity. To address this challenge, we developed an electrochemiluminescence (ECL) aptasensor for the detection of cardiac troponin I (cTnI) based on a two-step sequential assembly strategy. DNA nanotetrahedron (NTH)- assembled aptamers were immobilized onto magnetic beads to form multivalent capture probes for efficient target enrichment via magnetic separation. Meanwhile, a synergistic signal probe was constructed by functionalizing terbium-based metal-organic frameworks (Tb-MOF) loaded with cadmium sulfide quantum dots (CdS QDs) with single-stranded aptamers. Specific recognition of cTnI forms a sandwich-like complex, generating a robust ECL signal for quantitative readout. A systematic comparison between one-step and two-step incubation formats revealed that the latter offers a wider linear range and a lower detection limit (0.04 pg mL-1), owing to its cleaner binding environment and reduced steric interference. Importantly, the platform was successfully applied to quantify target cTnI at cellular, animal, and clinical sample levels, demonstrating the capability for multilevel detection of drug-induced MI. These findings establish a reliable tool for evaluating drug-induced MI with high sensitivity and translational versatility, advancing precision medicine in cancer therapy.
中文摘要:准确检测心肌损伤(MI)生物标志物以评估抗癌药物诱导的心脏毒性,长期以来受限于捕获效率不足和检测灵敏度有限。为应对这一挑战,我们开发了一种基于两步顺序组装策略的电化学发光(ECL)适配体传感器,用于检测心肌肌钙蛋白I(cTnI)。将DNA纳米四面体(NTH)组装的适配体固定在磁珠上,形成多价捕获探针,通过磁分离实现高效靶标富集。同时,通过将负载硫化镉量子点(CdS QDs)的铽基金属有机框架(Tb-MOF)与单链适配体功能化,构建了协同信号探针。对cTnI的特异性识别形成三明治样复合物,产生强ECL信号用于定量读出。对一步法与两步法孵育模式的系统比较显示,后者具有更宽的线性范围和更低的检测限(0.04 pg mL-1),这归因于其更清洁的结合环境和更低的位阻干扰。重要的是,该平台已成功应用于细胞、动物和临床样本水平的目标cTnI定量,展示了对药物诱导MI进行多层次检测的能力。这些发现建立了一种可靠工具,可用于高灵敏度和转化通用性地评估药物诱导MI,推动癌症治疗中的精准医学。
Cancer cell IF 56.1 2026-10-06 PMID: 42838052
Chromatin remodeling is prominent in cancers, yet it remains obscure how chromatin dynamics underlies stepwise tumorigenesis and informs anti-cancer therapeutics. By decoding a large-scale chromatin accessibility atlas of 650 multistage samples from 439 patients, we delineate epigenetic switches spanning multistep gastric tumorigenesis. A cancer-resembling epigenetic priming state in intestinal metaplasia licenses subsequent tumor initiation. In advanced malignancies, inter-tumoral diversity stratifies three epigenomic subtypes. The proliferative and mesenchymal-inflammatory subtypes are sensitive to neoadjuvant immunotherapy, while the pseudo-gastric subtype is intrinsically drug resistant. Mechanistically, the refractory subtype is featured by a unique gastric lineage-mimicking phenotype, governed in part by FOSL2 to up-regulate H+/K+ ATPase transporters and sculpt an acidic milieu suppressing CD8+ T cells. Inhibition of this phenotype by either FOSL2 depletion or vonoprazan, a clinically available acid blocker, sensitizes immunotherapy. Collectively, these findings highlight that chromatin accessibility dynamics facilitates sequential tumorigenesis from gastric pre-cancer and defines subtypes exploitable to guide immunotherapy and overcome drug resistance.
中文摘要:染色质重塑在癌症中十分突出,然而染色质动态如何支撑逐步肿瘤发生并指导抗癌治疗仍不清楚。通过解析来自439例患者的650份多阶段样本的大规模染色质可及性图谱,我们描绘了跨多步骤胃肿瘤发生的表观遗传开关。肠上皮化生中一种类似癌症的表观遗传预启动状态,为后续肿瘤起始创造了条件。在晚期恶性肿瘤中,肿瘤间多样性将其分为三种表观基因组亚型。增殖型和间充质炎症型亚型对新辅助免疫治疗敏感,而假胃型亚型则具有内在耐药性。机制上,难治性亚型以独特的胃谱系模拟表型为特征,部分由FOSL2调控,上调H+/K+ ATP酶转运体并塑造抑制CD8+ T细胞的酸性微环境。通过FOSL2缺失或伏诺拉生(一种临床可及的抑酸剂)抑制该表型,可使免疫治疗增敏。总之,这些发现强调,染色质可及性动态促进从胃癌前病变开始的序贯肿瘤发生,并界定了可用于指导免疫治疗和克服耐药性的亚型。
Cell metabolism IF 37.0 2026-10-06 PMID: 42838034
How nutrients shape gene expression has remained a fundamental question. Wu et al.1 show that extracellular arginine directly remodels the tRNA-codon axis, controlling codon-dependent translation of major histocompatibility complex class I mRNA independently of canonical amino acid stress signaling. This nutrient-sensing mechanism regulates immunity in colorectal cancer and viral infection while revealing new opportunities for therapeutic intervention.
中文摘要:营养如何塑造基因表达一直是一个基本问题。Wu等人1表明,细胞外精氨酸直接重塑tRNA-密码子轴,以不依赖经典氨基酸应激信号的方式控制主要组织相容性复合体I类mRNA的密码子依赖性翻译。这种营养感应机制调控结直肠癌和病毒感染中的免疫,同时揭示了治疗干预的新机会。
Archives of toxicology IF 10.9 2026-10-05 PMID: 42834146
Heterocyclic aromatic amines (HAAs) are procarcinogens formed during the cooking of meat and fish and could potentially contribute to hepatocellular carcinoma. Although several HAAs are classified as possible or probable human carcinogens, most mechanistic studies have relied on rodent models, despite well-documented interspecies differences in HAA bioactivation by cytochrome P450 (CYP) isoforms. In this study, we investigated the regulation of CYP1A by the HAA 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) using complementary primary human hepatocytes and Hepoid® with HepaRG cells, a long-term 3D liver spheroid model. IQ at concentrations ranging from 0.1 to 20 µM strongly induced CYP1A1 and CYP1A2 expression and enzymatic activity following acute and chronic exposure, whereas other major hepatic CYP isoforms remained unaffected. This response was specific to IQ among other HAAs tested and to human hepatocytes and persisted for up to 28 days in 3D spheroids. IQ-induced CYP1A expression required transcriptional activation and involved the aryl hydrocarbon receptor (AhR). Using complementary pharmacological and genetic approaches, luciferase reporter assays and ligand-binding assays, we demonstrate that IQ is a direct AhR ligand that activates the canonical AhR-xenobiotic response element (XRE) signaling pathway in human hepatocytes. These findings indicate that IQ is a potent and selective inducer of CYP1A through the AhR and induces a sustained human-specific response upon repeated treatment. Persistent CYP1A induction and AhR activation may enhance the bioactivation of IQ and other co-occurring CYP1A substrates, highlighting the value of long-term human-relevant models to improve risk assessment of chemical carcinogens.
中文摘要:杂环芳香胺(HAAs)是肉类和鱼类烹饪过程中形成的前致癌物,可能促进肝细胞癌发生。尽管若干HAAs被归类为可能或很可能的人类致癌物,但大多数机制研究仍依赖啮齿动物模型,而已有充分证据表明不同物种间细胞色素P450(CYP)同工酶对HAA的生物活化存在差异。在本研究中,我们使用互补的原代人肝细胞以及Hepoid®与HepaRG细胞的长期3D肝球体模型,研究HAA 2-氨基-3-甲基咪唑并[4,5-f]喹啉(IQ)对CYP1A的调控。IQ在0.1至20 µM浓度范围内,在急性及慢性暴露后强烈诱导CYP1A1和CYP1A2的表达及酶活性,而其他主要肝脏CYP同工酶未受影响。该反应在所测试的其他HAAs中为IQ所特有,并且对人肝细胞具有特异性,且在3D球体中可持续长达28天。IQ诱导的CYP1A表达需要转录激活并涉及芳香烃受体(AhR)。通过互补的药理学和遗传学方法、荧光素酶报告基因实验及配体结合实验,我们证明IQ是直接的AhR配体,可在人肝细胞中激活经典的AhR-异物反应元件(XRE)信号通路。这些发现表明,IQ是一种通过AhR发挥作用的强效且选择性的CYP1A诱导剂,并在重复处理后诱导持续的人类特异性反应。持续的CYP1A诱导和AhR激活可能增强IQ及其他共存的CYP1A底物的生物活化,突显了长期人类相关模型在改进化学致癌物风险评估中的价值。
Experimental hematology & oncology IF 17.5 2026-10-03 PMID: 42829436
Approximately 20% of cholangiocarcinomas harbor KRAS mutations, with codon 12 variants accounting for most of the cases. Among these, G12V is associated with a poor prognosis, whereas G12D is the most frequent subtype. RMC-6236, a novel RAS (ON) multi-selective inhibitor targeting multiple KRAS codon 12 mutations, has shown promise in early clinical studies in KRAS-mutant cholangiocarcinomas. We evaluated the therapeutic efficacy of the novel RAS (ON) inhibitor RMC-6236 as a monotherapy and in combination with gemcitabine and the anti-EGFR antibody cetuximab in KRAS-mutant cholangiocarcinoma (CCA) models. Antitumor activity and signaling alterations were assessed using in vitro cell-based assays, western blot analysis, and in vivo xenograft models. RMC-6236 potently inhibited cell proliferation in KRAS-mutant (G12D and G12V) cell lines at nanomolar concentrations (10-30 nM) and effectively suppressed pERK signaling. Notably, RMC-6236 treatment was accompanied by increased pEGFR expression, indicating adaptive EGFR feedback activation as a potential mechanism of resistance. In vitro, combination treatments significantly enhanced growth inhibition compared with monotherapy. In xenograft models, RMC-6236 treatment induced dose-dependent tumor regression, whereas combination with cetuximab or gemcitabine further enhanced the antitumor efficacy. EGFR-mediated feedback represents a targetable vulnerability in KRAS-mutant cholangiocarcinomas. Targeting EGFR signaling attenuates adaptive feedback reactivation induced by pan-RAS (ON) inhibition and supports the clinical development of combination strategies with EGFR blockade or cytotoxic chemotherapy.
中文摘要:约20%的胆管癌存在KRAS突变,其中12号密码子变异占大多数。在这些变异中,G12V与不良预后相关,而G12D是最常见的亚型。RMC-6236是一种新型RAS (ON)多选择性抑制剂,靶向多种KRAS 12号密码子突变,在KRAS突变胆管癌的早期临床研究中显示出前景。我们在KRAS突变胆管癌(CCA)模型中评估了新型RAS (ON)抑制剂RMC-6236单药以及与吉西他滨和抗EGFR抗体西妥昔单抗联合治疗的疗效。采用体外细胞实验、蛋白质印迹分析和体内异种移植模型评估抗肿瘤活性和信号改变。RMC-6236在纳摩尔浓度(10-30 nM)下强效抑制KRAS突变(G12D和G12V)细胞系的细胞增殖,并有效抑制pERK信号。值得注意的是,RMC-6236治疗伴随pEGFR表达升高,提示适应性EGFR反馈激活是潜在耐药机制。在体外,与单药治疗相比,联合治疗显著增强生长抑制。在异种移植模型中,RMC-6236治疗诱导剂量依赖性肿瘤消退,而与西妥昔单抗或吉西他滨联合进一步增强了抗肿瘤疗效。EGFR介导的反馈是KRAS突变胆管癌中可靶向的脆弱点。靶向EGFR信号可减弱泛RAS (ON)抑制诱导的适应性反馈再激活,并支持与EGFR阻断或细胞毒性化疗联合策略的临床开发。
Cell metabolism IF 37.0 2026-10-02 PMID: 42826714
Fungi are crucial components of the human gut microbiota. Here, we investigated the role of fungi in metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma (MASLD-HCC). Rhizopus arrhizus was the top enriched fungus across the progression from MASLD to MASLD-HCC, accelerating tumorigenesis in multiple mouse models. R. arrhizus-conditioned medium increased cell proliferation while reducing cell cycle arrest and apoptosis in human MASLD-HCC cells. Kynurenic acid (KYNA) was identified as the crucial metabolite generated from R. arrhizus, and its upregulation was confirmed in portal vein, liver tissues, and stools of R. arrhizus-treated mice. KYNA promoted the proliferation of MASLD-HCC cells and accelerated tumorigenesis in mice. Mechanistically, KYNA directly bound to IQ motif containing GTPase activating protein 1 (IQGAP1) in tumor cells and activated the oncogenic mitogen-activated protein kinase (MAPK) signaling pathway, thereby facilitating MASLD-HCC development. In summary, R. arrhizus is a pathogenic fungus that promotes MASLD-HCC by producing KYNA. Blocking this host-fungi interaction is a potential therapeutic strategy to suppress MASLD-HCC.
中文摘要:真菌是人类肠道微生物群的重要组成部分。本研究探讨了真菌在代谢功能障碍相关脂肪性肝病相关肝细胞癌(MASLD-HCC)中的作用。少根根霉(Rhizopus arrhizus)是在从MASLD向MASLD-HCC进展过程中富集程度最高的真菌,并在多种小鼠模型中加速肿瘤发生。少根根霉条件培养基可促进人MASLD-HCC细胞增殖,同时减少细胞周期阻滞和凋亡。犬尿喹啉酸(KYNA)被鉴定为少根根霉产生的关键代谢物,并且在少根根霉处理小鼠的门静脉、肝组织和粪便中证实其上调。KYNA促进MASLD-HCC细胞增殖并加速小鼠肿瘤发生。机制上,KYNA直接结合肿瘤细胞中的含IQ基序GTP酶激活蛋白1(IQGAP1),激活致癌性促分裂原活化蛋白激酶(MAPK)信号通路,从而促进MASLD-HCC发展。总之,少根根霉是一种通过产生KYNA促进MASLD-HCC的致病真菌。阻断这种宿主-真菌相互作用是抑制MASLD-HCC的潜在治疗策略。
Cancer research IF 22.6 2026-10-02 PMID: 42826094
Tumors display marked similarities with embryos, exploiting embryonic developmental programs. Beyond the embryo, the placenta also shares features with malignant tumors, such as invasion, immune evasion, and rapid nutrient exchange, highlighting the need for mechanistic investigations of tumor development through the lens of placental biology. In this study, by screening placental-specific genes with aberrant expression in hepatocellular carcinoma (HCC), we found that the paternally expressed gene 10 (PEG10, a retrovirus-like gene) was overexpressed in HCC and associated with poor patient prognosis. Liver-specific deletion of Peg10 significantly impeded hepatocarcinogenesis and tumor progression in a hydrodynamic tail vein injection-induced HCC mouse model. PEG10 drove tumor cells to co-opt the metabolic phenotype of trophoblast cells by upregulating key glucose metabolic regulators glucose transporter 1 (GLUT1) and hexokinase 2 (HK2). Mechanistically, as an RNA-binding protein (RBP), PEG10 inhibited the Staufen1-mediated mRNA decay (SMD) pathway, stabilizing GLUT1 and HK2 mRNA to enhance glucose uptake and aerobic glycolysis. Furthermore, retinoic acid pharmacologically suppressed PEG10 expression, effectively abrogating the adaptive metabolic advantage and acting synergistically with sorafenib to restrict tumor growth. Collectively, this study reveals how HCC aberrantly reactivates the placental gene PEG10 to orchestrate oncogenic glucose uptake and metabolism, identifying it as a compelling therapeutic target for metabolic intervention in cancer.
中文摘要:肿瘤与胚胎表现出显著相似性,会利用胚胎发育程序。除胚胎外,胎盘也与恶性肿瘤具有共同特征,如侵袭、免疫逃逸和快速营养交换,这凸显了从胎盘生物学角度对肿瘤发生进行机制研究的必要性。在本研究中,我们通过筛选在肝细胞癌(HCC)中异常表达的胎盘特异性基因,发现父源表达基因10(PEG10,一种类逆转录病毒基因)在HCC中过表达,并与患者不良预后相关。在流体动力学尾静脉注射诱导的HCC小鼠模型中,肝特异性敲除Peg10可显著阻碍肝癌发生和肿瘤进展。PEG10通过上调关键葡萄糖代谢调节因子葡萄糖转运蛋白1(GLUT1)和己糖激酶2(HK2),驱动肿瘤细胞采用滋养层细胞的代谢表型。机制上,作为一种RNA结合蛋白(RBP),PEG10抑制Staufen1介导的mRNA降解(SMD)通路,稳定GLUT1和HK2 mRNA,从而增强葡萄糖摄取和有氧糖酵解。此外,维甲酸可在药理学上抑制PEG10表达,有效消除这种适应性代谢优势,并与索拉非尼协同作用以限制肿瘤生长。总之,本研究揭示了HCC如何异常重新激活胎盘基因PEG10,以协调致癌性葡萄糖摄取和代谢,并将其确定为癌症代谢干预的一个有吸引力的治疗靶点。
Molecular biomedicine IF 13.0 2026-10-02 PMID: 42825856
Bile acids (BAs), cholesterol-derived amphipathic metabolites which are traditionally regarded as digestive surfactants, are now recognized as pleiotropic signaling molecules that act through ligand-, receptor-, and tissue-specific mechanisms to maintain systemic homeostasis. They exert biological functions via nuclear receptors (FXR, PXR, VDR, CAR) and membrane receptors (TGR5, S1PR2, MRGPRX4). These receptors activate transcriptional and membrane-initiated programs, including FXR-SHP/FGF19 feedback, TGR5-cAMP-PKA signaling, S1PR2-ERK/AKT/RhoA pathways, MRGPRX4-dependent Ca2⁺ signaling, PXR/CAR/VDR-driven detoxification responses, and non-receptor-mediated membrane and mitochondrial stress pathways. This review discusses how the diversity of BA structures, hepatic synthesis, conjugation, transportation, enterohepatic circulation, and microbiota-mediated transformation generates receptor- and tissue-specific signals. Furthermore, we summarize the physiological functions of BA signaling in lipid, glucose, and energy metabolism, intestinal epithelial integrity, mucosal immunity, neuroendocrine regulation, musculoskeletal adaptation, and renal water-salt balance. Additionally, we discuss the effects of disrupted BA signaling on cholestatic and metabolic liver diseases, alcohol-associated liver disease, hepatocellular carcinoma, inflammatory bowel disease, BA diarrhea, colorectal cancer, obesity, type 2 diabetes, atherosclerosis, and biliary tract diseases. Finally, the therapeutic strategies that modulate BA signaling, including the use of FXR and TGR5 agonists, FGF19 analogues, transporter inhibitors, enzyme-targeting methods, microbiota-based treatments, and hydrophilic BA therapies, are evaluated. By categorizing BA biology according to the production of ligands, receptor activation, tissue responses, and disease mechanisms, this review highlights BA signaling as an integrated regulatory network and a tractable therapeutic axis in health and disease.
中文摘要:胆汁酸(BAs)是胆固醇衍生的两亲性代谢物,传统上被视为消化表面活性剂,如今被认为是通过配体、受体和组织特异性机制发挥作用的多效性信号分子,以维持全身稳态。它们通过核受体(FXR、PXR、VDR、CAR)和膜受体(TGR5、S1PR2、MRGPRX4)发挥生物学功能。这些受体激活转录性和膜启动的程序,包括FXR-SHP/FGF19反馈、TGR5-cAMP-PKA信号、S1PR2-ERK/AKT/RhoA通路、MRGPRX4依赖性Ca2⁺信号、PXR/CAR/VDR驱动的解毒反应以及非受体介导的膜和线粒体应激通路。本综述讨论BA结构的多样性、肝脏合成、结合、转运、肠肝循环以及微生物群介导的转化如何产生受体和组织特异性信号。此外,我们总结BA信号在脂质、葡萄糖和能量代谢、肠上皮完整性、黏膜免疫、神经内分泌调节、肌肉骨骼适应以及肾脏水盐平衡中的生理功能。我们还讨论BA信号紊乱对胆汁淤积性和代谢性肝病、酒精相关性肝病、肝细胞癌、炎症性肠病、胆汁酸性腹泻、结直肠癌、肥胖、2型糖尿病、动脉粥样硬化和胆道疾病的影响。最后,评估调节BA信号的治疗策略,包括使用FXR和TGR5激动剂、FGF19类似物、转运体抑制剂、酶靶向方法、基于微生物群的治疗以及亲水性BA疗法。通过根据配体产生、受体激活、组织反应和疾病机制对BA生物学进行分类,本综述强调BA信号是一个整合的调控网络,也是健康和疾病中可干预的治疗轴。
Science advances IF 13.9 2026-10-02 PMID: 42814834
In situ cancer vaccines exhibit promising therapeutic potential; however, their efficacy is constrained by limited antigen release, suboptimal spatiotemporal immune coordination, and adaptive immune resistance. In this study, we identify zinc ions (Zn2+) as synergistic agents with chemotherapeutics in modulating PANoptosis and immune signaling pathways. Capitalizing on this concept, a chemo-metallic nanodriver was developed for effective in situ cancer vaccination. This system used zinc-aluminum layered double hydroxides as the structural base and efficiently loaded cisplatin (DDP) and indocyanine green via coordination-driven polymerization, forming a spatiotemporally controllable nanodriver, which facilitated the simultaneous release of drug and metal ions upon photoactivation. The released Zn2+ specifically disrupted zinc homeostasis in tumor cells, inducing mitochondrial dysfunction. This effect acted in concert with DDP-mediated DNA damage, not only effectively activating the cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) pathway but also promoting the assembly and activation of AIM2-PANoptosome complex to execute PANoptosis. This STING-PANoptosis cascade led to a burst release of damage-associated molecular patterns, markedly enhanced dendritic cell maturation, and stimulated the secretion of pro-inflammatory cytokines. Furthermore, the nanodriver elicited a robust antitumor immune response and established durable immune memory in mouse models. These findings not only provide an optimized strategy for precise immunotherapy of gastric cancer but also increase the understanding of the applications of metal ion immunology and PANoptosis in disease intervention.
中文摘要:原位癌症疫苗展现出有前景的治疗潜力;然而,其疗效受到抗原释放有限、时空免疫协调欠佳以及适应性免疫抵抗的制约。在本研究中,我们发现锌离子(Zn2+)可作为化疗药物的协同剂,调控PANoptosis和免疫信号通路。基于这一概念,开发了一种化学-金属纳米驱动器,用于有效的原位癌症疫苗接种。该系统以锌铝层状双氢氧化物为结构基础,通过配位驱动聚合高效负载顺铂(DDP)和吲哚菁绿,形成时空可控的纳米驱动器,在光激活下促进药物和金属离子的同步释放。释放的Zn2+特异性扰乱肿瘤细胞中的锌稳态,诱导线粒体功能障碍。该效应与DDP介导的DNA损伤协同作用,不仅有效激活cGAS-STING(环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子)通路,还促进AIM2-PANoptosome复合物的组装和激活,从而执行PANoptosis。这一STING-PANoptosis级联反应导致损伤相关分子模式爆发释放,显著增强树突状细胞成熟,并刺激促炎细胞因子分泌。此外,该纳米驱动器在小鼠模型中引发了强烈的抗肿瘤免疫应答,并建立了持久的免疫记忆。这些发现不仅为胃癌的精准免疫治疗提供了优化策略,也加深了对金属离子免疫学和PANoptosis在疾病干预中应用的理解。
Science advances IF 13.9 2026-10-02 PMID: 42814826
Second near-infrared (NIR-II; 1000 to 1700 nanometers) aggregation-induced emission luminogens (AIEgens) hold great promise for imaging-guided precision tumor phototherapy yet are limited by the intrinsic trade-off between fluorescence brightness and photothermal performance. Existing design strategies often yield complex molecular structures while inadequately addressing this trade-off. Herein, we propose a "Minor Tweaks, Major Leaps" concept: Simple modification of the star NIR-II AIEgen 2TT-oC6B (less than 5% change in molecular weight) markedly improves both NIR-II fluorescence brightness and photothermal performance. The thus-obtained new NIR-II AIEgen, ST-CZ, ranks among leading phototheranostic agents, exhibiting a long emission maximum at 1082 nanometers, a high fluorescence quantum yield of 4.3%, and a great photothermal conversion efficiency of 69% in nanoparticles. Leveraging these superior properties, ST-CZ enables cerebrovascular imaging with an advanced resolution of 19.0 micrometers, and the derived multifunctional platform achieves tumor progression-associated vascular remodeling visualization and efficient metastatic tumor ablation via synergistic photothermal immunotherapy. This work provides a robust strategy for developing high-performance NIR-II AIEgens for advanced biomedical applications.
中文摘要:第二近红外(NIR-II;1000至1700纳米)聚集诱导发光发光体(AIEgens)在成像引导的精准肿瘤光治疗中具有巨大前景,但受限于荧光亮度与光热性能之间的内在权衡。现有设计策略通常产生复杂的分子结构,却未能充分解决这一权衡。在此,我们提出「小幅调整,重大飞跃」概念:对明星NIR-II AIEgen 2TT-oC6B进行简单修饰(分子量变化小于5%),即可显著提高NIR-II荧光亮度和光热性能。由此获得的新型NIR-II AIEgen ST-CZ位居领先的光诊疗剂之列,在纳米颗粒中表现出1082纳米的较长最大发射波长、4.3%的高荧光量子产率和69%的优异光热转换效率。利用这些优越性质,ST-CZ能够以19.0微米的高分辨率实现脑血管成像,并且衍生的多功能平台通过协同光热免疫治疗实现了肿瘤进展相关血管重塑的可视化以及高效转移瘤消融。这项工作为开发用于先进生物医学应用的高性能NIR-II AIEgens提供了稳健策略。
Nature methods IF 28.3 2026-10 PMID: 42834226
Cells in complex organisms function through extensive interactions, yet mapping these interaction networks at scale remains challenging. Here we present CCI-seq, a high-throughput method to unbiasedly capture cell-cell interactions across a proximity continuum by combining cell clump combinatorial indexing with single-cell sequencing. CCI-seq identified known interactions and fine-grained cellular organization in mouse kidney and intestine, and uncovered aberrant interactions and disrupted spatial organization in adenomatous polyposis coli knockout (Apc-KO) intestines. Applied to human colorectal cancer, it revealed subtype-specific interactions linked to clinical classifications. By leveraging a single-cell RNA sequencing backbone, CCI-seq achieves deep transcriptome coverage, enabling analysis of molecular states arising from interactions. This functional resolution revealed that interacting cells associate with distinct transcriptional programs-driving ion transport in kidney, antigen presentation in Apc-KO villi and NF-κB inflammatory activation in colorectal cancer. Thus, CCI-seq provides a scalable platform to unveil large-scale cell-cell interaction networks and dissect their molecular and functional impacts, enhancing our understanding of complex multicellular systems.
中文摘要:复杂生物体中的细胞通过广泛的相互作用行使功能,但大规模绘制这些相互作用网络仍具挑战性。在此,我们提出CCI-seq,一种高通量方法,通过将细胞团组合索引与单细胞测序相结合,无偏地捕获跨越邻近连续区的细胞间相互作用。CCI-seq识别了小鼠肾脏和肠道中已知的相互作用及精细细胞组织结构,并揭示了腺瘤性息肉病基因敲除(Apc-KO)肠道中的异常相互作用和空间组织破坏。将其应用于人类结直肠癌时,它揭示了与临床分型相关的亚型特异性相互作用。借助单细胞RNA测序骨架,CCI-seq实现了深度转录组覆盖,从而能够分析由相互作用产生的分子状态。这种功能分辨率揭示,相互作用的细胞与不同的转录程序相关——在肾脏中驱动离子转运,在Apc-KO绒毛中驱动抗原呈递,在结直肠癌中驱动NF-κB炎症激活。因此,CCI-seq提供了一个可扩展平台,用于揭示大规模细胞间相互作用网络并解析其分子和功能影响,从而增进我们对复杂多细胞系统的理解。
Nature microbiology IF 18.7 2026-10-01 PMID: 42823533
Gut dysmotility is a common long-term effect of enterotoxigenic Bacteroides fragilis (ETBF) colonization but the underlying mechanisms are not clear. Here, using mouse colonization models, we found that ETBF-secreted B. fragilis toxin (BFT) causes loss of colonic myenteric neurons, which are crucial regulators of intestinal motility. BFT induced apoptosis in these neurons through the NOD1-RIPK2-CASP9-CASP3 pathway, leading to gut dysmotility that persisted even after the clearance of ETBF. Analyses of human inflammatory bowel disease and colorectal cancer patient cohorts showed a positive correlation between ETBF and Fusobacterium nucleatum abundance. In mice, F. nucleatum-derived 2-hydroxybutyric acid enhanced BFT production in ETBF by alleviating RprY-mediated suppression and aggravated neurotoxicity and dysmotility. This enteric neuron loss and dysmotility enhanced susceptibility to dextran sulfate sodium-induced colitis in mice. Therapeutically, a Bifidobacterium-based probiotic attenuated neuron toxicity and improved intestinal motility. Our findings reveal bacterial interactions regulating intestinal function and a potential clinical therapeutic approach to preventing outcomes of ETBF colonization.
中文摘要:肠道运动功能障碍是产肠毒素脆弱拟杆菌(ETBF)定植常见的长期后果,但其机制尚不清楚。在此,我们利用小鼠定植模型发现,ETBF分泌的脆弱拟杆菌毒素(BFT)导致结肠肌间神经元丢失,而这些神经元是肠道运动的关键调节者。BFT通过NOD1-RIPK2-CASP9-CASP3通路诱导这些神经元凋亡,导致即使清除ETBF后仍持续存在的肠道运动功能障碍。对人类炎症性肠病和结直肠癌患者队列的分析显示,ETBF与具核梭杆菌丰度呈正相关。在小鼠中,具核梭杆菌来源的2-羟基丁酸通过缓解RprY介导的抑制增强ETBF的BFT产生,并加重神经毒性和运动功能障碍。这种肠道神经元丢失和运动功能障碍增加了小鼠对硫酸葡聚糖钠诱导结肠炎的易感性。在治疗方面,一种基于双歧杆菌的益生菌减轻了神经元毒性并改善了肠道运动。我们的发现揭示了调节肠道功能的细菌相互作用,以及一种可能用于预防ETBF定植结局的临床治疗途径。
Pharmacological research IF 12.2 2026-10-01 PMID: 42822554
Reticulon-3 (RTN3) was initially studied as an endoplasmic reticulum (ER)-resident reticulon family protein involved in membrane shaping, apoptosis, and amyloid precursor protein processing. More recent work has considerably expanded this view and now places RTN3 at the intersection of ER remodeling, selective ER-phagy, cargo trafficking, lipid handling, and stress signaling. This shift is especially relevant to pharmacology, because RTN3 appears to exhibit heterogeneous effects across tissues and disease states: RTN3 upregulation is maladaptive in obesity, nonalcoholic fatty liver disease, cardiac lipotoxicity, post-myocardial infarction heart failure, and some vascular conditions, whereas RTN3 loss aggravates renal injury, renal fibrosis, and pulmonary fibrosis. Viral infection and hepatocellular carcinoma further illustrate that RTN3 can either support membrane remodeling programs or constrain disease progression, depending on the biological environment. In this review, we reorganize RTN3 biology around mechanism-driven processes and discuss how these processes converge on cardiometabolic, fibrotic, infectious, and oncologic phenotypes. Current evidence suggests that RTN3 is better regarded as a membrane organizing regulator with therapeutic potential rather than a disease specific marker. However, future efforts to target RTN3 will likely need to consider tissue type and pathway specificity.
中文摘要:Reticulon-3(RTN3)最初是作为内质网(ER)驻留的reticulon家族蛋白被研究,参与膜塑形、凋亡和淀粉样前体蛋白加工。近期研究显著拓展了这一认识,现将RTN3置于内质网重塑、选择性内质网自噬、货物运输、脂质处理和应激信号的交汇点。这一转变对药理学尤为重要,因为RTN3在不同组织和疾病状态下似乎表现出异质性效应:RTN3上调在肥胖、非酒精性脂肪性肝病、心脏脂毒性、心肌梗死后心力衰竭以及某些血管病变中具有适应不良作用,而RTN3缺失则加重肾损伤、肾纤维化和肺纤维化。病毒感染和肝细胞癌进一步表明,取决于生物环境,RTN3既可支持膜重塑程序,也可限制疾病进展。在这篇综述中,我们围绕机制驱动过程重新组织RTN3生物学,并讨论这些过程如何汇聚于心脏代谢、纤维化、感染和肿瘤表型。当前证据提示,RTN3更应被视为具有治疗潜力的膜组织调节因子,而非疾病特异性标志物。然而,未来靶向RTN3的努力可能需要考虑组织类型和通路特异性。
Cancer discovery IF 29.5 2026-10-01 PMID: 42817716
In this issue of Cancer Discovery, Chen and colleagues leverage single-cell RNA sequencing of neutrophils in the tumor microenvironment of colorectal cancer liver metastases to characterize neutrophil heterogeneity within the metastatic immune landscape. They show that the glucose-deprived metastatic microenvironment drives BHLHE40 upregulation in neutrophils, inducing a senescent tumor-associated neutrophil (TAN) population, TAN1, that actively promotes angiogenesis and excludes CD8+ T cells from the tumor, thereby supporting tumor growth and survival. See related article by Chen et al., p. 2130.
中文摘要:在本期《Cancer Discovery》中,Chen及其同事利用单细胞RNA测序对结直肠癌肝转移肿瘤微环境中的中性粒细胞进行分析,以刻画转移性免疫景观中的中性粒细胞异质性。他们表明,葡萄糖剥夺的转移微环境驱动中性粒细胞中BHLHE40上调,诱导出衰老性肿瘤相关中性粒细胞(TAN)群体TAN1,该群体积极促进血管生成并将CD8+ T细胞排除出肿瘤,从而支持肿瘤生长和存活。参见Chen等人第2130页的相关文章。
MedComm IF 14.1 2026-10 PMID: 42769546
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly aggressive phenotype and limited therapeutic options, primarily attributable to diagnostic delays and intrinsic chemotherapy resistance, thereby underscoring the critical need for the development of more effective therapeutic strategies. Tripterine (TP) is a natural compound with potent antitumor activity, but has shown limited clinical use due to its multi-organ toxicity. Here, we overcame this limitation by formulating TP into liposomes (TP-lipo). We evaluated the therapeutic potential of TP-lipo showing that TP-lipo exhibited antitumor activity in vitro (murine Pdx1-Cre/LSL-KrasG12D/+ /LSL-Trp53R172H/+ pancreatic cancer cells, KPC cells) and in vivo (PDAC mouse) models. TP-lipo reshaped the tumor immune microenvironment by promoting macrophage polarization toward the M1 phenotype, increasing the proportion of interferon-γ (IFN-γ)-secreting CD8+ T cells. In vitro, TP-lipo promoted IFN-γ and granzyme B production in CD8+ T cells, while TP-lipo-pretreated macrophages enhanced T-cell differentiation into cytotoxic T lymphocytes. Notably, combination therapy with TP-lipo and PD-1 antagonist exerted a synergistic antitumor effect and significantly prolonged median survival in PDAC-bearing mice. TP-lipo showed substantially lower toxicity than the free drug, highlighting its improved safety profile and therapeutic potential. Collectively, these findings suggest TP-lipo, particularly in combination with PD-1 blockade, as a promising therapeutic strategy for PDAC.
中文摘要:胰腺导管腺癌(PDAC)具有高度侵袭性的表型且治疗选择有限,这主要归因于诊断延迟和内在的化疗耐药,因此迫切需要开发更有效的治疗策略。雷公藤红素(TP)是一种具有强效抗肿瘤活性的天然化合物,但由于其多器官毒性,临床应用受限。在此,我们通过将TP制备成脂质体(TP-lipo)克服了这一局限。我们评估了TP-lipo的治疗潜力,结果显示TP-lipo在体外(小鼠Pdx1-Cre/LSL-KrasG12D/+ /LSL-Trp53R172H/+胰腺癌细胞,KPC细胞)和体内(PDAC小鼠)模型中均表现出抗肿瘤活性。TP-lipo通过促进巨噬细胞向M1表型极化、增加分泌干扰素-γ(IFN-γ)的CD8+ T细胞比例,重塑了肿瘤免疫微环境。在体外,TP-lipo促进CD8+ T细胞产生IFN-γ和颗粒酶B,而经TP-lipo预处理的巨噬细胞则增强T细胞向细胞毒性T淋巴细胞分化。值得注意的是,TP-lipo与PD-1拮抗剂联合治疗发挥了协同抗肿瘤效应,并显著延长了荷PDAC小鼠的中位生存期。TP-lipo的毒性明显低于游离药物,凸显了其改善的安全性特征和治疗潜力。总之,这些发现提示TP-lipo,尤其是与PD-1阻断联合,是PDAC的一种有前景的治疗策略。
Acta biomaterialia IF 10.4 2026-10 PMID: 42692233
This study examines the important role of neuro-tumoral crosstalk in oral squamous cell carcinoma (OSCC) progression and therapy. We identified that dorsal root ganglia (DRG)-secreted substance P (SP) activates a pro-metastatic Tacr1-Tlr7 neuroinflammatory axis. To therapeutically disrupt this axis, a multifunctional photosensitive hydrogel patch (PDA/Rop-Ce6@DA-HA) was engineered. This patch co-delivers the local anesthetic ropivacaine (Rop) to block SP release from neurons and the photosensitizer chlorin e6 (Ce6) for combined photothermal (PTT) and photodynamic therapy (PDT). Under near-infrared irradiation, the patch enabled controlled drug release and synergistic PTT/PDT effects. In orthotopic and subcutaneous OSCC models, this combinatorial strategy markedly reduced SP levels, inhibited the Tacr1-Tlr7 axis and downstream PI3K/Akt signaling, increased tumor cell apoptosis, and produced stronger antitumor effects. The results support a biomaterial-based strategy that combines local neuromodulation with phototherapy for OSCC treatment. STATEMENT OF SIGNIFICANCE: This study develops a photosensitive PDA/Rop-Ce6@DA-HA hydrogel patch that integrates photothermal therapy, photodynamic therapy, and local neural modulation for oral squamous cell carcinoma. By blocking DRG-derived substance P release and suppressing the SP-Tacr1-Tlr7 axis, the biomaterial targets neuro-tumoral crosstalk while enabling localized light-triggered tumor ablation. The work links biomaterial design with a defined neuroinflammatory mechanism and provides a combined strategy for improving oral cancer treatment.
中文摘要:本研究考察了神经-肿瘤串扰在口腔鳞状细胞癌(OSCC)进展和治疗中的重要作用。我们发现,背根神经节(DRG)分泌的P物质(SP)会激活促转移的Tacr1-Tlr7神经炎症轴。为从治疗上破坏该轴,构建了一种多功能光敏水凝胶贴片(PDA/Rop-Ce6@DA-HA)。该贴片共同递送局部麻醉药罗哌卡因(Rop)以阻断神经元释放SP,并递送光敏剂二氢卟吩e6(Ce6)以用于联合光热治疗(PTT)和光动力治疗(PDT)。在近红外照射下,该贴片实现药物控释和协同PTT/PDT效应。在原位和皮下OSCC模型中,这种联合策略显著降低SP水平,抑制Tacr1-Tlr7轴及下游PI3K/Akt信号,增加肿瘤细胞凋亡,并产生更强的抗肿瘤效应。结果支持一种基于生物材料的策略,该策略将局部神经调控与光疗相结合用于OSCC治疗。意义声明:本研究开发了一种光敏PDA/Rop-Ce6@DA-HA水凝胶贴片,其将光热治疗、光动力治疗和局部神经调控整合用于口腔鳞状细胞癌。通过阻断DRG来源的P物质释放并抑制SP-Tacr1-Tlr7轴,该生物材料靶向神经-肿瘤串扰,同时实现局部光触发肿瘤消融。该工作将生物材料设计与明确的神经炎症机制相联系,并提供了一种改善口腔癌治疗的联合策略。
Acta biomaterialia IF 10.4 2026-10 PMID: 42692231
Zirconium-based metal-organic framework (MOF-808) materials were selected as drug delivery carriers, with 5-fluorouracil (5-Flu) as the model drug. MOF-808@5-Flu drug-loaded carriers were designed and prepared at different ratios. The drug release behavior of the MOF-808@5-Flu nanocomposite was investigated under different pH conditions (7.4/6.5/5.0). The results showed that when the mass ratio of MOF-808 to 5-Flu was 1:0.25, the material released 55.56% of the drug within 50 h at pH 5.0, compared with 47.85% and 48.00% at pH 7.4 and 6.5, respectively. The drug release behavior was well fitted by the Higuchi model the Higuchi model. Cell and animal experiments demonstrated that MOF-808@5-Flu exhibited good biocompatibility and significantly inhibited the growth of Hepa1-6 cells, indicating its potential as a targeted nanocarrier to enhance therapeutic efficacy. Studies indicate that MOF-808@5-Flu induces cancer cell death through the apoptotic pathway. The catalytic activity of Zr4+ acted synergistically with the pharmacological effects of 5-Flu, generated a large amount of reactive oxygen species (ROS), significantly reducing tumor cell viability. Theoretical calculations indicated that MOF-808@5-Flu exhibits synergistic effects through multiple interactions, including π-π stacking, electrostatic attraction, and hydrophobic interactions. This results further highlights the advantages of MOF-808@5-Flu as a drug delivery platform. In summary, MOF-808@5-Flu shows great potential as a targeted nanocarrier for anticancer drug delivery. STATEMENT OF SIGNIFICANCE: Developed MOF-808@5-Flu nanocarriers with strong potential for targeted anticancer drug delivery. Achieved pH-responsive 5-Flu release, with the highest release rate of 55.56% at pH 5.0 within 50 h. Confirmed that the drug release profile follows the Higuchi model. Demonstrated good biocompatibility and effective inhibition of Hepa1-6 tumor cell growth. Revealed a "carrier-drug" synergistic mechanism driven by Zr4+ catalysis and multiple intermolecular interactions.
中文摘要:以锆基金属有机框架(MOF-808)材料作为药物递送载体,以5-氟尿嘧啶(5-Flu)为模型药物。设计并制备了不同比例的MOF-808@5-Flu载药载体。研究了MOF-808@5-Flu纳米复合材料在不同pH条件(7.4/6.5/5.0)下的药物释放行为。结果表明,当MOF-808与5-Flu的质量比为1:0.25时,材料在pH 5.0下50 h内释放55.56%的药物,而在pH 7.4和6.5下分别释放47.85%和48.00%。药物释放行为很好地符合Higuchi模型。细胞和动物实验表明,MOF-808@5-Flu具有良好的生物相容性,并显著抑制Hepa1-6细胞生长,表明其作为靶向纳米载体增强治疗效果的潜力。研究表明,MOF-808@5-Flu通过凋亡通路诱导癌细胞死亡。Zr4+的催化活性与5-Flu的药理作用协同,产生大量活性氧(ROS),显著降低肿瘤细胞活力。理论计算表明,MOF-808@5-Flu通过多种相互作用表现出协同效应,包括π-π堆积、静电吸引和疏水相互作用。这一结果进一步凸显了MOF-808@5-Flu作为药物递送平台的优势。总之,MOF-808@5-Flu作为靶向纳米载体用于抗癌药物递送显示出巨大潜力。意义声明:开发了具有强大靶向抗癌药物递送潜力的MOF-808@5-Flu纳米载体。实现了pH响应性5-Flu释放,在pH 5.0下50 h内最高释放率为55.56%。证实药物释放曲线符合Higuchi模型。证明了良好的生物相容性,并有效抑制Hepa1-6肿瘤细胞生长。揭示了由Zr4+催化和多种分子间相互作用驱动的「载体-药物」协同机制。
Molecular aspects of medicine IF 13.8 2026-10 PMID: 42641246
Pancreatitis is a complex inflammatory condition of the pancreas and can be classified into acute pancreatitis (AP) and chronic pancreatitis (CP). The pathogenesis of the disease remains unclear, and effective preventive or therapeutic strategies are currently lacking. Non-coding RNA (ncRNA) regulatory networks consist primarily of miRNAs, lncRNAs, and circRNAs, which precisely regulate gene expression through complex interactions and play a key role in fibrosis and inflammation. In terms of AP, ncRNAs could modulate the activity of pancreatic acinar cells, autophagic flux, inflammatory cell infiltration and the integrity of the intestinal mucosal barrier, which regulates local pancreatic and systemic inflammation. During the progression of CP, ncRNAs mediate the pancreatic persistent inflammation and collagen deposition by regulating the interactions between pancreatic stellate cells and immune cells. ncRNAs serve as promising non-invasive biomarkers for pancreatitis, enabling early diagnosis, severity stratification, complication prediction and differential diagnosis between CP and pancreatic cancer. Therapeutically, ncRNAs represent potential precision intervention targets due to their high regulatability and specificity, although ncRNA-based therapies currently remain at the preclinical stage. Key challenges such as delivery efficiency and targeting specificity must be addressed to facilitate clinical translation. Overall, ncRNAs offer a novel avenue for improving the clinical management of pancreatitis.
中文摘要:胰腺炎是胰腺的一种复杂炎症性疾病,可分为急性胰腺炎(AP)和慢性胰腺炎(CP)。该病发病机制尚不清楚,目前缺乏有效的预防或治疗策略。非编码RNA(ncRNA)调控网络主要由miRNA、lncRNA和circRNA组成,它们通过复杂的相互作用精确调控基因表达,并在纤维化和炎症中发挥关键作用。在AP方面,ncRNA可调节胰腺腺泡细胞活性、自噬流、炎症细胞浸润和肠黏膜屏障完整性,从而调控胰腺局部及全身炎症。在CP进展过程中,ncRNA通过调节胰腺星状细胞与免疫细胞之间的相互作用,介导胰腺持续性炎症和胶原沉积。ncRNA可作为胰腺炎有前景的非侵入性生物标志物,有助于早期诊断、严重程度分层、并发症预测以及CP与胰腺癌的鉴别诊断。在治疗方面,由于ncRNA具有高度可调控性和特异性,其代表潜在的精准干预靶点,尽管基于ncRNA的治疗目前仍处于临床前阶段。为促进临床转化,必须解决递送效率和靶向特异性等关键挑战。总体而言,ncRNA为改善胰腺炎的临床管理提供了新途径。
Redox biology IF 16.2 2026-10 PMID: 42617575
Chemotherapy resistance remains a significant challenge in colorectal cancer (CRC) treatment, with disrupted redox balance playing a central role. Here we identify CHTOP as a key regulator of oxidative stress and chemoresistance in CRC. Mechanistically, CHTOP promotes NRF2 transcriptional activity by recruiting the SENP3-containing 5FMC complex to deSUMOylate NRF2, thereby sustaining HO-1 expression and redox balance. Notably, CHTOP expression itself is tightly controlled by a feedback mechanism. The p52 isoform of PSIP1 inhibits CHTOP expression by interfering with HNRNPH1-mediated splicing, leading to CHTOP degradation via nonsense-mediated decay (NMD). Conversely, elevated oxidative stress stabilizes SENP3, which promotes deSUMOylation and degradation of p52, thereby relieving p52-mediated suppression of CHTOP expression. This establishes an oxidative stress-SENP3-p52-CHTOP feedback loop that fine-tunes CHTOP levels. In 5-FU-resistant CRC cells, CHTOP downregulation shifts cells into an elevated oxidative stress state, which correlates with reduced 5-FU sensitivity. Notably, either restoring CHTOP expression or further depleting CHTOP disrupts this redox balance and resensitizes resistant cells to 5-FU. These findings suggest that modulating CHTOP expression may offer a therapeutic strategy to overcome chemoresistance in CRC through redox regulation.
中文摘要:化疗耐药仍是结直肠癌(CRC)治疗中的重大挑战,氧化还原平衡紊乱在其中发挥核心作用。本研究发现CHTOP是CRC氧化应激和化疗耐药的关键调控因子。机制上,CHTOP通过募集含SENP3的5FMC复合物使NRF2去SUMO化,从而促进NRF2转录活性,进而维持HO-1表达和氧化还原平衡。值得注意的是,CHTOP表达本身受到反馈机制的严密调控。PSIP1的p52亚型通过干扰HNRNPH1介导的剪接抑制CHTOP表达,导致CHTOP经无义介导的mRNA降解(NMD)途径降解。相反,氧化应激升高可稳定SENP3,SENP3促进p52去SUMO化并使其降解,从而解除p52对CHTOP表达的抑制。这建立了一个氧化应激-SENP3-p52-CHTOP反馈环路,精细调节CHTOP水平。在5-FU耐药的CRC细胞中,CHTOP下调使细胞进入氧化应激升高的状态,这与5-FU敏感性降低相关。值得注意的是,恢复CHTOP表达或进一步耗竭CHTOP均可破坏这一氧化还原平衡,并使耐药细胞对5-FU重新敏感。这些发现提示,通过氧化还原调控来调节CHTOP表达可能为克服CRC化疗耐药提供一种治疗策略。
Carbohydrate polymers IF 13.2 2026-10-01 PMID: 42586632
In this study, we engineered pH/glutathione dual-responsive nanoparticles (LP/CC-Cu-Cur NPs) based on a poly-γ-glutamic acid (γ-PGA)/chitosan (CS) core-shell architecture for synergistic chemo/chemodynamic therapy of glioma. The nanoparticles feature a core of CC-Cu-Cur NPs, formed via Cu2+-coordinated self-assembly of caffeic acid-grafted CS and curcumin (Cur), encapsulated within a phenylboronic acid-conjugated γ-PGA shell through pH-sensitive borate ester bonds. Surface modification with lactoferrin conferred brain-penetrating and glioma-targeting capabilities. The resulting spherical nanoparticles had a uniform size of 235.89 nm, a zeta potential of -22.66 mV, and high Cur loading (6.02%) and encapsulation efficiency (83.09%). Upon exposure to the acidic tumor microenvironment, the nanoparticle shell detaches, reversing surface charge from negative to positive, thereby enhancing cellular uptake and mitochondrial targeting. Intracellular glutathione then triggers core degradation, releasing Cur and Cu2+. Cur induces mitochondrial apoptosis, while Cu2+ catalyzes a Fenton-like reaction, converting endogenous hydrogen peroxide into highly cytotoxic reactive oxygen species. In vitro, the nanoparticles showed enhanced blood-brain barrier penetration, efficient lysosomal escape, and potent cytotoxicity against GL-261 cells (IC50 = 18.34 μg/mL) via a synergistic action of Cu2+ and Cur (CI = 0.28). In vivo, LP/CC-Cu-Cur NPs achieved superior brain accumulation and antitumor efficacy, highlighting their potential as a promising strategy for glioma therapy.
中文摘要:本研究基于聚-γ-谷氨酸(γ-PGA)/壳聚糖(CS)核壳结构,构建了pH/谷胱甘肽双重响应纳米颗粒(LP/CC-Cu-Cur NPs),用于胶质瘤的化疗/化学动力学协同治疗。该纳米颗粒以CC-Cu-Cur NPs为核,由Cu2+配位自组装的咖啡酸接枝CS与姜黄素(Cur)形成,并通过pH敏感的硼酸酯键包封于苯硼酸偶联的γ-PGA壳内。表面经乳铁蛋白修饰后赋予其穿透血脑屏障和靶向胶质瘤的能力。所得球形纳米颗粒尺寸均一,为235.89 nm,Zeta电位为-22.66 mV,具有较高的Cur载药量(6.02%)和包封率(83.09%)。暴露于酸性肿瘤微环境后,纳米颗粒外壳脱落,表面电荷由负转正,从而增强细胞摄取和线粒体靶向。随后,细胞内谷胱甘肽触发核降解,释放Cur和Cu2+。Cur诱导线粒体凋亡,而Cu2+催化类Fenton反应,将内源性过氧化氢转化为高细胞毒性的活性氧。体外实验中,该纳米颗粒表现出增强的血脑屏障穿透、有效的溶酶体逃逸,并通过Cu2+与Cur的协同作用对GL-261细胞产生强细胞毒性(IC50 = 18.34 μg/mL,CI = 0.28)。体内实验中,LP/CC-Cu-Cur NPs实现了优异的大脑蓄积和抗肿瘤疗效,凸显其作为胶质瘤治疗有前景策略的潜力。
Food chemistry IF 10.4 2026-10-01 PMID: 42580062
This study modeled and optimized ultrasound-assisted extraction (UAE) of phenolic compounds from 'Granny Smith' apple peel (RM) and biofortified peel subjected to controlled abiotic stresses (RM-E). A Box-Behnken design evaluated the effects of extraction ratio, ethanol concentration, and ultrasound power on total phenolic compounds (TPC), while extraction kinetics were described using the Peleg model. Optimal conditions were 1:36 w/v, 76% ethanol, and 52% ultrasound power, yielding extracts with 20-23 g kg-1 TPC and a profile dominated by flavonols and flavan-3-ols. After simulated gastrointestinal digestion, the biofortified UAE extract (USRM-E) showed 39.8% TPC bioaccessibility. Its intestinal fraction exhibited antiproliferative effects against HT-29 and Caco-2 colorectal cancer cells and showed antioxidant, anti-inflammatory, and anti-adipogenic responses in vitro. Overall, combining abiotic stress-induced biofortification with UAE improved phenolic recovery and bioaccessibility, supporting apple peel by-products as sustainable sources of bioactive ingredients for functional food applications through green extraction technologies and valorization strategies.
中文摘要:本研究对采用超声辅助提取(UAE)从「Granny Smith」苹果皮(RM)以及经受控非生物胁迫处理的生物强化苹果皮(RM-E)中提取酚类化合物的过程进行了建模与优化。采用Box-Behnken设计评估提取比例、乙醇浓度和超声功率对总酚化合物(TPC)的影响,并用Peleg模型描述提取动力学。最优条件为1:36 w/v、76%乙醇和52%超声功率,所得提取物的TPC为20–23 g kg-1,且以黄酮醇和黄烷-3-醇为主。经模拟胃肠消化后,生物强化UAE提取物(USRM-E)的TPC生物可及性为39.8%。其肠段组分对HT-29和Caco-2结直肠癌细胞表现出抗增殖作用,并在体外表现出抗氧化、抗炎和抗脂肪生成反应。总体而言,将非生物胁迫诱导的生物强化与UAE相结合可改善酚类回收率和生物可及性,支持苹果皮副产物通过绿色提取技术和增值策略成为功能性食品应用中生物活性成分的可持续来源。
Cancer letters IF 11.8 2026-10-01 PMID: 42425191
Methionine dependence represents a well-known metabolic vulnerability in cancer. Despite promising preclinical results, methionine restriction is impaired by the presence of methionine-independent cancer cells. After confirming both inter- and intra-tumoral heterogeneity in methionine dependence, we demonstrate that "methionine-independent" cells are rather "methionine self-sufficient," relying on the vitamin B12 (B12)-dependent methionine synthase (MTR) to sustain growth without exogenous methionine, which renders them highly vulnerable to B12 deprivation. Dual methionine and B12 deprivation produced synergistic cytotoxicity, inhibiting proliferation and inducing apoptosis across multiple cancer types and primary tumor cells, while sparing fibroblasts. This synergy persisted under moderate nutrient restriction, supporting translational potential. Moreover, dual therapy prevented the adaptive metabolic shift seen with methionine deprivation alone, avoiding rebound proliferation and resistance. In vivo, a methionine-restricted diet plus a synthesized B12 antagonist significantly suppressed growth of methionine-independent pancreatic xenografts without hematologic toxicity. These findings uncover a selective, synergistic anticancer strategy targeting methionine self-sufficiency.
中文摘要:甲硫氨酸依赖是癌症中一种众所周知的代谢脆弱性。尽管临床前结果令人鼓舞,但甲硫氨酸限制受到甲硫氨酸非依赖性癌细胞存在的削弱。在确认甲硫氨酸依赖性存在肿瘤间和肿瘤内异质性后,我们证明「甲硫氨酸非依赖性」细胞其实是「甲硫氨酸自给自足」细胞,它们依赖维生素B12(B12)依赖性甲硫氨酸合酶(MTR)在无外源性甲硫氨酸的情况下维持生长,这使其对B12剥夺高度敏感。甲硫氨酸和B12双重剥夺产生协同性细胞毒性,在多种癌症类型和原发肿瘤细胞中抑制增殖并诱导凋亡,同时不损伤成纤维细胞。这种协同作用在适度营养限制下仍然存在,支持其转化潜力。此外,双重治疗阻止了单独甲硫氨酸剥夺时出现的适应性代谢转变,避免了反弹增殖和耐药。在体内,甲硫氨酸限制饮食加一种合成的B12拮抗剂显著抑制了甲硫氨酸非依赖性胰腺异种移植瘤的生长,且无血液学毒性。这些发现揭示了一种靶向甲硫氨酸自给自足的选择性协同抗癌策略。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42420594
Colorectal cancer (CRC) remains a significant global health challenge, characterized by high post-surgical recurrence and poor survival outcomes. This study explores the therapeutic potential of odoroside A (OA), a natural compound derived from Nerium oleander, focusing on its ability to modulate lipid metabolism and induce cancer cell death on CRC. In a subcutaneous xenograft tumor model with HT29 and RKO cells, OA achieved inhibition ratios of 81.07% and 78.26% at a dose of 1.5 mg/kg, respectively. Mechanistic insights revealed that OA induced lipid accumulation and triggered cell death through lipid peroxidation, primarily by inhibiting fatty acid oxidation (FAO) pathways. This effect was supported by decreased mitochondrial FAO activity and reduced expression of FAO-related proteins, including CPT1A, CPT1B, CPT1C, CPT2, and ACSL1. Additionally, OA targeted ubiquitin-specific peptidase 8 (USP8), promoting the ubiquitination and degradation of liver X receptor beta (LXRβ), a critical regulator of lipid metabolism. This downregulation of LXRβ further disrupted FAO. This study establishes a foundation for developing OA as a natural compound-based anticancer therapy for CRC and identifies a novel link between USP8 and LXRβ, offering new insights into lipid metabolism on CRC.
中文摘要:结直肠癌(CRC)仍然是全球重大的健康挑战,其特点是术后复发率高且生存结局差。本研究探讨源自夹竹桃的天然化合物odoroside A(OA)的治疗潜力,重点关注其调节脂质代谢并诱导结直肠癌细胞死亡的能力。在HT29和RKO细胞的皮下异种移植肿瘤模型中,OA在1.5 mg/kg剂量下分别达到81.07%和78.26%的抑制率。机制研究显示,OA可诱导脂质蓄积,并通过脂质过氧化触发细胞死亡,主要通过抑制脂肪酸氧化(FAO)通路实现。线粒体FAO活性降低以及FAO相关蛋白(包括CPT1A、CPT1B、CPT1C、CPT2和ACSL1)表达减少支持了这一作用。此外,OA靶向泛素特异性肽酶8(USP8),促进脂质代谢的关键调节因子肝X受体β(LXRβ)的泛素化和降解。LXRβ的下调进一步破坏了FAO。本研究为将OA开发为基于天然化合物的结直肠癌抗癌疗法奠定了基础,并揭示了USP8与LXRβ之间的新联系,为结直肠癌脂质代谢提供了新见解。
Physiological reviews IF 35.7 2026-10-01 PMID: 42319154
The human gastric mucosa contends with insults throughout the course of its normal functions. Superficial injuries are rapidly resolved by the normal cellular lineages within the glandular epithelium. Deeper injuries often cause loss of acid-secreting cells, necessitating extensively coordinated repair mechanisms that significantly alter the cellular content of the gastric glands, culminating in pyloric metaplasia. Pyloric metaplasia is defined by the hyperplastic expansion of foveolar and mucous neck cell lineages as well as spasmolytic polypeptide-expressing metaplasia (SPEM) cells transdifferentiated from zymogenic chief cells. SPEM cells resemble mucus-secreting deep antral gland cells and possess proliferative qualities meant to aid in wound healing. Chief cell transdifferentiation into SPEM cells is regulated by an orderly process in which differentiated zymogenic cells reenter the cell cycle after downregulating mature transcriptional programs. The resolution of injury is followed by the restitution of normal cell lineages. However, metaplasia can persist when there is continuing inflammation and/or severe chronic injury. The aberrant persistence of proliferative SPEM cells can drive glandular intestinalization. The resulting intestinal metaplasia glands, particularly those with mixed gastric and intestinal lineages, are at increased risk for progression to dysplasia and ultimately gastric cancer. Understanding the dynamics of metaplastic cell lineage progression and uncovering lineage transition markers is critical to identifying targets suitable for therapeutic intervention. Here, we discuss the current knowledge, controversies, and remaining questions pertaining to the establishment and progression of metaplasia in response to deep gastric mucosal injury.
中文摘要:人类胃黏膜在其正常功能过程中会持续遭受各种损伤。浅表损伤可由腺上皮内正常细胞谱系迅速修复。较深的损伤常导致泌酸细胞丢失,需要广泛协调的修复机制,这些机制会显著改变胃腺的细胞组成,最终形成幽门化生。幽门化生定义为小凹细胞和黏液颈细胞谱系的增生性扩张,以及由酶原主细胞转分化而来的表达解痉多肽的化生(SPEM)细胞。SPEM细胞类似于分泌黏液的深部胃窦腺细胞,并具有旨在促进伤口愈合的增殖特性。主细胞向SPEM细胞的转分化受一个有序过程调控,其中分化成熟的酶原细胞在下调成熟转录程序后重新进入细胞周期。损伤消退后,正常细胞谱系得以恢复。然而,当存在持续炎症和/或严重慢性损伤时,化生可能持续存在。增殖性SPEM细胞的异常持续存在可驱动腺体肠化。由此形成的肠化生腺体,尤其是同时具有胃和肠谱系的腺体,进展为异型增生并最终发展为胃癌的风险增加。理解化生细胞谱系演变的动态并发现谱系转变标志物,对于确定适合治疗干预的靶点至关重要。在此,我们讨论关于深部胃黏膜损伤后化生建立和进展的当前知识、争议和仍待解决的问题。
Cancer letters IF 11.8 2026-10-01 PMID: 42288240
Biomolecular condensates formed through liquid-liquid phase separation (LLPS) are emerging as key regulators of chromatin organization and gene expression. However, how phase separation is coupled to specific noncanonical DNA structures to confer locus-selective transcriptional regulation remains poorly understood. G-quadruplex DNA (G4 DNA) is enriched at promoters, CpG islands, and other regulatory genomic regions, suggesting a potential role in guiding chromatin regulators to defined genomic loci. KDM2B is a CpG island-binding chromatin regulator involved in transcriptional repression, yet whether and how it senses G4 DNA to establish gene-specific regulatory programs in hepatocellular carcinoma (HCC) remains unclear. Here, we identify KDM2B as a G4 DNA-responsive phase-separating chromatin regulator. KDM2B undergoes LLPS through its intrinsically disordered regions and preferentially recognizes parallel G4 DNA structures. Mechanistically, G4 DNA promotes KDM2B condensate assembly and facilitates its chromatin targeting to G4-and CpG-rich regulatory loci. This process establishes a local repressive chromatin environment and restrains inflammatory transcriptional programs. Conversely, loss of KDM2B impairs G4-dependent condensate formation and weakens chromatin-associated transcriptional repression, leading to a proinflammatory secretory phenotype characterized by increased cytokines and chemokines, including IL-6 and CXCL8. This inflammatory remodeling promotes SPP1+ macrophage accumulation, reshapes the tumor immune microenvironment, and accelerates HCC progression. Together, these findings reveal that KDM2B-G4 DNA phase-separated condensates function as an epigenetic regulatory platform that couples noncanonical genome architecture with locus-selective inflammatory gene repression, thereby restraining inflammation-associated HCC progression.
中文摘要:通过液-液相分离(LLPS)形成的生物分子凝聚体正成为染色质组织和基因表达的关键调控者。然而,相分离如何与特定非经典DNA结构耦合以赋予位点选择性转录调控仍知之甚少。G-四链体DNA(G4 DNA)富集于启动子、CpG岛及其他调控基因组区域,提示其可能在引导染色质调控因子至特定基因组位点中发挥作用。KDM2B是一种参与转录抑制的CpG岛结合染色质调控因子,但其是否能以及如何感知G4 DNA以在肝细胞癌(HCC)中建立基因特异性调控程序仍不清楚。在此,我们将KDM2B鉴定为一种响应G4 DNA的相分离染色质调控因子。KDM2B通过其内在无序区发生LLPS,并优先识别平行G4 DNA结构。机制上,G4 DNA促进KDM2B凝聚体组装,并促进其染色质靶向至富含G4和CpG的调控位点。该过程建立局部抑制性染色质环境,并抑制炎症转录程序。相反,KDM2B缺失会损害G4依赖性凝聚体形成,并削弱染色质相关转录抑制,导致以细胞因子和趋化因子(包括IL-6和CXCL8)增加为特征的促炎分泌表型。这种炎症重塑促进SPP1+巨噬细胞积聚,重塑肿瘤免疫微环境,并加速HCC进展。总之,这些发现揭示KDM2B-G4 DNA相分离凝聚体作为表观遗传调控平台,将非经典基因组结构与位点选择性炎症基因抑制耦合,从而抑制炎症相关HCC进展。
Archives of toxicology IF 10.9 2026-10 PMID: 42259957
Microcystins (MCs) are cyanobacterial toxins found in water and food and are suspected to pose significant health risks, particularly to the liver. To gain insight into the mechanisms of hepatotoxicity and the potential carcinogenicity of MCs, this study investigated the effects of MC-LR, -LA, and -RR (congeners differing in cellular uptake and detoxification efficiency) on PP2A activity, cell proliferation, and gene expression profiling focused on toxicity pathways and carcinogenesis in HepaRG cells. The three MCs similarly inhibited PP2A activity; however, only MC-LR and -LA significantly increased cell proliferation. Gene expression profiles (mRNA) revealed strong, similar treatment effects induced by MC-LR and -LA (R2 = 0.66), whereas -RR affected fewer genes, showing weak correlations with the other two congeners (-LRx-RR - R2 = 0.31; -LAx-RR - R2 = 0.06). Moreover, MC-LR and -LA, but not -RR, affected several liver-enriched toxicity pathways, which correlate most closely to hepatocellular/liver carcinoma, cholestasis, and fibrosis. All congeners altered carcinogenesis-related miRNA expression, but no consistent pattern was observed among them. Overall, the present findings reinforce the congener-specific toxicity of MCs, likely driven by differences in toxicokinetics among congeners. Furthermore, the findings indicate that MC-induced liver effects also involve PP2A-independent mechanisms, as MC-LR/-LA and -RR elicited markedly different biological responses despite comparable PP2A inhibition. Finally, the study demonstrates the applicability of the NAM-based approach for evaluating liver effects (hepatocytes) in the MC family and, as structurally different congeners were investigated, provides data that could be used for read-across and grouping.
中文摘要:微囊藻毒素(MCs)是存在于水和食物中的蓝藻毒素,被认为可造成显著健康风险,尤其对肝脏。为深入了解MCs的肝毒性机制及其潜在致癌性,本研究在HepaRG细胞中考察了MC-LR、-LA和-RR(这三种同系物在细胞摄取和解毒效率方面存在差异)对PP2A活性、细胞增殖以及聚焦于毒性通路和癌变的基因表达谱的影响。三种MCs对PP2A活性的抑制作用相似;然而,仅MC-LR和-LA显著增加细胞增殖。基因表达谱(mRNA)显示,MC-LR和-LA诱导的处理效应强且相似(R²=0.66),而-RR影响的基因较少,与其他两种同系物的相关性较弱(-LRx-RR的R²=0.31;-LAx-RR的R²=0.06)。此外,MC-LR和-LA,而非-RR,影响了若干肝脏富集的毒性通路,这些通路与肝细胞癌/肝癌、胆汁淤积和纤维化关系最为密切。所有同系物均改变了与癌变相关的miRNA表达,但未观察到它们之间一致的模式。总体而言,本研究结果强化了MCs同系物特异性毒性的观点,这可能是由同系物之间毒代动力学的差异所驱动。此外,研究结果表明,MC诱导的肝脏效应还涉及PP2A非依赖机制,因为尽管对PP2A的抑制程度相当,MC-LR/-LA与-RR却引发了明显不同的生物学反应。最后,该研究证明了基于NAM的方法适用于评估MC家族对肝脏(肝细胞)的影响,并且由于研究了结构不同的同系物,提供了可用于交叉参照和分组的数据。
Autophagy IF 18.6 2026-10 PMID: 42210578
Hepatocellular carcinoma (HCC) is a highly lethal liver cancer with complex pathogenesis intertwined with metabolic and mitochondrial dysfunction. MEN1/menin is a protein with context-dependent functions in liver diseases. While MEN1 has been linked to HCC progression and mitochondrial homeostasis, its precise regulatory mechanism in these processes remains incompletely understood. Here, we report that MEN1 localizes to the outer mitochondrial membrane (OMM) in HCC cells, which is mediated by its N-terminal mitochondrial targeting sequence and the TOMM20 translocase complex. In a genetically engineered DEN- and CCl4-induced HCC mouse model, hepatocyte-specific men1 deficiency significantly suppressed tumorigenesis, a phenotype associated with impaired mitochondrial homeostasis. Mechanistically, MEN1 deficiency disrupted mitochondrial function by manifesting as promoted mitochondrial fission, impaired oxidative phosphorylation, reduced ATP levels, and elevated reactive oxygen species during energy stress. Critically, MEN1 loss inhibited mitophagy via downregulating the PINK1-PRKN/Parkin pathway, which impaired clearance of dysfunctional mitochondria and promotes their cytotoxic accumulation. Moreover, MEN1 expression was upregulated in human HCC tissues, correlated with poor clinical outcomes and was positively associated with autophagy signatures. Notably, pharmacological activation of mitophagy reversed the tumor-suppressive effects of MEN1 deficiency in vitro and in vivo. These findings identified a noncanonical role of mitochondrial MEN1 in driving HCC progression via regulating mitophagy homeostasis, and highlight the MEN1-mitophagy axis as a potential therapeutic target for HCC.Abbreviations: Alb-Cre: albumin promoter-driven recombinase Cre; Baf A1: bafilomycin A1; CCCP: carbonyl cyanide m-chlorophenyl hydrazone; CCl4: carbon tetrachloride; Co-IP: co-immunoprecipitation; CQ: chloroquine; DEN: diethylnitrosamine; DNM1L: dynamin 1 like; DQ-BSA: self-quenched BODIPY-conjugated bovine serum albumin; Gal: galactose; GOT1/AST: glutamic-oxaloacetic transaminase 1; GPT/ALT: glutamic-pyruvic transaminase; HCC: hepatocellular carcinoma; WT: wild type; HMKO: hepatocyte-specific men1 knockout; IF: immunofluorescence; IHC: immunohistochemistry; IMM: inner mitochondrial membrane; KEGG: Kyoto Encyclopedia of Genes and Genomes; MEFs: mouse embryonic fibroblasts; MEN1-FL: full-length MEN1; MFF: mitochondrial fission factor; MFN1: mitofusin 1; MTS: mitochondrial targeting sequence; OCR: oxygen consumption rate; OMM: outer mitochondrial membrane; OXPHOS: oxidative phosphorylation; PINK1: PTEN induced kinase1; PRKAA1: protein kinase AMP-activated catalytic subunit alpha 1; PRKN: parkin RBR E3 ubiquitin protein ligase; qPCR: RNA extraction and quantitative polymerase chain reaction; RNA-seq: RNA-sequencing; ROS: reactive oxygen species; shMEN1: small hairpin RNA-mediated MEN1 knockdown; TCGA: The Cancer Genome Atlas; TEM: transmission electron microscopy; TOMM20: translocase of outer mitochondrial membrane 20.
中文摘要:肝细胞癌(HCC)是一种高度致命的肝癌,其复杂发病机制与代谢和线粒体功能障碍相互交织。MEN1/menin 是一种在肝脏疾病中具有背景依赖性功能的蛋白。尽管 MEN1 已被认为与 HCC 进展和线粒体稳态有关,但其在这些过程中的确切调控机制仍未被完全阐明。在此,我们报道 MEN1 定位于 HCC 细胞的线粒体外膜(OMM),这由其 N 端线粒体靶向序列和 TOMM20 转位酶复合体介导。在经 DEN 和 CCl4 诱导的基因工程 HCC 小鼠模型中,肝细胞特异性 men1 缺失显著抑制了肿瘤发生,该表型与线粒体稳态受损相关。从机制上看,MEN1 缺失通过表现为促进线粒体分裂、氧化磷酸化受损、ATP 水平降低以及能量应激期间活性氧升高,从而破坏线粒体功能。关键的是,MEN1 缺失通过下调 PINK1-PRKN/Parkin 通路抑制线粒体自噬,这损害了功能异常线粒体的清除,并促进其细胞毒性蓄积。此外,MEN1 表达在人 HCC 组织中上调,与不良临床结局相关,并与自噬特征正相关。值得注意的是,药物激活线粒体自噬在体外和体内逆转了 MEN1 缺失的肿瘤抑制作用。这些发现确定了线粒体 MEN1 通过调控线粒体自噬稳态驱动 HCC 进展的非经典作用,并突出 MEN1-线粒体自噬轴作为 HCC 潜在治疗靶点。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42185682
Colorectal cancer (CRC) is a major cause of cancer mortality worldwide. Here, we identified the antipsychotic drug penfluridol as a potent anticancer agent that induces cuproptosis in CRC through a newly defined signaling mechanism. Using real-world clinical datasets, we demonstrated that PDPK1 is significantly upregulated in CRC and further increases in its expression level are correlated with a worse outcome, whereas CTR1 is downregulated in CRC and further decreases in its expression level are correlated with favourable outcomes, directly establishing the clinical relevance of these two proteins to CRC. Mechanistically, drug affinity responsive target stability assays revealed PDPK1 as a direct binding target of penfluridol. Penfluridol inhibited PDPK1 kinase activity and reduced AKT1 phosphorylation, which in turn decreased CTR1 ubiquitination and stabilized CTR1 on the plasma membrane. Enhanced CTR1 expression promoted intracellular copper influx, leading to copper overload and cuproptosis. Functionally, penfluridol suppressed CRC growth in cell lines, patient-derived organoids, and PDX models and was well-tolerated with limited systemic toxicity. Genetic and pharmacologic modulation confirmed that the PDPK1-p-AKT1-CTR1 axis governs copper homeostasis and mediates penfluridol-induced cell death. Collectively, our findings revealed a previously unrecognized link between oncogenic kinase signaling and copper metabolism, established PDPK1 and CTR1 as clinically relevant biomarkers, and provided a strong rationale for repurposing penfluridol as a dual-function therapeutic that induces cuproptosis and enhances chemosensitivity in colorectal cancer.
中文摘要:结直肠癌(CRC)是全球癌症死亡的主要原因之一。在此,我们发现抗精神病药物五氟利多是一种强效抗癌剂,可通过一种新定义的信号机制诱导结直肠癌发生铜死亡。利用真实世界临床数据集,我们证明PDPK1在结直肠癌中显著上调,且其表达水平进一步升高与更差结局相关,而CTR1在结直肠癌中下调,且其表达水平进一步降低与良好结局相关,从而直接确立了这两种蛋白与结直肠癌的临床相关性。在机制上,药物亲和反应靶点稳定性实验显示PDPK1是五氟利多的直接结合靶点。五氟利多抑制PDPK1激酶活性并降低AKT1磷酸化,进而减少CTR1泛素化并使CTR1在质膜上稳定。CTR1表达增强促进细胞内铜流入,导致铜超载和铜死亡。在功能上,五氟利多抑制细胞系、患者来源类器官和PDX模型中的结直肠癌生长,并且耐受良好、全身毒性有限。遗传学和药理学调控证实,PDPK1-p-AKT1-CTR1轴调控铜稳态并介导五氟利多诱导的细胞死亡。总之,我们的发现揭示了致癌激酶信号与铜代谢之间此前未被认识的联系,确立了PDPK1和CTR1作为临床相关生物标志物,并为将五氟利多重新定位为一种诱导铜死亡并增强结直肠癌化疗敏感性的双功能治疗药物提供了有力依据。
Cancer discovery IF 29.5 2026-10-01 PMID: 42165710
Pancreatic intraepithelial neoplasia (PanIN) precedes pancreatic cancer, a deadly disease characterized by an extensive tumor microenvironment. How the microenvironment evolves during cancer progression is largely unknown, as PanINs are microscopic and nondiseased pancreas samples are exceedingly rare, while adjacent normal samples are disrupted by the presence of malignancy. Leveraging donor organs and spatial technologies, we mapped the evolution of PanIN to cancer. The PanIN epithelial component falls on a continuum with cancer, whereas the PanIN microenvironment is drastically distinct. Progression to cancer is accompanied by profound geographic reorganization of myeloid cells and lymphocytes and the formation of a cancer-specific fibroblast population characterized by high levels of smooth muscle actin, LRRC15, and the WNT signaling component LEF1. Together, our data show asynchronous evolution of epithelial and stromal components during pancreatic carcinogenesis. Lack of stromal reprogramming might explain why most PanINs do not progress to cancer. Compiled data available at https://www.pancreas-precancer-atlas.com/. Pancreatic cancer precursor lesions are widely prevalent in the population, but progression to invasive cancer is uncommon. Identifying barriers to cancer progression is critical for cancer interception. Our findings describe unique features of the precancer microenvironment that are likely responsible for keeping precursor lesions from progressing to malignancy.
中文摘要:胰腺上皮内瘤变(PanIN)是胰腺癌的前驱病变,胰腺癌是一种以广泛肿瘤微环境为特征的致命疾病。微环境在癌症进展过程中如何演化在很大程度上仍不清楚,因为PanIN为微观病灶,且非病变胰腺样本极为罕见,而癌旁正常样本又会因恶性肿瘤的存在而受到干扰。我们利用供体器官和空间技术,绘制了从PanIN到癌症的演化图谱。PanIN的上皮成分与癌症处于同一连续谱系,而PanIN的微环境则截然不同。向癌症进展伴随髓系细胞和淋巴细胞的显著空间重组织,以及形成一种癌症特异性成纤维细胞群体,该群体以高水平平滑肌肌动蛋白、LRRC15和WNT信号组分LEF1为特征。总体而言,我们的数据表明胰腺癌发生过程中上皮和间质成分呈异步演化。间质重编程的缺乏可能解释为何大多数PanIN不进展为癌症。汇编数据可在 https://www.pancreas-precancer-atlas.com/ 获取。胰腺癌前驱病变在人群中广泛流行,但进展为浸润性癌症并不常见。识别癌症进展的障碍对于癌症拦截至关重要。我们的发现描述了癌前微环境的独特特征,这些特征可能负责阻止前驱病变进展为恶性肿瘤。
Cancer discovery IF 29.5 2026-10-01 PMID: 42053430
High-fat diet (HFD) intake has been linked to an increased risk of pancreatic ductal adenocarcinoma (PDAC), a lethal and therapy-resistant cancer. However, whether and how specific dietary fats drive cancer development remains unresolved. Leveraging an oncogenic Kras-driven mouse model that closely mimics human PDAC progression, we screened a dozen isocaloric HFDs differing solely in fat source and representing the diversity of human fat consumption. Unexpectedly, diets rich in oleic acid-a monounsaturated fatty acid (MUFA) typically associated with good health-markedly enhanced tumorigenesis. Conversely, diets high in polyunsaturated fatty acids (PUFA) suppressed tumor progression. Relative dietary fatty acid saturation levels (PUFA/MUFA) governed pancreatic membrane phospholipid composition, lipid peroxidation, and ferroptosis sensitivity in mice, concordant with circulating PUFA/MUFA levels being linked to altered PDAC risk in humans. These findings directly implicate dietary unsaturated fatty acids in controlling ferroptosis susceptibility and tumorigenesis, supporting potential "precision nutrition" strategies for PDAC prevention. This study reveals that dietary unsaturated fatty acids divergently influence pancreatic cancer progression by incorporating into tissue phospholipids to modulate ferroptosis sensitivity. Dietary MUFAs promote tumorigenesis, whereas PUFAs confer protection. These findings suggest that alterations in dietary fat intake could affect cancer risk. See related commentary by Jeong and Lien, p. 1961.
中文摘要:高脂饮食(HFD)摄入与胰腺导管腺癌(PDAC)风险增加相关,PDAC是一种致死性强且治疗耐药的癌症。然而,特定膳食脂肪是否以及如何驱动癌症发生仍未明确。利用一种由致癌性Kras驱动、能密切模拟人类PDAC进展的小鼠模型,我们筛选了十几种等热量高脂饮食,这些饮食仅在脂肪来源上不同,并代表了人类脂肪摄入的多样性。出乎意料的是,富含油酸——一种通常被认为有益健康的单不饱和脂肪酸(MUFA)——的饮食显著促进了肿瘤发生。相反,富含多不饱和脂肪酸(PUFA)的饮食抑制了肿瘤进展。膳食脂肪酸相对饱和度水平(PUFA/MUFA)决定了小鼠胰腺膜磷脂组成、脂质过氧化和铁死亡敏感性,这与人类循环PUFA/MUFA水平与PDAC风险改变相关一致。这些发现直接表明膳食不饱和脂肪酸控制铁死亡易感性和肿瘤发生,支持用于PDAC预防的潜在「精准营养」策略。本研究揭示,膳食不饱和脂肪酸通过掺入组织磷脂以调节铁死亡敏感性,从而对胰腺癌进展产生不同影响。膳食MUFA促进肿瘤发生,而PUFA提供保护。这些发现提示,膳食脂肪摄入的改变可能影响癌症风险。参见Jeong和Lien的相关评论,第1961页。
Biomaterials IF 13.6 2026-10 PMID: 42025045
Fluorescent molecular probes are promising imaging tools for tumor surgical navigation. However, achieving both precise diagnosis and long-term surgical navigation in complex tumor environments remains challenging. In this study, we developed a "catch and light-up" fluorescent probe (CyTB) that enables specific fluorescence retention and activation, thereby enhancing imaging navigation accuracy. The probe consists of a hemicyanine unit as the near-infrared fluorescence signal reporter, tetrazine (Tz) reactive group bicyclo [6.1.0]nonyne (BCN) and trans-cyclooctene (TCO). Once arrival at the tumor site labeled by Tz in advance, the BCN group of probes was anchored through ligation reaction to enhance the probe retention. Concurrently, the TCO group can rapidly be cleaved by Tz leading to the light-up of fluorescence. The retention time of the probe at the tumor site can reach 130 h, while the tumor-to-normal tissue ratio in metastatic microtumor of pancreatic cancer (< 2 mm) still reaches 6.5, enabling efficient tumor tracking and precise marginal resection, thus providing a promising strategy for surgical navigation.
中文摘要:荧光分子探针是用于肿瘤手术导航的有前景的成像工具。然而,在复杂肿瘤环境中同时实现精确诊断与长期手术导航仍具挑战性。在本研究中,我们开发了一种「捕获并点亮」荧光探针(CyTB),其能够实现特异性荧光滞留与激活,从而提高成像导航准确性。该探针由作为近红外荧光信号报告基团的花菁单元、四嗪(Tz)反应基团、双环[6.1.0]壬炔(BCN)和反式环辛烯(TCO)组成。一旦到达预先用Tz标记的肿瘤部位,探针的BCN基团通过连接反应被锚定,以增强探针滞留。同时,TCO基团可被Tz快速裂解,导致荧光点亮。探针在肿瘤部位的滞留时间可达130 h,而在胰腺癌转移性微肿瘤(< 2 mm)中,肿瘤与正常组织比值仍达到6.5,从而能够高效进行肿瘤追踪和精确边缘切除,为手术导航提供了一种有前景的策略。
Biomaterials IF 13.6 2026-10 PMID: 41980379
Surgery remains the primary cancer treatment, but postoperative trauma disrupts the local immune microenvironment by altering the critical balance between M1 and M2 macrophages while simultaneously elevating reactive oxygen species (ROS) levels at the surgical site. The critical clinical dilemma in postoperative tumor management lies in achieving re-balancing over macrophage polarization within the post-operative niche - specifically maintaining tumor-suppressing M1 phenotype while permitting necessary wound-healing M2 function. Here, we developed an in situ thermosensitive hydrogel platform capable of co-delivering two nanoparticle systems (BC12D NPs and PPS NPs) to alleviate the immunosuppressive microenvironment. Specifically, CRISPR/Cas9-loaded nanoparticles (BC12D@CRISPR NPs) were incorporated into the hydrogel for addressing the high proportion of M2-type macrophages at the resection site, reprogramming the macrophages with an effective M1/M2 ratio to exert potent antitumor functions. Meanwhile, the PPS nanoparticles were employed for the clearance of ROS at the surgical site, thereby ensuring that the normal wound healing process remained unimpeded. Using an in situ tumor resection model, the synergistic effects of ROS clearance and macrophage repolarization at the postoperative site were leveraged to achieve efficient immune microenvironment modulation.
中文摘要:手术仍是癌症的主要治疗手段,但术后创伤通过改变M1与M2巨噬细胞之间的关键平衡,同时提高手术部位活性氧(ROS)水平,从而破坏局部免疫微环境。术后肿瘤管理中的关键临床困境在于如何在术后微环境中重新平衡巨噬细胞极化——具体而言,既要维持具有肿瘤抑制作用的M1表型,又要允许伤口愈合所必需的M2功能。在此,我们开发了一种原位热敏水凝胶平台,能够共递送两种纳米颗粒系统(BC12D NPs和PPS NPs)以缓解免疫抑制微环境。具体而言,将负载CRISPR/Cas9的纳米颗粒(BC12D@CRISPR NPs)掺入水凝胶,以应对切除部位高比例的M2型巨噬细胞,将巨噬细胞重编程至有效的M1/M2比例,从而发挥强效抗肿瘤功能。同时,采用PPS纳米颗粒清除手术部位的ROS,从而确保正常伤口愈合过程不受阻碍。利用原位肿瘤切除模型,术后部位ROS清除与巨噬细胞重极化的协同作用被用于实现高效的免疫微环境调控。
Biomaterials IF 13.6 2026-10 PMID: 41966551
Nanozymes are nanomaterials with enzyme-mimicking catalytic activities that have extraordinary potential in biotechnology. Metal‒organic frameworks (MOFs), emerging nanoporous materials with atomically defined active sites and ordered porous architectures, have been established as an important subclass of nanozymes. In this review, we systematically summarize the recent advances in MOF-based nanozymes. We first comprehensively describe the diverse bioinspired nanozyme activities of pristine MOFs and subsequently provide a critical overview of activity regulation strategies and rational design principles for constructing high-performance nanozyme platforms. These MOF-based nanozymes feature well-defined active sites that effectively mimic the catalytic microenvironments of natural enzymes, displaying exceptional catalytic activity and substrate selectivity. Leveraging the superior catalytic performance and inherent advantages of MOFs, MOF-based nanozymes with microenvironmental responsiveness exhibit promising prospects in various disease therapies and multimodal synergistic treatments. We highlight their potential therapeutic applications in cancer, inflammatory diseases, and infection treatment. The challenges and prospects of MOF-based nanozymes are also presented.
中文摘要:纳米酶是具有模拟酶催化活性的纳米材料,在生物技术中具有非凡潜力。金属有机框架(MOFs)是新兴的纳米多孔材料,具有原子级精确的活性位点和有序的多孔结构,已成为纳米酶的重要亚类。在这篇综述中,我们系统总结了基于MOF的纳米酶的最新进展。我们首先全面描述了原始MOFs的多种仿生纳米酶活性,随后对构建高性能纳米酶平台的活性调控策略和合理设计原则进行了批判性概述。这些基于MOF的纳米酶具有明确界定的活性位点,能够有效模拟天然酶的催化微环境,表现出优异的催化活性和底物选择性。利用MOFs优越的催化性能和固有优势,具有微环境响应性的基于MOF的纳米酶在多种疾病治疗和多模式协同治疗中展现出广阔前景。我们重点介绍了它们在癌症、炎症性疾病和感染治疗中的潜在治疗应用。同时也提出了基于MOF的纳米酶所面临的挑战和前景。
Biomaterials IF 13.6 2026-10 PMID: 41931969
The cGAS-STING signaling pathway is crucial for radiotherapy (RT)-induced immune modulation. However, under hypoxic conditions, reduced DNA damage and enhanced DNA damage repair (DDR) lead to lower cytosolic double-stranded DNA (dsDNA) levels, making standard RT doses inadequate for sustained cGAS-STING activation, resulting in transient immune responses. In this study, we developed the As-Mn@MnO2@Alb nanosystem as a potent radiosensitizer and cGAS-STING pathway amplifier. Arsenic trioxide (ATO)-mediated radiosensitization suppresses DDR, enhances immunogenic cell death, and increases tumor-associated antigens and cytosolic dsDNA levels. Concurrently, degradable MnO2 releases Mn2+ in tumors, boosting cGAS recognition and sensitivity, while generating oxygen to alleviate hypoxia and improve RT efficacy. The synchronized delivery of Mn2+ and accumulated cytosolic dsDNA amplifies cGAS-STING activation, promoting dendritic cell (DC) maturation, enhancing CD8+ T cell infiltration, reducing immunosuppressive Treg infiltration, and significantly inhibiting both irradiated local tumors and non-irradiated distal CRC tumors while inducing robust immune memory effects, all with no notable toxicity. This study demonstrates that effective RT sensitization, coupled with synchronized STING activation, represents a robust strategy to overcome radio-immunotherapy resistance in colorectal cancer.
中文摘要:cGAS-STING信号通路对放疗(RT)诱导的免疫调节至关重要。然而,在缺氧条件下,DNA损伤减少且DNA损伤修复(DDR)增强,导致胞质双链DNA(dsDNA)水平降低,使标准RT剂量不足以持续激活cGAS-STING,从而产生短暂的免疫应答。在本研究中,我们构建了As-Mn@MnO2@Alb纳米系统,作为一种强效放射增敏剂和cGAS-STING通路放大器。三氧化二砷(ATO)介导的放射增敏可抑制DDR,增强免疫原性细胞死亡,并增加肿瘤相关抗原和胞质dsDNA水平。同时,可降解的MnO2在肿瘤中释放Mn2+,增强cGAS识别和敏感性,并产生氧气以缓解缺氧、提高RT疗效。Mn2+与积累的胞质dsDNA的同步递送可放大cGAS-STING激活,促进树突状细胞(DC)成熟,增强CD8+ T细胞浸润,减少免疫抑制性Treg浸润,并显著抑制受照射的局部肿瘤和未照射的远端CRC肿瘤,同时诱导强效免疫记忆效应,且无明显毒性。本研究表明,有效的RT增敏与同步STING激活相结合,是克服结直肠癌放射免疫治疗耐药的一种强效策略。
Cell death and differentiation IF 13.6 2026-10 PMID: 41844894
BTAF1, an ATP-dependent remodeler of the TBP-DNA complex, is frequently mutated in gastric cancer. However, its role in DNA repair and therapeutic relevance remains largely undefined. Here, we show that BTAF1 knockout leads to accumulation of double-strand breaks (DSBs) by impairing DNA end-resection process of homologous recombination (HR) repair, thereby sensitizing cells to genotoxic agents both in vitro and in vivo. Mechanistically, BTAF1 prevents ubiquitin-mediated degradation of MRE11, maintaining its protein stability, promoting DNA end resection and HR, and consequently enhancing cellular resistance to DNA-damaging stress. Notably, the interaction between BTAF1 and MRE11 is dynamically regulated by PARP1-mediated PARylation of BTAF1 during the DNA damage response. Loss of BTAF1 also increases chemosensitivity in gastric cancer xenograft and organoid models. Clinically, high BTAF1 expression correlates with poor prognosis in gastric cancer patients receiving neoadjuvant chemotherapy. Collectively, our findings identify BTAF1 as a critical regulator of HR repair through stabilization of MRE11 and propose BTAF1 as a potential biomarker for predicting response to genotoxic chemotherapy. BTAF1 is frequently mutated in gastric cancer, yet its role in DNA repair remains unclear. BTAF1 promotes homologous recombination and chemoresistance in gastric cancer by stabilizing MRE11. BTAF1 loss impairs DNA end resection, sensitizing cells to genotoxic agents. The BTAF1-MRE11 interaction is regulated by PARP1 mediated PARylation.
中文摘要:BTAF1是TBP-DNA复合物的ATP依赖性重塑因子,在胃癌中频繁发生突变。然而,其在DNA修复中的作用及治疗相关性在很大程度上仍不明确。在本研究中,我们发现BTAF1敲除会通过损害同源重组(HR)修复中的DNA末端切除过程,导致双链断裂(DSB)积累,从而使细胞在体外和体内对基因毒性药物增敏。在机制上,BTAF1可阻止MRE11经泛素介导的降解,维持其蛋白稳定性,促进DNA末端切除与HR,进而增强细胞对DNA损伤应激的耐受能力。值得注意的是,在DNA损伤应答过程中,BTAF1与MRE11之间的相互作用受PARP1介导的BTAF1 PAR化动态调控。BTAF1缺失还可提高胃癌异种移植瘤和类器官模型的化疗敏感性。在临床层面,高BTAF1表达与接受新辅助化疗的胃癌患者的不良预后相关。总体而言,我们的发现确定了BTAF1是通过稳定MRE11来调控HR修复的关键因子,并提出BTAF1可作为预测基因毒性化疗应答的潜在生物标志物。BTAF1在胃癌中频繁突变,但其在DNA修复中的作用仍不清楚。BTAF1通过稳定MRE11促进胃癌中的同源重组和化疗耐药。BTAF1缺失会损害DNA末端切除,使细胞对基因毒性药物敏感。BTAF1-MRE11的相互作用受PARP1介导的PAR化调控。
Cell death and differentiation IF 13.6 2026-10 PMID: 41826730
Chemoradiotherapy resistance remains a major obstacle in gastric cancer treatment, primarily due to enhanced DNA repair mechanisms that allow tumor cells to overcome therapeutic damage. Here, we demonstrate that nuclear-localized Exocyst Complex Component 4 (EXOC4) promotes chemoradiotherapy resistance in gastric cancer by enhancing non-homologous end joining-mediated DNA repair. Specifically, p300-mediated acetylation of EXOC4 at lysine 433 induces its nuclear translocation. In the nucleus, EXOC4 facilitates the interaction between PRMT5 and KU70, inducing PRMT5-catalyzed methylation of KU70 at arginine 318. This modification increases the DNA-binding affinity of the KU complex, thereby accelerating double-strand break repair. A peptide targeting EXOC4 K433 inhibits acetylation-dependent nuclear import, reducing KU70 methylation and restoring chemoradiotherapy sensitivity in preclinical models. Collectively, our findings identify the p300-EXOC4-KU70 axis as a critical mediator of chemoradiotherapy resistance and a promising therapeutic target.
中文摘要:放化疗耐药仍是胃癌治疗的主要障碍,其主要原因在于DNA修复机制增强,使肿瘤细胞能够克服治疗所致损伤。在此,我们证明核定位的Exocyst复合体组分4(EXOC4)通过增强非同源末端连接介导的DNA修复,促进胃癌的放化疗耐药。具体而言,p300介导的EXOC4第433位赖氨酸乙酰化诱导其核转位。在细胞核内,EXOC4促进PRMT5与KU70之间的相互作用,诱导PRMT5催化KU70第318位精氨酸甲基化。该修饰提高KU复合物的DNA结合亲和力,从而加速双链断裂修复。靶向EXOC4 K433的肽抑制乙酰化依赖性核输入,降低KU70甲基化,并在临床前模型中恢复放化疗敏感性。总之,我们的研究结果确定p300-EXOC4-KU70轴是放化疗耐药的关键介质,并是一个有前景的治疗靶点。
Journal of advanced research IF 17.1 2026-10 PMID: 41554478
Activation of hepatic stellate cells (HSCs) is a core driver of liver fibrosis and may contribute to the evolution to hepatocellular carcinoma (HCC). Exosomes mediate intercellular signaling by transporting bioactive molecules, yet the role of activated HSC-derived exosomes in hepatocarcinogenesis remains unexplored. This study aims to investigate whether and how activated HSCs induce hepatocarcinogenesis through the mediation of exosomes. Exosomes from activated HSCs were isolated and applied to hepatocytes to assess malignant transformation via immunoblotting, soft-agar colony formation, and xenograft assays. Oncogenic miRNAs were screened by sequencing and validated by qPCR. Target genes and signaling pathways were identified through transcriptomics, bioinformatics, and dual-luciferase assays. Functional roles of miRNAs and downstream pathways were confirmed via gain/loss-of-function experiments. Clinical correlations and diagnostic potential of exosomal miRNAs were evaluated using patient samples. Exosomes from activated HSCs induced hepatocyte malignant transformation in vitro and tumorigenesis in vivo. MiR-23a-3p was markedly enriched in activated HSC-derived exosomes and exerted oncogenic effect upon delivery to recipient hepatocytes. Mechanistically, exosomal miR-23a-3p directly targeted DUSP5 in hepatocytes, thereby suppressing its expression and subsequently activating pro-oncogenic ERK signaling. Notably, the miR-23a-3p/DUSP5/ERK signaling axis exhibited progressive activation that paralleled histopathological transitions from fibrosis to HCC in both murine models and clinical specimens. Clinically, elevated plasma exosomal miR-23a-3p levels demonstrated significant diagnostic merit for detecting precancerous lesions and predicting HCC onset in patient cohorts. Our results indicate that activated HSCs secrete exosomes enriched with miR-23a-3p, which directly target to inhibit DUSP5, and subsequently activate ERK signaling in hepatocytes, leading to the initiation of cellular malignant transformation and tumorigenesis.
中文摘要:肝星状细胞(HSC)的活化是肝纤维化的核心驱动因素,并可能促进其向肝细胞癌(HCC)演变。外泌体通过转运生物活性分子介导细胞间信号传导,但活化HSC来源外泌体在肝癌发生中的作用尚未明确。本研究旨在探讨活化HSC是否以及如何通过外泌体介导肝细胞癌发生。我们分离活化的HSC来源外泌体,并将其应用于肝细胞,通过免疫印迹、软琼脂集落形成和异种移植实验评估恶性转化。通过测序筛选致癌miRNA,并用qPCR验证。通过转录组学、生物信息学和双荧光素酶实验鉴定靶基因和信号通路。通过功能获得/缺失实验证实miRNA和下游通路的功能作用。利用患者样本评估外泌体miRNA的临床相关性及诊断潜力。活化的HSC来源外泌体在体外诱导肝细胞恶性转化,并在体内促进肿瘤发生。miR-23a-3p在活化HSC来源外泌体中显著富集,并在递送至受体肝细胞后发挥致癌作用。机制上,外泌体miR-23a-3p直接靶向肝细胞中的DUSP5,从而抑制其表达,随后激活促癌的ERK信号通路。值得注意的是,miR-23a-3p/DUSP5/ERK信号轴呈现进行性激活,与小鼠模型和临床标本中从纤维化到HCC的组织病理学转变相平行。临床上,血浆外泌体miR-23a-3p水平升高在患者队列中对检测癌前病变和预测HCC发生具有显著诊断价值。我们的结果表明,活化的HSC分泌富含miR-23a-3p的外泌体,这些外泌体直接靶向抑制DUSP5,随后激活肝细胞中的ERK信号通路,导致细胞恶性转化和肿瘤发生的启动。

4临床/流行病学 (37篇)

临床研究 (31篇)

JAMA surgery IF 15.6 2026-10-07 PMID: 42842268
Minimally invasive radical hysterectomy was introduced to reduce perioperative morbidity in early-stage cervical cancer, but concerns regarding oncologic safety have limited its use. High-quality prospective randomized data evaluating perioperative safety and recovery after robot-assisted radical hysterectomy remain limited. To compare perioperative safety and health-related quality of life (HRQOL) after robot-assisted vs open radical hysterectomy. The Robot-Assisted Approach to Cervical Cancer (RACC) trial, a multicenter, noninferiority, phase 3 randomized clinical trial, was conducted at tertiary centers in Europe. Female participants aged 18 years and older with cervical cancer (International Federation of Gynecology and Obstetrics [FIGO] 2018 stage IB [excluding IB3] or IIA1) were enrolled. Patients were randomized between 2019 and 2025. Robot-assisted laparoscopic radical hysterectomy. Prespecified secondary outcomes included intraoperative complications (graded using standardized classification systems), postoperative complications within 30 days (Clavien-Dindo), and HRQOL at 1 month (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module, and EuroQol 5-Dimension 3-Level questionnaire). These prespecified secondary analyses were exploratory and were not powered for confirmatory inference. Of 900 randomized patients (robotic surgery, median [IQR] age, 46 [39-53] years; open surgery, median [IQR] age, 45 [37-54] years), 809 (90%) were included in the intraoperative safety analysis, 798 (89%) in the postoperative safety analysis, and 723 (80%) in the 1-month HRQOL analysis. Intraoperative complications occurred in 24 of 419 patients (5.7%) in the robot-assisted group vs 39 of 390 patients (10.0%) in the open surgery group (risk difference, -4.3 percentage points; 95% CI, -8.0 to -0.6 percentage points); most were minor, whereas major complications were infrequent and similar. Postoperative complications within 30 days were similar (33.4% vs 34.8%; risk difference, -1.4 percentage points; 95% CI, -7.9 to 5.2 percentage points), including readmission and reoperation. At 1 month, robot-assisted surgery was associated with small differences in selected domains, including physical functioning (+5 points; 95% CI, 3-8 points), role functioning (+8 points; 95% CI, 4-13 points), and lower pain (+5 points; 95% CI, 2-9 points), whereas most domains did not meet thresholds for clinically important differences. Results of this secondary analysis of the RACC randomized clinical trial show that robot-assisted radical hysterectomy was associated with fewer intraoperative complications, primarily reflecting lower-grade events, with similar postoperative morbidity compared with open surgery. Differences in early HRQOL were small, and overall findings indicate no improvement in clinically consequential postoperative outcomes or recovery. ClinicalTrials.gov Identifier: NCT03719547.
中文摘要:微创根治性子宫切除术的引入旨在降低早期宫颈癌的围手术期并发症发生率,但对其肿瘤学安全性的担忧限制了其应用。评估机器人辅助根治性子宫切除术后围手术期安全性和恢复的高质量前瞻性随机数据仍然有限。比较机器人辅助与开放根治性子宫切除术后的围手术期安全性和健康相关生活质量(HRQOL)。宫颈癌机器人辅助入路(RACC)试验是一项在欧洲三级医疗中心开展的多中心、非劣效性、3期随机临床试验。纳入年龄18岁及以上、患有宫颈癌(国际妇产科联盟[FIGO]2018年IB期[不包括IB3]或IIA1期)的女性参与者。患者于2019年至2025年间随机分组。干预为机器人辅助腹腔镜根治性子宫切除术。预设次要结局包括术中并发症(采用标准化分类系统分级)、术后30天内并发症(Clavien-Dindo分级)以及1个月时的HRQOL(欧洲癌症研究与治疗组织生活质量问卷核心30、欧洲癌症研究与治疗组织生活质量问卷-宫颈癌模块和EuroQol 5维度3水平问卷)。这些预设次要分析为探索性分析,未针对验证性推断进行效能计算。在900例随机分组患者中(机器人手术组中位[IQR]年龄为46[39-53]岁;开放手术组中位[IQR]年龄为45[37-54]岁),809例(90%)纳入术中安全性分析,798例(89%)纳入术后安全性分析,723例(80%)纳入1个月HRQOL分析。机器人辅助组419例患者中有24例(5.7%)发生术中并发症,而开放手术组390例患者中有39例(10.0%)发生术中并发症(风险差为-4.3个百分点;95%CI为-8.0至-0.6个百分点);大多数为轻微并发症,而严重并发症不常见且两组相似。术后30天内并发症相似(33.4% vs 34.8%;风险差为-1.4个百分点;95%CI为-7.9至5.2个百分点),包括再入院和再次手术。在1个月时,机器人辅助手术与部分选定领域的较小差异相关,包括躯体功能(+5分;95%CI为3-8分)、角色功能(+8分;95%CI为4-13分)和疼痛更轻(+5分;95%CI为2-9分),而大多数领域未达到临床重要差异的阈值。这项RACC随机临床试验的次要分析结果表明,与开放手术相比,机器人辅助根治性子宫切除术与术中并发症更少相关,主要反映为较低级别事件,并且术后并发症发生率相似。早期HRQOL差异较小,总体结果表明,在具有临床意义的术后结局或恢复方面并无改善。ClinicalTrials.gov标识符:NCT03719547。
JAMA dermatology IF 10.9 2026-10-07 PMID: 42842243
Children of melanoma survivors have a 2-fold increased lifetime risk of melanoma, yet they inconsistently practice sun protection and experience preventable sunburns. To evaluate a telehealth-delivered behavioral intervention for skin cancer prevention among children of melanoma survivors. This parallel-group randomized clinical trial assigned survivor-child dyads to the family, lifestyles, actions, and risk education (FLARE) intervention or a control condition between April 2020 and October 2023. Participants were recruited through a cancer registry and statewide and clinical databases. Eligible survivors had a confirmed melanoma diagnosis and at least 1 child aged 8 to 17 years with 1 or more sunburns during the previous year. Of 520 eligible survivors, 364 dyads enrolled, completed baseline assessment, and were randomized. Data were analyzed from 2025 to 2026. Both conditions were telehealth education modules delivered over 4 weeks. FLARE included familial melanoma risk education and skills building that targeted child sun protection. The control included general skin cancer education on identifying reputable sources of health information. The primary outcome was child sunburn occurrence, which was evaluated as the change from baseline through the 2 postintervention assessments. Secondary outcomes included child sun-protective behaviors and tanning. A total of 364 survivor-child dyads were recruited and randomized (parents: mean [SD] age, 45.1 [6.2] years; 228 female individuals [62.6%]; children: mean [SD] age, 12.9 [2.6] years; 189 female individuals [51.9%]). The primary analysis, which included 364 dyads (180 FLARE [49.5%], 184 control [50.5%]) in the intention-to-treat analyses, found no significant between-group differences in rate of sunburn change across time. However, at the first postintervention assessment, child-reported sunburn occurrence was lower in the FLARE group compared with the control group (B = -0.17; 95% CI, -0.30 to -0.04; P = .01). Relative to the control group, FLARE participants demonstrated greater increases in child sun-protective behaviors from baseline through the second postintervention assessment (B = 0.26; 95% CI, 0.14-0.38; P < .001). No significant between-group differences were observed for intentional or unintentional tanning, which were infrequently reported at baseline. In this randomized clinical trial, FLARE failed to reduce child sunburn over time compared with an active educational control. Although FLARE improved sun-protective behaviors and was associated with lower child-reported sunburn immediately postintervention, additional strategies may be needed for sustained reductions in high-risk children. ClinicalTrials.gov Identifier: NCT04201223.
中文摘要:黑色素瘤幸存者的子女终生罹患黑色素瘤的风险增加2倍,但他们的防晒措施不一致,并会发生可预防的晒伤。旨在评估一种通过远程医疗实施的行为干预,用于黑色素瘤幸存者子女的皮肤癌预防。这项平行组随机临床试验于2020年4月至2023年10月将幸存者-子女二元组分配至家庭、生活方式、行动与风险教育(FLARE)干预组或对照组。参与者通过癌症登记处以及全州和临床数据库招募。符合条件的幸存者经确诊患有黑色素瘤,且至少有1名8至17岁子女,该子女在过去一年中发生1次或多次晒伤。在520名符合条件的幸存者中,364个二元组入组、完成基线评估并接受随机化。数据分析时间为2025年至2026年。两种干预均为为期4周通过远程医疗提供的教育模块。FLARE包括家族性黑色素瘤风险教育以及针对儿童防晒的技能培养。对照组包括关于识别可靠健康信息来源的一般皮肤癌教育。主要结局是儿童晒伤发生情况,评估从基线到干预后2次评估的变化。次要结局包括儿童防晒行为和晒黑。共招募并随机化364个幸存者-子女二元组(父母:平均[SD]年龄45.1[6.2]岁;228名女性[62.6%];子女:平均[SD]年龄12.9[2.6]岁;189名女性[51.9%])。主要分析在意向治疗分析中纳入364个二元组(FLARE组180个[49.5%],对照组184个[50.5%]),未发现两组之间晒伤发生率随时间变化存在显著差异。然而,在第一次干预后评估时,FLARE组儿童报告的晒伤发生低于对照组(B=-0.17;95% CI,-0.30至-0.04;P=.01)。与对照组相比,FLARE参与者在从基线到第二次干预后评估期间儿童防晒行为增加更明显(B=0.26;95% CI,0.14-0.38;P<.001)。在有意图或无意图晒黑方面未观察到显著的组间差异,而基线时这些行为报告较少。在这项随机临床试验中,与积极的健康教育对照组相比,FLARE未能随时间减少儿童晒伤。尽管FLARE改善了防晒行为,并与干预后即刻较低的儿童报告晒伤相关,但可能需要额外策略才能在高风险儿童中持续减少晒伤。ClinicalTrials.gov标识符:NCT04201223。
Journal of hepatology IF 40.1 2026-10-06 PMID: 42838226
Clinical trials in unresectable hepatocellular carcinoma (uHCC) often exclude patients with poor prognostic factors, including impaired liver function, poor functional status or main trunk portal vein thrombosis (Vp4). The dual immune checkpoint inhibitor regimen STRIDE (Single Tremelimumab Regular Interval Durvalumab) is a standard-of-care treatment for first-line uHCC. The phase IIIb SIERRA (NCT05883644) study previously reported early safety of STRIDE in participants of poor prognosis. Here, we present safety and efficacy results from the primary analysis of the SIERRA study. Adults with uHCC with either Child-Pugh B7/B8 liver function (Child-Pugh B7/B8 cohort), Eastern Cooperative Oncology Group performance status 2 (ECOG PS 2 cohort) or Vp4 (Vp4 cohort) were enrolled. All participants received STRIDE (tremelimumab 300 mg plus durvalumab 1500 mg once, followed by durvalumab 1500 mg every 4 weeks) until disease progression, unacceptable toxicity or withdrawal. Primary endpoints were Grade 3 or 4 adverse events possibly related to study treatment within 6 months of treatment initiation (Grade 3/4 PRAEs ≤6 months) and objective response rate (ORR; data cut-off: 22 September 2025). In total, 111 participants were included (Child-Pugh B7/B8 n = 44, ECOG PS 2 n = 47, Vp4 n = 20). The incidence of Grade 3/4 PRAEs ≤6 months (95% confidence interval [CI]) was 19.8% (12.9-28.5): Child-Pugh B7/B8, 18.2% (8.2-32.7); ECOG PS 2, 19.1% (9.1-33.3); and Vp4, 25.0% (8.7-49.1). ORR (95% CI) was 14.4% (8.5-22.4): Child-Pugh B7/B8, 6.8% (1.4-18.7); ECOG PS 2, 21.3% (10.7-35.7); and Vp4, 15.0% (3.2-37.9). SIERRA safety and efficacy findings were indicative of a favourable risk-benefit profile for STRIDE in this participant population with a high unmet need. Participants with poor prognosis (e.g. Child-Pugh B/C, Eastern Cooperative Oncology Group performance status >1 or main trunk portal vein thrombosis [Vp4]) remain underrepresented in global, phase III trials despite comprising up to 65% of patients with unresectable hepatocellular carcinoma (uHCC) in clinical practice. To address this unmet need, the phase IIIb SIERRA study (NCT05883644) evaluated STRIDE (Single Tremelimumab Regular Interval Durvalumab) in participants with poor prognostic factors. Safety and efficacy findings as per the co-primary endpoints are indicative of a favourable risk-benefit profile for STRIDE in this participant population with a high unmet need, with an incidence of Grade 3 or 4 PRAEs within 6 months of 19.8% and ORR of 14.4% in the total population. This is the first prospective interventional study to provide data informing the safety and efficacy of STRIDE in patients with uHCC in a previously underrepresented population of poor prognosis that are excluded from other phase III trials. NCT05883644.
中文摘要:不可切除肝细胞癌(uHCC)的临床试验常排除具有不良预后因素的患者,包括肝功能受损、功能状态差或门静脉主干癌栓(Vp4)。双免疫检查点抑制剂方案STRIDE(单次曲美木单抗、固定间隔度伐利尤单抗)是不可切除肝细胞癌一线治疗的标准方案。IIIb期SIERRA研究(NCT05883644)此前报告了STRIDE在预后不良受试者中的早期安全性。在此,我们报告SIERRA研究主要分析的安全性和有效性结果。入组者为患有uHCC且符合以下任一情况的成人:Child-Pugh B7/B8肝功能(Child-Pugh B7/B8队列)、美国东部肿瘤协作组体能状态评分2(ECOG PS 2队列)或Vp4(Vp4队列)。所有受试者接受STRIDE(曲美木单抗300 mg加度伐利尤单抗1500 mg一次,随后度伐利尤单抗1500 mg每4周一次),直至疾病进展、出现不可接受的毒性或退出。主要终点为治疗开始后6个月内可能与研究治疗相关的3或4级不良事件(≤6个月的3/4级PRAE)和客观缓解率(ORR;数据截止日期:2025年9月22日)。共纳入111名受试者(Child-Pugh B7/B8 n=44,ECOG PS 2 n=47,Vp4 n=20)。≤6个月的3/4级PRAE发生率(95%置信区间[CI])为19.8%(12.9-28.5):Child-Pugh B7/B8为18.2%(8.2-32.7);ECOG PS 2为19.1%(9.1-33.3);Vp4为25.0%(8.7-49.1)。ORR(95% CI)为14.4%(8.5-22.4):Child-Pugh B7/B8为6.8%(1.4-18.7);ECOG PS 2为21.3%(10.7-35.7);Vp4为15.0%(3.2-37.9)。SIERRA的安全性和有效性结果表明,在这一需求高度未满足的受试者人群中,STRIDE具有有利的风险-获益特征。预后不良的受试者(例如Child-Pugh B/C、美国东部肿瘤协作组体能状态>1或门静脉主干癌栓[Vp4])尽管在临床实践中占不可切除肝细胞癌(uHCC)患者的比例高达65%,但在全球III期试验中仍代表性不足。为满足这一未满足需求,IIIb期SIERRA研究(NCT05883644)评估了STRIDE(单次曲美木单抗、固定间隔度伐利尤单抗)在具有不良预后因素受试者中的应用。根据共同主要终点得出的安全性和有效性结果表明,在这一需求高度未满足的受试者人群中,STRIDE具有有利的风险-获益特征,总人群中治疗开始后6个月内3或4级PRAE发生率为19.8%,ORR为14.4%。这是首个前瞻性干预性研究,为STRIDE在uHCC患者中的应用提供安全性和有效性数据,这些患者属于既往代表性不足、被其他III期试验排除的预后不良人群。NCT05883644。
Endoscopy IF 11.8 2026-10-06 PMID: 42838103
The benefit of additional gastrectomy after eCuraC-2 non-curative endoscopic resection for early gastric cancer in older patients is uncertain because of competing mortality. This nationwide retrospective cohort included 1,038 patients aged ≥75 years with eCuraC-2 resection at 22 Korean hospitals (352 additional gastrectomy; 686 surveillance). The primary outcome was overall survival (OS). Secondary outcomes were gastric cancer (GC)-specific mortality and any recurrence. Multivariable Cox and competing-risk analyses were performed. Inverse probability of treatment weighting (IPTW) was used for sensitivity analysis. At 5 years, OS was 76.5% with surveillance versus 83.0% after additional gastrectomy (hazard ratio [HR] 1.37, 95% confidence interval [CI] 1.08-1.74; P=0.01). However, surveillance patients were older (≥80 years: 43.3% vs 24.1%) and more frequently had ECOG-PS 2-4 (11.7% vs. 6.8%), whereas gastrectomy patients had higher-risk pathology, including lymphovascular invasion (60.8% vs 37.0%). Although recurrence was more frequent with surveillance (9.9% vs. 1.8%; adjusted SHR 5.71, 95% CI 2.57-12.69), GC-specific death was rare (17 events; 1.3% vs. 1.1%). The unadjusted SHR for surveillance versus gastrectomy was imprecise (1.62, 95% CI 0.53-4.96; P=0.40), whereas the IPTW-weighted sensitivity estimate was larger (SHR 3.34, 95% CI 1.28-8.72; P=0.014). The derived all-cause/GC-specific mortality-rate ratios were 22.2 with surveillance and 27.3 after gastrectomy. In elderly patients with non-curative ESD, prognosis is driven more by competing non-GC mortality than by GC-related death. Additional gastrectomy may improve cancer-specific outcomes in selected patients, but its OS benefit appears limited. Management should therefore be individualized rather than based on curability criteria alone, balancing pathological risk against operative risk, postoperative functional consequences, physiological reserve, and patient preferences.
中文摘要:对于老年早期胃癌患者,在eCuraC-2非治愈性内镜切除术后追加胃切除术的获益因竞争性死亡风险而不确定。这项全国性回顾性队列研究纳入来自韩国22家医院的1,038例年龄≥75岁且接受eCuraC-2切除的患者(352例追加胃切除术;686例监测)。主要结局为总生存期(OS)。次要结局为胃癌特异性死亡和任何复发。研究进行了多变量Cox回归和竞争风险分析。采用逆概率治疗加权(IPTW)进行敏感性分析。5年时,监测组OS为76.5%,追加胃切除术组为83.0%(风险比[HR] 1.37,95%置信区间[CI] 1.08-1.74;P=0.01)。然而,监测组患者年龄更大(≥80岁:43.3% vs 24.1%),且ECOG-PS 2-4更常见(11.7% vs 6.8%),而胃切除术组具有更高危病理,包括淋巴血管侵犯(60.8% vs 37.0%)。尽管监测组复发更频繁(9.9% vs 1.8%;校正亚分布风险比[SHR] 5.71,95% CI 2.57-12.69),胃癌特异性死亡罕见(17例事件;1.3% vs 1.1%)。监测组相较胃切除术组的未校正SHR不精确(1.62,95% CI 0.53-4.96;P=0.40),而IPTW加权敏感性估计值更大(SHR 3.34,95% CI 1.28-8.72;P=0.014)。推导的全因/胃癌特异性死亡率比在监测组为22.2,在胃切除术后为27.3。在非治愈性ESD的老年患者中,预后更多由竞争性非胃癌死亡驱动,而非胃癌相关死亡。对经选择的患者,追加胃切除术可能改善癌症特异性结局,但其OS获益似乎有限。因此,治疗管理应个体化,而非仅基于可治愈性标准,需权衡病理风险与手术风险、术后功能后果、生理储备和患者偏好。
Annals of internal medicine IF 17.2 2026-10-06 PMID: 42832800
Vasomotor symptoms (VMS) are common in perimenopausal and postmenopausal females. To evaluate benefits, harms, patient values and preferences, and cost-effectiveness of pharmacologic treatments for VMS. MEDLINE ALL, Embase, and Cochrane Central Register of Controlled Trials from inception to 3 March 2026. Randomized trials of at least 8 weeks' duration of eligible medications in females with VMS reporting VMS frequency and severity, menopause-related quality of life (QoL), sleep quality, endometrial hyperplasia or cancer, and/or serious adverse events (SAEs); U.S. Food and Drug Administration and European Medicines Agency labels for additional harms. Data were abstracted by 1 reviewer and verified by a second reviewer. Independent, dual risk-of-bias assessments were performed. Certainty of evidence (COE) was assessed by 1 reviewer and overread by a second reviewer. Ninety trials were included. COE was low to moderate for most comparisons. Compared with placebo, estrogens with or without progestogens, conjugated estrogen with bazedoxifene (CE/BZA), and oxybutynin reduced VMS frequency and severity. Compared with placebo, neurokinin receptor antagonists (NKRAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), gabapentin, and progestogens reduced VMS frequency but not severity. Estrogen efficacy varied by dose but not route. Estrogens with and without progestogens, CE/BZA, NKRAs, SNRIs, and SSRIs improved menopause-related QoL; gabapentin, NKRAs, oxybutynin, SNRIs, and SSRIs improved sleep quality. Few SAEs were reported. Evidence was insufficient for patient values and preferences. Estrogens with or without progestogens are of high economic value (high COE). The NKRA fezolinetant has low value (moderate COE). Most studies were short-term and were not designed to evaluate SAEs or long-term harms. Observational studies that could address long-term harms were not included. Estrogens reduced VMS frequency and severity and improved QoL (with or without progestogens and with BZA). NKRAs, SNRIs, and SSRIs improved VMS frequency, QoL, and sleep. Estrogens with and without progestogens were of high economic value. Harms data were limited. Little comparative information exists. American College of Physicians. (PROSPERO: CRD42024558116).
中文摘要:血管舒缩症状(VMS)在围绝经期和绝经后女性中常见。旨在评估VMS药物治疗的获益、危害、患者价值观与偏好以及成本效果。检索MEDLINE ALL、Embase和Cochrane Central Register of Controlled Trials,自建库至2026年3月3日。纳入针对有VMS女性的合格药物的随机试验,疗程至少8周,报告VMS频率和严重程度、绝经相关生活质量(QoL)、睡眠质量、子宫内膜增生或癌症和/或严重不良事件(SAEs);同时检索美国食品药品监督管理局和欧洲药品管理局说明书以补充危害信息。数据由1名评价者提取,并由第2名评价者核实。进行独立、双人偏倚风险评估。证据确定性(COE)由1名评价者评估,并由第2名评价者复核。共纳入90项试验。大多数比较的COE为低至中等。与安慰剂相比,雌激素联合或不联合孕激素、共轭雌激素联合巴多昔芬(CE/BZA)以及奥昔布宁降低了VMS频率和严重程度。与安慰剂相比,神经激肽受体拮抗剂(NKRA)、5-羟色胺-去甲肾上腺素再摄取抑制剂(SNRI)、选择性5-羟色胺再摄取抑制剂(SSRI)、加巴喷丁和孕激素降低了VMS频率,但未降低严重程度。雌激素疗效因剂量而异,但不因给药途径而异。雌激素联合或不联合孕激素、CE/BZA、NKRA、SNRI和SSRI改善了绝经相关QoL;加巴喷丁、NKRA、奥昔布宁、SNRI和SSRI改善了睡眠质量。报告的SAEs较少。关于患者价值观与偏好的证据不足。雌激素联合或不联合孕激素具有高经济价值(高COE)。NKRA非唑奈坦价值低(中等COE)。大多数研究为短期研究,未设计用于评估SAEs或长期危害。能够评估长期危害的观察性研究未被纳入。雌激素降低了VMS频率和严重程度并改善了QoL(联合或不联合孕激素以及与BZA联合)。NKRA、SNRI和SSRI改善了VMS频率、QoL和睡眠。雌激素联合或不联合孕激素具有高经济价值。危害数据有限。比较性信息很少。美国医师学会。(PROSPERO:CRD42024558116)。
Journal of hepatology IF 40.1 2026-10-05 PMID: 42833311
Resmetirom, a thyroid hormone receptor beta agonist, improves metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis in patients with non-cirrhotic MASH. Risk genotypes of PNPLA3, HSD17B13, TM6SF2, MTARC1, MBOAT7, and SERPINA1 have been associated with altered susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD), MASH, fibrosis, cirrhosis, and/or hepatocellular carcinoma. We evaluated the impact of MASLD risk genotypes on baseline characteristics and the response to resmetirom vs. placebo with respect to MASH, fibrosis, MRI-proton density fat fraction (MRI-PDFF), and other biomarkers. Testing the effects of MASLD risk genotypes or combinations of high-risk alleles on liver biopsy, MRI-PDFF, and biomarker responses to resmetirom was a pre-specified analysis in 738 patients enrolled in the MAESTRO-NASH phase III trial who consented to DNA collection, were genotyped for all genes, and had liver biopsies at baseline and Week 52. At baseline, patients with high-risk genotypes of PNPLA3 or HSD17B13 had a lower frequency of metabolic risk factors, including type 2 diabetes mellitus and hypertension, than patients with low-risk genotypes. Interaction analyses and efficacy assessments indicated that resmetirom had similar positive effects on MASH resolution, fibrosis improvement on liver biopsy, MRI-PDFF response, and biomarkers at Week 52 in MAESTRO-NASH patients with high-risk genotypes of PNPLA3, HSD17B13, TM6SF2, MTARC1, and MBOAT7, either individually or as part of a composite genetic risk score. These effects were independent of sex, Hispanic ethnicity, and metabolic risk factors. Due to the limited sample size, the study was not powered to detect small effects of risk genotypes on resmetirom efficacy. Resmetirom's effects on MASH, liver fibrosis, MRI-PDFF, and MASH biomarkers in the MAESTRO-NASH trial were not significantly impacted by the presence of common MASH risk genotypes, suggesting that resmetirom's mechanism of action may help mitigate the deleterious effects of MASH risk variants. Number: NCT03900429 IMPACT AND IMPLICATIONS: Resmetirom has recently been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). It leads to MASH resolution and improvement of fibrosis in patients with non-cirrhotic MASH. Patients with MASH have higher prevalence of certain genetic variants which can be associated with more severe disease. In this study we evaluated the relationship between the presence of select MASH risk genotypes (e.g. PNPLA3, TM6SF2, or HSD17B13) or the combined total of MASH genetic risk alleles on the response to resmetirom and placebo in 738 patients with non-cirrhotic MASH with serial liver biopsies at baseline and week 52. Within the limitation of study sample size, resmetirom's benefits on MASH resolution, fibrosis improvement and hepatic steatosis were independent of the presence of MASH genetic risk genotypes either alone or in combination.
中文摘要:Resmetirom是一种甲状腺激素受体β激动剂,可改善非肝硬化性代谢功能障碍相关脂肪性肝炎(MASH)患者的MASH和肝纤维化。PNPLA3、HSD17B13、TM6SF2、MTARC1、MBOAT7和SERPINA1的风险基因型与代谢功能障碍相关脂肪性肝病(MASLD)、MASH、纤维化、肝硬化及/或肝细胞癌易感性的改变相关。我们评估了MASLD风险基因型对基线特征以及resmetirom与安慰剂相比在MASH、纤维化、MRI质子密度脂肪分数(MRI-PDFF)和其他生物标志物方面反应的影响。检测MASLD风险基因型或高风险等位基因组合对肝活检、MRI-PDFF和生物标志物对resmetirom反应的影响,是MAESTRO-NASH III期试验中738例患者的一项预先指定分析;这些患者同意DNA采集,接受了所有基因的基因分型,并在基线和第52周进行了肝活检。在基线时,PNPLA3或HSD17B13高风险基因型患者中代谢危险因素(包括2型糖尿病和高血压)的频率低于低风险基因型患者。相互作用分析和疗效评估表明,在MAESTRO-NASH患者中,无论PNPLA3、HSD17B13、TM6SF2、MTARC1和MBOAT7高风险基因型是单独存在还是作为复合遗传风险评分的一部分,resmetirom在第52周对MASH消退、肝活检纤维化改善、MRI-PDFF反应和生物标志物均具有相似的积极作用。这些作用独立于性别、西班牙裔族裔背景和代谢危险因素。由于样本量有限,本研究不足以检测风险基因型对resmetirom疗效的微小影响。在MAESTRO-NASH试验中,resmetirom对MASH、肝纤维化、MRI-PDFF和MASH生物标志物的作用未受到常见MASH风险基因型存在的显著影响,提示resmetirom的作用机制可能有助于减轻MASH风险变异的有害影响。编号:NCT03900429。影响和意义:Resmetirom最近已被批准用于治疗代谢功能障碍相关脂肪性肝炎(MASH)。它可使非肝硬化性MASH患者的MASH消退并改善纤维化。MASH患者中某些遗传变异的患病率较高,这些变异可能与更严重的疾病相关。在本研究中,我们评估了在738例非肝硬化性MASH患者中,选定的MASH风险基因型(如PNPLA3、TM6SF2或HSD17B13)的存在或MASH遗传风险等位基因总和与resmetirom和安慰剂反应之间的关系,这些患者在基线和第52周进行了系列肝活检。在研究样本量的限制下,resmetirom对MASH消退、纤维化改善和肝脂肪变性的益处独立于MASH遗传风险基因型的存在,无论是单独还是组合存在。
JAMA internal medicine IF 26.3 2026-10-05 PMID: 42832241
The COVID-19 pandemic disproportionately affected patients with autoimmune and rheumatic diseases. Understanding whether certain medications affect the response to a SARS-CoV-2 supplemental dose vaccination is critical for counseling and treating patients receiving targeted immunomodulatory medications. The effect of holding these medications around the time of COVID-19 vaccination on immunogenicity and rheumatic disease outcomes has not been well studied. To assess whether temporarily holding biologic or targeted synthetic disease-modifying antirheumatic drug therapy improves humoral immunogenicity following COVID-19 supplemental dose vaccination in patients with inflammatory arthritis as well as evaluate whether such interruption worsened disease activity. The COVID-19 Vaccine Response (COVER) trial was a multicenter randomized clinical pragmatic trial conducted from November 2021 to May 2024 of patients with rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis who were receiving care in the Excellence Network in Rheumatology to Innovate Care and High-Impact Research (ENRICH) practice-based network. Data were analyzed from June 2024 to April 2026. Patients had received a primary messenger RNA COVID-19 vaccine series and were receiving stable immunomodulatory therapy with anti-tumor necrosis factor, anti-interleukin-17, abatacept, and a Janus kinase inhibitor (JAKi). Patients were randomized to continue or hold therapy for 2 weeks following their next COVID-19 supplemental dose administration. The primary outcome was change in immunoglobulin G levels against the SARS-CoV-2 spike protein from baseline to 6-week follow-up, expressed as the geometric mean fold rise (GMFR). The primary analysis followed an intention-to-treat (ITT) principle, with missing outcomes addressed through multiple imputations. A per-protocol sensitivity analysis was also conducted. Secondary outcomes included disease flares and vaccine-related adverse events. Among 840 randomized participants (continue group: 319 female individuals [76%]; mean [SD] age, 60.0 [12.9] years; hold group: 336 female individuals [80%]; mean [SD] age, 59.1 [12.9] years), substantial increases in SARS-CoV-2 spike immunoglobulin G antibody levels were observed across all groups from baseline to the postdose visit. In the primary ITT analysis, the GMFR ratio (hold/continue) was 0.96 (95% CI, 0.36-2.56), indicating no significant difference in humoral immunogenicity between arms. Results were consistent across drug subgroups and drug half-life categories. Holding therapy significantly increased disease flare risk (odds ratio, 2.27; 95% CI, 1.41-3.65), which was most pronounced among those who used JAKi; the Outcome Measures in Rheumatology RA Flare Questionnaire corroborated this perivaccination signal (54 of 256 [21.1%] vs 23 of 253 [9.1%] with ≥10-point worsening; risk difference, 12.0%; 95% CI, 5.9%-18.1%), with full recovery in both arms by 6-week follow-up. Adverse events were comparable between medication arms and were more frequent in the hold group. This randomized clinical trial found that, among patients with inflammatory arthritis, holding select biologic or JAKi therapies for 2 weeks at the time of supplemental COVID-19 vaccine dose did not significantly enhance humoral immunogenicity and was associated with transient but clinically meaningful disease flare. Routine interruption of these therapies at the time of COVID-19 dose administration is likely not warranted. ClinicalTrials.gov Identifier: NCT05080218.
中文摘要:COVID-19 大流行对自身免疫性和风湿性疾病患者造成了不成比例的影响。了解某些药物是否影响对 SARS-CoV-2 补充剂次疫苗接种的反应,对于接受靶向免疫调节药物治疗患者的咨询和治疗至关重要。在 COVID-19 疫苗接种前后暂停这些药物对免疫原性和风湿病结局的影响尚未得到充分研究。旨在评估在炎性关节炎患者中,暂时停用生物制剂或靶向合成改善病情抗风湿药是否可提高 COVID-19 补充剂次疫苗接种后的体液免疫原性,并评估这种中断是否加重疾病活动度。COVID-19 疫苗反应(COVER)试验是一项多中心随机临床实用性试验,于2021年11月至2024年5月开展,纳入在风湿病学创新照护与高影响研究卓越网络(ENRICH)实践网络中接受照护的类风湿关节炎、银屑病关节炎和轴性脊柱关节炎患者。数据分析时间为2024年6月至2026年4月。患者已接受信使 RNA COVID-19 疫苗基础免疫系列,并正在接受稳定的免疫调节治疗,包括抗肿瘤坏死因子、抗白细胞介素-17、阿巴西普和 Janus 激酶抑制剂(JAKi)。患者被随机分配为在下一剂 COVID-19 补充剂次接种后继续用药或暂停用药2周。主要结局为从基线至6周随访时针对 SARS-CoV-2 刺突蛋白的免疫球蛋白 G 水平变化,以几何平均倍数升高(GMFR)表示。主要分析遵循意向性治疗(ITT)原则,缺失结局通过多重插补处理。还进行了符合方案敏感性分析。次要结局包括疾病发作和疫苗相关不良事件。在840名随机化参与者中(继续用药组:319名女性[76%];平均[SD]年龄60.0[12.9]岁;暂停用药组:336名女性[80%];平均[SD]年龄59.1[12.9]岁),从基线至接种后访视,所有组均观察到 SARS-CoV-2 刺突免疫球蛋白 G 抗体水平大幅升高。在主要 ITT 分析中,GMFR 比值(暂停/继续)为0.96(95% CI,0.36-2.56),表明两组间体液免疫原性无显著差异。结果在各药物亚组和药物半衰期类别中一致。暂停用药显著增加疾病发作风险(比值比2.27;95% CI,1.41-3.65),在 JAKi 使用者中最为明显;风湿病学结局指标 RA 发作问卷也证实了这一围疫苗接种期信号(≥10分加重:256例中54例[21.1%] vs 253例中23例[9.1%];风险差12.0%;95% CI,5.9%-18.1%),两组均在6周随访时完全恢复。药物组间不良事件相当,暂停组更频繁。这项随机临床试验发现,在炎性关节炎患者中,在 COVID-19 疫苗补充剂次接种时暂停特定生物制剂或 JAKi 治疗2周并未显著增强体液免疫原性,且与短暂但具有临床意义的疾病发作相关。因此,在 COVID-19 疫苗接种时常规中断这些治疗很可能并无必要。ClinicalTrials.gov 标识符:NCT05080218。
JAMA internal medicine IF 26.3 2026-10-05 PMID: 42832233
Colorectal cancer is the second leading cause of cancer mortality worldwide. Early detection through screenings has been shown to improve morbidity and mortality. While fecal immunochemical test (FIT) or fecal occult blood test (FOBT) are established cost-effective screening modalities for colorectal cancer, follow-up colonoscopy screening rates remain suboptimal. To evaluate interventions targeting colonoscopy completion and the prevalence of colonoscopy completion after an abnormal FIT/FOBT result. MEDLINE, Embase, and Cochrane databases were searched from inception to May 9, 2026, and the bibliographies of relevant studies were screened. Original studies, published in English, examining nonrandomized interventional studies or randomized clinical trials comparing interventions to improve follow-up colonoscopy after an abnormal FIT/FOBT result were included. Prevalence and risk ratios (RRs) with accompanying 95% CIs for each study were computed, and the results were pooled using a random-effects meta-analysis. This study was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline. Two authors reviewed each study and extracted the data independently, with discrepancies referred to a third independent author. Outcomes included prevalence and RR of various interventions. A total of 21 studies involving 19 613 patients (8101 female individuals [41.3%] and 11 512 male individuals [58.7%]; age range, 50-75 years) evaluating interventions to improve colonoscopy completion after an abnormal FIT/FOBT result were included. Patient navigation (RR, 1.24; 95% CI, 1.15-1.33; I2 = 57.1), patient reminders (RR, 1.32; 95% CI, 1.04-1.67; I2 = 89.9), clinician reminders (RR, 1.36; 95% CI, 1.12-1.65; I2 = 94.4), and automated referrals to gastrointestinal consult (RR, 1.68; 95% CI, 1.09-2.60; I2 = 91.9) were effective in increasing follow-up colonoscopy completion with moderate to high heterogeneity detected within and across intervention types. Sensitivity analyses excluding outliers resulted in low heterogeneity for patient navigation, patient reminders (messaging), and clinician reminders, while moderate heterogeneity remained for automated referrals. Follow-up colonoscopy increased from 4755 of 10 263 in control to 6272 of 9350 after interventions; pooled prevalence estimates were 47.8% and 69.1%, respectively. In this systematic review and meta-analysis, patient-level and system-level interventions, including patient navigation, patient reminders, and clinician reminders, are associated with increased completion of follow-up colonoscopy after an abnormal FIT/FOBT result. More studies are required to evaluate the efficacy of automated referrals to gastrointestinal consult due to large heterogeneity between studies and to study the incremental effect of each intervention in multicomponent interventions.
中文摘要:结直肠癌是全球癌症死亡的第二大原因。通过筛查进行早期发现已被证明可改善发病率和死亡率。尽管粪便免疫化学检测(FIT)或粪便隐血试验(FOBT)是结直肠癌既定且具有成本效益的筛查方式,但后续结肠镜检查的筛查率仍不理想。旨在评估针对结肠镜检查完成的干预措施以及FIT/FOBT结果异常后结肠镜检查完成率。检索了MEDLINE、Embase和Cochrane数据库,自建库至2026年5月9日,并筛查了相关研究的参考文献。纳入以英文发表的原创研究,这些研究为比较旨在改善FIT/FOBT结果异常后后续结肠镜检查的干预措施的非随机干预性研究或随机临床试验。计算了每项研究的完成率和风险比(RR)及其95%CI,并使用随机效应荟萃分析合并结果。本研究按照系统评价和荟萃分析首选报告项目(PRISMA)报告指南进行。两名作者独立审阅每项研究并提取数据,分歧交由第三位独立作者处理。结局包括各种干预措施的完成率和RR。共纳入21项研究,涉及19613例患者(8101名女性个体[41.3%]和11512名男性个体[58.7%];年龄范围50-75岁),评估改善FIT/FOBT结果异常后结肠镜检查完成的干预措施。患者导航(RR,1.24;95%CI,1.15-1.33;I²=57.1)、患者提醒(RR,1.32;95%CI,1.04-1.67;I²=89.9)、临床医生提醒(RR,1.36;95%CI,1.12-1.65;I²=94.4)以及自动转诊至胃肠科会诊(RR,1.68;95%CI,1.09-2.60;I²=91.9)均能有效提高后续结肠镜检查完成率,在干预类型内部和不同类型之间检测到中至高度异质性。排除离群值的敏感性分析使患者导航、患者提醒(消息推送)和临床医生提醒的异质性降低,而自动转诊仍存在中度异质性。后续结肠镜检查从对照组的10263例中的4755例增加到干预后的9350例中的6272例;合并完成率估计分别为47.8%和69.1%。在这项系统评价和荟萃分析中,患者层面和系统层面的干预措施,包括患者导航、患者提醒和临床医生提醒,与FIT/FOBT结果异常后后续结肠镜检查完成率增加相关。由于研究间异质性较大,需要更多研究评估自动转诊至胃肠科会诊的疗效,并研究多组分干预中每种干预措施的增量效应。
European urology IF 29.1 2026-10-03 PMID: 42829266
Prostate-specific membrane antigen positron emission tomography (PSMA-PET) improves lesion detection, leading to treatment intensification via PSMA-guided radiotherapy (PSMAgRT), but its impact on patient outcomes remains undefined. We evaluated whether PSMAgRT improves failure-free survival (FFS). This phase 2, two-center, open-label randomized trial enrolled patients planned for standard-of-care (SOC) radiotherapy (RT). Patients were randomized 1:1 to SOC or PSMAgRT to all detected sites across four strata: salvage post-radical prostatectomy (RP), high-risk, oligometastatic, and salvage post-RT. Between 2018 and 2021, 262 patients were randomized (253 treated/analyzed). The primary FFS end point (measured from RT completion) comprised prostate-specific antigen (PSA)/radiological progression, next-line therapy, or death. Secondary end points included freedom from biochemical progression (FFBP; PSA rise ≥0.2 ng/ml post-RP or ≥2 ng/ml above nadir in other strata). Prespecified analyses used a one-sided threshold of p1 < 0.10, whereas post hoc analyses used two-sided p < 0.05 thresholds and 95% confidence intervals (CIs). Among 253 patients, median follow-up was 66 mo (range 9-91). The 5-yr primary FFS was 66% with PSMAgRT versus 62% in controls (hazard ratio [HR] = 0.80; one-sided 90% CI, upper bound 1.04; p1 = 0.14). FFBP favored PSMAgRT: 72% versus 65% overall (subdistribution HR [sHR] 0.70, one-sided 90% CI upper bound 0.92; p1 = 0.048), 81% versus 66% in patients with high-risk disease (sHR 0.54; p1 = 0.07), and 80% versus 68% in patients in post-RP stratum (sHR 0.54; p1 = 0.037). In an exploratory, post hoc analysis combining patients with high-risk disease and those in the post-RP stratum, FFBP favored PSMAgRT (sHR 0.54, 95% CI = 0.32-0.91; two-sided p = 0.02). Only one grade ≥3 event was possibly related to dose escalation. Limitations include a phase 2 design with a heterogeneous population. Although the primary FFS end point was not met in the overall population, treatment-effect estimates favored PSMAgRT in the high-risk and post-RP strata. These findings provide a meaningful rationale for the target populations currently being evaluated in the definitive phase 3 PATRON trial. ClinicalTrials.gov NCT03525288.
中文摘要:前列腺特异性膜抗原正电子发射断层扫描(PSMA-PET)可提高病灶检出率,从而通过PSMA引导的放疗(PSMAgRT)进行治疗强化,但其对患者结局的影响尚未明确。我们评估了PSMAgRT能否改善无失败生存(FFS)。这项2期、两中心、开放标签随机试验入组了计划接受标准治疗(SOC)放疗(RT)的患者。患者按1:1随机分配至SOC或PSMAgRT,后者照射所有检出的病灶,并按四个分层进行:根治性前列腺切除术后挽救治疗(RP)、高危、寡转移和RT后挽救治疗。2018年至2021年间,262例患者被随机分配(253例接受治疗/分析)。主要FFS终点(从RT完成时开始测量)包括前列腺特异性抗原(PSA)/影像学进展、下一线治疗或死亡。次要终点包括无生化进展生存(FFBP;RP后PSA升高≥0.2 ng/ml,或其他分层中PSA较最低值升高≥2 ng/ml)。预设分析使用单侧阈值p1<0.10,而事后分析使用双侧p<0.05阈值和95%置信区间(CI)。在253例患者中,中位随访时间为66个月(范围9-91)。5年主要FFS在PSMAgRT组为66%,对照组为62%(风险比[HR]=0.80;单侧90%CI上限1.04;p1=0.14)。FFBP有利于PSMAgRT:总体为72%对65%(亚分布风险比[sHR]0.70,单侧90%CI上限0.92;p1=0.048),高危疾病患者为81%对66%(sHR 0.54;p1=0.07),RP后分层患者为80%对68%(sHR 0.54;p1=0.037)。在一项探索性事后分析中,合并高危疾病患者和RP后分层患者,FFBP有利于PSMAgRT(sHR 0.54,95%CI=0.32-0.91;双侧p=0.02)。仅1例≥3级事件可能与剂量递增相关。局限性包括2期设计以及人群异质性。尽管主要FFS终点在总体人群中未达到,但治疗效应估计在高危和RP后分层中有利于PSMAgRT。这些发现为目前正在确证性3期PATRON试验中评估的目标人群提供了有意义的依据。ClinicalTrials.gov NCT03525288。
MedComm IF 14.1 2026-10 PMID: 42828116
Colorectal cancer (CRC) remains a leading cause of cancer incidence and mortality worldwide and is increasingly characterized by two converging realities: a substantial global burden and a rising incidence of early-onset CRC. This review synthesizes current advances in CRC epidemiology, risk factors, signaling biology, clinical presentation, screening, diagnosis, and management across the care continuum. We frame CRC as a systems-level disease in which genomic instability, epigenetic dysregulation, metabolic remodeling, tumor microenvironmental evolution, and gut microbiota interactions converge on interconnected pathways, including Wnt/β-catenin, MAPK, PI3K/AKT/mTOR, TGF-β, and immune-regulatory networks. We distinguish established standards of care from recent practice-changing developments and investigational strategies. Within this framework, we discuss blood-based screening, AI-assisted endoscopy, ctDNA-informed residual disease assessment, biomarker-defined molecular workup, immunotherapy strategies for dMMR disease, and targeted approaches for KRAS G12C-mutated, BRAF V600E-mutated, and HER2-positive metastatic CRC. Despite substantial progress, major challenges remain, including limited immunotherapy benefit in microsatellite-stable CRC, unequal access to high-quality screening and molecular testing, and uncertainty regarding implementation of newer biomarkers across diverse populations. An integrated framework linking population risk, tumor ecology, evidence-based biomarker use, and equitable precision care is essential for the next phase of CRC prevention and management.
中文摘要:结直肠癌(CRC)仍是全球癌症发病和死亡的主要原因,并且日益呈现出两个相互交汇的现实:巨大的全球疾病负担以及早发性结直肠癌发病率的上升。本综述综合了结直肠癌在流行病学、危险因素、信号生物学、临床表现、筛查、诊断以及贯穿诊疗全程的管理方面的当前进展。我们将结直肠癌视为一种系统层面的疾病,其中基因组不稳定性、表观遗传失调、代谢重塑、肿瘤微环境演化以及肠道微生物群相互作用汇聚于相互关联的通路,包括Wnt/β-catenin、MAPK、PI3K/AKT/mTOR、TGF-β和免疫调节网络。我们区分了已确立的标准治疗与近期改变实践的发展和研究性策略。在此框架内,我们讨论了基于血液的筛查、人工智能辅助内镜、基于ctDNA的残留病灶评估、生物标志物定义的分子检测、针对dMMR疾病的免疫治疗策略,以及针对KRAS G12C突变、BRAF V600E突变和HER2阳性转移性结直肠癌的靶向治疗。尽管取得了实质性进展,但重大挑战依然存在,包括微卫星稳定型结直肠癌中免疫治疗获益有限、高质量筛查和分子检测的可及性不平等,以及在不同人群中实施新型生物标志物的不确定性。一个将人群风险、肿瘤生态、循证生物标志物应用和公平精准诊疗联系起来的整合框架,对于结直肠癌预防和管理的下一阶段至关重要。
JAMA network open IF 11.7 2026-10-01 PMID: 42842248
Adolescents and young adults (AYAs) with hereditary cancer predisposition face high rates of lifetime cancer risk. Models to support their understanding of cancer risk have not been developed. To assess the effect of an electronic chatbot-based cancer risk communication tool on AYAs' understanding of cancer risk. This randomized clinical trial was conducted at the Dana-Farber Cancer Institute, Emory University/Children's Healthcare of Atlanta, University of Chicago, and University of Utah Huntsman Cancer Institute between December 20, 2022, and May 30, 2025 and compared cancer predisposition visits alone vs visits with an electronic chatbot-based cancer risk communication tool, AYA Risk Information and Screening Education, using baseline and follow-up surveys to assess changes in knowledge of cancer risk by age 30 years and over their lifetime, knowledge of recommended screening, and level of psychological distress. Eligible participants were English speakers aged 12 to 24 years, who had 1 of 9 hereditary cancer predisposition syndromes. The primary analysis was conducted according to the intention-to-treat principle. Data were analyzed from July 21 to September 3, 2025. Chatbot-based intervention with cancer risk and recommended screening information tailored to each syndrome. Additional links to resource pages with chat summary content (learn), recommended age-based screening (plan), guidance about talking with peers (share), links to support organizations (connect), and coping and bereavement support (grow). The primary outcome was knowledge of cancer risk. The secondary outcomes were knowledge of recommended screening and level of psychological distress. Of 798 AYAs assessed, 106 AYAs were randomized and enrolled (54 to the intervention group and 52 to the control group). Participants' mean (SD) age was 18.3 (SD, 3.9) years, and 64% (68 of 106) were girls or women. At baseline, 38% of AYAs (20 of 52) in the control group and 52% (28 of 54) of AYAs in the intervention group had accurate knowledge of cancer risk by age 30 years. Following the clinic visit, 37% (19 of 52) of AYAs in the control group and 78% (42 of 54) in the chatbot-based intervention group had accurate knowledge, reflecting greater improvement in knowledge of cancer risk by age 30 years (OR, 3.50; 95% CI, 1.45-9.19; P = .005). AYAs in the intervention group had non-statistically significant improvements in knowledge of recommended screening (OR, 2.17; 95% CI, 0.85-5.59; P = .11) and reductions in distress compared with AYAs in the control group (distress thermometer, β = -0.50; 95% CI, -1.09 to 0.08; P = .09). In this randomized clinical trial, use of a chatbot-based intervention combined with a cancer predisposition clinic visit improved knowledge of cancer risk by age 30 years over a clinic visit alone, without increasing distress. Combining human interaction in the clinic with personalized, accurate electronic information can support AYAs with cancer predisposition and other serious conditions. ClinicalTrials.gov Identifier: NCT04323774.
中文摘要:患有遗传性癌症易感性的青少年和年轻成人(AYAs)终生癌症风险较高。支持其理解癌症风险的模型尚未开发。旨在评估基于电子聊天机器人的癌症风险沟通工具对AYAs理解癌症风险的效果。本随机临床试验于2022年12月20日至2025年5月30日在丹娜-法伯癌症研究所、埃默里大学/亚特兰大儿童医疗中心、芝加哥大学和犹他大学亨茨曼癌症研究所开展,比较单纯癌症易感性门诊就诊与就诊时联合基于电子聊天机器人的癌症风险沟通工具AYA风险信息与筛查教育,使用基线和随访调查评估对30岁前及终生癌症风险知识的改变、对推荐筛查知识的改变以及心理痛苦水平。符合条件的参与者为12至24岁、讲英语、患有9种遗传性癌症易感综合征之一者。主要分析按意向性治疗原则进行。数据分析时间为2025年7月21日至9月3日。聊天机器人干预提供针对每种综合征定制的癌症风险和推荐筛查信息。附加链接包括包含聊天摘要内容的资源页面(学习)、推荐的基于年龄的筛查(计划)、关于与同伴交谈的指导(分享)、支持组织链接(联系)以及应对和丧亲支持(成长)。主要结局为癌症风险知识。次要结局为推荐筛查知识和心理痛苦水平。在评估的798名AYAs中,106名AYAs被随机分组并入组(54名进入干预组,52名进入对照组)。参与者平均(SD)年龄为18.3(SD,3.9)岁,64%(106名中的68名)为女孩或女性。基线时,对照组38%的AYAs(52名中的20名)和干预组52%的AYAs(54名中的28名)准确了解30岁前癌症风险。门诊就诊后,对照组37%(52名中的19名)的AYAs和基于聊天机器人干预组78%(54名中的42名)的AYAs具有准确知识,反映出30岁前癌症风险知识的改善更大(OR,3.50;95% CI,1.45-9.19;P = .005)。与对照组AYAs相比,干预组AYAs在推荐筛查知识方面有非统计学显著改善(OR,2.17;95% CI,0.85-5.59;P = .11),痛苦减少(痛苦温度计,β = -0.50;95% CI,-1.09至0.08;P = .09)。在本随机临床试验中,与单纯门诊就诊相比,基于聊天机器人的干预联合癌症易感性门诊就诊改善了30岁前癌症风险知识,且未增加痛苦。将门诊中的人际互动与个性化、准确的电子信息结合可以支持患有癌症易感性和其他严重疾病的AYAs。ClinicalTrials.gov标识符:NCT04323774。
Journal of the American Academy of Dermatology IF 12.3 2026-10-01 PMID: 42822768
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although prognosis is generally favorable, a subset of tumors behaves aggressively. Most established prognostic factors are defined after excision, limiting preoperative risk assessment. The neutrophil-to-lymphocyte ratio (NLR) is an accessible marker of systemic inflammation, but its prognostic value in cSCC remains insufficiently defined. To evaluate the prognostic utility of preoperative NLR in patients with high-risk cSCC. We conducted a single-center retrospective cohort study including 420 patients with high-risk cSCC who underwent surgical excision and had a complete blood count within 40 days before surgery. NLR was analyzed continuously and using a ROC-derived cut-off of ≥3. Fine-Gray models addressed competing mortality for cSCC-specific endpoints, whereas Cox regression was used for overall survival (OS). The optimal NLR cut-off for recurrence-free survival (RFS) was 2.97, rounded to 3 (AUC=0.622[0.554-0.690]). NLR≥3 was independently associated with RFS (sHR=2.43[1.62-3.66], P=<0.001) OS (HR=1.49[1.14-1.94], P=0.003), and all other cSCC-specific endpoints. Retrospective single-center design, modest discriminatory ability of NLR alone, and possible residual confounding from unrecorded inflammatory conditions. Preoperative NLR is a low-cost complementary biomarker independently associated with poor outcomes in high-risk cSCC and may complement current risk stratification.
中文摘要:皮肤鳞状细胞癌(cSCC)是第二常见的皮肤癌。尽管总体预后良好,但一部分肿瘤表现为侵袭性。大多数已确立的预后因素是在切除后确定的,限制了术前风险评估。中性粒细胞与淋巴细胞比值(NLR)是一种易于获取的全身炎症标志物,但其在cSCC中的预后价值仍不明确。评估术前NLR在高危cSCC患者中的预后价值。我们开展了一项单中心回顾性队列研究,纳入420例接受手术切除且术前40天内完成全血细胞计数的高危cSCC患者。NLR分别作为连续变量分析,并使用受试者工作特征(ROC)曲线得出的≥3作为截断值。针对cSCC特异性终点,采用Fine-Gray模型处理竞争性死亡风险;总生存期(OS)则采用Cox回归。无复发生存期(RFS)的最佳NLR截断值为2.97,取整为3(AUC=0.622[0.554-0.690])。NLR≥3与RFS(sHR=2.43[1.62-3.66],P<0.001)、OS(HR=1.49[1.14-1.94],P=0.003)以及所有其他cSCC特异性终点独立相关。回顾性单中心设计、NLR单独判别能力有限,以及未记录炎症状况可能导致的残余混杂。术前NLR是一种低成本补充生物标志物,与高危cSCC的不良结局独立相关,并可能补充当前的风险分层。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42820762
Meningiomas are graded using histologic and molecular criteria according to the World Health Organization (WHO) classification. However, there is scant evidence considering the specific value of each individual atypical histological feature that contributes to WHO grading. There is also little evidence-based guidance as to which cases should receive molecular testing. Detailed histological information was collected for 1058 resected meningiomas, including cases with genomic DNA methylation and copy number variant (CNV) data, next-generation sequencing, and RNA risk score. Integrated analyses were conducted using known prognostic variables, including WHO Grade, Ki-67, mitotic index (MI), and atypical histologic features (necrosis, hypercellularity, macronucleoli, sheeting, and small cells). Necrosis, elevated MI, and increased WHO grade correlated with specific DNA methylation patterns, RNA risk groups, and chromosomal CNVs. Predictive analysis identified MI as the strongest single correlate, and suggested the presence of ≥ 2 atypical features as an optimal threshold for recurrence prediction. Sheeting architecture was the only independent histologic correlate of recurrence. Integration of histologic and molecular features suggests that tumors with high MI have poor prognosis regardless of molecular profile. Further analysis of low MI tumors revealed specific predictors of unfavorable molecular profiles. These data indicate that some atypical histopathologic features are more powerful than others, and can be used on initial screening to increase the yield of molecular profiling of meningiomas. Furthermore, we propose that molecular testing may actually have greatest added value in cases with low, not high, MI.
中文摘要:脑膜瘤根据世界卫生组织(WHO)分类的组织学和分子标准进行分级。然而,关于每个参与WHO分级的非典型组织学特征的具体价值,证据仍然不足。对于哪些病例应接受分子检测,也缺乏基于证据的指导。我们收集了1058例切除脑膜瘤的详细组织学信息,包括具有基因组DNA甲基化和拷贝数变异(CNV)数据、二代测序以及RNA风险评分的病例。研究利用已知的预后变量进行整合分析,包括WHO分级、Ki-67、核分裂指数(MI)以及非典型组织学特征(坏死、细胞丰富、大核仁、片状排列和小细胞)。坏死、MI升高和WHO分级升高与特定的DNA甲基化模式、RNA风险分组和染色体CNV相关。预测分析确定MI是最强的单一相关因素,并提示存在≥2个非典型特征是预测复发的最佳阈值。片状结构是唯一与复发独立相关的组织学因素。组织学与分子特征的整合提示,无论分子特征如何,高MI肿瘤均预后不良。对低MI肿瘤的进一步分析揭示了不良分子特征的特定预测因素。这些数据表明,某些非典型组织病理学特征比其他特征更有力,可用于初始筛查,以提高脑膜瘤分子检测的产出。此外,我们提出,分子检测可能实际上在低MI而非高MI病例中具有最大的附加价值。
MedComm IF 14.1 2026-10 PMID: 42798798
Meningeal lymphatic vessels (mLVs) are crucial in intracranial tumor progression. This study investigated whether incorporating mLVs functional indicators into machine learning models enhances prognostic prediction for intracranial malignant tumors. We prospectively enrolled 246 patients, assessing baseline mLVs function via dynamic contrast-enhanced MRI. After 2.5 years' follow-up, 100 patients (51 survivors, 49 deceased) were finally included. The mean area under the receiver operating characteristic curve (AUROC) of the XGBoost model excluding DCE-MRI-based dural drainage function indicators (DDFIs) was 0.746 (95% CI: 0.621-0.871), which increased to 0.808 (95% CI: 0.733-0.883) with the inclusion of DDFIs. Kaplan-Meier survival curves demonstrated significantly better discrimination when DDFIs were included (p = 5.66 × 10-8 vs. p = 1.22 × 10-4). The c-index of the Cox regression model excluding DDFIs was 0.919 (95% CI: 0.916-0.940), rising to 0.948 (95% CI: 0.946-0.955) with their inclusion. In the glioma subgroup (n = 43), AUROC rose from 0.804 (95% CI: 0.629-0.980) to 0.904 (95% CI: 0.717-1.000). These findings indicate that integrating mLVs function significantly refines long-term prognostic accuracy in intracranial malignant tumors, supporting its potential clinical utility.
中文摘要:脑膜淋巴管(mLVs)在颅内肿瘤进展中至关重要。本研究探讨将mLVs功能指标纳入机器学习模型是否能提高颅内恶性肿瘤的预后预测。我们前瞻性纳入246例患者,通过动态对比增强MRI评估基线mLVs功能。随访2.5年后,最终纳入100例患者(51例存活,49例死亡)。未纳入基于DCE-MRI的硬脑膜引流功能指标(DDFIs)的XGBoost模型的平均受试者工作特征曲线下面积(AUROC)为0.746(95% CI:0.621-0.871),纳入DDFIs后升至0.808(95% CI:0.733-0.883)。Kaplan-Meier生存曲线显示,纳入DDFIs时区分度显著更优(p = 5.66 × 10-8 对 p = 1.22 × 10-4)。未纳入DDFIs的Cox回归模型的c指数为0.919(95% CI:0.916-0.940),纳入后升至0.948(95% CI:0.946-0.955)。在胶质瘤亚组(n = 43)中,AUROC从0.804(95% CI:0.629-0.980)升至0.904(95% CI:0.717-1.000)。这些发现表明,整合mLVs功能可显著改善颅内恶性肿瘤的长期预后准确性,支持其潜在的临床效用。
EClinicalMedicine IF 12.8 2026-10 PMID: 42774582
Chronic disseminated candidiasis (CDC) is a severe manifestation of invasive candidiasis predominantly affecting patients with haematological malignancies. Treatment recommendations are based on limited observational data, and the impact of widespread antifungal prophylaxis on CDC epidemiology and outcomes remains poorly characterised. We aimed to comprehensively characterise CDC and explore associations between antifungal treatment strategies and clinical outcomes. We performed a retrospective, multinational cohort study including adults with possible, probable, or proven CDC diagnosed between 2007 and 2025 identified through the FungiScope® registry (ClinicalTrials.gov: NCT01731353) and collaborating networks in 19 countries. Diagnostic findings, treatment strategies, and outcomes were analysed over 12 months. Exploratory comparative analyses assessed the association between antifungal treatment strategies and treatment response (composite of clinical, radiological, and mycological findings) and overall survival using inverse probability of treatment weighting to account for the time-varying confounders neutropenia and corticosteroid exposure. Of 111 patients, CDC was classified as possible in 23.4% (n = 26), probable in 50.5% (n = 56), and proven in 26.1% (n = 29) of patients. The predominant species were Candida albicans (32.4%, n = 36) and Candida tropicalis (24.3%, n = 27); no species was identified in 30.6% (n = 34). Breakthrough CDC occurred in 24.8% (27/109) of patients. PET/CT was used in 26.1% (n = 29) of patients for follow-up. Caspofungin (36.9%, 41/111) and liposomal amphotericin B (23/111; 20.7%) were the most frequently first-line agents for antifungal treatment. No statistically significant associations were detected between first-to-second-line treatment strategy, azole selection, and treatment response. Median treatment duration was 107 days (IQR 49-182), and no CDC relapse occurred after discontinuation. Corticosteroids for immune reconstitution inflammatory syndrome were used in 4.5% of patients. All-cause mortality was 33.3% (37/111), CDC-attributable mortality was 4.5% (5/111). Overall survival was higher among patients with breakthrough CDC than without (88.9% vs 58.5%; p = 0.004). No statistically significant associations between antifungal treatment strategy and treatment response or survival were detected in this retrospective dataset. However, the comparative treatment analyses were exploratory and the study was not powered to exclude clinically meaningful differences between antifungal strategies. Median treatment duration was shorter than previously reported. Future prospective studies integrating immunological biomarkers and the use of PET/CT-guided strategies are needed to optimise individualised treatment decision-making. This study received no dedicated external funding. FungiScope® receives unrestricted grants for registry maintenance and infrastructure from Basilea Pharmaceutica, Melinta Therapeutics LLC, Mundipharma Ltd., and Pfizer Inc, which had no role in the study design, conduct analysis, interpretation, manuscript preparation, or the decision to submit for publication.
中文摘要:慢性播散性念珠菌病(CDC)是侵袭性念珠菌病的严重表现,主要影响血液系统恶性肿瘤患者。治疗建议基于有限的观察性数据,广泛抗真菌预防对CDC流行病学和结局的影响仍缺乏充分描述。我们旨在全面描述CDC,并探讨抗真菌治疗策略与临床结局之间的关联。我们开展了一项回顾性、多国队列研究,纳入2007年至2025年间通过FungiScope®登记处(ClinicalTrials.gov:NCT01731353)及19个国家的合作网络诊断的可能、很可能或确诊CDC的成人患者。对诊断发现、治疗策略和12个月内的结局进行分析。探索性比较分析评估抗真菌治疗策略与治疗反应(临床、影像学和真菌学发现的复合终点)及总生存之间的关联,并使用逆概率治疗加权以校正随时间变化的混杂因素中性粒细胞减少和皮质类固醇暴露。111例患者中,CDC分类为可能的占23.4%(n=26),很可能的占50.5%(n=56),确诊的占26.1%(n=29)。主要菌种为白色念珠菌(32.4%,n=36)和热带念珠菌(24.3%,n=27);30.6%(n=34)未鉴定出菌种。突破性CDC发生在24.8%(27/109)的患者中。26.1%(n=29)的患者使用PET/CT进行随访。卡泊芬净(36.9%,41/111)和脂质体两性霉素B(23/111;20.7%)是最常用的一线抗真菌治疗药物。未检测到一线至二线治疗策略、唑类药物选择与治疗反应之间存在统计学显著关联。中位治疗持续时间为107天(IQR 49-182),停药后无CDC复发。4.5%的患者因免疫重建炎症综合征使用皮质类固醇。全因死亡率为33.3%(37/111),CDC归因死亡率为4.5%(5/111)。突破性CDC患者的总生存高于无突破性CDC者(88.9% vs 58.5%;p=0.004)。在该回顾性数据集中,未检测到抗真菌治疗策略与治疗反应或生存之间存在统计学显著关联。然而,比较性治疗分析为探索性,且该研究把握度不足以排除抗真菌策略之间具有临床意义的差异。中位治疗持续时间短于既往报道。未来需要整合免疫生物标志物和PET/CT指导策略的前瞻性研究,以优化个体化治疗决策。本研究未获得专门的外部资助。FungiScope®从Basilea Pharmaceutica、Melinta Therapeutics LLC、Mundipharma Ltd.和Pfizer Inc获得用于登记处维护和基础设施的无限制资助,这些资助方在研究设计、实施分析、解释、手稿准备或决定提交发表方面均无角色。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42747321
High-grade astrocytoma with piloid features (HGAP) is a recently defined tumor type that is not well understood. Prognostic factors of clinical outcomes are not well established. Methylation profiling was performed on tumor samples, many at the National Cancer Institute (NCI) Laboratory of Pathology, and others from publicly available sources. Methylation classifier scores of ≥0.90 to the HGAP class on the NCI-Bethesda classifier version 3 were included. Clinical features were collected from the medical record. Survival analyses were performed using the Kaplan-Meier and Cox-proportional hazards methods. The cohort comprised 421 patients. There were high rates of ATRX alteration (62%), CDKN2A/B homozygous loss (78%) and MGMT promoter methylation (53%). MAPK alterations were identified in 74% of evaluable samples. The median age was 46 years, and posterior fossa location was predominant (52%). The median overall survival was 88 months. Older age (P = .01) and the presence of an ATRX alteration (P = .04) were found to be negative prognostic factors. The presence of cystic features on magnetic resonance imaging (MRI) was found to be favorably prognostic (P = .01). Factors that were not significantly associated with prognosis included histologic high-grade features, CDKN2A/B homozygous deletion, MGMT promoter methylation, extent of resection, and presence of NF1 syndrome. This large cohort establishes relative frequencies of several important markers. Additionally, older age, the presence of an ATRX alteration, and cystic features on MRI were found to be prognostic. Our work may aid in optimizing treatment regimens for patients with this tumor type.
中文摘要:伴毛样特征的高级别星形细胞瘤(HGAP)是一种最近定义的肿瘤类型,目前对其认识仍不充分。其临床结局的预后因素尚未很好确立。对肿瘤样本进行了甲基化谱分析,其中许多样本来自美国国家癌症研究所(NCI)病理实验室,另一些来自公开可获取的来源。纳入标准为在NCI-Bethesda分类器第3版中HGAP分类的甲基化分类器评分≥0.90。临床特征从病历中收集。采用Kaplan-Meier法和Cox比例风险模型进行生存分析。该队列共纳入421例患者。ATRX改变(62%)、CDKN2A/B纯合缺失(78%)和MGMT启动子甲基化(53%)的发生率较高。在可评估样本中,74%鉴定出MAPK改变。中位年龄为46岁,后颅窝位置占主导(52%)。中位总生存期为88个月。年龄较大(P=.01)和存在ATRX改变(P=.04)被发现有不良预后意义。磁共振成像(MRI)上存在囊性特征被发现有良好预后意义(P=.01)。与预后无显著相关的因素包括组织学高级别特征、CDKN2A/B纯合缺失、MGMT启动子甲基化、切除范围以及NF1综合征的存在。这一大型队列确定了若干重要标志物的相对频率。此外,年龄较大、存在ATRX改变以及MRI上的囊性特征被发现有预后意义。我们的工作可能有助于优化该肿瘤类型患者的治疗方案。
Drugs IF 14.7 2026-10 PMID: 42745024
Chronic inflammatory pouch disorders may affect up to 20% of patients within 5 years after ileal pouch-anal anastomosis and remains a major therapeutic challenge. Within this spectrum, chronic antibiotic-refractory pouchitis is associated with impaired quality of life, long-term pouch-related complications, and potential risk for pouch failure and excision. Current recommendations support the use of probiotics for primary and secondary prevention in selected patients. Increasingly, targeted advanced therapies, including biologics and small molecules approved for the treatment of ulcerative colitis and Crohn's disease, are being used to reduce antibiotic dependence and maintain disease control in patients with pouch inflammation. Vedolizumab is the only advanced therapy approved in Europe for chronic pouchitis, whereas evidence for tumor necrosis factor (TNF) antagonists, ustekinumab, and newer agents, such as interleukin (IL)-23p19 antagonists and Janus kinase (JAK) inhibitors is largely based on observational data from clinical practice and real-world experience. Fecal microbiota transplantation is biologically attractive but remains investigational, with early studies showing inconsistent efficacy. Dietary patterns may modify pouch inflammation; however, most evidence is observational. Overall, current management strategies for chronic pouchitis are limited by incomplete understanding of disease pathogenesis, and by persistent methodological gaps, including poorly standardized treatment outcomes and the lack of validated treat-to-target strategies for this population. Well designed prospective and controlled studies are needed to define appropriate antibiotic-sparing strategies, optimal treatment positioning, and long-term durability of response.
中文摘要:慢性炎症性储袋疾病可能影响高达20%的回肠储袋肛管吻合术后患者,且在术后5年内仍是重大治疗挑战。在该疾病谱中,慢性抗生素难治性储袋炎与生活质量受损、长期储袋相关并发症以及储袋失败和切除的潜在风险相关。当前推荐支持在部分患者中采用益生菌进行一级和二级预防。针对溃疡性结肠炎和克罗恩病获批的生物制剂和小分子等靶向先进治疗正越来越多地用于减少抗生素依赖并维持储袋炎症患者的疾病控制。维得利珠单抗是欧洲唯一获批用于慢性储袋炎的先进治疗,而肿瘤坏死因子(TNF)拮抗剂、乌司奴单抗以及白细胞介素(IL)-23p19拮抗剂和Janus激酶(JAK)抑制剂等较新药物的证据主要基于临床实践和真实世界经验的观察性数据。粪菌移植在生物学上具有吸引力,但仍处于研究阶段,早期研究显示疗效不一致。饮食模式可能调节储袋炎症;然而,大多数证据为观察性证据。总体而言,当前慢性储袋炎的管理策略受到对疾病发病机制理解不完整以及持续存在的方法学差距的限制,包括治疗结局标准化不足以及该人群缺乏经过验证的达标治疗策略。需要设计良好的前瞻性和对照研究来确定适当的减少抗生素策略、最佳治疗定位以及长期应答持久性。
Pharmacological research IF 12.2 2026-10 PMID: 42668074
This meta-analysis aimed to comprehensively evaluate the prognostic impacts of seven classes of antidiabetic medications in patients with cancer, predominantly in the setting of concomitant type 2 diabetes mellitus (T2DM), and to elucidate their potential differential effects. A systematic search of PubMed, Embase, Cochrane Library, and the Web of Science was conducted from inception to May 2025, utilizing keywords including "antidiabetic drugs," "cancer," and "prognosis." Based on predefined criteria, eligible English-language randomized controlled trials and cohort studies were included if they compared the prognostic impacts of metformin, insulin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and thiazolidinediones in patients with cancer. The primary outcome domain was all-cause survival, represented by all-cause mortality (ACM) or overall survival (OS) according to the terminology of the original studies. Secondary cancer-related outcomes included cancer-specific mortality (CSM), disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS). Multiple independent investigators performed data extraction and quality assessment. Statistical analyses were performed using OnlineMeta V1.1. DerSimonian-Laird random-effects models were used for all primary meta-analyses to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), while fixed-effects estimates were examined as complementary sensitivity analyses. Study quality was assessed using the Newcastle-Ottawa Scale and the Cochrane risk-of-bias tool for randomized trials. A total of 61 studies comprising 1,106,966 patients with cancer were included. Metformin use was associated with lower ACM (HR=0.82, 95% CI: 0.74-0.91, P=0.0001) and CSM (HR=0.77, 95% CI: 0.69-0.87, P<0.0001), whereas insulin use was associated with higher ACM (HR=2.03, 95% CI: 1.63-2.51, P<0.0001). Among the drug classes analyzed, SGLT2 inhibitor use showed a nonsignificant inverse trend with ACM (HR=0.44, 95% CI: 0.11-1.71, P=0.24) and was associated with lower CSM (HR=0.21, 95% CI: 0.20-0.22, P<0.0001), although these estimates were based on few observational studies with study-specific comparator groups and do not establish superiority over other drug classes. In adjusted-HR-only sensitivity analyses, the direction of association was generally consistent for the major metformin outcomes and insulin-related ACM, whereas several other comparisons were attenuated or could not be pooled because too few studies reported adjusted estimates. This meta-analysis identified heterogeneous associations between antidiabetic drug use and cancer-related survival outcomes, with variation across drug classes, cancer types, and study-level mean age groups. Because the evidence was derived predominantly from observational studies with study-specific comparator groups, substantial between-study heterogeneity, and limited data for newer agents, the pooled estimates should not be interpreted as evidence of treatment superiority or used to rank drug classes. These findings are hypothesis-generating and warrant confirmation in prospective studies using clinically comparable treatment groups, standardized outcome definitions, and rigorous control of confounding.
中文摘要:这项荟萃分析旨在全面评估七类抗糖尿病药物对癌症患者预后的影响,主要针对合并2型糖尿病(T2DM)的情况,并阐明其潜在差异效应。研究系统检索了PubMed、Embase、Cochrane Library和Web of Science,检索时间自建库至2025年5月,使用关键词包括「antidiabetic drugs」「cancer」和「prognosis」。根据预设标准,纳入符合条件的英文随机对照试验和队列研究,这些研究比较了二甲双胍、胰岛素、磺脲类、二肽基肽酶-4(DPP-4)抑制剂、钠-葡萄糖共转运蛋白2(SGLT2)抑制剂、胰高血糖素样肽-1(GLP-1)受体激动剂和噻唑烷二酮类在癌症患者中的预后影响。主要结局领域为全因生存,根据原始研究术语以全因死亡率(ACM)或总生存期(OS)表示。次要癌症相关结局包括癌症特异性死亡率(CSM)、无病生存期(DFS)、无进展生存期(PFS)和无复发生存期(RFS)。多名独立研究者进行数据提取和质量评估。统计分析使用OnlineMeta V1.1进行。所有主要荟萃分析均采用DerSimonian-Laird随机效应模型计算风险比(HR)和95%置信区间(CI),并检查固定效应估计作为补充敏感性分析。研究质量使用纽卡斯尔-渥太华量表和Cochrane随机试验偏倚风险工具进行评估。共纳入61项研究,包含1,106,966例癌症患者。二甲双胍使用与较低的ACM(HR=0.82,95% CI:0.74-0.91,P=0.0001)和CSM(HR=0.77,95% CI:0.69-0.87,P<0.0001)相关,而胰岛素使用与较高的ACM(HR=2.03,95% CI:1.63-2.51,P<0.0001)相关。在分析的药物类别中,SGLT2抑制剂使用与ACM呈非显著反向趋势(HR=0.44,95% CI:0.11-1.71,P=0.24),并与较低的CSM相关(HR=0.21,95% CI:0.20-0.22,P<0.0001),尽管这些估计基于少数观察性研究且比较组因研究而异,并不能确立其优于其他药物类别。在仅纳入调整后HR的敏感性分析中,二甲双胍主要结局和胰岛素相关ACM的关联方向总体一致,而其他若干比较的关联减弱或因报告调整估计的研究过少而无法合并。这项荟萃分析发现抗糖尿病药物使用与癌症相关生存结局之间存在异质性关联,并且在不同药物类别、癌症类型和研究层面平均年龄组之间存在差异。由于证据主要来自采用研究特定比较组的观察性研究,存在显著的间研究异质性,且新型药物的数据有限,这些合并估计不应被解释为治疗优效性的证据,也不应用于对药物类别进行排序。这些发现具有假说生成性质,需要在采用临床可比治疗组、标准化结局定义和严格混杂控制的前瞻性研究中加以验证。
JAMA surgery IF 15.6 2026-10-01 PMID: 42647025
Adhesions commonly occur after abdominal and pelvic surgery, causing infertility, intestinal obstruction, and pelvic pain. Existing anti-adhesion materials are often difficult to use on uneven organ surfaces, highlighting the need for novel solutions; SI-449, a cross-linked, powder-formed chondroitin sulfate (CS), may address these limitations. To evaluate the anti-adhesion effect of the SI-449 adhesion barrier system (cs barrier) in patients undergoing open rectal resection for rectal cancer. This multicenter, prospective, randomized, open, and blinded-end point (PROBE) method pivotal clinical trial was conducted at 53 hospitals in Japan from September 2020 to June 2023. The study participants and efficacy assessors on the central review board were blinded. Patients aged 20 years or older with clinical stage I through IV rectal cancer who underwent open rectal resection and were scheduled for follow-up ileostomy closure were eligible for inclusion. Data were analyzed from July 2023 through September 2023. The control group received no additional procedure before abdominal closure, while the experimental group received 2 to 3 g of SI-449 applied to the abdominal or pelvic cavity immediately before closure. The primary end point was the incidence of adhesions under the incision. Secondary end points included adhesion number, severity, and extent; number and type of adhered organs; and number of adhesions per organ. Safety and operability were also evaluated. Among 155 screened patients, 131 met the inclusion criteria and were randomized. Of these, 128 underwent the intervention (safety analysis population; control group: n = 64; experimental group: n = 64), and 118 completed a second surgery (modified intention-to-treat population; control group: n = 60; experimental group: n = 58). Overall mean (SD) patient age was 68.2 (10.3) years, and 34 patients of 118 (29%) were female. Adhesion incidence was significantly lower in the experimental group (26 of 58 [45%]) compared to the control group (56 of 60 [93%]) (P < .001). The experimental group also showed significantly reduced adhesion severity and extent. No safety concerns were identified, and operability was good. In this randomized clinical trial, SI-449 in the powdered form reduced the incidence of adhesions, and the adhesion barrier system had good operability and no safety concerns. Thus, this system may provide a new anti-adhesion option for use in open surgery. jrct.mhlw.go.jp Identifier: jRCT1080225247.
中文摘要:腹部和盆腔手术后常发生粘连,可导致不孕、肠梗阻和盆腔疼痛。现有防粘连材料常难以用于不平整的器官表面,凸显了对新型解决方案的需求;SI-449是一种交联、粉末形式的硫酸软骨素(CS),可能克服这些限制。旨在评估SI-449防粘连系统(cs屏障)在接受直肠癌开放直肠切除术患者中的防粘连效果。这项多中心、前瞻性、随机、开放、盲法终点(PROBE)关键性临床试验于2020年9月至2023年6月在日本53家医院开展。研究参与者和中央审查委员会的疗效评估者设盲。纳入标准为年龄20岁及以上、临床分期I至IV期直肠癌、接受开放直肠切除术并计划随访性回肠造口还纳的患者。数据分析时间为2023年7月至2023年9月。对照组在关腹前不接受额外处理,试验组在关腹前即刻将2至3g SI-449应用于腹腔或盆腔。主要终点为切口下粘连发生率。次要终点包括粘连数量、严重程度和范围;粘连器官的数量和类型;以及每个器官的粘连数量。同时评估安全性和可操作性。在155例筛查患者中,131例符合纳入标准并随机分组。其中128例接受了干预(安全性分析人群;对照组n=64;试验组n=64),118例完成了第二次手术(改良意向治疗人群;对照组n=60;试验组n=58)。患者总体平均(SD)年龄为68.2(10.3)岁,118例患者中34例(29%)为女性。试验组粘连发生率(58例中26例[45%])显著低于对照组(60例中56例[93%])(P<.001)。试验组还显示粘连严重程度和范围显著降低。未发现安全性问题,可操作性良好。在这项随机临床试验中,粉末形式的SI-449降低了粘连发生率,该防粘连系统可操作性良好且无安全性问题。因此,该系统可能为开放手术提供新的防粘连选择。jrct.mhlw.go.jp标识符:jRCT1080225247。
British journal of anaesthesia IF 10.3 2026-10 PMID: 42618366
Ketamine is commonly used perioperatively as an anaesthetic and analgesic adjunct and has demonstrated potential antitumour effects in preclinical studies. However, clinical and epidemiological data on its association with long-term outcomes after oncologic surgery remain limited. We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults (≥18 yr) undergoing major solid tumour cancer surgery between January 1, 2014, and April 1, 2023. The primary exposure was ketamine administration on the day of surgery. Propensity score matching (1:1) was performed using patient characteristics, comorbidities, oncologic diagnoses, and surgery type. The primary outcome was 3-yr mortality, and the secondary outcome was 5-yr mortality. Among 176 149 eligible patients, 29 547 matched pairs were analysed. Perioperative ketamine administration was not associated with lower 3-yr mortality (16.7% vs 16.0%; hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.00-1.09; q=0.187). There was no difference in 5-yr mortality. Across sensitivity and subgroup analyses by cancer type and perioperative exposures, ketamine was not associated with improved survival after adjustment for multiple comparisons. In an exploratory analysis, ketamine exposure was associated with a lower risk of a composite of surrogate markers suggestive of cancer progression or advanced disease, including initiation of chemotherapy, radiotherapy, or palliative care ≥6 months after surgery (HR, 0.82; 95% CI, 0.74-0.92; q=0.013). In this research network study, perioperative ketamine use was not associated with reduced mortality after major cancer surgery. This finding aligns with previous large-scale studies showing no long-term survival benefit for specific anaesthetic agents in oncologic surgery.
中文摘要:氯胺酮常在围术期作为麻醉和镇痛辅助用药,临床前研究显示其具有潜在抗肿瘤作用。然而,关于其与肿瘤手术后长期结局相关性的临床和流行病学数据仍有限。我们利用TriNetX美国协作网络开展了一项回顾性队列研究,纳入2014年1月1日至2023年4月1日期间接受实体瘤大型癌症手术的成人(≥18岁)。主要暴露为手术当日使用氯胺酮。采用倾向性评分匹配(1:1),匹配变量包括患者特征、合并症、肿瘤诊断和手术类型。主要结局为3年死亡率,次要结局为5年死亡率。在176 149例符合条件的患者中,分析了29 547对匹配患者。围术期使用氯胺酮与较低的3年死亡率无关(16.7% 对 16.0%;风险比[HR],1.04;95%置信区间[CI],1.00-1.09;q=0.187)。5年死亡率无差异。在按癌种和围术期暴露进行的敏感性和亚组分析中,经多重比较校正后,氯胺酮与生存改善无关。在一项探索性分析中,氯胺酮暴露与提示癌症进展或晚期疾病的替代标志物复合终点风险较低相关,包括术后≥6个月开始化疗、放疗或姑息治疗(HR,0.82;95% CI,0.74-0.92;q=0.013)。在这项研究网络研究中,围术期使用氯胺酮与大型癌症手术后死亡率降低无关。该发现与既往大规模研究一致,这些研究显示特定麻醉药物在肿瘤手术中无长期生存获益。
JAMA surgery IF 15.6 2026-10-01 PMID: 42616512
Modulating perioperative inflammation could be associated with fewer postoperative complications and better outcomes in major digestive surgery. The clinical benefit of corticosteroids with this purpose remains controversial. To assess whether preoperative high-dose corticosteroids improve postoperative outcomes after surgery for digestive cancer. This double-blind, placebo-controlled, superiority randomized clinical trial included patients undergoing elective surgery with curative intent for digestive cancer. This was a multicenter trial with the participation of 23 French hospitals working as a reference for digestive surgical oncology. Among patients referred for major digestive surgery to the participating centers, those undergoing surgery for digestive cancer with a curative intent between 2019 and 2023 were randomized. Patients undergoing only hepatic surgery without digestive anastomosis were excluded. Patients included were randomized to receive either 20 mg/kg of intravenous methylprednisolone at the time of anesthesia or a placebo with an identical aspect. The primary end point was the onset of major postoperative complications within 30 days after surgery. Secondary end points were postoperative infections, intra-abdominal infections, wound infections, unsatisfactory wound healing within 30 days after surgery, and the length of hospital stay after surgery. Among 2461 patients referred for major digestive surgery, 1210 patients (mean [SD] age, 65.9 [11.3] years; 762 male [63%]) undergoing surgery for digestive cancer were randomized. Among the 1188 patients with follow-up at postoperative day 30 (594 per arm), major postoperative complications did not significantly differ between the 2 groups (139 of 594 [23%] receiving methylprednisolone vs 119 of 594 [20%] receiving placebo; P = .16). Secondary outcomes did not differ either between the group receiving methylprednisolone and the group receiving placebo (postoperative infections: 182 of 594 [31%] vs 177 of 594 [30%]; P = .75; intra-abdominal infections: 142 of 594 [24%] vs 126 of 594 [21%]; P = .27; unsatisfactory wound healing: 87 of 594 [15%] vs 69 of 594 [12%]; P = .13; mean [SD] length of hospital stay: 13.21 [8.59] days vs 12.97 [8.1] days; P = .93). A preoperative pulse dose of corticosteroids had no benefit on postoperative outcomes in elective digestive cancer surgery and should not be recommended in routine practice. ClinicalTrials.gov Identifier: NCT03875690.
中文摘要:调节围手术期炎症可能与减少大型消化外科手术的术后并发症和改善结局相关。为此使用糖皮质激素的临床获益仍存在争议。评估术前高剂量糖皮质激素是否改善消化系统肿瘤手术后的术后结局。这项双盲、安慰剂对照、优效性随机临床试验纳入接受以治愈为目的的择期消化系统肿瘤手术的患者。这是一项多中心试验,有23家作为消化外科肿瘤学参考中心的法国医院参与。在转诊至参与中心接受大型消化外科手术的患者中,2019年至2023年间接受以治愈为目的的消化系统肿瘤手术者被随机分组。仅接受肝脏手术且无消化道吻合的患者被排除。纳入患者被随机分配为在麻醉时接受20 mg/kg静脉注射甲泼尼龙或外观相同的安慰剂。主要终点为术后30天内发生主要术后并发症。次要终点为术后感染、腹腔内感染、伤口感染、术后30天内伤口愈合不理想以及术后住院时间。在2461例转诊接受大型消化外科手术的患者中,1210例接受消化系统肿瘤手术的患者(平均[SD]年龄65.9[11.3]岁;762例男性[63%])被随机分组。在1188例于术后第30天有随访的患者中(每组594例),两组主要术后并发症无显著差异(接受甲泼尼龙组594例中139例[23%] vs 接受安慰剂组594例中119例[20%];P=.16)。次要结局在接受甲泼尼龙组与接受安慰剂组之间也无差异(术后感染:594例中182例[31%] vs 594例中177例[30%];P=.75;腹腔内感染:594例中142例[24%] vs 594例中126例[21%];P=.27;伤口愈合不理想:594例中87例[15%] vs 594例中69例[12%];P=.13;平均[SD]住院时间:13.21[8.59]天 vs 12.97[8.1]天;P=.93)。术前冲击剂量糖皮质激素对择期消化系统肿瘤手术的术后结局无获益,不应在常规实践中推荐。ClinicalTrials.gov注册号:NCT03875690。
Intensive care medicine IF 22.0 2026-10 PMID: 42616082
Septic shock in cancer patients remains associated with a grim prognosis. With regard to the high prevalence of anemia, the optimal hemoglobin target to restore tissue oxygenation remains uncertain. This was a multicenter superiority randomized controlled trial carried out in 18 centers in France. Adult patients with hematological or solid malignancies presenting with septic shock with lactate level > 2.0 mmol/L and hemoglobin level < 9.0 g/dL were randomly assigned to liberal or restrictive red blood cell (RBC) transfusion directed by hemoglobin thresholds of 9.0 g/dL or 7.0 g/dL during the first 48 h of resuscitation. The primary endpoint was 12-h lactate reduction, defined as normalization ≤ 2.0 mmol/L or relative decrease by 30% from baseline. Key secondary endpoints included ICU-acquired infections, arterial and venous thrombotic events, and 28-day mortality. The trial was designed to enroll 260 patients but was prematurely stopped for safety concerns. Finally, 187 patients were enrolled, distributed into 93 in the liberal arm and 94 in the restrictive arm. Twelve-hour lactate reduction was achieved in 52% and 50% of patients in the liberal and restrictive arms, respectively (odds ratio 1.07; 95% confidence interval 0.60 to 1.90; P = 0.82). Arterial or venous thrombotic events occurred more frequently in the liberal group (13% vs. 1%; P = 0.001), and 28-day mortality rates were 46% and 53% (P = 0.34), respectively. In cancer patients with septic shock, this trial did not demonstrate superiority of liberal over restrictive transfusion strategy. The absence of mortality benefit and the uncertainty surrounding the observed imbalance in adverse events do not support the routine preference of either transfusion strategy over the other.
中文摘要:癌症患者中的脓毒性休克仍与不良预后相关。鉴于贫血高发,恢复组织氧合的最佳血红蛋白目标仍不确定。这是一项在法国18个中心开展的多中心优效性随机对照试验。患有血液系统或实体恶性肿瘤且出现脓毒性休克、乳酸水平>2.0 mmol/L、血红蛋白水平<9.0 g/dL的成人患者,在复苏最初48小时内被随机分配至自由或限制性红细胞输注策略,血红蛋白阈值分别为9.0 g/dL或7.0 g/dL。主要终点为12小时乳酸下降,定义为乳酸恢复正常≤2.0 mmol/L或较基线相对下降30%。关键次要终点包括ICU获得性感染、动脉和静脉血栓事件以及28天死亡率。该试验设计入组260例患者,但因安全性担忧提前终止。最终入组187例患者,自由组93例,限制组94例。自由组和限制组分别有52%和50%的患者达到12小时乳酸下降(比值比1.07;95%置信区间0.60至1.90;P=0.82)。自由组动脉或静脉血栓事件发生更频繁(13%对1%;P=0.001),28天死亡率分别为46%和53%(P=0.34)。在脓毒性休克的癌症患者中,该试验未证明自由输血策略优于限制性输血策略。缺乏死亡率获益以及观察到的不良事件失衡所伴随的不确定性,不支持常规优先选择任一种输血策略而非另一种。
Journal of hepatology IF 40.1 2026-10 PMID: 42601275
Liquid biomarkers hold substantial promise in liver cancer, with potential applications in risk stratification, surveillance and early detection, therapeutic decision-making, and treatment-response monitoring. In parallel with oncologic advances, liquid biopsy has gained increasing attention. However, despite expanded research efforts, prospective clinical validation remains limited. While cell-free DNA-based detection of actionable alterations has entered clinical practice in select contexts, most candidate liquid biomarkers still require rigorous evaluation through translational research embedded in clinical trials and prospective cohort studies. In this review, we summarise the current landscape of blood-based biomarkers across the cancer care continuum for individuals at risk, or diagnosed with hepatocellular carcinoma and biliary tract cancers, and discuss the key challenges and opportunities that lie ahead.
中文摘要:液体生物标志物在肝癌中具有巨大前景,可能在风险分层、监测和早期检测、治疗决策以及治疗反应监测等方面得到应用。随着肿瘤学进展,液体活检受到越来越多关注。然而,尽管研究力度不断扩大,前瞻性临床验证仍然有限。虽然基于游离DNA的可操作变异检测已在部分情况下进入临床实践,但大多数候选液体生物标志物仍需通过嵌入临床试验和前瞻性队列研究中的转化研究进行严格评估。在这篇综述中,我们总结了在覆盖癌症诊疗全过程的血液生物标志物现状,针对有风险或已诊断为肝细胞癌和胆道癌的个体,并讨论未来的关键挑战和机遇。
JAMA internal medicine IF 26.3 2026-10-01 PMID: 42574003
For more than 10 years, the US Preventive Services Task Force has recommended annual lung cancer screening (LCS), but adherence to annual screening remains low. To test 2 multilevel, patient-centered interventions to increase adherence to guideline-concordant annual LCS. A pragmatic 2 × 2 factorial randomized clinical trial was conducted at Kaiser Permanente Washington among patients who completed LCS with normal findings from November 21, 2022, to April 5, 2024. The date of last follow-up was July 4, 2025. Data were analyzed from July to December 2025. The 4 arms included usual care, health communication, Stepped Reminders, or both interventions. The health communication intervention addressed patient screening knowledge barriers with print and video messaging. The Stepped Reminders intervention pended LCS scan orders for primary care physicians (PCPs) and sent outreach to patients to remind them to schedule scans. Both interventions were facilitated by a system-level LCS coordinator with electronic health record registry to deliver interventions. The primary outcome was completion of screening low-dose computed tomography (LDCT) or chest CT 9 to 15 months after index LDCT. All participants eligible for annual screening were included in the modified intent-to-treat analysis. Participants were censored due to lung cancer diagnosis, death, early LDCT or chest CT, or disenrollment from the health plan. Among 1837 trial participants, the mean (SD) age was 66.3 (6.5) years; 897 (48.8%) were female and 940 (51.2%) were male; 17 (1.0%) were American Indian or Alaska Native, 47 (2.7%) were Asian, 55 (3.1%) were Black, 10 (0.6%) were Native Hawaiian or Other Pacific Islander, 1560 (88.7%) were White, 37 (2.1%) were multiracial, and 32 (1.8%) were another race; and 875 (47.6%) were currently using tobacco. A total of 459 were randomized to the usual care group, 460 to the health communication group, 460 to the Stepped Reminders group, and 458 to the both interventions group. Adherence to annual screening was 4.7 percentage points lower in those who received the health communication intervention relative to those who did not (59.2% [476 of 804] vs 63.3% [516 of 815]; relative risk, 0.93; 95% CI, 0.86-1.00; P = .04) and 27.7 percentage points higher in those who received the Stepped Reminders intervention relative to those who did not (75.5% [604 of 800] vs 47.4% [388 of 819]; relative risk, 1.59; 95% CI, 1.47-1.72; P < .001). The Stepped Reminders intervention improved screening rates significantly more among participants currently using tobacco (received Stepped Reminders, 281 [73.0%]; did not receive Stepped Reminders, 160 [41.2%]; risk difference, 32.3 percentage points; 95% CI, 25.9-38.8) compared with former users (received Stepped Reminders, 323 [77.8%]; did not receive Stepped Reminders, 228 [52.9%]; risk difference, 24.1 percentage points; 95% CI, 18.1-30.0) (P for interaction = .03). In this randomized clinical trial, appropriately timed multilevel reminders directed to PCPs to order and patients to schedule LDCT scans were effective at improving annual LCS adherence in programs led by PCPs. ClinicalTrials.gov Identifier: NCT05747443.
中文摘要:10多年来,美国预防服务工作组一直建议每年进行肺癌筛查(LCS),但年度筛查的依从性仍然较低。旨在测试2种多层面、以患者为中心的干预措施,以提高对符合指南的年度LCS的依从性。这项实用性2×2析因随机临床试验在Kaiser Permanente Washington开展,纳入2022年11月21日至2024年4月5日期间完成LCS且结果为正常的患者。末次随访日期为2025年7月4日。数据分析时间为2025年7月至12月。4个组分别为常规照护、健康传播、阶梯式提醒或两种干预同时进行。健康传播干预通过印刷材料和视频信息解决患者筛查知识障碍。阶梯式提醒干预将LCS扫描医嘱暂挂给初级保健医生(PCP),并向患者发送外展提醒以提醒其安排扫描。两种干预均由系统级LCS协调员通过电子健康记录登记系统实施。主要结局为在索引LDCT后9至15个月完成筛查性低剂量计算机断层扫描(LDCT)或胸部CT。所有符合年度筛查条件的参与者均纳入改良意向治疗分析。参与者因肺癌诊断、死亡、提前进行LDCT或胸部CT,或退出健康计划而被删失。在1837名试验参与者中,平均(SD)年龄为66.3(6.5)岁;897名(48.8%)为女性,940名(51.2%)为男性;17名(1.0%)为美洲印第安人或阿拉斯加原住民,47名(2.7%)为亚洲人,55名(3.1%)为黑人,10名(0.6%)为夏威夷原住民或其他太平洋岛民,1560名(88.7%)为白人,37名(2.1%)为多种族,32名(1.8%)为其他种族;875名(47.6%)当前使用烟草。共有459人被随机分配至常规照护组,460人至健康传播组,460人至阶梯式提醒组,458人至两种干预组。与未接受健康传播干预者相比,接受健康传播干预者的年度筛查依从性低4.7个百分点(59.2%[804例中476例] vs 63.3%[815例中516例];相对风险,0.93;95%CI,0.86-1.00;P=.04);与未接受阶梯式提醒干预者相比,接受阶梯式提醒干预者的年度筛查依从性高27.7个百分点(75.5%[800例中604例] vs 47.4%[819例中388例];相对风险,1.59;95%CI,1.47-1.72;P<.001)。与既往使用者相比(接受阶梯式提醒,323例[77.8%];未接受阶梯式提醒,228例[52.9%];风险差,24.1个百分点;95%CI,18.1-30.0),阶梯式提醒干预在当前使用烟草的参与者中提高筛查率的幅度显著更大(接受阶梯式提醒,281例[73.0%];未接受阶梯式提醒,160例[41.2%];风险差,32.3个百分点;95%CI,25.9-38.8)(交互作用P=.03)。在这项随机临床试验中,适时开展的多层面提醒——针对PCP下达医嘱和针对患者安排LDCT扫描——在由PCP主导的项目中有效提高了年度LCS依从性。ClinicalTrials.gov标识符:NCT05747443。
Stroke IF 11.1 2026-10 PMID: 42544483
Raised inflammatory biomarkers predict an increased short-term risk of recurrent vascular events after stroke or transient ischemic attack, but it is uncertain whether the hazard is maintained thereafter. In the absence of previous population-based studies, we aimed to determine the predictive value of biomarkers for the long-term risk of recurrent stroke in intensively treated patients following transient ischemic attack or stroke. We studied 12 blood biomarkers related to inflammation, neuronal cell damage, and thrombosis soon after transient ischemic attack or stroke in a population-based study (OXVASC [Oxford Vascular Study]; 2002-2011) with follow-up to 2025. We used Cox and negative binomial regressions to assess associations between each log-transformed biomarker (per SD increase) and recurrent stroke (first event and total number), adjusted for age, sex, and baseline vascular risk factors. Of 1292 consecutive patients (mean/SD age, 73.1/13.2 years; 47.8% male), 365 recurrent strokes occurred in 280 patients during 11 336 patient-years. All inflammatory biomarkers were associated with 10-year risk of recurrence, with little impact of adjustment for other risk factors (adjusted incidence rate ratio: IL-6 [interleukin-6], 1.21 [95% CI, 1.04-1.42]; CRP [C-reactive protein], 1.29 [95% CI, 1.11-1.49]; TNFR-1 [tumor necrosis factor receptor-1], 1.24 [95% CI, 1.05-1.46]; and NGAL [neutrophil gelatinase-associated lipocalin], 1.15 [95% CI, 0.99-1.33]). Moreover, number of elevated (top quartile) inflammatory markers was associated with higher burden of recurrence (incidence rate ratio, 1.31 [95% CI, 1.15-1.50]; P<0.001), with no diminution over time (90 days: hazard ratio, 1.24 [95% CI, 0.98-1.57]; 90 days-1 year: 1.24 [95% CI, 0.95-1.62]; 1-5 years: 1.22 [95% CI, 1.01-1.47]; and 5-10 years: 1.34 [95% CI, 1.06-1.68]), and similar associations for transient ischemic attack and minor stroke. Biomarkers related to neuronal cell damage or thrombosis were generally less predictive of recurrent stroke. Inflammatory biomarkers were more predictive of long-term recurrent stroke than neuronal or thrombotic biomarkers, particularly when several inflammatory markers were raised. Predictive value was independent of other vascular risk factors and did not diminish with duration of follow-up, supporting trials of anti-inflammatory strategies for long-term secondary prevention.
中文摘要:升高的炎症生物标志物可预测卒中或短暂性脑缺血发作后短期复发性血管事件风险增加,但此后该风险是否持续尚不确定。由于此前缺乏基于人群的研究,我们旨在确定在短暂性脑缺血发作或卒中后接受强化治疗的患者中,生物标志物对长期复发性卒中风险的预测价值。我们在基于人群的研究(OXVASC[牛津血管研究];2002-2011)中,对短暂性脑缺血发作或卒中后不久检测的12种与炎症、神经元细胞损伤和血栓形成相关的血液生物标志物进行了研究,随访至2025年。我们使用Cox回归和负二项回归评估各对数转换生物标志物(每增加1个标准差)与复发性卒中(首次事件和总事件数)之间的关联,并校正年龄、性别和基线血管危险因素。在1292例连续患者中(平均/标准差年龄,73.1/13.2岁;47.8%为男性),随访11336患者年期间,280例患者发生了365次复发性卒中。所有炎症生物标志物均与10年复发风险相关,校正其他危险因素后影响甚微(校正发病率比:IL-6[白细胞介素-6]为1.21[95%CI,1.04-1.42];CRP[C反应蛋白]为1.29[95%CI,1.11-1.49];TNFR-1[肿瘤坏死因子受体-1]为1.24[95%CI,1.05-1.46];NGAL[中性粒细胞明胶酶相关脂质运载蛋白]为1.15[95%CI,0.99-1.33])。此外,升高的(最高四分位数)炎症标志物数量与更高的复发负担相关(发病率比,1.31[95%CI,1.15-1.50];P<0.001),且随时间未见减弱(90天:风险比,1.24[95%CI,0.98-1.57];90天至1年:1.24[95%CI,0.95-1.62];1至5年:1.22[95%CI,1.01-1.47];5至10年:1.34[95%CI,1.06-1.68]),短暂性脑缺血发作和轻型卒中的关联相似。与神经元细胞损伤或血栓形成相关的生物标志物对复发性卒中的预测作用通常较弱。炎症生物标志物对长期复发性卒中的预测作用强于神经元或血栓形成生物标志物,尤其是当多个炎症标志物升高时。其预测价值独立于其他血管危险因素,且不随随访时间延长而减弱,支持开展抗炎策略用于长期二级预防的试验。
Journal of hepatology IF 40.1 2026-10 PMID: 42436054
Liver cancer surveillance is supported by a strong rationale and observational research; however, evidence from randomised trials is lacking, limiting support from organisations beyond hepatology, such as national screening committees. The absence of such trials has been acknowledged in the hepatology community for over 25 years. Screening is often performed in low-prevalence populations, and screening tests are imperfect. As a result, most positive results are false positives. Although novel screening modalities are being investigated to complement or replace ultrasound for liver cancer surveillance, challenges remain, particularly regarding the weak evidence base. The ultimate aim of liver cancer surveillance is to improve survival, but many patients do not experience notable benefits due to low cancer incidence, limited test sensitivity, and competing mortality risks. Implementing risk-based hepatocellular carcinoma surveillance, as recommended by some guidelines, may enhance outcomes by tailoring surveillance to individual patient risk profiles. Many risk prediction models exist, and they have been implemented for patients with chronic hepatitis B. Stronger evidence, persistent advocacy, and consultations with national and international screening committees could pave the way for improved liver cancer surveillance practices.
中文摘要:肝癌监测有强有力的理论依据和观察性研究支持;然而,缺乏来自随机试验的证据,这限制了肝病学领域以外的组织(如国家筛查委员会)的支持。此类试验的缺失已在肝病学界被认识到超过25年。筛查常在低患病率人群中进行,且筛查试验并不完美。因此,大多数阳性结果为假阳性。尽管正在研究新的筛查方式以补充或替代超声用于肝癌监测,但挑战依然存在,尤其是在证据基础薄弱方面。肝癌监测的最终目标是提高生存率,但由于癌症发生率低、检测敏感性有限以及竞争性死亡风险,许多患者并未获得显著获益。按照一些指南的建议,实施基于风险的肝细胞癌监测,可能通过根据个体患者风险特征定制监测来提高结局。已存在许多风险预测模型,并已用于慢性乙型肝炎患者。更强的证据、持续倡导以及与国家和国际筛查委员会的协商,可能为改进肝癌监测实践铺平道路。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42377275
Thalamic gliomas (TGs) remain a formidable clinical challenge for accurate diagnosis and effective therapy. This study aims to refine molecular diagnosis and surgical management of TGs by integrating clinicopathological and multiomics data. We analyzed 106 TGs, comprising 65 diffuse midline glioma (DMG) and 41 non-DMG, using genomic profiling, single-cell RNA sequencing, and orthogonal assays. Surgical outcomes were evaluated using rigorous causal inference frameworks, including propensity score matching and difference-in-differences analyses. Genomic profiling revealed striking mutual exclusivity between H3F3A mutations and CDKN2A/B (9p21) loss. Single-cell and orthogonal assays validated that 9p21 loss emerged as a highly specific adjunctive marker favoring non-DMG over DMG. Causal inference analyses consistently demonstrated that microsurgical third ventriculostomy (mTV) confers profound protection against postoperative hydrocephalus (risk reduction >60%). Multivariate analysis identified the transfrontal approach as an independent predictor of postoperative motor deficits. Survival analysis showed that the median overall survival of this cohort following surgical resection was 21.0 months. Extent of resection and tumor mutational burden emerged as the principal independent determinants of prognosis, whereas postoperative Karnofsky performance status showed survival stratification in univariable/subgroup analyses but was not independently significant in the multivariable model. In this 106-patient cohort study, we delineated the somatic mutational landscape of TG and showed that 9p21 loss is mutually exclusive with H3F3A mutations, providing a highly specific adjunctive marker for TG. We further demonstrated that maximal surgical resection confers a survival benefit and intraoperative mTV serves as a standardized treatment workflow to optimize care for TG.
中文摘要:丘脑胶质瘤(TGs)在准确诊断和有效治疗方面仍是巨大的临床挑战。本研究旨在通过整合临床病理学和多组学数据,优化丘脑胶质瘤的分子诊断和外科管理。我们分析了106例丘脑胶质瘤,包括65例弥漫性中线胶质瘤(DMG)和41例非DMG,采用基因组分析、单细胞RNA测序和正交试验。使用严格的因果推断框架评估手术结局,包括倾向评分匹配和双重差分分析。基因组分析显示,H3F3A突变与CDKN2A/B(9p21)缺失之间存在显著的互斥性。单细胞和正交试验验证,9p21缺失是一个高度特异性的辅助标志物,支持非DMG而非DMG。因果推断分析一致表明,显微外科第三脑室造瘘术(mTV)对术后脑积水具有显著的保护作用(风险降低超过60%)。多变量分析确定经额入路是术后运动缺陷的独立预测因素。生存分析显示,该队列手术切除后的中位总生存期为21.0个月。切除范围和肿瘤突变负荷是预后的主要独立决定因素,而术后卡氏功能状态评分在单变量/亚组分析中显示出生存分层,但在多变量模型中并非独立显著。在这项106例患者的队列研究中,我们描绘了丘脑胶质瘤的体细胞突变图谱,并表明9p21缺失与H3F3A突变互斥,为丘脑胶质瘤提供了高度特异性的辅助标志物。我们进一步证明,最大程度的手术切除可带来生存获益,而术中mTV可作为标准化治疗流程,以优化丘脑胶质瘤的诊疗。
Endoscopy IF 11.8 2026-10 PMID: 42365851
Computer-aided detection (CADe) increases adenoma detection in colonoscopy, but its effectiveness in postpolypectomy surveillance remains uncertain. This study compared the adenoma detection rate (ADR) of CADe-assisted versus standard high definition colonoscopy during surveillance. We conducted a population-based, randomized controlled trial in the Galician colorectal cancer screening program. Colonoscopy days were randomized in a 1 : 1 ratio to high definition colonoscopy with or without CADe. The primary end point was the ADR. Prespecified subgroup analyses evaluated endoscopist baseline performance (median ADR in the standard arm). Effect estimates are reported as adjusted risk ratios (aRRs) with 95%CI. Of 5309 randomized surveillance colonoscopies, 4824 surveillance colonoscopies were included in the final analysis (2469 standard; 2355 CADe-assisted) after exclusion of incomplete examinations. The ADR did not differ between the groups (57.4% vs. 58.8%; aRR 1.02, 95%CI 0.95-1.10). CADe increased ADR among low performing (ADR <54.5%) endoscopists (45.5% vs. 52.1%; aRR 1.15, 95%CI 1.01-1.30), but not among high performing endoscopists (65.9% vs. 63.5%; aRR 0.96, 95%CI 0.88-1.05). In a high performing screening program, CADe did not increase ADR in surveillance colonoscopy. Its benefit may be limited to lower performing endoscopists.
中文摘要:计算机辅助检测(CADe)可提高结肠镜检查中的腺瘤检出,但其在息肉切除术后监测中的有效性仍不确定。本研究比较了监测期间CADe辅助与标准高清结肠镜的腺瘤检出率(ADR)。我们在加利西亚结直肠癌筛查项目中开展了一项基于人群的随机对照试验。结肠镜检查日按1:1比例随机分配至接受或不接受CADe的高清结肠镜检查。主要终点为ADR。预设亚组分析评估了内镜医师的基线表现(标准组的中位ADR)。效应估计以校正风险比(aRR)及95%CI报告。在5309例随机分配的监测结肠镜检查中,排除不完整检查后,最终分析纳入4824例监测结肠镜检查(2469例标准组;2355例CADe辅助组)。两组ADR无差异(57.4% vs. 58.8%;aRR 1.02,95%CI 0.95-1.10)。CADe提高了低表现内镜医师(ADR <54.5%)的ADR(45.5% vs. 52.1%;aRR 1.15,95%CI 1.01-1.30),但未提高高表现内镜医师的ADR(65.9% vs. 63.5%;aRR 0.96,95%CI 0.88-1.05)。在一个高表现的筛查项目中,CADe未提高监测结肠镜检查的ADR。其获益可能限于表现较低的内镜医师。
Endoscopy IF 11.8 2026-10 PMID: 42331035
The impact of computer-aided detection (CADe) systems on lesion detection remains uncertain. We evaluated whether a CADe system improves adenoma detection rate (ADR) in a colorectal cancer (CRC) screening program. This multicenter randomized clinical trial included patients aged 40-79 years who underwent colonoscopy after a positive fecal immunochemical test (FIT) or for surveillance. Patients were randomized to either conventional or CADe-assisted colonoscopy. The primary end point was ADR. Secondary end points were detection rates for serrated lesions (SLDR), polyps (PDR), advanced adenomas (AADR), and advanced serrated lesions (ASLDR). We performed subgroup analysis according to indication, endoscopist ADR, and bowel cleansing. Effect estimates were reported as adjusted risk ratios (aRRs) and 95%CIs. 857 patients were randomized and 827 were included in the analysis. Baseline characteristics were comparable between groups (mean age: 61.7 [SD 6.5]; male 490; positive FIT: 552). We did not find statistically significant differences between CADe-assisted and conventional colonoscopy for ADR (60.8% vs. 57.7%; aRR 1.05, 95%CI 0.94-1.17). No significant differences were observed for SLDR (8.8% vs. 7.2%; aRR 1.04, 0.65-1.64), PDR (69.6% vs. 68.8%; aRR 1.00, 0.91-1.10), AADR (23.6% vs. 24.4%; aRR 0.90, 0.71-1.14), or ASLDR (4.9% vs. 4.8%; aRR 0.93, 0.51-1.68). Subgroup analysis showed no significant differences. In colonoscopies performed in a CRC screening program, CADe-assisted colonoscopy did not increase ADR compared with conventional colonoscopy.
中文摘要:计算机辅助检测(CADe)系统对病变检出的影响仍不确定。我们评估了CADe系统是否能提高结直肠癌(CRC)筛查项目中的腺瘤检出率(ADR)。这项多中心随机临床试验纳入年龄40-79岁、因粪便免疫化学检测(FIT)阳性或接受监测而进行结肠镜检查的患者。患者被随机分配至传统结肠镜检查或CADe辅助结肠镜检查。主要终点为ADR。次要终点包括锯齿状病变检出率(SLDR)、息肉检出率(PDR)、进展期腺瘤检出率(AADR)和进展期锯齿状病变检出率(ASLDR)。我们根据检查指征、内镜医师ADR和肠道准备情况进行了亚组分析。效应估计以校正风险比(aRR)和95%CI报告。共857例患者被随机分组,827例纳入分析。两组基线特征相当(平均年龄61.7岁[SD 6.5];男性490例;FIT阳性552例)。我们未发现CADe辅助结肠镜检查与传统结肠镜检查在ADR方面存在统计学显著差异(60.8% vs. 57.7%;aRR 1.05,95%CI 0.94-1.17)。SLDR(8.8% vs. 7.2%;aRR 1.04,0.65-1.64)、PDR(69.6% vs. 68.8%;aRR 1.00,0.91-1.10)、AADR(23.6% vs. 24.4%;aRR 0.90,0.71-1.14)或ASLDR(4.9% vs. 4.8%;aRR 0.93,0.51-1.68)均未观察到显著差异。亚组分析未显示显著差异。在CRC筛查项目中进行的结肠镜检查中,与传统结肠镜检查相比,CADe辅助结肠镜检查并未提高ADR。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42202212
Leptomeningeal disease (LMD) is a devastating complication of cancer, and its incidence is rising. The inaugural LMD Think Tank Meeting took place in 2023 during the Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) Central Nervous System (CNS) annual meeting, convening an international group of clinicians and scientists dedicated to understanding and treating LMD in a multidisciplinary fashion. While this meeting laid the foundation for a SNO/ASCO consensus review on the clinical management of LMD, the frequent exclusion of LMD patients from trials was identified as a clear and pervasive challenge. To address this gap, a follow-up assembly convened in 2024 with a goal of developing an SNO/ASCO consensus on best practices for clinical research; this included addressing the role of industry and basic scientists in clinical trials, providing guidance for improved clinical trial design, and accelerating the enrollment of LMD patients into clinical trials. Academic-industry partnerships and multi-institutional collaborations are crucial to advance our understanding of LMD, expand treatment access, and ultimately, improve survival and quality of life for our patients.
中文摘要:软脑膜疾病(LMD)是癌症的一种毁灭性并发症,其发病率正在上升。首届LMD智囊团会议于2023年在神经肿瘤学会(SNO)与美国临床肿瘤学会(ASCO)中枢神经系统(CNS)年会期间举行,汇集了一个致力于以多学科方式理解和治疗LMD的国际临床医生和科学家小组。虽然这次会议为SNO/ASCO关于LMD临床管理的共识综述奠定了基础,但LMD患者常被排除在试验之外被确定为一个明确且普遍存在的挑战。为弥补这一差距,2024年召开了一次后续会议,目标是制定SNO/ASCO关于临床研究最佳实践的共识;这包括讨论产业界和基础科学家在临床试验中的作用、为改进临床试验设计提供指导,并加速LMD患者入组临床试验。学术与产业合作以及多机构协作对于推进我们对LMD的理解、扩大治疗可及性,并最终改善患者的生存和生活质量至关重要。
European urology IF 29.1 2026-10 PMID: 41956861
Interim [68Ga]Ga-prostate-specific membrane-antigen positron emission tomography/computed tomography (PSMA-PET/CT) has prognostic potential for overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC), although evidence is limited. This ENZA-p sub-study evaluated 3-mo PSMA-total-tumor-volume (PSMA-TTV) as a prognostic biomarker for OS with enzalutamide ± [177Lu]Lu-PSMA-617. ENZA-p is a randomized, phase 2 trial. Participants with mCRPC and risk factors for early treatment failure with enzalutamide were randomized (1:1) to enzalutamide or enzalutamide + [177Lu]Lu-PSMA-617. Participants underwent baseline and 3-mo [68Ga]Ga-PSMA-11-PET/CT, quantified to derive PSMA-TTV. We evaluated the prognostic value of PSMA-TTV change, and residual PSMA-TTV at 3-mo for OS (NCT04419402). This sub-study included 152/162 (94%) randomized participants with a 3-mo PSMA-PET. Median OS was 27 mo (95% confidence interval [CI] 23-30). Baseline median PSMA-TTV 230 ml (interquartile range [IQR] 75-635) and 3-mo PSMA-TTV 103 ml (IQR 24-457). The median change in PSMA-TTV from baseline was -34% (IQR -76% to 16%) with 50/152 (33%) participants with increase in PSMA-TTV. Any increase versus decrease in PSMA-TTV at 3-mo was associated with shorter OS (HR 2.52, 95% CI 1.65-3.85) and decreased 2-yr survival 30% (95% CI 17-43) versus 67% (95% CI 56-75) (log-rank p < 0.0001). Residual 3-mo PSMA-TTV higher versus lower than the median (103 ml) was associated with shorter OS (HR 3.76, 95% CI 2.39-5.92) and lower 2-yr survival 34% (95% CI 23-45) versus 76% (95% CI 64-84) (log-rank p < 0.0001). This association was independent of treatment arm and prostate-specific antigen (PSA) response. PSMA-TTV at 3 mos was prognostic for OS independent of study treatment and PSA response in ENZA-p, warranting further prospective validation of interim PSMA-PET response criteria.
中文摘要:中期[68Ga]Ga-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描(PSMA-PET/CT)对转移性去势抵抗性前列腺癌(mCRPC)的总生存期(OS)具有预后潜力,但证据有限。这项ENZA-p子研究评估了3个月时PSMA-总肿瘤体积(PSMA-TTV)作为恩扎卢胺±[177Lu]Lu-PSMA-617治疗中OS的预后生物标志物。ENZA-p是一项随机、2期试验。具有mCRPC且存在恩扎卢胺早期治疗失败危险因素的参与者按1:1随机分配至恩扎卢胺或恩扎卢胺+[177Lu]Lu-PSMA-617。参与者在基线和3个月时接受[68Ga]Ga-PSMA-11-PET/CT,并进行量化以得出PSMA-TTV。我们评估了PSMA-TTV变化以及3个月时残余PSMA-TTV对OS的预后价值(NCT04419402)。本子研究纳入152/162(94%)例有3个月PSMA-PET的随机参与者。中位OS为27个月(95%置信区间[CI]23-30)。基线中位PSMA-TTV为230 ml(四分位距[IQR]75-635),3个月时PSMA-TTV为103 ml(IQR 24-457)。PSMA-TTV自基线的中位变化为-34%(IQR -76%至16%),其中50/152(33%)例参与者PSMA-TTV增加。3个月时PSMA-TTV任何增加相比降低与更短OS相关(HR 2.52,95% CI 1.65-3.85),2年生存率降低:30%(95% CI 17-43)对67%(95% CI 56-75)(log-rank p < 0.0001)。3个月时残余PSMA-TTV高于中位数(103 ml)相比低于中位数与更短OS相关(HR 3.76,95% CI 2.39-5.92),2年生存率更低:34%(95% CI 23-45)对76%(95% CI 64-84)(log-rank p < 0.0001)。这种相关性独立于治疗组和前列腺特异性抗原(PSA)反应。在ENZA-p中,3个月时PSMA-TTV对OS具有预后价值,且独立于研究治疗和PSA反应,值得进一步前瞻性验证中期PSMA-PET反应标准。

基础研究 (6篇)

Cancer research IF 22.6 2026-10-02 PMID: 42430560
Cancer is the leading cause of disease-related deaths among children in high-income countries. Tumor heterogeneity and the lack of mechanism of action-based therapeutic options are key challenges to overcome to improve the survival of pediatric patients with cancer. To address these challenges, we formed the European Union-Innovative Medicines Initiative 2 (EU-IMI2) funded public-private partnership "Innovative Therapies for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform" (ITCC-P4), which built a large repertoire of patient-derived xenograft (PDX) models representing all major high-risk solid pediatric cancer types for in vivo drug testing. A total of 353 PDX models were established from diagnostic and relapsed pediatric cancers and molecularly characterized, together with matched germline/tumor samples. Serial PDX models were also established, spanning diagnostic/posttreatment, primary/relapse, and metastasis-derived pairs. Proof-of-concept in vivo drug screening data in neuroblastoma and rhabdomyosarcoma models identified potential predictive biomarkers for targeted therapy. Molecular data from the PDX models, accessible at https://r2platform.com/itcc-p4, allowed the selection of models for preclinical testing based on oncogenic drivers and/or potential biomarkers. Operated by a nonprofit entity, this sustainable platform aids academic and industrial researchers in developing and prioritizing innovative therapies for pediatric cancer. The ITCC-P4 platform comprises models of diagnostic/refractory/relapsed pediatric cancers that mimic patient tumors and feature intertumoral heterogeneity, providing a resource of molecularly characterized patient-derived models for in vivo testing.
中文摘要:癌症是高收入国家儿童疾病相关死亡的主要原因。肿瘤异质性以及缺乏基于作用机制的治疗选择,是提高儿童癌症患者生存率所需克服的关键挑战。为应对这些挑战,我们组建了由欧盟创新药物计划2(EU-IMI2)资助的公私合作项目「儿童癌症创新疗法儿科临床前概念验证平台」(ITCC-P4),该平台建立了大量患者来源异种移植(PDX)模型,涵盖所有主要高危儿童实体瘤类型,用于体内药物测试。共从诊断时和复发的儿童癌症中建立了353个PDX模型,并与匹配的生殖系/肿瘤样本一起进行了分子特征分析。还建立了系列PDX模型,涵盖诊断/治疗后、原发/复发以及转移来源的配对模型。在神经母细胞瘤和横纹肌肉瘤模型中获得的概念验证性体内药物筛选数据,识别出了用于靶向治疗的潜在预测性生物标志物。PDX模型的分子数据可在 https://r2platform.com/itcc-p4 获取,能够根据致癌驱动因素和/或潜在生物标志物选择用于临床前测试的模型。该可持续平台由一家非营利实体运营,帮助学术和产业研究人员开发并优先推进儿童癌症的创新疗法。ITCC-P4平台包含诊断/难治/复发儿童癌症的模型,这些模型模拟患者肿瘤并具有肿瘤间异质性,为体内测试提供了经分子特征分析的患者来源模型资源。
MedComm IF 14.1 2026-10 PMID: 42802774
The widespread application of radiotherapy for malignancies underscores the urgent clinical challenge of radiation-induced multiorgan injury, which severely impacts patient prognosis and quality of life. The heart, skin, lungs, intestines, hematopoietic system, oral, kidney, and brain are the most frequently affected sites, each following distinct and complex injury trajectories. Despite growing research into these organ-specific injuries, a substantial translational gap remains between mechanistic insights and effective therapeutic interventions. This review systematically delineates the unique epidemiological and pathological processes in these eight critical systems. It then critically evaluates current clinical management alongside emerging therapeutic strategies, including advanced radioprotectors, mitigators, antifibrotic agents, and innovative stem cell therapies. Central to our analysis is the synthesis of these findings into a comprehensive view of the complex interactive networks and functional imbalances driven by aberrant intercellular communication within damaged tissues. By offering a systematic analysis of mechanism-network-targeted therapeutics, this review establishes a critical framework to guide the future development of more effective, integrated, and personalized patient care strategies in radiation oncology.
中文摘要:放疗引起的不良反应:流行病学、发病机制、预防和治疗。摘要:放疗在恶性肿瘤中的广泛应用凸显了放射性多器官损伤这一紧迫的临床挑战,其严重影响患者预后和生活质量。心脏、皮肤、肺、肠道、造血系统、口腔、肾脏和脑是最常受累的部位,每个部位都遵循不同且复杂的损伤轨迹。尽管针对这些器官特异性损伤的研究日益增多,但在机制认识与有效治疗干预之间仍存在巨大的转化鸿沟。本综述系统阐述了这八个关键系统中独特的流行病学和病理过程。随后,本综述批判性评估了当前临床管理以及新兴治疗策略,包括先进的放射防护剂、缓解剂、抗纤维化药物和创新的干细胞疗法。我们分析的核心在于将这些发现综合为对受损组织内异常细胞间通讯所驱动的复杂相互作用网络和功能失衡的全面认识。通过对机制-网络-靶向治疗进行系统分析,本综述建立了一个关键框架,以指导放射肿瘤学中更有效、整合且个性化的患者照护策略的未来发展。
Pharmacological research IF 12.2 2026-10 PMID: 42679870
Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by progressive inflammation and fibrosis. Left untreated, MASH can progress to cirrhosis, hepatocellular carcinoma, and liver failure. MASH has become the leading indication for liver transplantation worldwide. While global prevalence is increasing, effective and mechanism-oriented therapies remain limited. Based on earlier independent studies showing that lysosomes are impaired and autophagy is dysregulated in MASH, our aim was to finely map autophagy dysfunction in an experimental mouse model of MASH and explore the capacity of a modulator of chaperone-mediated autophagy to mitigate the course of the disease. We effectively identified a number of markers whose expression was pathologically increased or decreased in various autophagy pathways. In vivo, pharmacological modulation with the phosphopeptide P140 -currently evaluated in phase III-clinical trials for lupus- corrected the expression of some of these markers and restored lysosomal and mitochondrial autophagy programs. It reduced steatohepatitis and fibrosis, and improved systemic inflammatory features without, however, broadly correcting metabolic parameters. Mechanistically, consistent with its established HSPA8 interaction, P140 restored lysosomal/autophagy markers, supporting modulation of this proteostasis network. Our data indicate that this pharmacological restoration of lysosomal proteostasis engages key transcriptional regulators (Mediator complex), leading to the selective remodeling of pro-fibrotic and inflammatory pathways. Collectively, we identified a coordinated disruption of lysosomal quality control networks across multiple autophagy pathways in a validated mouse model of advanced MASH. We established lysosomal autophagy as a druggable vulnerability in MASH and support therapeutic repositioning of P140 as a safe strategy to counter progressive liver diseases.
中文摘要:代谢功能障碍相关脂肪性肝炎(MASH)以进行性炎症和纤维化为特征。若不治疗,MASH可进展为肝硬化、肝细胞癌和肝衰竭。MASH已成为全球肝移植的主要适应证。尽管全球患病率不断上升,有效且针对机制的疗法仍然有限。基于早期独立研究表明MASH中溶酶体受损且自噬失调,我们的目标是在实验性MASH小鼠模型中精细描绘自噬功能障碍,并探索分子伴侣介导的自噬调节剂减轻疾病进程的能力。我们有效鉴定出多种标志物,其表达在各种自噬通路中发生病理性升高或降低。在体内,使用磷酸肽P140——目前正在针对狼疮进行III期临床试验评估——进行药理学调节,可纠正其中一些标志物的表达,并恢复溶酶体和线粒体自噬程序。它减轻了脂肪性肝炎和纤维化,并改善了全身炎症特征,但并未广泛纠正代谢参数。在机制上,与其已确立的HSPA8相互作用一致,P140恢复了溶酶体/自噬标志物,支持对该蛋白稳态网络的调节。我们的数据表明,这种对溶酶体蛋白稳态的药理学恢复可招募关键转录调节因子(Mediator复合物),从而选择性重塑促纤维化和炎症通路。总之,我们在一个经过验证的晚期MASH小鼠模型中,鉴定出多种自噬通路中溶酶体质量控制网络的协调性破坏。我们确立了溶酶体自噬是MASH中可成药的脆弱点,并支持将P140的治疗重定位作为对抗进行性肝病的安全策略。
Autophagy IF 18.6 2026-10 PMID: 42144738
Macroautophagy/autophagy represents a promising therapeutic target in oncology, exhibiting context-dependent roles in tumor progression. Kinase inhibitors are a large group of anti-cancer drugs, and elucidating the regulatory effects of different kinase inhibitors on autophagy offers a valuable strategy to advance our understanding of autophagy regulation in cancer and develop innovative anti-cancer therapies. In this study, we developed a drug screening platform and performed high-content screening using a kinase inhibitor library. The screening identified PTK2/FAK (protein tyrosine kinase 2) inhibitors as potent autophagy inducers. Mechanistic investigations revealed that PTK2/FAK inhibition triggers rapid autophagic flux through a non-classical mechanism dependent on PTK2/FAK expression, which is associated with the spatial redistribution of ER exit sites (ERES). Further analysis demonstrated that PTK2/FAK inhibitor (FAKi)-induced ERES-associated autophagy is not contingent upon full PREB/SEC12 and SEC16 expression, but is sensitized to TMED9 expression level. Additionally, we identified AKAP13 as a novel FAKi-responsive protein that undergoes dephosphorylation upon FAKi treatment and contributes to TMED9-mediated ERES-associated autophagy. Given that ERES-associated autophagy is initiated through membrane contact between ERES and the ER-Golgi intermediate compartment (ERGIC), we further observed enhanced TMED9-ERGIC interactions following FAKi treatment. Furthermore, functional studies confirmed that FAKi-induced autophagy promotes pancreatic ductal adenocarcinoma (PDAC) cell survival both in vitro and in vivo. Collectively, our work unveils a previously unrecognized mechanism of FAKi-mediated autophagy induction and provides new insights for developing targeted therapies against PDAC.Abbreviations: AKAP13: A-kinase anchoring protein 13; AMPK: AMP-activated protein kinase; BAF: bafilomycin A1; ECM: extracellular matrix; ER: endoplasmic reticulum; ERES: endoplasmic reticulum exit sites; ERGIC: ER-Golgi intermediate compartment; GSK: GSK2256098; MTOR: mechanistic target of rapamycin kinase; PDAC: pancreatic ductal adenocarcinoma; PI3K: phosphoinositide 3-kinase; PI4KB: phosphatidylinositol 4-kinase beta; PTK2/FAK: protein tyrosine kinase 2; TMED9: transmembrane p24 trafficking protein 9; ULK1: unc-51 like autophagy activating kinase 1.
中文摘要:大自噬/自噬是肿瘤学中一个有前景的治疗靶点,其在肿瘤进展中发挥依赖情境的作用。激酶抑制剂是一大类抗肿瘤药物,阐明不同激酶抑制剂对自噬的调控作用,为推进我们对肿瘤中自噬调控的理解并开发创新性抗肿瘤疗法提供了有价值的策略。在本研究中,我们建立了一个药物筛选平台,并利用激酶抑制剂文库进行了高内涵筛选。该筛选鉴定出PTK2/FAK(蛋白酪氨酸激酶2)抑制剂是强效的自噬诱导剂。机制研究揭示,PTK2/FAK抑制通过一种依赖PTK2/FAK表达的非经典机制触发快速的自噬流,该机制与内质网出口位点(ERES)的空间重分布相关。进一步分析表明,PTK2/FAK抑制剂(FAKi)诱导的ERES相关自噬并不依赖于完整的PREB/SEC12和SEC16表达,但对TMED9表达水平敏感。此外,我们鉴定出AKAP13是一种新的FAKi响应蛋白,其在FAKi处理后发生去磷酸化,并参与TMED9介导的ERES相关自噬。鉴于ERES相关自噬是通过ERES与内质网-高尔基体中间体(ERGIC)之间的膜接触而启动的,我们进一步观察到FAKi处理后TMED9-ERGIC相互作用增强。此外,功能研究证实,FAKi诱导的自噬在体外和体内均促进胰腺导管腺癌(PDAC)细胞存活。总之,我们的工作揭示了FAKi介导的自噬诱导的一种此前未被认识到的机制,并为开发针对PDAC的靶向治疗提供了新见解。缩写:AKAP13:A激酶锚定蛋白13;AMPK:AMP活化蛋白激酶;BAF:巴弗洛霉素A1;ECM:细胞外基质;ER:内质网;ERES:内质网出口位点;ERGIC:内质网-高尔基体中间体;GSK:GSK2256098;MTOR:雷帕霉素机械靶蛋白激酶;PDAC:胰腺导管腺癌;PI3K:磷酸肌醇3-激酶;PI4KB:磷脂酰肌醇4-激酶β;PTK2/FAK:蛋白酪氨酸激酶2;TMED9:跨膜p24转运蛋白9;ULK1:unc-51样自噬激活激酶1。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42080900
Ependymoma (EPN) is the third most common pediatric brain tumor with no targeted therapies available to patients. In supratentorial ependymoma, the most frequent driver alteration is a gene fusion between ZFTA and RELA (denoted ZR), which leads to constitutive localization of ZR in the nucleus. Because ZR is not currently druggable, we tested whether ZR expression leads to aberrant protein interactions that could represent therapeutic vulnerabilities. Using CRISPR-Cas9 pooled screening, we identified many novel druggable ZR-interacting proteins including XPO1, CARM1, SMARCA4, and CDK1. We focused on the nuclear export protein (XPO1), given the ability of most XPO1 inhibitors (ie, selinexor) to cross the blood-brain barrier, FDA approval, and have documented safety profiles in children. We found that specific nuclear ZR levels are needed for cell proliferation and are regulated by XPO1. Increased ZR accumulation in the nucleus does not increase oncogenic gene expression but drives tumor cells out of the cell cycle, as compared to a defective ZR DNA-binding mutant. Treatment of ZR-driven patient-derived mouse models with selinexor impairs cell growth and extends survival of animals in vivo. The combination of selinexor treatment with gemcitabine and ribociclib (used in a clinical trial for relapsed EPN at St. Jude Children's Research Hospital [SJDAWN]) further extends mouse survival. Our findings demonstrate that ZR-interacting proteins constitute therapeutic leads and that XPO1 is critical for titrating "goldilocks" levels of ZR nuclear expression. We identify a novel combination therapy of selinexor, gemcitabine, and ribociclib that may be immediately translated into clinical trials for EPN patients that are currently without targeted treatments.
中文摘要:室管膜瘤(EPN)是第三常见的儿童脑肿瘤,目前患者尚无靶向治疗可用。在幕上室管膜瘤中,最常见的驱动改变是ZFTA与RELA之间的基因融合(称为ZR),导致ZR持续定位于细胞核。由于目前无法对ZR进行药物靶向,我们检验了ZR表达是否会导致异常蛋白相互作用,从而可能成为治疗易感性。利用CRISPR-Cas9混合筛选,我们鉴定出许多新的可成药ZR相互作用蛋白,包括XPO1、CARM1、SMARCA4和CDK1。我们聚焦于核输出蛋白XPO1,因为大多数XPO1抑制剂(即塞利尼索)能够穿过血脑屏障、已获FDA批准,并且在儿童中具有已记录的安全性。我们发现,细胞增殖需要特定的核内ZR水平,且该水平受XPO1调控。与缺陷型ZR DNA结合突变体相比,核内ZR蓄积增加并不会增加致癌基因表达,而是驱动肿瘤细胞退出细胞周期。用塞利尼索治疗ZR驱动的患者来源小鼠模型可损害细胞生长并延长动物体内生存。塞利尼索与吉西他滨和瑞波西利联合治疗(圣犹大儿童研究医院[SJDAWN]用于复发EPN的临床试验中所用方案)进一步延长小鼠生存。我们的发现表明,ZR相互作用蛋白构成了治疗线索,且XPO1对于调节ZR核表达的「金发姑娘」水平至关重要。我们鉴定出一种塞利尼索、吉西他滨和瑞波西利的新型联合治疗,可能可立即转化为针对目前尚无靶向治疗的EPN患者的临床试验。
Biomaterials IF 13.6 2026-10 PMID: 42035586
Malignant ascites (MA), a life-threatening complication of advanced intra-abdominal cancers, poses a formidable clinical challenge due to its complex pathophysiology and the scarcity of effective, low-toxicity treatments. Here, we developed an intelligent respiratory pressure-responsive piezoelectric nanoplatform with a multilayer metal@mesoporous TiO2@mesoporous BaTiO3 architecture (MTB) for piezoelectric therapy of MA. By integrating a metal-TiO2 Schottky junction and a TiO2-BaTiO3 heterojunction into a mesoporous sandwich configuration, the nanoplatform achieves amplified polarization and suppressed charge recombination, thereby enabling efficient piezocatalytic activation driven by subtle intraperitoneal pressure oscillations from physiological diaphragmatic respiration. Systematic core screening identifies Au@mesoporous TiO2@mesoporous BaTiO3 (AuTB) as the optimal configuration, exhibiting superior piezoelectric responsiveness and reactive oxygen species (ROS) generation capability. Under the mild intra-abdominal pressure oscillations stimulation, AuTB efficiently produces ROS and induces immunogenic cell death (ICD) in tumor cells. In murine MA models, intraperitoneal administration of AuTB markedly suppresses tumor progression, reduces ascites accumulation, and significantly prolongs survival. Mechanistic studies reveal that AuTB-mediated piezocatalysis remodels the immunosuppressive microenvironment by promoting dendritic cell maturation, enhancing cytotoxic CD8+ T-cell activation, and reducing regulatory T cells and myeloid-derived suppressor cells. In conclusion, our work establishes a physiologically piezoelectric paradigm that converts endogenous respiratory mechanical energy into sustained antitumor activity, providing a promising translational nanotherapeutic strategy for MA.
中文摘要:恶性腹水(MA)是晚期腹腔内癌症的一种危及生命的并发症,由于其复杂的病理生理机制以及缺乏有效且低毒的治疗方法,构成了严峻的临床挑战。在此,我们开发了一种智能呼吸压力响应型压电纳米平台,具有多层金属@介孔TiO2@介孔BaTiO3结构(MTB),用于MA的压电治疗。通过将金属-TiO2肖特基结和TiO2-BaTiO3异质结整合到介孔三明治构型中,该纳米平台实现了极化增强和电荷复合抑制,从而能够由生理性膈肌呼吸引起的细微腹腔内压力振荡驱动高效压电催化激活。系统的核心筛选确定Au@介孔TiO2@介孔BaTiO3(AuTB)为最佳构型,其表现出优异的压电响应性和活性氧(ROS)生成能力。在温和的腹腔内压力振荡刺激下,AuTB高效产生ROS并诱导肿瘤细胞发生免疫原性细胞死亡(ICD)。在小鼠MA模型中,腹腔给予AuTB可显著抑制肿瘤进展、减少腹水积聚并显著延长生存期。机制研究揭示,AuTB介导的压电催化通过促进树突状细胞成熟、增强细胞毒性CD8+ T细胞活化以及减少调节性T细胞和髓源性抑制细胞来重塑免疫抑制微环境。总之,我们的工作建立了一种生理性压电范式,将内源性呼吸机械能转化为持续的抗肿瘤活性,为MA提供了一种有前景的转化纳米治疗策略。

5肿瘤基础/转化 (36篇)

临床研究 (1篇)

Journal of the American Academy of Dermatology IF 12.3 2026-10-01 PMID: 42822770
The American Joint Committee on Cancer (AJCC8) and Brigham and Women's Hospital are the most commonly used staging systems for cutaneous squamous cell carcinoma (CSCC). Both have limitations. To develop a novel CSCC staging system (COMPASS-SCC) with improved performance. This study utilized a retrospective CSCC database from 12 international centers. Univariable and multivariable Fine and Gray models assessed risk factors' impact on major poor outcomes (MPO; metastasis and disease specific death) for inclusion and weight in the staging system. Sensitivity, specificity, positive and negative predictive value (PPV/NPV), Area Under the Receiver Operating Characteristic curve (AUROC), and Uno's c-index were calculated. 20,972 primary tumors were included. Diameter (1 point for ≥2 but <5, 2 points for ≥5 centimeters), depth (1 point for beyond fat or >6 millimeters), differentiation (1 point for moderate, 2 points for poor), large-caliber perineural invasion (1 point), and lymphovascular invasion (1 point) were included in the system, with stages from T1 (0 points) to T4 (≥5 points). Sensitivity, NPV, AUROC, and Uno's c-index were significantly higher in COMPASS-SCC than in AJCC8 and BWH. Retrospective design. COMPASS-SCC is a novel CSCC staging system with improved prognostic performance compared to AJCC8 and BWH.
中文摘要:美国癌症联合委员会第8版(AJCC8)和布莱根妇女医院分期系统是皮肤鳞状细胞癌(CSCC)最常用的分期系统。两者均存在局限性。旨在开发一种性能更优的新型CSCC分期系统(COMPASS-SCC)。本研究利用了来自12个国际中心的回顾性CSCC数据库。采用单因素和多因素Fine and Gray模型评估危险因素对主要不良结局(MPO;转移和疾病特异性死亡)的影响,以确定其是否纳入分期系统及权重。计算了敏感性、特异性、阳性预测值和阴性预测值(PPV/NPV)、受试者工作特征曲线下面积(AUROC)以及Uno C指数。共纳入20,972例原发肿瘤。直径(≥2但<5厘米计1分,≥5厘米计2分)、深度(超过脂肪层或>6毫米计1分)、分化程度(中分化计1分,低分化计2分)、大管径神经周围侵犯(1分)和淋巴血管侵犯(1分)被纳入该系统,分期从T1(0分)至T4(≥5分)。COMPASS-SCC的敏感性、NPV、AUROC和Uno C指数均显著高于AJCC8和BWH。回顾性设计。与AJCC8和BWH相比,COMPASS-SCC是一种具有更优预后性能的新型CSCC分期系统。

基础研究 (35篇)

Circulation research IF 18.0 2026-10-07 PMID: 42841196
Transcriptional regulation is fundamental to vascular homeostasis, ensuring vessel stability and function. Disruption of this regulation underlies pathological angiogenesis in cancer and vascular malformations. While RUNX3 (Runt-related transcription factor 3), a Runt-domain transcription factor, is established as a tumor suppressor and regulator of lymphocyte development, its role in endothelial cells has remained unknown. To define the vascular function of RUNX3, we generated endothelial-specific RUNX3 knockout mice and analyzed postnatal retinal angiogenesis and oxygen-induced retinopathy. Mechanistic insights were obtained through ATAC-sequencing data analysis, coimmunoprecipitation, proximity ligation assay, electrophoretic mobility shift assay, and ChIP-qPCR. Loss of endothelial RUNX3 induced hypersprouting angiogenesis with excessive tip cell formation and reduced DLL4 (delta-like ligand 4) expression. RUNX3 deficiency disrupted vascular integrity by lowering VE-cadherin (vascular endothelial cadherin) and claudin-5 levels, while increasing ICAM1 (intercellular adhesion molecule 1) expression, retinal hemorrhage, and leukocyte infiltration. In the oxygen-induced retinopathy model, endothelial RUNX3 deletion aggravated pathological neovascularization. Mechanistically, RUNX3 cooperated with ERG (ETS-related gene) at ETS:RUNX motifs to regulate genes controlling sprouting (DLL4), junctional stability (CDH5, CLDN5), and leukocyte adhesion (ICAM1). RUNX3 formed complexes with ERG, p300, and HDAC3 (histone deacetylase 3), and proximity ligation assays showed that these interactions were enriched in the nucleus upon VEGF-A (vascular endothelial growth factor-A) stimulation. ChIP-qPCR further demonstrated that RUNX3 was required for the recruitment of these coregulators to target loci. Through differential coregulator engagement, RUNX3 functioned bidirectionally, acting as a transcriptional activator of CDH5, CLDN5, and DLL4 while serving as a repressor of ICAM1. Consistently, single-cell transcriptome analysis of human arteriovenous malformations revealed dysregulated RUNX3 and target gene expression, underscoring translational relevance. This study provides the first evidence that RUNX3 is a pivotal transcriptional coordinator in endothelial cells. By integrating ERG and chromatin regulators at ETS:RUNX motifs, RUNX3 safeguards the balance between angiogenic activation and vascular stability. These findings establish RUNX3 as a gatekeeper of endothelial transcriptional identity and highlight its potential as a therapeutic target in pathological angiogenesis.
中文摘要:转录调控是血管稳态的基础,确保血管稳定性和功能。这种调控的破坏是癌症和血管畸形中病理性血管生成的基础。RUNX3(Runt相关转录因子3)是一种Runt结构域转录因子,已被确立为肿瘤抑制因子和淋巴细胞发育调节因子,但其在内皮细胞中的作用仍不清楚。为了确定RUNX3的血管功能,我们构建了内皮细胞特异性RUNX3敲除小鼠,并分析了出生后视网膜血管生成和氧诱导视网膜病变。通过ATAC测序数据分析、免疫共沉淀、邻近连接试验、电泳迁移率变动分析和ChIP-qPCR获得了机制性见解。内皮RUNX3缺失诱导了过度出芽的血管生成,伴有尖端细胞形成过多和DLL4(delta样配体4)表达降低。RUNX3缺乏通过降低VE-钙黏蛋白(血管内皮钙黏蛋白)和claudin-5水平,同时增加ICAM1(细胞间黏附分子1)表达、视网膜出血和白细胞浸润,破坏了血管完整性。在氧诱导视网膜病变模型中,内皮RUNX3缺失加重了病理性新生血管形成。在机制上,RUNX3与ERG(ETS相关基因)在ETS:RUNX基序上协同,调控控制出芽(DLL4)、连接稳定性(CDH5、CLDN5)和白细胞黏附(ICAM1)的基因。RUNX3与ERG、p300和HDAC3(组蛋白去乙酰化酶3)形成复合物,邻近连接试验表明,在VEGF-A(血管内皮生长因子-A)刺激后,这些相互作用在细胞核中富集。ChIP-qPCR进一步证明,RUNX3是将这些共调节因子募集到靶位点所必需的。通过差异性共调节因子招募,RUNX3发挥双向功能,作为CDH5、CLDN5和DLL4的转录激活因子,同时作为ICAM1的抑制因子。一致地,对人类动静脉畸形的单细胞转录组分析揭示了RUNX3及其靶基因表达失调,强调了转化相关性。本研究首次提供证据表明RUNX3是内皮细胞中的关键转录协调因子。通过在ETS:RUNX基序上整合ERG和染色质调节因子,RUNX3维护血管生成激活与血管稳定性之间的平衡。这些发现确立了RUNX3作为内皮转录身份的守门人,并强调其作为病理性血管生成治疗靶点的潜力。
MedComm IF 14.1 2026-10 PMID: 42840628
Microorganisms within tumors, also known as intratumoral microbiota, actively shape the tumor microenvironment (TME), influencing cancer progression and treatment response. Research has therefore expanded beyond the gut microbiota to intratumoral bacterial and fungal communities. Advances in low-biomass sequencing, contamination control, and spatial profiling have made it possible to detect these low-abundance microbes within the TME and map their marked heterogeneity across cancer types and tissue compartments. However, their origins, causal functions, and clinical relevance remain debated. Here, we summarize contamination-sensitive workflows and high-resolution techniques required for low-biomass tissues, and compare representative taxa in major cancer settings. We further explore microbial origins, taxonomic diversity, and localized interactions with malignant, immune, and stromal cells. We synthesize mechanistic evidence linking intratumoral microbes to genomic instability, epigenetic regulation, oncogenic signaling, metabolic reprogramming, and metastasis. Based on these insights, we evaluate their impact on cancer therapies, alongside emerging microbial interventions and barriers to clinical translation. Ultimately, this review provides a framework for assessing intratumoral microbiota as biomarkers, treatment-response modifiers, and therapeutic targets, while highlighting the key evidence needed to translate these findings into the clinic.
中文摘要:肿瘤内微生物,也称为瘤内微生物群,主动塑造肿瘤微环境(TME),影响癌症进展和治疗反应。因此,研究已从肠道微生物群扩展到瘤内细菌和真菌群落。低生物量测序、污染控制和空间图谱技术的进展,使得检测TME中这些低丰度微生物并绘制其在癌种和组织区室间的显著异质性成为可能。然而,它们的来源、因果功能及临床相关性仍存争议。在此,我们总结低生物量组织所需的污染敏感工作流程和高分辨率技术,并比较主要癌症场景中的代表性类群。我们进一步探讨微生物来源、分类学多样性及其与恶性细胞、免疫细胞和基质细胞的局部相互作用。我们综合将瘤内微生物与基因组不稳定性、表观遗传调控、致癌信号、代谢重编程和转移联系起来的机制证据。基于这些见解,我们评估其对癌症治疗的影响,并讨论新兴微生物干预措施及临床转化障碍。最终,本综述提供一个框架,用于评估瘤内微生物群作为生物标志物、治疗反应调节因子和治疗靶点,同时强调将这些发现转化为临床应用所需的关键证据。
Nature cancer IF 28.0 2026-10-06 PMID: 42839060
Tumor-infiltrating neutrophils (TINs) promote colorectal cancer progression and therapeutic resistance, but their reprogramming mechanisms remain unclear. Using mouse models and multiomics profiling, we reveal that intestinal epithelial glycogen synthase kinase-3-β (GSK3β) orchestrates fumarate-dependent TIN polarization. GSK3β-primed T3 neutrophils express FTH1 and PD-L1, conferring ferroptosis resistance and immune evasion. Mechanistically, nuclear GSK3β phosphorylates linker histone H1FX, triggering its proteasomal degradation via USP43 dissociation and elevating chromatin accessibility for glycolytic gene transcription. Lactate inactivates fumarate hydratase through lactylation, driving intratumoral fumarate accumulation. Fumarate inhibits KDM2B activity in TINs, elevating histone H3 lysine 36 dimethylation to trigger epigenetic reprogramming toward immunosuppressive T3 neutrophils. Pharmacological GSK3β inhibition with tideglusib attenuates T3 polarization and potentiates checkpoint blockade in preclinical colorectal cancer models. Our work establishes a metabolic-epigenetic axis controlling TIN reprogramming and suggests combinatorial immunotherapies for CRC.
中文摘要:肿瘤浸润性中性粒细胞(TINs)促进结直肠癌进展和治疗耐药,但其重编程机制尚不清楚。我们利用小鼠模型和多组学分析,揭示肠上皮糖原合成酶激酶-3β(GSK3β)协调延胡索酸依赖性的TIN极化。GSK3β诱导的T3中性粒细胞表达FTH1和PD-L1,赋予其铁死亡抵抗和免疫逃逸能力。在机制上,核内GSK3β磷酸化连接组蛋白H1FX,通过USP43解离触发其蛋白酶体降解,并提高糖酵解基因转录的染色质可及性。乳酸通过乳酰化使延胡索酸水合酶失活,驱动肿瘤内延胡索酸蓄积。延胡索酸抑制TINs中KDM2B活性,升高组蛋白H3第36位赖氨酸二甲基化,从而触发向免疫抑制性T3中性粒细胞的表观遗传重编程。在临床前结直肠癌模型中,使用tideglusib进行药理学GSK3β抑制可减弱T3极化并增强检查点阻断疗效。我们的工作确立了控制TIN重编程的代谢-表观遗传轴,并提示结直肠癌的联合免疫治疗策略。
Ageing research reviews IF 15.5 2026-10-06 PMID: 42838290
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality, with substantial residual risk persisting despite contemporary lipid-lowering, antithrombotic, and anti-inflammatory therapies. Increasing evidence indicates that vascular smooth muscle cells (VSMCs) actively shape plaque composition, progression, and stability through cellular programs that partially resemble those involved in tumor evolution. Within this framework, tumor-like transformation refers to the convergence of selected pathological features, including genomic instability, clonal selection, phenotypic plasticity, non-mutational state reprogramming, inflammatory microenvironmental remodeling, and pathological angiogenesis, rather than malignant transformation in the strict sense. This review examines vascular aging as an overarching factor that promotes these processes by impairing genomic and epigenetic homeostasis, altering extracellular matrix and mechanical cues, inducing cellular senescence and senescence-associated secretory activity, and reshaping local selective niches. We then discuss four interconnected mechanisms underlying VSMC tumor-like remodeling: DNA damage accumulation and repair imbalance, epigenetic reprogramming, clonal expansion coupled with multilineage phenotypic plasticity, and pathological microvascular remodeling within the plaque microenvironment. Therapeutic opportunities are considered along three corresponding axes: preservation of DNA damage response and genomic stability, promotion of fibrous cap-associated protective states while restricting harmful clonal and phenotypic trajectories, and lesion-targeted inhibition of intraplaque neovascularization. Although these strategies provide a mechanistic basis for precision plaque stabilization, most supporting evidence remains preclinical. Future studies should define stage- and state-specific therapeutic windows and develop targeted, spatially restricted interventions that account for the cellular and regional heterogeneity of atherosclerotic plaques.
中文摘要:动脉粥样硬化性心血管疾病(ASCVD)仍是致病和致死的主要原因,尽管当前已有降脂、抗血栓和抗炎治疗,仍存在显著残余风险。越来越多证据表明,血管平滑肌细胞(VSMC)通过部分类似肿瘤演化过程的细胞程序,主动塑造斑块组成、进展和稳定性。在此框架下,肿瘤样转化是指若干病理特征的汇聚,包括基因组不稳定性、克隆选择、表型可塑性、非突变性状态重编程、炎症微环境重塑和病理性血管新生,而非严格意义上的恶性转化。本综述将血管衰老视为促进这些过程的上位因素,其通过损害基因组和表观遗传稳态、改变细胞外基质和机械信号、诱导细胞衰老及衰老相关分泌活动,并重塑局部选择生态位来发挥作用。随后,我们讨论VSMC肿瘤样重塑背后的四个相互关联机制:DNA损伤积累与修复失衡、表观遗传重编程、克隆扩增与多谱系表型可塑性偶联,以及斑块微环境中的病理性微血管重塑。治疗机会沿三条相应轴线加以考虑:维持DNA损伤应答和基因组稳定性,促进纤维帽相关保护状态同时限制有害的克隆和表型轨迹,以及病灶靶向抑制斑块内新生血管形成。尽管这些策略为精准稳定斑块提供了机制基础,但大多数支持性证据仍处于临床前阶段。未来研究应界定分期和状态特异性的治疗窗口,并开发考虑动脉粥样硬化斑块细胞和区域异质性的靶向、空间限制性干预措施。
Clinical reviews in allergy & immunology IF 11.5 2026-10-06 PMID: 42836902
Ataxia-Telangiectasia (A-T) is a rare, autosomal recessive disorder caused by biallelic pathogenic variants in the ATM gene. Loss of ataxia-telangiectasia mutated (ATM) protein function impairs DNA damage responses, leading to progressive neurodegeneration, genomic instability, immunodeficiency, and an increased risk of malignancy. Some A-T patients develop cancers at a young age and display extreme sensitivity to ionizing radiation and certain chemotherapeutics. Therefore, standard treatments often cause severe, life-threatening toxicities in these patients. This review discusses the dual role of ATM as a tumor suppressor and key DNA repair kinase, the mechanisms by which ATM deficiency promotes oncogenesis, and the unique challenges of treating malignancies in the context of A-T. We highlight emerging, less genotoxic therapies for ATM-deficient cancers including cancer vaccines, immune checkpoint inhibitors, CAR T-cell therapy, and synthetic lethal approaches such as Poly(ADP-ribose) polymerase (PARP) and Ataxia Telangiectasia and Rad3-related (ATR) inhibitors. These novel strategies may improve outcomes for A-T patients while minimizing treatment toxicity. We also outline future directions and clinical implications, emphasizing the need for tailored therapeutic approaches and multidisciplinary care for this high-risk population. Because prospective, A-T-specific therapeutic data are scarce, we draw extensively on the broader literature on somatic ATM-mutant cancers to inform management, while highlighting the additional constraints imposed by germline ATM loss.
中文摘要:共济失调毛细血管扩张症(A-T)是一种由ATM基因双等位基因致病性变异引起的罕见常染色体隐性遗传病。共济失调毛细血管扩张突变(ATM)蛋白功能缺失会损害DNA损伤应答,导致进行性神经退行性变、基因组不稳定性、免疫缺陷以及恶性肿瘤风险增加。部分A-T患者在年幼时即发生癌症,并对电离辐射和某些化疗药物表现出极度敏感。因此,标准治疗常在这些患者中引起严重甚至危及生命的毒性。本综述讨论了ATM作为抑癌因子和关键DNA修复激酶的双重作用、ATM缺陷促进肿瘤发生的机制,以及在A-T背景下治疗恶性肿瘤所面临的独特挑战。我们重点介绍了针对ATM缺陷癌症的新兴、遗传毒性较低的治疗方法,包括肿瘤疫苗、免疫检查点抑制剂、CAR T细胞疗法,以及聚(ADP-核糖)聚合酶(PARP)和共济失调毛细血管扩张症和Rad3相关(ATR)抑制剂等合成致死策略。这些新策略可能在改善A-T患者结局的同时尽量减少治疗毒性。我们还概述了未来方向和临床意义,强调对这一高风险人群需要量身定制的治疗方法和多学科照护。由于前瞻性、针对A-T的治疗数据匮乏,我们广泛借鉴关于体细胞ATM突变癌症的更广泛文献以指导管理,同时强调胚系ATM缺失所带来的额外限制。
Redox biology IF 16.2 2026-10-05 PMID: 42837695
Tumors persist under sustained redox stress by coupling increased reactive-species production to antioxidant buffering, metabolic plasticity and multicellular support. This creates therapeutic vulnerabilities whose tractability depends on the biological state of the exposed compartment. Here, we frame redox nanomedicine as state-matched manipulation of oxidant flux, antioxidant buffering, oxygen and substrate availability, localization, duration and spatial coverage. We propose that therapeutic outcome emerges from chemistry, exposure and the presence of an executable redox dependency together with the machinery required for adaptation, apoptosis, ferroptosis, pyroptosis or cuproptosis. Redox perturbations also propagate through immune, vascular, stromal and metabolic compartments, generating both therapeutic benefits and liabilities. We therefore integrate redox-state dependence, cell-fate assignment, multicompartment effects and translational target engagement into a unified framework. A state-matched development strategy begins with a defined biological dependency, measures local exposure and target engagement, and uses pharmacokinetic, safety and biomarker data to refine product design and patient selection. This framework positions redox nanomedicine as mechanistically testable control of tumor redox states within a defined therapeutic window.
中文摘要:肿瘤在持续氧化还原应激下通过将活性物质产生增加与抗氧化缓冲、代谢可塑性及多细胞支持相偶联而得以存续。这产生了治疗脆弱性,其可干预性取决于所暴露区室的生物学状态。在此,我们将氧化还原纳米医学界定为对氧化剂通量、抗氧化缓冲、氧与底物可利用性、定位、持续时间及空间覆盖进行状态匹配式调控。我们提出,治疗结局源于化学性质、暴露以及存在可执行的氧化还原依赖,同时具备适应、凋亡、铁死亡、焦亡或铜死亡所需的机制。氧化还原扰动还会通过免疫、血管、基质和代谢区室传播,既产生治疗获益也带来治疗风险。因此,我们将氧化还原状态依赖性、细胞命运指定、多区室效应及转化靶点结合整合为一个统一框架。状态匹配的开发策略始于明确的生物学依赖性,测量局部暴露和靶点结合,并利用药代动力学、安全性和生物标志物数据来优化产品设计和患者选择。该框架将氧化还原纳米医学定位为在既定治疗窗内对肿瘤氧化还原状态进行机制上可检验的调控。
Archives of toxicology IF 10.9 2026-10-05 PMID: 42834150
Oxidative stress is a major contributor to xenobiotic-induced tissue injury, mitochondrial dysfunction, inflammation, ferroptosis, and carcinogenesis. Ursolic acid (UA), a naturally occurring pentacyclic triterpenoid, has emerged as a context-dependent regulator of redox homeostasis. This review summarizes current evidence regarding the dual effects of UA on oxidative stress and its toxicological implications. Under non-malignant conditions, UA generally exerts antioxidant and cytoprotective effects in the majority of experimental models examined. Reduced reactive oxygen species (ROS) accumulation, modulation of nuclear factor erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein 1 (Keap1) signalin, preservation of mitochondrial homeostasis, and attenuation of inflammatory and apoptotic responses appear to underlie these protective activities. Protective effects have been reported in experimental models of hepatic, renal, cardiovascular, neurological, and radiation-associated injury. By contrast, in tumor cells characterized by elevated basal oxidative stress, UA has frequently been shown to exert pro-oxidative actions, though this response is influenced by concentration, exposure duration, and cellular context. In malignant models, UA has been shown to enhance ROS accumulation, disturb redox balance, suppress antioxidant defenses, and promote cell death associated with ferroptosis and apoptosis, thereby increasing sensitivity to chemotherapy and radiotherapy. Despite promising preclinical findings, several limitations continue to restrict clinical translation, including poor oral bioavailability, variable pharmacokinetics, potential herb-drug interactions, and insufficient long-term toxicological evaluation. Overall, current evidence supports UA as a context-dependent redox modulator with dual antioxidant and pro-oxidant activities, although further mechanistic, pharmacokinetic, and translational studies remain necessary.
中文摘要:氧化应激是外源物诱导的组织损伤、线粒体功能障碍、炎症、铁死亡和癌变的重要促成因素。熊果酸(UA)是一种天然存在的五环三萜类化合物,已成为一种情境依赖性的氧化还原稳态调节因子。本文综述了目前关于UA对氧化应激的双重作用及其毒理学意义的证据。在非恶性条件下,UA在所考察的大多数实验模型中通常发挥抗氧化和细胞保护作用。减少活性氧(ROS)积累、调节核因子E2相关因子2(Nrf2)/Kelch样ECH相关蛋白1(Keap1)信号、维持线粒体稳态以及减弱炎症和凋亡反应,可能是这些保护活性的基础。在肝脏、肾脏、心血管、神经系统和辐射相关损伤的实验模型中已有保护作用的报道。相比之下,在基础氧化应激升高的肿瘤细胞中,UA常被证明具有促氧化作用,尽管这种反应受浓度、暴露时间和细胞情境的影响。在恶性模型中,UA已被证明可增强ROS积累、扰乱氧化还原平衡、抑制抗氧化防御,并促进与铁死亡和凋亡相关的细胞死亡,从而提高对化疗和放疗的敏感性。尽管临床前研究结果令人鼓舞,但若干局限性仍限制其临床转化,包括口服生物利用度差、药代动力学多变、潜在的草药-药物相互作用以及长期毒理学评价不足。总体而言,当前证据支持UA是一种情境依赖性的氧化还原调节剂,具有抗氧化和促氧化双重活性,但仍需进一步的机制、药代动力学和转化研究。
Cancer research IF 22.6 2026-10-05 PMID: 42831554
Excessive cyclin D1 accumulation is a frequent oncogenic event in head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC). Although classically associated with enhanced proliferation and genomic instability, we revealed that cyclin D1 dysregulation induces metabolic rewiring that leads to unexpected metabolic dependencies. Sustained nuclear retention of cyclin D1 drove metabolic reprogramming through activation of CDK4/6 and downregulation of mitochondrial isocitrate dehydrogenase 3 (IDH3), reducing α-ketoglutarate and NADH production. This metabolic alteration increased glutamine dependence and elevated autophagic flux, and co-targeting autophagy and glutamine metabolism suppressed the growth of squamous cell carcinoma models in vitro and in vivo. Together, these findings highlight a therapeutic strategy for HNSCC and ESCC that leverages metabolic reprogramming induced by dysregulated cyclin D1/CDK4 activity, with potential applicability to patients with tumors refractory to conventional therapies.
中文摘要:细胞周期蛋白D1过度积累是头颈部鳞状细胞癌(HNSCC)和食管鳞状细胞癌(ESCC)中常见的致癌事件。尽管传统上认为其与增殖增强和基因组不稳定性相关,但我们发现细胞周期蛋白D1失调可诱导代谢重编程,导致意想不到的代谢依赖性。细胞周期蛋白D1持续滞留于细胞核,通过激活CDK4/6并下调线粒体异柠檬酸脱氢酶3(IDH3)驱动代谢重编程,减少α-酮戊二酸和NADH生成。这种代谢改变增加了谷氨酰胺依赖性并提高了自噬流,联合靶向自噬和谷氨酰胺代谢可抑制鳞状细胞癌模型在体外和体内的生长。总之,这些发现突显了一种针对HNSCC和ESCC的治疗策略,该策略利用由细胞周期蛋白D1/CDK4活性失调所诱导的代谢重编程,并可能适用于对常规治疗耐药的肿瘤患者。
MedComm IF 14.1 2026-10 PMID: 42827658
Cancer metastasis is a spatiotemporal dynamic process jointly driven by the intrinsic evolution of cancer cells and continuous microenvironmental selection, rather than a simple linear accumulation of genetic alterations. The metastatic diversity of cancers is driven by heterogeneity in physicochemical properties, cellular composition, and signaling networks among primary tumors, dissemination routes, and target organs. Currently, the stage-dependent and route-dependent molecular mechanisms underlying metastasis and potential pan-cancer therapeutic targets remain incompletely defined. Here, we systematically discuss the genomic, chromosomal, and epigenetic evolution of metastatic tumor cells (MTCs) following their spatiotemporal trajectory from in situ evolution to metastatic colonization. We describe their migration behaviors and interaction patterns within the migratory tumor microenvironment across hematogenous, lymphatic, and perineural routes, and the establishment and remodeling of organ-specific metastatic niches. We also review the progress and limitations of metastasis-oriented diagnostic stratification and therapeutic interventions. We argue for the shift of antimetastatic strategies from target-centric approaches to precise interventions that match timing, routes, biomarkers, and endpoints. By integrating the molecular mechanisms underlying spatiotemporal changes during cancer metastasis, this review delineates the spatiotemporal evolutionary landscape of metastasis and the MTC-microenvironment interaction patterns, thereby offering insights for future clinical translation of metastasis‑targeted therapies.
中文摘要:癌症转移是一个时空动态过程,由癌细胞内在演化与微环境的持续选择共同驱动,而非基因改变的简单线性累积。癌症转移的多样性由原发肿瘤、播散途径和靶器官之间在理化性质、细胞组成和信号网络上的异质性所驱动。目前,转移的阶段依赖性和途径依赖性分子机制以及潜在的泛癌治疗靶点仍未被完全阐明。在此,我们沿转移性肿瘤细胞(MTCs)从原位移演化到转移定植的时空轨迹,系统讨论其基因组、染色体和表观遗传演化。我们描述其在经血行、淋巴和神经周围途径的迁移性肿瘤微环境中的迁移行为和相互作用模式,以及器官特异性转移龛的建立与重塑。我们还综述以转移为导向的诊断分层和治疗干预的进展与局限。我们主张抗转移策略应从以靶点为中心的方法转向与时机、途径、生物标志物和终点相匹配的精准干预。通过整合癌症转移过程中时空变化背后的分子机制,本综述描绘了转移的时空演化图景和MTC-微环境相互作用模式,从而为转移靶向治疗的未来临床转化提供见解。
Molecular cell IF 16.0 2026-10-02 PMID: 42826715
MYC amplification is common and often extrachromosomal (ecDNA) in cancer. To define how MYC DNA copy gains arise from diploid genomes, we assessed whether epigenetic enzymes directly control focal MYC over-replication and amplification. We demonstrate that H3K4 methylation primes MYC for amplification by the H3K9/K36 tri-demethylase KDM4C, while the H3K36 tri-methyltransferase SETD2 restrains copy gains. These relationships are also observed in tumor datasets. SETD2 loss or inhibition promotes recruitment of catalytically active KDM4C, which initiates and drives stepwise MYC copy gains. Suppressing apoptosis or losing TP53 accelerates the emergence of higher-level MYC amplification events, including extrachromosomal circular ecDNAs (eccDNAs) and inherited copy gains. Non-transformed cells with these alterations are tumorigenic. Furthermore, KDM4C inhibition suppresses MYC amplification. These data define a chromatin-apoptotic axis directly controlling the initiation and progression of MYC amplification from diploid to hyper-amplification while also identifying potential biomarkers and therapeutic targets to constrain MYC-amplified tumors.
中文摘要:MYC扩增在癌症中常见,且常以染色体外DNA(ecDNA)形式存在。为明确MYC DNA拷贝数增加如何从二倍体基因组产生,我们评估了表观遗传酶是否直接控制MYC局灶性过度复制和扩增。我们证明H3K4甲基化通过H3K9/K36三去甲基化酶KDM4C为MYC扩增做好准备,而H3K36三甲基转移酶SETD2则抑制拷贝数增加。这些关系也在肿瘤数据集中观察到。SETD2缺失或抑制促进催化活性KDM4C的募集,后者启动并驱动逐步的MYC拷贝数增加。抑制凋亡或TP53缺失加速了更高水平MYC扩增事件的出现,包括染色体外环状ecDNA(eccDNA)和可遗传的拷贝数增加。具有这些改变的非转化细胞具有致瘤性。此外,抑制KDM4C可抑制MYC扩增。这些数据定义了一个染色质-凋亡轴,直接控制MYC扩增从二倍体到超扩增的起始和进展,同时也确定了潜在的生物标志物和治疗靶点,以限制MYC扩增的肿瘤。
Science advances IF 13.9 2026-10-02 PMID: 42814839
Recent studies have described an ability of cancer cells to survive engagement of apoptotic pathways following chemical and therapeutic insults, challenging the prevailing model that caspase activation inevitably leads to cellular demise. Gasdermin E (GSDME), whose expression is frequently down-regulated or silenced in many tumors and tumor-derived cell lines, is a putative tumor suppressor capable of facilitating the induction of antitumor immunity. We found that GSDME expression precluded high caspase activity before cellular membrane rupture downstream of chemical and immune-mediated insults, and its absence allowed for enhanced activities downstream of caspase activation, including the DNA-damaging effects of caspase-activated deoxyribonuclease. Loss of GSDME allowed cells that had sustained DNA damage to survive, resulting in development and propagation of mutated clones. We conclude that GSDME functions as a key rheostat for determining cell death outcomes by tuning the tolerance to the activities of caspases and their substrates during apoptosis. In analyzing solid tumors in The Cancer Genome Atlas, we found that tumor mutational burden was higher in tumors with low GSDME expression and high immune signatures, supporting the possibility that the effects we describe affect tumor mutation in response to immune assault.
中文摘要:近期研究描述了癌细胞在化学和治疗性损伤后仍可在凋亡通路被激活的情况下存活,这挑战了caspase激活必然导致细胞死亡的主流模型。Gasdermin E(GSDME)在许多肿瘤及肿瘤来源细胞系中表达频繁下调或沉默,是一种可能促进抗肿瘤免疫诱导的候选抑癌因子。我们发现,在化学和免疫介导损伤下游,GSDME表达可阻止细胞膜破裂前出现高caspase活性;而GSDME缺失则允许caspase激活下游效应增强,包括caspase激活的脱氧核糖核酸酶所致的DNA损伤效应。GSDME缺失使已发生DNA损伤的细胞得以存活,从而导致突变克隆的形成和传播。我们得出结论:GSDME通过调节凋亡过程中对caspase及其底物活性的耐受性,发挥决定细胞死亡结局的关键变阻器作用。在分析癌症基因组图谱中的实体瘤时,我们发现GSDME低表达且免疫特征高的肿瘤具有更高的肿瘤突变负荷,这支持我们所描述的作用可能影响免疫攻击下的肿瘤突变。
Cancer discovery IF 29.5 2026-10-01 PMID: 42817714
Obesity and high dietary fat consumption are associated with an increased risk of pancreatic ductal adenocarcinoma (PDAC), and Ruiz and colleagues show that in addition to total fat consumption, distinct types of dietary fat contribute differently to tumor initiation in murine PDAC models. Diets rich in monounsaturated fatty acids enhance tumor progression, whereas dietary polyunsaturated fatty acids suppress tumorigenesis by increasing pancreatic cell susceptibility to lipid peroxidation and ferroptosis. See related article by Ruiz et al., p. 2108.
中文摘要:肥胖和高膳食脂肪摄入与胰腺导管腺癌(PDAC)风险增加相关,Ruiz及其同事表明,除了总脂肪摄入外,不同类型的膳食脂肪在小鼠PDAC模型中对肿瘤起始的作用不同。富含单不饱和脂肪酸的饮食促进肿瘤进展,而膳食多不饱和脂肪酸通过增加胰腺细胞对脂质过氧化和铁死亡的易感性来抑制肿瘤发生。参见Ruiz等人发表于第2108页的相关文章。
Nature IF 56.1 2026-10 PMID: 42778593
Extrachromosomal DNA (ecDNA) comprises megabase-sized circular DNA elements that frequently carry oncogene amplifications, driving aggressive tumour phenotypes, therapeutic resistance and poor clinical outcomes across many cancers1-4. Although ecDNA is thought to arise from canonical double-strand break repair, the pathways that maintain it remain unclear. Here we show that inhibition of microhomology-mediated end joining, but not non-homologous end joining or homologous recombination, selectively depletes ecDNA, induces ecDNA-specific damage and promotes its sequestration into micronuclei, compromising the fitness of cancer cells that depend on ecDNA-driven oncogene amplification. Mechanistically, TA-rich loci on ecDNA are hotspots for DNA damage and breakage5,6. The DNA translocase FANCM suppresses break formation at these sites, while breaks that escape FANCM surveillance are cleaved by ERCC1-ERCC4 and channelled into microhomology-mediated end joining for repair. Single-cell whole-genome sequencing shows that disrupting FANCM or polymerase θ (Polθ) in COLO320DM cells causes structural instability characterized by deletions and small duplications, with breakpoints enriched at TA-rich regions. This fragility is recapitulated in human tumours, in which ecDNA rearrangements are enriched at TA repeats. Collectively, our findings reveal TA repeat fragility as an intrinsic vulnerability of circular DNA and identify Polθ inhibition as a promising strategy to potentially destabilize ecDNA and sensitize ecDNA-driven tumours to therapeutic intervention.
中文摘要:染色体外DNA(ecDNA)由兆碱基大小的环状DNA元件组成,常携带癌基因扩增,驱动侵袭性肿瘤表型、治疗耐药和多种癌症的不良临床结局1-4。尽管ecDNA被认为起源于经典的双链断裂修复,但维持它的通路仍不清楚。本研究表明,抑制微同源介导的末端连接(MMEJ),而非非同源末端连接或同源重组,会选择性地耗竭ecDNA,诱导ecDNA特异性损伤,并促使其被隔离到微核中,从而损害依赖ecDNA驱动癌基因扩增的癌细胞的适应度。在机制上,ecDNA上富含TA的位点是DNA损伤和断裂的热点5,6。DNA转位酶FANCM抑制这些位点的断裂形成,而逃逸FANCM监视的断裂由ERCC1-ERCC4切割,并被导入微同源介导的末端连接进行修复。单细胞全基因组测序显示,在COLO320DM细胞中破坏FANCM或聚合酶θ(Polθ)会导致以缺失和小片段重复为特征的结构不稳定性,其断点富集于富含TA的区域。这种脆弱性在人类肿瘤中得以重现,其中ecDNA重排富集于TA重复序列。总体而言,我们的发现揭示了TA重复脆弱性是环状DNA的一种内在易感性,并确定抑制Polθ是一种有前景的策略,可能使ecDNA不稳定,并使ecDNA驱动的肿瘤对治疗干预更敏感。
Pharmacological research IF 12.2 2026-10 PMID: 42722240
Epigenetic dysregulation is a hallmark of cancer and contributes to tumor initiation, progression, metastasis, and therapeutic resistance. Consequently, epigenetic drugs (epidrugs) targeting DNA methylation, histone modifications, and chromatin-associated proteins have emerged as an important class of anticancer agents. Approved therapies such as DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis) have demonstrated clinical benefit, particularly in hematological malignancies; however, their efficacy is often limited by off-target toxicity, acquired resistance, and incomplete target selectivity. In recent years, metallorganic compounds have gained attention as a novel generation of epigenetic modulators. The incorporation of metal centers provides unique structural, redox, and coordination properties that enable interactions with multiple epigenetic targets and facilitate the design of multifunctional agents. This review summarizes the major classes of epidrugs and discusses emerging metallorganic epigenetic therapeutics based on ruthenium, platinum, tin, copper, iridium, iron, technetium, rhenium, and gold. We examine their mechanisms of action against key epigenetic regulators, including DNMTs, HDACs, histone methyltransferases, bromodomain proteins, and chromatin-associated complexes. Particular attention is given to the potential of metal-based epidrugs to overcome therapeutic resistance through multimodal mechanisms that combine epigenetic reprogramming with modulation of DNA damage responses, oxidative stress, protein homeostasis, and chromatin organization. Although most metallorganic epidrugs remain in preclinical development, accumulating evidence suggests that they may offer advantages over conventional organic epigenetic inhibitors by enabling multi-target engagement and more durable antitumor responses. Together, these findings highlight the growing potential of metal-based epigenetic therapies and support their further development as innovative strategies for precision oncology.
中文摘要:表观遗传失调是癌症的标志,参与肿瘤发生、进展、转移和治疗耐药。因此,靶向DNA甲基化、组蛋白修饰和染色质相关蛋白的表观遗传药物(epidrugs)已成为一类重要的抗癌药物。已获批的疗法如DNA甲基转移酶抑制剂(DNMTis)和组蛋白去乙酰化酶抑制剂(HDACis)已显示出临床获益,尤其是在血液系统恶性肿瘤中;然而,其疗效常受限于脱靶毒性、获得性耐药和不完全的靶点选择性。近年来,金属有机化合物作为新一代表观遗传调节剂受到关注。金属中心的引入提供了独特的结构、氧化还原和配位性质,使其能够与多个表观遗传靶点相互作用,并促进多功能药物的设计。本综述总结了主要类别的表观遗传药物,并讨论了基于钌、铂、锡、铜、铱、铁、锝、铼和金的新兴金属有机表观遗传治疗药物。我们考察了它们针对关键表观遗传调节因子的作用机制,包括DNMT、HDAC、组蛋白甲基转移酶、溴结构域蛋白和染色质相关复合物。特别关注金属基表观遗传药物通过多模式机制克服治疗耐药的潜力,这些机制将表观遗传重编程与DNA损伤反应、氧化应激、蛋白质稳态和染色质组织的调节相结合。尽管大多数金属有机表观遗传药物仍处于临床前开发阶段,但不断积累的证据表明,与传统的有机表观遗传抑制剂相比,它们可能通过实现多靶点作用及更持久的抗肿瘤反应而具有优势。总之,这些发现凸显了金属基表观遗传疗法日益增长的潜力,并支持将其进一步开发为精准肿瘤学的创新策略。
Redox biology IF 16.2 2026-10 PMID: 42641477
OXIDATIVE STRESS: good or evil? Oxidative stress occurs when the balance between reactive oxygen species (ROS) and antioxidant defenses shifts toward an excess of ROS; while essential in physiological processes, it plays a context-dependent role in cancer, contributing to both the promotion and inhibition of tumorigenesis. Small to moderate amounts of ROS activate pathways supporting tumor progression and proliferation, while large amounts lead to genomic instability and cell death. ROS are generated endogenously and exogenously. In cancer, ROS activate pathways that prompt tumor development (KRAS, MYC, PI3K-Akt-mTOR) and block tumor suppressors (p53, BRCA1), allowing tumorigenesis and drug resistance. They also modulate the tumor microenvironment (TME) by altering tumor, stromal and immune cell interactions, which initiate angiogenesis, epithelial-mesenchymal transition (EMT), inflammation and metastasis. Myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) contribute to ROS-driven immunosuppression. Cancer cells mainly rely on glycolysis and oxidative phosphorylation (OXPHOS) to sustain their energetic and metabolic requirements. Generated ROS act as metabolic byproducts and signaling molecules supporting proliferation and tumorigenesis. Cancer stem cells (CSCs) produce low ROS levels by activating antioxidant pathways and mitochondria remodeling, ensuring recurrence and persistence. There is a redox duality that presents challenges and opportunities for therapies. Pro-oxidant approaches attempt to overwhelm the tumor's defenses, while antioxidants preserve healthy tissues. Advances in targeted redox modulation with immunotherapies improve therapy effectiveness. We propose a new "Adaptive Directed Redox Therapy" (ADRT), which involves a dynamic, feedback-controlled methodology that alternates pro- and antioxidant phases to selectively collapse tumor redox balance while preserving normal tissues.
中文摘要:氧化应激:是善还是恶?氧化应激发生于活性氧(ROS)与抗氧化防御之间的平衡向ROS过量偏移时;虽然它在生理过程中必不可少,但在癌症中发挥依赖环境的作用,既促进也抑制肿瘤发生。少量至中等量的ROS激活支持肿瘤进展和增殖的通路,而大量ROS则导致基因组不稳定性与细胞死亡。ROS可由内源性和外源性途径产生。在癌症中,ROS激活促使肿瘤发展的通路(KRAS、MYC、PI3K-Akt-mTOR),并抑制抑癌因子(p53、BRCA1),从而促进肿瘤发生和耐药。它们还通过改变肿瘤细胞、基质细胞和免疫细胞之间的相互作用来调节肿瘤微环境(TME),从而启动血管生成、上皮-间质转化(EMT)、炎症和转移。髓源性抑制细胞(MDSCs)和癌症相关成纤维细胞(CAFs)促进ROS驱动的免疫抑制。癌细胞主要依赖糖酵解和氧化磷酸化(OXPHOS)来维持其能量和代谢需求。所产生的ROS既作为代谢副产物,也作为信号分子支持增殖和肿瘤发生。癌症干细胞(CSCs)通过激活抗氧化通路和线粒体重塑来维持低ROS水平,从而确保复发和持续存在。氧化还原的双重性为治疗带来了挑战和机遇。促氧化策略试图压倒肿瘤的防御,而抗氧化剂则保护健康组织。将靶向氧化还原调节与免疫疗法结合方面的进展可提高治疗有效性。我们提出一种新的「适应性定向氧化还原治疗」(ADRT),其涉及一种动态、反馈控制的方法,交替采用促氧化和抗氧化阶段,以选择性瓦解肿瘤氧化还原平衡,同时保护正常组织。
Molecular cell IF 16.0 2026-10-01 PMID: 42636809
Cells undergoing division mount a unique response to DNA damage that ensures accurate chromosome segregation. The CIP2A-TOPBP1 complex has emerged as an important mitotic genome maintenance factor, but its function remains unclear. Here, we report that DDIAS is a DNA-binding effector of the CIP2A pathway in human cells. DDIAS physically interacts with TOPBP1, and its inactivation causes synthetic lethality with BRCA1 and BRCA2 deficiency. Homologous recombination (HR)-deficient tumors upregulate DDIAS to enable HR-deficient cells to tolerate their genomic instability. Mechanistically, DDIAS is a single-stranded DNA (ssDNA)-binding protein that promotes the repair of ssDNA carried from interphase into mitosis. Mitotic ssDNA in HR-deficient cells is exacerbated by poly(ADP-ribose) polymerase (PARP) inhibition, and DDIAS-dependent suppression of these lesions involves mitotic DNA synthesis, which promotes accurate chromosome segregation and survival. We propose that DDIAS defines a mitotic DNA repair system downstream of CIP2A that mitigates the threat of mitotic ssDNA for genome integrity.
中文摘要:进行分裂的细胞会启动一种独特的 DNA 损伤应答,以确保染色体准确分离。CIP2A-TOPBP1 复合物已成为重要的有丝分裂基因组维护因子,但其功能仍不清楚。在此,我们报道 DDIAS 是人类细胞中 CIP2A 通路的 DNA 结合效应因子。DDIAS 与 TOPBP1 发生物理相互作用,其失活会导致与 BRCA1 和 BRCA2 缺陷的合成致死。同源重组(HR)缺陷的肿瘤上调 DDIAS,以使 HR 缺陷细胞能够耐受其基因组不稳定性。机制上,DDIAS 是一种单链 DNA(ssDNA)结合蛋白,可促进从间期带入有丝分裂的 ssDNA 的修复。HR 缺陷细胞中的有丝分裂 ssDNA 会因聚(ADP-核糖)聚合酶(PARP)抑制而加剧,而对这些损伤的 DDIAS 依赖性抑制涉及有丝分裂 DNA 合成,后者促进准确的染色体分离和存活。我们提出,DDIAS 定义了一个位于 CIP2A 下游的有丝分裂 DNA 修复系统,可减轻有丝分裂 ssDNA 对基因组完整性的威胁。
Pharmacological research IF 12.2 2026-10 PMID: 42628855
Despite advances in cancer therapeutics, there are still challenges in improving drug toxicity and selectivity. Peptides from various venous species have recently garnered attention for their biopharmaceutical potential, particularly in cancer. The present study aimed to conduct a meta-analysis of the antitumor activity of scorpion venom-derived peptides (SVDPs) previously reported in preclinical models. The bibliographic research included original and review articles written in English published from 2015 to 2026. Studies within the scope were retrieved from the EBSCO Discovery Service, PubMed, and WIPO databases. A total of 27 articles that met the inclusion and exclusion criteria were included in this research, and the collected data were synthesized through a meta-analysis. In the included in vitro and in vivo studies, the effect of SVDPs on breast/mammary gland, cervical, colon, glioblastoma, liver, lung, oral, or prostate cancer cell lines was reported. The meta-analyses indicated that SVDPs affected cancer cells by reducing cell viability, with a greater effect on lung cancer cells (IC50 pooled mean: 12.69 μM; 95% CI: 5.80-19.57). Additionally, SVDPs induce early apoptosis (SMD: 5.11; 95% CI: 2.54-7.68), and reduce tumor volume in animal models (SMD = -7.29; 95% CI: -12.73- -1.85). Furthermore, the peptides modulated the key oncogenic pathways, including caspase-mediated apoptosis, autophagy, the cell cycle, PI3K/AKT, EGFR/RAS/RAF, and MAPK signaling, by regulating altered proteins and genes in cancer cells. In addition, this review highlights promising outcomes and discusses the mechanistic knowledge gaps to inform future research directions.
中文摘要:尽管癌症治疗取得了进展,但在改善药物毒性和选择性方面仍面临挑战。来自不同毒液物种的肽因具有生物制药潜力而最近受到关注,尤其是在癌症领域。本研究旨在对既往在临床前模型中报道的蝎毒来源肽(SVDPs)的抗肿瘤活性进行荟萃分析。文献检索纳入了2015年至2026年发表的英文原创论文和综述。符合范围的研究从EBSCO Discovery Service、PubMed和WIPO数据库中检索。共有27篇符合纳入和排除标准的文章被纳入本研究,并对收集的数据进行了荟萃分析。在纳入的体外和体内研究中,报道了SVDPs对乳腺/乳房、宫颈、结肠、胶质母细胞瘤、肝脏、肺、口腔或前列腺癌细胞系的作用。荟萃分析表明,SVDPs通过降低细胞活力影响癌细胞,其中对肺癌细胞的作用更大(IC50合并均值:12.69 μM;95% CI:5.80-19.57)。此外,SVDPs诱导早期凋亡(SMD:5.11;95% CI:2.54-7.68),并减少动物模型中的肿瘤体积(SMD = -7.29;95% CI:-12.73--1.85)。此外,这些肽通过调节癌细胞中发生改变的蛋白质和基因,调控关键致癌通路,包括caspase介导的凋亡、自噬、细胞周期、PI3K/AKT、EGFR/RAS/RAF和MAPK信号传导。此外,本综述强调了有前景的结果,并讨论了机制方面的知识空白,以指导未来的研究方向。
Redox biology IF 16.2 2026-10 PMID: 42607496
Transcription factors often exhibit a striking paradox: they function as tumor suppressors in one context and promote oncogenesis in another. The underlying mechanisms of this context dependence have remained elusive. We propose a novel conceptual framework, systemic redox switching, to resolve this paradox. Based on our research on upstream stimulatory factor 2 (USF2) and convergent observations on other factors, our model suggests that redox regulation is network-embedded rather than driven by discrete cysteine switches. We propose that transcription factors occupy distinct regulatory regimes (homeostatic, adaptive, and survival states) which are connected by threshold-like, hysteretic transitions. Beyond classical graded input-output views, this framework explicitly posits discrete, hysteretic regime transitions at the transcriptional-network level and links them to a minimal dynamical model of the USF2-TFEB-NRF2-redox motif. These transitions convert continuous redox inputs into distinct changes in promoter occupancy and transcriptional programs. USF2 exemplifies a kinase-integrated, non-canonical switch that decodes mitochondrial and autophagy signals via phosphorylation (e.g., Ser155) and context-dependent cooperation with NRF2 and HIFs. Extending this logic to diverse archetypes (NRF2, HIFs, FOXOs, c-MYC, and AHR) demonstrates the framework's generalizability. The model is experimentally tractable; targeted perturbations of primary sensing modules (e.g., KEAP1 mutation, PHD inhibition, or USF2 phosphorylation disruption) should predictably alter regime transitions. By reframing paradoxical behaviors as controlled state transitions, this framework provides a unifying, network-level understanding with direct implications for targeting therapies in cancer, metabolic diseases, and age-related pathologies.
中文摘要:转录因子常常表现出一个显著悖论:它们在一种背景下发挥肿瘤抑制作用,而在另一种背景下促进肿瘤发生。这种背景依赖性的潜在机制一直难以阐明。我们提出一个新的概念框架——系统性氧化还原开关,以解决这一悖论。基于我们对上游刺激因子2(USF2)的研究以及对其他因子的趋同观察,我们的模型提示,氧化还原调控是嵌入网络之中的,而非由离散的半胱氨酸开关驱动。我们提出,转录因子占据不同的调控状态(稳态、适应性和生存状态),这些状态通过阈值样、滞后的转换相连。超越经典的梯度输入-输出观点,该框架明确在转录网络层面提出离散的、滞后的状态转换,并将其与USF2-TFEB-NRF2-氧化还原基序的最小动力学模型联系起来。这些转换将连续的氧化还原输入转化为启动子占据和转录程序的不同变化。USF2体现了一个整合激酶的非经典开关,通过磷酸化(如Ser155)以及与NRF2和HIFs的背景依赖性协同,解码线粒体和自噬信号。将这一逻辑扩展到多种原型(NRF2、HIFs、FOXOs、c-MYC和AHR)证明了该框架的普适性。该模型在实验上可行;对初级感知模块的靶向扰动(如KEAP1突变、PHD抑制或USF2磷酸化破坏)应能可预测地改变状态转换。通过将悖论性行为重新表述为受控的状态转换,该框架提供了一种统一的、网络层面的理解,并对癌症、代谢疾病和年龄相关病理的靶向治疗具有直接意义。
Redox biology IF 16.2 2026-10 PMID: 42594484
Metabolic reprogramming and the evasion of regulated cell death are two canonical hallmarks of cancer, yet the mechanistic threads connecting these distinct biological phenomena remain incompletely understood. The "Warburg effect," characterized by robust aerobic glycolysis, results in the massive accumulation of lactate. Once dismissed as a metabolic waste product, lactate has recently emerged as a pivotal signaling molecule and an epigenetic precursor for lysine lactylation (Kla), a novel post-translational modification that fundamentally reshapes the chromatin landscape. Concurrently, ferroptosis-an iron-dependent form of non-apoptotic cell death driven by unrestrained lipid peroxidation-has garnered intense interest as a therapeutic vulnerability in therapy-resistant tumors. However, a paradoxical observation persists highly glycolytic tumors, despite generating abundant ROS (reactive oxygen species), often display intrinsic resistance to ferroptosis. In this review, we propose that histone and non-histone lactylation serves as the critical "epigenetic bridge" coupling metabolic flux to ferroptosis evasion. We dissect the molecular machinery by which the "Lactate-Kla axis" transcriptionally activates antioxidant defenses (e.g., GPX4, SLC7A11) and remodels the tumor microenvironment to suppress ferroptotic triggers. Furthermore, we delineate how targeting the writers and erasers of lactylation can dismantle this metabolic shield, offering a rational strategy to re-sensitize refractory tumors to ferroptosis-inducing therapies. This synthesis highlights a new frontier in cancer biology where metabolism, epigenetics, and cell fate decisions converge.
中文摘要:代谢重编程与调控性细胞死亡的逃逸是癌症的两大经典标志,然而连接这两种不同生物学现象的机制线索仍未完全阐明。以旺盛的有氧糖酵解为特征的「Warburg效应」导致乳酸大量积累。乳酸曾被视为代谢废物,近来却被发现是关键信号分子,也是赖氨酸乳酰化(Kla)的表观遗传前体,而Kla是一种从根本上重塑染色质景观的新型翻译后修饰。与此同时,铁死亡——一种由不受约束的脂质过氧化驱动、依赖铁的非凋亡性细胞死亡——作为治疗抵抗性肿瘤的治疗脆弱点而受到强烈关注。然而,一个悖论性观察持续存在:高糖酵解肿瘤尽管产生大量ROS(活性氧),却常表现出对铁死亡的内在抵抗。在本综述中,我们提出组蛋白与非组蛋白乳酰化是偶联代谢通量与铁死亡逃逸的关键「表观遗传桥梁」。我们剖析了「乳酸-Kla轴」在转录层面激活抗氧化防御(如GPX4、SLC7A11)并重塑肿瘤微环境以抑制铁死亡触发因素的分子机制。此外,我们阐述了靶向乳酰化的书写器与擦除器如何拆解这一代谢护盾,从而为重新敏化难治性肿瘤对诱导铁死亡疗法提供合理策略。这一综合凸显了癌症生物学的新前沿,即代谢、表观遗传与细胞命运决定在此交汇。
Ageing research reviews IF 15.5 2026-10 PMID: 42521026
Aging is characterized by progressive physiological decline and accumulation of senescent cells that drive chronic "inflammaging" through the senescence-associated secretory phenotype (SASP). The complement system, traditionally viewed as a systemic extracellular defense mechanism, is now recognized as an essential intracellular network (the complosome). This review synthesizes current research on how intracellular C3 (intC3), and intracellular C5 (intC5) in certain contexts engage in extensive crosstalk with the mTOR, NF-κB, and AMPK pathways to modulate core cellular processes. We detail how intC3 intersects with multiple canonical hallmarks of aging-including cellular senescence, mitochondrial dysfunction, proteostasis loss, genomic instability, epigenetic alterations, altered intercellular communication, stem cell exhaustion, and deregulated nutrient sensing. Furthermore, we examine organ-specific consequences of intC3 dysregulation across the aging brain, liver, eye, kidney, vasculature, lung, and immune system, as well as cancer. Finally, we discuss therapeutic strategies-including complement inhibitors, senolytics, senomorphics, RNA interference, proteolysis targeting chimeras (PROTACs), and nanotechnology-enabled delivery-and outline critical gaps in compartment-specific tools, conditional knockouts, and longitudinal models. Precision strategies that preserve systemic complement function while selectively modulating intracellular pools will be essential to translate complosome biology into durable interventions for age-related diseases.
中文摘要:衰老的特征是进行性生理功能衰退以及衰老细胞积累,后者通过衰老相关分泌表型(SASP)驱动慢性炎性衰老。补体系统传统上被视为系统性细胞外防御机制,如今被认为是一个重要的细胞内网络(补体组)。本综述综合了当前关于细胞内C3(intC3)以及在某些情境下细胞内C5(intC5)如何与mTOR、NF-κB和AMPK通路发生广泛串扰,从而调控核心细胞过程的研究。我们详细阐述了intC3如何与多个衰老经典标志相互作用,包括细胞衰老、线粒体功能障碍、蛋白稳态丧失、基因组不稳定、表观遗传改变、细胞间通讯改变、干细胞耗竭和营养感知失调。此外,我们考察了intC3失调在衰老脑、肝、眼、肾、血管、肺和免疫系统中以及癌症中的器官特异性后果。最后,我们讨论了治疗策略,包括补体抑制剂、衰老细胞清除剂、衰老形态调节剂、RNA干扰、蛋白水解靶向嵌合体(PROTACs)和纳米技术赋能的递送,并概述了在区室特异性工具、条件性敲除和纵向模型方面的关键空白。精准策略若能保留全身补体功能,同时选择性调控细胞内补体池,对于将补体组生物学转化为针对年龄相关疾病的持久干预措施至关重要。
Molecular aspects of medicine IF 13.8 2026-10 PMID: 42492338
Epigenetic regulation is intimately linked to cellular metabolism, enabling environmental and nutritional cues to shape gene expression programs through dynamic modifications of chromatin structure. This metabolism-epigenetics interface is mediated, in part, by the dependence of chromatin-modifying enzymes on key metabolites, including S-adenosylmethionine (SAM), acetyl-CoA, UDP-GlcNAc, and α-ketoglutarate, which serve as substrates or cofactors for DNA and histone modifications. Among these regulators, EZH2, the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), has emerged as a key mediator linking metabolic state to epigenetic regulation by translating metabolic inputs into changes in chromatin architecture and gene expression. EZH2 governs developmental cell fate through H3K27me3-mediated gene repression and is frequently dysregulated in cancer, where it promotes dedifferentiation, tumor progression, and metabolic reprogramming. Importantly, EZH2 activity is itself modulated by cellular metabolic status through posttranslational modifications, including phosphorylation, acetylation, methylation, ubiquitination, and O-GlcNAcylation, which influence its stability, catalytic activity, and chromatin-binding capacity. These modifications are responsive to nutrient availability and signaling pathways involving glucose, SAM, NAD+, and other metabolic intermediates. Consequently, disruption of this finely tuned regulatory network can contribute to developmental abnormalities, metabolic dysfunction, and oncogenesis. In this review, we examine the molecular mechanisms governing EZH2 regulation and discuss how metabolic control of EZH2 shapes chromatin dynamics, cell fate decisions, and disease pathogenesis. Elucidating how metabolic signals modulate EZH2 activity will advance our understanding of development and disease while uncovering potential therapeutic opportunities to target metabolism-driven epigenetic dysregulation.
中文摘要:表观遗传调控与细胞代谢密切相关,使环境和营养线索能够通过染色质结构的动态修饰来塑造基因表达程序。这种代谢-表观遗传界面部分由染色质修饰酶对关键代谢物的依赖所介导,这些代谢物包括S-腺苷甲硫氨酸(SAM)、乙酰辅酶A、UDP-GlcNAc和α-酮戊二酸,它们作为DNA和组蛋白修饰的底物或辅因子。在这些调节因子中,EZH2作为多梳抑制复合物2(PRC2)的催化亚基,已成为连接代谢状态与表观遗传调控的关键介导者,可将代谢输入转化为染色质结构和基因表达的变化。EZH2通过H3K27me3介导的基因抑制调控发育中的细胞命运,并在癌症中经常失调,促进去分化、肿瘤进展和代谢重编程。重要的是,EZH2活性本身受细胞代谢状态通过翻译后修饰调节,包括磷酸化、乙酰化、甲基化、泛素化和O-GlcNAc糖基化,这些修饰影响其稳定性、催化活性和染色质结合能力。这些修饰对营养可利用性以及涉及葡萄糖、SAM、NAD+和其他代谢中间产物的信号通路作出响应。因此,这一精细调控网络的破坏可导致发育异常、代谢功能障碍和肿瘤发生。在这篇综述中,我们审视调控EZH2的分子机制,并讨论EZH2的代谢控制如何塑造染色质动态、细胞命运决定和疾病发病机制。阐明代谢信号如何调节EZH2活性将增进我们对发育和疾病的理解,同时揭示针对代谢驱动的表观遗传失调的潜在治疗机会。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42486946
Colorectal cancer (CRC) ranks as the third most common malignancy worldwide, with metastasis representing the primary cause of mortality. Aberrant activation of the Wnt/β-catenin pathway drives epithelial‒mesenchymal transition (EMT) and CRC metastasis, making β-catenin a key therapeutic target. Josephin domain containing 2 (JOSD2), a deubiquitinase with protumorigenic roles in multiple cancers, has an undefined function in CRC metastasis. Herein, by screening a protein homeostasis-related inhibitor library, we identified HY041004, a reported JOSD2 inhibitor, which potently suppresses β-catenin transcriptional activity. Mechanistically, JOSD2 modulates β-catenin protein abundance and functional activity via the RAS-ERK signaling cascade rather than through direct deubiquitination of β-catenin. Functional assays further demonstrated that JOSD2 inhibition via RNA interference or pharmacological inhibition significantly attenuated CRC metastasis both in vitro and in vivo. Collectively, our findings identify JOSD2 as a critical oncogenic factor that promotes β-catenin activity and validate JOSD2 as an underlying therapeutic target for metastatic CRC (mCRC).
中文摘要:结直肠癌(CRC)是全球第三大常见恶性肿瘤,转移是其致死的主要原因。Wnt/β-catenin通路的异常激活驱动上皮-间质转化(EMT)和CRC转移,使β-catenin成为关键治疗靶点。含Josephin结构域蛋白2(JOSD2)是一种去泛素化酶,在多种癌症中发挥促肿瘤作用,但其在CRC转移中的功能尚不明确。在此,我们通过筛选蛋白质稳态相关抑制剂文库,鉴定出HY041004——一种已报道的JOSD2抑制剂,其能强效抑制β-catenin转录活性。机制上,JOSD2通过RAS-ERK信号级联而非直接去泛素化β-catenin来调控β-catenin蛋白丰度和功能活性。功能实验进一步表明,通过RNA干扰或药理抑制JOSD2可显著减弱体外和体内CRC转移。总体而言,我们的研究结果确定了JOSD2是促进β-catenin活性的关键致癌因子,并验证JOSD2是转移性CRC(mCRC)的潜在治疗靶点。
Cancer letters IF 11.8 2026-10-01 PMID: 42372903
Cancer therapy resistance remains a major barrier to durable clinical benefit across chemotherapy, targeted therapy, cell-cycle-directed therapy, and immunotherapy. Although genetic alterations and epigenetic rewiring have long been recognized as major contributors to treatment failure, increasing evidence indicates that post-transcriptional regulation by the epitranscriptome represents an additional and highly dynamic layer of adaptive resistance. Among RNA modifications, N6-methyladenosine (m6A) has emerged as the most abundant internal modification in eukaryotic mRNA and a pivotal regulator of cancer progression, immune remodeling, and therapeutic response. Accumulating studies show that dysregulated m6A writers, erasers, and readers promote resistance by sustaining cellular plasticity and stemness, rewiring glucose and amino acid metabolism, reinforcing redox buffering and ferroptosis suppression, reshaping autophagy and mitochondrial homeostasis, and enhancing DNA damage repair and RNA processing programs. Beyond tumor-intrinsic survival, m6A also modulates immune escape by altering checkpoint responsiveness, immunometabolic suppression, and tumor-microenvironment communication. Recent advances have further expanded the conceptual framework of the field, revealing noncanonical functions of m6A regulators in adaptive translation, biomolecular condensate formation, and crosstalk with post-translational modifications such as lactylation. These findings position the m6A epitranscriptome not merely as a regulator of RNA fate, but as a systems-level coordinator of therapy-adaptive tumor states. In this review, we summarize current progress in understanding how m6A drives cancer therapy resistance across distinct therapeutic contexts, highlight emerging mechanistic frontiers, and discuss the translational potential and current challenges of targeting m6A regulators for overcoming resistant disease.
中文摘要:癌症治疗耐药仍然是化疗、靶向治疗、细胞周期导向治疗和免疫治疗获得持久临床获益的主要障碍。尽管遗传改变和表观遗传重塑早已被认为是导致治疗失败的重要因素,但越来越多证据表明,表观转录组的转录后调控构成了额外且高度动态的适应性耐药层面。在RNA修饰中,N6-甲基腺苷(m6A)已成为真核mRNA中最丰富的内部修饰,并且是癌症进展、免疫重塑和治疗反应的关键调控因子。不断积累的研究显示,失调的m6A写入因子、擦除因子和识别因子通过维持细胞可塑性和干性、重编程葡萄糖和氨基酸代谢、增强氧化还原缓冲并抑制铁死亡、重塑自噬和线粒体稳态,以及增强DNA损伤修复和RNA加工程序来促进耐药。除了肿瘤内在存活之外,m6A还通过改变检查点反应性、免疫代谢抑制和肿瘤微环境通讯来调节免疫逃逸。近期进展进一步拓展了该领域的概念框架,揭示了m6A调控因子在适应性翻译、生物分子凝聚体形成以及与乳酰化等翻译后修饰串扰中的非经典功能。这些发现使m6A表观转录组不仅是RNA命运的调控者,而且是治疗适应性肿瘤状态的系统级协调者。在这篇综述中,我们总结了关于m6A如何在不同的治疗背景下驱动癌症治疗耐药的理解进展,强调了新兴的机制前沿,并讨论了靶向m6A调控因子以克服耐药性疾病的转化潜力和当前挑战。
Bioactive materials IF 23.6 2026-10 PMID: 42165001
Castration-resistant prostate cancer (CRPC) remains lethal due to adaptive resistance mechanisms such as stress-induced autophagy and NF-κB survival signaling. Here, an injectable fiber-in-hydrogel depot is developed for sequential delivery of a multi-enzyme nanozyme (cobalt-epigallocatechin gallate coordination nanozyme, CoNZ) and the lysosomal inhibitor chloroquine (CQ). The preferentially released CoNZ catalytically generates reactive oxygen species, including hydroxyl radicals, and oxygen in situ, inflicting oxidative damage while relieving tumor hypoxia. Simultaneously, it depletes antioxidants (glutathione, NADPH) and impedes NF-κB nuclear translocation, priming CRPC cells for apoptosis. The subsequently released CQ impedes enzymatic degradation or cleavage in endolysosomes and autolysosomes and blocks TLR9/NF-κB signaling, preventing tumor cells from repairing damage or activating pro-survival pathways. In vitro and in vivo, this two-pronged approach synergistically overcomes CRPC's defenses, achieving markedly enhanced cancer cell apoptosis and ∼80% tumor suppression (with occasional complete regression), resulting in an approximately 10-fold reduction in final tumor volume compared to the untreated control, without systemic toxicity, far surpassing single or co-administered treatments. This work demonstrates a spatiotemporally orchestrated combination of nanocatalytic therapy and lysosomal inhibition that dismantles CRPC's resistance mechanisms, highlighting a broadly applicable paradigm for overcoming therapeutic resistance in aggressive cancers.
中文摘要:去势抵抗性前列腺癌(CRPC)由于应激诱导的自噬和NF-κB生存信号等适应性耐药机制,仍然致命。在此,开发了一种可注射的水凝胶内纤维储库,用于顺序递送多酶纳米酶(钴-表没食子儿茶素没食子酸酯配位纳米酶,CoNZ)和溶酶体抑制剂氯喹(CQ)。优先释放的CoNZ催化产生包括羟自由基在内的活性氧以及原位氧气,造成氧化损伤并缓解肿瘤缺氧。同时,它消耗抗氧化剂(谷胱甘肽、NADPH)并阻碍NF-κB核转位,使CRPC细胞易于凋亡。随后释放的CQ阻碍内溶酶体和自溶酶体中的酶促降解或切割,并阻断TLR9/NF-κB信号传导,阻止肿瘤细胞修复损伤或激活促生存通路。在体外和体内,这种双管齐下的策略协同克服CRPC的防御,显著增强癌细胞凋亡并实现约80%的肿瘤抑制(偶见完全消退),与未治疗对照相比最终肿瘤体积减少约10倍,且无全身毒性,远超单一或联合给药治疗。这项工作展示了纳米催化疗法与溶酶体抑制的时空协同组合,瓦解了CRPC的耐药机制,突出了一种广泛适用的范式,用于克服侵袭性癌症中的治疗耐药。
Cancer discovery IF 29.5 2026-10-01 PMID: 42154581
Neutrophils are major players in innate immunity. However, their landscape and functions in colorectal cancer liver metastasis (CRLM) remain poorly understood. In this study, using single-cell RNA sequencing and spatial-enhanced-resolution-omics sequencing, we provide a comprehensive transcriptional landscape of tumor-associated neutrophils (TAN) in CRLM. Our analysis reveals that a terminally differentiated protumor neutrophil subset (TAN1), characterized by a glycolysis signature and a senescent phenotype, is significantly enriched in liver metastasis and associated with poor prognosis. Mechanistically, TAN1 arises from other TAN subsets through the upregulation of BHLHE40, driven by glucose deprivation in the metastatic microenvironment. Functionally, TAN1 promotes angiogenesis via VEGFA and recruits immunosuppressive macrophages through potential CCL3L1-CCR1 signaling, thereby fostering an angiogenic immunosuppressive niche. As a result, neutrophil-specific knockout of Bhlhe40 in mice significantly promotes antitumor immunity and suppresses tumor growth. Our data uncover the critical role of BHLHE40+ senescent-like neutrophils in shaping the immunosuppressive microenvironment of CRLM. This study identifies a protumoral BHLHE40+ senescent-like neutrophil subset in CRLM that orchestrates vascular immunosuppressive niches to drive tumor progression, highlighting a potential target for neutrophil-specific therapeutic intervention. See related commentary by Droin and Garner, p. 1958.
中文摘要:中性粒细胞是固有免疫的重要参与者。然而,它们在结直肠癌肝转移(CRLM)中的图谱与功能仍知之甚少。在本研究中,我们利用单细胞RNA测序和空间增强分辨率组学测序,提供了CRLM中肿瘤相关中性粒细胞(TAN)的全面转录图谱。我们的分析揭示,一个终末分化的促肿瘤中性粒细胞亚群(TAN1),以糖酵解特征和衰老表型为特征,在肝转移中显著富集并与不良预后相关。机制上,TAN1由其他TAN亚群通过BHLHE40上调而产生,这一过程由转移微环境中的葡萄糖剥夺驱动。功能上,TAN1通过VEGFA促进血管生成,并通过潜在的CCL3L1-CCR1信号招募免疫抑制性巨噬细胞,从而营造血管生成-免疫抑制微环境。因此,小鼠中中性粒细胞特异性敲除Bhlhe40可显著增强抗肿瘤免疫并抑制肿瘤生长。我们的数据揭示了BHLHE40+衰老样中性粒细胞在塑造CRLM免疫抑制微环境中的关键作用。本研究鉴定出CRLM中一个促肿瘤的BHLHE40+衰老样中性粒细胞亚群,其编排血管-免疫抑制微环境以驱动肿瘤进展,凸显了其作为中性粒细胞特异性治疗干预靶点的潜力。参见Droin和Garner的相关评论,第1958页。
Autophagy IF 18.6 2026-10 PMID: 42152515
Disruption of proteostasis is a defining feature of cancer and other chronic diseases. The AAA+ ATPase VCP/p97 (valosin containing protein) is a key regulator of proteostasis by disassembling ubiquitinated substrates for degradation. VCP overexpression supports cancer cell survival and correlates with poor prognosis, promoting the development of VCP inhibitors as anti-cancer agents. However, the molecular basis for cancer-selective vulnerability of VCP inhibition remains unclear. Here, we demonstrate that allosteric VCP inhibition triggers cell-type specific macroautophagy/autophagy through dynamic reorganization of organelle contact sites. In human umbilical vein endothelial cells (HUVECs), VCP inhibition induces adaptive autophagy through coordinated reorganization of plasma membrane (PM)-ER-mitochondria contacts. Controlled opening of the mitochondrial permeability transition pore (mPTP) releases calcium into the cytosol, activating AMP-activated protein kinase (AMPK) and TFEB pathways, collectively enhancing autophagic flux and sustaining endothelial survival. Critically, calcium-activated kinase inhibitor or calcium chelators blocked VCP inhibitor-induced autophagy in HUVECs, confirming calcium signaling as the central mediator of adaptive autophagy. In contrast, HCT116 colon cancer cells fail to maintain calcium homeostasis under VCP inhibition, leading to mitochondrial calcium overload, defective autophagy, and cell death. Together, our findings identify organelle contact reorganization and calcium homeostasis as key determinants of cell fate under conditions of proteotoxic stress, revealing how VCP inhibition selectively suppresses tumor progression while preserving vascular integrity that could enhance drug delivery and reduce tumor hypoxia.Abbreviations: ATF4: activating transcription factor 4; ATG3: autophagy related 3; ATG7: autophagy related 7; ATP: adenosine triphosphate; CAMKK2: calcium/calmodulin dependent protein kinase 2; CETSA: cellular thermal shift assay; CQ: chloroquine; CTS: cryptotanshinone; DDIT3/CHOP: DNA damage inducible transcript 3; DQ-BSA: dye quenched-bovine serum albumin; EIF2A: eukaryotic initiation factor 2A; ER: endoplasmic reticulum; ERAD: endoplasmic reticulum-associated protein degradation; HCT116: human colon carcinoma cell line; HSPA5: heat shock protein family A (Hsp70) member 5; HUVECs: human umbilical vein endothelial cells; ITPR1/IP3R1: inositol 1,4,5-trisphosphate receptor type 1; MAP1LC3B/LC3: microtubule associated protein 1 light chain 3 beta; mPTP: mitochondrial permeability transition pore; MT-ND1: mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1; MTOR: mechanistic target of rapamycin kinase; ORAI1: ORAI calcium release-activated calcium modulator 1; PLA: proximity ligation assay; PM: plasma membrane; PRKAA/AMPK: protein kinase AMP-activated catalytic subunit alpha; ROS: reactive oxygen species; SQSTM1/p62: sequestosome 1; STIM1: stromal interaction molecule 1; TFEB: transcription factor EB; U87MG: human glioblastoma astrocytoma cell line; FAF2/UBXD8: Fas associated factor family member 2; UPR: unfolded protein response; VCP/p97: valosin containing protein; VDAC1: voltage dependent anion channel 1.
中文摘要:蛋白质稳态破坏是癌症和其他慢性疾病的定义性特征。AAA+ ATP酶VCP/p97(含缬酪肽蛋白)通过拆解泛素化底物以促使其降解,是蛋白质稳态的关键调节因子。VCP过表达支持癌细胞存活并与不良预后相关,促进了VCP抑制剂作为抗癌药物的开发。然而,VCP抑制对癌症选择性易感性的分子基础仍不清楚。在此,我们证明变构性VCP抑制通过细胞器接触位点的动态重组触发细胞类型特异性的大自噬/自噬。在人脐静脉内皮细胞(HUVEC)中,VCP抑制通过质膜-内质网-线粒体接触的协调重组诱导适应性自噬。线粒体通透性转换孔(mPTP)的受控开放将钙释放到胞质,激活AMPK和TFEB通路,共同增强自噬流并维持内皮存活。关键的是,钙激活激酶抑制剂或钙螯合剂阻断了VCP抑制剂在HUVEC中诱导的自噬,证实钙信号是适应性自噬的核心介质。相反,HCT116结肠癌细胞在VCP抑制下无法维持钙稳态,导致线粒体钙超载、自噬缺陷和细胞死亡。总之,我们的发现确定了细胞器接触重组和钙稳态是蛋白质毒性应激条件下细胞命运的关键决定因素,揭示了VCP抑制如何选择性抑制肿瘤进展,同时保持血管完整性,从而可能增强药物递送并减少肿瘤缺氧。缩写:ATF4:激活转录因子4;ATG3:自噬相关3;ATG7:自噬相关7;ATP:三磷酸腺苷;CAMKK2:钙/钙调蛋白依赖性蛋白激酶2;CETSA:细胞热迁移实验;CQ:氯喹;CTS:隐丹参酮;DDIT3/CHOP:DNA损伤诱导转录本3;DQ-BSA:染料淬灭-牛血清白蛋白;EIF2A:真核起始因子2A;ER:内质网;ERAD:内质网相关蛋白降解;HCT116:人结肠癌细胞系;HSPA5:热休克蛋白家族A(Hsp70)成员5;HUVECs:人脐静脉内皮细胞;ITPR1/IP3R1:1,4,5-三磷酸肌醇受体1型;MAP1LC3B/LC3:微管相关蛋白1轻链3β;mPTP:线粒体通透性转换孔;MT-ND1:线粒体编码NADH:泛醌氧化还原酶核心亚基1;MTOR:雷帕霉素激酶机制性靶点;ORAI1:ORAI钙释放激活钙调节因子1;PLA:邻近连接实验;PM:质膜;PRKAA/AMPK:蛋白激酶AMP激活催化亚基α;ROS:活性氧;SQSTM1/p62:螯合体1;STIM1:基质相互作用分子1;TFEB:转录因子EB;U87MG:人胶质母细胞瘤星形细胞瘤细胞系;FAF2/UBXD8:Fas相关因子家族成员2;UPR:未折叠蛋白反应;VCP/p97:含缬酪肽蛋白;VDAC1:电压依赖性阴离子通道1。
Autophagy IF 18.6 2026-10 PMID: 42152489
Influenza A virus (IAV) is an important zoonotic pathogen responsible for substantial respiratory morbidity and mortality. Elucidating the mechanisms by which IAV evades host innate immunity is critical for developing novel antiviral strategies. Although the IAV non-structural protein 2 (NS2) is well-characterized for the export of viral ribonucleoproteins (vRNPs) from the host cell nucleus, the function of NS2 in evading host innate immunity, especially the NFKB/NF-κB (nuclear factor kappa B) signaling pathway, remains poorly understood. The present study uncovered that NS2 is a novel viral inhibitor of the NFKB pathway. Mechanistically, NS2 interacted with and mediated the degradation of the NFKB essential modulator (IKBKG/NEMO), thereby suppressing downstream signal transduction. The macroautophagy/autophagy receptor OPTN (optineurin) was exploited by NS2 to mediate the selective autophagic degradation. Furthermore, the K72 residue was critical for the NS2-mediated degradation of IKBKG/NEMO, as the K72R substitution in NS2 disrupted the IKBKG/NEMO-NS2 interaction and abrogated the autophagic degradation. In addition, NS2K72R mutant virus displayed less viral load and milder pathogenicity in mice. In conclusion, these findings highlighted the novel biological function of IAV NS2 in exploiting selective autophagy to evade host defenses, and offered a potential target for controlling IAV infections.Abbreviations: 3-MA: 3-methyladenine; AIV: avian influenza virus; ATG7: autophagy related 7; CALCOCO2/NDP52: calcium binding and coiled-coil domain 2; CHX: cycloheximide; co-IP: co-immunoprecipitation; CHUK/IKKα: component of inhibitor of nuclear factor kappa B kinase complex; DAPI: 4', 6-diamidino-2-phenylindole, dihydrochloride; dsRNA: double-stranded RNA; dpi: days post-infection; EID50: 50% egg infective dose; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; hpi: hours post-infection; IAV: influenza A virus; IFN: interferon; IKBKB/IKKβ: inhibitor of nuclear factor kappa B kinase subunit beta; IFNG: interferon gamma; IKBKG/NEMO: inhibitor of nuclear factor kappa B kinase subunit gamma; IKK: IκB kinase; IP: immunoprecipitation; IRF3: interferon regulatory factor 3; IRF7: interferon regulatory factor 7; LAMP1: lysosome associated membrane protein 1; LIR: LC3-interacting region; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP3K14/NIK: mitogen-activated protein kinase kinase kinase 14; MAVS: mitochondrial antiviral signaling protein; MLD50: 50% mouse lethal dose; MOI: multiplicity of infection; MRV/Sendai virus: murine respirovirus; NBR1: NBR1 autophagy cargo receptor; NEP: nuclear export protein; NFKB/NF-κB: nuclear factor kappa B; NFKB2/p100: nuclear factor kappa B subunit 2; NFKBIA/IκBα: NFK inhibitor alpha; NP: nucleoprotein; NS1: non-structural protein 1; OPTN: optineurin; PB1: basic polymerase 1; PBS: phosphate-buffered saline; poly(I:C): polyriboinosinic polyribocytidylic acid; PRRs: pattern recognition receptors; RELA/p65: RELA proto-oncogene, NF-kB subunit; RELB: RELB proto-oncogene, NF-kB subunit; RIGI: RNA sensor RIG-I; RIGI-IN: RIGI-CARD; RLR: RIGI-like-receptor; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SIM: SUMO-interacting motif; siRNA: small interfering RNA; SQSTM1/p62: sequestosome 1; TBK1: TANK binding kinase 1; TNF: tumor necrosis factor; TRAF6: TNF receptor associated factor 6; TOLLIP: toll interacting protein; Vec: empty vector; vRNP: viral ribonucleoprotein.
中文摘要:甲型流感病毒(IAV)是一种重要的人兽共患病原体,可导致显著的呼吸道发病率和死亡率。阐明IAV逃避宿主先天免疫的机制对于开发新型抗病毒策略至关重要。尽管IAV非结构蛋白2(NS2)在将病毒核糖核蛋白(vRNP)从宿主细胞核输出方面已被充分表征,但NS2在逃避宿主先天免疫,尤其是NFKB/NF-κB(核因子κB)信号通路方面的功能仍知之甚少。本研究发现NS2是一种新型的NFKB通路病毒抑制因子。机制上,NS2与NFKB必需调节因子(IKBKG/NEMO)相互作用并介导其降解,从而抑制下游信号转导。NS2利用巨自噬/自噬受体OPTN(optineurin)介导选择性自噬降解。此外,K72残基对于NS2介导的IKBKG/NEMO降解至关重要,因为NS2中的K72R替换破坏了IKBKG/NEMO-NS2相互作用并消除了自噬降解。此外,NS2K72R突变病毒在小鼠中显示出较低的病毒载量和较轻的致病性。总之,这些发现强调了IAV NS2在利用选择性自噬逃避宿主防御方面的新生物学功能,并为控制IAV感染提供了潜在靶点。缩写:3-MA:3-甲基腺嘌呤;AIV:禽流感病毒;ATG7:自噬相关7;CALCOCO2/NDP52:钙结合和卷曲螺旋结构域2;CHX:放线菌酮;co-IP:共免疫沉淀;CHUK/IKKα:核因子κB激酶复合物抑制因子组分;DAPI:4',6-二脒基-2-苯基吲哚二盐酸盐;dsRNA:双链RNA;dpi:感染后天数;EID50:50%鸡胚感染剂量;GAPDH:甘油醛-3-磷酸脱氢酶;GFP:绿色荧光蛋白;hpi:感染后小时数;IAV:甲型流感病毒;IFN:干扰素;IKBKB/IKKβ:核因子κB激酶抑制因子β亚基;IFNG:干扰素γ;IKBKG/NEMO:核因子κB激酶抑制因子γ亚基;IKK:IκB激酶;IP:免疫沉淀;IRF3:干扰素调节因子3;IRF7:干扰素调节因子7;LAMP1:溶酶体相关膜蛋白1;LIR:LC3相互作用区域;MAP1LC3/LC3:微管相关蛋白1轻链3;MAP3K14/NIK:丝裂原活化蛋白激酶激酶激酶14;MAVS:线粒体抗病毒信号蛋白;MLD50:50%小鼠致死剂量;MOI:感染复数;MRV/Sendai virus:鼠呼吸道病毒/仙台病毒;NBR1:NBR1自噬货物受体;NEP:核输出蛋白;NFKB/NF-κB:核因子κB;NFKB2/p100:核因子κB亚基2;NFKBIA/IκBα:NFK抑制因子α;NP:核蛋白;NS1:非结构蛋白1;OPTN:视神经蛋白;PB1:碱性聚合酶1;PBS:磷酸盐缓冲液;poly(I:C):聚肌胞苷酸;PRRs:模式识别受体;RELA/p65:RELA原癌基因,NF-κB亚基;RELB:RELB原癌基因,NF-κB亚基;RIGI:RNA传感器RIG-I;RIGI-IN:RIG-I-CARD;RLR:RIG-I样受体;SARS-CoV-2:严重急性呼吸综合征冠状病毒2;SIM:SUMO相互作用基序;siRNA:小干扰RNA;SQSTM1/p62:螯合体1;TBK1:TANK结合激酶1;TNF:肿瘤坏死因子;TRAF6:TNF受体相关因子6;TOLLIP:Toll相互作用蛋白;Vec:空载体;vRNP:病毒核糖核蛋白。
Autophagy IF 18.6 2026-10 PMID: 42152468
Psychological stress impairs adult hippocampal neurogenesis (AHN) and contributes to cognitive dysfunction. Previously, we reported that chronic psychological stress or the stress hormone corticosterone (CORT) induces autophagic cell death (ACD) in adult hippocampal neural stem cells (ahNSCs). However, the regulatory mechanisms underlying this process remain largely unknown. The tumor suppressor gene Trp53/p53 is abundantly expressed in ahNSCs, yet its function under stress conditions has not been fully elucidated. Here, we demonstrate that, contrary to its well-established pro-apoptotic role, TRP53 acts as a survival factor that protects ahNSCs from stress-induced ACD. Conditional deletion of Trp53 in neural stem cells heightened vulnerability to chronic restraint stress (CRS), resulting in worsened memory deficits and mood disturbances compared to wild-type controls. Mechanistically, CORT facilitated MAP1LC3/LC3-mediated autophagic degradation of TRP53 through its LC3-interacting region (LIR), thereby promoting ACD. However, overexpression of either wild-type TRP53 or a degradation-resistant LIR mutant suppressed ACD by interfering with the ATG14-containing PIK3C3/VPS34 complex. Moreover, treatment with RITA, a small-molecule activator of TRP53, disrupted the TRP53-LC3 interaction, stabilized TRP53 levels, and protected ahNSCs from ACD, ultimately preventing CRS-induced cognitive impairment in the hippocampus. These findings identify TRP53 as a key negative regulator of ACD in ahNSCs and suggest that TRP53-stabilizing small molecules could represent a novel class of antidepressant therapies by preserving AHN.Abbreviations: ahNSC: adult hippocampal neural stem cell; AHN: adult hippocampal neurogenesis; ACD: autophagic cell death; BafA1: bafilomycin A1; ACTB actin, beta; CRS chronic restraint stress; c.CASP3: cleaved caspase 3; cKO conditional knockout; CORT: corticosterone; DG: dentate gyrus; i.p: intraperitoneal; KO: knockout; LABORAS: Laboratory Behavior Observation Registration and Analysis System; LIR LC3-interacting region; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MDM2: MDM2 proto-oncogene; NSC: neural stem cell; PFA: paraformaldehyde; PLA: proximity ligation assay; RITA: reactivation of TRP53 and induction of tumor cell apoptosis; SGK: serum/glucocorticoid regulated kinase; SGZ: subgranular zone; STS: staurosporine; TAM: tamoxifen; TRP53: transformation related protein 53; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling; UVRAG: UV radiation resistance associated.
中文摘要:心理应激损害成年海马神经发生(AHN)并导致认知功能障碍。此前,我们报道慢性心理应激或应激激素皮质酮(CORT)可诱导成年海马神经干细胞(ahNSC)发生自噬性细胞死亡(ACD)。然而,该过程的调控机制在很大程度上仍不清楚。肿瘤抑制基因Trp53/p53在ahNSC中高表达,但其在应激条件下的功能尚未完全阐明。在这里,我们证明,与其公认的促凋亡作用相反,TRP53作为生存因子保护ahNSC免受应激诱导的ACD。神经干细胞中Trp53的条件性缺失增加了对慢性束缚应激(CRS)的易感性,与野生型对照相比导致更严重的记忆缺陷和情绪障碍。在机制上,CORT通过TRP53的LC3相互作用区域(LIR)促进MAP1LC3/LC3介导的TRP53自噬降解,从而促进ACD。然而,过表达野生型TRP53或抗降解的LIR突变体可通过干扰含ATG14的PIK3C3/VPS34复合物抑制ACD。此外,使用TRP53小分子激活剂RITA处理可破坏TRP53-LC3相互作用,稳定TRP53水平,并保护ahNSC免受ACD,最终预防CRS诱导的海马认知损害。这些发现确定TRP53是ahNSC中ACD的关键负调控因子,并提示稳定TRP53的小分子可能通过保护AHN成为一类新型抗抑郁疗法。缩写:ahNSC:成年海马神经干细胞;AHN:成年海马神经发生;ACD:自噬性细胞死亡;BafA1:巴弗洛霉素A1;ACTB:β-肌动蛋白;CRS:慢性束缚应激;c.CASP3:裂解型caspase 3;cKO:条件性敲除;CORT:皮质酮;DG:齿状回;i.p:腹腔注射;KO:敲除;LABORAS:实验室行为观察记录与分析系统;LIR:LC3相互作用区域;MAP1LC3/LC3:微管相关蛋白1轻链3;MDM2:MDM2原癌基因;NSC:神经干细胞;PFA:多聚甲醛;PLA:邻位连接试验;RITA:重激活TRP53并诱导肿瘤细胞凋亡;SGK:血清/糖皮质激素调节激酶;SGZ:颗粒下区;STS:星形孢菌素;TAM:他莫昔芬;TRP53:转化相关蛋白53;TUNEL:末端脱氧核苷酸转移酶dUTP缺口末端标记;UVRAG:UV辐射抵抗相关。
Gastroenterology IF 29.7 2026-10 PMID: 42102979
Pancreatic ductal adenocarcinoma (PDAC) metastasizes early and frequently to the liver, limiting therapeutic options and resulting in poor prognosis. Neutrophils are key immune players in cancer progression, yet their role in PDAC liver metastases remains unclear. This study investigates how neutrophils influence hepatic macrophages and modulate the immune landscape in the metastatic microenvironment using intravital calcium imaging and single-cell RNA sequencing. Intravital microscopy was used to monitor neutrophil behavior and interactions within the metastatic niche. We used intravital calcium imaging in LysMcre-PCG5-tdt mice to visualize real-time immune cell interactions and their functional impact in a PDAC metastasis model. To dissect the effect of neutrophils on the immune landscape, we performed single-cell RNA sequencing of liver-infiltrating leukocytes in tumor-bearing mice. Intravital calcium imaging revealed that neutrophils are recruited to hepatic metastases by CCL2/CCL5, where they take up tumor cell fragments via trogocytosis and subsequently present these tumor fragments to hepatic macrophages. This neutrophil-driven immunomodulation was abolished on neutrophil depletion, resulting in a permissive tumor-promoting macrophage phenotype. Single-cell RNA sequencing identified distinct macrophage subpopulations, demonstrating that neutrophils suppress the development of immunosuppressive macrophages by C3-dependent signaling and enhance antitumor pathways. This study provides in vivo evidence of neutrophil-macrophage crosstalk in PDAC liver metastases and highlights the functional consequences of neutrophil depletion. By integrating intravital calcium imaging with single-cell RNA sequencing, we uncovered a previously unrecognized mechanism of neutrophil-driven immunomodulation, emphasizing the potential for therapeutic strategies targeting neutrophil-macrophage interactions in metastatic PDAC.
中文摘要:胰腺导管腺癌(PDAC)早期且常转移至肝脏,限制了治疗选择并导致预后不良。中性粒细胞是癌症进展中的关键免疫细胞,但其在PDAC肝转移中的作用仍不清楚。本研究利用活体钙成像和单细胞RNA测序,探讨中性粒细胞如何影响肝脏巨噬细胞并调节转移微环境中的免疫格局。采用活体显微镜监测转移龛内中性粒细胞的行为和相互作用。我们在LysMcre-PCG5-tdt小鼠中使用活体钙成像,以在PDAC转移模型中实时可视化免疫细胞相互作用及其功能影响。为剖析中性粒细胞对免疫格局的影响,我们对荷瘤小鼠肝脏浸润白细胞进行了单细胞RNA测序。活体钙成像显示,中性粒细胞被CCL2/CCL5招募至肝转移灶,在那里它们通过胞啃作用摄取肿瘤细胞碎片,随后将这些肿瘤碎片呈递给肝脏巨噬细胞。这种中性粒细胞驱动的免疫调节在中性粒细胞清除后被消除,导致形成一种允许肿瘤进展的促肿瘤巨噬细胞表型。单细胞RNA测序识别出不同的巨噬细胞亚群,表明中性粒细胞通过C3依赖性信号抑制免疫抑制性巨噬细胞的发展,并增强抗肿瘤通路。本研究提供了PDAC肝转移中中性粒细胞与巨噬细胞串扰的体内证据,并强调了中性粒细胞清除的功能后果。通过整合活体钙成像与单细胞RNA测序,我们揭示了一种此前未被认识的中性粒细胞驱动免疫调节机制,强调了针对转移性PDAC中中性粒细胞与巨噬细胞相互作用的治疗策略潜力。
Biomaterials IF 13.6 2026-10 PMID: 41950646
Ferroptosis represents a promising antitumor strategy, yet its efficacy in colon cancer is compromised by excessive antioxidant glutathione (GSH) and insufficient reactive oxygen species (ROS). To address this limitation, we rationally designed integrated nanoplatforms (FeBMnDC NPs) by covalently conjugating albumin-MnO2 complexes with ferritin to codeliver the ROS-responsive dihydroartemisinin (DHA) dimer and photosensitizer Chlorin e6 (Ce6). This design synergistically disrupts redox homeostasis to induce ferroptosis and immune activation. Upon tumor accumulation and laser irradiation, the FeBMnDC NPs release oxygen, Mn2+, ferritin, DHA, and Ce6. Laser-triggered ROS initiates a self-amplifying feedback loop that further releases DHA and Ce6, enhancing ROS generation via chemodynamic and photodynamic therapies, while MnO2 degradation and ferric ion reduction deplete GSH. Severe oxidative stress promotes apoptosis, ferroptosis, and immunogenic cell death. In vitro and in vivo studies confirmed that FeBMnDC NPs enhance lipid peroxidation and dendritic cell maturation, achieving potent antitumor efficacy without apparent side effects. Moreover, integrated transcriptomic and proteomic analyses revealed that laser irradiation reprograms GSH metabolism and activates ferroptosis-executing pathways, identifying AMPD3 as a novel ferroptosis-associated gene in colon cancer. This work presents a self-amplifying nanoplatform enabling multimodal redox intervention, offering a mechanism-driven strategy for colon cancer treatment.
中文摘要:铁死亡是一种有前景的抗肿瘤策略,但其在结肠癌中的疗效受到抗氧化谷胱甘肽(GSH)过量与活性氧(ROS)不足的限制。为克服这一局限,我们通过将白蛋白-MnO2复合物与铁蛋白共价偶联,合理设计了集成纳米平台(FeBMnDC NPs),以共递送ROS响应性双氢青蒿素(DHA)二聚体和光敏剂二氢卟吩e6(Ce6)。该设计协同破坏氧化还原稳态,从而诱导铁死亡和免疫激活。在肿瘤蓄积和激光照射后,FeBMnDC NPs释放氧气、Mn2+、铁蛋白、DHA和Ce6。激光触发的ROS启动自放大反馈回路,进一步释放DHA和Ce6,通过化学动力学疗法和光动力学疗法增强ROS生成,同时MnO2降解和三价铁离子还原消耗GSH。严重氧化应激促进细胞凋亡、铁死亡和免疫原性细胞死亡。体外和体内研究证实,FeBMnDC NPs增强脂质过氧化和树突状细胞成熟,实现强效抗肿瘤疗效且无明显副作用。此外,整合转录组学和蛋白质组学分析显示,激光照射重编程GSH代谢并激活铁死亡执行通路,鉴定出AMPD3是结肠癌中一个新的铁死亡相关基因。这项工作提出了一种能够实现多模式氧化还原干预的自放大纳米平台,为结肠癌治疗提供了一种机制驱动的策略。
Cell death and differentiation IF 13.6 2026-10 PMID: 41792243
Histone lactylation couples glycolytic metabolism to oncogenic transcription, but its mechanistic readers remain poorly defined. Here, we identify bromodomain-containing protein 9 (BRD9) as a lactyl-lysine reader that links lactate-driven H3K18 lactylation (H3K18la) to chromatin remodeling in hepatocellular carcinoma (HCC). Clinically, elevated H3K18la levels correlate with poor HCC prognosis. Structural (NMR) and biophysical analyses demonstrate that BRD9's bromodomain engages H3K18la with weak, transient affinity through its conserved acetyl-lysine pocket, distinct from its stable H3K18ac binding. This enables BRD9 to function as a metabolic-epigenetic sensor, dynamically recruited to chromatin in response to glycolytic flux. Multi-omics profiling reveals that H3K18la recruits BRD9 and the non-canonical BRG1-associated factor (ncBAF) chromatin remodeling complex to active enhancers and promoters, promoting chromatin accessibility and driving oncogenic transcription (SPARC, TMEM64, ANGEL1, SCARB1). Glycolytic inhibition or BRD9 targeting displaces BRD9 from chromatin, suppresses oncogenes, and impairs HCC proliferation. Modulating the lactylation vis p300 or HDAC inhibition attenuates transcription and reduces tumor viability. In vivo, glycolytic inhibition suppresses tumor growth. Our findings establish a feedforward loop wherein glycolytic flux promotes H3K18la-dependent BRD9-ncBAF recruitment to remodel chromatin and sustain oncogenic transcription, defining BRD9 as a critical metabolic-epigenetic mediator and a promising therapeutic target in HCC.
中文摘要:组蛋白乳酸化将糖酵解代谢与致癌转录耦合,但其机制性阅读器仍未被充分界定。在此,我们将含溴结构域蛋白9(BRD9)鉴定为一种乳酸化赖氨酸阅读器,其将乳酸驱动的H3K18乳酸化(H3K18la)与肝细胞癌(HCC)中的染色质重塑联系起来。临床上,升高的H3K18la水平与HCC不良预后相关。结构(NMR)和生物物理学分析表明,BRD9的溴结构域通过其保守的乙酰赖氨酸口袋以微弱、瞬时的亲和力结合H3K18la,这不同于其稳定的H3K18ac结合。这使BRD9能够作为代谢-表观遗传传感器,响应糖酵解通量而被动态募集至染色质。多组学分析显示,H3K18la将BRD9和非经典BRG1相关因子(ncBAF)染色质重塑复合物募集到活跃增强子和启动子,促进染色质可及性并驱动致癌转录(SPARC、TMEM64、ANGEL1、SCARB1)。糖酵解抑制或BRD9靶向可使BRD9从染色质上移位,抑制癌基因,并损害HCC增殖。通过p300或HDAC抑制调节乳酸化可减弱转录并降低肿瘤活力。在体内,糖酵解抑制可抑制肿瘤生长。我们的发现建立了一个前馈环路,其中糖酵解通量促进H3K18la依赖性的BRD9-ncBAF募集以重塑染色质并维持致癌转录,从而将BRD9定义为关键的代谢-表观遗传介质和HCC中有前景的治疗靶点。
Cell death and differentiation IF 13.6 2026-10 PMID: 41776086
YEATS2, a crucial component of histone acetyltransferase (HAT) complexes, has been identified as overexpressed in multiple human cancers and is correlated with tumor advancement and unfavorable clinical outcomes. The precise role of YEATS2 in hepatocellular carcinoma (HCC) remains to be fully elucidated. This study seeks to investigate the function and mechanisms by which YEATS2 facilitates HCC growth and metastasis. Our results demonstrate that YEATS2 expression is markedly elevated in HCC tissues and is correlated with unfavorable clinical characteristics and decreased survival rates. Functional assays conducted both in vitro and in vivo reveal that YEATS2 enhances HCC cell proliferation, migration, and invasion. Through RNA sequencing and mass spectrometry analyses, this study revealed YEATS2 activates the TAZ/AKT signaling pathway and promotes aerobic glycolysis via the upregulation of TGFBR2. Chromatin immunoprecipitation and co-immunoprecipitation assays further confirm that YEATS2 interacts with KAT2A, leading to increased levels of H3K9ac and H3K14ac within the promoter region of TGFBR2, thereby promoting its transcriptional activation. Moreover, increased matrix stiffness was found to induce YEATS2 expression through augmenting the binding of HIF-1α to the YEATS2 promoter. Collectively, these results delineate a novel YEATS2-TGFBR2-TAZ-AKT signaling axis that connects matrix stiffness to metabolic reprogramming and HCC progression, highlighting YEATS2 as a potential therapeutic target for HCC.
中文摘要:YEATS2是组蛋白乙酰转移酶(HAT)复合物的重要组成部分,已被发现在多种人类癌症中过表达,并与肿瘤进展和不良临床结局相关。YEATS2在肝细胞癌(HCC)中的确切作用仍有待充分阐明。本研究旨在探讨YEATS2促进HCC生长和转移的功能及机制。我们的结果表明,YEATS2在HCC组织中表达显著升高,并与不良临床特征和较低的生存率相关。体外和体内功能实验显示,YEATS2增强HCC细胞增殖、迁移和侵袭。通过RNA测序和质谱分析,本研究发现YEATS2激活TAZ/AKT信号通路,并通过上调TGFBR2促进有氧糖酵解。染色质免疫沉淀和共免疫沉淀实验进一步证实,YEATS2与KAT2A相互作用,导致TGFBR2启动子区域H3K9ac和H3K14ac水平升高,从而促进其转录激活。此外,研究发现基质硬度增加通过增强HIF-1α与YEATS2启动子的结合来诱导YEATS2表达。总之,这些结果描绘了一条新的YEATS2-TGFBR2-TAZ-AKT信号轴,将基质硬度与代谢重编程和HCC进展联系起来,突显YEATS2作为HCC潜在治疗靶点。
Cell death and differentiation IF 13.6 2026-10 PMID: 41680474
Cancer-testis antigens are considered clinically attractive targets for cancer treatment, but their functions and mechanisms are not well elucidated. Here, based on comprehensive bioinformatics analyses, we identify PRAME, a nuclear cancer-testis antigen, as a potential regulator of metastasis in clear cell renal cell carcinoma (ccRCC). Subsequent RNA-Seq and functional studies illustrate that Netrin-4 (NTN4) is a major downstream effector of PRAME, involved in its oncogenic functions. Mechanism analyses reveal that PRAME interacts with the transcription factor CCAAT/enhancer-binding protein beta (C/EBPβ) and the histone methyltransferase enhancer of zeste homolog 2 (EZH2) simultaneously, thereby forming a ternary complex. Subsequently, this complex co-occupies the NTN4 promoter locus, leading to increased trimethylation of histone H3 lysine 27 and epigenetic repression of NTN4 expression, resulting in AKT activation and promotion of ccRCC development. Interestingly, C/EBPβ is characterized to stimulate PRAME expression by binding to the PRAME promoter. Additionally, a cell-permeable peptide has been designed to disrupt the ternary complex and inhibit ccRCC progression in tumor cells and patient-derived xenografts. Thus, our findings not only provide new insights into the prominent role of PRAME in mediating C/EBPβ and EZH2 regulation of NTN4 and tumor metastasis, but also highlight a promising strategy for ccRCC therapy by targeting the C/EBPβ-PRAME-EZH2 complex.
中文摘要:癌症-睾丸抗原被认为是临床上具有吸引力的癌症治疗靶点,但其功能和机制尚未得到充分阐明。在此,基于全面的生物信息学分析,我们鉴定出PRAME——一种核内癌症-睾丸抗原——是透明细胞肾细胞癌(ccRCC)转移的潜在调控因子。随后的RNA-Seq和功能研究表明,Netrin-4(NTN4)是PRAME的主要下游效应分子,参与其致癌功能。机制分析揭示,PRAME同时与转录因子CCAAT/增强子结合蛋白β(C/EBPβ)和组蛋白甲基转移酶zeste同源物增强子2(EZH2)相互作用,从而形成三元复合物。随后,该复合物共同占据NTN4启动子位点,导致组蛋白H3第27位赖氨酸三甲基化增加以及NTN4表达的表观遗传抑制,进而引起AKT激活并促进ccRCC发展。有趣的是,C/EBPβ可通过结合PRAME启动子刺激PRAME表达。此外,已设计一种细胞穿透肽来破坏该三元复合物,并在肿瘤细胞和患者来源异种移植瘤中抑制ccRCC进展。因此,我们的发现不仅为PRAME在介导C/EBPβ和EZH2调控NTN4及肿瘤转移中的重要作用提供了新见解,也突显了通过靶向C/EBPβ-PRAME-EZH2复合物治疗ccRCC的有前景策略。
Journal of advanced research IF 17.1 2026-10 PMID: 41513131
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality. Epigenetic dysregulation, particularly through methyltransferase METTL4, plays a critical role in HCC progression. METTL4 is known to catalyze m6Am methylation of mRNA, yet its pathological significance in liver cancer remains unclear. This study aims to firstly investigate the role of METTL4 in the pathogenesis of HCC, and then to evaluate the antitumor efficacy of targeting METTL4 in inhibiting HCC growth and metastasis. In a total of 802 postoperative HCC patients from four independent cohorts, we analyzed METTL4 expression in HCC tissues and its correlation with tumor staging and survival rates. Functional assays assessed the impact of METTL4 knockdown on HCC cell proliferation and metastasis, and patient-derived organoids (PDO) were used to evaluate the therapeutic efficacy of targeting METTL4. m6A-seq analyses identified GLI1 as a direct target of METTL4, investigating how METTL4-mediated m6Am modification affects GLI1 mRNA translation. Finally, we developed a siMETTL4-carrying nanoparticle and explored their efficacy in treating HCC in orthotopic and spontaneous liver tumor models. METTL4 was significantly upregulated in HCC tissues, correlating with higher tumor staging and poorer survival. Knockdown of METTL4 significantly inhibited HCC cell proliferation, migration, tumor growth, and lung metastasis. Meanwhile, targeting METTL4 effectively inhibited the growth of HCC PDO. METTL4-mediated m6Am modification enhanced GLI1 mRNA translation, with recognized target sites confirmed. Finally, siMETTL4-encapsulated nanoparticles effectively inhibited the growth and metastasis of orthotopic and spontaneous liver tumors. Our findings highlight the role of METTL4-mediated m6Am modification in promoting HCC progression by enhancing GLI1 translation. Targeting METTL4 with siMETTL4-Nanoparticles represents a novel therapeutic strategy, bridging molecular insights in RNA epitranscriptomics with translational applications for HCC treatment.
中文摘要:肝细胞癌(HCC)是癌症相关死亡的主要原因。表观遗传失调,尤其是通过甲基转移酶METTL4介导的表观遗传失调,在HCC进展中发挥关键作用。已知METTL4可催化mRNA的m6Am甲基化,但其在肝癌中的病理意义仍不清楚。本研究旨在首先探讨METTL4在HCC发病机制中的作用,然后评估靶向METTL4在抑制HCC生长和转移方面的抗肿瘤疗效。在来自四个独立队列的总共802例术后HCC患者中,我们分析了HCC组织中METTL4的表达及其与肿瘤分期和生存率的相关性。功能实验评估了敲低METTL4对HCC细胞增殖和转移的影响,并使用患者来源的类器官(PDO)评估靶向METTL4的治疗疗效。m6A-seq分析确定GLI1是METTL4的直接靶点,研究METTL4介导的m6Am修饰如何影响GLI1 mRNA翻译。最后,我们开发了一种携带siMETTL4的纳米颗粒,并探索了其在原位和自发肝肿瘤模型中治疗HCC的疗效。METTL4在HCC组织中显著上调,与更高的肿瘤分期和更差的生存相关。敲低METTL4显著抑制HCC细胞增殖、迁移、肿瘤生长和肺转移。同时,靶向METTL4有效抑制HCC PDO的生长。METTL4介导的m6Am修饰增强了GLI1 mRNA翻译,并确认了已知的靶位点。最后,封装siMETTL4的纳米颗粒有效抑制了原位和自发肝肿瘤的生长和转移。我们的发现强调了METTL4介导的m6Am修饰通过增强GLI1翻译促进HCC进展的作用。使用siMETTL4纳米颗粒靶向METTL4代表了一种新的治疗策略,将RNA表观转录组学的分子见解与HCC治疗的转化应用联系起来。
Journal of advanced research IF 17.1 2026-10 PMID: 41500421
Hepatocellular carcinoma (HCC) remains a highly lethal malignant tumor with limited treatment options. The guaianolide dimer KGA-1002 exhibited significant inhibitory effects on HCC cells, but the specific target and mechanism remain unclear. To further evaluate the antiHCC efficacy of KGA-1002 and clarify its molecular target and mechanism. BrdU, flow cytometry, Transwell, and colony formation assays were utilized to evaluate the in vitro antiHCC efficacy of KGA-1002. Drug affinity responsive target stability (DARTS) and bioinformatics analyses were applied to identify its target. The binding site was confirmed through Mass spectra analysis and amino acid mutation. Knockdown cell lines were used to validate the GRP94-dependent effects of KGA-1002. Pulldown assays were performed to detect protein-protein interactions. Xenograft tumor models were employed to examine the in vivo efficacy and mechanism. KGA-1002 inhibited the proliferation and metastasis of HCC cells, induced apoptosis and cell-cycle arrest at the G0/G1 phase. GRP94 was identified as its direct target, and Ser106 was confirmed as the covalent binding site. KGA-1002 targeting GRP94 triggered the unfolded protein response (UPR)-associated degradation and disrupted the GRP94-AKT interaction, resulting in AKT degradation. The degradation of AKT induced ferroptosis and reduced the stability of SKP2. The impairment of AKT and SKP2 promoted the nuclear accumulation of P21, which further induced apoptosis in HCC cells. In vivo, KGA-1002 (60 mg/kg) inhibited tumor growth by 61.6 %, and the effect was GRP94-dependent. KGA-1002 was identified as a highly promising lead compound for antiHCC. Its mechanism involved triggering UPR-associated degradation and disrupting the GRP94-AKT interaction. KGA-1002 simultaneously induced apoptosis and ferroptosis in HCC cells through the GRP94/AKT/SKP2/P21 signaling axis.
中文摘要:肝细胞癌(HCC)仍是治疗选择有限、致死率高的恶性肿瘤。Guaianolide二聚体KGA-1002对HCC细胞表现出显著抑制作用,但其特异性靶点和机制仍不清楚。为进一步评估KGA-1002的抗HCC疗效并阐明其分子靶点和机制。采用BrdU、流式细胞术、Transwell和集落形成实验评估KGA-1002的体外抗HCC疗效。应用药物亲和响应靶点稳定性(DARTS)和生物信息学分析鉴定其靶点。通过质谱分析和氨基酸突变确认结合位点。使用敲低细胞系验证KGA-1002的GRP94依赖性效应。进行Pulldown实验检测蛋白质-蛋白质相互作用。采用异种移植肿瘤模型检查体内疗效和机制。KGA-1002抑制HCC细胞增殖和转移,诱导凋亡和细胞周期停滞于G0/G1期。GRP94被鉴定为其直接靶点,Ser106被确认共价结合位点。KGA-1002靶向GRP94触发未折叠蛋白反应(UPR)相关降解,并破坏GRP94-AKT相互作用,导致AKT降解。AKT降解诱导铁死亡并降低SKP2稳定性。AKT和SKP2受损促进P21核积累,进一步诱导HCC细胞凋亡。体内,KGA-1002(60 mg/kg)抑制肿瘤生长61.6%,且该效应呈GRP94依赖性。KGA-1002被确定为一种极具前景的抗HCC先导化合物。其机制涉及触发UPR相关降解并破坏GRP94-AKT相互作用。KGA-1002通过GRP94/AKT/SKP2/P21信号轴同时诱导HCC细胞凋亡和铁死亡。

6乳腺癌 (27篇)

临床研究 (5篇)

Biosensors & bioelectronics IF 11.8 2026-10-07 PMID: 42843104
PIWI-interacting RNA (piRNA) as a type of small non-coding RNA holds great promise for managing disease occurrence and progression. Herein, we construct a ligation-assisted DNA strand displacement strategy for enhanced CRISPR/Cas14 cleavage, which provides remarkable SERS and electrochemical responses to indicate trace piRNA information. The upstream reaction is rationally designed to integrate traditional strand displacement amplification (SDA) and ligation-mediated target recycling, which benefits improvement of the efficiency. The generated single-stranded DNA products can activate trans-cleavage activity of Cas14, enabling the DNA structural changes on the sensing interface and subsequent signal measurements. By coupling ligation-assisted SDA (LSDA) and CRISPR/Cas14 system, ultrahigh sensitivity is achieved with low background signal. This method not only reports consistent results comparing with standard qRT-PCR technique, but can discriminates piRNA expressions in samples from breast cancer patients. Therefore, a reliable and practical tool is provided for piRNA related clinical applications.
中文摘要:PIWI相互作用RNA(piRNA)作为一种小非编码RNA,在管理疾病发生和进展方面具有巨大前景。在此,我们构建了一种连接辅助的DNA链置换策略,用于增强CRISPR/Cas14切割,该策略可提供显著的SERS和电化学响应以指示痕量piRNA信息。上游反应经过合理设计,整合了传统链置换扩增(SDA)和连接介导的靶标循环,有利于提高效率。生成的单链DNA产物可激活Cas14的反式切割活性,使传感界面上的DNA结构发生变化,并随后进行信号测量。通过将连接辅助的SDA(LSDA)与CRISPR/Cas14系统偶联,实现了超高灵敏度且背景信号低。该方法不仅与标准qRT-PCR技术相比报告了一致的结果,而且能够区分乳腺癌患者样本中的piRNA表达。因此,为piRNA相关的临床应用提供了一种可靠且实用的工具。
MedComm IF 14.1 2026-10 PMID: 42830862
This prospective single-arm study evaluated neoadjuvant disitamab vedotin plus penpulimab in Stage II-III HER2-low breast cancer (immunohistochemistry 1+ or 2+, fluorescence in situ hybridization-negative), a population lacking targeted neoadjuvant options. Twenty patients received the combination every 3 weeks for six cycles before surgery. In the intention-to-treat population, the pathologic complete response (pCR) was 20.0% (four out of 20; 95% CI, 5.7-43.7%), and the objective response rate (ORR) was 45.0% (nine out of 20; 95% CI, 23.1-68.5%). Among 16 patients who completed protocol-defined treatment and surgery, pCR was 25.0% (four out of 16; 95% CI, 7.3-52.4%), ORR was 56.3% (nine out of 16; 95% CI, 29.9-80.2%), and 31.3% achieved residual cancer burden Class 0-1. Grade ≥3 adverse events occurred in 25.0%; no treatment-related deaths occurred. pCR-associated tumors had a pretreatment immune-active microenvironment enriched in inflammatory proteins, transcripts, and tumor-infiltrating lymphocytes, whereas nonresponders displayed a higher M2/M1 macrophage ratio. An exploratory baseline score combining CCL19 and the M2/M1 ratio showed pCR/non-pCR separation (AUC = 0.8889) but attenuated on internal validation (LOOCV AUC = 0.6667, optimism-corrected bootstrap AUC = 0.8375). This combination showed preliminary antitumor activity with manageable safety; however, given the small sample size and wide confidence intervals, these findings preclude definitive conclusions about efficacy and warrant validation in larger randomized controlled trials.
中文摘要:这项前瞻性单臂研究评估了新辅助维迪西妥单抗联合派安普利单抗用于II-III期HER2低表达乳腺癌(免疫组化1+或2+、荧光原位杂交阴性)患者,该人群缺乏靶向新辅助治疗选择。20例患者接受该联合方案,每3周一次,共6个周期,之后手术。在意向治疗人群中,病理完全缓解(pCR)率为20.0%(20例中4例;95% CI,5.7-43.7%),客观缓解率(ORR)为45.0%(20例中9例;95% CI,23.1-68.5%)。在完成方案规定治疗和手术的16例患者中,pCR率为25.0%(16例中4例;95% CI,7.3-52.4%),ORR为56.3%(16例中9例;95% CI,29.9-80.2%),31.3%达到残余肿瘤负荷0-1类。≥3级不良事件发生率为25.0%;未发生治疗相关死亡。与pCR相关的肿瘤在治疗前具有免疫活跃微环境,富含炎症蛋白、转录本和肿瘤浸润淋巴细胞,而无应答者显示更高的M2/M1巨噬细胞比值。一个探索性基线评分联合CCL19和M2/M1比值可区分pCR/非pCR(AUC=0.8889),但在内部验证中减弱(LOOCV AUC=0.6667,乐观校正Bootstrap AUC=0.8375)。该联合方案显示出初步抗肿瘤活性和可控的安全性;然而,鉴于样本量小且置信区间宽,这些发现无法就疗效得出确定性结论,需要在更大规模随机对照试验中验证。
Cancer research IF 22.6 2026-10-02 PMID: 42391342
Intrinsic and acquired resistance to CDK4/6 inhibitors (CDK4/6i) is a critical challenge in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). CDK2 inhibitors (CDK2i) show promise in this context, with several currently under early-phase clinical evaluation. In this study, by analyzing tumor and liquid biopsies from patients treated with the selective CDK2i PF-07104091, we observed that PF-07104091 monotherapy achieved disease stabilization in a cohort of patients with CDK4/6i-resistant HR+/HER2- MBC. Notably, responses were observed irrespective of retinoblastoma (RB) expression and phosphorylation, whereas nonprogressive disease appeared more frequently among patients whose tumors retained wild-type TP53. Studies in established and patient-derived cell lines further substantiated that the growth-suppressive effects of CDK2i were independent of RB status in CDK4/6i-resistant models. CDK2i activity reduced the DNA replication rate, increased DNA damage, and inhibited mitotic entry, with growth inhibition dependent on p53 expression. These findings indicate that CDK dependency shifts from CDK4/6 toward CDK2 as cells transition from a CDK4/6i-sensitive to a CDK4/6i-resistant state. The distinct mechanisms of CDK2i and CDK4/6i support enhanced synergistic activity in HR+/HER2- MBC with acquired resistance to CDK4/6i therapy. Integrated analysis of CDK2 inhibitor-treated patients and experimental models reveals RB1-independent and p53-dependent mechanisms of CDK2 inhibition in breast cancer, supporting biomarker-guided therapeutic strategies and rational combination approaches.
中文摘要:CDK4/6抑制剂(CDK4/6i)的固有性和获得性耐药是激素受体阳性(HR+)、人表皮生长因子受体2阴性(HER2-)转移性乳腺癌(MBC)中的关键挑战。CDK2抑制剂(CDK2i)在这一背景下显示出前景,目前已有数种处于早期临床评价阶段。在本研究中,通过分析接受选择性CDK2i PF-07104091治疗患者的肿瘤活检和液体活检,我们观察到PF-07104091单药治疗使一组CDK4/6i耐药的HR+/HER2- MBC患者获得疾病稳定。值得注意的是,缓解与视网膜母细胞瘤(RB)表达和磷酸化状态无关,而未出现疾病进展更多见于肿瘤保留野生型TP53的患者。在已建立细胞系和患者来源细胞系中的研究进一步证实,在CDK4/6i耐药模型中,CDK2i的生长抑制作用不依赖于RB状态。CDK2i活性降低了DNA复制速率,增加了DNA损伤,并抑制了有丝分裂进入,其生长抑制依赖于p53表达。这些发现表明,当细胞从CDK4/6i敏感状态转变为CDK4/6i耐药状态时,CDK依赖性从CDK4/6转向CDK2。CDK2i与CDK4/6i的不同机制支持二者在获得性CDK4/6i治疗耐药的HR+/HER2- MBC中产生增强的协同活性。对接受CDK2抑制剂治疗的患者和实验模型的整合分析揭示了乳腺癌中CDK2抑制的RB1非依赖性和p53依赖性机制,支持生物标志物指导的治疗策略和合理的联合治疗方案。
JAMA surgery IF 15.6 2026-10-01 PMID: 42616513
Many patients are diagnosed with atypical lesions or lobular carcinoma in situ (LCIS); however, evidence- and consensus-based guidelines for the management of many of these lesions are limited. The American Society of Breast Surgeons, in collaboration with the Society of Breast Imaging and College of American Pathology, assembled a steering group to create guidelines for the management of atypical lesions and LCIS, inclusive of flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), classic LCIS (C-LCIS), and the variant LCIS forms pleomorphic LCIS (P-LCIS) and florid LCIS (F-LCIS). The natural history of ADH, ALH, and C-LCIS suggests that these lesions are associated with an elevated future breast cancer risk; therefore, patients diagnosed with these lesions should be recommended to undergo comprehensive risk assessment and counseling about breast cancer risk-reducing strategies. The magnitude of future breast cancer risk associated with P-LCIS and F-LCIS remains uncertain, yet if these lesions are determined to be hormone receptor positive, risk-reducing medications should be considered. There is no evidence that FEA is associated with an elevated future breast cancer risk. A second pathology review confirmation is recommended for ADH, should be considered for FEA, and is not necessary for ALH or LCIS. Currently available evidence supports the need to diagnostically excise most ADH, P-LCIS, and F-LCIS cases identified on core biopsy, although some ADH cases fulfilling strict criteria and multidisciplinary consensus can be observed. P-LCIS and F-LCIS require a negative margin, but ADH does not. ALH and C-LCIS can be safely observed if the core biopsy diagnosis is concordant with imaging features (ie, radiographic-pathologic concordance is established). Provided radiologic-pathologic concordance is confirmed, diagnostic excision is generally not indicated after a diagnosis of FEA alone. These guidelines provide evidence-informed, consensus-based recommendations for the management of atypical lesions of the breast, including ADH, ALH, FEA, C-LCIS, P-LCIS, and F-LCIS. Practicing clinicians who treat patients with atypical breast lesions or LCIS should consider integrating these guidelines into clinical management.
中文摘要:许多患者被诊断为非典型病变或小叶原位癌(LCIS);然而,针对其中许多病变管理的循证和共识指南仍有限。美国乳腺外科医师学会与乳腺影像学会及美国病理学家学会合作,组建了一个指导小组,以制定非典型病变和LCIS的管理指南,包括扁平上皮非典型增生(FEA)、非典型导管增生(ADH)、非典型小叶增生(ALH)、经典型LCIS(C-LCIS),以及变异型LCIS形式多形性LCIS(P-LCIS)和旺炽性LCIS(F-LCIS)。ADH、ALH和C-LCIS的自然史提示,这些病变与未来乳腺癌风险升高相关;因此,诊断为这些病变的患者应被建议接受全面风险评估,并接受关于降低乳腺癌风险策略的咨询。P-LCIS和F-LCIS相关的未来乳腺癌风险程度仍不确定,但如果确定这些病变为激素受体阳性,则应考虑使用降低风险的药物。没有证据表明FEA与未来乳腺癌风险升高相关。建议对ADH进行第二次病理复核确认,对FEA应考虑进行,而对ALH或LCIS则不需要。目前可获得的证据支持对空芯针活检发现的大多数ADH、P-LCIS和F-LCIS病例进行诊断性切除,尽管一些符合严格标准并经多学科共识的ADH病例可以观察。P-LCIS和F-LCIS需要切缘阴性,但ADH不需要。如果空芯针活检诊断与影像学特征一致(即已建立影像-病理一致性),ALH和C-LCIS可以安全观察。在确认影像-病理一致性后,单纯诊断FEA后通常不需要诊断性切除。这些指南为乳腺非典型病变的管理提供了循证、基于共识的建议,包括ADH、ALH、FEA、C-LCIS、P-LCIS和F-LCIS。治疗非典型乳腺病变或LCIS患者的执业临床医生应考虑将这些指南整合到临床管理中。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 42552467
Triple-negative breast cancer (TNBC) is a clinically aggressive and molecularly heterogeneous subtype defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression. Chemotherapy remains the mainstay of treatment, but recent advances in immune checkpoint inhibitors, DNA damage response-targeted therapies, antibody-drug conjugates, and small-molecule inhibitors have expanded therapeutic options. Despite these developments, clinical outcomes are still limited by tumor heterogeneity, suboptimal biomarker selection, resistance, and treatment-related toxicity. In this review, we summarize current and emerging therapeutic strategies for TNBC with a focus on their underlying biological rationale. We highlight key approaches targeting DNA repair deficiency, immune regulation, oncogenic signaling pathways, and antigen-directed therapies, and discuss their clinical development and application. We also address the role of molecular subtyping and biomarkers in guiding treatment selection, as well as the challenges posed by resistance and limited durability of response. Overall, this review provides an updated overview of TNBC treatment strategies and discusses ongoing challenges and future directions toward more effective and individualized therapies.
中文摘要:三阴性乳腺癌(TNBC)是一种临床上具有侵袭性且分子高度异质的亚型,其定义为雌激素受体、孕激素受体和人表皮生长因子受体2(HER2)表达缺失。化疗仍是主要治疗手段,但免疫检查点抑制剂、DNA损伤应答靶向治疗、抗体药物偶联物和小分子抑制剂的最新进展已拓展了治疗选择。尽管取得了这些进展,临床结局仍受限于肿瘤异质性、生物标志物选择欠佳、耐药以及治疗相关毒性。在这篇综述中,我们总结了TNBC当前及新兴的治疗策略,重点阐述其背后的生物学依据。我们重点介绍靶向DNA修复缺陷、免疫调节、致癌信号通路和抗原导向治疗的关键方法,并讨论其临床开发与应用。我们还探讨了分子分型和生物标志物在指导治疗选择中的作用,以及耐药和缓解持续时间有限所带来的挑战。总体而言,本综述提供了TNBC治疗策略的最新概述,并讨论了持续存在的挑战以及迈向更有效和个体化治疗的未来方向。

基础研究 (22篇)

Journal for immunotherapy of cancer IF 11.7 2026-10-07 PMID: 42843923
Poly (ADP-ribose) polymerase inhibitors (PARPis) have improved outcomes of BRCA-associated breast cancer; however, treatment-related toxicity remains a major clinical challenge. Currently approved PARPis broadly inhibit multiple members of the PARP protein family. However, preclinical studies suggest that inhibition of PARP1 alone is sufficient to drive antitumor efficacy. In contrast, inhibition of PARP2 has been implicated in hematological toxicities seen in patients receiving PARPi therapy. Therefore, selectively inhibiting PARP1 may reduce toxicity for patients. Here, we characterize and test the PARP1-selective inhibitor DSB1559 in preclinical models of Brca1-associated triple-negative breast cancer (TNBC). Pharmacokinetic/pharmacodynamic assays were performed to examine DSB1559 potency, selectivity, and in vivo behavior. Immunocompetent FVB/n mice bearing Brca1-deficient TNBC (CMV-Cre;Brca1fl/fl;Trp53fl/fl) tumors were treated with olaparib or DSB1559 and followed for survival. Flow cytometry and bulk RNA-sequencing were performed to measure the effects on the tumor microenvironment (TME). DSB1559 had superior selectivity for PARP1 and increased overall survival compared with olaparib. Analysis of the TME revealed a significant increase in cytotoxic T-cells, activated dendritic cells, and genes associated with antitumor immunity in mice treated with DSB1559. Taken together, DSB1559 is a highly selective PARP1 inhibitor that demonstrates superior efficacy and antitumor immune response compared with olaparib. A structurally related, clinical lead compound (DSB2455) is now being tested in a phase Ia/Ib clinical trial (NCT06458712).
中文摘要:聚(ADP-核糖)聚合酶抑制剂(PARPis)已改善BRCA相关乳腺癌的结局;然而,治疗相关毒性仍是主要临床挑战。目前获批的PARPis广泛抑制PARP蛋白家族的多个成员。然而,临床前研究提示,仅抑制PARP1就足以驱动抗肿瘤疗效。相反,抑制PARP2被认为与接受PARPi治疗患者中出现的血液学毒性有关。因此,选择性抑制PARP1可能降低患者毒性。在此,我们在Brca1相关三阴性乳腺癌(TNBC)的临床前模型中表征并测试了PARP1选择性抑制剂DSB1559。进行了药代动力学/药效学测定,以检查DSB1559的效力、选择性和体内行为。携带Brca1缺陷TNBC(CMV-Cre;Brca1fl/fl;Trp53fl/fl)肿瘤的免疫健全FVB/n小鼠接受奥拉帕利或DSB1559治疗,并随访生存。进行了流式细胞术和bulk RNA测序,以测量对肿瘤微环境(TME)的影响。与奥拉帕利相比,DSB1559对PARP1具有更优的选择性,并提高了总生存期。对TME的分析显示,在接受DSB1559治疗的小鼠中,细胞毒性T细胞、活化树突状细胞以及与抗肿瘤免疫相关的基因显著增加。总之,DSB1559是一种高度选择性的PARP1抑制剂,与奥拉帕利相比表现出更优的疗效和抗肿瘤免疫反应。一种结构相关的临床先导化合物(DSB2455)目前正在一项Ia/Ib期临床试验(NCT06458712)中接受测试。
Nature biomedical engineering IF 26.3 2026-10-06 PMID: 42839014
Cancer vaccines can elicit antigen-specific antitumour immunity, but their clinical efficacy is often limited by their inability to sustain T-cell activation in tumours. Here we report MOF-Vac, a nanoscale metal-organic framework (MOF)-based therapeutic vaccine platform that co-delivers peptide antigens and STING agonists with high loading capacity and phosphate-triggered intracellular release. This design enables coordinated antigen presentation and innate immune activation, resulting in sustained T-cell priming and intratumoural effector function. In murine models of melanoma, colorectal cancer, triple-negative breast cancer, lung cancer and oropharyngeal cancer, MOF-Vac induced tumour regression, immune memory and protection against metastasis. MOF-Vac also synergized with radiotherapy and immune checkpoint blockade to eradicate both primary and distant tumours. Single-cell RNA sequencing and immune depletion studies revealed that therapeutic efficacy predominantly depends on macrophage-mediated antigen presentation and remodelling of the tumour microenvironment towards a proinflammatory, immune-active state. MOF-Vac provides a modular platform for off-the-shelf and personalized cancer vaccination.
中文摘要:癌症疫苗能够引发抗原特异性抗肿瘤免疫,但其临床疗效常因无法在肿瘤内维持T细胞激活而受限。在此,我们报道MOF-Vac,一种基于纳米尺度金属有机框架(MOF)的治疗性疫苗平台,可共同递送肽抗原和STING激动剂,具有高负载能力及磷酸盐触发的细胞内释放。该设计能够实现抗原呈递与先天免疫激活的协同,从而产生持续的T细胞启动和瘤内效应功能。在黑色素瘤、结直肠癌、三阴性乳腺癌、肺癌和口咽癌的小鼠模型中,MOF-Vac诱导肿瘤消退、免疫记忆以及抗转移保护。MOF-Vac还可与放疗和免疫检查点阻断协同,根除原发瘤和远端瘤。单细胞RNA测序和免疫耗竭研究显示,治疗效果主要依赖于巨噬细胞介导的抗原呈递以及将肿瘤微环境重塑为促炎、免疫活跃状态。MOF-Vac为即用型和个性化癌症疫苗接种提供了一个模块化平台。
Cell death discovery IF 10.4 2026-10-06 PMID: 42838938
Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer with limited treatment options and a propensity towards chemoresistance. Given the lack of targetable receptors, treatment relies primarily on chemotherapy. While mechanisms leading to chemoresistance are vastly unknown, DNA damage tolerance (DDT) pathways have emerged as potential drivers of chemoresistance. Herein, we report a phenotypic characterization of four TNBC- and six non-TNBC cell lines, which supports the relevance of DDT in the TNBC response to chemotherapy. We unveiled an association between DDT pathway activation through PCNA-ubiquitination, augmented epithelial-to-mesenchymal transition (EMT) and stemness features, specifically in 3D spheroid culture from TNBC cells. Analysis of replication dynamics revealed a pronounced replication slowdown in 3D- versus 2D-cultured TNBC but not in non-TNBC cells. The exploration of DDT pathway usage in three TNBC cell lines (MDA-MB-231, Hs578t, MDA-MB-468) uncovers reliance on ZRANB3-, HLTF- and SMARCAL1-dependent fork reversal in 3D, while translesion DNA synthesis (TLS) polymerases (POLs) were more active under 2D conditions. Screening cytotoxicity with a panel of ten drugs targeting key DDT pathway components identified POLζ inhibition (JH-RE-06; IC50 ≤ 7 µM/48 h) and CHK1 inhibition (PF477736; IC50 ≤ 20 µM/48 h) as the most potent single-agent treatments in all three cell lines under both conditions. Mechanistically, both POLζ and CHK1 inhibition target several DDT pathways, in sum, causing replication slowdown, revealed consistently for CHK1. While TNBC cell lines were largely unresponsive to Olaparib mono-treatment, especially in 3D culture, all three cell lines were resensitized by combining Olaparib with low-dose POLζ-, CHK1-, or RAD51 inhibitor, except for 3D-cultured MDA-MB-231 cells, which may resist Olaparib due to their high ZRANB3 complex formation in the nucleus. These findings identify key DDT pathway components such as POLζ and CHK1 as druggable targets that alone or in combination with Olaparib may overcome chemoresistance in TNBC.
中文摘要:三阴性乳腺癌(TNBC)是乳腺癌中最具侵袭性的类型,治疗选择有限且易发生化疗耐药。由于缺乏可靶向的受体,治疗主要依赖化疗。尽管导致化疗耐药的机制在很大程度上仍不明确,DNA损伤耐受(DDT)通路已成为化疗耐药的潜在驱动因素。在此,我们对四种TNBC和六种非TNBC细胞系进行了表型表征,结果支持DDT在TNBC化疗反应中的相关性。我们揭示了通过PCNA泛素化激活DDT通路与上皮-间质转化(EMT)增强及干性特征之间的关联,尤其是在TNBC细胞的3D球状培养中。复制动态分析显示,与2D培养相比,3D培养的TNBC细胞出现明显的复制减慢,而非TNBC细胞则无此现象。对三种TNBC细胞系(MDA-MB-231、Hs578t、MDA-MB-468)中DDT通路使用情况的探索发现,在3D条件下依赖于ZRANB3、HLTF和SMARCAL1介导的复制叉逆转,而跨损伤DNA合成(TLS)聚合酶(POLs)在2D条件下更为活跃。用十种靶向DDT通路关键组分的药物进行细胞毒性筛选,发现POLζ抑制(JH-RE-06;IC50 ≤ 7 µM/48 h)和CHK1抑制(PF477736;IC50 ≤ 20 µM/48 h)是三种细胞系在两种条件下最有效的单药治疗。机制上,POLζ和CHK1抑制均靶向多条DDT通路,总之导致复制减慢,其中CHK1的效应得到一致验证。虽然TNBC细胞系对奥拉帕利单药治疗基本无反应,尤其在3D培养中,但所有三种细胞系在奥拉帕利与低剂量POLζ、CHK1或RAD51抑制剂联合后均被重新致敏,但3D培养的MDA-MB-231细胞除外,其可能因核内ZRANB3复合物形成较高而对奥拉帕利耐药。这些发现确定POLζ和CHK1等关键DDT通路组分是可成药靶点,单独或与奥拉帕利联合可能克服TNBC的化疗耐药。
Molecular cell IF 16.0 2026-10-06 PMID: 42838053
Cancer cells lacking BRCA1 or BRCA2 must adapt to proliferate despite pervasive genomic instability. To delineate BRCA1- and BRCA2-specific adaptation landscapes, we developed an isogenic screening platform enabling acute depletion of either protein. Genetic interaction profiling revealed hundreds of genes with shared, distinct, or opposing effects in the two BRCA-deficient states. We identified FANCM as essential in BRCA1-deficient cells. Conversely, FANCM is toxic in BRCA2-deficient cells, where it promotes replication fork degradation through RMI1/2 recruitment and sensitizes cells to PARP inhibition. FANCM loss restored fork integrity and alleviated genomic instability and proliferation defects without restoring homologous recombination or suppressing single-stranded DNA (ssDNA) gaps. Finally, we report a FANCM variant that disrupts RMI1/2 binding in a BRCA2m breast cancer patient that is associated with PARP-inhibitor resistance. These findings define fundamentally distinct adaptive routes to BRCA1 and BRCA2 loss and establish FANCM-RMI1/2 as a determinant of mutation-specific vulnerabilities and therapeutic responses.
中文摘要:缺乏 BRCA1 或 BRCA2 的癌细胞必须在普遍存在的基因组不稳定性下适应并增殖。为描绘 BRCA1 和 BRCA2 特异性的适应图谱,我们建立了一个同基因筛选平台,可实现对任一蛋白的急性耗竭。遗传相互作用谱分析揭示了数百个基因在两种 BRCA 缺陷状态下具有共享、不同或相反的作用。我们发现 FANCM 在 BRCA1 缺陷细胞中是必需的。相反,FANCM 在 BRCA2 缺陷细胞中具有毒性,它通过招募 RMI1/2 促进复制叉降解,并使细胞对 PARP 抑制敏感。FANCM 缺失可恢复复制叉完整性,并缓解基因组不稳定性和增殖缺陷,而不恢复同源重组,也不抑制单链 DNA(ssDNA)缺口。最后,我们报道在一名 BRCA2 突变乳腺癌患者中发现的 FANCM 变异可破坏 RMI1/2 结合,并与 PARP 抑制剂耐药相关。这些发现界定了针对 BRCA1 和 BRCA2 丢失的根本不同的适应途径,并确立 FANCM-RMI1/2 是突变特异性脆弱性和治疗反应的决定因素。
Molecular biomedicine IF 13.0 2026-10-05 PMID: 42830336
Triple-negative breast cancer (TNBC) remains an aggressive disease with limited treatment options. Oncolytic adenoviruses represent a promising platform, but their efficacy as single agents is often insufficient. This study examined whether an oncolytic adenovirus co-delivering decorin (DCN) and CD40 ligand (CD40L), designated rAd.DCN.CD40L, could enhance antitumor activity and immune activation against TNBC. Recombinant adenoviruses expressing DCN (rAd.DCN), CD40L (rAd.CD40L), or both proteins were constructed and evaluated in breast cancer cells using cell viability, apoptosis, migration, invasion, and damage-associated molecular pattern (DAMP) release assays. Compared with rAd.DCN or rAd.CD40L alone, rAd.DCN.CD40L triggered greater apoptosis and tumor cell death and elicited more pronounced DAMP release. Co-culture experiments also revealed enhanced dendritic cell function following rAd.DCN.CD40L treatment. For in vivo evaluation, syngeneic 4T1 and EMT-6 subcutaneous tumor models and a 4T1 lung metastasis model were employed. rAd.DCN.CD40L substantially delayed tumor growth and improved survival in tumor-bearing mice. Flow cytometric and histological analyses further confirmed enhanced local and systemic T-cell responses, elevated CD8⁺ T-cell activity, and modulated inflammatory macrophage phenotypes. Mechanistically, western blot analysis showed that rAd.DCN.CD40L may contribute to extracellular matrix remodeling and the down-regulation of the expression of epithelial-mesenchymal transition (EMT)-associated genes. Notably, CD8⁺ T-cell depletion markedly attenuated the therapeutic efficacy of rAd.DCN.CD40L, demonstrating that CD8⁺ T cells are critical functional effectors of tumor control. Collectively, these findings indicate that a DCN- and CD40L-armed oncolytic adenovirus represents a promising combinatorial strategy for TNBC immunotherapy, and warrants further preclinical and clinical investigation.
中文摘要:三阴性乳腺癌(TNBC)仍是一种侵袭性强且治疗选择有限的疾病。溶瘤腺病毒是一个有前景的平台,但作为单一药物的疗效往往不足。本研究探讨了一种共递送核心蛋白聚糖(decorin, DCN)和CD40配体(CD40L)的溶瘤腺病毒,命名为rAd.DCN.CD40L,能否增强针对TNBC的抗肿瘤活性和免疫激活。构建了表达DCN(rAd.DCN)、CD40L(rAd.CD40L)或同时表达两种蛋白的重组腺病毒,并通过细胞活力、凋亡、迁移、侵袭和损伤相关分子模式(DAMP)释放试验在乳腺癌细胞中进行评估。与单独使用rAd.DCN或rAd.CD40L相比,rAd.DCN.CD40L引发更强的凋亡和肿瘤细胞死亡,并诱导更明显的DAMP释放。共培养实验还显示,rAd.DCN.CD40L处理后树突状细胞功能增强。在体内评估中,采用了同基因4T1和EMT-6皮下肿瘤模型以及4T1肺转移模型。rAd.DCN.CD40L显著延缓荷瘤小鼠的肿瘤生长并改善生存。流式细胞术和组织学分析进一步证实局部和全身T细胞反应增强、CD8⁺ T细胞活性升高以及炎性巨噬细胞表型受到调节。在机制上,western blot分析显示,rAd.DCN.CD40L可能有助于细胞外基质重塑和上皮-间质转化(EMT)相关基因表达下调。值得注意的是,清除CD8⁺ T细胞显著减弱rAd.DCN.CD40L的治疗效果,表明CD8⁺ T细胞是肿瘤控制的关键功能性效应细胞。总体而言,这些发现表明,携带DCN和CD40L的溶瘤腺病毒代表了TNBC免疫治疗的一种有前景的组合策略,值得进一步的临床前和临床研究。
MedComm IF 14.1 2026-10 PMID: 42835397
Replication factor C subunit 4 (RFC4) dysregulation has been implicated in tumor progression and poor prognosis across multiple cancer types. Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor outcomes, underscoring the need for effective therapeutic targets. However, the role of RFC4 in TNBC progression and metastasis remains unclear. In the present study, integrated bioinformatics analyses, together with validation in 80 clinical TNBC samples, showed that RFC4 was markedly upregulated in TNBC. In vitro functional assays and experiments in nude mouse models further demonstrated that elevated RFC4 expression contributed to TNBC progression (p < 0.05). Mechanistically, the upstream transcription factor TRIM28 (Tripartite motif-containing 28) bound to the BS2 and BS3 sites within the RFC4 promoter region, thereby activating RFC4 transcription and increasing its expression. Furthermore, TRIM28 interacted with RFC4 and assembled K29-linked ubiquitin chains at K205 and K217, enhancing RFC4 ubiquitination and protein stability in a manner dependent on TRIM28 ubiquitin ligase activity (p < 0.05). Finally, we showed that RFC4 activates the Ras-associated protein 1 (Rap1)-PI3K-AKT pathway in a ubiquitination-dependent manner, thereby enhancing TNBC cell proliferation and metastasis. Together, these findings suggest that the TRIM28-RFC4 axis may represent a promising therapeutic target for TNBC.
中文摘要:复制因子C亚单位4(RFC4)失调已被认为与多种癌症类型的肿瘤进展和不良预后相关。三阴性乳腺癌(TNBC)是一种侵袭性亚型,治疗选择有限且预后较差,凸显了有效治疗靶点的需求。然而,RFC4在TNBC进展和转移中的作用仍不清楚。在本研究中,整合生物信息学分析以及对80例临床TNBC样本的验证表明,RFC4在TNBC中显著上调。体外功能实验和裸鼠模型实验进一步表明,RFC4表达升高促进TNBC进展(p < 0.05)。机制上,上游转录因子TRIM28(三重基序包含蛋白28)结合于RFC4启动子区域内的BS2和BS3位点,从而激活RFC4转录并增加其表达。此外,TRIM28与RFC4相互作用,并在K205和K217位点组装K29连接的泛素链,以依赖TRIM28泛素连接酶活性的方式增强RFC4泛素化及其蛋白稳定性(p < 0.05)。最后,我们发现RFC4以泛素化依赖的方式激活Ras相关蛋白1(Rap1)-PI3K-AKT通路,从而增强TNBC细胞增殖和转移。总之,这些发现提示TRIM28-RFC4轴可能是TNBC一个有前景的治疗靶点。
Science advances IF 13.9 2026-10-02 PMID: 42826203
Triple-negative breast cancer (TNBC) develops in hypoxic, nutrient-limited tumors enriched with macrophages and cell death. We show that metabolically distinct TNBCs differentially exploit macrophage-derived nutrients, influencing tumor growth and therapeutic response. Prolonged hypoxia reprogrammed mouse and human macrophages, enabling them to release metabolites that rescued the growth of select TNBC cell lines during glutamine deprivation or glutamine metabolism inhibition. Hypoxic macrophages reduced glutamine consumption, increased arginine utilization, and secreted higher levels of ornithine, an intermediate of arginine metabolism. Exogenous ornithine, but not arginine, restored the growth of responsive TNBC cells. Mechanistically, TNBC cells diverted ornithine into proline biosynthesis, supporting oxidative pentose phosphate pathway activity. In vivo, depletion of tumor-associated myeloid cells reduced tumor growth and impaired proline synthesis in glutaminase inhibitor-resistant TNBC. These findings identify hypoxia-driven metabolic cross-talk between macrophages and TNBC cells, revealing ornithine-dependent proline metabolism as a mechanism by which macrophages sustain tumor growth under nutrient stress and contribute to resistance to glutamine-targeted therapies.
中文摘要:三阴性乳腺癌(TNBC)发生于缺氧、营养受限且富含巨噬细胞和细胞死亡的肿瘤中。我们发现,代谢特征不同的TNBC对巨噬细胞来源营养物质的利用存在差异,从而影响肿瘤生长和治疗反应。长期缺氧重编程了小鼠和人巨噬细胞,使其能够释放代谢物,在谷氨酰胺剥夺或谷氨酰胺代谢抑制期间挽救部分TNBC细胞系的生长。缺氧巨噬细胞减少谷氨酰胺消耗,增加精氨酸利用,并分泌更高水平的鸟氨酸,鸟氨酸是精氨酸代谢的中间产物。外源性鸟氨酸而非精氨酸可恢复有反应TNBC细胞的生长。机制上,TNBC细胞将鸟氨酸导向脯氨酸生物合成,支持氧化磷酸戊糖途径活性。在体内,清除肿瘤相关髓系细胞可减少肿瘤生长,并损害谷氨酰胺酶抑制剂耐药TNBC中的脯氨酸合成。这些发现揭示了缺氧驱动的巨噬细胞与TNBC细胞之间的代谢串扰,表明依赖鸟氨酸的脯氨酸代谢是巨噬细胞在营养应激下维持肿瘤生长并促进对谷氨酰胺靶向治疗耐药的一种机制。
Cancer research IF 22.6 2026-10-02 PMID: 42825516
EZH2, the catalytic subunit of the histone methyltransferase complex PRC2, is overexpressed and associated with poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. Here, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA (dsRNA), triggering an essential integrated stress response (ISR) through PKR and PERK activation. By inducing ISR-mediated ATF4, EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacological targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC.
中文摘要:EZH2是组蛋白甲基转移酶复合物PRC2的催化亚基,在三阴性乳腺癌(TNBC)中过表达并与不良预后相关。尽管抑制EZH2会显著改变染色质格局和基因表达,但其对TNBC模型生长影响有限,提示存在适应性代偿机制。在此,我们证明抑制EZH2会导致错误折叠蛋白和双链RNA(dsRNA)积累,并通过PKR和PERK激活触发一种必需的整合应激反应(ISR)。通过诱导ISR介导的ATF4,抑制EZH2增强氨基酸通量并促进谷氨酰胺分解,以支持TNBC细胞存活。用谷氨酰胺酶抑制剂联合EZH2抑制对这一代谢轴进行药理学靶向,可显著损害TNBC细胞增殖和肿瘤生长。这些发现揭示了一种应激驱动的代谢适应,其在EZH2阻断后维持TNBC存活,并强调抑制该通路可作为提高EZH2抑制剂在TNBC中疗效的策略。
Science advances IF 13.9 2026-10-02 PMID: 42814811
Resistance to standard-of-care therapies remains a major clinical challenge in the treatment of the most common breast cancer, the hormone receptor-positive (HR+) subtype. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in early-stage HR+ disease, yet many patients relapse. Resistance mechanisms of relapsed tumors include genetic alterations, but in many cases, no genetic drivers are identified. Here, we investigated mechanisms underlying resistance to CDK4/6 inhibitors using breast cancer patient-derived models and tumors. We identified an unexpected, noncanonical nuclear function of fumarylacetoacetate hydrolase (FAH), an enzyme in the tyrosine catabolism pathway, as a driver of resistance. FAH translocated to the nucleus upon CDK4/6 inhibition, where it interacted with cyclin-dependent kinase 9 (CDK9), and promoted resistance. Nuclear FAH was enriched in tumors from relapsed patients, and inhibition of CDK9 reversed FAH-mediated resistance. These findings establish nuclear FAH as a biomarker of resistance and revealed CDK9 as a therapeutic vulnerability in CDK4/6 inhibitor-resistant HR+ breast cancer.
中文摘要:对标准治疗耐药仍是治疗最常见乳腺癌——激素受体阳性(HR+)亚型——的主要临床挑战。细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂改善了早期HR+疾病的结局,但许多患者仍会复发。复发肿瘤的耐药机制包括基因改变,但在许多病例中未发现遗传驱动因素。在此,我们利用乳腺癌患者来源模型和肿瘤,研究了CDK4/6抑制剂耐药的潜在机制。我们发现酪氨酸分解代谢通路中的酶延胡索酰乙酰乙酸水解酶(FAH)具有一种意想不到的非经典核功能,可作为耐药驱动因素。CDK4/6抑制后FAH易位至细胞核,在那里与细胞周期蛋白依赖性激酶9(CDK9)相互作用,并促进耐药。核FAH在复发患者肿瘤中富集,抑制CDK9可逆转FAH介导的耐药。这些发现确立了核FAH作为耐药生物标志物,并揭示CDK9是CDK4/6抑制剂耐药的HR+乳腺癌中的治疗脆弱点。
Science advances IF 13.9 2026-10-02 PMID: 42814810
Implantable wireless ultrasound microdevices for intratumoral therapy are hindered by inadequate miniaturization for deep-seated sites and toxic lead-based piezoelectrics. Here, we report an injectable, lead-free, submillimeter therapeutic dust (TheraDust; 1.0 millimeters by 1.0 millimeters by 0.9 millimeters) for ultrasound-driven wireless chemo-photodynamic combined therapy. The core of the device is a lead-free tin-doped barium titanate piezoelectric ceramic that features a multiphase coexistence at physiological temperature and exhibits a high piezoelectric coefficient (d33 = 460 picocoulombs per newton). The TheraDust integrates with an ultrasound-responsive drug-loaded hydrogel for precise intratumoral injection. Under programmable ultrasound, it generates light for photodynamic therapy and triggers on-demand chemotherapeutic release for enhanced treatment. In animal models of breast cancer, the device achieved potent tumor suppression, reducing the final tumor volume to less than 3% after five treatment sessions (5 minutes each) and could be retrieved minimally invasively posttreatment. This platform can be adapted to deliver a range of therapeutic stimuli wirelessly, offering a versatile strategy for treating deep-seated pathologies.
中文摘要:用于瘤内治疗的植入式无线超声微型器件受到以下因素阻碍:难以针对深部病灶充分小型化,以及含铅压电材料具有毒性。在此,我们报道一种可注射、无铅、亚毫米级治疗粉尘(TheraDust;1.0毫米×1.0毫米×0.9毫米),用于超声驱动的无线化疗-光动力联合治疗。该器件的核心是一种无铅锡掺杂钛酸钡压电陶瓷,其在生理温度下具有多相共存特征,并表现出高压电系数(d33 = 460皮库仑每牛顿)。TheraDust与超声响应型载药水凝胶整合,以实现精准瘤内注射。在可编程超声作用下,它产生用于光动力治疗的光,并触发按需化疗药物释放,以增强治疗效果。在乳腺癌动物模型中,该器件实现了强效肿瘤抑制,在五次治疗(每次5分钟)后使最终肿瘤体积降至不足3%,并且治疗后可通过微创方式取出。该平台可适配以无线方式递送多种治疗性刺激,为治疗深部病变提供了一种通用策略。
Cancer research IF 22.6 2026-10-02 PMID: 42423461
Obesity is a modifiable risk factor for postmenopausal breast cancer. As obesity-gut microbiome interactions are well known, obesity might also affect tissue-resident microbiome populations as a mechanism promoting breast cancer. Using noncancerous breast tissue samples, we demonstrated that obesity and aging interact to shift the tissue-resident microbiome in patients with breast cancer. Breast tissue from postmenopausal women with obesity displayed significantly different α-diversity and β-diversity compared with pre- and postmenopausal women without obesity. At the species level, breast tissue from postmenopausal women with obesity expressed elevated Akkermansia muciniphila abundance when compared with all other groups. A secondary cohort of noncancerous breast tissue from reduction mammoplasty patients indicated that participant body mass index correlates with breast A. muciniphila abundance. Elevated mammary gland (MG) A. muciniphila in female MMTV-PyMT mice fed a high-fat Western diet increased tumorigenesis, tumor multiplicity, and oxidative stress markers, and the administration of the antioxidant N-acetylcysteine reduced A. muciniphila-induced tumorigenesis and redox perturbations. In an orthotopic progression model, MG A. muciniphila in Western diet-fed mice promoted estrogen receptor-positive tumor growth and lung metastases. Taken together, these results suggest that obesity and aging interact to enrich breast A. muciniphila abundance, modifying tissue redox balance as a risk factor for obesity-mediated postmenopausal breast cancer. Obesity and aging alter the breast tissue microbiome, increasing abundance of tissue-resident Akkermansia muciniphila that promotes tumorigenesis and oxidative stress, revealing a microbial mechanism contributing to postmenopausal obesity-associated breast cancer risk.
中文摘要:肥胖是绝经后乳腺癌的可改变危险因素。由于肥胖与肠道微生物组的相互作用已广为人知,肥胖也可能通过影响组织驻留微生物群作为促进乳腺癌的一种机制。利用非癌性乳腺组织样本,我们证明肥胖与衰老相互作用,改变乳腺癌患者的组织驻留微生物组。与无肥胖的绝经前和绝经后女性相比,肥胖绝经后女性的乳腺组织显示显著不同的α多样性和β多样性。在物种水平上,与所有其他组相比,肥胖绝经后女性的乳腺组织表现出升高的嗜黏蛋白阿克曼菌(Akkermansia muciniphila)丰度。一个来自缩乳术患者的非癌性乳腺组织次要队列表明,参与者体重指数与乳腺嗜黏蛋白阿克曼菌丰度相关。在喂食高脂西方饮食的雌性MMTV-PyMT小鼠中,乳腺(MG)嗜黏蛋白阿克曼菌升高增加了肿瘤发生、肿瘤多发性和氧化应激标志物,而给予抗氧化剂N-乙酰半胱氨酸减少了嗜黏蛋白阿克曼菌诱导的肿瘤发生和氧化还原扰动。在原位进展模型中,西方饮食喂养小鼠的乳腺嗜黏蛋白阿克曼菌促进了雌激素受体阳性肿瘤生长和肺转移。总之,这些结果提示,肥胖与衰老相互作用,富集乳腺嗜黏蛋白阿克曼菌丰度,改变组织氧化还原平衡,作为肥胖介导的绝经后乳腺癌的危险因素。肥胖与衰老改变乳腺组织微生物组,增加组织驻留嗜黏蛋白阿克曼菌丰度,从而促进肿瘤发生和氧化应激,揭示了一种导致绝经后肥胖相关乳腺癌风险的微生物机制。
Cancer research IF 22.6 2026-10-02 PMID: 42412619
Metastatic disease remains a major cause of cancer-related mortality. Recent studies suggest that dissemination to other organs comes with metabolic changes that allow the metastasizing cancer cells to adapt to new microenvironments. A deeper knowledge of these specific metabolic features and associated vulnerabilities could lead to the development of more effective therapies against metastasis. We used in vivo and ex vivo models of MYC-driven breast tumorigenesis to explore the key metabolic pathways that change when mammary gland tumor (MGT) cells metastasize to the lung. Stable isotope-resolved metabolomics, mass spectrometry imaging, and single-cell RNA sequencing demonstrated that MGT-derived lung metastases have increased synthesis of glutathione fueled by increased cystine uptake. Metastatic cells relied heavily on the availability of extracellular cysteine or cystine, possibly due to downregulated intracellular cysteine synthesis through the transsulfuration pathway. When combined with focal radiotherapy, the amino acid degrader cyst(e)inase effectively reduced metastatic burden in the lungs. Together, these findings show that targeting cystine/cysteine exploits a metabolic dependency that is unique to metastatic cells and acts as a sensitizer to radiotherapy-induced oxidative stress, offering a promising targeted strategy. A radiotherapy-sensitizing combination with the amino acid degrader cyst(e)inase is an effective strategy to treat breast metastasis to the lungs, tackling the specific dependence of metastatic cells on cysteine and cystine.
中文摘要:转移性疾病仍是癌症相关死亡的主要原因。近期研究表明,向其他器官播散会伴随代谢变化,使转移的癌细胞能够适应新的微环境。更深入地了解这些特定代谢特征及相关脆弱性,可能有助于开发更有效的抗转移疗法。我们使用MYC驱动的乳腺肿瘤发生的体内和离体模型,探讨乳腺腺体肿瘤(MGT)细胞转移至肺时发生变化的关键代谢通路。稳定同位素解析代谢组学、质谱成像和单细胞RNA测序表明,MGT来源的肺转移瘤中谷胱甘肽合成增加,这是由胱氨酸摄取增加所驱动。转移细胞严重依赖细胞外半胱氨酸或胱氨酸的可利用性,这可能是由于经转硫途径进行的细胞内半胱氨酸合成下调所致。当与聚焦放疗联合时,氨基酸降解剂cyst(e)inase有效降低了肺部转移负荷。总之,这些发现表明,靶向胱氨酸/半胱氨酸利用了转移细胞特有的代谢依赖性,并作为放疗诱导的氧化应激的增敏剂,提供了一种有前景的靶向策略。与氨基酸降解剂cyst(e)inase联合的放疗增敏策略是治疗乳腺癌肺转移的有效策略,针对转移细胞对半胱氨酸和胱氨酸的特定依赖。
Acta biomaterialia IF 10.4 2026-10 PMID: 42716413
Breast cancer (BC) remains one of the most prevalent malignancies globally, with mastectomy frequently required as part of treatment. This creates a critical clinical demand for effective breast reconstruction strategies. Conventional reconstruction methods, such as silicone implants, autologous fat grafting, and free-flap surgery, have notable drawbacks. Scaffold-guided breast reconstruction (SGBR) is a promising alternative that relies on biocompatible, biodegradable scaffolds to support and direct the regeneration of vascularized soft tissue. This review summarizes the current state of SGBR approaches, emphasizing scaffold architecture, biomaterials, and fabrication techniques. Various scaffold configurations, including fibrous, porous, hydrogel-based, mesh-like, and composite architectures, are discussed, along with natural and synthetic polymeric biomaterials. The integration of advanced additive manufacturing (AM) technologies is also explored, highlighting their role in enabling patient-specific scaffold designs. The review outlines key biological and mechanical criteria for a successful reconstruction, with particular attention to challenges such as neovascularization and tumor recurrence. Although preclinical studies have yielded promising outcomes, clinical translation remains limited, highlighting the need for continued research to optimize scaffold functionality, integration, and long-term performance.
中文摘要:乳腺癌(BC)仍是全球最常见的恶性肿瘤之一,乳房切除术常作为治疗的一部分。这产生了对有效乳房重建策略的迫切临床需求。传统重建方法,如硅胶植入物、自体脂肪移植和游离皮瓣手术,存在明显不足。支架引导乳房重建(SGBR)是一种有前景的替代方案,其依赖生物相容、可生物降解的支架来支持和引导血管化软组织再生。本综述总结了SGBR方法的现状,重点讨论支架结构、生物材料和制造技术。文中讨论了多种支架构型,包括纤维型、多孔型、水凝胶型、网状和复合结构,以及天然和合成聚合物生物材料。还探讨了先进增材制造(AM)技术的整合,强调其在实现患者特异性支架设计中的作用。本综述概述了成功重建的关键生物学和力学标准,特别关注新生血管化和肿瘤复发等挑战。尽管临床前研究已取得有希望的结果,但临床转化仍然有限,凸显了持续研究以优化支架功能、整合和长期性能的必要性。
Acta biomaterialia IF 10.4 2026-10 PMID: 42665114
Cardiovascular disease (CVD) is the leading cause of death worldwide. Chemotherapy-induced CVD is increasingly recognized as a contributor to long-term morbidity in cancer survivors. Doxorubicin (DOX) is a widely used chemotherapeutic to treat breast cancer, one of the most common cancers in the United States. However, over 10% of treated women experience acute cardiotoxicity immediately following treatment, and approximately 2% develop severe cardiotoxicity up to 10 years after treatment, yet the mechanisms driving this delayed onset remain unclear. Here, we show that DOX treatment of cardiac cells changes their function and paracrine signaling profile. Subsequent exposure of healthy cells to altered extracellular vesicles (EVs) recapitulates the effects of direct DOX exposure in 2D/3D in vitro models, suggesting a mechanism for propagating initial injury. Plasma-EV miRNA profiling of blinded patient samples revealed distinct clustering by DOX-cardiotoxicity risk, with high-risk patients exhibiting miRNA signatures similar to those from DOX-treated models. Pathway analysis of miRNAs linked them to cardiac homeostasis and cardiotoxicity-related mechanisms, supporting the potential of plasma-EV miRNAs as noninvasive biomarkers for early risk stratification and personalized cardioprotective interventions in oncological care, and targeting of key miRNA clusters to enhance understanding of and intervention strategies for preventing the onset of DOX cardiotoxicity. STATEMENT OF SIGNIFICANCE: Doxorubicin is an effective chemotherapy drug, but its use is limited by cardiotoxicity that can appear during treatment or years later. The mechanisms driving this delayed injury remain poorly understood. In this study, we show for the first time that small EVs released from doxorubicin-treated human cardiac cells can propagate doxorubicin-like dysfunction to healthy human cardiac cells even in the absence of the drug itself. We further identify broad miRNA cargo changes in these EVs and show that related EV-associated miRNA shifts are also detectable in patient plasma. These findings provide new mechanistic insight into anthracycline cardiotoxicity and highlight EV-associated miRNAs as promising candidates for minimally invasive diagnosis and future therapeutic intervention.
中文摘要:心血管疾病(CVD)是全球主要死因。化疗诱导的CVD日益被认为是癌症幸存者长期疾病负担的一个因素。多柔比星(DOX)是治疗乳腺癌的一种广泛使用的化疗药物,而乳腺癌是美国最常见的癌症之一。然而,超过10%的接受治疗女性在治疗后立即出现急性心脏毒性,约2%在治疗后长达10年内发生严重心脏毒性,但驱动这种延迟发生的机制仍不清楚。在本研究中,我们发现DOX处理心脏细胞会改变其功能和旁分泌信号谱。随后,将健康细胞暴露于发生改变的细胞外囊泡(EVs)中,可在2D/3D体外模型中重现直接DOX暴露的效应,提示了一种传播初始损伤的机制。对盲法患者样本进行血浆EV miRNA谱分析显示,样本可按DOX心脏毒性风险形成明显聚类,高风险患者表现出与DOX处理模型相似的miRNA特征。对miRNA的通路分析将其与心脏稳态及心脏毒性相关机制联系起来,支持血浆EV miRNA作为无创生物标志物的潜力,用于肿瘤诊疗中的早期风险分层和个体化心脏保护干预,并支持靶向关键miRNA簇以加深对DOX心脏毒性发生机制的理解并改进预防策略。意义声明:多柔比星是一种有效的化疗药物,但其使用受到心脏毒性的限制,这种毒性可在治疗期间或数年之后出现。驱动这种延迟性损伤的机制仍知之甚少。在本研究中,我们首次表明,从多柔比星处理的人心脏细胞释放的小型EVs即使在药物本身不存在的情况下,也能将多柔比星样功能障碍传播至健康人心脏细胞。我们进一步发现这些EVs中广泛的miRNA货物变化,并表明相关的EV相关miRNA变化也可在患者血浆中检测到。这些发现为蒽环类心脏毒性提供了新的机制见解,并凸显EV相关miRNA作为微创诊断和未来治疗干预的有前景候选物。
Redox biology IF 16.2 2026-10 PMID: 42660058
Disulfidptosis is a metabolism-dependent form of cell death driven by disulfide stress that induces actin cytoskeletal collapse in SLC7A11-high cells under glucose deprivation. However, strategies to therapeutically exploit this vulnerability remain underdeveloped. Given the high dependence of triple-negative breast cancer (TNBC) on glucose metabolism, we engineered a tumor microenvironment-responsive MnOx nanoplatform for sustained delivery of the GLUT1 inhibitor BAY-876 and concurrent glutathione (GSH) depletion. Within this integrated system, BAY-876 restricts GLUT1-mediated glucose uptake, thereby reducing the availability of reduced nicotinamide adenine dinucleotide phosphate (NADPH), impairing the reduction of cystine to cysteine, and promoting intracellular cystine accumulation. In parallel, MnOx undergoes GSH-triggered degradation in the GSH-rich intracellular environment of tumor cells, releasing Mn2+ and consuming intracellular GSH, thereby weakening cellular antioxidant defenses. Glucose restriction-induced NADPH depletion and MnOx-mediated GSH depletion synergistically intensify disulfide stress. Beyond direct cytotoxicity, the resulting metabolic and redox imbalance promotes the surface exposure and extracellular release of damage-associated molecular patterns (DAMPs), thereby enhancing immunogenic cell death (ICD). This process facilitates dendritic cell maturation and antigen presentation, shifts the immunosuppressive tumor microenvironment toward an immune-active phenotype, and ultimately enhances T-cell-mediated antitumor immunity. Collectively, this work establishes disulfidptosis as a therapeutically actionable metabolic vulnerability and presents a nanotherapeutic strategy that integrates metabolic intervention with immune activation for TNBC treatment.
中文摘要:二硫死亡是一种代谢依赖性的细胞死亡形式,由二硫化物应激驱动,可在葡萄糖剥夺条件下诱导SLC7A11高表达细胞中的肌动蛋白细胞骨架塌陷。然而,利用这一脆弱性进行治疗策略仍不成熟。鉴于三阴性乳腺癌(TNBC)对葡萄糖代谢高度依赖,我们设计了一种肿瘤微环境响应型MnOx纳米平台,用于持续递送GLUT1抑制剂BAY-876并同时耗竭谷胱甘肽(GSH)。在该整合系统中,BAY-876限制GLUT1介导的葡萄糖摄取,从而减少还原型烟酰胺腺嘌呤二核苷酸磷酸(NADPH)的可用性,损害胱氨酸向半胱氨酸的还原,并促进细胞内胱氨酸积累。与此同时,MnOx在肿瘤细胞富含GSH的细胞内环境中发生GSH触发的降解,释放Mn2+并消耗细胞内GSH,从而削弱细胞抗氧化防御。葡萄糖限制诱导的NADPH耗竭与MnOx介导的GSH耗竭协同增强二硫化物应激。除直接细胞毒性外,由此产生的代谢与氧化还原失衡促进损伤相关分子模式(DAMPs)的表面暴露和细胞外释放,从而增强免疫原性细胞死亡(ICD)。该过程促进树突状细胞成熟和抗原呈递,使免疫抑制性肿瘤微环境向免疫激活表型转变,并最终增强T细胞介导的抗肿瘤免疫。总体而言,这项工作确立了二硫死亡作为一种治疗上可干预的代谢脆弱性,并提出了一种将代谢干预与免疫激活相结合用于TNBC治疗的纳米治疗策略。
Redox biology IF 16.2 2026-10 PMID: 42617574
Nitric oxide (NO) is a pleiotropic free radical that functions as a master regulator of gene expression, and its sustained production within the tumor microenvironment reshapes the epitranscriptomic state of cancer cells. We previously demonstrated that NO inhibits the m6A mRNA demethylases FTO and ALKBH5 through dinitrosyliron complex formation while leaving the methyltransferase METTL3 intact, a demethylase-specific perturbation that increases global m6A on mRNA. Here, integrating m6A-RIP-seq and RNA-seq from triple-negative breast cancer cells, we show that chronic NO does not produce the uniform hypermethylation anticipated from demethylase inhibition. Instead, it redistributes m6A on mRNA, enriching the 5'UTR and coding sequence while depleting the 3'UTR and departing from the canonical stop-codon and 3'UTR topology. We found that the position of m6A, rather than its intensity or mere presence, shapes the outcome, in part by determining which reader protein is predicted to recognize it. In parallel, NO drives a canonical NF-κB and inflammatory transcriptional program. The transcriptional program is independent of the m6A methylome in both which genes respond and how strongly they respond, ruling out a linear methylome-to-transcriptome cascade; even so, m6A position remains associated with the direction of change among responding transcripts. The 3'UTR is the primary site of m6A loss and shows a suggestive computational link to miRNA-mediated regulation. Sense-antisense coordination reinforces the transcriptional response without bridging the two programs. These findings demonstrate that NO not only increases m6A abundance, but it also rewrites the m6A positional code, establishing spatial reprogramming of the epitranscriptome as a previously unrecognized mode of gene regulation.
中文摘要:一氧化氮(NO)是一种多效性自由基,作为基因表达的主调控因子发挥作用,其在肿瘤微环境中的持续产生会重塑癌细胞的表观转录组状态。我们此前证明,NO通过形成二亚硝基铁复合物抑制m6A mRNA去甲基化酶FTO和ALKBH5,同时不影响甲基转移酶METTL3,这是一种去甲基化酶特异性的扰动,会增加mRNA上的整体m6A。在这里,我们整合三阴性乳腺癌细胞的m6A-RIP-seq和RNA-seq,表明慢性NO并不会产生由去甲基化酶抑制所预期的均一性高甲基化。相反,它重新分布mRNA上的m6A,使5′UTR和编码序列富集,同时使3′UTR耗竭,并偏离经典的终止密码子和3′UTR拓扑结构。我们发现,m6A的位置而非其强度或仅仅是否存在,决定了下游结果,部分原因在于它决定了预测可识别该修饰的读取蛋白。与此同时,NO驱动经典的NF-κB和炎症转录程序。该转录程序在哪些基因响应以及响应强度方面均独立于m6A甲基化组,从而排除线性的甲基化组到转录组级联;即便如此,在响应转录本中,m6A位置仍与变化方向相关。3′UTR是m6A丢失的主要位点,并显示出与miRNA介导调控之间提示性的计算联系。正义-反义协调增强了转录反应,但没有桥接这两个程序。这些发现表明,NO不仅增加m6A丰度,还重写m6A位置密码,从而将表观转录组的空间重编程确立为一种此前未被认识到的基因调控模式。
Acta biomaterialia IF 10.4 2026-10 PMID: 42603579
Triple-negative breast cancer (TNBC) exhibits profound resistance to immunotherapy, largely due to a tumor microenvironment constrained by dysregulated lipid metabolism and persistent hypoxia. Excessive fatty acid uptake mediated by the scavenger receptor CD36 (Cluster of differentiation 36) imposes metabolic stress on immune cells while simultaneously fueling tumor growth, whereas hypoxia independently enforces immune exhaustion and macrophage immunosuppression. Despite extensive efforts, targeting either pathway alone has yielded limited therapeutic benefit, underscoring the need for coordinated immunometabolic intervention. Here, we report a living biohybrid strategy that simultaneously regulates lipid metabolism and oxygen availability to reprogram the TNBC microenvironment. By engineering photosynthetic Synechococcus cyanobacteria with surface-displayed anti-CD36 antibodies, we construct a dual-functional system (Syne@aCD36) capable of blocking CD36-mediated fatty acid uptake while generating oxygen in situ under light stimulation. This coordinated regulation alleviates lipid-induced metabolic stress and hypoxia-driven immune suppression, thereby restoring CD8⁺ T cell cytotoxicity, reversing exhaustion phenotypes, and promoting pro-inflammatory macrophage polarization. In an aggressive 4T1 TNBC model, Syne@aCD36 induces robust tumor growth inhibition, enhances immune infiltration, and exhibits minimal systemic toxicity. This work establishes a previously unexplored paradigm for immunometabolic therapy by integrating metabolic checkpoint blockade with photosynthetic oxygenation, providing a promising strategy for immunometabolic remodeling in lipid-rich and hypoxic tumor microenvironments. STATEMENT OF SIGNIFICANCE: We focus on the fact that excessive fatty acid uptake and tumor hypoxia cooperatively drive immunosuppression and T cell exhaustion in the tumor microenvironment. Our Syne@aCD36 platform possesses two innovations: 1. A dual-function living therapeutic system. Syne@aCD36 blocks CD36-mediated fatty acid uptake on tumor and immune cells while simultaneously generating oxygen through photosynthesis under light stimulation, thereby alleviating lipid metabolic stress and tumor hypoxia in situ. 2. Synergistic immunometabolic reprogramming. By concurrently regulating lipid metabolism and oxygen availability, Syne@aCD36 restores CD8⁺ T cell cytotoxicity, reduces exhaustion phenotypes, and promotes pro-inflammatory macrophage polarization, leading to enhanced immune infiltration and tumor growth suppression. Our study provides a strategy for tumor immunotherapy through integrated regulation of metabolic checkpoints and the tumor microenvironment.
中文摘要:三阴性乳腺癌(TNBC)对免疫治疗表现出显著耐药,这在很大程度上归因于由脂质代谢失调和持续缺氧所限制的肿瘤微环境。清道夫受体CD36(分化簇36)介导的过度脂肪酸摄取给免疫细胞带来代谢压力,同时为肿瘤生长提供燃料,而缺氧则独立地促使免疫耗竭和巨噬细胞免疫抑制。尽管已有大量努力,单独靶向其中任一通路所获得的治疗获益有限,这凸显了协调性免疫代谢干预的必要性。在此,我们报道一种活体生物杂交策略,可同时调节脂质代谢和氧可利用性,从而重编程TNBC微环境。通过构建表面展示抗CD36抗体的光合聚球藻蓝细菌,我们构建了一种双功能系统(Syne@aCD36),能够在光刺激下阻断CD36介导的脂肪酸摄取,同时原位产生氧气。这种协调调节减轻了脂质诱导的代谢压力和缺氧驱动的免疫抑制,从而恢复CD8⁺ T细胞细胞毒性,逆转耗竭表型,并促进促炎巨噬细胞极化。在侵袭性4T1 TNBC模型中,Syne@aCD36诱导强烈的肿瘤生长抑制,增强免疫浸润,并表现出极低的全身毒性。这项工作通过将代谢检查点阻断与光合氧合相结合,建立了一种此前未被探索的免疫代谢治疗范式,为富含脂质和缺氧肿瘤微环境中的免疫代谢重塑提供了一种有前景的策略。意义声明:我们关注过度脂肪酸摄取和肿瘤缺氧协同驱动肿瘤微环境中的免疫抑制和T细胞耗竭这一事实。我们的Syne@aCD36平台具有两项创新:1. 一种双功能活体治疗系统。Syne@aCD36阻断肿瘤细胞和免疫细胞上CD36介导的脂肪酸摄取,同时通过光刺激下的光合作用产生氧气,从而原位缓解脂质代谢压力和肿瘤缺氧。2. 协同性免疫代谢重编程。通过同时调节脂质代谢和氧可利用性,Syne@aCD36恢复CD8⁺ T细胞细胞毒性,减少耗竭表型,并促进促炎巨噬细胞极化,导致免疫浸润增强和肿瘤生长抑制。我们的研究通过整合调节代谢检查点和肿瘤微环境,为肿瘤免疫治疗提供了一种策略。
Redox biology IF 16.2 2026-10 PMID: 42585792
Considering cancer within the framework of systemic redox and metabolic regulation may enhance our understanding of disease progression. However, the relationship between cancer and the host redox-metabolic reprogramming within other tissues remains largely unexplored. Brown adipose tissue (BAT), as an important regulator of whole-body metabolic homeostasis, has been implicated in breast cancer progression. Here, we investigated the redox-metabolic profile of BAT and its reprogramming regulated by nuclear factor erythroid 2-related factor 2 (Nrf2) in mice undergoing breast tumour growth. To this end, we established an orthotopic model of breast cancer in wild-type and in mice lacking functional Nrf2 (Nrf2KO) to investigate the Nrf2-driven structural, metabolic, and redox reprogramming of BAT in response to breast tumour growth (10-400 mg). Our results showed that breast tumour growth induced an early adaptive BAT response, characterised by increased uncoupling protein 1 expression. Nevertheless, in response to advanced breast tumours, BAT showed pronounced downregulation of key glycolytic and pentose phosphate pathway protein expression, particularly in Nrf2KO mice. These changes were accompanied by whitening, attenuated UCP1, decreased fatty acid synthesis protein levels, and disrupted β-oxidation protein expression in BAT from Nrf2KO mice bearing larger breast tumours. Furthermore, breast tumour growth altered the protein expression of antioxidant enzymes in BAT, with Nrf2 critical for maintaining glutathione-dependent antioxidant defence. Collectively, these findings highlight an integrative role for Nrf2 in BAT redox-metabolic homeostasis in the context of breast tumour growth, positioning it as a promising therapeutic target and advancing the understanding of breast cancer as a systemic metabolic disease.
中文摘要:将癌症置于全身氧化还原和代谢调控框架内考虑,可能有助于加深我们对疾病进展的理解。然而,癌症与宿主其他组织中的氧化还原-代谢重编程之间的关系仍很大程度上尚未被探索。棕色脂肪组织(BAT)作为全身代谢稳态的重要调节者,已被认为与乳腺癌进展有关。在此,我们研究了在发生乳腺肿瘤生长的小鼠中,BAT的氧化还原-代谢特征及其受核因子E2相关因子2(Nrf2)调控的重编程。为此,我们在野生型小鼠和缺乏功能性Nrf2的小鼠(Nrf2KO)中建立了乳腺癌原位模型,以研究BAT响应乳腺肿瘤生长(10-400 mg)时由Nrf2驱动的结构、代谢和氧化还原重编程。我们的结果显示,乳腺肿瘤生长诱导了早期适应性BAT反应,其特征是解偶联蛋白1表达增加。然而,在晚期乳腺肿瘤反应中,BAT关键糖酵解和磷酸戊糖途径蛋白表达显著下调,尤其在Nrf2KO小鼠中。这些变化伴随Nrf2KO小鼠携带较大乳腺肿瘤时BAT出现白化、UCP1减弱、脂肪酸合成蛋白水平下降以及β-氧化蛋白表达紊乱。此外,乳腺肿瘤生长改变了BAT中抗氧化酶的蛋白表达,其中Nrf2对于维持谷胱甘肽依赖性抗氧化防御至关重要。总体而言,这些发现凸显了Nrf2在乳腺肿瘤生长背景下对BAT氧化还原-代谢稳态的整合作用,将其定位为有前景的治疗靶点,并推进了将乳腺癌理解为一种全身性代谢疾病的认识。
Cancer letters IF 11.8 2026-10-01 PMID: 42425192
Mechanical stress profoundly influences tumor-bone interaction. However, the underlying mechanism is largely elusive. Here, we reveal that mechanical loading activates osteocyte connexin 43 (Cx43) hemichannels (HCs) and promotes the release of soluble factors, thus establishing a tumor-suppressive bone microenvironment that limits the growth of metastatic breast cancer in bone. Conditioned media from fluid flow shear stress (FFSS)-stimulated osteocyte MLO-Y4 cells significantly inhibited tumor spheroid expansion and migration of both triple-negative and ER-positive breast cancer cells. This inhibitory effect was abolished by blockade of Cx43 HCs. FFSS-activated osteocytes also reduced filopodial extensions and epithelial-mesenchymal transition (EMT) marker expression in cancer cells. Mechanistically, FFSS stimulation induced Cx43 HC-mediated release of prostaglandin E2 (PGE2) and ATP, which exerted opposing effects: PGE2 promoted, while ATP suppressed, breast cancer cells. The relative ATP:PGE2 ratio served as a key determinant of the extent of tumor inhibition. In vivo tibial loading for two weeks prior to tumor inoculation further demonstrated the anti-metastatic function of Cx43 HCs. Mechanical loading suppressed breast cancer proliferation, growth, and osteolytic damage in wild-type (WT) and R76W transgenic mice (defective in gap junctions (GJs) but retaining HCs), but not in Δ130-136 mice (defective in both HCs and GJs). Consistently, Cx43(M1)-mediated HC blockade attenuated the tumor-suppressive effects of mechanical loading. ATP and PGE2 levels were elevated in loaded tibiae of WT and R76W, but not Δ130-136 mice. Collectively, these findings identify Cx43 HC activation by mechanical stress as a key mechanism driving the bone's transition from a metastasis-permissive to a metastasis-resistant microenvironment, mediated by ATP-dominant paracrine signaling from osteocytes that suppresses breast cancer progression.
中文摘要:机械应力深刻影响肿瘤与骨之间的相互作用。然而,其潜在机制在很大程度上仍不清楚。在此,我们发现机械负荷可激活骨细胞连接蛋白43(Cx43)半通道(HCs),并促进可溶性因子的释放,从而建立一种抑制肿瘤的骨微环境,限制转移性乳腺癌在骨内的生长。来自流体流动剪切应力(FFSS)刺激的骨细胞MLO-Y4细胞的条件培养基显著抑制了三阴性和ER阳性乳腺癌细胞的肿瘤球扩展和迁移。阻断Cx43 HCs后,这种抑制作用被消除。FFSS激活的骨细胞还减少了癌细胞中的丝状伪足延伸和上皮-间质转化(EMT)标志物表达。在机制上,FFSS刺激诱导Cx43 HC介导的前列腺素E2(PGE2)和ATP释放,二者发挥相反作用:PGE2促进乳腺癌细胞,而ATP抑制乳腺癌细胞。ATP与PGE2的相对比值是肿瘤抑制程度的关键决定因素。在肿瘤接种前进行两周的体内胫骨加载进一步证明了Cx43 HCs的抗转移功能。机械加载抑制了野生型(WT)和R76W转基因小鼠(缝隙连接(GJs)缺陷但仍保留HCs)中的乳腺癌增殖、生长和溶骨性损伤,但在Δ130-136小鼠(HCs和GJs均缺陷)中则不然。一致地,Cx43(M1)介导的HC阻断减弱了机械加载的肿瘤抑制作用。WT和R76W小鼠的加载胫骨中ATP和PGE2水平升高,而Δ130-136小鼠中则没有。总之,这些发现确定机械应力激活Cx43 HC是驱动骨从促转移微环境向抗转移微环境转变的关键机制,其由骨细胞以ATP为主的旁分泌信号介导,从而抑制乳腺癌进展。
Cancer letters IF 11.8 2026-10-01 PMID: 42323004
Teneurin-4 (TENM4) has been reported as deregulated in a range of cancer histotypes; however, its functional contribution to tumour biology remains incompletely defined. Elevated TENM4 expression has been described in several malignancies, including breast, lung, colon, gastric, and pancreatic cancers, as well as in primary brain tumours, even if much of the available evidence remains correlative and predominantly based on in silico analyses. Emerging evidence, predominantly from triple negative breast cancer (TNBC) models, suggests a potential association between TENM4 expression and tumour cell plasticity, migratory behaviour, and stem-like properties, in part through focal adhesion kinase-associated signalling. Indeed, genetic silencing of TENM4 has been shown to reduce tumour spheroid formation and cell motility in murine and human in vitro TNBC models. In this review, we examine current knowledge of TENM4 expression patterns, structural characteristics, and reported molecular interactions in both physiological and pathological contexts. We review available interactome data, highlighting methodological constraints and variability between datasets, and discuss how proposed TENM4-associated networks may intersect with pathways regulating cytoskeletal dynamics, cell adhesion, and transcriptional programmes within the tumour microenvironment. We further outline key gaps in the field, including the need for more comprehensive in vivo validation and high-resolution interactomic approaches. The overview provided by this review highlights TENM4 as a relatively understudied molecule whose potential relevance in tumour cell plasticity and cancer progression requires further mechanistic and translational validation.
中文摘要:Teneurin-4(TENM4)已被报道在一系列癌症组织型中失调,但其对肿瘤生物学的功能贡献仍不完全清楚。已报道TENM4表达升高见于多种恶性肿瘤,包括乳腺癌、肺癌、结肠癌、胃癌和胰腺癌,以及原发性脑肿瘤,尽管现有证据大多为相关性证据,且主要基于计算机模拟分析。新出现的证据主要来自三阴性乳腺癌(TNBC)模型,提示TENM4表达与肿瘤细胞可塑性、迁移行为和干细胞样特性之间可能存在关联,部分通过黏着斑激酶相关信号传导。实际上,在鼠源和人源体外TNBC模型中,已显示对TENM4进行基因沉默可减少肿瘤球形成和细胞运动。在本综述中,我们审视了目前关于TENM4在生理和病理背景下的表达模式、结构特征以及已报道的分子相互作用的知识。我们回顾了可用的相互作用组数据,强调了方法学限制和数据集之间的变异性,并讨论了所提出的TENM4相关网络可能如何与调节细胞骨架动力学、细胞黏附和肿瘤微环境中转录程序的通路相交。我们进一步概述了该领域的关键空白,包括需要进行更全面的体内验证和高分辨率相互作用组学方法。本综述提供的概述强调TENM4是一个相对研究不足的分子,其在肿瘤细胞可塑性和癌症进展中的潜在相关性需要进一步的机制和转化验证。
Biomaterials IF 13.6 2026-10 PMID: 41934823
Triple-negative breast cancer (TNBC) poses significant therapeutic challenges due to its aggressive phenotype, high metastatic potential, and lack of targeted treatment options. Herein, we report zinc-doped ferrite magnetic nanoparticles (Zn0.2Fe2.8O4 MNPs) as a single-component theranostic platform for magnetic resonance (MRI)/photoacoustic (PAI) dual-mode imaging-guided synergistic therapy that enhances TNBC treatment and suppression metastasis. Through optimization of Zn2+ doping content, the NPs exhibit superior magnetic and optical properties, allowing high-performance T2-weighted MRI and high-resolution PAI under 808 nm laser irradiation, thereby facilitating detailed visualization of tumor vasculature. The same platform enables highly effective photothermal therapy (PTT) under 1064 nm laser excitation, leveraging deep-tissue penetration and a higher maximum permissible exposure. Moreover, the NPs generate localized magneto-mechanical forces (MMF) that disrupted cytoskeletal integrity, and notably suppressed metastatic progression by reversing epithelial-mesenchymal transition (EMT). In vivo studies demonstrate complete tumor eradication and significant inhibition of lung metastasis in TNBC models. This work presents a simple yet powerful strategy that integrates multimodal imaging with synergistic therapeutic functions within a single agent, offering a clinically translatable approach for combating TNBC and its metastatic recurrence.
中文摘要:三阴性乳腺癌(TNBC)由于其侵袭性表型、高转移潜能以及缺乏靶向治疗选择,带来了显著的治疗挑战。在此,我们报道了锌掺杂铁氧体磁性纳米颗粒(Zn0.2Fe2.8O4 MNPs)作为一种单组分诊疗一体化平台,用于磁共振(MRI)/光声(PAI)双模态成像引导的协同治疗,从而增强TNBC治疗效果并抑制转移。通过优化Zn2+掺杂含量,该纳米颗粒表现出优异的磁学和光学性能,可在808 nm激光照射下实现高性能T2加权MRI和高分辨率PAI,从而有助于详细可视化肿瘤血管。同一平台在1064 nm激光激发下可实现高效光热治疗(PTT),利用其深层组织穿透能力和更高的最大允许暴露量。此外,该纳米颗粒产生局部磁机械力(MMF),破坏细胞骨架完整性,并通过逆转上皮-间质转化(EMT)显著抑制转移进展。体内研究证明,在TNBC模型中可实现肿瘤完全消除并显著抑制肺转移。这项工作提出了一种简单而有力的策略,将多模态成像与协同治疗功能整合于单一制剂中,为对抗TNBC及其转移复发提供了一种具有临床转化前景的方法。
Acta pharmacologica Sinica IF 10.4 2026-10 PMID: 41876745
Circadian genes are closely associated with tumor development and its sensitivity to chemotherapeutic agents. In triple-negative breast cancer (TNBC), the core circadian gene BMAL1 exhibits an aberrant expression pattern, but its mechanism of influencing TNBC chemosensitivity remains unknown. In this study, we demonstrate that BMAL1 acts as an oncogene in TNBC. Using BMAL1 siRNA-loaded lipid nanoparticles (LNPs), we effectively silenced BMAL1 expression both in vitro and in vivo, resulting in enhanced apoptosis and reduced proliferation of TNBC cells. Notably, BMAL1 suppression following chemotherapy-induced DNA damage impairs the RPA-ATR-CHK1 DNA repair axis, leading to S-phase arrest and accumulation of unrepaired DNA damage. This synergistically increases the sensitivity of TNBC cells to etoposide. Our findings reveal BMAL1 as a promising therapeutic target and support the potential of silencing BMAL1 with siRNA as a neoadjuvant strategy in combination with chemotherapeutic agents for the treatment of TNBC.
中文摘要:昼夜节律基因与肿瘤发展及其对化疗药物的敏感性密切相关。在三阴性乳腺癌(TNBC)中,核心昼夜节律基因BMAL1表现出异常表达模式,但其影响TNBC化疗敏感性的机制仍不清楚。在本研究中,我们证明BMAL1在TNBC中作为癌基因发挥作用。使用负载BMAL1 siRNA的脂质纳米颗粒(LNPs),我们在体外和体内有效沉默了BMAL1表达,导致TNBC细胞凋亡增强、增殖减少。值得注意的是,化疗诱导DNA损伤后抑制BMAL1会损害RPA-ATR-CHK1 DNA修复轴,导致S期阻滞和未修复DNA损伤的积累。这协同增加了TNBC细胞对依托泊苷的敏感性。我们的发现揭示BMAL1是一个有前景的治疗靶点,并支持使用siRNA沉默BMAL1作为新辅助策略,与化疗药物联合用于TNBC治疗的可能性。

7神经系统肿瘤 (17篇)

临床研究 (5篇)

Neuro-oncology IF 13.1 2026-10-08 PMID: 42844996
Glioblastoma (GBM), the most common and lethal primary brain cancer, has a median survival of 15 months. Despite repeated efforts over 20 years to introduce life-extending therapies, little has changed in the standard of care. Recent studies have revealed that GBM cells express daily rhythms in gene expression and sensitivity to chemotherapy. In this review, we highlight the role of circadian biology in GBM growth, and its potential applications to GBM diagnosis and treatment. The hallmarks of cancer often show daily variation. We emphasize opportunities to advance our understanding of glioblastoma pathophysiology by considering how brain tumors integrate into the host circadian system and respond to daily rhythms in neuronal, paracrine, or hormonal signals to promote growth. Circadian treatment strategies include disrupting daily rhythms in GBM cells, blocking their synchronization to the host, or finding best times of day for biopsy, surgery, radiation, or chemotherapy. We discuss an ongoing temozolomide chronotherapy trial in the context of recent evidence against chronotherapy and suggest ways to critically assess time-of-day effects in GBM. With over 500 active clinical trials for GBM, it is time to evaluate, and control for, circadian rhythms in care for brain cancer patients.
中文摘要:胶质母细胞瘤(GBM)是最常见且最致命的原发性脑癌,中位生存期为15个月。尽管过去20年反复努力引入延长生命的疗法,标准治疗几乎没有变化。近期研究显示,GBM细胞在基因表达和对化疗的敏感性方面表现出每日节律。在这篇综述中,我们强调昼夜节律生物学在GBM生长中的作用,及其在GBM诊断和治疗中的潜在应用。癌症的标志性特征常表现出每日变化。我们强调通过考虑脑肿瘤如何整合到宿主昼夜节律系统,并对神经元、旁分泌或激素信号的每日节律作出反应以促进生长,从而推进我们对胶质母细胞瘤病理生理学理解的机会。昼夜节律治疗策略包括破坏GBM细胞的每日节律、阻断其与宿主的同步,或寻找活检、手术、放疗或化疗的最佳时间。我们结合近期反对时辰治疗的证据,讨论一项正在进行的替莫唑胺时辰治疗试验,并提出批判性评估GBM中时间效应的方法。鉴于GBM有超过500项正在进行的临床试验,现在是评估并控制脑癌患者照护中昼夜节律的时候了。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42820777
It is unclear whether glioma subtypes differ in health-related quality of life (HRQoL) over time. We analyzed data from the CODAGLIO 2.0 database, comprising 16 randomized controlled trials with HRQoL assessed using the EORTC QLQ-C30 and QLQ-BN20 questionnaires. Differences in mean HRQoL at baseline (before postoperative treatments) and 3 months were compared across glioma subtypes. Linear mixed models (LMMs) were used to identify factors independently associated with HRQoL, and anchor-based minimally important differences determined clinical relevance. A total of 4,301 patients had baseline HRQoL data; 75% completed follow-up. In stratified analyses, at 3 months, physical, social, role, and cognitive functioning were statistically and clinically significantly worse in glioblastoma than in astrocytoma or oligodendroglioma. In adjusted LMMs, compared with glioblastoma, patients with astrocytoma had worse physical (-2.78, 95% CI -4.68 to -1.01) and cognitive functioning (-3.63, -6.18 to -1.05), more pain (2.74, 0.41-4.95), communication deficits (5.03, 2.44-7.66), and seizures (4.49, 2.55-6.72). Patients with oligodendroglioma had worse social functioning (-5.39, -10.57 to -0.11), communication deficits (7.40, 1.63-12.81), and seizures (8.61, 4.17-14.26). None of these differences exceeded clinical relevance thresholds. Performance status was the only variable associated with clinically meaningful HRQoL changes across most scales. At 3 months, patients with glioblastoma show clinically worse HRQoL than IDH-mutant glioma patients in unadjusted analyses. However, after adjusting for clinical variables, glioblastoma patients exhibit statistically but not clinically better HRQoL in several domains. Performance status emerges as the key factor independently associated with HRQoL and should play a central role in clinical decision-making.
中文摘要:目前尚不清楚胶质瘤亚型在健康相关生活质量(HRQoL)随时间变化方面是否存在差异。我们分析了CODAGLIO 2.0数据库的数据,该数据库包含16项随机对照试验,其HRQoL采用EORTC QLQ-C30和QLQ-BN20问卷评估。比较了不同胶质瘤亚型在基线(术后治疗前)和3个月时的平均HRQoL差异。采用线性混合模型(LMM)识别与HRQoL独立相关的因素,并通过基于锚点的最小重要差异确定临床相关性。共有4,301例患者具有基线HRQoL数据;75%完成了随访。在分层分析中,3个月时,胶质母细胞瘤患者的躯体、社会、角色和认知功能在统计学和临床上均显著差于星形细胞瘤或少突胶质细胞瘤。在校正后的LMM中,与胶质母细胞瘤相比,星形细胞瘤患者的躯体功能(-2.78,95% CI -4.68至-1.01)和认知功能(-3.63,-6.18至-1.05)更差,疼痛(2.74,0.41-4.95)、交流缺陷(5.03,2.44-7.66)和癫痫发作(4.49,2.55-6.72)更多。少突胶质细胞瘤患者的社会功能(-5.39,-10.57至-0.11)、交流缺陷(7.40,1.63-12.81)和癫痫发作(8.61,4.17-14.26)更差。这些差异均未超过临床相关性阈值。体能状态是唯一在大多数量表上与具有临床意义的HRQoL变化相关的变量。在3个月时,未经校正分析显示胶质母细胞瘤患者的HRQoL在临床上差于IDH突变型胶质瘤患者。然而,在校正临床变量后,胶质母细胞瘤患者在若干领域表现出统计学上更好但并非临床上更好的HRQoL。体能状态是独立与HRQoL相关的关键因素,应在临床决策中发挥核心作用。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42377256
In brain tumors, the immunosuppressive microenvironment leads to tumor aggressiveness and immunotherapy resistance. To identify factors that regulate the glioma-immune landscape, we took advantage of the disease trajectory of the MAPK-driven glioma, pleomorphic xanthoastrocytoma (PXA), which evolves from an immune-rich low-grade tumor to an aggressive glioma. Using a multiomics approach that included single-nucleus RNA sequencing, spatial transcriptomics, and spatial proteomics, a cohort of 38 tumors, including 10 longitudinal pairs, was profiled. Tumor progression was associated with transition to a more proliferative progenitor state and increased hypoxia. Hypoxic reprogramming of the immune landscape included increased TGF-β signaling and altered chemokine signaling, including decreased CXC-chemokine ligand 14 (CXCL14) and CXCL16-CXCR6 signaling important in immune cell recruitment and activation. The resulting immune landscape was spatially reorganized with reduced HLA class II expression, reduced CD8+ and CD4+ T cells, and dominated by immunosuppressive myeloid cells. Hypoxia and chemokine signaling emerged as key components of the glioma-immune landscape that evolve with tumor progression. These findings identify potential therapeutic opportunities in PXA, and they argue that optimal immunomodulatory strategies in glioma will differ along the disease trajectory.
中文摘要:在脑肿瘤中,免疫抑制性微环境导致肿瘤侵袭性增强和免疫治疗耐药。为识别调控胶质瘤-免疫格局的因素,我们利用MAPK驱动的胶质瘤——多形性黄色星形细胞瘤(PXA)的疾病轨迹,该肿瘤从免疫丰富的低级别肿瘤演变为侵袭性胶质瘤。我们采用多组学方法,包括单核RNA测序、空间转录组学和空间蛋白质组学,对38个肿瘤样本(包括10对纵向配对样本)进行了分析。肿瘤进展与向更具增殖性的祖细胞状态转变以及缺氧增加相关。免疫格局的缺氧重编程包括TGF-β信号增强和趋化因子信号改变,其中包括在免疫细胞募集和激活中重要的CXC趋化因子配体14(CXCL14)以及CXCL16-CXCR6信号降低。由此形成的免疫格局发生空间重组织,表现为HLA II类表达降低、CD8+和CD4+ T细胞减少,并以免疫抑制性髓系细胞为主。缺氧和趋化因子信号成为随肿瘤进展而演变的胶质瘤-免疫格局的关键组成部分。这些发现为PXA提供了潜在治疗机会,并表明胶质瘤的最佳免疫调节策略将随疾病轨迹而不同。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42320046
Glioblastoma (GB) is the most aggressive primary brain tumor in adults. Tumor-associated epilepsy (TAE) at diagnosis is common, yet its prognostic significance remains unclear. We analyzed a retrospective multicenter test cohort of 855 GB patients (Aachen, Hamburg, Bielefeld) and validated findings in a prospectively collected cohort of 344 patients (Erlangen). Survival was assessed using multivariable Cox regression, propensity score matching, and interaction modeling of TAE and extent of resection (EOR). Molecular profiling included methylation-based classification, epigenetic deconvolution, and spatial transcriptomics. Tumor-associated epilepsy was independently associated with improved survival (hazard ratio [HR] 0.81, 95% CI 0.69-0.99, P = .036, absolute survival advantage ∼4-5 months). This effect was validated in the independent cohort (C-index 0.68, 95% CI 0.62-0.74) and persisted in propensity-matched analyses (HR 0.74, 95% CI 0.56-0.96, P = .027). Interaction modeling revealed that gross total resection (GTR) improved survival in both groups but particularly in patients with TAE (EOR interaction HR 0.69, 95% CI 0.49-0.99, P = .041). In this subgroup, partial resection provided no significant advantage over biopsy, whereas patients without seizures benefited incrementally from both partial resection and GTR. Molecular analysis demonstrated enrichment of the RTK II subtype, differentiated cell states, and an inflammatory microenvironment in GB with TAE; tumors without seizures displayed neuronal and stem-like features. Functional validation using electrogenomics showed that GB cortical slices with increased inflammatory score exhibited synchronization of action potentials characteristic for seizure-like epileptiform activity. Tumor-associated epilepsy at diagnosis is a favorable prognostic marker in GB, defining a biologically distinct subgroup. Seizure status modifies the prognostic effect of surgical resection, underscoring the importance of GTR particularly in patients presenting with TAE.
中文摘要:胶质母细胞瘤(GB)是成人中最具侵袭性的原发性脑肿瘤。诊断时出现的肿瘤相关性癫痫(TAE)较为常见,但其预后意义仍不明确。我们分析了一个回顾性多中心测试队列,共纳入855例GB患者(亚琛、汉堡、比勒费尔德),并在一个前瞻性收集的344例患者队列(埃尔朗根)中验证了相关发现。生存分析采用多变量Cox回归、倾向性评分匹配以及TAE与切除范围(EOR)的交互作用建模。分子分析包括基于甲基化谱的分类、表观遗传解卷积和空间转录组学。肿瘤相关性癫痫与生存改善独立相关(风险比[HR] 0.81,95%CI 0.69-0.99,P=.036,绝对生存获益约4-5个月)。这一效应在独立队列中得到验证(C指数0.68,95%CI 0.62-0.74),并在倾向性匹配分析中持续存在(HR 0.74,95%CI 0.56-0.96,P=.027)。交互作用建模显示,全切除(GTR)可改善两组患者的生存,但在TAE患者中尤为明显(EOR交互作用HR 0.69,95%CI 0.49-0.99,P=.041)。在该亚组中,部分切除相较活检未提供显著优势,而无癫痫发作的患者则从部分切除和GTR中获得递增获益。分子分析表明,伴有TAE的GB富集RTK II亚型、分化细胞状态和炎症微环境;无癫痫发作的肿瘤则表现出神经元和干性样特征。使用电基因组学进行的功能验证显示,炎症评分升高的GB皮质切片表现出动作电位同步化,呈现癫痫样放电活动特征。诊断时的肿瘤相关性癫痫是GB的有利预后标志物,定义了一个生物学上独特的亚组。癫痫发作状态会改变手术切除的预后效应,尤其强调了对出现TAE的患者进行GTR的重要性。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42261252
Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma, supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.
中文摘要:致癌性BRAF改变发生于各WHO级别的部分弥漫性胶质瘤中,并且通过现代分子诊断被越来越多地识别。除了标准胶质瘤治疗外,BRAF改变胶质瘤患者还可接受靶向治疗,其证据强度不一,涵盖随机试验、单臂研究和真实世界证据。这篇由神经肿瘤学会(SNO)与欧洲神经肿瘤学会(EANO)联合发布的共识综述,综合了关于不同年龄组、肿瘤级别和治疗线数下BRAF改变胶质瘤诊断与管理的当前知识。特别强调在高质量试验证据仍有限的临床情境中形成专家共识。该综述涉及BRAF改变检测的依据、靶向治疗的选择与监测、治疗相关毒性的管理、耐药应对策略以及未来研究的优先事项。其旨在为临床医生提供实用、循证的指导,同时指出需要前瞻性研究填补的空白。

基础研究 (12篇)

Nature chemical biology IF 15.8 2026-10-06 PMID: 42839082
Histone lysine demethylase 4 (KDM4) enzymes are frequently overexpressed in cancer and are considered to be promising therapeutic targets. QC6352, which is widely used as a best-in-class KDM4 chemical probe, shows potent antitumor activity across cancer models. Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition. Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity. Uridine supplementation and expression of an inhibitor-resistant DHODH mutant fully abrogate growth inhibition, whereas the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352. These findings establish QC6352 and zavondemstat as dual KDM4-DHODH inhibitors and identify DHODH inhibition as the dominant driver of their antiglioblastoma efficacy, as well as demonstrating the need for orthogonal chemical probes to accurately define drug mechanisms in cells.
中文摘要:组蛋白赖氨酸去甲基化酶4(KDM4)酶在癌症中常过表达,被认为是颇有前景的治疗靶点。QC6352作为一种被广泛用作同类最佳KDM4化学探针的化合物,在多种癌症模型中显示出强效抗肿瘤活性。我们在胶质母细胞瘤模型中采用综合性化学生物学方法,证明QC6352及其临床类似物zavondemstat的疗效并不依赖于KDM4抑制。相反,我们鉴定出二氢乳清酸脱氢酶(DHODH)——从头嘧啶生物合成中的关键酶——是驱动其抗增殖活性的功能性靶点。补充尿苷以及表达对抑制剂耐药的DHODH突变体可完全消除生长抑制,而缺乏DHODH抑制作用的正交KDM4抑制剂ML324则不能重现QC6352的表型。这些发现确立QC6352和zavondemstat为双重KDM4-DHODH抑制剂,并表明DHODH抑制是其抗胶质母细胞瘤疗效的主要驱动因素,同时证明需要正交化学探针来准确界定细胞中的药物机制。
IEEE transactions on medical imaging IF 12.4 2026-10-06 PMID: 42837229
Quantitative imaging methods, such as magnetic resonance fingerprinting (MRF), aim to extract interpretable pathology biomarkers by estimating biophysical tissue parameters from signal evolutions. However, the pattern-matching algorithms or neural networks used in such inverse problems often lack principled uncertainty quantification, which limits the trustworthiness and transparency, required for clinical acceptance. Here, we describe a physics-structured variational autoencoder (PS-VAE) designed for rapid extraction of voxelwise multi-parameter posterior distributions. Our approach integrates a differentiable spin physics simulator with self-supervised learning, and provides a full covariance that captures the inter-parameter correlations in the latent biophysical space. The method was validated in a multi-proton pool chemical exchange saturation transfer (CEST) and semisolid magnetization transfer (MT) molecular MRF study, across in-vitro phantoms, tumor-bearing mice, healthy human volunteers, and subjects with glioblastoma and Alzheimer's Disease. The resulting multi-parametric posteriors are in good agreement with those calculated using a brute-force Bayesian analysis, while providing an orders-of-magnitude acceleration in whole brain quantification. In addition, we demonstrate how monitoring the multi-parameter posterior dynamics across progressively acquired signals provides practical insights for protocol optimization and may facilitate real-time adaptive acquisition. The code and sample data are available at https://github.com/momentum-laboratory/ps-vae.
中文摘要:定量成像方法,如磁共振指纹(MRF),旨在通过从信号演化中估计生物物理组织参数来提取可解释的病理学生物标志物。然而,此类逆问题中使用的模式匹配算法或神经网络通常缺乏有原则的不确定性量化,这限制了临床接受所需的可信度和透明度。在此,我们描述了一种物理结构化变分自编码器(PS-VAE),旨在快速提取体素级多参数后验分布。我们的方法将可微分自旋物理模拟器与自监督学习相结合,并提供了能够捕捉潜在生物物理空间中参数间相关性的完整协方差。该方法在多质子池化学交换饱和转移(CEST)和半固体磁化转移(MT)分子MRF研究中得到了验证,涵盖体外体模、荷瘤小鼠、健康人类志愿者以及胶质母细胞瘤和阿尔茨海默病患者。由此得到的多参数后验分布与使用穷举式贝叶斯分析计算的结果高度一致,同时在全脑定量中提供了数量级的加速。此外,我们展示了如何通过监测逐步采集信号过程中的多参数后验动态,为协议优化提供实用见解,并可能促进实时自适应采集。代码和示例数据可在 https://github.com/momentum-laboratory/ps-vae 获取。
Cancer research IF 22.6 2026-10-05 PMID: 42831833
Glioblastoma (GBM) is a lethal, treatment-resistant brain cancer characterized by diffuse brain invasion, complex neuron-glioma signaling, and cellular, molecular, and spatial heterogeneity. Surgery is the current mainstay of treatment, aimed at maximizing tumor cytoreduction, decompressing the brain to improve neurological function, and providing material for analyses to inform prognostication and adjuvant treatment selection. To accurately model GBM surgical resection and tissue sampling in preclinical animal models, we developed the Maximal Safe Intracranial Surgery (MSIS) system. MSIS integrated a miniaturized neurosurgical resection device and enabled a safe, tunable, and reproducible approach for intracranial tumor resection, multi-regional biopsy, and longitudinal tissue sampling in murine models, with stereotactic, sterile, and high-viability tissue collection. MSIS was applied across five distinct orthotopic brain tumor models to reproducibly generate histologically and radiologically representative models of post-surgical GBM. Similar to humans, increasing the extent of resection correlated with improved animal survival, and recurrent growth patterns varied significantly by model type. Transcriptional profiles of matched primary vs. post-surgical recurrent tumors revealed enrichment of margin-associated transcriptional states consistent with neuron-glioma signaling. Overall, the MSIS system offers opportunities to model the standard-of-care, dissect the spatial and temporal dynamics of GBM, and pair therapeutic discovery with contextual tumor pathobiology.
中文摘要:胶质母细胞瘤(GBM)是一种致死性、治疗抵抗的脑癌,其特征是弥漫性脑浸润、复杂的神经元-胶质瘤信号传导以及细胞、分子和空间异质性。手术是当前的主要治疗手段,旨在最大化肿瘤减灭、为大脑减压以改善神经功能,并提供组织材料用于分析,以指导预后判断和辅助治疗选择。为了在临床前动物模型中准确模拟GBM手术切除和组织取样,我们开发了最大安全颅内手术(MSIS)系统。MSIS整合了一个微型神经外科切除装置,能够在鼠模型中实现安全、可调、可重复的颅内肿瘤切除、多区域活检和纵向组织取样,并进行立体定位、无菌和高活力组织采集。MSIS应用于五种不同的原位脑肿瘤模型,可重复地生成具有组织学和影像学代表性的术后GBM模型。与人类相似,增加切除范围与动物生存改善相关,复发生长模式因模型类型不同而显著变化。配对原发肿瘤与术后复发肿瘤的转录谱显示,与边缘相关的转录状态富集,并与神经元-胶质瘤信号传导一致。总体而言,MSIS系统为模拟标准治疗、剖析GBM的空间和时间动态,并将治疗发现与情境性肿瘤病理生物学相结合提供了机会。
Molecular cell IF 16.0 2026-10-01 PMID: 42822414
Glioma cells experience profound metabolic stress in hypoxic tumor regions, where mitochondrial respiration is constrained and redox balance becomes difficult to maintain. A recent study by Vettore and colleagues1 in Molecular Cell identifies nicotinamide nucleotide transhydrogenase as a key mitochondrial enzyme that connects NADH oxidation to NADPH production, thereby supporting proline synthesis and growth under hypoxia. This work highlights how distinct redox pools are coordinated in cancer cells and suggests that NNT-dependent metabolism may represent a vulnerability in hypoxic tumors.
中文摘要:胶质瘤细胞在缺氧肿瘤区域经历严重的代谢应激,此时线粒体呼吸受限,氧化还原平衡难以维持。Vettore及其同事在《Molecular Cell》上的一项近期研究鉴定出烟酰胺核苷酸转氢酶是一个关键线粒体酶,它将NADH氧化与NADPH生成连接起来,从而支持缺氧下的脯氨酸合成和生长。这项工作强调了癌细胞中不同氧化还原池是如何协调的,并提示依赖NNT的代谢可能代表缺氧肿瘤的一个脆弱点。
Cancer discovery IF 29.5 2026-10-01 PMID: 42820945
The surgical margin is the primary site of glioblastoma recurrence, yet its molecular features remain poorly characterized. We performed histology-guided sampling and single-cell spatial transcriptomics of surgical margin and adjacent recurrent tumor regions, with matched primary tumors from 40 patients. The surgical margin constituted a distinct wound-healing microenvironment in the post-treatment setting. We also identified malignant states with pronounced mesenchymal transcriptomic and histological features that were enriched at the surgical margin and defined a "stromal" subtype. Patients who transitioned to this subtype at recurrence were characterized by early TP53 mutation, sustained proliferation during adjuvant temozolomide treatment, and shorter survival. Conversely, patients with TP53-wild-type tumors recurring during temozolomide treatment transitioned toward the mesenchymal subtype, with increased p53 pathway activity and reduced proliferation. Functional validation showed TP53 loss-of-function increased temozolomide resistance in a patient-derived glioblastoma model. Our findings identify distinct glioblastoma recurrence trajectories linked to genomic context, treatment exposure, and clinical outcomes.
中文摘要:手术切缘是胶质母细胞瘤复发的主要部位,但其分子特征仍未被充分阐明。我们对40例患者的手术切缘和相邻复发肿瘤区域进行了组织学引导的采样和单细胞空间转录组学分析,并纳入匹配的原发肿瘤。在治疗后背景下,手术切缘构成了一个独特的伤口愈合微环境。我们还识别出具有显著间质性转录组和组织学特征的恶性状态,这些状态在手术切缘处富集,并定义为「基质型」亚型。复发时转变为该亚型的患者以早期TP53突变、辅助替莫唑胺治疗期间持续增殖和较短生存期为特征。相反,TP53野生型肿瘤在替莫唑胺治疗期间复发的患者向间质性亚型转变,伴有p53通路活性增加和增殖减少。功能验证显示,在患者来源的胶质母细胞瘤模型中,TP53功能缺失增加了替莫唑胺耐药性。我们的研究结果确定了与基因组背景、治疗暴露和临床结局相关的不同胶质母细胞瘤复发轨迹。
Trends in pharmacological sciences IF 24.0 2026-10 PMID: 42697770
Tumor-intrinsic voltage-gated Cav3 calcium channels, comprising the Cav3.1, Cav3.2 and Cav3.3 isoforms, have been implicated in cancer cell proliferation and survival. Recent work by Dube et al. reveals a role for microenvironmental Cav3.2 channels in glioblastoma, promoting neuron-cancer cell crosstalk and identifying changes in immune-related programs associated with Cav3.2 deficiency.
中文摘要:肿瘤内在的电压门控Cav3钙通道,包括Cav3.1、Cav3.2和Cav3.3亚型,已被认为与癌细胞增殖和存活有关。Dube等人最近的工作揭示了微环境中的Cav3.2通道在胶质母细胞瘤中的作用,促进神经元与癌细胞的串扰,并识别出与Cav3.2缺陷相关的免疫相关程序变化。
Cellular & molecular immunology IF 23.9 2026-10 PMID: 42595853
The immunosuppressive microenvironment is a hallmark of glioblastoma (GBM), limiting the efficacy of contemporary immunotherapies. While the central nervous system (CNS) relies on specialized cytokine networks to maintain immune homeostasis under physiological conditions, how these homeostatic signals are subverted during gliomagenesis remains poorly understood. Here, we report that interleukin-17D (IL-17D) is a CNS-intrinsic tumor suppressor whose expression is downregulated during gliomagenesis. Restoring IL-17D substantially extends survival in orthotopic GBM models by selectively reprogramming the myeloid compartment. Mechanistically, IL-17D engages its receptor CD93 to assemble a novel costimulatory receptor complex with SCARB1 in a lipid raft-dependent manner. This structural assembly engages Fyn/BCAP to trigger PI3K/AKT/NF-κB signaling, effectively inverting the function of SCARB1 from tolerogenic efferocytosis to active antigen presentation. Our study demonstrated that the restoration of IL-17D expression reshaped the GBM immune landscape, highlighting its potential as a therapeutic target to enhance the efficacy of immunotherapy.
中文摘要:免疫抑制性微环境是胶质母细胞瘤(GBM)的标志性特征,限制了当代免疫治疗的疗效。虽然中枢神经系统(CNS)在生理条件下依赖特化的细胞因子网络维持免疫稳态,但这些稳态信号在胶质瘤发生过程中如何被颠覆仍知之甚少。在此,我们报道白细胞介素-17D(IL-17D)是一种CNS内源性肿瘤抑制因子,其表达在胶质瘤发生过程中下调。恢复IL-17D可通过选择性重编程髓系细胞区室,在原位GBM模型中显著延长生存期。机制上,IL-17D与其受体CD93结合,以脂筏依赖的方式与SCARB1组装成一种新型共刺激受体复合物。该结构组装招募Fyn/BCAP,触发PI3K/AKT/NF-κB信号通路,从而有效地将SCARB1的功能从耐受性胞葬作用逆转为主动抗原呈递。我们的研究表明,恢复IL-17D表达重塑了GBM免疫格局,突显其作为治疗靶点以增强免疫治疗疗效的潜力。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42434963
Glioblastoma is the most aggressive primary brain tumor, with a poor prognosis and limited treatment options. Natural killer (NK) cell therapy is a promising immunotherapeutic strategy; yet, its efficacy remains limited. We evaluated FT538, a clinical-grade NK product derived from induced pluripotent stem cells (iPSCs), in glioblastoma models. FT538, engineered with a high-affinity noncleavable CD16 Fc receptor, a membrane-bound IL-15/IL-15Rα fusion protein, and CD38 knockout, was tested against 13 patient-derived glioblastoma stem-like cells (GSCs) in vitro and in orthotopic xenograft models. Intracranial persistence and neurotoxicity were assessed in mice. Surface proteomics identified therapeutic targets, and a B7-H3-targeted tri-specific killer engager (TriKE) was evaluated with FT538 and NKG2C+ adaptive NK cells. Glioblastoma stem-like cells were classified as sensitive (38%), moderately sensitive (38%), or resistant (23%) to FT538. Intracranial administration in mice was well tolerated, persisted for at least 35 days, and caused no neurotoxicity. A single intratumoral dose induced complete regression in sensitive xenografts. Surface profiling identified B7-H3 as a target to overcome resistance. Combination therapy with FT538 and a B7-H3 TriKE enhanced antitumor efficacy in resistant models, an effect also observed with adaptive NK cells. FT538 exhibits potent tumoricidal activity in 77% of GSC lines (NK-sensitive and moderately sensitive), with curative potential in sensitive models, and demonstrates favorable persistence and tolerability in vivo. B7-H3-targeted TriKE restores NK sensitivity in resistant tumors. These findings provide a strong preclinical rationale for further clinical evaluation of FT538, alone or combined with B7-H3-targeted TriKE, for glioblastoma and other solid tumors.
中文摘要:胶质母细胞瘤是侵袭性最强的原发性脑肿瘤,预后差且治疗选择有限。自然杀伤(NK)细胞治疗是一种有前景的免疫治疗策略,但其疗效仍然有限。我们在胶质母细胞瘤模型中评估了FT538,这是一种来源于诱导多能干细胞(iPSC)的临床级NK产品。FT538经过工程化改造,具有高亲和力不可切割的CD16 Fc受体、膜结合型IL-15/IL-15Rα融合蛋白以及CD38敲除,并在体外针对13例患者来源的胶质母细胞瘤干样细胞(GSC)以及原位异种移植模型中进行了测试。我们在小鼠中评估了其颅内持续存在时间和神经毒性。表面蛋白质组学鉴定了治疗靶点,并评估了一种靶向B7-H3的三特异性杀伤衔接器(TriKE)与FT538及NKG2C+适应性NK细胞的联合应用。胶质母细胞瘤干样细胞被分为对FT538敏感(38%)、中度敏感(38%)或耐药(23%)。小鼠颅内给药耐受良好,至少持续存在35天,且未引起神经毒性。单次瘤内给药使敏感异种移植瘤完全消退。表面分析鉴定B7-H3为克服耐药的靶点。FT538与B7-H3 TriKE联合治疗在耐药模型中增强了抗肿瘤疗效,在适应性NK细胞中也观察到这一效应。FT538在77%的GSC系(NK敏感和中度敏感)中表现出强效杀瘤活性,在敏感模型中具有治愈潜力,并在体内表现出良好的持续存在性和耐受性。靶向B7-H3的TriKE可恢复耐药肿瘤的NK敏感性。这些发现为FT538单用或联合靶向B7-H3的TriKE用于胶质母细胞瘤及其他实体瘤的进一步临床评估提供了强有力的临床前依据。
Cancer letters IF 11.8 2026-10-01 PMID: 42398851
Aldo-keto reductase family 1 member C3 (AKR1C3) is a pivotal metabolic enzyme involved in arachidonic acid (AA) metabolism and cancer metabolic reprogramming, which plays a critical role in the initiation and progression of glioblastoma (GBM). We integrated single-cell and transcriptome data to characterize AA metabolism features in GBM and identify the key gene AKR1C3. Using CCK8 assays, wound-healing assays, transwell assays, and mouse tumor formation experiments, we elucidated the effects of AKR1C3. Dual-luciferase reporter assays and ChIP-PCR experiments were performed to investigate the regulation of transcription factor JUN on AKR1C3 expression. RNA-seq analysis, combined with rescue experiments, demonstrated that AKR1C3 significantly regulates the RhoA/ROCK pathway. Arachidonic acid metabolism is closely associated with clinical outcomes in glioma, with AKR1C3 identified as a key gene within this pathway. AKR1C3 knockdown enhanced tumor cell proliferation, migration, and invasion, whereas AKR1C3 overexpression suppressed these malignant behaviors. In vivo experiments further confirmed the inhibitory effect of AKR1C3 on glioma progression. Dual-luciferase reporter and ChIP-PCR assays demonstrated that JUN acts as an upstream regulator of AKR1C3. ELISA results indicated that AKR1C3 overexpression reduced cellular PGD2 levels. RNA-seq analysis suggested that the RhoA/ROCK pathway was a downstream effector of AKR1C3, and exogenous PGD2 supplementation could reverse AKR1C3-mediated regulation of this pathway. We identified curcumin, a natural product with anti-cancer metabolic regulatory activity, as an upstream modulator that suppresses JUN expression, thereby activating the JUN/AKR1C3 axis and inhibiting malignant phenotypes in GBM cells. JUN/AKR1C3 axis influences glioma progression via modulating PGD2-mediated RhoA/ROCK Signaling.
中文摘要:醛酮还原酶家族1成员C3(AKR1C3)是参与花生四烯酸(AA)代谢和肿瘤代谢重编程的关键代谢酶,在胶质母细胞瘤(GBM)的发生和进展中发挥重要作用。我们整合单细胞和转录组数据以刻画GBM中AA代谢特征并鉴定关键基因AKR1C3。使用CCK8实验、划痕实验、transwell实验和小鼠成瘤实验,我们阐明了AKR1C3的作用。通过双荧光素酶报告实验和ChIP-PCR实验研究转录因子JUN对AKR1C3表达的调控。RNA-seq分析结合挽救实验表明,AKR1C3显著调控RhoA/ROCK通路。花生四烯酸代谢与胶质瘤临床结局密切相关,AKR1C3被鉴定为该通路中的关键基因。AKR1C3敲低增强肿瘤细胞增殖、迁移和侵袭,而AKR1C3过表达抑制这些恶性行为。体内实验进一步证实AKR1C3对胶质瘤进展的抑制作用。双荧光素酶报告和ChIP-PCR实验表明JUN是AKR1C3的上游调控因子。ELISA结果表明AKR1C3过表达降低细胞PGD2水平。RNA-seq分析提示RhoA/ROCK通路是AKR1C3的下游效应器,外源性PGD2补充可逆转AKR1C3介导的对该通路的调控。我们鉴定出姜黄素,一种具有抗癌代谢调节活性的天然产物,作为上游调节因子抑制JUN表达,从而激活JUN/AKR1C3轴并抑制GBM细胞的恶性表型。JUN/AKR1C3轴通过调节PGD2介导的RhoA/ROCK信号影响胶质瘤进展。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42351295
Diffuse midline glioma (DMG) is a lethal pediatric brain tumor, driven by profound epigenetic dysregulation, raising the possibility that targeting epigenetic regulators such as histone deacetylases (HDACs) could provide a therapeutic benefit. However, despite preclinical activity, currently available HDAC inhibitors have shown limited clinical translation due to poor central nervous system (CNS) penetration and a lack of HDAC isoform selectivity. We combined CRISPR/Cas9 screening and pharmacologic HDAC inhibition to identify isoform-specific dependencies in DMG cell lines. Mechanistic studies were performed using bulk RNA-seq and HiChIP, and therapeutic efficacy was evaluated in orthotopic patient-derived xenograft mouse models. We identify that the nuclear-localized Class I HDAC isoforms are dependencies in DMG and demonstrate that HDAC2 represents a selective dependency that is highly expressed in patient tumors. We further identify a CNS-penetrant HDAC inhibitor, Compound 26, with preferential HDAC1/2 isoform selectivity. Transcriptomic and chromatin conformation analyses reveal that Compound 26 induces rapid transcriptional reprogramming, restores physiologic pontine histone patterns, and induces cell cycle arrest through chromatin reorganization. Consistent with these effects, Compound 26 slows DMG growth in vitro and in orthotopic in vivo models. Our findings establish HDAC2 as a critical and therapeutically actionable dependency in DMG. Genetic or pharmacological targeting of HDAC2 disrupts DMG chromatin architecture and induces cell cycle arrest. The HDAC1/2-selective inhibitor Compound 26 exhibits favorable CNS-penetration, tolerability, and antitumor activity in disease-relevant patient-derived xenograft models. Collectively, these data support isoform-selective HDAC inhibition as a rational strategy to overcome the translational limitations of pan-HDAC inhibitors in DMG.
中文摘要:弥漫性中线胶质瘤(DMG)是一种致死性儿童脑肿瘤,由显著的表观遗传失调驱动,这提示靶向组蛋白去乙酰化酶(HDAC)等表观遗传调控因子可能带来治疗获益。然而,尽管现有HDAC抑制剂在临床前具有活性,但由于中枢神经系统(CNS)穿透性差以及缺乏HDAC亚型选择性,其临床转化仍有限。我们结合CRISPR/Cas9筛选与药理学HDAC抑制,在DMG细胞系中识别亚型特异性依赖。使用bulk RNA-seq和HiChIP进行机制研究,并在原位患者来源异种移植小鼠模型中评估治疗疗效。我们发现核内定位的I类HDAC亚型是DMG的依赖因子,并证明HDAC2代表一种选择性依赖,且在患者肿瘤中高表达。我们进一步鉴定出一种CNS穿透性HDAC抑制剂Compound 26,其偏好性选择HDAC1/2亚型。转录组和染色质构象分析显示,Compound 26诱导快速转录重编程,恢复生理性脑桥组蛋白模式,并通过染色质重组诱导细胞周期阻滞。与这些效应一致,Compound 26在体外和原位体内模型中减缓DMG生长。我们的发现确立HDAC2是DMG中关键且具治疗可操作性的依赖因子。遗传或药理学靶向HDAC2破坏DMG染色质结构并诱导细胞周期阻滞。HDAC1/2选择性抑制剂Compound 26在疾病相关患者来源异种移植模型中表现出良好的CNS穿透性、耐受性和抗肿瘤活性。总体而言,这些数据支持亚型选择性HDAC抑制作为克服DMG中泛HDAC抑制剂转化局限性的合理策略。
Biomaterials IF 13.6 2026-10 PMID: 41967385
Glioblastoma (GBM) is a highly invasive and infiltrative primary brain tumor with a poor prognosis. This tumor avidly acquires cholesterol from its environment through the low-density lipoprotein receptor (LDLR) to facilitate their aggressive and rapid proliferative phenotype. The blood-brain barrier (BBB) remains a major challenge for drug delivery to GBM as it restricts the entry of most therapeutics limiting their treatment efficacy. Focused ultrasound (FUS) with microbubbles is a non-invasive and safe method to transiently open the BBB to improve the delivery of the therapeutic agents to the brain. In this study, we aim to establish a facile and effective drug delivery strategy to GBM that integrates FUS-mediated BBB disruption and LDLR targeted delivery. Herein, an invasive intracranial mouse model of GBM was developed with the PS5A cell line. GBM bearing mice received intravenous injection of low-density lipoprotein (LDL) nanoparticles loaded with oleic acid and carbocyanine fluorescent dye with and without pulse FUS sonication in the tumor region of the brain. Tumor bearing mice without LDL nanoparticle or FUS intervention served as untreated controls. Initial confirmation of tumor progression and BBB opening was evaluated by magnetic resonance Imaging (MRI). Fluorescent imaging of the brain tissues post treatment revealed a markedly higher fluorescent signal in the sonicated tumor area when compared to the contralateral hemisphere, groups receiving LDL nanoparticle alone or untreated controls. The combination of LDLR targeting and FUS enabled enhanced intracellular delivery of LDL nanoparticles to GBM cells in the bulk tumor and surrounding peritumor regions in the striatum. These findings indicate that drug delivery can be achieved not only to bulk tumor but also to tumor cells infiltrating surrounding brain tissue behind the BBB. In summary, the current study establishes a foundational framework for the combination of FUS and receptor-targeted delivery of LDL nanoparticles to GBM.
中文摘要:胶质母细胞瘤(GBM)是一种高度侵袭性和浸润性的原发性脑肿瘤,预后较差。该肿瘤通过低密度脂蛋白受体(LDLR)从环境中大量获取胆固醇,以促进其侵袭性和快速增殖表型。血脑屏障(BBB)仍是向GBM递送药物的主要挑战,因为它限制大多数治疗药物进入,从而限制其治疗效果。聚焦超声(FUS)联合微泡是一种无创且安全的方法,可短暂开放BBB,以改善治疗药物向脑内的递送。在本研究中,我们旨在建立一种简便有效的GBM药物递送策略,将FUS介导的BBB破坏与LDLR靶向递送相结合。在此,我们使用PS5A细胞系建立了侵袭性颅内小鼠GBM模型。荷GBM小鼠接受静脉注射载有油酸和羰花青荧光染料的低密度脂蛋白(LDL)纳米颗粒,并在脑肿瘤区域接受或不接受脉冲FUS超声处理。未接受LDL纳米颗粒或FUS干预的荷瘤小鼠作为未治疗对照。通过磁共振成像(MRI)评估肿瘤进展和BBB开放的初步确认。治疗后脑组织的荧光成像显示,与对侧半球、仅接受LDL纳米颗粒的组或未治疗对照组相比,超声处理的肿瘤区域荧光信号显著更高。LDLR靶向与FUS的结合使得LDL纳米颗粒能够增强向纹状体中主体肿瘤及周围瘤周区域的GBM细胞的细胞内递送。这些发现表明,药物递送不仅可到达主体肿瘤,还可到达BBB后方浸润周围脑组织的肿瘤细胞。总之,本研究为FUS与LDL纳米颗粒受体靶向递送相结合治疗GBM建立了基础框架。
Cell death and differentiation IF 13.6 2026-10 PMID: 41844900
Glioblastoma, IDH1 wildtype, aggressive primary brain tumors with a dismal prognosis, promote the recruitment of microglia, brain resident innate immune cells, and ultimately their activation toward a tumor-supportive phenotype that increases gliomal proliferation and invasion capability. Here, we report that upon stimulation by glioma cells, microglia transit via a reactive state holding anti-tumoral properties coupled to reduced DNA methyltransferase 3 A (DNMT3A) chromatin occupancy and DNA demethylation that promote the expression of gene sets related to the transforming growth factor beta (TGF-β)-dependent microglial homeostasis and the microglial sensome. We find that upon repression of Dnmt3a expression in microglia, those cells maintain anti-tumoral attributes in vitro and in vivo. In a syngeneic immunocompetent glioblastoma mouse model, brain delivery of antisense oligonucleotide targeting Dnmt3a expression led to microglial activation and reduced tumor growth. Taken together, our results reveal the involvement of DNA demethylation in the control of glioma cells-induced microglia activation and indicate that microglial DNMT3A is a potentially therapeutic target to treat brain neoplasms such as glioblastoma that include a microglial component.
中文摘要:胶质母细胞瘤(IDH1野生型)是一种侵袭性原发性脑肿瘤,预后极差,它会促进小胶质细胞(脑内固有的先天免疫细胞)的募集,并最终使其活化朝向支持肿瘤的表型,从而增强胶质瘤的增殖和侵袭能力。在此,我们报道:在胶质瘤细胞刺激下,小胶质细胞会经过一种具有抗肿瘤特性的反应性状态,该状态伴随DNA甲基转移酶3A(DNMT3A)染色质占位的减少以及DNA去甲基化,后者促进与转化生长因子β(TGF-β)依赖的小胶质细胞稳态和小胶质细胞感知组相关的基因集表达。我们发现,在小胶质细胞中抑制Dnmt3a表达后,这些细胞在体外和体内均保持抗肿瘤属性。在同基因免疫健全的胶质母细胞瘤小鼠模型中,脑内递送靶向Dnmt3a表达的反义寡核苷酸可导致小胶质细胞活化并减少肿瘤生长。综上,我们的结果揭示了DNA去甲基化参与调控胶质瘤细胞诱导的小胶质细胞活化,并提示小胶质细胞DNMT3A是治疗包括小胶质细胞成分在内的脑肿瘤(如胶质母细胞瘤)的潜在治疗靶点。

8肺癌 (16篇)

临床研究 (8篇)

MedComm IF 14.1 2026-10 PMID: 42830869
This study reports efficacy and biomarker results from a multicenter, randomized, open-label Phase III study (NCT04009317). Treatment-naive anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients were centrally randomized 1:1 to envonalkib or crizotinib, stratified by brain metastases and chemotherapy lines. The primary endpoint was progression-free survival (PFS) assessed by independent review committee. This analysis updated investigator-assessed PFS. A total of 264 patients were randomized (envonalkib: 131, crizotinib: 133). Median follow-up was 46.5 and 46.8 months for envonalkib and crizotinib, respectively. Envonalkib significantly improved PFS over crizotinib (median PFS: 30.4 vs. 12.0 months, p < 0.0001; hazard ratio [HR] = 0.48, 95% CI: 0.35-0.65). Overall survival (OS) data remained immature. In the envonalkib group, circulating tumor DNA (ctDNA) analysis revealed poor prognosis for patients with co-mutations in p53 pathway genes (TP53, CDKN2A, MDM2, MDM4) or other concurrent oncogenic drivers (median PFS: 15.7 and 8.3 months). Among 52 patients with post-progression ctDNA data, putative resistance mechanisms were identified in 14 (26.9%), including secondary ALK mutations (n = 9) and/or bypass pathway activations (n = 9). Final follow-up confirms the robust benefit of envonalkib over crizotinib, supporting its role as a first-line option for ALK-positive NSCLC. Biomarker analyses validate the prognostic impact of genomic co-alterations and delineate resistance mechanisms.
中文摘要:本研究报道了一项多中心、随机、开放标签的III期研究(NCT04009317)的疗效与生物标志物结果。初治的ALK阳性非小细胞肺癌(NSCLC)患者按1:1比例集中随机分配至恩沃利尼(envonalkib)或克唑替尼组,并按脑转移和化疗线数进行分层。主要终点是由独立评审委员会评估的无进展生存期(PFS)。本次分析更新了研究者评估的PFS。共264例患者被随机分组(恩沃利尼组:131例,克唑替尼组:133例)。恩沃利尼组和克唑替尼组的中位随访时间分别为46.5个月和46.8个月。恩沃利尼较克唑替尼显著改善PFS(中位PFS:30.4个月对12.0个月,p < 0.0001;风险比[HR] = 0.48,95%置信区间[CI]:0.35-0.65)。总生存期(OS)数据仍不成熟。在恩沃利尼组中,循环肿瘤DNA(ctDNA)分析显示,p53通路基因(TP53、CDKN2A、MDM2、MDM4)存在共突变或其他并存致癌驱动基因改变的患者预后较差(中位PFS:15.7个月和8.3个月)。在52例具有进展后ctDNA数据的患者中,14例(26.9%)发现了推测的耐药机制,包括继发性ALK突变(n = 9)和/或旁路通路激活(n = 9)。最终随访证实恩沃利尼较克唑替尼具有显著获益,支持其作为ALK阳性NSCLC一线治疗选择的作用。生物标志物分析验证了基因组共改变的预后影响,并阐明了耐药机制。
Journal for immunotherapy of cancer IF 11.7 2026-10-01 PMID: 42823088
Immune-checkpoint inhibitors (ICIs) plus chemotherapy have demonstrated survival benefits in extensive-stage small cell lung cancer (SCLC). The integration of immunotherapy with concurrent chemoradiotherapy (CCRT) may improve survival outcomes in limited-stage SCLC (LS-SCLC). This phase II randomized controlled study was designed to evaluate the efficacy and safety of toripalimab consolidation versus observation in patients with LS-SCLC after CCRT. We conducted this phase II, randomized controlled trial in patients with LS-SCLC who had completed CCRT. Eligible patients were randomized 1:1 to either toripalimab consolidation (240 mg every 3 weeks for up to 6 months) or observation. Randomization was stratified according to disease stage (I or II vs III) and the receipt of prophylactic cranial irradiation (PCI) (yes vs no). The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), objective response rate and toxicities. Between June 30, 2020, and May 31, 2024, a total of 98 patients were randomized to receive either toripalimab consolidation (n=49) or observation (n=49) after CCRT. The trial was prematurely terminated on May 31, 2024. Objective responses were observed in 14 of 23 patients (60.9%) in the toripalimab group and in 9 of 24 patients (37.5%) in the observation group. The median PFS was not reached in the toripalimab group, compared with 14.1 months (95% CI 2.8 to 25.4) in the observation group (HR, 0.55; 95% CI 0.31 to 0.96). The median OS was not reached with toripalimab, compared with 30.3 months (95% CI 20.4 to 40.2) with observation (HR, 0.39; 95% CI 0.19 to 0.80). Treatment-related toxicities were generally mild. Adverse events led to discontinuation of study drug in 6 of 48 patients (12.5%) in the toripalimab group. Grade 3 pneumonitis or radiation pneumonitis occurred in two patient (4.2%) in the toripalimab group and one patient (2.0%) in the observation group. No grade 4 or 5 adverse events occurred in either group. Subgroup analyses of PFS and OS favored toripalimab over observation across all predefined subgroups, including age, sex, Eastern Cooperative Oncology Group performance status, smoking status, disease stage, response to CCRT and the receipt of PCI. Consolidative toripalimab showed promising signals of improved PFS and OS with a manageable safety profile in patients with LS-SCLC. These findings warrant confirmation in larger, adequately powered randomized trials.
中文摘要:免疫检查点抑制剂联合化疗已在广泛期小细胞肺癌中显示出生存获益。将免疫治疗与同步放化疗整合可能改善局限期小细胞肺癌的生存结局。这项II期随机对照研究旨在评估特瑞普利单抗巩固治疗与观察相比在完成同步放化疗的局限期小细胞肺癌患者中的疗效和安全性。我们在完成同步放化疗的局限期小细胞肺癌患者中开展了这项II期随机对照试验。符合条件的患者按1:1随机分配至特瑞普利单抗巩固治疗组(240 mg,每3周一次,最长6个月)或观察组。随机化根据疾病分期(I或II期 vs III期)和是否接受预防性颅脑照射进行分层。主要终点为无进展生存期。次要终点包括总生存期、客观缓解率和毒性。2020年6月30日至2024年5月31日期间,共有98例患者被随机分配至同步放化疗后接受特瑞普利单抗巩固治疗(n=49)或观察(n=49)。该试验于2024年5月31日提前终止。特瑞普利单抗组23例患者中有14例(60.9%)观察到客观缓解,观察组24例患者中有9例(37.5%)。特瑞普利单抗组的中位无进展生存期未达到,而观察组为14.1个月(95%CI 2.8至25.4)(HR,0.55;95%CI 0.31至0.96)。特瑞普利单抗组的中位总生存期未达到,而观察组为30.3个月(95%CI 20.4至40.2)(HR,0.39;95%CI 0.19至0.80)。治疗相关毒性总体较轻。特瑞普利单抗组48例患者中有6例(12.5%)因不良事件停用研究药物。特瑞普利单抗组有2例患者(4.2%)发生3级肺炎或放射性肺炎,观察组有1例患者(2.0%)。两组均未发生4级或5级不良事件。无进展生存期和总生存期的预设亚组分析均显示,包括年龄、性别、美国东部肿瘤协作组体能状态评分、吸烟状态、疾病分期、对同步放化疗的缓解和是否接受预防性颅脑照射在内的所有预设亚组中,特瑞普利单抗均优于观察。在局限期小细胞肺癌患者中,巩固性特瑞普利单抗显示出改善无进展生存期和总生存期的有希望信号,且安全性可控。这些发现需要在更大规模、有足够检验效能的随机试验中加以确认。
MedComm IF 14.1 2026-10 PMID: 42812841
The optimal treatment duration of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remains undefined. We conducted a multicenter retrospective cohort study of 1054 patients with NSCLC treated with ICIs across six hospitals in China and one in the United States. Using a training cohort of 372 patients, we constructed a counterfactual random forest reward-estimation matrix incorporating age, tumor diameter, and derived neutrophil-to-lymphocyte ratio, and an Optimal Policy Survival Tree (OPST) was developed to characterize phenotype-specific associations between baseline clinical features, treatment duration patterns (short-, intermediate-, and long-course), and survival outcomes. Two external cohorts (n = 324 and n = 358) were used for validation. The OPST reproducibly defined seven patient subgroups across datasets. Subgroups 4 and 6 (37.8%) showed more favorable overall survival (OS) associations with short-course therapy (median OS 28.6 and 24.5 months), whereas Subgroups 3 and 5 (41.5%) showed more favorable associations with long-course therapy (median OS 27.0 and 22.0 months; all p < 0.001). The OPST framework identified a subset of patients (18.1%) potentially associated with limited incremental survival benefit from prolonged treatment exposure. This transparent and interpretable framework based on routine clinical data may help inform future prospective evaluation of individualized ICI duration strategies, with the potential to support individualized treatment planning while reducing unnecessary treatment exposure.
中文摘要:非小细胞肺癌(NSCLC)中免疫检查点抑制剂(ICIs)的最佳治疗持续时间仍未明确。我们开展了一项多中心回顾性队列研究,纳入中国六家医院和美国一家医院接受ICIs治疗的1054例NSCLC患者。使用372例患者的训练队列,我们构建了一个反事实随机森林奖励估计矩阵,纳入年龄、肿瘤直径和衍生中性粒细胞与淋巴细胞比值,并开发了最优策略生存树(OPST),用以刻画基线临床特征、治疗持续时间模式(短程、中程和长程)与生存结局之间表型特异性的关联。两个外部队列(n = 324和n = 358)用于验证。OPST在各数据集中可重复地定义了七个患者亚组。亚组4和6(37.8%)显示短程治疗与更有利的总生存(OS)相关(中位OS 28.6和24.5个月),而亚组3和5(41.5%)显示长程治疗与更有利的相关(中位OS 27.0和22.0个月;所有p < 0.001)。OPST框架识别出一部分患者(18.1%),其延长治疗暴露可能与有限的增量生存获益相关。这一基于常规临床数据的透明且可解释的框架,可能有助于为未来个体化ICI持续时间策略的前瞻性评估提供信息,并有可能支持个体化治疗规划,同时减少不必要的治疗暴露。
EClinicalMedicine IF 12.8 2026-10 PMID: 42775005
Small molecule inhibitors (SMIs) have become the cornerstone of treatment for patients with oncogene-driven non-small cell lung cancer (NSCLC), substantially improving clinical outcomes. Over the past decade, numerous agents targeting distinct oncogenic drives have been developed, each exhibiting unique pharmacokinetic and pharmacodynamic profiles that complicate clinical prescribing. This review highlights principal drug-interactions affecting SMI exposure, including concomitant food intake, gastric acid suppressants, modulators of cytochrome P450 (CYP) enzymes and drug transporters. Awareness of these factors may help prevent early treatment failure or severe adverse events due to under- or overexposure. Finally, the most prevalent and clinically relevant toxicities are discussed, including corrected QT interval (QTc) prolongation, pneumonitis, mucositis, weight gain, pyrexia, and ocular-, hepatic-, and neuro-toxicity. In line with recommendations from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), this review which is based on extensive search of the scientific literature provides evidence-based practical guidance for prescribing SMIs in clinical practice.
中文摘要:小分子抑制剂(SMIs)已成为驱动基因阳性非小细胞肺癌(NSCLC)患者治疗的基石,显著改善了临床结局。过去十年间,针对不同致癌驱动因素的众多药物相继被开发出来,每种药物都具有独特的药代动力学和药效学特征,使临床处方变得复杂。本综述重点阐述了影响SMI暴露的主要药物相互作用,包括同时摄入食物、胃酸抑制剂、细胞色素P450(CYP)酶调节剂以及药物转运体。认识这些因素有助于避免因暴露不足或过度暴露而导致的早期治疗失败或严重不良事件。最后,本文讨论了最常见且具有临床相关性的毒性反应,包括校正QT间期(QTc)延长、肺炎、黏膜炎、体重增加、发热以及眼毒性、肝毒性和神经毒性。依据美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)的建议,本综述基于对科学文献的广泛检索,为临床实践中SMIs的处方提供循证的实际指导。
Cancer discovery IF 29.5 2026-10-01 PMID: 42689323
The first-in-class pan-RAS inhibitor daraxonrasib shrank tumors in more than 30% of patients with previously treated RAS-mutant non-small cell lung cancer. The findings build on results that recently earned approval for the drug against pancreatic cancer and support an ongoing phase III trial in lung cancer.
中文摘要:首创性泛RAS抑制剂daraxonrasib使超过30%的既往接受过治疗的RAS突变非小细胞肺癌患者肿瘤缩小。这些发现基于近期使该药获批用于胰腺癌的结果,并支持正在进行的肺癌III期试验。
Cancer letters IF 11.8 2026-10-01 PMID: 42413815
In recent years, the combination of radiotherapy and immunotherapy has emerged as a major focus of research in the treatment of unresectable lung cancer. With a growing understanding of the synergistic mechanisms between radiotherapy and immunotherapy, together with the accumulation of clinical evidence, this combined approach has demonstrated promising therapeutic potential. Members of the Multidisciplinary Diagnosis and Treatment Committee of the Chinese Anti-Cancer Association, the Radiation Oncology Committee of the Chinese Anti-Cancer Association, the Lung Cancer Committee of the Chinese Anti-Cancer Association, the Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), and the Lung Cancer Group of the Respiratory Diseases Branch of the Chinese Medical Association systematically reviewed recent high-quality evidence regarding radiotherapy combined with immunotherapy for unresectable non-small cell lung cancer and small cell lung cancer. Through extensive discussion and multiple rounds of revision, this consensus has been updated from the 2024 version to provide the latest evidence-based recommendations and practical guidance for clinical decision-making.
中文摘要:近年来,放疗与免疫治疗的联合已成为不可切除肺癌治疗领域的研究重点。随着对放疗与免疫治疗协同机制认识的不断深入,以及临床证据的积累,这种联合治疗策略展现出良好的治疗潜力。中国抗癌协会多学科诊断与治疗专业委员会、中国抗癌协会放射肿瘤学专业委员会、中国抗癌协会肺癌专业委员会、中国临床肿瘤学会(CSCO)小细胞肺癌专家委员会以及中华医学会呼吸病学分会肺癌学组的成员,系统回顾了近年来关于放疗联合免疫治疗不可切除非小细胞肺癌和小细胞肺癌的高质量证据。经过广泛讨论和多轮修订,本共识在2024版基础上进行了更新,旨在为临床决策提供最新的循证推荐和实践指导。
Cancer letters IF 11.8 2026-10-01 PMID: 42398850
SMARCA4-deficient non-small cell lung cancer (SD-NSCLC) is associated with poor prognosis and lacks a standard treatment strategy. This multicenter retrospective study evaluated immunotherapy-based regimens and characterized the immune features of advanced SD-NSCLC using next-generation sequencing, flow cytometry, multiplex immunofluorescence, single-cell RNA and TCR sequencing, and a CRISPR/Cas9-mediated SMARCA4 knockout model. A total of 162 patients with advanced SD-NSCLC were enrolled from four Chinese cancer centers. Genomic analysis identified TP53, KEAP1, STK11, and KRAS as the primary co-mutated genes. Compared to single-agent chemotherapy, immunotherapy combined with chemotherapy and antiangiogenesis therapy demonstrated significantly longer median progression-free survival (mPFS) (12.10 vs. 2.77 months, p < 0.001). Furthermore, responders to this combination also exhibited elevated CD8+ T cell infiltration (p < 0.01). In vivo, the three-drug combination regimen significantly inhibited the growth of SMARCA4-knock-out mouse tumor cells in mice, increased infiltration of CD8+ T cells, and reduced the presence of regulatory T cells (Tregs) in the tumor microenvironment. In this mouse model, single-cell RNA-seq revealed a significant decrease in CTLA4+ Tregs with active intercellular communication following anti-PD-1 therapy. Ex vivo experiments demonstrated that treatment with anti-PD-1 markedly reduced the proportion of Tregs and concurrently increased the proportions of IFN-γ and TNF-α producing cells. Lastly, single-cell TCR-seq confirmed the expansion of specific TCR clones, particularly within CCR7+ and LEF1+ naive T cells. Collectively, these findings suggest that immunotherapy-based combination regimens may provide substantial clinical benefit for patients with SD-NSCLC by enhancing CD8+ T cell activity, suppressing CTLA4+ Tregs, and expanding tumor-reactive TCR clones.
中文摘要:SMARCA4缺陷型非小细胞肺癌(SD-NSCLC)预后较差,且缺乏标准治疗策略。这项多中心回顾性研究评估了以免疫治疗为基础的方案,并通过下一代测序、流式细胞术、多重免疫荧光、单细胞RNA和TCR测序以及CRISPR/Cas9介导的SMARCA4敲除模型,刻画了晚期SD-NSCLC的免疫特征。共纳入来自中国四家癌症中心的162例晚期SD-NSCLC患者。基因组分析确定TP53、KEAP1、STK11和KRAS为主要共突变基因。与单药化疗相比,免疫治疗联合化疗和抗血管生成治疗显示出显著更长的中位无进展生存期(mPFS)(12.10个月 vs. 2.77个月,p<0.001)。此外,该联合方案的应答者也表现出CD8+ T细胞浸润升高(p<0.01)。在体内,三药联合方案显著抑制了SMARCA4敲除小鼠肿瘤细胞在小鼠体内的生长,增加了CD8+ T细胞浸润,并减少了肿瘤微环境中调节性T细胞(Tregs)的存在。在该小鼠模型中,单细胞RNA测序显示,抗PD-1治疗后CTLA4+ Tregs显著减少,且细胞间通讯活跃。离体实验表明,抗PD-1治疗显著降低了Tregs比例,同时增加了产生IFN-γ和TNF-α的细胞比例。最后,单细胞TCR测序证实了特定TCR克隆的扩增,尤其是在CCR7+和LEF1+初始T细胞中。总之,这些发现表明,以免疫治疗为基础的联合方案可能通过增强CD8+ T细胞活性、抑制CTLA4+ Tregs并扩增肿瘤反应性TCR克隆,为SD-NSCLC患者提供显著的临床获益。
Cancer letters IF 11.8 2026-10-01 PMID: 42392400
Early-onset lung cancer, commonly defined as disease diagnosed at or before 50 years of age, represents a growing but insufficiently characterized subset of lung cancer in clinical practice. However, much of the evidence informing current diagnostic and therapeutic practice has been generated from age-unselected or older, smoking-dominant populations and may not fully capture the clinical characteristics of younger patients. Consequently, younger individuals with lung cancer may face delayed risk recognition, incomplete molecular evaluation, and treatment decisions not fully informed by age-associated clinicobiological features. Accumulating evidence indicates that early-onset non-small cell lung cancer (NSCLC) is enriched for actionable oncogenic alterations, particularly gene fusions and selected HER2/ERBB2 alterations, and is frequently associated with lower tumor mutational burden and a less inflamed tumor microenvironment. Although these features do not yet establish early-onset NSCLC as a separate treatment category, they support age-informed refinement of guideline-based management, particularly in initial molecular testing, interpretation of immunotherapy-relevant immune features, treatment transitions, and survivorship planning. In this review, we synthesize current evidence on disease burden, etiologic heterogeneity, age-related genomic features, and treatment-relevant tumor immune context in early-onset lung cancer, with a focus on issues relevant to clinical interpretation and management prioritization. We further outline age-informed clinical management for molecular evaluation, resistance reassessment, and survivorship care, aiming to complement rather than replace established NSCLC guidelines for patients aged ≤50 years.
中文摘要:早发性肺癌通常定义为50岁及以前确诊的疾病,是临床实践中日益增多但特征仍不充分的一类肺癌。然而,当前诊断和治疗实践所依据的许多证据来自未按年龄选择或年龄偏大、以吸烟为主的人群,可能无法充分反映年轻患者的临床特征。因此,年轻肺癌患者可能面临风险识别延迟、分子评估不完整以及治疗决策未能充分纳入年龄相关临床生物学特征的问题。越来越多证据表明,早发性非小细胞肺癌(NSCLC)富含可操作致癌改变,尤其是基因融合和部分HER2/ERBB2改变,并常与较低的肿瘤突变负荷和炎症程度较低的肿瘤微环境相关。尽管这些特征尚未使早发性NSCLC成为独立的治疗类别,但它们支持在指南基础上进行结合年龄因素的管理优化,特别是在初始分子检测、免疫治疗相关免疫特征解读、治疗转换以及生存者规划方面。在本综述中,我们总结早发性肺癌疾病负担、病因异质性、年龄相关基因组特征和治疗相关肿瘤免疫背景的现有证据,重点关注与临床解读和管理优先次序相关的问题。我们进一步概述针对分子评估、耐药重评和生存者照护的年龄因素指导临床管理,旨在补充而非替代针对50岁及以下患者的既有NSCLC指南。

基础研究 (8篇)

Science advances IF 13.9 2026-10-09 PMID: 42842653
The cis-regulatory potential of human endogenous retroviruses (HERVs) that have accumulated in our genome affects diverse host processes, including embryonic development and malignancy, where HERV epigenetic control is reduced. Non-small cell lung cancer optimal growth requires cancer cell-intrinsic expression of the calcium-binding protein calbindin under the control of a HERVH integrant on chromosome 8q21.3. Chimeric transcription of HERVH and CALB1, encoding calbindin, is also observed in human embryonic stem cells (ESCs), but its significance remained uncertain. Here, we show that HERVH integration on 8q21.3 during Homininae evolution coincides with acquisition of expression of CALB1 in preimplantation embryos. We further show that CALB1 expression is critical for human ESC growth and the prevention of cellular senescence and for the formation of ESC-derived preimplantation blastoids and postgastrulation amnioids. Thus, the co-option of HERVH 8q21.3 cis-regulatory activity in lung cancer may echo its essential requirement for human embryo development.
中文摘要:我们基因组中积累的人内源性逆转录病毒(HERVs)具有顺式调控潜能,影响多种宿主过程,包括胚胎发育和恶性肿瘤;在恶性肿瘤中,HERV的表观遗传控制减弱。非小细胞肺癌的最佳生长需要癌细胞内在表达钙结合蛋白calbindin,其受8q21.3染色体上HERVH整合体的控制。在编码calbindin的CALB1基因中,也观察到HERVH与CALB1的嵌合转录存在于人胚胎干细胞(ESCs)中,但其意义尚不确定。在这里,我们表明,Homininae进化过程中8q21.3上的HERVH整合与植入前胚胎中CALB1表达的获得相一致。我们进一步表明,CALB1表达对于人ESC生长、防止细胞衰老以及形成ESC来源的植入前类囊胚和原肠胚后类羊膜体至关重要。因此,肺癌中HERVH 8q21.3顺式调控活性的被征用可能呼应其对人类胚胎发育的必要需求。
Nature IF 56.1 2026-10-07 PMID: 42844481
Late-stage non-small cell lung cancer (NSCLC) is rarely curable1, underscoring a need to intervene earlier in the disease process. Growing evidence suggests that antitumour T cell responses are mounted but become progressively dysregulated during early tumorigenesis2,3. Tracking and targeting preinvasive T cell regulation may inform new approaches to detect and intercept lung cancer development. Here we explore how the T cell network is remodelled during NSCLC development via multi-omic, cross-tissue immune profiling in patients with preinvasive lung lesions surveilled by autofluorescence bronchoscopy and computed tomography (CT) imaging. Effector regulatory CD4+ T cells (eTreg cells) expressing basic leucine zipper ATF-like transcription factor (BATF) accumulated in high-grade premalignant airway lesions and were clonally related to circulating eTreg cells. Circulating eTreg cells were increasingly elevated during preinvasive progression, enabling lung tumorigenesis to be tracked through analysis of peripheral blood. Emergence of this clonally coordinated eTreg cell circuit defined rapid progression in patients with early-stage NSCLC detected during CT screening. In mice, carcinogen-driven lung tumorigenesis triggered an analogous preinvasive eTreg cell axis across the blood, airways and draining lymph nodes (dLNs). This culminated in an expansion of lung BATF+ Treg cells and Treg cell-rich peribronchial immature tertiary lymphoid structures (iTLSs). Immune interception via phosphoinositide 3-kinase-δ (PI3Kδ) inhibition abrogated formation of Treg cell-rich iTLSs, reduced circulating and pulmonary Treg cells, increased local conventional type 1 dendritic cells (cDC1s) and reduced lung tumour incidence and size. These data reveal a conserved eTreg cell network that emerges across tissues during early pulmonary tumorigenesis and provide a theranostic framework to track and target preinvasive immune regulation for lung cancer interception.
中文摘要:晚期非小细胞肺癌(NSCLC)很少能够治愈1,这凸显了在疾病进程中更早干预的必要性。越来越多证据表明,抗肿瘤T细胞反应会被启动,但在早期肿瘤发生过程中逐渐失调2,3。追踪并靶向前侵袭期的T细胞调控,可能为检测和拦截肺癌发展提供新方法。在本研究中,我们通过对接受自发荧光支气管镜和计算机断层扫描(CT)成像监测的癌前肺部病变患者进行多组学、跨组织免疫图谱分析,探索NSCLC发展过程中T细胞网络如何被重塑。表达碱性亮氨酸拉链ATF样转录因子(BATF)的效应调节性CD4+ T细胞(eTreg细胞)在高危癌前气道病变中积聚,并与循环eTreg细胞存在克隆相关性。循环eTreg细胞在侵袭前进展过程中逐渐升高,使得通过外周血分析即可追踪肺部肿瘤发生。这一克隆协调的eTreg细胞环路的出现,定义了CT筛查中发现的早期NSCLC患者的快速进展。在小鼠中,致癌物驱动的肺部肿瘤发生引发了血液、气道和引流淋巴结(dLNs)中类似的侵袭前eTreg细胞轴。这最终导致肺部BATF+ Treg细胞扩增以及富含Treg细胞的支气管周围未成熟三级淋巴结构(iTLSs)形成。通过抑制磷酸肌醇3-激酶δ(PI3Kδ)进行免疫拦截,可消除富含Treg细胞的iTLSs形成,减少循环和肺部Treg细胞,增加局部经典1型树突状细胞(cDC1s),并降低肺部肿瘤发生率和大小。这些数据揭示了一个在早期肺部肿瘤发生过程中跨组织出现的保守eTreg细胞网络,并提供了一个诊疗一体化框架,用以追踪和靶向侵袭前免疫调控,从而实现肺癌拦截。
MedComm IF 14.1 2026-10 PMID: 42840361
KRAS is one of the most frequently altered oncogenic drivers across human solid tumors and has long represented a central challenge in precision oncology. The clinical success of covalent KRAS G12C inhibitors has transformed a historically "undruggable" target into a tractable therapeutic class, but durable benefit remains limited by adaptive feedback, acquired resistance, co-mutation context, and tumor-lineage-specific barriers. A major unresolved question is how to extend this success across diverse KRAS alleles and cancer types. This review summarizes the molecular epidemiology and therapeutic landscape of KRAS-mutant cancers, with emphasis on non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. We compare G12C-directed therapy with emerging G12D-, G12V-, and pan-KRAS strategies and dissect resistance architectures involving EGFR feedback, RTK/MAPK/PI3K pathway reactivation, phenotypic plasticity, stromal constraints, and immune or metabolic adaptation. We further discuss resistance-informed combination therapy, targeted protein degraders, immune-based approaches, antibody-drug conjugates, biomarker-guided sequencing, and strategies for rare KRAS variants. Particular attention is given to how allele identity, tumor lineage, and adaptive signaling jointly shape therapeutic vulnerability. By framing KRAS therapy through the "same mutation, different outcomes" paradigm, this review provides a context-informed roadmap for extending KRAS-directed precision oncology beyond G12C monotherapy.
中文摘要:KRAS是人类实体瘤中最常发生改变的致癌驱动基因之一,长期以来一直是精准肿瘤学面临的核心挑战。共价KRAS G12C抑制剂的临床成功使这一历史上「不可成药」的靶点转变为可干预的治疗类别,但持久获益仍受适应性反馈、获得性耐药、共突变背景以及肿瘤谱系特异性屏障的限制。一个尚未解决的主要问题是如何将这一成功拓展至多种KRAS等位基因和癌种。本综述总结了KRAS突变癌症的分子流行病学与治疗格局,重点聚焦非小细胞肺癌、结直肠癌和胰腺导管腺癌。我们将G12C靶向治疗与新兴的G12D、G12V及泛KRAS策略进行比较,并剖析涉及EGFR反馈、RTK/MAPK/PI3K通路再激活、表型可塑性、基质限制以及免疫或代谢适应的耐药架构。我们进一步讨论基于耐药机制的组合治疗、靶向蛋白降解剂、免疫治疗方法、抗体药物偶联物、生物标志物指导的序贯治疗以及针对罕见KRAS变异的策略。特别关注等位基因身份、肿瘤谱系和适应性信号如何共同塑造治疗脆弱性。通过以「相同突变,不同结局」范式来审视KRAS治疗,本综述提供了一个结合背景信息的路线图,以将KRAS导向的精准肿瘤学拓展至G12C单药治疗之外。
Pharmacological research IF 12.2 2026-10-03 PMID: 42829139
Tumor-immune cell crosstalk critically shapes the progression of non-small cell lung cancer (NSCLC), yet the mechanisms underlying exosome-mediated immune suppression remain incompletely understood. Here, we identify a previously unrecognized exosomal lncRNA-mediated immunoregulatory axis targeted by the natural compound Ophiopogonin D (OP-D). Transcriptomic profiling and mechanistic rescue experiments revealed that Lewis lung carcinoma (LLC)-derived exosomal MALAT1 suppresses dendritic cell (DC) maturation by increasing SIRT1 expression and attenuating p65 phosphorylation. Computational modeling combined with molecular dynamics simulation predicted a stable interaction between OP-D and MALAT1, which was further validated by biolayer interferometry (BLI) and microscale thermophoresis (MST) assays, supporting MALAT1 as a direct molecular target of OP-D. In vivo, OP-D markedly inhibited tumor growth and enhanced intratumoral DC activation. Mechanistically, OP-D reduced MALAT1 abundance in LLC-derived exosomes and decreased the accumulation of exosomal MALAT1 in recipient DCs, thereby suppressing SIRT1 signaling, restoring p65 phosphorylation, and promoting DC maturation and antitumor immune responses. Furthermore, MALAT1 overexpression attenuated the immunostimulatory effects of OP-D, confirming the functional importance of the exosomal MALAT1-SIRT1/p-p65 axis. Collectively, these findings identify exosomal MALAT1 as a critical mediator of tumor-induced DC dysfunction and establish OP-D as a promising immunomodulatory natural compound capable of reprogramming tumor-immune communication in NSCLC.
中文摘要:肿瘤-免疫细胞串扰对非小细胞肺癌(NSCLC)的进展具有关键塑造作用,但外泌体介导的免疫抑制机制仍未完全阐明。在此,我们发现了一个此前未被认识的外泌体lncRNA介导的免疫调节轴,并可被天然化合物麦冬皂苷D(OP-D)靶向。转录组谱分析和机制性挽救实验显示,路易斯肺癌(LLC)来源的外泌体MALAT1通过增加SIRT1表达并减弱p65磷酸化来抑制树突状细胞(DC)成熟。计算建模结合分子动力学模拟预测OP-D与MALAT1之间存在稳定相互作用,并进一步通过生物膜层干涉(BLI)和微量热泳动(MST)实验验证,支持MALAT1是OP-D的直接分子靶点。在体内,OP-D显著抑制肿瘤生长并增强瘤内DC活化。机制上,OP-D降低LLC来源外泌体中MALAT1丰度,并减少外泌体MALAT1在受体DC中的累积,从而抑制SIRT1信号、恢复p65磷酸化并促进DC成熟和抗肿瘤免疫应答。此外,MALAT1过表达减弱了OP-D的免疫刺激效应,证实了外泌体MALAT1-SIRT1/p-p65轴的功能重要性。总体而言,这些发现确定外泌体MALAT1是肿瘤诱导DC功能障碍的关键介质,并确立OP-D作为一种有前景的免疫调节天然化合物,能够重编程NSCLC中的肿瘤-免疫通讯。
Cancer research IF 22.6 2026-10-02 PMID: 42825474
Activating mutations in KRAS drive pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Although mutant-selective KRAS inhibitors and pan-RAS inhibitors provide clinical benefits, the development of resistance limits durable responses. Here, transcriptomic and proteomic analyses revealed that, despite effective suppression of mutant KRAS signaling, resistant cells sustain cell cycle progression. Distinct orthogonal mitogenic pathways were engaged in a context-dependent manner to bypass KRAS inhibition. While these pathways could be broadly inhibited using the pan-RAS-ON inhibitor RMC-6236, cells remained capable of developing acquired resistance where cell proliferation was uncoupled from RAS signaling. Combinatorial drug screens and genome-wide CRISPR-Cas9 screens showed that perturbing cell cycle nodes via targeting cyclin dependent kinases CDK4/6 and CDK2 restored sensitivity to KRAS/RAS inhibitors. Co-targeting CDK4/6 induced G1 arrest and suppressed E2F-regulated proteins across all resistant models. In contrast, co-targeting CDK2 exerted a broader effect by impairing DNA replication, inducing G2 arrest, preventing mitotic entry, and yielding a more durable cytostatic response that delayed cellular outgrowth after drug withdrawal. Finally, concurrent inhibition of KRAS with either CDK4/6 or CDK2 yielded durable tumor control in vivo in xenografts derived from models with acquired resistance. In conclusion, these findings identify sustained cell cycle activity as a defining feature of resistance to KRAS-directed therapies and establish cell cycle co-targeting as an effective strategy to overcome KRAS/RAS inhibitor resistance.
中文摘要:KRAS激活突变驱动胰腺导管腺癌(PDAC)和非小细胞肺癌(NSCLC)。尽管突变选择性KRAS抑制剂和泛RAS抑制剂可带来临床获益,但耐药的发生限制了持久缓解。本研究通过转录组学和蛋白质组学分析发现,尽管突变KRAS信号被有效抑制,耐药细胞仍维持细胞周期进程。不同的正交促有丝分裂通路以背景依赖的方式被激活,从而绕过KRAS抑制。虽然这些通路可通过泛RAS-ON抑制剂RMC-6236被广泛抑制,但细胞仍能够发展出获得性耐药,在此过程中细胞增殖与RAS信号解偶联。联合药物筛选和全基因组CRISPR-Cas9筛选显示,通过靶向细胞周期蛋白依赖性激酶CDK4/6和CDK2干扰细胞周期节点,可恢复对KRAS/RAS抑制剂的敏感性。共同靶向CDK4/6在所有耐药模型中诱导G1期阻滞并抑制E2F调控蛋白。相比之下,共同靶向CDK2产生更广泛的作用,包括损害DNA复制、诱导G2期阻滞、阻止有丝分裂进入,并产生更持久的细胞静止反应,从而延缓撤药后的细胞生长。最后,在来自获得性耐药模型的异种移植瘤中,KRAS与CDK4/6或CDK2的同时抑制可在体内实现持久肿瘤控制。总之,这些发现将持续的细胞周期活性确定为KRAS导向治疗耐药的一个决定性特征,并确立细胞周期共同靶向作为克服KRAS/RAS抑制剂耐药的有效策略。
Nature IF 56.1 2026-10 PMID: 42717093
Tyrosine kinase inhibitors (TKIs) targeting anaplastic lymphoma kinase (ALK) have transformed the treatment landscape of ALK fusion-positive non-small-cell lung carcinoma (ALK-positive NSCLC), but the limited options for patients who progress on approved TKIs highlight a continued need for an orthogonal therapeutic approach1,2. TRI-611 is a potent, brain-penetrant molecular glue degrader of ALK fusion proteins with the potential to address this need. TRI-611 promotes the proximity of the ALK kinase domain and CRL4 substrate adaptor CRBN through a unique degron interface distal from the kinase active site. The unique binding interface of TRI-611 leads to selectivity across the proteome including known CRBN neosubstrates and other kinases. TRI-611 treatment induces degradation of all forms of ALK fusion proteins, including wild-type and ALK TKI-resistant versions, leading to regression of cell line and patient-derived subcutaneous and intracranial tumour models of ALK-positive NSCLC. TRI-611 can be combined with orthosteric ALK TKIs, achieving synergistic and durable tumour regressions. TRI-611 represents to our knowledge the first clinical-stage molecular glue degrader targeting an oncogenic gene fusion and has the potential to expand the arsenal of therapeutic options for patients with ALK-positive NSCLC .
中文摘要:靶向间变性淋巴瘤激酶(ALK)的酪氨酸激酶抑制剂(TKI)已经改变了ALK融合阳性非小细胞肺癌(ALK阳性NSCLC)的治疗格局,但对于在已获批TKI治疗中进展的患者,有限的选择凸显出对正交治疗策略的持续需求。TRI-611是一种强效、可穿透血脑屏障的ALK融合蛋白分子胶降解剂,有望满足这一需求。TRI-611通过一个远离激酶活性位点的独特降解决定子界面,促进ALK激酶结构域与CRL4底物衔接蛋白CRBN的靠近。TRI-611独特的结合界面使其在蛋白质组范围内具有选择性,包括已知的CRBN新底物和其他激酶。TRI-611处理可诱导所有形式ALK融合蛋白的降解,包括野生型和ALK TKI耐药版本,从而导致ALK阳性NSCLC细胞系模型以及患者来源的皮下和颅内肿瘤模型消退。TRI-611可与正构ALK TKI联合使用,实现协同且持久的肿瘤消退。据我们所知,TRI-611是首个靶向致癌基因融合的临床阶段分子胶降解剂,有望扩大ALK阳性NSCLC患者的治疗选择。
Cancer discovery IF 29.5 2026-10-01 PMID: 42678278
Cancer cachexia is a devastating wasting syndrome with no approved therapies. In this study, we identify the tumor-derived glycoprotein ADAMTSL4 as a circulating factor associated with body weight loss in preclinical cachexia models and patients with colorectal and lung cancers. In mice, Adamtsl4 overexpression converted non-cachexia-inducing tumors into cachexia-inducing tumors, whereas its deletion in cachexia-inducing tumors spared fat and muscle, blunted muscle atrophy signatures, and reduced cachexia severity. ADAMTSL4 engages the latency-associated peptide (LAP) of TGFβ1, promoting local activation of TGFβ1 at muscle cell membranes. Genetic blockade of proTGFβ1 or pharmacologic inhibition of TGFβ signaling reduced ADAMTSL4-dependent wasting in adipocytes and muscle cells. Suppression of tumor-derived ADAMTSL4 attenuated skeletal muscle fibrosis in mice. Together, the association between increased circulating ADAMTSL4 levels and TGFβ-driven muscle atrophy and fibrosis gene signatures in patients with cachectic cancer identifies ADAMTSL4 as an upstream regulator of TGFβ1 and a potential therapeutic target in cancer cachexia. Cancer cachexia lacks effective therapies and remains a major cause of cancer-related morbidity and mortality. We identify tumor-derived ADAMTSL4 as an upstream regulator of latent TGFβ activation via LAP engagement that promotes multiorgan wasting and fibrosis-related remodeling. Targeting ADAMTSL4 may provide a selective therapeutic strategy without systemic TGFβ pathway blockade. See related commentary by Liu and Janowitz, p. 1964.
中文摘要:癌症恶病质是一种毁灭性的消耗综合征,目前尚无获批疗法。在本研究中,我们将肿瘤来源的糖蛋白ADAMTSL4鉴定为一种循环因子,在临床前恶病质模型以及结直肠癌和肺癌患者中与体重下降相关。在小鼠中,Adamtsl4过表达可将不诱导恶病质的肿瘤转化为诱导恶病质的肿瘤,而在诱导恶病质的肿瘤中缺失Adamtsl4则可保留脂肪和肌肉,削弱肌肉萎缩特征,并减轻恶病质严重程度。ADAMTSL4与TGFβ1的潜伏相关肽(LAP)结合,促进TGFβ1在肌细胞膜局部的激活。对proTGFβ1进行遗传阻断或对TGFβ信号进行药理学抑制,可减少脂肪细胞和肌肉细胞中ADAMTSL4依赖性的消耗。抑制肿瘤来源的ADAMTSL4可减轻小鼠骨骼肌纤维化。总之,在恶病质癌症患者中,循环ADAMTSL4水平升高与TGFβ驱动的肌肉萎缩和纤维化基因特征之间的关联,表明ADAMTSL4是TGFβ1的上游调节因子,也是癌症恶病质的潜在治疗靶点。癌症恶病质缺乏有效疗法,仍是癌症相关发病率和死亡率的主要原因。我们将肿瘤来源的ADAMTSL4鉴定为通过结合LAP激活潜伏TGFβ的上游调节因子,可促进多器官消耗和纤维化相关重塑。靶向ADAMTSL4可能提供一种选择性治疗策略,而无需系统性阻断TGFβ通路。参见Liu和Janowitz的相关评论,第1964页。
Redox biology IF 16.2 2026-10 PMID: 42623935
NRF2 is a master regulator of redox and metabolic homeostasis that protects normal tissues from stress but is frequently hijacked by cancers to sustain survival and therapy resistance. Although NRF2 is dispensable for normal tissue function, its role in maintaining cancer cells within the native tumor microenvironment has remained undefined. Here, we uncover an essential and previously unrecognized tumor-specific dependency on NRF2. Using an inducible KrasFSF.G12D/+;Nrf2Fl/Fl;Rosa26CreERT2/CreERT2 (KNR) mouse lung cancer model, we demonstrate that NRF2 deletion alone, without pharmacologic intervention, eradicates cancer cells, reduces tumor burden, and prolongs survival. Single-cell RNA sequencing coupled with artificial intelligence-based genotype classification revealed that NRF2-deleted cancer cells are selectively eliminated, whereas non-cancerous cells tolerate NRF2 loss. Mechanistically, NRF2 deletion induces ferroptosis, a regulated iron-dependent cell death pathway, evidenced by induction of canonical ferroptotic genes (Ptgs2, Acsl4, Tfrc) and protein markers (SO2/3-PRDX3, COX2, TfR1). Importantly, these data support that NRF2 loss induces ferroptotic cell death in vivo within established tumors, in the absence of exogenous ferroptosis inducers or external stress. These findings establish that cancer cells depend on NRF2 to suppress intrinsic ferroptotic stress for survival, a dependency not shared by normal tissues. This discovery fundamentally redefines the pathological role of NRF2 and positions NRF2 inhibition as a standalone, tumor-selective therapeutic strategy to eliminate Kras-driven malignancies by unleashing ferroptosis.
中文摘要:NRF2是氧化还原和代谢稳态的主调控因子,保护正常组织免受应激,但常被癌症劫持以维持生存和治疗抵抗。尽管NRF2对正常组织功能并非必需,但其在天然肿瘤微环境中维持癌细胞的作用尚未明确。在此,我们揭示了一种必要且此前未被认识到的肿瘤特异性对NRF2的依赖。使用可诱导的KrasFSF.G12D/+;Nrf2Fl/Fl;Rosa26CreERT2/CreERT2 (KNR) 小鼠肺癌模型,我们证明仅删除NRF2,无需药物干预,即可清除癌细胞、减少肿瘤负荷并延长生存。单细胞RNA测序结合基于人工智能的基因型分类显示,NRF2缺失的癌细胞被选择性清除,而非癌细胞可耐受NRF2缺失。机制上,NRF2缺失诱导铁死亡,这是一种受调控的铁依赖性细胞死亡通路,表现为经典铁死亡基因(Ptgs2、Acsl4、Tfrc)和蛋白标志物(SO2/3-PRDX3、COX2、TfR1)的诱导。重要的是,这些数据支持在已形成肿瘤体内、在没有外源性铁死亡诱导剂或外部应激的情况下,NRF2缺失诱导铁死亡性细胞死亡。这些发现确立癌细胞依赖NRF2抑制内在铁死亡应激以生存,而正常组织并不共享这种依赖。这一发现从根本上重新定义了NRF2的病理作用,并将NRF2抑制定位为一种独立的、肿瘤选择性的治疗策略,通过释放铁死亡来消除Kras驱动的恶性肿瘤。

9其他实体瘤 (13篇)

临床研究 (2篇)

Cancer research IF 22.6 2026-10-02 PMID: 42554637
High-dimension spatial technologies are broadly being used to map the cellular and molecular organization of human cancers including tumor antigens and drug targets. This has revealed extensive spatial heterogeneity of target proteins but does not quantify drug distribution itself. Exposing additional complexities for drug targeting and delivery, Lu and colleagues recently applied highly multiplexed spatial proteomics to tumors from patients treated with fluorescently labeled antibody therapeutics. Quantifying drug penetration and distribution on cells of specific phenotypes, this approach identified compounding challenges that would limit therapeutic success as both target and therapeutic distribution are highly variable between patients and within individual tumors. Macrophage uptake, stromal barriers, vascularization differences, and epithelial permeability were all associated with altered antibody distribution. As expected, highly desmoplastic pancreatic cancers had poor drug delivery, and similar fibroblast- and extracellular matrix-rich microenvironments were also identified in head and neck squamous cell carcinomas as broadly prevalent barriers to drug delivery. Providing a measurement strategy for single-cell drug distribution, this work points toward opportunities to predict these barriers in precision medicine and design drugs that overcome them as a clinically impactful frontier.
中文摘要:高维空间技术正被广泛用于绘制人类癌症的细胞和分子组织图谱,包括肿瘤抗原和药物靶点。这揭示了靶蛋白广泛的空间异质性,但并未量化药物分布本身。Lu及其同事最近将高度多重空间蛋白质组学应用于接受荧光标记抗体治疗的患者的肿瘤,从而揭示了药物靶向和递送方面的更多复杂性。该方法量化了药物在特定表型细胞上的穿透和分布,识别出可能限制治疗成功的叠加挑战,因为靶点和治疗药物的分布在患者之间以及单个肿瘤内部均高度可变。巨噬细胞摄取、基质屏障、血管化差异和上皮通透性均与抗体分布改变相关。正如预期,高度促纤维增生性胰腺癌的药物递送较差,而在头颈部鳞状细胞癌中也发现了类似的富含成纤维细胞和细胞外基质的微环境,作为普遍存在的药物递送屏障。这项工作提供了一种单细胞药物分布的测量策略,指出了在精准医学中预测这些屏障并设计能够克服这些屏障的药物的机会,这是一个具有临床影响力的前沿方向。
Signal transduction and targeted therapy IF 81.2 2026-10-01 PMID: 42816483
We developed a novel carbon nanoparticle-Fe (II) complex prepared via suspension injection (CNSI-Fe) to induce cancer cell ferroptosis through direct intratumoral delivery of ferrous iron. Preclinical studies have demonstrated that CNSI-Fe has promising antitumour effects, thereby prompting this first-in-human, single-arm, open-label, dose-escalation phase I trial in patients with refractory solid tumors. Primary objectives included assessments of safety and tolerability and the determination of dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD). Secondary objectives included the determination of preliminary antitumour efficacy and pharmacokinetics. Applying a 3 + 3 design across five doses (30-150 mg), a total of 19 enrolled patients received CNSI-Fe treatment. The MTD was not reached, and only one patient (in the 90 mg cohort) experienced DLT events. For all treated patients (n = 19), the common adverse events included injection site pain (89.5%), hypertension (52.6%), elevated serum iron levels (47.4%), and anemia (47.4%). Pharmacokinetic analysis revealed rapid iron absorption (peak time: 0.15-0.41 h) and clearance (half-life: 1.96-5.06 h), with peak serum concentrations ranging from 3520.33 to 13961.67 ng/mL. Preliminary efficacy estimates revealed an overall response rate of 10.5% and a disease control rate (DCR) of 84.2%. Notably, the DCR reached 100% in patients with lymph node and sarcoma lesions. Overall, CNSI-Fe demonstrated a favorable safety profile and promising antitumour activity (ClinicalTrials.gov identifier: NCT06048367), supporting further investigations in a phase II trial.
中文摘要:我们开发了一种新型碳纳米颗粒-Fe(II)复合物,通过混悬注射液制备(CNSI-Fe),旨在通过直接瘤内递送亚铁离子诱导癌细胞铁死亡。临床前研究表明CNSI-Fe具有有前景的抗肿瘤作用,因此促成了这项在难治性实体瘤患者中开展的首个人体、单臂、开放标签、剂量递增I期试验。主要目标包括评估安全性和耐受性,并确定剂量限制性毒性(DLT)和最大耐受剂量(MTD)。次要目标包括确定初步抗肿瘤疗效和药代动力学。采用3+3设计,跨越五个剂量(30-150 mg),共19例入组患者接受了CNSI-Fe治疗。未达到MTD,仅1例患者(90 mg队列)发生DLT事件。对于所有接受治疗的患者(n=19),常见不良事件包括注射部位疼痛(89.5%)、高血压(52.6%)、血清铁水平升高(47.4%)和贫血(47.4%)。药代动力学分析显示铁吸收迅速(达峰时间:0.15-0.41 h)和清除迅速(半衰期:1.96-5.06 h),血清峰浓度范围为3520.33至13961.67 ng/mL。初步疗效估计显示总缓解率为10.5%,疾病控制率(DCR)为84.2%。值得注意的是,在淋巴结和肉瘤病变患者中,DCR达到100%。总体而言,CNSI-Fe表现出良好的安全性特征和有前景的抗肿瘤活性(ClinicalTrials.gov标识符:NCT06048367),支持在II期试验中进一步研究。

基础研究 (11篇)

Cancer letters IF 11.8 2026-10-07 PMID: 42843585
Cancer cells adapt to microenvironmental cues through the coordinated integration of metabolic reprogramming, epigenetic remodeling, and immune regulation. An emerging central regulator of this adaptive network is coordinated nicotinamide metabolism, which controls both nicotinamide adenine dinucleotide (NAD) biosynthesis and cellular methylation potential. Within this network, the nicotinamide-metabolizing enzymes nicotinamide phosphoribosyltransferase (NAMPT) and nicotinamide N-methyltransferase (NNMT) govern the metabolic fate of nicotinamide (NAM), thereby coupling energy metabolism to epigenetic regulation and adaptive cellular responses. NAMPT, the rate-limiting enzyme of the NAD salvage pathway, sustains intracellular NAD pools required for redox homeostasis, mitochondrial function, DNA repair, and stress responses. Conversely, NNMT diverts NAM from NAD biosynthesis by catalyzing its methylation while consuming S-adenosylmethionine (SAM), thereby creating a methylation sink that remodels chromatin organization and promotes transcriptional plasticity. Beyond intracellular metabolism, coordinated nicotinamide metabolism extends to the tumor microenvironment through extracellular mediators, including extracellular NAMPT (eNAMPT), the emerging extracellular functions of NNMT (eNNMT) and its metabolite 1-methylnicotinamide (1-MNA), which regulate stromal remodeling, immune cell function, chronic inflammation, and immune evasion. Collectively, these complementary intracellular and extracellular activities establish a multilevel adaptive network that integrates metabolic homeostasis, epigenetic remodeling, and immunometabolic communication, thereby promoting tumor plasticity, therapeutic adaptation, and resistance. Here, we propose a conceptual framework in which NAMPT and NNMT function as complementary regulators of coordinated nicotinamide metabolism operating across interconnected intracellular and extracellular levels. By integrating metabolic, epigenetic, and immune crosstalk into a unified model of tumor adaptation, this perspective provides new insights into tumor progression and therapy resistance while highlighting context-dependent opportunities for mechanism-based combination therapies in cancer.
中文摘要:癌细胞通过代谢重编程、表观遗传重塑和免疫调节的协同整合来适应微环境信号。这一适应性网络中一个新出现的核心调节因素是协同的烟酰胺代谢,它同时控制烟酰胺腺嘌呤二核苷酸(NAD)生物合成和细胞甲基化潜力。在该网络中,烟酰胺代谢酶烟酰胺磷酸核糖转移酶(NAMPT)和烟酰胺N-甲基转移酶(NNMT)决定烟酰胺(NAM)的代谢去向,从而将能量代谢与表观遗传调控及适应性细胞反应耦合起来。NAMPT是NAD补救途径的限速酶,维持用于氧化还原稳态、线粒体功能、DNA修复和应激反应的细胞内NAD池。相反,NNMT通过催化NAM甲基化并消耗S-腺苷甲硫氨酸(SAM),使NAM偏离NAD生物合成,从而形成甲基化汇,重塑染色质组织并促进转录可塑性。除细胞内代谢外,协同的烟酰胺代谢还通过细胞外介质延伸至肿瘤微环境,包括细胞外NAMPT(eNAMPT)、NNMT新出现的细胞外功能(eNNMT)及其代谢物1-甲基烟酰胺(1-MNA),它们调节基质重塑、免疫细胞功能、慢性炎症和免疫逃逸。总体而言,这些互补的细胞内和细胞外活动建立了一个多层次适应性网络,整合代谢稳态、表观遗传重塑和免疫代谢通讯,从而促进肿瘤可塑性、治疗适应和耐药。在此,我们提出一个概念框架,其中NAMPT和NNMT作为协同烟酰胺代谢的互补调节因子,在相互关联的细胞内和细胞外层面发挥作用。通过将代谢、表观遗传和免疫串扰整合为一个统一的肿瘤适应模型,这一观点为肿瘤进展和治疗耐药提供了新见解,同时强调癌症中基于机制的联合治疗具有情境依赖性的机会。
Signal transduction and targeted therapy IF 81.2 2026-10-07 PMID: 42838963
Epigenetic regulation and gene transcription are dynamically modulated by extracellular signals, including focal adhesions; however, the role of integrins in these processes remains poorly understood. In this study in HPV-negative head and neck squamous cell carcinoma, (HNSCC), we combined investigations in physiological three-dimensional, matrix-embedded cell models and patient-derived organoids with multi-omics analyses, bioinformatics and artificial intelligence, to unmask the integrin effector signaling network that reshapes chromatin to drive cancer. Among the 12 α/β1 integrin receptors, α7 integrin (ITGA7) emerged as the most potent modulator of histone post-translational modifications, associated with significant changes in gene transcription and chromatin accessibility. Depletion of ITGA7, achieved independently by CRISPR/Cas9 knockout and RNA interference, reduced chromatin accessibility at the AURKA locus and downregulated an AURKA-centered transcriptional program. Mechanistically, phosphoproteomics revealed significant inhibition of MAPK- and PI3K/AKT-dependent signaling with concomitant functional impairment of cell cycling and cell survival upon ITGA7 depletion. Across all analyses, machine-learning-based feature selection consistently nominated AURKA as the dominant downstream node, and tumor ITGA7 expression stratified patient overall survival in a non-linear manner. In summary, these findings establish α7 integrin as a key co-regulator of chromatin accessibility and gene transcription in HPV-negative HNSCC, acting through an AURKA-centered axis that couples adhesion signaling to cell cycle control and patient survival, and nominate AURKA, potentially targetable with clinical Aurora-A inhibitors such as alisertib, as an actionable therapeutic node downstream of the currently non-druggable ITGA7.
中文摘要:表观遗传调控和基因转录受细胞外信号(包括黏着斑)的动态调节;然而,整合素在这些过程中的作用仍知之甚少。本研究在HPV阴性头颈部鳞状细胞癌(HNSCC)中,将生理性三维基质包埋细胞模型和患者来源类器官的研究与多组学分析、生物信息学和人工智能相结合,以揭示重塑染色质从而驱动癌症的整合素效应信号网络。在12种α/β1整合素受体中,α7整合素(ITGA7)成为组蛋白翻译后修饰最强效的调节因子,并与基因转录和染色质可及性的显著变化相关。通过CRISPR/Cas9敲除和RNA干扰分别实现的ITGA7缺失,降低了AURKA位点的染色质可及性,并下调了以AURKA为中心的转录程序。机制上,磷酸化蛋白质组学显示,ITGA7缺失后MAPK和PI3K/AKT依赖性信号显著受抑,同时细胞周期和细胞存活功能受损。在所有分析中,基于机器学习的特征选择一致地提名AURKA为主要下游节点,并且肿瘤ITGA7表达以非线性方式对患者总生存期进行分层。总之,这些发现确立了α7整合素是HPV阴性HNSCC中染色质可及性和基因转录的关键共调节因子,其通过以AURKA为中心的轴将黏附信号与细胞周期控制和患者生存耦联,并提名AURKA——可能可用alisertib等临床Aurora-A抑制剂靶向——作为目前不可成药的ITGA7下游的可干预治疗节点。
Cancer research IF 22.6 2026-10-06 PMID: 42836582
Aberrant epigenetic regulation is a central driver of tumorigenesis, and the reversibility of epigenetic modifications underscores their potential as therapeutic targets. Epigenetic factors often function in a highly context-dependent manner, necessitating rigorous study of their dynamic and complex roles. Here, we uncovered an intricate regulation of tumor development and plasticity by the KDM6 family of H3K27me3 histone demethylases in pancreatic ductal adenocarcinoma (PDAC), a disease with sustained high mortality and limited treatment options. Temporally resolving KRAS-driven tumor development revealed a switch from tumor suppressive to oncogenic functions for KDM6B, with implications for tumor aggressiveness in rodents and patients. These oncogenic functions were mediated by regulation of NOTCH signaling, a pathway known to promote PDAC tumorigenesis. Concurrent elimination of KDM6A and KDM6B led to profound phenotypic changes resembling sarcomatoid carcinomas, a rare, poorly characterized subtype of human PDAC. These tumors exhibited altered oncogenic networks, including NOTCH and JNK signaling, that may support development of therapies tailored to molecular subtypes. Given the critical and distinct activities of KDM6 histone demethylases during PDAC development, targeting KDM6 activities may be beneficial in the right cellular and temporal context.
中文摘要:异常的表观遗传调控是肿瘤发生的核心驱动因素,而表观遗传修饰的可逆性凸显了其作为治疗靶点的潜力。表观遗传因子常以高度依赖背景的方式发挥作用,因此需要对其动态且复杂的作用进行严谨研究。在此,我们揭示了H3K27me3组蛋白去甲基化酶KDM6家族在胰腺导管腺癌(PDAC)中对肿瘤发展和可塑性的复杂调控,而PDAC是一种死亡率持续较高且治疗选择有限的疾病。对KRAS驱动肿瘤发展进行时间维度解析,发现KDM6B从抑癌功能向促癌功能转换,并对啮齿动物和患者的肿瘤侵袭性具有意义。这些促癌功能由对NOTCH信号的调控所介导,而NOTCH通路已知可促进PDAC肿瘤发生。同时消除KDM6A和KDM6B会导致类似肉瘤样癌的显著表型改变,肉瘤样癌是人类PDAC中一种罕见且特征尚不明确的亚型。这些肿瘤表现出改变的促癌网络,包括NOTCH和JNK信号,这可能支持开发针对分子亚型定制的疗法。鉴于KDM6组蛋白去甲基化酶在PDAC发展过程中具有关键且不同的活性,在合适的细胞和时间背景下靶向KDM6活性可能是有益的。
Science advances IF 13.9 2026-10-02 PMID: 42826198
Despite substantial treatment improvements, the 5-year survival rate for metastatic osteosarcoma (OS) is still as low as 20%. Immunocompetent genetic mouse models of OS have been introduced, enabling in vivo OS studies. Here, we present the ROCCIA mouse, a quintuple-mutant extension of these models that develops multifluorescent OS tumors, allowing distinct fluorescently labeled OS cell populations to be identified and traced both within tumors and in the circulation. In addition, this model enables postnatal inactivation of the p53 and Rb1 genes, thus resembling development and progression of OS in humans. Using this model, we show that osterix (Osx)-expressing fluorescent tumor cells appear in circulation upon OS development and predominate in lung metastases, thus representing a potential target for future therapies. We also show that the immunological landscape of this model's tumor microenvironment mimics the previously described human OS microenvironment. Therefore, this immunocompetent, quintuple mutant, multifluorescent mouse model represents a powerful resource to analyze OS tumor development and metastasis in real time and to test translational therapies.
中文摘要:尽管治疗取得了实质性进展,转移性骨肉瘤(OS)的5年生存率仍低至20%。目前已引入具有免疫健全性的OS基因工程小鼠模型,使体内OS研究得以开展。在此,我们提出ROCCIA小鼠,它是这些模型的五重突变扩展,可发生多荧光OS肿瘤,从而能够在肿瘤内和循环中识别并追踪不同的荧光标记OS细胞群。此外,该模型可实现出生后p53和Rb1基因的失活,因而与人OS的发生和进展相似。利用该模型,我们表明,表达osterix(Osx)的荧光肿瘤细胞在OS发生时出现在循环中,并在肺转移灶中占优势,因此代表未来治疗的潜在靶点。我们还表明,该模型肿瘤微环境的免疫学特征与既往描述的人OS微环境相似。因此,这种具有免疫健全性、五重突变、多荧光的小鼠模型是实时分析OS肿瘤发展和转移以及测试转化治疗的有力资源。
Science advances IF 13.9 2026-10-02 PMID: 42814831
Maintenance of fissed mitochondria is viewed as a defining feature of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant cancers. However, regulation of this process by accompanying comutations or environmental factors is not clearly defined. Here, by analyzing a subset of pancreatic cancer lesions driven by concurrent KrasG12D and GNAS complex locus gene (GNASR201C/H) mutations, we found that despite the presence of mutant Kras, hyperactive GnasR201C maintains mitochondria predominantly in a fused state, which is necessary for tumor growth. Multiplex proteomics, super-resolution microscopy, loss- and gain-of-function studies, coupled with metabolite rescue experiments, revealed that GnasR201C-regulated branched-chain amino acid (BCAA) pathway is a previously unidentified regulator of mitochondrial morphology. Mechanistically, the BCAA pathway, the associated tricarboxylic acid cycle, and aspartate metabolism converge on nicotinamide adenine dinucleotide (NADH-NAD+) metabolites to promote mitochondrial elongation. NAD+ availability is crucial for mitochondrial fusion, as facilitating NAD+ generation through alternative means promotes fusion. Collectively, we unraveled a new mechanism that drives mitochondrial fusion and showed that the combination of oncogenic signaling and metabolism can maintain distinct mitochondrial morphology within genetic subsets of KRAS-mutant pancreatic cancer.
中文摘要:维持线粒体分裂状态被视为Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)突变癌症的一个决定性特征。然而,伴随共突变或环境因素对这一过程的调控尚不明确。在这里,通过分析由KrasG12D和GNAS复杂位点基因(GNASR201C/H)突变共同驱动的一部分胰腺癌病灶,我们发现尽管存在突变Kras,过度活跃的GnasR201C仍使线粒体主要维持融合状态,而这对肿瘤生长是必需的。多重蛋白质组学、超分辨显微成像、功能缺失和功能获得研究,结合代谢物挽救实验,揭示GnasR201C调控的支链氨基酸(BCAA)通路是线粒体形态的一个此前未被识别的调控因子。机制上,BCAA通路、相关的三羧酸循环以及天冬氨酸代谢汇聚于烟酰胺腺嘌呤二核苷酸(NADH-NAD+)代谢物,以促进线粒体延长。NAD+可用性对线粒体融合至关重要,因为通过替代方式促进NAD+生成可促进融合。总体而言,我们揭示了一种驱动线粒体融合的新机制,并表明致癌信号与代谢的结合可在KRAS突变胰腺癌的特定遗传亚群中维持独特的线粒体形态。
Cell research IF 31.1 2026-10 PMID: 42693250
Innate immunity provides a critical first line of defense against pathogens and homeostatic perturbations. Pattern recognition receptors detect these disruptions and initiate immune responses through multi-protein complex formation to drive inflammatory signaling and cell death pathways. Key cytosolic complexes formed by these sensors include inflammasomes and PANoptosomes. Inflammasomes induce caspase-1 activation and the subsequent maturation of interleukin (IL)-1β and IL-18, and they can act as integral components of larger PANoptosomes, whose formation and functions have been defined by genetic, biochemical, and single-cell imaging evidence. PANoptosomes induce lytic, inflammatory cell death (PANoptosis) and promote the release of damage-associated molecular patterns (DAMPs) and cytokines beyond IL-1β and IL-18, including TNF, IFNs, IL-6, and others. Given their critical functions in driving cell death and the release of cytokines and DAMPs, dysregulation of innate immune sensors is associated with a wide range of diseases, including infections, autoinflammatory syndromes, cardiovascular disorders, neurodegeneration, metabolic conditions, and cancer. Therefore, understanding innate immune sensors and how they assemble inflammasomes and PANoptosomes to drive cell death is critical for identifying therapeutic strategies. In this review, we discuss innate immune sensors that form inflammasomes and PANoptosomes, such as NLRP1, NLRP3, NLRC4, AIM2, Pyrin, and others. We highlight recent structural and mechanistic insights into these sensors, along with emerging structural studies of inflammasome assemblies and the biochemical and functional evidence supporting the formation of PANoptosomes. Given the physiological relevance of innate immune sensors and the complexes they form across the disease spectrum, an improved understanding of their structure-function relationships will be critical for informing therapeutic strategies that target these molecules, their associated complexes, and their physiological functions.
中文摘要:先天免疫为抵御病原体和稳态扰动提供了关键的第一道防线。模式识别受体检测这些破坏,并通过形成多蛋白复合物启动免疫应答,从而驱动炎症信号和细胞死亡通路。这些传感器形成的关键胞质复合物包括炎症小体和PANoptosome。炎症小体诱导caspase-1激活以及随后的白细胞介素(IL)-1β和IL-18成熟,并且它们可以作为更大的PANoptosome的组成部分,其形成和功能已由遗传学、生物化学和单细胞成像证据所界定。PANoptosome诱导致裂性、炎症性细胞死亡(PANoptosis),并促进损伤相关分子模式(DAMPs)以及除IL-1β和IL-18之外的细胞因子释放,包括TNF、IFN、IL-6等。鉴于其在驱动细胞死亡以及细胞因子和DAMPs释放中的关键功能,先天免疫传感器的失调与多种疾病相关,包括感染、自身炎症综合征、心血管疾病、神经退行性变、代谢性疾病和癌症。因此,理解先天免疫传感器以及它们如何组装炎症小体和PANoptosome以驱动细胞死亡,对于确定治疗策略至关重要。在本综述中,我们讨论形成炎症小体和PANoptosome的先天免疫传感器,如NLRP1、NLRP3、NLRC4、AIM2、Pyrin等。我们重点介绍关于这些传感器的最新结构和机制见解,以及炎症小体组装的新兴结构研究,以及支持PANoptosome形成的生化和功能证据。鉴于先天免疫传感器及其形成的复合物在整个疾病谱中的生理相关性,更好地理解其结构-功能关系对于指导靶向这些分子、其相关复合物及其生理功能的治疗策略至关重要。
Trends in microbiology IF 18.7 2026-10 PMID: 42586808
Gut microbial metabolites, particularly short-chain fatty acids (SCFAs), bile acid (BAs) derivatives, and tryptophan-derived metabolites (TDMs), act as signaling molecules, receptor ligands, and epigenetic modulators in regulating host metabolic and immune homeostasis. They exert local effects in the gut and reach distant tissues via hepatic, lymphatic, neural, and immune-hormonal routes, thereby regulating immunity, metabolism, and neural function. Disruptions in these pathways are associated with inflammatory diseases, neurodegeneration, and cancer. This review discusses the importance of SCFAs, BAs, and TDMs in different host metabolic and immunological contexts, dissects their molecular mechanisms of action on target cells, evaluates the therapeutic implications of targeting these microbial pathways, and outlines a roadmap for possible future clinical translations.
中文摘要:肠道微生物代谢物,尤其是短链脂肪酸(SCFAs)、胆汁酸(BAs)衍生物和色氨酸衍生代谢物(TDMs),作为信号分子、受体配体和表观遗传调节因子,调节宿主代谢和免疫稳态。它们在肠道内发挥局部作用,并通过肝、淋巴、神经和免疫激素途径到达远处组织,从而调节免疫、代谢和神经功能。这些通路的紊乱与炎症性疾病、神经退行性疾病和癌症相关。本综述讨论了SCFAs、BAs和TDMs在不同宿主代谢和免疫背景中的重要性,剖析了它们对靶细胞的分子作用机制,评估了靶向这些微生物通路的治疗意义,并勾勒了未来可能临床转化的路线图。
Cancer letters IF 11.8 2026-10-01 PMID: 42392399
Ewing sarcoma (EwS) shows a limited clinical response to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), despite promising preclinical data. In this study, we compared five PARPi with different PARP-trapping capacities in PDX-derived cell lines and mouse models. Talazoparib, the strongest PARP-trapping agent, showed markedly greater efficacy than olaparib or veliparib. It triggered extensive DNA damage, micronuclei formation, and activation of the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway, leading to robust type I interferon and pro-inflammatory cytokine release, an effect not seen in osteosarcoma. In vivo, talazoparib also reshaped the tumor microenvironment, increasing macrophage infiltration and reducing tumor growth. In vitro, conditioned media from treated EwS cells promoted M0-like macrophage polarization towards an inflammatory M1-like status. These immunostimulatory effects were initiated by tumor-derived interferons and were absent in talazoparib-resistant and olaparib-treated EwS cells, underscoring the importance of the PARP trapping activity of PARPi rather than catalytic inhibition. Combination of talazoparib with exogenous 2'-3'-cyclic GMP-AMP (cGAMP) does not further increase phagocytosis of EwS cells when co-cultured with macrophages, and no additive effects were observed under the tested conditions. Thus, talazoparib is a potent cytotoxic agent with innate immune activation/macrophage-mediated effects, prompting further clinical evaluation in this tumor type.
中文摘要:尤因肉瘤(EwS)对聚(ADP-核糖)聚合酶(PARP)抑制剂(PARPi)的临床反应有限,尽管临床前数据令人鼓舞。在本研究中,我们在PDX来源的细胞系和小鼠模型中比较了五种具有不同PARP捕获能力的PARPi。Talazoparib作为最强的PARP捕获剂,其疗效显著优于olaparib或veliparib。它引发了广泛的DNA损伤、微核形成以及环鸟苷酸-腺苷酸合成酶(cGAS)/干扰素基因刺激因子(STING)通路的激活,导致强烈的I型干扰素和促炎细胞因子释放,而骨肉瘤中未见此效应。在体内,talazoparib还重塑了肿瘤微环境,增加巨噬细胞浸润并减少肿瘤生长。在体外,经处理的EwS细胞条件培养基促进M0样巨噬细胞向炎症性M1样状态极化。这些免疫刺激效应由肿瘤来源的干扰素启动,且在talazoparib耐药和olaparib处理的EwS细胞中缺失,凸显了PARPi的PARP捕获活性而非催化抑制的重要性。在巨噬细胞共培养条件下,talazoparib与外源性2'-3'-环鸟苷酸-腺苷酸(cGAMP)联合并未进一步增加对EwS细胞的吞噬作用,且在所测试条件下未观察到叠加效应。因此,talazoparib是一种有效的细胞毒性药物,具有天然免疫激活/巨噬细胞介导的效应,值得在该肿瘤类型中进一步开展临床评价。
Cancer letters IF 11.8 2026-10-01 PMID: 42342022
Melanoma differentiation associated gene-9 (MDA-9), also known as Syntenin-1 or SDCBP, exhibits elevated expression in multiple cancers, promoting invasion, migration, and tumor cell survival. The TCGA database reveals high MDA-9 expression in late-stage HPV (-) HNSCC tissues, which associates with poor patient survival. Moreover, bioinformatics analyses support a potential role of MDA-9 in promoting cancer stemness in HNSCC tissues. We characterized the functional role of MDA-9 in HNSCC tumorigenesis, particularly in relation to cancer stem cell maintenance. Knockdown of MDA-9 suppresses BMI1, a functional cancer stem cell marker in HNSCC, and the self-renewal of cultured HNSCC cells. Mechanistically, MDA-9 controls expression of BMI1 through NF-κB p65. Targeting MDA-9 with a specific small molecule pharmacological inhibitor, IVMT-Rx-4, inhibits HNSCC growth and metastasis in a HNSCC xenograft mouse model. In vivo lineage tracing reveals that IVMT-Rx-4 potently inhibits self-renewal and tumorigenicity of Bmi1+ cancer stem cells in a spontaneous model of HNSCC. Additionally, IVMT-Rx-4 significantly improves treatment with cisplatin by eliminating cisplatin-enriched Bmi1+ cancer stem cells, thereby overcoming cisplatin resistance. Taken together, our results demonstrate that targeting MDA-9 with IVMT-Rx-4 is an effective strategy for treating HNSCC by eliminating cancer stem cells, and IVMT-Rx-4 is a promising chemical entity that may be amenable for developing an effective therapy for HNSCC.
中文摘要:黑色素瘤分化相关基因9(MDA-9),也称为Syntenin-1或SDCBP,在多种癌症中表达升高,促进侵袭、迁移和肿瘤细胞存活。TCGA数据库显示,MDA-9在晚期HPV(-)头颈部鳞状细胞癌(HNSCC)组织中高表达,并与患者生存不良相关。此外,生物信息学分析支持MDA-9在HNSCC组织中促进癌症干性的潜在作用。我们刻画了MDA-9在HNSCC肿瘤发生中的功能作用,特别是与癌症干细胞维持相关的作用。敲低MDA-9可抑制BMI1(HNSCC中一种功能性癌症干细胞标志物)以及培养的HNSCC细胞的自我更新。在机制上,MDA-9通过NF-κB p65控制BMI1的表达。用一种特异性小分子药理抑制剂IVMT-Rx-4靶向MDA-9,可在HNSCC异种移植小鼠模型中抑制HNSCC生长和转移。体内谱系追踪显示,IVMT-Rx-4在HNSCC自发模型中有效抑制Bmi1+癌症干细胞的自我更新和致瘤性。此外,IVMT-Rx-4通过消除顺铂富集的Bmi1+癌症干细胞,显著改善顺铂治疗,从而克服顺铂耐药。总之,我们的结果表明,用IVMT-Rx-4靶向MDA-9是通过消除癌症干细胞来治疗HNSCC的有效策略,并且IVMT-Rx-4是一种有前景的化学实体,可能适合开发有效的HNSCC疗法。
Neuro-oncology IF 13.1 2026-10-01 PMID: 42334961
Silent corticotroph adenomas (SCAs) are an aggressive pituitary neuroendocrine tumor (PitNET) subtype lacking effective medical therapies and showing a high rate of recurrence. The molecular mechanisms driving their proliferation remain poorly understood. Although metabolic reprogramming is a hallmark of cancer, neither lipid metabolism nor its regulatory pathways have been systematically investigated in SCAs. We performed integrative analyses of bulk and single-cell RNA sequencing datasets from SCAs, functioning corticotroph adenomas (FCAs), and normal pituitary tissue to characterize GAL expression and associated signaling pathways. Mechanistic studies employed GAL gain- and loss-of-function models, RNA sequencing, luciferase reporter assays, lipidomics, and pharmacological inhibition. Regulation of GAL by MYCN was assessed through promoter transactivation assays. The therapeutic efficacy of SREBP1 inhibition (fatostatin) was evaluated both in vitro and in vivo. We identified a marked downregulation of galanin (GAL) in SCAs and demonstrated that GAL loss promotes tumor cell proliferation. GAL deficiency activated the PI3K-Akt-mTOR signaling cascade, resulting in increased activity of SREBP1, a key transcriptional regulator of lipogenesis. Enhanced fatty-acid synthesis provided metabolic support for SCA growth. We further uncovered a linear regulatory axis in which MYCN directly upregulates GAL; however, MYCN downregulation in SCAs suppresses GAL expression, thereby enabling SREBP1-driven lipogenesis. Pharmacological inhibition of SREBP1 with fatostatin reduced lipogenesis and significantly suppressed SCA growth in vitro and in vivo. Our findings reveal a previously unrecognized MYCN-GAL-SREBP1 lipogenic axis that drives SCA proliferation. SREBP1-dependent lipogenesis represents a promising and druggable therapeutic vulnerability for the treatment of SCAs.
中文摘要:静默性促肾上腺皮质激素细胞腺瘤(SCAs)是一种侵袭性垂体神经内分泌肿瘤(PitNET)亚型,缺乏有效的药物治疗且复发率高。驱动其增殖的分子机制仍知之甚少。尽管代谢重编程是癌症的标志之一,但SCAs中的脂质代谢及其调控通路均未被系统研究。我们对来自SCAs、功能性促肾上腺皮质激素腺瘤(FCAs)和正常垂体组织的批量及单细胞RNA测序数据集进行整合分析,以刻画甘丙肽(GAL)表达及相关信号通路。机制研究采用GAL功能获得和缺失模型、RNA测序、荧光素酶报告基因实验、脂质组学及药理学抑制。通过启动子反式激活实验评估MYCN对GAL的调控。在体外和体内评估SREBP1抑制(法托司他汀)的治疗效果。我们发现在SCAs中甘丙肽(GAL)显著下调,并证明GAL缺失促进肿瘤细胞增殖。GAL缺乏激活PI3K-Akt-mTOR信号级联,导致脂肪生成的关键转录调控因子SREBP1活性增加。增强的脂肪酸合成为SCA生长提供代谢支持。我们进一步揭示了一条线性调控轴:MYCN直接上调GAL;然而SCAs中MYCN下调抑制GAL表达,从而使SREBP1驱动的脂肪生成得以发生。用法托司他汀对SREBP1进行药理学抑制可减少脂肪生成,并在体外和体内显著抑制SCA生长。我们的研究结果揭示了一条此前未被认识的MYCN-GAL-SREBP1脂肪生成轴,其驱动SCA增殖。依赖SREBP1的脂肪生成是治疗SCAs的一个有前景且可成药的治疗脆弱性。
Bioactive materials IF 23.6 2026-10 PMID: 42253917
[This corrects the article DOI: 10.1016/j.bioactmat.2024.10.021.].
中文摘要:本文是对文章 DOI: 10.1016/j.bioactmat.2024.10.021 的更正。

10泌尿生殖肿瘤 (4篇)

临床研究 (4篇)

JAMA network open IF 11.7 2026-10-01 PMID: 42821259
Medical debt affects millions of US residents and has been associated with higher cancer mortality. Whether medical debt burden is associated with incidence of advanced stage cancer, a key determinant of survival, remains unclear. To examine the association between medical debt and cancer incidence in the US. This cross-sectional study used ecological county-level data linking 2016 medical debt with age-adjusted incidence rates of 9 cancers from January 1, 2017, to December 31, 2021. The study included 2958 US counties with available data on medical debt in collections and cancer incidence rates. Population-based data were obtained and analyzed from January 11, 2025, to February 15, 2026. Percentage of residents with any medical debt in collections in 2016. Age-adjusted all-stage and late-stage (regional or distant) cancer incidence rates per 100 000 person-years from 2017 to 2021. Multivariable models adjusted for urban-rural status, Social Vulnerability Index (SVI), primary care physician density, and states were used to estimate differences in age-adjusted incidence rates of cancer associated with county-level medical debt burden. Among the 2958 US counties included in the analysis, 1154 (39.0%) were urban and 1804 (61.0%) were rural. The mean (SD) prevalence of medical debt in collections was 21.1% (9.6%), with a mean (SD) primary care physician density of 0.54 (0.35) physicians per 1000 population. The prevalence of medical debt ranged from 1.2% to 51.8%. The mean (SD) medical debt prevalence was higher in rural than urban counties (21.5% [10.0%] vs 20.5% [8.9%]; P = .007) and in counties in the highest vs lowest SVI quartile (27.4% [9.0%] vs 13.9% [6.9%]; P < .001). After adjustment, each 10percentage point increase in county-level medical debt was associated with a higher incidence of late-stage lung cancer (5.15 [95% CI, 4.62-5.68] additional cases per 100 000 person-years), colorectal cancer (0.69 [95% CI, 0.44-0.94] additional cases per 100 000 person-years), cervical cancer (0.39 [95% CI, 0.23-0.55] additional cases per 100 000 person-years), melanoma (0.59 [95% CI, 0.48-0.70] additional cases per 100 000 person-years), kidney and renal pelvis cancer (0.38 [95% CI, 0.27-0.49] additional cases per 100 000 person-years), bladder cancer (0.24 [95% CI, 0.16-0.32] additional cases per 100 000 person-years), and head and neck cancer (0.92 [95% CI, 0.77-1.07] additional cases per 100 000 person-years). Similar patterns were observed for overall cancer incidence. In this cross-sectional study of US counties, higher medical debt burden was associated with higher incidence rates of late-stage and overall cancer across multiple cancer types. These findings suggest that medical debt may reflect structural and financial barriers associated with cancer diagnosis and outcomes at the population level.
中文摘要:医疗债务影响数百万美国居民,并与更高的癌症死亡率相关。医疗债务负担是否与晚期癌症发病率——生存的关键决定因素——相关,仍不清楚。为探讨美国医疗债务与癌症发病率之间的关联。这项横断面研究使用县级生态学数据,将2016年医疗债务与2017年1月1日至2021年12月31日期间9种癌症的年龄调整发病率相关联。研究纳入2958个具有进入催收程序的医疗债务数据及癌症发病率数据的美国县。基于人群的数据获取与分析时间为2025年1月11日至2026年2月15日。暴露为2016年有进入催收程序医疗债务的居民百分比。结局为2017年至2021年每10万人年年龄调整的所有分期及晚期(区域性或远处转移)癌症发病率。使用多变量模型,并调整城乡状态、社会脆弱性指数(SVI)、初级保健医生密度和州,以估计与县级医疗债务负担相关的年龄调整癌症发病率差异。在纳入分析的2958个美国县中,1154个(39.0%)为城市,1804个(61.0%)为农村。进入催收程序的医疗债务平均(SD)比例为21.1%(9.6%),初级保健医生平均(SD)密度为每1000人口0.54(0.35)名医生。医疗债务比例范围为1.2%至51.8%。农村县的医疗债务平均(SD)比例高于城市县(21.5% [10.0%] 对 20.5% [8.9%];P = .007),社会脆弱性指数最高四分位县高于最低四分位县(27.4% [9.0%] 对 13.9% [6.9%];P < .001)。调整后,县级医疗债务每增加10个百分点,与晚期肺癌发病率升高相关(每10万人年增加5.15例 [95% CI,4.62-5.68])、结直肠癌(每10万人年增加0.69例 [95% CI,0.44-0.94])、宫颈癌(每10万人年增加0.39例 [95% CI,0.23-0.55])、黑色素瘤(每10万人年增加0.59例 [95% CI,0.48-0.70])、肾及肾盂癌(每10万人年增加0.38例 [95% CI,0.27-0.49])、膀胱癌(每10万人年增加0.24例 [95% CI,0.16-0.32])以及头颈癌(每10万人年增加0.92例 [95% CI,0.77-1.07])。总体癌症发病率也观察到相似模式。在这项针对美国县的横断面研究中,更高的医疗债务负担与多种癌症的晚期及总体癌症发病率升高相关。这些发现提示,医疗债务可能反映在人群层面与癌症诊断和结局相关的结构性和财务性障碍。
European urology IF 29.1 2026-10 PMID: 42493341
Upfront combination therapy in mHSPC improves outcomes; however, without guaranteed postprogression therapy in control arms, survival benefits may partly reflect undertreatment in the control groups rather than true superiority. Trial designs incorporating planned treatment sequencing are needed to support rational deescalation strategies.
中文摘要:转移性激素敏感性前列腺癌的初始联合治疗可改善结局;然而,如果对照组未保证进展后治疗,生存获益可能部分反映对照组治疗不足,而非真正的优效性。需要纳入预设治疗序贯的试验设计,以支持合理的降阶梯策略。
European urology IF 29.1 2026-10 PMID: 42025513
Carbonic anhydrase IX (CAIX) is a cell surface protein expressed in over 90% of clear cell renal cell carcinoma (ccRCC), driven by hypoxia or Von-Hippel Lindau (VHL) loss. The phase 3 ZIRCON trial evaluated [89Zr]girentuximab, a CAIX-targeted positron emission tomography (PET) radiotracer, and met its primary endpoint for the accurate detection of ccRCC in patients with renal masses. Many aggressive forms of non-ccRCC (nccRCC) can express CAIX, which is linked to a hypoxic state. A reanalysis of the trial was performed demonstrating the tracer also identified nccRCC, particularly in forms of papillary RCC (pRCC) with higher CAIX expression (H score) and PET avidity (SUVmax). The positive predictive value for any renal malignancy was 98%, with sensitivity/specificity of 82% and 87%, respectively. This suggests [89Zr]girentuximab has applications beyond the detection of ccRCC in primary renal masses and may have implications to management of nccRCC. PATIENT SUMMARY: The ZIRCON phase 3 trial used an imaging agent ([89Zr]girentuximab) with a primary focus to detect the most common kidney cancer, clear cell renal cell carcinoma. Other forms of kidney cancer can express the marker that the imaging agent can identify. The additional analysis showed that when positive, 98% of cases were correctly identified as any form of cancer.
中文摘要:碳酸酐酶IX(CAIX)是一种细胞表面蛋白,在超过90%的透明细胞肾细胞癌(ccRCC)中表达,其表达由缺氧或Von-Hippel Lindau(VHL)缺失驱动。3期ZIRCON试验评估了[89Zr]girentuximab,这是一种靶向CAIX的正电子发射断层扫描(PET)放射性示踪剂,并在准确检测有肾脏肿块患者的ccRCC方面达到主要终点。许多侵袭性非ccRCC(nccRCC)类型可表达CAIX,而CAIX与缺氧状态相关。对该试验进行的再分析显示,该示踪剂也能识别nccRCC,尤其是在CAIX表达较高(H评分)和PET摄取较高(SUVmax)的乳头状肾细胞癌(pRCC)类型中。对于任何肾恶性肿瘤,阳性预测值为98%,敏感性和特异性分别为82%和87%。这提示[89Zr]girentuximab的应用不仅限于检测原发性肾脏肿块中的ccRCC,并可能对nccRCC的管理具有意义。患者摘要:ZIRCON 3期试验使用一种显像剂([89Zr]girentuximab),主要关注检测最常见的肾癌,即透明细胞肾细胞癌。其他类型的肾癌也可表达该显像剂所能识别的标志物。额外分析显示,当结果为阳性时,98%的病例被正确识别为任何类型的癌症。
Journal of advanced research IF 17.1 2026-10 PMID: 41500423
New effective early diagnosis strategies and therapeutic targets are desperately needed for high-grade serous ovarian cancer (HGSOC). Previous functional interpretation of HGSOC genome-wide association studies (GWAS) have largely overlooked the role of long non-coding RNAs (lncRNAs). Our study aims to identify novel causal genes, particularly lncRNAs, that contribute to HGSOC susceptibility and to explore whether their may provide preliminary insights relevant to early detection or therapeutic development. We mapped genotype effects on the expression of both protein-coding genes (PCGs) and lncRNAs in 348 HGSOC tumor samples. By performing Bayesian colocalization analysis, we prioritized causal genes in HGSOC tumors and whole blood, respectively. Next, we generated a single-nucleus full-length transcriptome map of HGSOC tumor using snRandom-seq. Furthermore, we conducted in vitro assays to validate the functional role of lncRNA CRHR1-IT1 in HGSOC. Our findings reveal that genetic variants significantly drive expression changes in both PCGs and lncRNAs. Notably, lncRNAs contribute a greater proportion of HGSOC heritability than PCGs. Using Bayesian colocalization analysis, we prioritized 22 high-fidelity causal genes in HGSOC tumors and whole blood, including ARL17A and CRHR1-IT1. Through snRandom-seq, we characterized the single-cell expression patterns of candidate susceptibility PCGs and lncRNAs in HGSOC tumors. Furthermore, we showed that elevated CRHR1-IT1 expression promotes apoptosis and inhibits the growth of HGSOC cells in vitro. Our study highlights the significant regulatory role of genetic variants on both protein-coding genes and lncRNAs in HGSOC. While these findings enhance our understanding of HGSOC susceptibility and may inform future efforts toward biomarker discovery or immune-related therapeutic exploration.
中文摘要:高级别浆液性卵巢癌(HGSOC)亟需新的有效早期诊断策略和治疗靶点。既往对HGSOC全基因组关联研究(GWAS)的功能解读在很大程度上忽视了长链非编码RNA(lncRNA)的作用。本研究旨在识别新的致病基因,尤其是lncRNA,以阐明其在HGSOC易感性中的作用,并探讨这些发现是否能为早期检测或治疗开发提供初步线索。我们在348例HGSOC肿瘤样本中绘制了基因型对蛋白编码基因(PCG)和lncRNA表达的影响图谱。通过贝叶斯共定位分析,我们分别在HGSOC肿瘤和全血中筛选出优先致病基因。随后,我们利用snRandom-seq构建了HGSOC肿瘤的单核全长转录组图谱。此外,我们通过体外实验验证了lncRNA CRHR1-IT1在HGSOC中的功能作用。研究结果显示,遗传变异显著驱动PCG和lncRNA的表达变化。值得注意的是,lncRNA对HGSOC遗传力的贡献比例高于PCG。利用贝叶斯共定位分析,我们在HGSOC肿瘤和全血中优先确定了22个高可信度致病基因,包括ARL17A和CRHR1-IT1。通过snRandom-seq,我们刻画了候选易感PCG和lncRNA在HGSOC肿瘤中的单细胞表达模式。此外,我们证明CRHR1-IT1表达升高可在体外促进HGSOC细胞凋亡并抑制其生长。本研究凸显了遗传变异对HGSOC中蛋白编码基因和lncRNA的重要调控作用。这些发现加深了我们对HGSOC易感性的理解,并可能为未来的生物标志物发现或免疫相关治疗探索提供参考。

11其他 (9篇)

临床研究 (1篇)

Annals of internal medicine IF 17.2 2026-10-06 PMID: 42832793
Emergency Med: [Formula: see text] GIM/FP/GP: [Formula: see text] Oncology: [Formula: see text] Hematology: [Formula: see text].
中文摘要:急诊医学:[公式:见正文]。全科/家庭医学/普通内科:[公式:见正文]。肿瘤学:[公式:见正文]。血液学:[公式:见正文]。

基础研究 (8篇)

Nature biomedical engineering IF 26.3 2026-10-05 PMID: 42834084
Gastrointestinal (GI) diseases impose a growing global health burden, extending beyond localized pathology to disrupt systemic metabolism, immunity and cancer risk. Despite advances in conventional animal and cell models, critical mechanisms driving chronic inflammation, tumour initiation and host-microbiome dysregulation remain incompletely understood, limiting translational progress. Microphysiological systems, including organoids and organ-on-a-chip technologies, have transformed our ability to model human GI biology and pathology with increasing cellular, spatial and mechanical fidelity. Here we synthesize recent advances in organoid and organ-on-a-chip models of GI disease, highlighting their applications across inflammatory, infectious and neoplastic conditions throughout the GI tract. We integrate emerging engineering approaches with mechanistic and clinical insights, assessing how these systems advance disease modelling while identifying remaining gaps in complexity, translation and scalability. By bridging microengineering innovation with clinical gastroenterology, we outline how next-generation, human-relevant models can inform mechanistic discovery, guide targeted therapeutic development and support precision medicine in GI disease.
中文摘要:胃肠(GI)疾病造成日益加重的全球健康负担,其影响不仅局限于局部病理,还会扰乱全身代谢、免疫和癌症风险。尽管传统动物和细胞模型取得进展,但驱动慢性炎症、肿瘤起始和宿主-微生物组失调的关键机制仍未完全阐明,限制了转化进展。微生理系统,包括类器官和器官芯片技术,已改变我们以日益提高的细胞、空间和机械保真度来模拟人类胃肠生物学和病理学的能力。在此,我们总结胃肠疾病类器官和器官芯片模型的最新进展,重点介绍其在全消化道炎症性、感染性和肿瘤性疾病中的应用。我们将新兴工程方法与机制和临床见解相结合,评估这些系统如何推进疾病建模,同时指出在复杂性、转化和可扩展性方面仍存在的差距。通过将微工程创新与临床胃肠病学相衔接,我们概述下一代人源相关模型如何促进机制发现、指导靶向治疗开发并支持胃肠疾病精准医学。
ACS sensors IF 10.9 2026-10-01 PMID: 42825477
Tumor necrosis factor-α (TNF-α) is an important inflammatory cytokine whose rapid and quantitative detection is essential for disease diagnosis and monitoring. However, conventional methods are often limited by bulky instrumentation and are not well suited for analysis in complex biological environments. Herein, a portable CRISPR/Cas12a-based aptasensor system was developed for detection of TNF-α by integrating aptamer recognition, Cas12a trans-cleavage signal amplification, and a miniaturized fluorescence detection device. An aptamer for TNF-α was designed to regulate the accessibility of the target sequence to the CRISPR RNA (crRNA), and the resulting change in Cas12a activity was converted into fluorescence signals. The portable device integrated light-emitting diode (LED) excitation and photodiode-based detection, with modulated signals wirelessly transmitted to a smartphone for readout. The aptasensor showed concentration-dependent responses, and the inhibition rate exhibited a linear relationship with TNF-α concentration. The applicability of the system was validated in cell culture supernatants and cervical tissue samples, including tumor and adjacent normal tissues. Distinct TNF-α levels were observed between these samples, showing good agreement with enzyme-linked immunosorbent assay (ELISA) results. This portable CRISPR/Cas12a aptasensor system provides a practical approach for point-of-care TNF-α detection and extends CRISPR-based sensing to protein biomarkers.
中文摘要:肿瘤坏死因子-α(TNF-α)是一种重要的炎症细胞因子,其快速、定量检测对疾病诊断和监测至关重要。然而,传统方法常受限于笨重的仪器,难以适用于复杂生物环境中的分析。在此,我们开发了一种便携式基于CRISPR/Cas12a的适配体传感器系统,用于检测TNF-α,该系统整合了适配体识别、Cas12a反式切割信号放大以及小型化荧光检测装置。研究设计了针对TNF-α的适配体,用以调控目标序列对CRISPR RNA(crRNA)的可及性,并将由此引起的Cas12a活性变化转化为荧光信号。该便携装置集成了发光二极管(LED)激发和基于光电二极管的检测,调制信号可通过无线方式传输至智能手机进行读取。该适配体传感器表现出浓度依赖性响应,且抑制率与TNF-α浓度呈线性关系。该系统的适用性在细胞培养上清和宫颈组织样本中得到了验证,样本包括肿瘤组织和癌旁正常组织。在这些样本中观察到了不同的TNF-α水平,且与酶联免疫吸附测定(ELISA)结果显示出良好一致性。这种便携式CRISPR/Cas12a适配体传感器系统为TNF-α的即时检测提供了一种实用方法,并将基于CRISPR的传感拓展至蛋白质生物标志物领域。
Molecular cell IF 16.0 2026-10-01 PMID: 42822412
Papers in Molecular Cell and Cell by Xue et al.1 and Tsukuda2 et al., respectively, reveal that DDIAS serves as an essential single-stranded DNA (ssDNA)-binding effector of the CIP2A-TOPBP1 complex that safeguards genome integrity by shielding post-replicative ssDNA lesions during mitosis, with implications for human cancer and neurodevelopment.
中文摘要:Xue等人1和Tsukuda等人2分别发表在Molecular Cell和Cell上的论文揭示,DDIAS作为CIP2A-TOPBP1复合物中必需的单链DNA(ssDNA)结合效应因子,通过在丝分裂期间保护复制后脆弱的单链DNA损伤来维护基因组完整性,这对人类癌症和神经发育具有潜在意义。
Cancer discovery IF 29.5 2026-10-01 PMID: 42817717
Cancer cachexia is increasingly recognized as a coordinated, tumor-induced, unsustainable alteration in interorgan communication. Machado and colleagues identify a new molecular mechanism that promotes cachexia, in which tumor-secreted ADAMTSL4 drives tissue wasting by promoting local activation of latent TGFβ1, revealing post-secretory control of ligand activation as a potential therapeutic vulnerability in cancer cachexia. See related article by Machado et al., p. 2172.
中文摘要:癌症恶病质日益被认为是一种由肿瘤诱导的、多器官通讯中协调发生且不可持续的异常改变。Machado及其同事发现了一种促进恶病质的新分子机制:肿瘤分泌的ADAMTSL4通过促进潜伏型TGFβ1的局部激活来驱动组织消耗,从而揭示配体激活的分泌后调控可能成为癌症恶病质的一个潜在治疗脆弱点。参见Machado等发表于第2172页的相关文章。
Trends in pharmacological sciences IF 24.0 2026-10 PMID: 42728154
Mitochondrial quality control is essential for maintaining cellular and tissue homeostasis. Mitophagy, the selective autophagic removal of damaged mitochondria, is a central component of this process, and defects in mitophagy are increasingly linked to neurodegeneration, cardiovascular disease, cancer, and inherited mitochondrial disorders. Ubiquitin-dependent tagging of outer mitochondrial membrane proteins is a major mechanism for marking damaged mitochondria for clearance; however, recent advances reveal that mitochondrial deubiquitinases (DUBs) shape ubiquitin signaling at damaged mitochondria, thereby influencing the efficiency and selectivity of mitochondrial turnover. Moreover, DUBs are emerging as context-dependent editors of the mitochondrial ubiquitin code that link mitophagy to disease pathogenesis and therapeutic intervention. Here, we synthesize current understanding of mitochondrial DUBs in physiology and disease and discuss emerging pharmacological strategies to guide the development of mitophagy-targeted therapeutics.
中文摘要:线粒体质量控制对于维持细胞和组织稳态至关重要。线粒体自噬,即选择性自噬清除受损线粒体,是这一过程的核心组成部分,而线粒体自噬缺陷日益被认为与神经退行性疾病、心血管疾病、癌症以及遗传性线粒体疾病相关。外线粒体膜蛋白的泛素依赖性标记是标记受损线粒体以待清除的主要机制;然而,近期进展揭示,线粒体去泛素化酶(DUBs)塑造受损线粒体处的泛素信号,从而影响线粒体周转的效率和选择性。此外,DUBs正逐渐成为线粒体泛素密码的情境依赖性编辑者,将线粒体自噬与疾病发病机制和治疗干预联系起来。在此,我们综合当前关于线粒体DUBs在生理和疾病中作用的认识,并讨论新兴的药理学策略,以指导线粒体自噬靶向治疗药物的开发。
Trends in cell biology IF 25.3 2026-10 PMID: 42642259
Nuclear CGAS has previously been shown to promote tumor progression by inhibiting DNA repair. Recent data from Zhang et al. demonstrate that, upon phosphorylation by PKCα, CGAS translocates to the nucleus and initiates a CTNNB1-dependent program supporting metastatic dissemination. Thus, nuclear CGAS emerges as a multifaceted driver of cancer progression.
中文摘要:细胞核CGAS此前已被证明通过抑制DNA修复促进肿瘤进展。Zhang等人最近的数据表明,CGAS在PKCα磷酸化后易位至细胞核,并启动一个依赖CTNNB1的程序,支持转移性播散。因此,核内CGAS成为癌症进展的多方面驱动因素。
Ageing research reviews IF 15.5 2026-10 PMID: 42580600
Cellular senescence is a stress-response program characterized by durable proliferative arrest, but senescence entry does not determine a single biological outcome. Confusion between the fate of an individual cell and the behavior of a senescent-cell population has obscured interpretation across development, ageing and disease. This Review develops a fate-resolved framework that distinguishes continued arrest, cell death, physical shedding and, under restricted conditions, sustained proliferative recovery from population-level resolution or persistence. We reserve senescence escape for sustained proliferation by the same cell or lineage after validated senescence entry; failed resolution is instead one process that can produce persistence. We examine how checkpoint integrity, chromatin organization, metabolism, secretory signaling and immune surveillance shape these outcomes in development, tissue repair, ageing-associated disorders and cancer. The strength of evidence differs sharply by context. Longitudinal cancer models provide the clearest support for strict escape, alongside a restricted developmental lineage-tracing example, whereas fibrosis, neurodegeneration and metabolic or vascular disease more often support population persistence or impaired resolution without demonstrated cell-cycle re-entry. Accordingly, static markers, single-cell and spatial profiles, and computational trajectories can identify senescence-associated states but cannot establish subsequent fate without lineage tracing, live imaging or equivalent temporal evidence. Therapeutic strategies should therefore be matched to the dominant biological problem: preserving beneficial physiological senescence, resolving or modulating harmful persistent populations, or preventing recovery of residual senescent tumour cells. Because most approaches remain preclinical or early-stage, translation will require appropriate timing, cell-type specificity and protection of beneficial senescent populations.
中文摘要:细胞衰老是一种应激反应程序,其特征是持久的增殖停滞,但进入衰老并不决定单一的生物学结局。将单个细胞的命运与衰老细胞群体的行为相混淆,已妨碍了对发育、衰老和疾病中的解读。本综述建立了一个以命运为分辨的框架,区分持续停滞、细胞死亡、物理性脱落以及在受限条件下持续的增殖恢复,与群体层面的消除或持续存在。我们将衰老逃逸保留给经过验证的衰老进入后同一细胞或谱系的持续增殖;未能消除则只是可导致持续存在的一种过程。我们考察检查点完整性、染色质组织、代谢、分泌性信号和免疫监视如何在发育、组织修复、衰老相关疾病和癌症中塑造这些结局。证据强度因情境而差异显著。纵向癌症模型为严格意义上的逃逸提供了最清晰支持,同时还有一个受限的发育谱系追踪例子,而纤维化、神经退行性疾病以及代谢或血管疾病更常支持群体持续存在或消除受损,但未证明细胞周期重新进入。因此,静态标志物、单细胞和空间图谱以及计算轨迹可以识别衰老相关状态,但若无谱系追踪、活细胞成像或等同的时间证据,就不能确定其后续命运。治疗策略应与主要生物学问题相匹配:保留有益的生理性衰老、消除或调节有害的持续存在群体,或防止残留衰老肿瘤细胞恢复。由于大多数方法仍处于临床前或早期阶段,转化将需要合适的时机、细胞类型特异性以及对有益衰老群体的保护。
Cancer discovery IF 29.5 2026-10-01 PMID: 42554760
Researchers have discovered that black splotches on brown bullhead catfish in lakes in New England and Canada are likely caused by a transmissible cancer, the first one found in fish. The discovery raises questions about the cancer's origin, how it might spread, and how widespread the phenomenon might be-and could offer insights into cancer biology more broadly.
中文摘要:研究人员发现,新英格兰和加拿大湖泊中褐首鲶身上的黑色斑点很可能是由一种传染性癌症引起的,这是首次在鱼类中发现此类癌症。这一发现引发了关于该癌症的起源、可能如何传播以及该现象可能有多普遍等问题,并可能为更广泛地理解癌症生物学提供启示。